|
Ontario, Canada
(State or other jurisdiction of
incorporation or organization) |
| |
2833
(Primary Standard Industrial
Classification Code Number) |
| |
Not Applicable
(I.R.S. Employer
Identification No.) |
|
|
Mark C. Lee
Rimon, P.C. 423 Washington Street, Suite 600 San Francisco, CA 94111 Tel: +1 (916) 603-3444 |
| |
Eric Foster
Dentons Canada LLP 77 King Street West, Suite 400 Toronto-Dominion Centre Toronto, ON M5K 0A1 Canada Tel: +1 (416) 863-4511 |
| |
Louis A. Bevilacqua
Bevilacqua PLLC 1050 Connecticut Ave., NW, Suite 500 Washington, DC 20036 Tel: +1 (202) 869-0888 |
|
| | |
Per Common Share
|
| |
Total
|
| ||||||
Initial public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(1)
|
| | | $ | | | | | $ | | | ||
Proceeds to us (before expenses)
|
| | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | iii | | | |
| | | | 1 | | | |
| | | | 9 | | | |
| | | | 11 | | | |
| | | | 35 | | | |
| | | | 36 | | | |
| | | | 37 | | | |
| | | | 38 | | | |
| | | | 41 | | | |
| | | | 65 | | | |
| | | | 72 | | | |
| | | | 76 | | | |
| | | | 84 | | | |
| | | | 87 | | | |
| | | | 89 | | | |
| | | | 91 | | | |
| | | | 94 | | | |
| | | | 97 | | | |
| | | | 106 | | | |
| | | | 111 | | | |
| | | | 112 | | | |
| | | | 112 | | | |
| | | | 112 | | | |
| | | | 113 | | | |
| | | | F-1 | | |
| | |
As of 30 September, 2021
|
| |||||||||||||||
(in [thousands/millions], except share amounts)
|
| |
Actual(1)
|
| |
Pro Forma(1)
|
| |
Pro Forma,
as Adjusted(3) |
| |||||||||
Cash and cash equivalents
|
| | | $ | 959,832 | | | | | $ | 6,204,752 | | | | | $ | 24,048,201 | | |
Debt: | | | | | | | | | | | | | | | | | | | |
Total current liabilities
|
| | | $ | 11,313,959 | | | | | $ | 3,304,188 | | | | | $ | 3,304,188 | | |
Total non-current liabilities
|
| | | $ | 3,405,581 | | | | | $ | 3,405,581 | | | | | $ | 3,405,581 | | |
Total debt:
|
| | | $ | 14,719,540 | | | | | $ | 6,709,769 | | | | | $ | 6,709,769 | | |
Shareholders’ equity: | | | | | | | | | | | | | | | | | | | |
Common Shares (28,136,797 issued, unlimited
authorized) |
| | | $ | 251,775 | | | | | $ | 29,560,069 | | | | | $ | 47,403,517 | | |
Underwriter fee arrangement warrants issued
|
| | | | — | | | | | | — | | | | | | — | | |
Retained earnings (accumulated deficit)
|
| | | $ | (9,683,353) | | | | | $ | (12,607,730) | | | | | $ | (12,607,730) | | |
Reserves
|
| | | $ | 21,053 | | | | | $ | 21,053 | | | | | $ | 21,053 | | |
Other comprehensive income
|
| | | $ | 196,568 | | | | | $ | (13,127,438) | | | | | $ | (12,930,870) | | |
Total shareholders’ equity (deficiency)
|
| | | $ | (9,213,957) | | | | | $ | 4,042,522 | | | | | $ | 21,885,971 | | |
Total capitalization
|
| | | $ | 5,505,583 | | | | | $ | 10,752,291 | | | | | $ | 28,595,740 | | |
|
Assumed initial public offering price per Common Share
|
| | | $ | 5.00 | | | | | |
|
Net tangible book value per Common Share before this offering (as of September 30,
2021) |
| | | $ | (1.89) | | | | | |
|
Increase in net tangible book value per Common Share attributable to existing shareholders due to the issuance of Common Shares after September 30, 2021
|
| | | $ | (0.42) | | | | | |
|
Pro forma net tangible book value per Common Share before this offering (as of September 30, 2021)
|
| | | $ | (0.07) | | | | | |
|
Increase in net tangible book value per Common Share attributable to purchasers in this offering
|
| | | $ | 0.61 | | | | | |
|
Pro forma, as adjusted net tangible book value per Common Share immediately after this offering
|
| | | $ | 0.68 | | | | | |
|
Dilution in pro forma, as adjusted net tangible book value per Common Share to purchasers in
this offering |
| | | $ | 4.32 | | | | | |
| | |
Common Shares
|
| |
Total Consideration
|
| ||||||||||||||||||||||||
|
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| |
Weighted
Average Price Per Share |
| |||||||||||||||||
Existing shareholders
|
| | | | 24,567,128 | | | | | | 86.00% | | | | | $ | 31,733,188 | | | | | | 64.34% | | | | | $ | 1.29 | | |
Purchasers in this offering
|
| | | | 4,000,000 | | | | | | 14.00% | | | | | $ | 20,000,000 | | | | | | 38.66% | | | | | $ | 5.00 | | |
Total
|
| | | | 28,567,128 | | | | | | % | | | | | $ | 51,733,188 | | | | | | | | | | | $ | 1.81 | | |
| | |
July 16, 2021
(Inception) to August 31, 2021 |
| |||
Operating expenses: | | | | | | | |
Legal fees
|
| | | $ | 31,898 | | |
Total operating expenses
|
| | | | 31,898 | | |
Loss from operations
|
| | | | (31,898) | | |
Net and comprehensive loss
|
| | | $ | (31,898) | | |
| | |
Period Ended
August 31, |
| | | | |||
| | |
2021
|
| |
Change
|
| |||
Cash used in operating activities
|
| | | $ | 4,263 | | | |
Not Applicable
|
|
Cash used in investing activities
|
| | | $ | — | | | |
Not Applicable
|
|
Cash provided by financing activities
|
| | | $ | 250,001 | | | |
Not Applicable
|
|
| | |
July 16, 2021 (Inception) to
September 30, 2021 |
| |||
Operating expenses: | | | | | | | |
Accounting and audit fees
|
| | | $ | 16,822 | | |
Consultant fees
|
| | | | 32,904 | | |
Directors’ remuneration
|
| | | | 12,275 | | |
Legal fees
|
| | | | 39,474 | | |
Total operating expenses
|
| | | | 101,475 | | |
Other income: | | | | | | | |
Foreign exchange gains
|
| | | $ | 5,296 | | |
Total other income
|
| | | | 5,296 | | |
Net loss
|
| | | | (96,179) | | |
Other comprehensive loss
|
| | | | (102) | | |
Net and comprehensive loss
|
| | | $ | (96,281) | | |
| | |
Period Ended
September 30, |
| | | | |||
| | |
2021
|
| |
Change
|
| |||
Cash used in operating activities
|
| | | $ | (9,420) | | | |
Not Applicable
|
|
Cash used in investing activities
|
| | | $ | — | | | |
Not Applicable
|
|
Cash provided by financing activities
|
| | | $ | 254,227 | | | |
Not Applicable
|
|
| | |
Note
|
| |
July 1, 2020
(Inception) to December 31, 2020 |
| |||
Net sales
|
| | | | | | $ | — | | |
Net and Comprehensive loss
|
| | | | | | $ | — | | |
| | |
July 1, 2020
(Inception) to December 31, 2020 |
| |
Change
|
| ||||||
Cash used in operating activities
|
| | | $ | — | | | | | | Not Applicable | | |
Cash used in investing activities
|
| | | $ | — | | | | | | Not Applicable | | |
Cash provided by financing activities
|
| | | $ | 1,477 | | | | | | Not Applicable | | |
| | |
January 1, 2021 to
September 30, 2021 |
| |
July 1, 2020 (Inception) to
September 30, 2020 |
| ||||||
Net sales
|
| | | $ | — | | | | | | — | | |
Other comprehensive income: | | | | | | | | | | | | | |
Foreign exchange loss
|
| | | | (81) | | | | | | — | | |
Net and comprehensive loss
|
| | | $ | (81) | | | | | | — | | |
| | |
January 1, 2021 to
September 30, |
| |
July 1, 2020
(Inception) to September 30, |
| | | | | | | |||
| | |
2021
|
| |
2020
|
| |
Change
|
| ||||||
Cash used in operating activities
|
| |
$—
|
| | | $ | — | | | | | | Nil | | |
Cash used in investing activities
|
| |
$—
|
| | | $ | — | | | | | | Nil | | |
Cash provided by financing activities
|
| |
$ —
|
| | | $ | 1,477 | | | | | $ | (1,477) | | |
| | |
Note
|
| |
August 4, 2021
(Inception) to August 31, 2021 |
| |||
Net sales
|
| | | | | | $ | — | | |
Comprehensive loss
|
| | | | | | $ | — | | |
| | |
Period Ended
August 31, |
| | | | |||
| | |
2021
|
| |
Change
|
| |||
Cash used in operating activities
|
| | | $ | — | | | |
Not Applicable
|
|
Cash used in investing activities
|
| | | $ | — | | | |
Not Applicable
|
|
Cash provided by financing activities
|
| | | $ | 138 | | | |
Not Applicable
|
|
| | |
August 4, 2021
(Inception) to September 30, 2021 |
| |||
Net sales
|
| | | $ | — | | |
Foreign exchange translation through other comprehensive loss
|
| | | | (3) | | |
Net and Comprehensive loss
|
| | | $ | (3) | | |
| | |
Period Ended
September 30, |
| | | | | | | |||
| | |
2021
|
| |
Change
|
| ||||||
Cash used in operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . | | | | $ | — | | | | | | NotApplicable | | |
Cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . | | | | $ | — | | | | | | NotApplicable | | |
Cash provided by financing activities
|
| | | $ | 138 | | | | | | NotApplicable | | |
| | |
Nine Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2020 |
| |
Year Ended
December 31, 2020 |
| |
Year ended
December 31, 2019 |
| ||||||||||||
Sales
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Cost of sales
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Gross profit
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Amortization and depreciation
|
| | | | 231,427 | | | | | | 173,971 | | | | | | 248,743 | | | | | | 198,824 | | |
Consulting and professional fees
|
| | | | 504,866 | | | | | | 454,721 | | | | | | 701,985 | | | | | | 365,641 | | |
Biological Assets costs
|
| | | | — | | | | | | — | | | | | | 58,429 | | | | | | — | | |
Short term accommodation expense
|
| | | | — | | | | | | 31,912 | | | | | | 45,482 | | | | | | 26,269 | | |
Office expenses
|
| | | | 33,216 | | | | | | 14,171 | | | | | | 26,874 | | | | | | 13,116 | | |
Personnel expenses
|
| | | | 955,032 | | | | | | 223,345 | | | | | | 374,900 | | | | | | 100,256 | | |
Travel expenses
|
| | | | 57,063 | | | | | | 4,789 | | | | | | 5,154 | | | | | | 30,582 | | |
General & Administration expenses
|
| | | | 1,317,292 | | | | | | 163,654 | | | | | | 201,768 | | | | | | 166,515 | | |
Loss from operations
|
| | | | (3,098,896) | | | | | | (1,066,563) | | | | | | (1,663,334) | | | | | | (901,203) | | |
Interest income
|
| | | | 25,782 | | | | | | 9,529 | | | | | | 10,187 | | | | | | 399 | | |
Interest expenses
|
| | | | (393,186) | | | | | | (487,069) | | | | | | (645,162) | | | | | | (493,807) | | |
Net loss before income tax
|
| | | | (3,466,300) | | | | | | (1,544,103) | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Income tax expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | |
Nine Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2020 |
| |
Year Ended
December 31, 2020 |
| |
Year ended
December 31, 2019 |
| ||||||||||||
Net Loss for the year
|
| | | | (3,466,300) | | | | | | (1,544,103) | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Other comprehensive income: | | | | | | | | | | | | | | | | | | | | | |||||
Foreign currency translation
|
| | | | 83,016 | | | | | | 604,902 | | | | | | 150,742 | | | | | | (42,565) | | |
Total comprehensive loss for the year
|
| | | | (3,383,284) | | | | | | (939,201) | | | | | | (2,147,568) | | | | | | (1,437,176) | | |
Basic and diluted loss per ordinary share
|
| | | | (16) | | | | | | (6.95) | | | | | | (9.66) | | | | | | (33.26) | | |
Weighted average number of ordinary shares outstanding
|
| | | | 222,212 | | | | | | 222,212 | | | | | | 222,212 | | | | | | 43,206 | | |
|
| | |
Year Ended
December 31, 2020 |
| |
Year Ended
December 31, 2019 |
| |
Change
|
| |||||||||
Cash used in operating activities
|
| | | $ | (1,353,959) | | | | | $ | (660,007) | | | | | $ | (693,952) | | |
Cash used in investing activities
|
| | | $ | (432,203) | | | | | $ | (677,145) | | | | | $ | (244,942) | | |
Cash provided by financing activities
|
| | | $ | 1,032,008 | | | | | $ | 2,116,312 | | | | | $ | (1,084,304) | | |
| | |
Nine Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2021 |
| |
Change
|
| |||||||||
Cash used in operating activities
|
| | | $ | (2,774,139) | | | | | $ | (690,371) | | | | | $ | (2,083,768) | | |
Cash used in investing activities
|
| | | $ | (554,858) | | | | | $ | (381,159) | | | | | $ | (173,699) | | |
Cash provided by financing activities
|
| | | $ | 4,070,078 | | | | | $ | 239,864 | | | | | $ | 3,830,214 | | |
Contractual Obligation
|
| |
Less than
One Year |
| |
1 – 5 Years
|
| |
Over 5 Years
|
| |||||||||
Land and buildings
|
| | | $ | 283,976 | | | | | $ | 1,135,903 | | | | | $ | 3,762,677 | | |
Contractual Obligation
|
| |
Less than
One Year |
| |
1 – 5 Years
|
| |
Over 5 Years
|
| |||||||||
Land and buildings . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | $ | 45,662 | | | | | $ | 1,369,863 | | | | | $ | 3,150,685 | | |
Presented in $
|
| |
Note
|
| |
Nine Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2020 |
| |
Year Ended
December 31, 2020 |
| |
Year Ended
December 31, 2019 |
| ||||||||||||
Sales
|
| | | | 17,359 | | | | | | 1,788 | | | | | | 2,062 | | | | | | — | | | | | |
Cost of Sales
|
| | | | (11,469) | | | | | | (1,531) | | | | | | (1,809) | | | | | | — | | | | | |
Presented in $
|
| |
Note
|
| |
Nine Months Ended
September 30, 2021 |
| |
Nine Months Ended
September 30, 2020 |
| |
Year Ended
December 31, 2020 |
| |
Year Ended
December 31, 2019 |
| ||||||||||||
Gross Profit
|
| | | | 5,890 | | | | | | 257 | | | | | | 253 | | | | | | — | | | | | |
General & administrative expenses
|
| | | | (93,650) | | | | | | (514) | | | | | | (1,101) | | | | | | (32) | | | | | |
License costs
|
| | | | (1,267) | | | | | | (894) | | | | | | (1,491) | | | | | | — | | | | | |
Salaries and wages
|
| | | | (339,556) | | | | | | — | | | | | | — | | | | | | — | | | | | |
Consulting and professional fees
|
| | | | (565,614) | | | | | | — | | | | | | (31) | | | | | | — | | | | | |
Loss from operating activities
|
| | | | (994,197) | | | | | | (1,151) | | | | | | (2,623) | | | | | | (32) | | | | | |
Finance income
|
| | | | 50 | | | | | | 1 | | | | | | 1 | | | | | | 2 | | | | ||
Finance expenses | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||
Foreign exchange through profit and loss
|
| | | | 35,911 | | | | | | — | | | | | | — | | | | | | — | | | | ||
Other income
|
| | | | 54 | | | | | | 136 | | | | | | 108 | | | | | | — | | | | ||
Net Profit / (Loss)
|
| | | | (958,182) | | | | | | (1,014) | | | | | | (2,261) | | | | | | (30) | | | | | |
Exchange differences on foreign
currency translation |
| | | | 5,678 | | | | | | (22) | | | | | | (116) | | | | | | (1) | | | | ||
Comprehensive Profit / (Loss)
|
| | | | (952,504) | | | | | | (1,036) | | | | | | (2,377) | | | | | | (31) | | | | | |
Basic and dilutive loss per ordinary share
|
| | | | (476,252) | | | | | | (518.20) | | | | | | (1,189) | | | | | | (15.50) | | | | | |
Weighted average number of ordinary shares outstanding
|
| | | | 2 | | | | | | 2 | | | | | | 2 | | | | | | 2 | | | | | |
|
| | |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||
|
2020
|
| |
2019
|
| ||||||||||||||
Cash provided by operating activities
|
| | | $ | 1,491 | | | | | $ | 17,677 | | | | | $ | (16,186) | | |
Cash used in investing activities
|
| | | $ | — | | | | | $ | (15,625) | | | | | $ | (15,625) | | |
Cash provided by financing activities
|
| | | $ | — | | | | | $ | 2 | | | | | $ | (2) | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | |||||||||
| | |
2021
|
| |
2020
|
| |
Change
|
| | |||||||||||
Cash used by operating activities
|
| | | $ | (785,048) | | | | | $ | (2,862) | | | | | $ | (782,186) | | | | ||
Cash used in investing activities
|
| | | $ | — | | | | | $ | (14,779) | | | | | $ | (14,799) | | | | ||
Cash provided by financing activities
|
| | | $ | 969,282 | | | | | $ | 18,140 | | | | | $ | 951,142 | | | |
Name
|
| |
Position
|
| |
Age
|
|
Louisa Mojela | | |
Executive Chairman and Director
|
| |
65
|
|
Tejinder Virk | | |
Chief Executive Officer and Director
|
| |
40
|
|
Aslihan Akkar-Schenkl | | |
President
|
| |
43
|
|
Trevor Scott | | |
Chief Financial Officer
|
| |
42
|
|
Philip van den Berg(1) | | |
Director
|
| |
63
|
|
Charles Kié(2) | | |
Director
|
| |
58
|
|
Gila Jones(2) | | |
Director Nominee
|
| |
40
|
|
Gugu Dingaan(2) | | |
Director Nominee
|
| |
46
|
|
| | |
Salary
($) |
| |
Stock
awards ($) |
| |
Option
awards ($) |
| |
Non-equity
incentive plan compensation ($) |
| |
Change in
pension value and nonqualified deferred compensation earnings |
| |
All other
compensation ($) |
| |
Total
($) |
| |||||||||||||||||||||
Louisa Mojela (Executive
Chairman) |
| | | | 270,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 270,000 | | |
Tejinder Virk (Chief Executive Officer)
|
| | | | 337,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,798 | | | | | | 347,298 | | |
Charles Kié* (Lead Independent Director*)
|
| | | | 77,590 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 77,590 | | |
Philip Van Den Berg (Non Executive Director)
|
| | | | 25,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,000 | | |
Trevor Scott* (Chief Financial Officer)
|
| | | | 231,099 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 231,099 | | |
Dr. Aslihan Akkar-Schenkl (President)
|
| | | | 59,508 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,079 | | | | | | 64,587 | | |
Total | | | | | 1,000,697 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 14.877 | | | | | | 1,015,574 | | |
Name of Beneficial Owner
|
| |
Common Shares
Beneficially Owned Immediately Prior to this Offering(1) |
| |
Common Shares
Beneficially Owned Immediately After this Offering(1) |
| ||||||||||||||||||
|
Shares
|
| |
Percentage
|
| |
Shares
|
| |
Percentage
|
| ||||||||||||||
Executive Officers, Directors, and Director Nominees: | | | | | | | | | | | | | | | | | | | | | | | | | |
Louisa Mojela, Executive Chairman and Director
|
| | | | 2,855,602 | | | | | | 12.8% | | | | | | 2,855,602 | | | | | | 10.0% | | |
Tejinder Virk, Chief Executive Officer and Director
|
| | | | 1,875,602 | | | | | | 8.4% | | | | | | 1,875,602 | | | | | | 6.6% | | |
Dr. Aslihan Akkar-Schenkl, President
|
| | | | — | | | | | | * | | | | | | — | | | | | | * | | |
Trevor Scott, Chief Financial Officer
|
| | | | 40,000 | | | | | | * | | | | | | 40,000 | | | | | | * | | |
Philip van den Berg, Director(2)
|
| | | | — | | | | | | * | | | | | | — | | | | | | * | | |
Charles Kié, Director
|
| | | | 29,200 | | | | | | * | | | | | | 29,200 | | | | | | * | | |
Gila Jones, Director Nominee
|
| | | | 20,000 | | | | | | * | | | | | | 20,000 | | | | | | * | | |
Gugu Dingaan, Director Nominee
|
| | | | 4,000 | | | | | | * | | | | | | 4,000 | | | | | | * | | |
All executive officers, directors, and director nominees as a
group |
| | | | 4,824,404 | | | | | | 21.6% | | | | | | 4,824,404 | | | | | | 16.9% | | |
5% or more Shareholders: | | | | | | | | | | | | | | | | | | | | | | | | | |
Halo Collective Inc.(3)
|
| | | | 11,029,212 | | | | | | 49.3% | | | | | | 12,341,060(6) | | | | | | 43.2%(6) | | |
1306077 B.C. LTD.(4)
|
| | | | 2,100,000 | | | | | | 9.4% | | | | | | 2,100,000 | | | | | | 7.4% | | |
Raj Beri(5)
|
| | | | 1,875,602 | | | | | | 8.4% | | | | | | 1,875,602 | | | | | | 6.6% | | |
Underwriters
|
| |
Number of Shares
|
| |||
Boustead Securities, LLC
|
| | | | 4,000,000 | | |
Total
|
| | | | 4,000,000 | | |
| | |
Per Share
|
| |
Total Without
Exercise of Over-Allotment Option |
| |
Total With
Exercise of Over-Allotment Option |
| |||||||||
Public offering price
|
| | | $ | 5.00 | | | | | $ | 20,000,000 | | | | | $ | 23,000,000 | | |
Underwriting discounts (7%)(1)
|
| | | $ | 0.35 | | | | | $ | 1,400,000 | | | | | $ | 1,610,000 | | |
Non-accountable expense allowance
|
| | | $ | 0.50 | | | | | $ | 200,000 | | | | | $ | 230,000 | | |
Proceeds, before expenses, to us
|
| | | $ | 4.15 | | | | | $ | 18,400,000 | | | | | $ | 21,390,000 | | |
Description
|
| |
Amount
|
| |||
U.S. Securities and Exchange Commission registration fee
|
| | | $ | 2,782.39 | | |
Financial Industry Regulatory Authority filing fee
|
| | | $ | 3,268.62 | | |
Nasdaq Capital Market entry and listing fee
|
| | | $ | 75,000 | | |
Accounting and Audit fees and expenses
|
| | | $ | 160,500 | | |
Legal fees and expenses
|
| | | $ | 250,000 | | |
Printing expenses
|
| | | $ | 15,000 | | |
Miscellaneous
|
| | | $ | 50,000 | | |
Total
|
| | | $ | 556,551.01 | | |
| | |
Page
|
| |||
AKANDA CORP. | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
| | | | F-8 | | | |
| | | | F-9 | | | |
| | | | F-10 | | | |
CANNAHEALTH LTD. | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-17 | | | |
| | | | F-18 | | | |
| | | | F-19 | | | |
| | | | F-20 | | | |
| | | | F-21 | | | |
BOPHELO HOLDINGS LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-27 | | | |
| | | | F-28 | | | |
| | | | F-29 | | | |
| | | | F-30 | | | |
| | | | F-31 | | | |
BOPHELO BIO SCIENCE AND WELLNESS (PTY) LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-37 | | | |
| | | | F-38 | | | |
| | | | F-39 | | | |
| | | | F-40 | | | |
| | | | F-41 | | |
| | |
Page
|
| |||
CANMART LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-57 | | | |
| | | | F-58 | | | |
| | | | F-59 | | | |
| | | | F-60 | | | |
| | | | F-61 | | | |
Audited Financial Statements of Akanda Corp. (Expressed in United States Dollars) | | | | | | | |
| | | | F-78 | | | |
| | | | F-79 | | | |
| | | | F-80 | | | |
| | | | F-81 | | | |
| | | | F-82 | | | |
| | | | F-83 | | | |
Audited Financial Statements of Cannahealth Limited (Expressed in United States Dollars) | | | | | | | |
| | | | F-90 | | | |
| | | | F-91 | | | |
| | | | F-92 | | | |
| | | | F-93 | | | |
| | | | F-94 | | | |
| | | | F-95 | | | |
Audited Financial Statements of Bophelo Holdings Ltd (Expressed in United States Dollars) | | | | | | | |
| | | | F-101 | | | |
| | | | F-102 | | | |
| | | | F-103 | | | |
| | | | F-104 | | | |
| | | | F-105 | | | |
| | | | F-106 | | | |
Audited Financial Statements of Bophelo Bioscience and Wellness (PTY) Ltd. for the Fiscal Years Ended December 31, 2020 and 2019 (Expressed in United States Dollars)
|
| | | | | | |
| | | | F-112 | | | |
| | | | F-113 | | | |
| | | | F-114 | | | |
| | | | F-115 | | | |
| | | | F-116 | | | |
| | | | F-117 | | |
| | |
Page
|
| |||
Audited Financial Statements of Canmart Ltd for the Fiscal Years Ended December 31, 2020 and 2019
(Expressed in United States Dollars) |
| | | | | | |
| | | | F-137 | | | |
| | | | F-138 | | | |
| | | | F-139 | | | |
| | | | F-140 | | | |
| | | | F-141 | | | |
| | | | F-142 | | |
| | |
Page
|
| |||
Unaudited Pro Forma Consolidated Financial Statements of Akanda Corp. as at December 31, 2020 (Expressed in United States Dollars)
|
| | | | | | |
| | | | F-152 | | | |
| | | | F-153 | | | |
| | | | F-155 | | |
| | |
Page
|
| |||
AKANDA CORP. | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
| | | | F-8 | | | |
| | | | F-9 | | | |
| | | | F-10 | | |
| | |
Note
|
| |
September 30,
2021 (Unaudited) |
| |
August 31,
2021 |
| |||||||||
ASSETS | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | |
Cash, held in trust
|
| | | | | | | | | $ | 250,001 | | | | | | 250,001 | | |
Total Current Assets
|
| | | | | | | | | $ | 250,001 | | | | | | 250,001 | | |
Total Assets
|
| | | | | | | | | $ | 250,001 | | | | | | 250,001 | | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | | | | | | | $ | 92,055 | | | | | | 27,635 | | |
Loan from shareholder
|
| | | | | | | | | | 4,226 | | | | | | 4,263 | | |
Total Current Liabilities
|
| | | | | | | | | $ | 96,281 | | | | | | 31,898 | | |
Total Liabilities
|
| | | | | | | | | $ | 96,281 | | | | | | 31,898 | | |
Shareholders’ Equity | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 5 | | | | | $ | 250,001 | | | | | | 250,001 | | |
Accumulated deficit
|
| | | | | | | | | | (96,179) | | | | | | (31,898) | | |
Accumulated other comprehensive loss
|
| | | | | | | | | | (102) | | | | | | — | | |
Total Shareholders’ Equity
|
| | | | | | | | | $ | 153,720 | | | | | | 218,103 | | |
Total Liabilities and Shareholders’ Equity
|
| | | | | | | | | $ | 250,001 | | | | | | 250,001 | | |
| | |
July 16, 2021 (Inception)
to September 30, 2021 |
| |||
Operating expenses: | | | | | | | |
Accounting and audit fees
|
| | | $ | 16,822 | | |
Consultant fees
|
| | | | 32,904 | | |
Directors’ remuneration
|
| | | | 12,275 | | |
Legal fees
|
| | | | 39,474 | | |
Total operating expenses
|
| | | | 101,475 | | |
Other income: | | | | | | | |
Foreign exchange gains
|
| | | $ | 5,296 | | |
Total other income
|
| | | | 5,296 | | |
Net loss
|
| | | | (96,179) | | |
Other comprehensive loss
|
| | | | (102) | | |
Net and comprehensive loss
|
| | | $ | (96,281) | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Accumulated
Other Comprehensive Loss |
| |
Total
Shareholders’ Equity |
| |||||||||||||||
Inception, July 16, 2021
|
| | | | | | | | | $ | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
Share issuance
|
| | | | 5 | | | | | | 250,001 | | | | | | — | | | | | | — | | | | | | 250,001 | | |
Net loss
|
| | | | | | | | | | — | | | | | | (31,898) | | | | | | — | | | | | | (31,898) | | |
Balance, August 31, 2021
|
| | | | | | | | | $ | 250,001 | | | | | $ | (31,898) | | | | | | — | | | | | $ | 218,103 | | |
Net loss
|
| | | | | | | | | | — | | | | | | (64,281) | | | | | | (102) | | | | | | (64,383) | | |
Balance, September 30, 2021
|
| | | | | | | | | $ | 250,001 | | | | | $ | (96,179) | | | | | | (102) | | | | | $ | 153,720 | | |
| | |
Note
|
| |
July 16, 2021
(Inception) to September 30, 2021 |
| |||
Cash flows from Operating Activities | | | | | | | | | | |
Net loss
|
| | | | | | $ | (96,179) | | |
Foreign exchange movements through profit and loss
|
| | | | | | | (5,296) | | |
Increase in accounts payable
|
| | | | | | | 92,055 | | |
Cash used in operating activities
|
| | | | | | $ | (9,420) | | |
Cash flows from Financing Activities | | | | | | | | | | |
Proceeds from share issuances
|
| | | | | | $ | 250,001 | | |
Loan received from shareholder
|
| | | | | | | 4,226 | | |
Cash flows provided by financing activities
|
| | | | | | $ | 254,227 | | |
Effect of foreign exchange translation
|
| | | | | | | 5,194 | | |
Change in cash during the period
|
| | | | | | $ | 250,001 | | |
Cash at beginning of period
|
| | | | | | | — | | |
Cash at end of period
|
| | | | | | $ | 250,001 | | |
| | |
Number of
common shares |
| |
Share capital
2021 |
| ||||||
Inception at July 16, 2021
|
| | | | — | | | | | | — | | |
Shares issued to founders
|
| | | | 5,626,806 | | | | | | 1 | | |
Shares issued- August 26, 2021
|
| | | | 468,900 | | | | | | 250,000 | | |
Issued and outstanding at September 30, 2021
|
| | | | 6,095,706 | | | | | $ | 250,001 | | |
| | |
Page
|
| |||
CANNAHEALTH LTD. | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-17 | | | |
| | | | F-18 | | | |
| | | | F-19 | | | |
| | | | F-20 | | | |
| | | | F-21 | | |
| | |
Note
|
| |
September 30, 2021
(Unaudited) |
| |
December 31, 2020
|
| |||||||||
ASSETS | | | | | | | | | | | | | | | | | | | |
Current assets
|
| | | | | | | | | | — | | | | | | | | |
Cash, held in trust
|
| | | | | | | | | $ | 1,396 | | | | | | 1,477 | | |
Total Assets
|
| | | | | | | | | $ | 1,396 | | | | | | 1,477 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | | | | | | | | | | | | | |
Shareholder’s Equity
|
| | | | | | | | | | — | | | | | | | | |
Share capital
|
| | | | 5 | | | | | $ | 1,477 | | | | | | 1,477 | | |
Accumulated deficit
|
| | | | | | | | | | — | | | | | | | | |
Accumulated comprehensive loss
|
| | | | | | | | | | (81) | | | | | | | | |
Total Shareholder’s Equity
|
| | | | | | | | | | 1,396 | | | | | | 1,477 | | |
Total Liabilities and Shareholder’s Equity
|
| | | | | | | | | $ | 1,396 | | | | | | 1,477 | | |
| | |
January 1, 2021 to
September 30, 2021 |
| |
July 1, 2020
(Inception) to September 30, 2020 |
| ||||||
Net sales
|
| | | $ | — | | | | | | — | | |
Other comprehensive income: | | | | | | | | | | | | | |
Foreign exchange loss
|
| | | | (81) | | | | | | — | | |
Net and comprehensive loss
|
| | | $ | (81) | | | | | | — | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Accumulated
Comprehensive Loss |
| |
Total
Shareholder’s Equity |
| |||||||||||||||
Inception, July 1, 2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Share issuance at inception
|
| | | | 5 | | | | | $ | 1,477 | | | | | $ | — | | | | | $ | — | | | | | | 1,477 | | |
Balance, September 30 , 2020
|
| | | | | | | | | $ | 1,477 | | | | | $ | — | | | | | $ | — | | | | | | 1,477 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance, January 1, 2021
|
| | | | | | | | | $ | 1,477 | | | | | $ | — | | | | | $ | — | | | | | | 1,477 | | |
Effect of foreign exchange translation
|
| | | | 5 | | | | | $ | — | | | | | | — | | | | | | (81) | | | | | | (81) | | |
Balance, September 30, 2021
|
| | | | | | | | | $ | 1,477 | | | | | $ | — | | | | | $ | (81) | | | | | | 1,396 | | |
| | |
January 1, 2021 to
September 30, 2021 |
| |
July 1, 2020
(Inception) to September 30, 2020 |
| ||||||
Cash Flows from Operating Activities
|
| | | $ | — | | | | | | — | | |
Cash Flows from Financing Activities
|
| | | $ | — | | | | | | — | | |
Proceeds from share issue
|
| | | $ | — | | | | | | 1,477 | | |
Cash flows provided by financing activities
|
| | | $ | — | | | | | | 1,477 | | |
Net change in cash
|
| | | $ | — | | | | | | — | | |
Cash at beginning of period
|
| | | $ | 1,477 | | | | | | — | | |
Foreign currency translation movement
|
| | | $ | (81) | | | | | | — | | |
Cash at end of period
|
| | | $ | 1,396 | | | | | | 1,477 | | |
| | |
Number of
ordinary shares |
| |
Share capital
2021 |
| ||||||
Inception at July 1, 2020 | | | | | | | | | | | | | |
Share issuance at inception
|
| | | | 1,200 | | | | | $ | 1,477 | | |
Issued and outstanding at September 30, 2020
|
| | | | | | | | | | 1,477 | | |
Issued and outstanding at January 1, 2021
|
| | | | | | | | | | 1,477 | | |
Issued and outstanding at September 30, 2021
|
| | | | | | | | | | 1,477 | | |
| | |
Page
|
| |||
BOPHELO HOLDINGS LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-27 | | | |
| | | | F-28 | | | |
| | | | F-29 | | | |
| | | | F-30 | | | |
| | | | F-31 | | |
| | |
Note
|
| |
September 30, 2021
(Unaudited) |
| |
August 31, 2021
|
| |||||||||
ASSETS | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | $ | 135 | | | | | | 138 | | |
Total assets
|
| | | | | | | | | $ | 135 | | | | | | 138 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | | | | | | | | | | | | | |
Shareholder’s Equity | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 5 | | | | | $ | 138 | | | | | | 138 | | |
Accumulated other comprehensive loss
|
| | | | | | | | | | (3) | | | | | | — | | |
Total Shareholder’s Equity
|
| | | | | | | | | $ | 135 | | | | | | 138 | | |
Total Liabilities and Shareholder’s Equity
|
| | | | | | | | | $ | 135 | | | | | | 138 | | |
| | |
August 4, 2021
(Inception) to September 30, 2021 |
| |||
Net sales
|
| | | $ | — | | |
Foreign exchange translation through other comprehensive loss
|
| | | | (3) | | |
Net and Comprehensive loss
|
| | | $ | (3) | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Accumulated other
comprehensive loss |
| |
Total
Shareholder’s Equity |
| | | |||||||||||||||||||
Inception, August 4, 2021
|
| | | | | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | | — | | | | | ||||
Share issuance at inception
|
| | | | 5 | | | | | | 138 | | | | | | — | | | | | | — | | | | | | 138 | | | | | ||||
Balance, August 31, 2021
|
| | | | | | | | | $ | 138 | | | | | $ | — | | | | | $ | — | | | | | | 138 | | | | | ||||
Effect of foreign exchange
|
| | | | 5 | | | | | | | | | | | | — | | | | | | (3) | | | | | | — | | | | | | | | |
Balance, September 30, 2021
|
| | | | | | | | | $ | 138 | | | | | $ | — | | | | | $ | (3) | | | | | | 135 | | | | |
| | |
August 4, 2021
(Inception) to September 30, 2021 |
| |||
Cash Flows from Operating Activities
|
| | | $ | | | |
Cash flows from Financing Activities
|
| | | | — | | |
Proceeds from share issue
|
| | | | 138 | | |
Cash flows provided by financing activities
|
| | | | 138 | | |
Effect of foreign exchange
|
| | | | (3) | | |
Net change in cash
|
| | | | 135 | | |
Cash at beginning of period
|
| | | | — | | |
Cash at end of period
|
| | | $ | 135 | | |
| | |
Number of
ordinary shares |
| |
Share capital
2021 |
| ||||||
Inception at August 4, 2021 | | | | | | | | | | | | | |
Share issuance at inception
|
| | | | 100 | | | | | $ | 138 | | |
Issued and outstanding at August 31, 2021
|
| | | | 100 | | | | | $ | 138 | | |
Less: Effect of foreign exchange
|
| | | | | | | | | | (3) | | |
Issued and outstanding at September 30, 2021
|
| | | | 100 | | | | | $ | 135 | | |
| | |
Page
|
| |||
BOPHELO BIO SCIENCE AND WELLNESS (PTY) LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-37 | | | |
| | | | F-38 | | | |
| | | | F-39 | | | |
| | | | F-40 | | | |
| | | | F-41 | | |
| | |
Note
|
| |
$
|
| |
September 30,
2021 (Unaudited) |
| |
December 31,
2020 |
| |||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | | | | | 480,444 | | | | | | 10,120 | | |
Prepayments
|
| | | | 8 | | | | | | | | | 108,659 | | | | | | 113,485 | | |
Shareholders’ loan
|
| | | | | | | | | | | | | 6 | | | | | | 7 | | |
Total Current Assets
|
| | | | | | | | | | | | | 589,109 | | | | | | 123,612 | | |
Non-Current Assets | | | | | | | | | | | | | | | | | | | | | | |
Property, plant and equipment
|
| | | | 5 | | | | | | | | | 1,515,188 | | | | | | 742,887 | | |
Capital work in progress
|
| | | | 9 | | | | | | | | | 487,875 | | | | | | 883,145 | | |
Right-of-use asset
|
| | | | 7 | | | | | | | | | 2,035,074 | | | | | | 2,199,779 | | |
Intangible assets
|
| | | | 6 | | | | | | | | | 264,188 | | | | | | 304,260 | | |
Total Non-Current Assets
|
| | | | | | | | | | | | | 4,302,325 | | | | | | 4,130,071 | | |
Total Assets
|
| | | | | | | | | | | | | 4,891,434 | | | | | | 4,253,683 | | |
LIABILITIES AND SHAREHOLDERS’ DEFICIT | | | | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | | | | |
Trade and other payables
|
| | | | 12 | | | | | | | | | 245,600 | | | | | | 182,878 | | |
Loans and borrowings
|
| | | | 10 | | | | | | | | | 10,603,444 | | | | | | 2,263,605 | | |
Lease liability
|
| | | | 11 | | | | | | | | | 45,662 | | | | | | 283,976 | | |
Total Current Liabilities
|
| | | | | | | | | | | | | 10,894,706 | | | | | | 2,730,459 | | |
Non-Current Liabilities | | | | | | | | | | | | | | | | | | | | | | |
Lease liability
|
| | | | 11 | | | | | | | | | 2,432,073 | | | | | | 2,598,176 | | |
Loans and borrowings
|
| | | | 10 | | | | | | | | | — | | | | | | 3,977,108 | | |
Total Non-Current Liabilities
|
| | | | | | | | | | | | | 2,432,073 | | | | | | 6,575,284 | | |
Total Liabilities
|
| | | | | | | | | | | | | 13,326,779 | | | | | | 9,305,743 | | |
Shareholders’ Deficit | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 13 | | | | | | | | | 156 | | | | | | 156 | | |
Reserves
|
| | | | 13 | | | | | | | | | 7 | | | | | | 7 | | |
Accumulated deficit
|
| | | | | | | | | | | | | (8,626,701) | | | | | | (5,160,401) | | |
Accumulated other comprehensive income
|
| | | | | | | | | | | | | 191,193 | | | | | | 108,177 | | |
Total Shareholders’ Deficit
|
| | | | | | | | | | | | | (8,435,345) | | | | | | (5,052,061) | | |
Total Liabilities and Shareholders’ Deficit
|
| | | | | | | | | | | | | 4,891,434 | | | | | | 4,253,683 | | |
| | |
$
|
| |
2021
(Unaudited) |
| |
2020
(Unaudited) |
| ||||||
Sales
|
| | | | | | | — | | | | | | — | | |
Cost of sales (excluding amortization and depreciation)
|
| | | | | | | — | | | | | | — | | |
| | | | | | | | — | | | | | | — | | |
Operating Expenses: | | | | | | | | | | | | | | | | |
Amortization and depreciation
|
| | | | | | | 231,427 | | | | | | 173,971 | | |
Consulting and professional fees
|
| | | | | | | 504,866 | | | | | | 454,721 | | |
General & Administration expenses
|
| | | | | | | 1,317,292 | | | | | | 163,654 | | |
Office expenses
|
| | | | | | | 33,216 | | | | | | 14,171 | | |
Personnel expenses
|
| | | | | | | 955,032 | | | | | | 223,345 | | |
Short term accommodation expense
|
| | | | | | | — | | | | | | 31,912 | | |
Travel expenses
|
| | | | | | | 57,063 | | | | | | 4,789 | | |
Total Operating expenses
|
| | | | | | | (3,098,896) | | | | | | (1,066,563) | | |
Loss from operations
|
| | | | | | | (3,098,896) | | | | | | (1,066,563) | | |
Other Income / (Expense): | | | | | | | | | | | | | | | | |
Interest income
|
| | | | | | | 25,782 | | | | | | 9,529 | | |
Interest expenses
|
| | | | | | | (393,186) | | | | | | (487,069) | | |
Total Other Income / Expense
|
| | | | | | | (367,404) | | | | | | (477,540) | | |
Loss before tax
|
| | | | | | | (3,466,300) | | | | | | (1,544,103) | | |
Income tax expense
|
| | | | | | | — | | | | | | — | | |
Net loss for the year
|
| | | | | | | (3,466,300) | | | | | | (1,544,103) | | |
Other comprehensive income: | | | | | | | | | | | | | | | | |
Foreign currency translation
|
| | | | | | | 83,016 | | | | | | 604,902 | | |
Total comprehensive loss for the year
|
| | | | | | | (3,383,284) | | | | | | (939,201) | | |
Basic and diluted loss per ordinary share
|
| | | | | | | (16) | | | | | | (6.95) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | 222,212 | | | | | | 222,212 | | |
| | |
$
|
| |
Number of
Shares |
| |
Share
Capital |
| |
Reserves
|
| |
Accumulated
Deficit |
| |
Accumulated other
comprehensive income |
| |
Total
Shareholders’ Deficit |
| ||||||||||||||||||
Balance, January 1, 2020
|
| | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (2,862,091) | | | | | | (42,565) | | | | | | (2,904,493) | | |
Effect of foreign exchange translation
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 604,902 | | | | | | 604,902 | | |
Net loss
|
| | | | | | | | | | | | | | | | | | | | | | | | | (1,544,103) | | | | | | | | | | | | (1,544,103) | | |
Balance, September 30, 2020
|
| | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (4,406,194) | | | | | | 562,337 | | | | | | (3,843,694) | | |
Balance, January 1, 2021
|
| | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (5,160,401) | | | | | | 108,177 | | | | | | (5,052,061) | | |
Effect of foreign exchange translation
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 83,016 | | | | | | 83,016 | | |
Net loss
|
| | | | | | | | | | | | | | | | | | | | | | | | | (3,466,300) | | | | | | | | | | | | (3,466,300) | | |
Balance September 30, 2021
|
| | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (8,626,701) | | | | | | 191,193 | | | | | | (8,435,345) | | |
| | |
$
|
| |
2021
(Unaudited) |
| |
2020
(Unaudited) |
| ||||||
Cash Flows from Operating Activities | | | | | | | | | | | | | | | | |
Net loss
|
| | | | | | | (3,466,300) | | | | | | (1,544,103) | | |
Non-cash items included in net income: | | | | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | | | | 231,427 | | | | | | 173,971 | | |
Interest expenses
|
| | | | | | | 393,186 | | | | | | 487,069 | | |
Write off of property, plant and equipment
|
| | | | | | | — | | | | | | — | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | | | | |
Prepayments
|
| | | | | | | 4,826 | | | | | | (98,457) | | |
Trade and other payables
|
| | | | | | | 62,723 | | | | | | 291,149 | | |
Net cash used in operating activities
|
| | | | | | | (2,774,139) | | | | | | (690,371) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | | | | |
Additions to capital WIP
|
| | | | | | | — | | | | | | (146,866) | | |
Additions to property, plant and equipment
|
| | | | | | | (554,858) | | | | | | (241,208) | | |
Proceeds from advances received
|
| | | | | | | — | | | | | | 6,916 | | |
Net cash used in investing activities
|
| | | | | | | (554,858) | | | | | | (381,159) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | | | | |
Repayment of lease liability
|
| | | | | | | (404,417) | | | | | | — | | |
Loans received
|
| | | | | | | 4,474,495 | | | | | | 239,864 | | |
Net cash provided by financing activities:
|
| | | | | | | 4,070,078 | | | | | | 239,864 | | |
Net change in cash
|
| | | | | | | 741,081 | | | | | | (831,665) | | |
Effects of currency translation on cash
|
| | | | | | | (270,758) | | | | | | 82,597 | | |
Cash at beginning of period
|
| | | | | | | 10,120 | | | | | | 818,447 | | |
Cash at end of period
|
| | | | | | | 480,443 | | | | | | 69,379 | | |
Supplemental cash flow disclosure
|
| | | | | | | | | | | | | | | |
Interest paid
|
| | | | | | $ | — | | | | | $ | — | | |
Tax paid
|
| | | | | | $ | — | | | | | $ | — | | |
| Plant and equipment | | | 10 years | |
| Leasehold improvements | | | 20 years | |
| Motor vehicles | | | 4 years | |
| Computers | | | 3 years | |
| Furniture and fixtures | | | 6 years | |
| | |
$
|
| |
Plant and
equipment |
| |
Leasehold
improvement |
| |
Motor
vehicles |
| |
Computers
|
| |
Furniture
and Fixtures |
| |
Total
|
| ||||||||||||||||||
Cost at January 1, 2020
|
| |
|
| | | | 449,044 | | | | | | 304,770 | | | | | | 38,427 | | | | | | — | | | | | | — | | | | | | 792,241 | | |
Additions
|
| | | | | | | 172,369 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 172,369 | | |
Write-offs
|
| | | | | | | (23,748) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (23,748) | | |
Foreign exchange movements
|
| | | | | | | (11,304) | | | | | | (11,333) | | | | | | (1,429) | | | | | | — | | | | | | — | | | | | | (24,066) | | |
Cost at December 31, 2020
|
| | | | | | | 586,361 | | | | | | 293,437 | | | | | | 36,998 | | | | | | — | | | | | | — | | | | | | 916,796 | | |
Additions
|
| | | | | | | 32,418 | | | | | | 822,928 | | | | | | 87,044 | | | | | | 4,213 | | | | | | 4,437 | | | | | | 879,954 | | |
Cost at September 30, 2021
|
| | | | | | | 618,779 | | | | | | 1,116,365 | | | | | | 50,046 | | | | | | 4,213 | | | | | | 4,437 | | | | | | 1,793,750 | | |
Accumulated Depreciation at January 1, 2020
|
| | | | | | | (67,113) | | | | | | (22,489) | | | | | | (4,803) | | | | | | — | | | | | | — | | | | | | (94,405) | | |
| | |
$
|
| |
Plant and
equipment |
| |
Leasehold
improvement |
| |
Motor
vehicles |
| |
Computers
|
| |
Furniture
and Fixtures |
| |
Total
|
| ||||||||||||||||||
Depreciation
|
| | | | | | | (60,212) | | | | | | (14,950) | | | | | | (9,425) | | | | | | — | | | | | | — | | | | | | (84,587) | | |
Foreign exchange movements
|
| | | | | | | 3,615 | | | | | | 1,114 | | | | | | 354 | | | | | | — | | | | | | — | | | | | | 5,083 | | |
Accumulated Depreciation at December 31, 2020
|
| | | | | | | (123,710) | | | | | | (36,325) | | | | | | (13,874) | | | | | | — | | | | | | — | | | | | | (173,909) | | |
Depreciation
|
| | | | | | | (48,297) | | | | | | (55,434) | | | | | | (8,335) | | | | | | (412) | | | | | | (287) | | | | | | (112,765) | | |
Foreign exchange movements
|
| | | | | | | 5,208 | | | | | | 9,257 | | | | | | 636 | | | | | | 7 | | | | | | 5 | | | | | | 15,113 | | |
Accumulated Depreciation at September 30, 2021
|
| | | | | | | (166,799) | | | | | | (82,502) | | | | | | (21,573) | | | | | | (405) | | | | | | (282) | | | | | | (278,562) | | |
Carrying value at January 1, 2020
|
| | | | | | | 381,931 | | | | | | 282,281 | | | | | | 33,624 | | | | | | — | | | | | | — | | | | | | 697,836 | | |
Additions
|
| | | | | | | 172,369 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 172,369 | | |
Disposals
|
| | | | | | | (23,748) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (23,748) | | |
Depreciation
|
| | | | | | | (60,212) | | | | | | (14,950) | | | | | | (9,425) | | | | | | — | | | | | | — | | | | | | (84,587) | | |
Foreign exchange movements
|
| | | | | | | (7,689) | | | | | | (10,219) | | | | | | (1,075) | | | | | | — | | | | | | — | | | | | | (18,983) | | |
Carrying value at December 31, 2020
|
| | | | | | | 462,651 | | | | | | 257,112 | | | | | | 23,124 | | | | | | — | | | | | | — | | | | | | 742,887 | | |
Additions
|
| | | | | | | 32,418 | | | | | | 822,928 | | | | | | 87,044 | | | | | | 4,213 | | | | | | 4,437 | | | | | | 879,954 | | |
Disposals | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Depreciation
|
| | | | | | | (48,297) | | | | | | (55,434) | | | | | | (8,335) | | | | | | (412) | | | | | | (287) | | | | | | (112,765) | | |
Foreign exchange movements
|
| | | | | | | 5,208 | | | | | | 9,257 | | | | | | 636 | | | | | | 7 | | | | | | 5 | | | | | | 15,113 | | |
Carrying value at September 30, 2021
|
| | | | | | | 451,981 | | | | | | 1,026,862 | | | | | | 28,473 | | | | | | 3,808 | | | | | | 4,064 | | | | | | 1,515,188 | | |
|
| | |
$
|
| |
Licenses
|
| |
Total
|
| ||||||
Cost at January 1, 2020
|
| | | | | | | 421,348 | | | | | | 421,348 | | |
Foreign exchange movements
|
| | | | | | | (15,668) | | | | | | (15,668) | | |
Cost at December 31, 2020
|
| | | | | | | 405,680 | | | | | | 405,680 | | |
Foreign exchange movements
|
| | | | | | | (14,291) | | | | | | (14,291) | | |
Cost at September 30, 2021
|
| | | | | | | 391,389 | | | | | | 391,389 | | |
Accumulated amortization at January 1, 2020
|
| | | | | | | (63,202) | | | | | | (63,202) | | |
Amortization
|
| | | | | | | (41,337) | | | | | | (41,337) | | |
Foreign exchange translation
|
| | | | | | | 3,119 | | | | | | 3,119 | | |
Accumulated amortization at December 31, 2020
|
| | | | | | | (101,420) | | | | | | (101,420) | | |
Accumulated amortization at December 31, 2020
|
| | | | | | | (101,420) | | | | | | (101,420) | | |
Amortization
|
| | | | | | | (29,880) | | | | | | (29,880) | | |
Foreign exchange translation
|
| | | | | | | 4,908 | | | | | | 4,908 | | |
Accumulated amortization at December 31, 2020
|
| | | | | | | (127,202) | | | | | | (127,202) | | |
Carrying value at January 1, 2020
|
| | | | | | | 358,146 | | | | | | 358,146 | | |
Amortization
|
| | | | | | | (41,337) | | | | | | (41,337) | | |
| | |
$
|
| |
Licenses
|
| |
Total
|
| ||||||
Foreign exchange translation
|
| | | | | | | (12,549) | | | | | | (12,549) | | |
Carrying value at December 31, 2020
|
| | | | | | | 304,260 | | | | | | 304,260 | | |
Amortization
|
| | | | | | | (29,880) | | | | | | (29,880) | | |
Foreign exchange translation
|
| | | | | | | (9,383) | | | | | | (9,383) | | |
Carrying value at September 30, 2021
|
| | | | | | | 264,188 | | | | | | 264,188 | | |
|
| | |
$
|
| |
Land Lease
|
| |
Total
|
| |||||||||
Cost: | | | | | | | | | | | | | | | | | | | |
Balance as at January 1, 2020
|
| | | | | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Additions during the year
|
| | | | | | | | | | — | | | | | | — | | |
Balance as at December 31, 2020
|
| | | | | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Additions during the year
|
| | | | | | | | | | — | | | | | | — | | |
foreign exchange movement
|
| | | | (178,028) | | | | | | (178,028) | | | | |||||
Balance as at September 30, 2021
|
| | | | | | | | | | 2,325,799 | | | | | | 2,503,827 | | |
Accumulated Depreciation: | | | | | | | | | | | | | | | | | | | |
Balance as at January 1, 2020
|
| | | | | | | | | | 93,893 | | | | | | 93,893 | | |
Charge for the year
|
| | | | | | | | | | 122,820 | | | | | | 122,820 | | |
Effects of Currency Translation
|
| | | | | | | | | | 87,335 | | | | | | 87,335 | | |
Balance as at December 31, 2020
|
| | | | | | | | | | 304,048 | | | | | | 304,048 | | |
Charge for the year
|
| | | | | | | | | | 88,781 | | | | | | 88,781 | | |
Effects of Currency Translation
|
| | | | | | | | | | (102,044) | | | | | | (102,044) | | |
Balance as at September 30, 2021
|
| | | | | | | | | | (290,725) | | | | | | (290,725) | | |
Net Book Value: | | | | | | | | | | | | | | | | | | | |
At December 31, 2020
|
| | | | | | | | | | 2,199,779 | | | | | | 2,199,779 | | |
At September 31, 2021
|
| | | | | | | | | | 2,035,074 | | | | | | 2,035,074 | | |
| | |
$
|
| |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Prepaid expenses
|
| | | | | | | 108,659 | | | | | | 113,485 | | |
| | | | | | | | 108,659 | | | | | | 113,485 | | |
| | |
$
|
| |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Capital work in progress
|
| | | | | | | 487,875 | | | | | | 883,145 | | |
| | | | | | | | 487,875 | | | | | | 883,145 | | |
| | |
$
|
| |
Louisa
Mojela |
| |
Granny
Seape |
| |
1942
Capital |
| |
Seedy
Lette |
| |
GMG/
Middleton |
| |
Halo
Collective Inc. |
| |
Total
|
| |||||||||||||||||||||
Value at January 1, 2020
|
| | | | | | | 2,191,396 | | | | | | 300,477 | | | | | | 1,285,146 | | | | | | 240,251 | | | | | | 1,049,322 | | | | | | (6,916) | | | | | | 5,059,674 | | |
Loans issued
|
| | | | | | | 438,420 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 731,375 | | | | | | 1,169,796 | | |
Loans carried off
|
| | | | | | | (1,147,260) | | | | | | (307,337) | | | | | | (1,314,361) | | | | | | (245,712) | | | | | | (1,030,158) | | | | | | 4,044,828 | | | | | | — | | |
Loans repaid
|
| | | | | | | (137,788) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (137,788) | | |
Interest on loans
|
| | | | | | | 278,901 | | | | | | 12,656 | | | | | | 54,190 | | | | | | 10,130 | | | | | | 753 | | | | | | — | | | | | | 356,631 | | |
Foreign exchange movements
|
| | | | | | | (71,182) | | | | | | (5,796) | | | | | | (24,974) | | | | | | (4,669) | | | | | | (19,917) | | | | | | (81,061) | | | | | | (207,598) | | |
Value at December 31, 2020
|
| | | | | | | 1,552,487 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,688,226 | | | | | | 6,240,714 | | |
Current portion
|
| | | | | | | 1,552,487 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 711,118 | | | | | | 2,263,605 | | |
Non-current portion
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,977,108 | | | | | | 3,977,108 | | |
Value at December 31,
2020 |
| | | | | | | 1,552,487 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,688,226 | | | | | | 6,240,714 | | |
Loans issued
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,474,495 | | | | | | 4,474,495 | | |
Loans carried off
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Loans repaid
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Interest on loans
|
| | | | | | | 190,220 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 190,221 | | |
Foreign exchange movements
|
| | | | | | | (1,690) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (300,296) | | | | | | (301,986) | | |
Value at September 30, 2021
|
| | | | | | | 1,741,017 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,862,425 | | | | | | 10,603,444 | | |
Current portion
|
| | | | | | | 1,741,017 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,862,425 | | | | | | 10,603,444 | | |
Non-current portion
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Value at September 30, 2021
|
| | | | | | | 1,741,017 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,862,425 | | | | | | 10,603,444 | | |
| | |
$
|
| |
Land
Lease |
| |
Total
|
| ||||||
Balance as at January 1, 2020
|
| | | | | | | 2,408,074 | | | | | | 2,408,074 | | |
Interest Expense
|
| | | | | | | 284,950 | | | | | | 284,950 | | |
Lease payments during the year
|
| | | | | | | — | | | | | | — | | |
| | |
$
|
| |
Land
Lease |
| |
Total
|
| ||||||
Effects of Currency Translation
|
| | | | | | | (105,816) | | | | | | (105,816) | | |
| | | | | | | | 2,882,152 | | | | | | 2,882,152 | | |
Less: current portion
|
| | | | | | | (283,976) | | | | | | (283,976) | | |
As at December 31, 2020
|
| | | | | | | 2,598,176 | | | | | | 2,598,176 | | |
Interest Expense
|
| | | | | | | 202,965 | | | | | | 202,965 | | |
Lease payments during the year
|
| | | | | | | (511,686) | | | | | | (511,686) | | |
Effects of Currency Translation
|
| | | | | | | (95,426) | | | | | | (95,426) | | |
| | | | | | | | 2,477,735 | | | | | | 2,477,735 | | |
Less: current portion
|
| | | | | | | (45,662) | | | | | | (46,517) | | |
As at September 30, 2021
|
| | | | | | | 2,432,073 | | | | | | 2,432,073 | | |
|
| | |
$
|
| |
September 31,
2021 |
| |||
Amounts payable within 1 year
|
| | | | | | | 45,662 | | |
Amounts payable between 1 and 5 years
|
| | | | | | | 1,369,863 | | |
Amounts payable after 5 years
|
| | | | | | | 3,150,685 | | |
Total payments
|
| | | | | | | 4,566,210 | | |
Interest on lease agreement
|
| | | | | | | 2,088,475 | | |
| | | | | | | | 2,432,073 | | |
| | |
$
|
| |
September 31,
2021 |
| |
December 31,
2020 |
| ||||||
Trade payables
|
| | | | | | | 99,158 | | | | | | 107,839 | | |
Directors’ remuneration payable
|
| | | | | | | 75,693 | | | | | | 48,584 | | |
Consulting fees payable
|
| | | | | | | 61,561 | | | | | | — | | |
LRA Duties
|
| | | | | | | 13 | | | | | | — | | |
Accrued payroll taxes
|
| | | | | | | 9,175 | | | | | | 26,455 | | |
| | | | | | | | 245,600 | | | | | | 182,878 | | |
| | |
$
|
| |
Number of
shares |
| |
Par value
|
| |
Share
capital |
| |
Reserves
|
| |
Total
|
| |||||||||||||||
Balance at December 31, 2020
|
| | | | | | | 222,212 | | | | | | 0.0007 | | | | | | 156 | | | | | | 7 | | | | | | 163 | | |
Issued and outstanding as at September 30 2021
|
| | | | | | | 222,212 | | | | | | 0.0007 | | | | | | 156 | | | | | | 7 | | | | | | 163 | | |
| | |
$
|
| |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Net loss for the year
|
| | | | | | | (3,466,300) | | | | | | (2,298,310) | | |
Statutory income tax rate
|
| | | | | | | 25% | | | | | | 25% | | |
Expected tax recovery at statutory income tax rates
|
| | | | | | | (866,575) | | | | | | (574,578) | | |
Change in deferred tax assets not recognized
|
| | | | | | | 866,575 | | | | | | 574,578) | | |
| | | | | | | | — | | | | | | —) | | |
| | |
$
|
| |
September 30,
2021 |
| |
December 31,
2020 |
| ||||||
Deferred tax assets | | | | | | | | | | | | | | | | |
Net operating loss carried forward
|
| | | | | | | 8,626,701 | | | | | | 5,160,401) | | |
Deferred tax assets not recognized
|
| | | | | | | (8,626,701) | | | | | | (5,160,401) | | |
Net deferred tax assets
|
| | | | | | | — | | | | | | —) | | |
| | |
Page
|
| |||
CANMART LTD | | | | | | | |
Unaudited Condensed Financial Statements: | | | | | | | |
| | | | F-57 | | | |
| | | | F-58 | | | |
| | | | F-59 | | | |
| | | | F-60 | | | |
| | | | F-61 | | |
Presented in US Dollars
|
| |
Note
|
| |
$
|
| |
September 30,
2021 (Unaudited) |
| |
December 31,
2020 |
| |||||||||
ASSETS
|
| | | | | | | |
|
| | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | | | | | 227,856 | | | | | | 1,907 | | |
Inventory
|
| | | | | | | | | | | | | 12,597 | | | | | | 611 | | |
Trade and other receivables
|
| | | | | | | | | | | | | 105,142 | | | | | | — | | |
Total Current Assets
|
| | | | | | | | | | | | | 345,595 | | | | | | 2,518 | | |
Non-Current Assets | | | | | | | | | | | | | | | | | | | | | | |
Intangible assets
|
| | | | 5 | | | | | | | | | 17,022 | | | | | | 17,146 | | |
Total Non-Current Assets
|
| | | | | | | | | | | | | 17,022 | | | | | | 17,146 | | |
Total Assets
|
| | | | | | | | | | | | | 362,617 | | | | | | 19,664 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY (DEFICIT) | | | | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | | | | |
Trade and other payables
|
| | | | 7 | | | | | | | | | 327,198 | | | | | | 1,024 | | |
| | | | | | | | | | | | | | 327,198 | | | | | | 1,024 | | |
Non-Current Liabilities | | | | | | | | | | | | | | | | | | | | | | |
Shareholder loan
|
| | | | | | | | | | | | | 969,282 | | | | | | — | | |
| | | | | | | | | | | | | | 969,282 | | | | | | — | | |
Total Liabilities
|
| | | | | | | | | | | | | 1,296,480 | | | | | | 1,024 | | |
Shareholder’s Equity (Deficit) | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 8 | | | | | | | | | 3 | | | | | | 3 | | |
Accumulated deficit
|
| | | | | | | | | | | | | (960,473) | | | | | | (2,291) | | |
Other reserves
|
| | | | | | | | | | | | | 21,046 | | | | | | 21,046 | | |
Accumulated other comprehensive income/ (loss)
|
| | | | | | | | | | | | | 5,561 | | | | | | (117) | | |
| | | | | | | | | | | | | | (933,863) | | | | | | 18,640 | | |
Total Liabilities and Shareholder’s Equity (Deficit)
|
| | | | | | | | | | | | | 362,617 | | | | | | 19,664 | | |
Presented in US Dollars
|
| |
Note
|
| |
2021
|
| |
2020
|
| ||||||
Sales
|
| | | | | | | 17,359 | | | | | | 1,788 | | |
Cost of sales
|
| | | | | | | (11,469) | | | | | | (1,531) | | |
| | | | | | | | 5,890 | | | | | | 257 | | |
Consulting and professional fees
|
| | | | | | | 565,614 | | | | | | — | | |
License costs
|
| | | | | | | 1,267 | | | | | | 894 | | |
Salaries and wages
|
| | | | | | | 339,556 | | | | | | — | | |
General & administrative expenses
|
| | | | | | | 93,650 | | | | | | 514 | | |
Total operating expenses
|
| | | | | | | 1,000,087 | | | | | | 1,408 | | |
Loss from Operations
|
| | | | | | | (994,197) | | | | | | (1,151) | | |
Other Income (Expense) | | | | | | | | | | | | | | | | |
Interest income
|
| | | | | | | 50 | | | | | | 1 | | |
Foreign exchange through profit and loss
|
| | | | | | | 35,911 | | | | | | — | | |
Other income
|
| | | | | | | 54 | | | | | | 136 | | |
Total Other Income (Expense)
|
| | | | | | | 36,015 | | | | | | 137 | | |
Net loss before income tax
|
| | | | | | | (958,182) | | | | | | (1,014) | | |
Income tax expense
|
| | | | | | | — | | | | | | — | | |
Net Loss for the Year
|
| | | | | | | (958,182) | | | | | | (1,014) | | |
Other Comprehensive Loss: | | | | | | | | | | | | | | | | |
Exchange differences on foreign currency translation
|
| | | | | | | 5,678 | | | | | | (22) | | |
Net and Comprehensive Loss
|
| | | | | | | (952,504) | | | | | | (1,036) | | |
Basic and dilutive loss per ordinary share
|
| | | | | | | (476,252) | | | | | | (518.20) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | 2 | | | | | | 2 | | |
Presented in US Dollars
|
| |
$
|
| |
Number
of Shares |
| |
Share
Capital |
| |
Accumulated
other comprehensive income/(loss) |
| |
Accumulated
Deficit |
| |
Other
Reserves |
| |
Total
Equity (Deficit) |
| ||||||||||||||||||
Balance, January 1, 2020
|
| |
|
| | | | 2 | | | | | | 3 | | | | | | (1) | | | | | | (30) | | | | | | — | | | | | | (28) | | |
Issue of shares
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | |
Currency translation
|
| | | | | | | — | | | | | | — | | | | | | (21) | | | | | | — | | | | | | | | | | | | (21) | | |
Contribution to reserves by owners
of the Company |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 18,140 | | | | | | 18,140 | | |
Net loss
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,014) | | | | | | — | | | | | | (1,014) | | |
Balance, September 30, 2020
|
| | | | | | | 2 | | | | | | 3 | | | | | | (22) | | | | | | (1,044) | | | | | | 18,140 | | | | | | 17,077 | | |
Balance, January 1, 2021
|
| | | | | | | 2 | | | | | | 3 | | | | | | (117) | | | | | | (2,291) | | | | | | 21,046 | | | | | | 18,641 | | |
Effect of foreign currency translation
|
| | | | | | | — | | | | | | — | | | | | | 5,678 | | | | | | — | | | | | | — | | | | | | 5,678 | | |
Net loss
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (958,182) | | | | | | | | | | | | (958,182) | | |
Balance, September 30, 2021
|
| | | | | | | 2 | | | | | | 3 | | | | | | 5,561 | | | | | | (960,473) | | | | | | 21,046 | | | | | | (933,863) | | |
Presented in US Dollars
|
| |
Note
|
| |
$
|
| |
January 1, 2020 to
September 30, 2021 |
| |
January 1, 2020 to
September 30, 2020 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | | | | | | | |
Net loss
|
| | | | | | | | | | (958,182) | | | | | | (1,014) | | |
Adjustments to reconcile net income to net cash provided by
(used in) operating activities: |
| | | | | | | | | | — | | | | | | — | | |
Foreign exchange through profit and loss
|
| | | | | | | | | | (35,911) | | | | | | | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | | | | | | | |
Increase in inventory
|
| | | | | | | | | | (11,986) | | | | | | — | | |
Increase in trade and other payables
|
| | | | | | | | | | 326,173 | | | | | | 303 | | |
Increase in trade and other receivables
|
| | | | | | | | | | (105,142) | | | | | | (2,151) | | |
Net cash provided by operating activities
|
| | | | | | | | | | (785,048) | | | | | | (2,862) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | | | | | | | |
Payments for acquisition of cannabis licenses
|
| | | | | | | | | | — | | | | | | (14,779) | | |
Net cash used in investing activities
|
| | | | | | | | | | — | | | | | | (14,779) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | | | | | | | |
Additional contributions to owners’ capital
|
| | | | | | | | | | — | | | | | | 18,140 | | |
Proceeds from shareholder’s loan
|
| | | | | | | | | | 969,282 | | | | | | — | | |
Net cash provided by financing activities:
|
| | | | | | | | | | 969,282 | | | | | | 18,140 | | |
Effects of foreign exchange translation on cash
|
| | | | | | | | | | 41,715 | | | | | | (1,163) | | |
Net change in cash
|
| | | | | | | | | | 225,949 | | | | | | (664) | | |
Cash at beginning of year
|
| | | | | | | | | | 1,907 | | | | | | 1,116 | | |
Cash at end of year
|
| | | | | | | | | | 227,856 | | | | | | 452 | | |
Supplemental cash flow information: | | | | | | | | | | | | | | | | | | | |
Interest paid
|
| | | | | | | | | | — | | | | | | — | | |
Taxes paid
|
| | | | | | | | | | — | | | | | | — | | |
Non-cash Investing and Financing Activities: | | | | | | | | | | | | | | | | | | | |
Contributions to reserves by shareholders due to waiver of balance due to related party
|
| | | | | | | | | | — | | | | | | — | | |
| | |
$
|
| |
Licences
|
| |
Total
|
| ||||||
Cost at January 1, 2020
|
| |
|
| | | | 16,563 | | | | | | 16,563 | | |
Amortisation
|
| | | | | | | — | | | | | | — | | |
Foreign exchange translation
|
| | | | | | | 583 | | | | | | 583 | | |
Cost at December 31, 2020
|
| | | | | | | 17,146 | | | | | | 17,146 | | |
Accumulated amortisation at December 31, 2020
|
| | | | | | | — | | | | | | — | | |
Carrying value at December 31, 2020
|
| | | | | | | 17,146 | | | | | | 17,146 | | |
Foreign exchange translation
|
| | | | | | | (124) | | | | | | (124) | | |
Amortisation
|
| | | | | | | — | | | | | | — | | |
Cost at September 30, 2021
|
| | | | | | | 17,022 | | | | | | 17,022 | | |
Accumulated amortisation at December 31,2020
|
| | | | | | | — | | | | | | — | | |
Carrying value at September 30,2021
|
| | | | | | | 17,022 | | | | | | 17,022 | | |
| | |
$
|
| |
September, 30 2021
|
| |
December, 31 2020
|
| ||||||
Trade receivables
|
| |
|
| | | | 12,366 | | | | | | 523 | | |
Allowance for bad debts
|
| | | | | | | — | | | | | | (523) | | |
VAT receivable
|
| | | | | | | 11,531 | | | | | | — | | |
PAYE receivables
|
| | | | | | | 81,245 | | | | | | — | | |
| | | | | | | | 105,142 | | | | | | — | | |
| | |
$
|
| |
September 30, 2021
|
| |
December 31, 2020
|
| ||||||
Net loss for the period
|
| |
|
| | | | (958,182) | | | | | | (2,261) | | |
Statutory income tax rate
|
| | | | | | | 18% | | | | | | 18% | | |
Expected tax recovery at statutory income tax rates
|
| | | | | | | (172,472) | | | | | | (407) | | |
Change in deferred tax assets not recognized
|
| | | | | | | 172,472 | | | | | | 407 | | |
| | | | | | | | —) | | | | | | —) | | |
| | |
$
|
| |
September 30, 2021
|
| |
December 31, 2020
|
| ||||||
Deferred tax assets | | | | | | | | | | | | | | | | |
Net operating loss carried forward
|
| |
|
| | | | 960,473) | | | | | | 2,291) | | |
Deferred tax assets not recognized
|
| | | | | | | (960,473) | | | | | | (2,291) | | |
Net deferred tax assets
|
| | | | | | | —) | | | | | | —) | | |
| | | | | |
Akanda
Corp. |
| |
Cannahealth
|
| |
Bophelo
Holdings |
| |
Canmart
|
| |
Bophelo
Bio Science |
| |
Total
|
| |
Proforma
Adjustments |
| |
Notes
|
| |
Proforma
As Adjusted |
| ||||||||||||||||||||||||
| | |
$
|
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| | | | | | | | | | | | | | | | ||||||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| |
|
| | | | 250,001 | | | | | | 1,396 | | | | | | 135 | | | | | | 227,856 | | | | | | 480,444 | | | | | | 959,832 | | | | | | 23,644,920 | | | |
4(a,c&d)
|
| | | | 24,604,752 | | |
Trade and other
receivables |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 105,142 | | | | | | — | | | | | | 105,142 | | | | | | — | | | | | | | | | 105,142 | | |
Prepayments
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 108,659 | | | | | | 108,659 | | | | | | — | | | | | | | | | 108,659 | | |
Inventory
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,597 | | | | | | — | | | | | | 12,597 | | | | | | — | | | | | | | | | 12,597 | | |
Loan to shareholder
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6 | | | | | | 6 | | | | | | — | | | | | | | | | 6 | | |
Total Current Assets
|
| | | | | | | 250,001 | | | | | | 1,396 | | | | | | 135 | | | | | | 345,595 | | | | | | 589,109 | | | | | | 1,186,236 | | | | | | 23,644,920 | | | | | | | | | 24,831,156 | | |
Non-Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Property, plant and equipment
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,515,188 | | | | | | 1,515,188 | | | | | | — | | | | | | | | | 1,515,188 | | |
Capital work in progress
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 487,875 | | | | | | 487,875 | | | | | | — | | | | | | | | | 487,875 | | |
Right-of-use asset
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,035,074 | | | | | | 2,035,074 | | | | | | — | | | | | | | | | 2,035,074 | | |
Intangible assets
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 17,022 | | | | | | 264,188 | | | | | | 281,210 | | | | | | — | | | | | | | | | 281,210 | | |
Total Non-Current Assets
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 17,022 | | | | | | 4,302,325 | | | | | | 4,319,347 | | | | | | — | | | | | | | | | 4,319,347 | | |
Total Assets
|
| | | | | | | 250,001 | | | | | | 1,396 | | | | | | 135 | | | | | | 362,617 | | | | | | 4,891,434 | | | | | | 5,505,583 | | | | | | 23,644,920 | | | | | | | | | 29,150,503 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Trade and other payables
|
| | | | | | | 92,055 | | | | | | — | | | | | | — | | | | | | 327,198 | | | | | | 245,600 | | | | | | 664,853 | | | | | | — | | | | | | | | | 664,853 | | |
Loans and borrowings
|
| | | | | | | 4,226 | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,603,444 | | | | | | 10,603,444 | | | | | | (8,009,785) | | | |
4(b&e)
|
| | | | 2,593,659 | | |
Lease liability
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 45,662 | | | | | | 45,662 | | | | | | — | | | | | | | | | 45,662 | | |
Total Current Liabilities
|
| | | | | | | 96,281 | | | | | | — | | | | | | — | | | | | | 327,198 | | | | | | 10,894,706 | | | | | | 11,313,959 | | | | | | (8,009,785)- | | | | | | | | | 3,304,174 | | |
Non-Current Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Lease liability
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,432,073 | | | | | | 2,432,073 | | | | | | — | | | | | | | | | 2,432,073 | | |
Loans and borrowings
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 969,282 | | | | | | — | | | | | | 973,508 | | | | | | — | | | | | | | | | 973,508 | | |
Total Non-Current
Liabilities |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 969,282 | | | | | | 2,432,073 | | | | | | 3,405,581 | | | | | | — | | | | | | | | | 3,405,581 | | |
Total Liabilities
|
| | | | | | | 96,281 | | | | | | — | | | | | | — | | | | | | 1,296,480 | | | | | | 13,326,779 | | | | | | 14,719,540 | | | | | | (8,009,785) | | | | | | | | | 6,709,755 | | |
Shareholders’ Equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Capital
|
| | | | | | | 250,001 | | | | | | 1,477 | | | | | | 138 | | | | | | 3 | | | | | | 156 | | | | | | 251,775 | | | | | | 45,531,612 | | | |
4(a,bc,d&e)
|
| | | | 45,783,387 | | |
Reserves
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 21,046 | | | | | | 7 | | | | | | 21,053 | | | | | | — | | | |
—
|
| | | | 21,053 | | |
Accumulated deficit
|
| | | | | | | (96,179) | | | | | | — | | | | | | — | | | | | | (960,473) | | | | | | (8,626,701) | | | | | | (9,683,353) | | | | | | (749,469) | | | | | | | | | (10,432,822) | | |
Other comprehensive
income |
| | | | | | | (102) | | | | | | (81) | | | | | | (3) | | | | | | 5,561 | | | | | | 191,193 | | | | | | 196,568 | | | | | | (13,127,438) | | | |
4(a)
|
| | | | (12,930,870)) | | |
Total Shareholders’ equity
|
| | | | | | | 153,720 | | | | | | 1,396 | | | | | | 135 | | | | | | (933,863) | | | | | | (8,435,345) | | | | | | (9,213,957) | | | | | | 31,654,705 | | | | | | | | | 22,440,748 | | |
Total Liabilities and Shareholders’ Equity
|
| | | | | | | 250,001 | | | | | | 1,396 | | | | | | 135 | | | | | | 362,617 | | | | | | 4,891,434 | | | | | | 5,505,583 | | | | | | 23,644,920 | | | | | | | | | 29,150,503 | | |
| | | | | |
Akanda
Corp. |
| |
Cannahealth
|
| |
Bophelo
Holdings |
| |
Canmart
|
| |
Bophelo
Bio Science |
| |
Total
|
| |
Proforma
Adjustments |
| |
Notes
|
| |
Proforma
As Adjusted |
| ||||||||||||||||||||||||
| | |
$
|
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| |
30 September
2021 |
| | | | | | | | | | | | | | | | | | | | | | |||||||||||||||
Sales
|
| |
|
| | | | — | | | | | | — | | | | | | — | | | | | | 17,359 | | | | | | — | | | | | | 17,359 | | | | | | — | | | | | | | | | 17,359 | | |
Cost of sales
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,469) | | | | | | — | | | | | | (11,469) | | | | | | — | | | | | | | | | (11,469) | | |
Gross Profit
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,890 | | | | | | — | | | | | | 5,890 | | | | | | — | | | | | | | | | 5,890 | | |
Accounting & Audit
|
| | | | | | | 16,822 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,822 | | | | | | — | | | | | | | | | 16,822 | | |
Amortisation and
depreciation |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | 231,427 | | | | | | 231,427 | | | | | | — | | | | | | | | | 231,427 | | |
Consulting and professional
fees |
| | | | | | | 32,904 | | | | | | — | | | | | | — | | | | | | 565,614 | | | | | | 504,866 | | | | | | 1,103,384 | | | | | | — | | | | | | | | | 1,103,384 | | |
General & administrative
expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 93,650 | | | | | | 1,317,292 | | | | | | 1,410,942 | | | | | | — | | | | | | | | | 1,410,942 | | |
Legal fees
|
| | | | | | | 39,474 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 39,474 | | | | | | — | | | | | | | | | 39,474 | | |
License costs
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,267 | | | | | | — | | | | | | 1,267 | | | | | | | | | | | | | | | 1,267 | | |
Office expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 33,216 | | | | | | 33,216 | | | | | | — | | | | | | | | | 33,216 | | |
Personnel expenses
|
| | | | | | | 12,275 | | | | | | — | | | | | | — | | | | | | 339,556 | | | | | | 955,032 | | | | | | 1,306,863 | | | | | | — | | | | | | | | | 1,306,863 | | |
Travel expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 57,063 | | | | | | 57,063 | | | | | | — | | | | | | | | | 57,063 | | |
Loss from Operations
|
| | | | | | | (101,475) | | | | | | — | | | | | | — | | | | | | (994,917) | | | | | | (3,098,896) | | | | | | (4,194,568) | | | | | | — | | | | | | | | | (4,194,568) | | |
Interest income
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 50 | | | | | | 25,782 | | | | | | 25,832 | | | | | | — | | | | | | | | | 25,832 | | |
Interest expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (393,186) | | | | | | (393,186) | | | | | | (749,469) | | | |
4(b)
|
| | | | (1,142,655) | | |
Foreign exchange gain
|
| | | | | | | 5,296 | | | | | | — | | | | | | — | | | | | | 35,911 | | | | | | — | | | | | | 41,207 | | | | | | | | | | | | | | | 41,207 | | |
Other income
|
| | | | | | | | | | | | | | | | | | | | | | | | | 54 | | | | | | — | | | | | | 54 | | | | | | | | | | | | | | | 54 | | |
Net loss from operations
|
| | | | | | | (96,179) | | | | | | — | | | | | | — | | | | | | (958,182) | | | | | | (3,466,300) | | | | | | (4,520,661) | | | | | | (749,469) | | | | | | | | | (5,270,130) | | |
Foreign exchange translation
|
| | | | | | | (102) | | | | | | (81) | | | | | | (3) | | | | | | 5,678 | | | | | | 83,016 | | | | | | 88,508 | | | | | | — | | | | | | | | | 88,508 | | |
Net and comprehensive loss
|
| | | | | | | (96,281) | | | | | | (81) | | | | | | (3) | | | | | | (952,504) | | | | | | (3,383,284) | | | | | | (4,432,153) | | | | | | (749,469) | | | | | | | | | (5,181,622) | | |
Basic and dilutive loss per ordinary
share |
| | | | | | | (0.02) | | | | | | — | | | | | | — | | | | | | (476,252) | | | | | | (15.23) | | | | | | | | | | | | | | | | | | | | | (0.18) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | 6,095,706 | | | | | | 1,200 | | | | | | 100 | | | | | | 2 | | | | | | 222,212 | | | | | | | | | | | | 21,817,577 | | | |
4(a,b,c,d&e)
|
| | | | 28,136,797 | | |
| | | | | |
Akanda
Corp. |
| |
Cannahealth
|
| |
Bophelo
Holdings |
| |
Canmart
|
| |
Bophelo Bio
Science |
| |
Total
|
| |
Proforma
Adjustments |
| |
Notes
|
| |
Proforma
As Adjusted |
| ||||||||||||||||||
| | |
$
|
| |
N/A
|
| |
30 September
2020 |
| |
N/A
|
| |
30 September
2020 |
| |
30 September
2020 |
| | | | | | | | | | | | | | | | | | | | | | |||||||||
Sales
|
| | | | | | | | | | — | | | | | | | | | 1,788 | | | | | | — | | | | | | 1,788 | | | | | | — | | | | | | | | | 1,788 | | |
Cost of sales
|
| | | | | | | | | | — | | | | | | | | | (1,531) | | | | | | — | | | | | | (1,531) | | | | | | — | | | | | | | | | (1,531) | | |
Gross Profit
|
| | | | | | | | | | — | | | | | | | | | 257 | | | | | | — | | | | | | 257 | | | | | | — | | | | | | | | | 257 | | |
Amortization and depreciation
|
| | | | | | | | | | — | | | | | | | | | — | | | | | | (173,971) | | | | | | (173,971 | | | | | | — | | | | | | | | | (173,971) | | |
Consulting and professional
fees |
| | | | | | | | | | — | | | | | | | | | — | | | | | | (454,721) | | | | | | (454,721 | | | | | | — | | | | | | | | | (454,721) | | |
General & Administration
expenses |
| | | | | | | | | | — | | | | | | | | | (1,408) | | | | | | (163,654) | | | | | | (165,062 | | | | | | — | | | | | | | | | (163,654) | | |
Office expenses
|
| | | | | | | | | | — | | | | | | | | | | | | | | | (14,171) | | | | | | (14,171 | | | | | | — | | | | | | | | | (14,171) | | |
Personnel expenses
|
| | | | | | | | | | — | | | | | | | | | | | | | | | (223,345) | | | | | | (223,345 | | | | | | | | | | | | | | | (223,345) | | |
Short term accommodation
expense |
| | | | | | | | | | — | | | | | | | | | | | | | | | (31,912) | | | | | | (31,912 | | | | | | — | | | | | | | | | (31,912) | | |
Travel expenses
|
| | | | | | | | | | — | | | | | | | | | | | | | | | (4,789) | | | | | | (4,789 | | | | | | — | | | | | | | | | (4,789) | | |
Loss from Operations
|
| | | | | | | | | | — | | | | | | | | | (1,151) | | | | | | (1,066,563)) | | | | | | (1,067,714) | | | | | | — | | | | | | | | | (1,067,714) | | |
Interest income
|
| | | | | | | | | | — | | | | | | | | | 1 | | | | | | 9,529 | | | | | | 9,530 | | | | | | — | | | | | | | | | 9,530 | | |
Interest expenses
|
| | | | | | | | | | — | | | | | | | | | — | | | | | | (487,069) | | | | | | (487,069) | | | | | | (749,469) | | | |
4(b)
|
| | | | (1,236,538) | | |
Foreign exchange gain
|
| | | | | | | | | | — | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | | | | — | | |
Other income
|
| | | | | | | | | | | | | | | | | | | 136 | | | | | | — | | | | | | 136 | | | | | | | | | | | | | | | 136 | | |
Net loss from operations
|
| | | | | | | | | | — | | | | | | | | | (1,014) | | | | | | (1,544,103) | | | | | | (1,545,117) | | | | | | (749,469) | | | | | | | | | (2,294,586) | | |
Foreign exchange translation
|
| | | | | | | | | | — | | | | | | | | | (22) | | | | | | 604,902 | | | | | | 604,880 | | | | | | — | | | | | | | | | 604,880 | | |
Net and comprehensive loss
|
| | | | | | | | | | — | | | | | | | | | (1,036) | | | | | | (939,201) | | | | | | (940,237) | | | | | | (749,469) | | | | | | | | | (1,689,706) | | |
Basic and dilutive loss per ordinary share
|
| | | | | | | | | | — | | | | | | | | | (518.20) | | | | | | (6.95) | | | | | | | | | | | | | | | | | | | | | (0.06) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | | | | 1,200 | | | | | | | | | 2 | | | | | | 222,212 | | | | | | | | | | | | 21,817,677 | | | |
4(a,b,c,d&e)
|
| | | | 28,136,797 | | |
| | |
Page
|
|
AKANDA CORP. | | | | |
| | | ||
Financial Statements: | | | | |
| | | ||
| | | ||
| | | ||
| | | ||
| | |
| | |
Note
|
| |
August 31,
2021 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current Assets
|
| | | | | | | | | | | | |
Cash, held in trust
|
| | | | | | | | | $ | 250,001 | | |
Total Current Assets
|
| | | | | | | | | | 250,001 | | |
Total Assets
|
| | | | | | | | | $ | 250,001 | | |
LIABILITIES AND SHAREHOLDERS’ DEFICIT | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | |
Accounts payable
|
| | | | | | | | | $ | 27,635 | | |
Loan from shareholder
|
| | | | | | | | | | 4,263 | | |
Total Liabilities
|
| | | | | | | | | | 31,898 | | |
Shareholders’ Equity | | | | | | | | | | | | | |
Share capital
|
| | | | 5 | | | | | $ | 250,001 | | |
Accumulated deficit
|
| | | | | | | | | | (31,898) | | |
Total Shareholders’ Equity
|
| | | | | | | | | | 218,103 | | |
Total Liabilities and Shareholders’ Equity
|
| | | | | | | | | $ | 250,001 | | |
| | |
July 16, 2021
(Inception) to August 31, 2021 |
| |||
Operating expenses: | | | | | | | |
Legal fees
|
| | | $ | 31,898 | | |
Total operating expenses
|
| | | | 31,898 | | |
Net and comprehensive loss
|
| | | $ | (31,898) | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| ||||||||||||
Inception, July 16, 2021
|
| | | | | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Share issuance
|
| | | | 5 | | | | | | 250,001 | | | | | | — | | | | | | 250,001 | | |
Net loss
|
| | | | | | | | | | — | | | | | | (31,898) | | | | | | (31,898) | | |
Balance, August 31, 2021
|
| | | | | | | | | $ | 250,001 | | | | | $ | (31,898) | | | | | $ | 218,103 | | |
| | |
Note
|
| |
July 16, 2021
(Inception) to August 31, 2021 |
| |||
Cash flows from Operating Activities | | | | | | | | | | |
Net income
|
| | | | | | $ | (31,898) | | |
Increase in accounts payable
|
| | | | | | | 27,635 | | |
Cash used in operating activities
|
| | | | | | $ | (4,263) | | |
Cash flows from Financing Activities | | | | | | | | | | |
Proceeds from share issuances
|
| | | | | | $ | 250,001 | | |
Loan received from shareholder
|
| | | | | | | 4,263 | | |
Cash flows provided by financing activities
|
| | | | | | $ | 254,264 | | |
Change in cash during the period
|
| | | | | | $ | 250,001 | | |
Cash at beginning of period
|
| | | | | | | — | | |
Cash at end of period
|
| | | | | | $ | 250,001 | | |
| | |
Number of
common shares |
| |
Share capital
2021 |
| ||||||
Inception at July 16, 2021
|
| | | | — | | | | | | — | | |
Shares issued to founders
|
| | | | 5,626,806 | | | | | | 1 | | |
Shares issued- August 26, 2021
|
| | | | 468,900 | | | | | | 250,000 | | |
Issued and outstanding at August 31, 2021
|
| | | | 6,095,706 | | | | | $ | 250,001 | | |
| | |
Page
|
|
CANNAHEALTH LIMITED | | | | |
| | | ||
Financial Statements: | | | | |
| | | ||
| | | ||
| | | ||
| | | ||
| | |
| | |
Note
|
| |
December 31,
2020 |
| |||
ASSETS | | | | | | | | | | |
Current assets | | | | | | | | | | |
Cash, held in trust
|
| | | | | | $ | 1,477 | | |
Total Assets
|
| | | | | | $ | 1,477 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | | | | |
Shareholder’s Equity | | | | | | | | | | |
Share capital
|
| |
5
|
| | | $ | 1,477 | | |
Accumulated deficit
|
| | | | | | | — | | |
Total Shareholder’s Equity
|
| | | | | | | 1,477 | | |
Total Liabilities and Shareholder’s Equity
|
| | | | | | $ | 1,477 | | |
| | |
July 1, 2020
(Inception) to December 31, 2020 |
| |||
Net sales
|
| | | $ | — | | |
Net and comprehensive loss
|
| | | $ | — | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholder’s Equity |
| ||||||||||||
Inception, July 1, 2020
|
| | | | | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Share issuance at inception
|
| | | | 5 | | | | | | 1,477 | | | | | | — | | | | | | 1,477 | | |
Balance, December 31, 2020
|
| | | | | | | | | $ | 1,477 | | | | | $ | — | | | | | $ | 1,477 | | |
| | |
July 1, 2020
(Inception) to December 31, 2020 |
| |||
Cash Flows from Operating Activities
|
| | | $ | — | | |
Cash Flows from Financing Activities | | | | | | | |
Proceeds from share issue
|
| | | | 1,477 | | |
Cash flows provided by financing activities
|
| | | | 1,477 | | |
Net change in cash
|
| | | $ | 1,477 | | |
Cash at beginning of period
|
| | | | — | | |
Cash at end of period
|
| | | $ | 1,477 | | |
| | |
Number of
ordinary shares |
| |
Share capital
2020 |
| ||||||
Inception at July 1, 2020 | | | | | | | | | | | | | |
Share issuance at inception
|
| | | | 1,200 | | | | | $ | 1,477 | | |
Issued and outstanding at December 31, 2020
|
| | | | | | | | | | 1,477 | | |
| | |
Page
|
|
BOPHELO HOLDINGS LTD | | | | |
| | | ||
Financial Statements: | | | | |
| | | ||
| | | ||
| | | ||
| | | ||
| | |
| | |
Note
|
| |
August 31,
2021 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | $ | 138 | | |
Total assets
|
| | | | | | | | | $ | 138 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | | | | | | | |
Shareholder’s Equity | | | | | | | | | | | | | |
Share capital
|
| | | | 5 | | | | | $ | 138 | | |
Accumulated deficit
|
| | | | | | | | | | — | | |
Total Shareholder’s Equity
|
| | | | | | | | | $ | 138 | | |
Total Liabilities and Shareholder’s Equity
|
| | | | | | | | | $ | 138 | | |
| | |
August 4, 2021
(Inception) to August 31, 2021 |
| |||
Net sales
|
| | | $ | — | | |
Net and Comprehensive loss
|
| | | $ | — | | |
| | |
Note
|
| |
Share
Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholder’s Equity |
| ||||||||||||
Inception, August 4, 2021
|
| | | | | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Share issuance at inception
|
| | | | 5 | | | | | | 138 | | | | | | — | | | | | | 138 | | |
Balance, August 31, 2021
|
| | | | | | | | | $ | 138 | | | | | $ | — | | | | | $ | 138 | | |
| | |
August 4, 2021
(Inception) to August 31, 2021 |
| |||
Cash Flows from Operating Activities
|
| | | $ | — | | |
Cash flows from Financing Activities | | | | | | | |
Proceeds from share issue
|
| | | | 138 | | |
Cash flows provided by financing activities
|
| | | | 138 | | |
Net change in cash
|
| | | | 138 | | |
Cash at beginning of period
|
| | | | — | | |
Cash at end of period
|
| | | $ | 138 | | |
| | |
Number of
ordinary shares |
| |
Share capital
2021 |
| ||||||
Inception at August 4, 2021 | | | | | | | | | | | | | |
Share issuance at inception
|
| | | | 100 | | | | | $ | 138 | | |
Issued and outstanding at August 31, 2021
|
| | | | 100 | | | | | $ | 138 | | |
| | |
Page
|
|
BOPHELO BIO SCIENCE AND WELLNESS (PTY) LTD | | | | |
| | | ||
Financial Statements: | | | | |
| | | ||
| | | ||
| | | ||
| | | ||
| | |
| | |
Note
|
| |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | | | | | | | | 10,120 | | | | | | 818,447 | | |
Prepayments
|
| | | | 8 | | | | | | | | | | | | 113,485 | | | | | | 310 | | |
Shareholders’ loan
|
| | | | | | | | | | | | | | | | 7 | | | | | | 156 | | |
Loans and borrowings
|
| | | | 10 | | | | | | | | | | | — | | | | | | 6,916 | | | |
Total Current Assets
|
| | | | | | | | | | | | | | | 123,612 | | | | | | 825,829 | | | |
Non-Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | |
Property, plant and equipment
|
| | | | 5 | | | | | | | | | | | | 742,887 | | | | | | 697,836 | | |
Capital work in progress
|
| | | | 9 | | | | | | | | | | | | 883,145 | | | | | | 616,377 | | |
Right-of-use asset
|
| | | | 7 | | | | | | | | | | | | 2,199,779 | | | | | | 2,409,933 | | |
Intangible assets
|
| | | | 6 | | | | | | | | | | | 304,260 | | | | | | 358,146 | | | |
Total Non-Current Assets
|
| | | | | | | | | | | | | | | 4,130,071 | | | | | | 4,082,292 | | | |
Total Assets
|
| | | | | | | | | | | | | | | 4,253,683 | | | | | | 4,908,121 | | | |
LIABILITIES AND SHAREHOLDER’S EQUITY | | | | | | | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | |
Trade and other payables
|
| | | | 12 | | | | | | | | | | | | 182,878 | | | | | | 43,006 | | |
Loans and borrowings
|
| | | | 10 | | | | | | | | | | | | 2,263,605 | | | | | | — | | |
Lease liability
|
| | | | 11 | | | | | | | | | | | 283,976 | | | | | | 294,944 | | | |
Total current liabilities
|
| | | | | | | | | | | | | | | 2,730,459 | | | | | | 337,950 | | | |
Non-Current Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | |
Lease liability
|
| | | | 11 | | | | | | | | | | | | 2,598,176 | | | | | | 2,408,074 | | |
Loans and borrowings
|
| | | | 10 | | | | | | | | | | | | 3,977,108 | | | | | | 5,066,590 | | |
Total Non-Current Liabilities
|
| | | | | | | | | | | | | | | | 6,575,284 | | | | | | 7,474,664 | | |
Total Liabilities
|
| | | | | | | | | | | | | | | | 9,305,743 | | | | | | 7,812,614 | | |
Shareholder’s Deficit | | | | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 13 | | | | | | | | | | | | 156 | | | | | | 156 | | |
Reserves
|
| | | | 13 | | | | | | | | | | | | 7 | | | | | | 7 | | |
Accumulated deficit
|
| | | | | | | | | | | | | | | | (5,160,401) | | | | | | (2,862,091) | | |
Accumulated other comprehensive income (loss)
|
| | | | | | | | | | | | | | | | 108,177 | | | | | | (42,565) | | |
Total shareholder’s deficit
|
| | | | | | | | | | | | | | | | (5,052,061) | | | | | | (2,904,493) | | |
Total Liabilities and Shareholder’s Deficit
|
| | | | | | | | | | | | | | | | 4,253,683 | | | | | | 4,908,121 | | |
| | |
$
|
| |
2020
|
| |
2019
|
| |||||||||
Sales
|
| | | | | | | | | | — | | | | | | — | | |
Operating Expenses | | | | | | | | | | | | | | | | | | | |
Amortization and depreciation
|
| | | | | | | | | | 248,743 | | | | | | 198,824 | | |
Consulting and professional fees
|
| | | | | | | | | | 701,985 | | | | | | 365,641 | | |
Biological Assets costs
|
| | | | | | | | | | 58,429 | | | | | | — | | |
Short term accommodation expense
|
| | | | | | | | | | 45,482 | | | | | | 26,269 | | |
Office expenses
|
| | | | | | | | | | 26,874 | | | | | | 13,116 | | |
Personnel expenses
|
| | | | | | | | | | 374,900 | | | | | | 100,256 | | |
Travel expenses
|
| | | | | | | | | | 5,154 | | | | | | 30,582 | | |
General & Administration expenses
|
| | | | | | | | | 201,768 | | | | | | 166,515 | | | |
Loss from operations
|
| | | | | | | | | | (1,663,334) | | | | | | (901,203) | | |
Interest income
|
| | | | | | | | | | 10,187 | | | | | | 399 | | |
Interest expenses
|
| | | | | | | | | | (645,162) | | | | | | (493,807) | | |
Net loss before income tax
|
| | | | | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Income tax expense
|
| | | | | | | | | | — | | | | | | — | | |
Net loss for the year
|
| | | | | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Other comprehensive income: | | | | | | | | | | | | | | | | | | | |
Foreign currency translation
|
| | | | | | | | | | 150,742 | | | | | | (42,565) | | |
Total comprehensive loss for the year
|
| | | | | | | | | | (2,147,568) | | | | | | (1,437,176) | | |
Basic and diluted loss per ordinary share
|
| | | | | | | | | | (9.66) | | | | | | (33.26) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | | | | 222,212 | | | | | | 43,206 | | |
| | |
$
|
| |
Number
of Shares |
| |
Share
Capital |
| |
Reserves
|
| |
Accumulated
Deficit |
| |
Accumulated
other comprehensive income |
| |
Total
Shareholders’ Deficit |
| |||||||||||||||||||||
Balance, January 1, 2019
|
| | | | | | | | | | 100 | | | | | | 7 | | | | | | — | | | | | | (1,467,480) | | | | | | | | | | | | (1,467,473) | | |
Effect of change in par value per share
|
| | | | | | | | | | — | | | | | | (7) | | | | | | 7 | | | | | | — | | | | | | — | | | | | | — | | |
Share issuance
|
| | | | | | | | | | 222,112 | | | | | | 156 | | | | | | — | | | | | | — | | | | | | — | | | | | | 156 | | |
Effect of foreign exchange translation
|
| | | | | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | (42,565) | | | | | | (42,565) | | |
Net loss
|
| | | | | | | | | — | | | | | | — | | | | | | | | | | | | (1,394,611) | | | | | | | | | | | | (1,394,611) | | | |
Balance, December 31, 2019
|
| | | | | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (2,862,091) | | | | | | (42,565) | | | | | | (2,904,493) | | |
Effect of foreign exchange translation
|
| | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | 150,742 | | | | | | 150,742 | | |
Net loss
|
| | | | | | | | | | — | | | | | | — | | | | | | | | | | | | (2,298,310) | | | | | | | | | | | | (2,298,310) | | |
Balance, December 31, 2020
|
| | | | | | | | | | 222,212 | | | | | | 156 | | | | | | 7 | | | | | | (5,160,401) | | | | | | 108,177 | | | | | | (5,052,061) | | |
| | |
$
|
| |
2020
|
| |
2019
|
| |||||||||
Cash Flows from Operating Activities | | | | | | | | | | | | | | | | | | | |
Net loss
|
| | | | | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Non-cash items included in net income: | | | | | | | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | | | | | | | 248,743 | | | | | | 198,824 | | |
Interest expenses
|
| | | | | | | | | | 645,162 | | | | | | 493,807 | | |
Write off of property, plant and equipment
|
| | | | | | | | | | 23,748 | | | | | | — | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | | | | | | | |
Prepayments
|
| | | | | | | | | | (113,175) | | | | | | (310) | | |
Trade and other payables
|
| | | | | | | | | 139,873 | | | | | | 42,283 | | | |
Net cash used in operating activities
|
| | | | | | | | | | (1,353,959) | | | | | | (660,007) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | | | | | | | |
Additions to capital WIP
|
| | | | | | | | | | (266,768) | | | | | | (616,377) | | |
Additions to property, plant and equipment
|
| | | | | | | | | | (172,369) | | | | | | (53,920) | | |
Proceeds from advances issued
|
| | | | | | | | | | 6,934 | | | | | | (6,848) | | |
Net cash used in investing activities
|
| | | | | | | | | | (432,203) | | | | | | (677,145) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | | | | | | | |
Loans received
|
| | | | | | | | | | 1,169,796 | | | | | | 2,116,312 | | |
Loans repaid
|
| | | | | | | | | | (137,788) | | | | | | — | | |
Net cash provided by financing activities:
|
| | | | | | | | | | 1,032,008 | | | | | | 2,116,312 | | |
Net change in cash
|
| | | | | | | | | | (754,155) | | | | | | 779,160 | | |
Effects of currency translation on cash
|
| | | | | | | | | | (54,172) | | | | | | 15,143 | | |
Cash at beginning of year
|
| | | | | | | | | | 818,447 | | | | | | 24,144 | | |
Cash at end of year
|
| | | | | | | | | | 10,120 | | | | | | 818,447 | | |
Supplemental cash flow disclosure Interest paid
|
| | | | | | | | | $ | — | | | | | $ | — | | |
Tax paid
|
| | | | | | | | | $ | — | | | | | $ | — | | |
|
Plant and equipment
|
| | 10 years | |
|
Leasehold improvements
|
| | 20 years | |
|
Motor vehicles
|
| | 4 years | |
| | |
$
|
| |
Plant and
equipment |
| |
Leasehold
improvement |
| |
Motor
vehicles |
| |
Total
|
| ||||||||||||
Cost at January 1, 2019
|
| | | | | | | 438,432 | | | | | | 286,482 | | | | | | — | | | | | | 724,914 | | |
Additions
|
| | | | | | | 1,911 | | | | | | 13,419 | | | | | | 38,590 | | | | | | 53,920 | | |
Foreign exchange movements
|
| | | | | | | 8,701 | | | | | | 4,869 | | | | | | (163) | | | | | | 13,407 | | |
Cost at December 31, 2019
|
| | | | | | | 449,044 | | | | | | 304,770 | | | | | | 38,427 | | | | | | 792,241 | | |
Additions
|
| | | | | | | 172,369 | | | | | | — | | | | | | — | | | | | | 172,369 | | |
Write-offs
|
| | | | | | | (23,748) | | | | | | — | | | | | | — | | | | | | (23,748) | | |
Foreign exchange movements
|
| | | | | | | (11,304) | | | | | | (11,333) | | | | | | (1,429) | | | | | | (24,066) | | |
Cost at December 31, 2020
|
| | | | | | | 586,361 | | | | | | 293,437 | | | | | | 36,998 | | | | | | 916,796 | | |
Accumulated depreciation at January 1, 2019
|
| | | | | | | (21,922) | | | | | | (7,162) | | | | | | — | | | | | | (29,084) | | |
Depreciation
|
| | | | | | | (44,325) | | | | | | (15,038) | | | | | | (4,757) | | | | | | (64,120) | | |
Foreign exchange movements
|
| | | | | | | (866) | | | | | | (289) | | | | | | (46) | | | | | | (1,201) | | |
Accumulated Depreciation at December 31, 2019
|
| | | | | | | (67,113) | | | | | | (22,489) | | | | | | (4,803) | | | | | | (94,405) | | |
Depreciation
|
| | | | | | | (60,212) | | | | | | (14,950) | | | | | | (9,425) | | | | | | (84,587) | | |
Foreign exchange movements
|
| | | | | | | 3,615 | | | | | | 1,114 | | | | | | 354 | | | | | | 5,083 | | |
Accumulated Depreciation at December 31, 2020
|
| | | | | | | (123,710) | | | | | | (36,325) | | | | | | (13,874) | | | | | | (173,909) | | |
Carrying value at January 1, 2019
|
| | | | | | | 416,510 | | | | | | 279,320 | | | | | | — | | | | | | 695,830 | | |
Additions
|
| | | | | | | 1,911 | | | | | | 13,419 | | | | | | 38,590 | | | | | | 53,920 | | |
Depreciation
|
| | | | | | | (44,325) | | | | | | (15,038) | | | | | | (4,757) | | | | | | (64,120) | | |
Foreign exchange movements
|
| | | | | | | 7,835 | | | | | | 4,580 | | | | | | (209) | | | | | | 12,206 | | |
Carrying value at December 31, 2019
|
| | | | | | | 381,931 | | | | | | 282,281 | | | | | | 33,624 | | | | | | 697,836 | | |
Additions
|
| | | | | | | 172,369 | | | | | | — | | | | | | — | | | | | | 172,369 | | |
Disposals
|
| | | | | | | (23,748) | | | | | | — | | | | | | — | | | | | | (23,748) | | |
Depreciation
|
| | | | | | | (60,212) | | | | | | (14,950) | | | | | | (9,425) | | | | | | (84,587) | | |
Foreign exchange movements
|
| | | | | | | (7,689) | | | | | | (10,219) | | | | | | (1,075) | | | | | | (18,983) | | |
Carrying value at December 31, 2020
|
| | | | | | | 462,651 | | | | | | 257,112 | | | | | | 23,124 | | | | | | 742,887 | | |
| | |
$
|
| |
Licenses
|
| |
Total
|
| ||||||
Cost at January 1, 2019
|
| | | | | | | 413,223 | | | | | | 413,223 | | |
Foreign exchange movements
|
| | | | | | | 8,125 | | | | | | 8,125 | | |
Cost at December 31, 2019
|
| | | | | | | 421,348 | | | | | | 421,348 | | |
Foreign exchange movements
|
| | | | | | | (15,668) | | | | | | (15,668) | | |
Cost at December 31, 2020
|
| | | | | | | 405,680 | | | | | | 405,680 | | |
Accumulated amortization at January 1, 2019
|
| | | | | | | (20,661) | | | | | | (20,661) | | |
Amortization
|
| | | | | | | (41,725) | | | | | | (41,725) | | |
Foreign exchange movement
|
| | | | | | | (816) | | | | | | (816) | | |
Accumulated amortization at December 31, 2019
|
| | | | | | | (63,202) | | | | | | (63,202) | | |
Accumulated amortization at December 31, 2019
|
| | | | | | | (63,202) | | | | | | (63,202) | | |
Amortization
|
| | | | | | | (41,337) | | | | | | (41,337) | | |
Foreign exchange translation
|
| | | | | | | 3,119 | | | | | | 3,119 | | |
Accumulated amortization at December 31, 2020
|
| | | | | | | (101,420) | | | | | | (101,420) | | |
Carrying value at January 1, 2019
|
| | | | | | | 392,562 | | | | | | 392,562 | | |
Amortization
|
| | | | | | | (41,725) | | | | | | (41,725) | | |
Foreign exchange movement
|
| | | | | | | 7,309 | | | | | | 7,309 | | |
Carrying value at December 31, 2019
|
| | | | | | | 358,146 | | | | | | 358,146 | | |
Amortization
|
| | | | | | | (41,337) | | | | | | (41,337) | | |
Foreign exchange translation
|
| | | | | | | (12,549) | | | | | | (12,549) | | |
Carrying value at December 31, 2020
|
| | | | | | | 304,260 | | | | | | 304,260 | | |
| | |
$
|
| |
Land Lease
|
| |
Total
|
| ||||||
Cost: | | | | | | | | | | | | | | | | |
Balance as at January 1, 2019
|
| | | | | | | — | | | | | | — | | |
Additions during the year
|
| | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Balance as at December 31, 2019
|
| | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Additions during the year
|
| | | | | | | — | | | | | | — | | |
Balance as at December 31, 2020
|
| | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Accumulated Depreciation: | | | | | | | | | | | | | | | | |
Balance as at January 1, 2019
|
| | | | | | | — | | | | | | — | | |
Charge for the year
|
| | | | | | | 92,979 | | | | | | 92,979 | | |
Effects of Currency Translation
|
| | | | | | | 914 | | | | | | 914 | | |
Balance as at December 31, 2019
|
| | | | | | | 93,893 | | | | | | 93,893 | | |
Charge for the year
|
| | | | | | | 122,820 | | | | | | 122,820 | | |
Effects of Currency Translation
|
| | | | | | | 87,335 | | | | | | 87,335 | | |
Balance as at December 31, 2020
|
| | | | | | | 304,048 | | | | | | 304,048 | | |
Net Book Value: | | | | | | | | | | | | | | | | |
At December 31, 2019
|
| | | | | | | 2,409,934 | | | | | | 2,409,934 | | |
At December 31, 2020
|
| | | | | | | 2,199,779 | | | | | | 2,199,779 | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Prepaid expenses
|
| | | | | | | 113,485 | | | | | | 310 | | |
| | | | | | | | 113,485 | | | | | | 310 | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Capital work in progress
|
| | | | | | | 883,145 | | | | | | 616,377 | | |
| | | | | | | | 883,145 | | | | | | 616,377 | | |
| | |
$
|
| |
Louisa
Mojela |
| |
Granny
Seape |
| |
1942
Capital |
| |
Seedy
Lette |
| |
GMG/
Middleton |
| |
Halo
Collective Inc. |
| |
Total
|
| |||||||||||||||||||||
Value at January 1, 2019
|
| | | | | | | 994,506 | | | | | | 232,276 | | | | | | 1,139,483 | | | | | | 213,020 | | | | | | — | | | | | | — | | | | | | 2,579,284 | | |
Loans issued
|
| | | | | | | 1,043,690 | | | | | | 34,771 | | | | | | — | | | | | | — | | | | | | 1,037,852 | | | | | | (6,848) | | | | | | 2,109,464 | | |
Interest on loans
|
| | | | | | | 122,183 | | | | | | 28,243 | | | | | | 122,057 | | | | | | 22,818 | | | | | | 1,254 | | | | | | — | | | | | | 296,555 | | |
Foreign exchange movements
|
| | | | | | | 31,017 | | | | | | 5,187 | | | | | | 23,606 | | | | | | 4,413 | | | | | | 10,216 | | | | | | (68) | | | | | | 74,371 | | |
Value at December 31,
2019 |
| | | | | | | 2,191,396 | | | | | | 300,477 | | | | | | 1,285,146 | | | | | | 240,251 | | | | | | 1,049,322 | | | | | | (6,916) | | | | | | 5,059,674 | | |
Current portion
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,916) | | | | | | (6,916) | | |
Non-current portion
|
| | | | | | | 2,191,396 | | | | | | 300,477 | | | | | | 1,285,146 | | | | | | 240,251 | | | | | | 1,049,322 | | | | | | — | | | | | | 5,066,590 | | |
Value at December 31,
2019 |
| | | | | | | 2,191,396 | | | | | | 300,477 | | | | | | 1,285,146 | | | | | | 240,251 | | | | | | 1,049,322 | | | | | | (6,916) | | | | | | 5,059,674 | | |
Loans issued
|
| | | | | | | 438,420 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 731,375 | | | | | | 1,169,796 | | |
Loans carried off
|
| | | | | | | (1,147,260) | | | | | | (307,337) | | | | | | (1,314,361) | | | | | | (245,712) | | | | | | (1,030,158) | | | | | | 4,044,828 | | | | | | — | | |
Loans repaid
|
| | | | | | | (137,788) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (137,788) | | |
Interest on loans
|
| | | | | | | 278,901 | | | | | | 12,656 | | | | | | 54,190 | | | | | | 10,130 | | | | | | 753 | | | | | | — | | | | | | 356,631 | | |
Foreign exchange movements
|
| | | | | | | (71,182) | | | | | | (5,796) | | | | | | (24,974) | | | | | | (4,669) | | | | | | (19,917) | | | | | | (81,061) | | | | | | (207,598) | | |
Value at December 31,
2020 |
| | | | | | | 1,552,487 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,688,226 | | | | | | 6,240,714 | | |
Current portion
|
| | | | | | | 1,552,487 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 711,118 | | | | | | 2,263,605 | | |
Non-current portion
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,977,108 | | | | | | 3,977,108 | | |
Value at December 31,
2020 |
| | | | | | | 1,552,487 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,688,226 | | | | | | 6,240,714 | | |
| | |
$
|
| |
Land Lease
|
| |
Total
|
| ||||||
Balance as at January 1, 2019
|
| | | | | |
|
—
|
| | | |
|
—
|
| |
Additions: | | | | | | | | | | | | | | | | |
Lease Liability – Initial adoption of IFRS 16
|
| | | | | | | 2,503,827 | | | | | | 2,503,827 | | |
Interest Expense
|
| | | | | | | 197,252 | | | | | | 197,252 | | |
Lease payments during the year
|
| | | | | | | — | | | | | | — | | |
Effects of Currency Translation
|
| | | | | | | 1,939 | | | | | | 1,939 | | |
| | | | | | | | 2,703,018 | | | | | | 2,703,018 | | |
Less: current portion
|
| | | | | | | (294,944) | | | | | | (294,944) | | |
Balance as at December 31, 2019
|
| | | | | | | 2,408,074 | | | | | | 2,408,074 | | |
Interest Expense
|
| | | | | | | 284,950 | | | | | | 284,950 | | |
Lease payments during the year
|
| | | | | | | — | | | | | | — | | |
Effects of Currency Translation
|
| | | | | | | (105,816) | | | | | | (105,816) | | |
| | | | | | | | 2,882,152 | | | | | | 2,882,152 | | |
Less: current portion
|
| | | | | | | (283,976) | | | | | | (283,976) | | |
As at December 31, 2020
|
| | | | | | | 2,598,176 | | | | | | 2,598,176 | | |
| | |
$
|
| |
December 31,
2020 |
| |||
Amounts payable within 1 year
|
| | | | | | | 283,976 | | |
Amounts payable between 1 and 5 years
|
| | | | | | | 1,135,903 | | |
Amounts payable after 5 years
|
| | | | | | | 3,762,677 | | |
Total payments
|
| | | | | | | 5,182,556 | | |
Interest on lease agreement
|
| | | | | | | (2,300,404) | | |
| | | | | | | | 2,882,152 | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Trade payables
|
| | | | | | | 107,839 | | | | | | 31,784 | | |
Directors’ remuneration payable
|
| | | | | | | 48,584 | | | | | | 10,533 | | |
Accrued payroll taxes
|
| | | | | | | 26,455 | | | | | | 688 | | |
| | | | | | | | 182,878 | | | | | | 43,006 | | |
| | |
$
|
| |
Number of
shares |
| |
Par value
|
| |
Share
capital |
| |
Share
premium |
| |
Total
|
| |||||||||||||||
Balance at December 31, 2018
|
| | | | | | | 100 | | | | | | 0.07 | | | | | | 7 | | | | | | — | | | | | | 7 | | |
Change in par value from 1 Loti to 1 Lisente per share
|
| | | | | | | — | | | | | | — | | | | | | (7) | | | | | | 7 | | | | | | — | | |
Additional shares issued
|
| | | | | | | 222,112 | | | | | | 0.0007 | | | | | | 156 | | | | | | — | | | | | | 156 | | |
Issued and outstanding as at December 31, 2019 and 2020
|
| | | | | | | 222,212 | | | | | | 0.0007 | | | | | | 156 | | | | | | 7 | | | | | | 163 | | |
| | |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Directors Remuneration
|
| | | | 116,448 | | | | | | 10,431 | | |
Director Professional fees
|
| | | | 121,467 | | | | | | 121,970 | | |
Key Management Remuneration
|
| | | | 268,326 | | | | | | 161,134 | | |
Short term accommodation expense
|
| | | | 45,482 | | | | | | 26,269 | | |
Office expenses for office space
|
| | | | 2,377 | | | | | | 9,388 | | |
Fuel expenses
|
| | | | — | | | | | | 4,172 | | |
Consulting fees to Seedy Lette
|
| | | | — | | | | | | 10,931 | | |
| | | | | 554,100 | | | | | | 344,295 | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Net loss for the year
|
| | | | | | | (2,298,310) | | | | | | (1,394,611) | | |
Statutory income tax rate
|
| | | | | | | 25% | | | | | | 25% | | |
Expected tax recovery at statutory income tax rates
|
| | | | | | | (574,578) | | | | | | (348,653) | | |
Change in deferred tax assets not recognized
|
| | | | | | | 574,578 | | | | | | 348,653 | | |
| | | | | | | | — | | | | | | — | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Deferred tax assets
|
| | | | | | | | | | | | | | | |
Net operating loss carried forward
|
| | | | | | | 5,160,401 | | | | | | 2,862,091 | | |
Deferred tax assets not recognized
|
| | | | | | | (5,160,401) | | | | | | (2,862,091) | | |
Net deferred tax assets
|
| | | | | | | — | | | | | | — | | |
| | |
Page
|
|
CANMART LTD | | | | |
| | | ||
Financial Statements: | | | | |
| | | ||
| | | ||
| | | ||
| | | ||
| | |
Presented in US Dollars
|
| |
Note
|
| |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | |
Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | | | | | | | | | | | | | | 1,907 | | | | | | 1,116 | | |
Inventory
|
| | | | | | | | | | | | | | | 611 | | | | | | — | | | |
Total Current Assets
|
| | | | | | | | | | | | | | | | 2,518 | | | | | | 1,116 | | |
Non-Current Assets | | | | | | | | | | | | | | | | | | | | | | | | | |
Intangible assets
|
| | | | 5 | | | | | | | | | | | | 17,146 | | | | | | 16,563 | | |
Total Non-Current Assets
|
| | | | | | | | | | | | | | | | 17,146 | | | | | | 16,563 | | |
Total Assets
|
| | | | | | | | | | | | | | | | 19,664 | | | | | | 17,679 | | |
LIABILITIES AND SHAREHOLDER’S EQUITY (DEFICIT)
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Current Liabilities | | | | | | | | | | | | | | | | | | | | | | | | | |
Trade and other payables
|
| | | | 7 | | | | | | | | | | | | 1,024 | | | | | | — | | |
Due to related parties
|
| | | | | | | | | | | | | | | | — | | | | | | 17,707 | | |
Total Liabilities
|
| | | | | | | | | | | | | | | | 1,024 | | | | | | 17,707 | | |
Shareholder’s Equity (Deficit) | | | | | | | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | | | 8 | | | | | | | | | | | | 3 | | | | | | 3 | | |
Accumulated deficit
|
| | | | | | | | | | | | | | | | (2,291) | | | | | | (30) | | |
Other reserves
|
| | | | | | | | | | | | | | | | 21,046 | | | | | | — | | |
Accumulated other comprehensive income
|
| | | | | | | | | | | | | | | | (117) | | | | | | (1) | | |
| | | | | | | | | | | | | | | | | 18,640 | | | | | | (28) | | |
Total Liabilities and Shareholder’s Equity (Deficit)
|
| | | | | | | | | | | | | | | | 19,664 | | | | | | 17,679 | | |
Presented in US Dollars
|
| |
Note
|
| |
$
|
| |
2020
|
| |
2019
|
| |||||||||
Sales
|
| | | | | | | | | | | | | 2,062 | | | | | | — | | |
Cost of sales
|
| | | | | | | | | | | | (1,809) | | | | | | — | | | |
Gross Profit
|
| | | | | | | | | | | | | 253 | | | | | | — | | |
Consulting and professional fees
|
| | | | | | | | | | | | | 31 | | | | | | — | | |
License costs
|
| | | | | | | | | | | | | 1,491 | | | | | | — | | |
General & administrative expenses
|
| | | | | | | | | | | | | 1,101 | | | | | | 32 | | |
Total operating expenses
|
| | | | | | | | | | | | | (2,623) | | | | | | (32) | | |
Loss from Operations
|
| | | | | | | | | | | | | (2,370) | | | | | | (32) | | |
Other Income (Expense) | | | | | | | | | | | | | | | | | | | | | | |
Finance income
|
| | | | | | | | | | | | | 1 | | | | | | 2 | | |
Finance expenses
|
| | | | | | | | | | | | | — | | | | | | — | | |
Other income
|
| | | | | | | | | | | | | 108 | | | | | | — | | |
Total Other Income (Expense)
|
| | | | | | | | | | | | | 109 | | | | | | 2 | | |
Net loss before income tax
|
| | | | | | | | | | | | | (2,261) | | | | | | (30) | | |
Income tax expense
|
| | | | | | | | | | | | | — | | | | | | — | | |
Net Loss for the Year
|
| | | | | | | | | | | | | (2,261) | | | | | | (30) | | |
Other Comprehensive Loss: | | | | | | | | | | | | | | | | | | | | | | |
Exchange differences on foreign currency translation
|
| | | | | | | | | | | | | (116) | | | | | | (1) | | |
Total Comprehensive Loss
|
| | | | | | | | | | | | | (2,377) | | | | | | (31) | | |
Basic and dilutive loss per ordinary share
|
| | | | | | | | | | | | | (1,188.50) | | | | | | (15.50) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | | | | | | | 2 | | | | | | 2 | | |
Presented in US Dollars
|
| |
$
|
| |
Number
of Shares |
| |
Share
Capital |
| |
Accumulated
other comprehensive income |
| |
Accumulated
Deficit |
| |
Other
Reserves |
| |
Total
Equity (Deficit) |
| |||||||||||||||||||||
Balance, December 31, 2018
|
| | | | | | | | | | 2 | | | | | | 3 | | | | | | — | | | | | | — | | | | | | — | | | | | | 3 | | |
Issue of shares
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | |
Currency translation
|
| | | | | | | | | | — | | | | | | — | | | | | | (1) | | | | | | — | | | | | | | | | | | | (1) | | |
Net loss
|
| | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (30) | | | | | | — | | | | | | (30) | | | |
Balance, December 31, 2019
|
| | | | | | | | | | 2 | | | | | | 3 | | | | | | (1) | | | | | | (30) | | | | | | — | | | | | | (28) | | |
Currency translation
|
| | | | | | | | | | — | | | | | | — | | | | | | (116) | | | | | | — | | | | | | — | | | | | | (116) | | |
Contribution to reserves by owners of the Company
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 21,046 | | | | | | 21,046 | | |
Net loss
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (2,261) | | | | | | | | | | | | (2,261) | | |
Balance, December 31, 2020
|
| | | | | | | | | | 2 | | | | | | 3 | | | | | | (117) | | | | | | (2,291) | | | | | | 21,046 | | | | | | 18,640 | | |
Presented in US Dollars
|
| |
Note
|
| |
$
|
| |
January 1, 2020 to
December 31, 2020 |
| |
January 1, 2019 to
December 31, 2019 |
| |||||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | | | | | | | | | | |
Net loss
|
| | | | | | | | | | | | | (2,261) | | | | | | (30) | | |
Adjustments to reconcile net income to net cash provided by
(used in) operating activities: |
| | | | | | | | | | | | | — | | | | | | — | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | | | | | | | | | | |
Increase in inventory
|
| | | | | | | | | | | | | (611) | | | | | | — | | |
Increase in trade and other payables
|
| | | | | | | | | | | | | 1,024 | | | | | | — | | |
Increase in due to related parties
|
| | | | | | | | | | | | 3,339 | | | | | | 17,707 | | | |
Net cash provided by operating activities
|
| | | | | | | | | | | | | 1,491 | | | | | | 17,677 | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | | | | | | | | | | |
Payments for acquisition of cannabis licenses
|
| | | | | | | | | | | | | — | | | | | | (15,625) | | |
Net cash used in investing activities
|
| | | | | | | | | | | | | — | | | | | | (15,625) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | | | | | | | | | | |
Proceeds from share subscriptions receivable
|
| | | | | | | | | | | | | — | | | | | | 2 | | |
Net cash provided by financing activities:
|
| | | | | | | | | | | | | — | | | | | | 2 | | |
Effects of foreign exchange translation on cash
|
| | | | | | | | | | | | | (700) | | | | | | (938) | | |
Net change in cash
|
| | | | | | | | | | | | | 791 | | | | | | 1,116 | | |
Cash at beginning of year
|
| | | | | | | | | | | | | 1,116 | | | | | | — | | |
Cash at end of year
|
| | | | | | | | | | | | | 1,907 | | | | | | 1,116 | | |
Supplemental cash flow information: | | | | | | | | | | | | | | | | | | | | | | |
Interest paid
|
| | | | | | | | | | | | | — | | | | | | — | | |
Taxes paid
|
| | | | | | | | | | | | | — | | | | | | — | | |
Non-cash Investing and Financing Activities: | | | | | | | | | | | | | | | | | | | | | | |
Contributions to reserves by shareholders due to waiver of balance due to related party
|
| | | | | | | | | | | | | 21,046 | | | | | | — | | |
| | |
$
|
| |
Licences
|
| |
Total
|
| ||||||
Cost at December 31, 2018
|
| | | | | | | — | | | | | | — | | |
Additions
|
| | | | | | | 15,625 | | | | | | 15,625 | | |
Amortisation
|
| | | | | | | — | | | | | | — | | |
Foreign exchange translation
|
| | | | | | | 938 | | | | | | 938 | | |
Cost at December 31, 2019
|
| | | | | | | 16,563 | | | | | | 16,563 | | |
Accumulated amortisation at December 31,2019
|
| | | | | | | — | | | | | | — | | |
Carrying value at December 31,2019
|
| | | | | | | 16,563 | | | | | | 16,563 | | |
Foreign exchange translation
|
| | | | | | | 583 | | | | | | 583 | | |
Amortisation
|
| | | | | | | — | | | | | | — | | |
Cost at December 31, 2020
|
| | | | | | | 17,146 | | | | | | 17,146 | | |
Accumulated amortisation at December 31,2020
|
| | | | | | | — | | | | | | — | | |
Carrying value at December 31,2020
|
| | | | | | | 17,146 | | | | | | 17,146 | | |
| | |
$
|
| |
December, 31
2020 |
| |
December, 31
2019 |
| ||||||
Trade receivables
|
| | | | | | | 523 | | | | | | — | | |
Allowance for bad debts
|
| | | | | | | (523) | | | | | | — | | |
| | | | | | | | — | | | | | | — | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Net loss for the year
|
| | | | | | | (2,261) | | | | | | (30) | | |
Statutory income tax rate
|
| | | | | | | 18% | | | | | | 19% | | |
Expected tax recovery at statutory income tax rates
|
| | | | | | | (407) | | | | | | (6) | | |
Change in deferred tax assets not recognized
|
| | | | | | | 407 | | | | | | 6 | | |
| | | | | | | | — | | | | | | — | | |
| | |
$
|
| |
December 31,
2020 |
| |
December 31,
2019 |
| ||||||
Deferred tax assets | | | | | | | | | | | | | | | | |
Net operating loss carried forward
|
| | | | | | | 2,291 | | | | | | 30 | | |
Deferred tax assets not recognized
|
| | | | | | | (2,291) | | | | | | (30) | | |
Net deferred tax assets
|
| | | | | | | — | | | | | | — | | |
| | |
$
|
| |
Akanda Corp.
|
| |
Cannahealth
|
| |
Bophelo
Holdings |
| |
Canmart
|
| |
Bophelo
Bio Science |
| |
Total
|
| |
Proforma
Adjustments |
| |
Notes
|
| |
Proforma As
Adjusted |
| ||||||||||||||||||||||||
| | | | | |
31 August 2021
|
| |
31 December 2020
|
| |
31 August 2021
|
| |
31 December 2020
|
| |
31 December 2020
|
| | | | | | | | | | | | | | | | | | | | | | |||||||||||||||
Sales
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,062 | | | | | | — | | | | | | 2,062 | | | | | | — | | | | | | | | | 2,062 | | |
Cost of sales
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,809) | | | | | | — | | | | | | (1,809) | | | | | | — | | | | | | | | | (1,809) | | |
Gross Profit
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 253 | | | | | | — | | | | | | 253 | | | | | | — | | | | | | | | | 253 | | |
Amortisation and
depreciation |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | (248,743) | | | | | | (248,743) | | | | | | — | | | | | | | | | (248,873) | | |
Consulting and professional fees
|
| | | | | | | (31,898) | | | | | | — | | | | | | — | | | | | | (31) | | | | | | (701,985) | | | | | | (733,914) | | | | | | — | | | | | | | | | (702,016) | | |
Fair value adjustment
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (58,429) | | | | | | (58,429) | | | | | | — | | | | | | | | | (58,429) | | |
Lease costs
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (45,482) | | | | | | (45,482) | | | | | | — | | | | | | | | | (45,482) | | |
Office
expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (26,874) | | | | | | (26,874) | | | | | | — | | | | | | | | | (26,874) | | |
Personnel expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (374,900) | | | | | | (374,900) | | | | | | — | | | | | | | | | (374,900) | | |
Travel
expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (5,154) | | | | | | (5,154) | | | | | | — | | | | | | | | | (5,154) | | |
General &
administrative expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (2,592) | | | | | | (201,768) | | | | | | (248,743) | | | | | | — | | | | | | | | | (204,360) | | |
Loss from Operations
|
| | | | | | | (31,898) | | | | | | — | | | | | | — | | | | | | (2,370) | | | | | | (1,663,335) | | | | | | (1,697,603) | | | | | | — | | | | | | | | | (1,697,603) | | |
Finance income
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 1 | | | | | | 10,187 | | | | | | 10,188 | | | | | | — | | | | | | | | | 10,188 | | |
Finance
expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (645,162) | | | | | | (645,162) | | | | | | (849,187) | | | |
4(d)
|
| | | | (1,494,349) | | |
Other income
|
| | | | | | | | | | | | | | | | | | | | | | | | | 108 | | | | | | — | | | | | | 108 | | | | | | | | | | | | | | | 108 | | |
Net loss from operations
|
| | | | | | | (31,898) | | | | | | — | | | | | | — | | | | | | (2,261) | | | | | | (2,298,310) | | | | | | (2,332,469) | | | | | | (849,187) | | | | | | | | | (3,181,656) | | |
Foreign exchange translation
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (116) | | | | | | 150,742 | | | | | | 150,626 | | | | | | — | | | | | | | | | 150,626 | | |
Net and comprehensive loss
|
| | | | | | | (31,898) | | | | | | — | | | | | | — | | | | | | (2,377) | | | | | | (2,147,568) | | | | | | (2,181,843) | | | | | | (849,187) | | | | | | | | | (3,031,030) | | |
Basic and dilutive
loss per ordinary share |
| | | | | | | (0.01) | | | | | | — | | | | | | — | | | | | | (1,189) | | | | | | (9.66) | | | | | | | | | | | | — | | | | | | | | | (0.11) | | |
Weighted average number of ordinary shares outstanding
|
| | | | | | | 6,095,705 | | | | | | 1,200 | | | | | | 100 | | | | | | 2 | | | | | | 222,212 | | | | | | | | | | | | 20,505,726 | | | |
4(a,b,c&d)
|
| | | | 26,824,945 | | |
| | |
$
|
| |
Akanda
Corp. |
| |
Cannahealth
|
| |
Bophelo
Holdings |
| |
Canmart
|
| |
Bophelo
Bio Science |
| |
Total
|
| |
Proforma
Adjustments |
| |
Notes
|
| |
Proforma
As Adjusted |
| ||||||||||||||||||||||||
| | | | | |
N/A
|
| |
N/A
|
| |
N/A
|
| |
31 December 2019
|
| |
31 December 2019
|
| | | | | | | | | | | | | | | | | | | | | | |||||||||||||||
Sales
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | |
Cost of sales
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | |
Gross Profit
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | |
Amortisation and depreciation
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (198,824) | | | | | | (198,824) | | | | | | — | | | | | | | | | (198,824) | | |
Consulting and professional fees
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (365,641) | | | | | | (365,641) | | | | | | — | | | | | | | | | (365,641) | | |
Biological Assets costs
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | |
Short term accommodation
expense |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (26,269) | | | | | | (26,269) | | | | | | — | | | | | | | | | (26,269) | | |
Office expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (13,116) | | | | | | (13,116) | | | | | | — | | | | | | | | | (13,116) | | |
Personnel expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (100,256) | | | | | | (100,256) | | | | | | — | | | | | | | | | (100,256) | | |
Travel expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (30,582) | | | | | | (30,582) | | | | | | — | | | | | | | | | (30,582) | | |
General & Administration
expenses |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (32) | | | | | | (166,515) | | | | | | (166,547) | | | | | | — | | | | | | | | | (166,547) | | |
Loss from Operations
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (32) | | | | | | (901,203) | | | | | | (901,235) | | | | | | — | | | | | | | | | (901,235) | | |
Finance income
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 2 | | | | | | 399 | | | | | | 401 | | | | | | — | | | | | | | | | 401 | | |
Finance expenses
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (493,807) | | | | | | (493,807) | | | | | | (1,100,000) | | | |
4(d)
|
| | | | (1,593,807) | | |
Other income
|
| | | | | | | | | | | | | — | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net loss from operations
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (30) | | | | | | (1,394,611) | | | | | | (1,394,641) | | | | | | (1,100,000 | | | | | | | | | (2,494,641) | | |
Foreign exchange translation
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (1) | | | | | | (42,565) | | | | | | (42,566) | | | | | | — | | | | | | | | | (42,566) | | |
Net and comprehensive loss
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (31) | | | | | | (1,437,176) | | | | | | (1,437,207) | | | | | | (1,100,000 | | | | | | | | | (2,537,207) | | |
Basic and dilutive loss per ordinary share
|
| | | | | | | — | | | | | | — | | | | | | — | | | | | | (15.50) | | | | | | (33.26) | | | | | | | | | | | | — | | | | | | | | | (0.12) | | |
Weighted average number of ordinary
shares outstanding |
| | | | | | | — | | | | | | — | | | | | | — | | | | | | 2 | | | | | | 43,206 | | | | | | | | | | | | 20,686,032 | | | |
4(a,b,c&d)
|
| | | | 20,729,240 | | |
|
Exhibit
Number |
| |
Description
|
|
|
1.1
|
| | | |
|
2.1
|
| | | |
|
3.1
|
| | | |
|
3.2
|
| | | |
|
3.3
|
| | | |
|
4.1
|
| | | |
|
4.2
|
| | | |
|
4.3
|
| | | |
|
5.1
|
| | Form of Opinion of Dentons Canada LLP. | |
|
8.1
|
| | Form of Opinion of Dentons Canada LLP as to Canadian tax matters (included in Exhibit 5.1). | |
|
10.1§
|
| | | |
|
10.2
|
| | | |
|
10.3
|
| | | |
|
10.4
|
| | | |
|
10.5
|
| | | |
|
10.6§
|
| | | |
|
10.7§
|
| | | |
|
10.8§
|
| | | |
|
10.9
|
| | | |
|
10.10
|
| | | |
|
10.11
|
| | | |
|
10.12
|
| | | |
|
10.13
|
| | |
|
Exhibit
Number |
| |
Description
|
|
|
14.1
|
| | | |
|
14.2
|
| | | |
|
14.3
|
| | | |
|
21.1
|
| | | |
|
23.1
|
| | | |
|
23.2
|
| | | |
|
24.1
|
| | | |
|
99.1
|
| | | |
|
99.2
|
| | | |
|
99.3
|
| | | |
|
99.4
|
| | | |
|
99.5
|
| | Consent of Gugu Dingaan | |
|
107
|
| | |
| Date: January 31, 2022 | | |
Akanda Corp.
|
|
| | | |
By:
/s/ Tejinder Virk
Name: Tejinder Virk
Title: Chief Executive Officer and Director |
|
|
/s/ Tejinder Virk
Name: Tejinder Virk
Title: Chief Executive Officer and Director (Principal Executive Officer) |
| | Date: January 31, 2022 | |
|
/s/ Trevor Scott
Name: Trevor Scott
Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
| | Date: January 31, 2022 | |
|
/s/ Louisa Mojela
Name: Louisa Mojela
Title: Executive Chairman and Director |
| | Date: January 31, 2022 | |
|
/s/ Philip van den Berg
Name: Philip van den Berg
Title: Director |
| | Date: January 31, 2022 | |
|
/s/ Charles Kié
Name: Charles Kié
Title: Director |
| | Date: January 31, 2022 | |
Exhibit 1.1
AKANDA CORP.
UNDERWRITING AGREEMENT
[__________], 2022
Boustead Securities, LLC
6 Venture, Suite 395
Irvine, CA 92618
Attn: Keith Moore, Chief Executive Officer
Attn: Daniel J. McClory, Managing Director
Ladies and Gentlemen:
This underwriting agreement (this “Agreement”) constitutes the agreement between Akanda Corp., a company incorporated in the Province of Ontario (the “Company”), on the one hand, and Boustead Securities, LLC (the “Representative”), for itself as underwriter and as representative of the several underwriters listed on Schedule I hereto (the “Underwriters”), on the other hand, pursuant to which the Underwriters shall serve as the underwriters for the Company in connection with the proposed offering (the “Offering”) by the Company of its Offered Securities (as defined below).
The Company proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters an aggregate of [*] authorized but unissued common shares (the “Firm Shares”), without par value, of the Company (such shares generally, the “Common Shares”), and to grant the Representative the option to purchase an aggregate of up to [*] additional Common Shares (the “Option Shares”) as may be necessary to cover over-allotments made in connection with the Offering. The Firm Shares and Option Shares are collectively referred to as the “Offered Securities.” The Offered Securities and the Representative’s Warrant (as defined below) and the Warrant Shares (as defined below) are collectively referred to herein as the “Securities.”
The Company hereby confirms its agreement with the Representative as follows:
Section 1. Fees and Expenses; Survival and Other Activities.
(a) Underwriting Discount; Representative’s Warrants; Expenses.
(i) Underwriting Discount. The Underwriters shall be entitled to receive an underwriting discount equal to 7% of the gross proceeds from the sale of the Offered Securities on a Closing Date, as defined in Section 3(c) herein, which will be paid to and allocated by the Representative among the Underwriters or selling syndicate and soliciting dealers.
(ii) Non-Accountable Expense Allowance. The Underwriters shall be entitled to receive a non-accountable expense allowance equal to 1% of the gross proceeds from the sale of the Offered Securities on a Closing Date, which will be paid to and allocated by the Representative among the Underwriters.
(iii) Representative’s Warrants. The Company hereby agrees to issue to the Representative (and/or its permitted designees) on a Closing Date, a warrant or warrants, as applicable (in the form attached as Exhibit A hereto, the “Representative’s Warrant”) to purchase the number of Common Shares equal to seven percent (7%) of the number of Firm shares and Option Shares, if any, issued in the Offering (“Warrant Shares”).
The Representative’s Warrants will be exercisable for a term of five (5) years from the effective date (the “Effective Date”) of the Registration Statement (as defined below) at an initial exercise price equal to 125% of the price per share paid by investors in the Offering. The Representative’s Warrants shall include a “cashless” exercise feature, and shall contain provisions for registration rights for the Representative’s Warrants and the underlying Common Shares, as set forth in the Representative’s Warrants. The Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s Warrants and the Warrant Shares during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than the circumstances listed under FINRA Rule 5110(e)(2). Delivery of the Representative’s Warrants shall be made on a Closing Date and shall be issued in the name or names and in such authorized denominations as the Representative may request.
(iv) Expenses. Whether or not the transactions contemplated by this Agreement and the Registration Statement are consummated or this Agreement is terminated, the Company hereby agrees to pay all costs and expenses incident to the Offering, including the following:
A. all expenses in connection with the preparation, printing, formatting for EDGAR and filing of the Registration Statement, and any and all amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers;
B. all fees and expenses in connection with filings with FINRA’s Public Offering System;
C. all fees, disbursements and expenses of the Company’s counsel and accountants in connection with the registration of the Offered Securities under the Securities Act of 1933, as amended (the “Securities Act”) and the Offering;
D. all reasonable expenses in connection with the qualifications of the Offered Securities for offering and sale under state or blue sky laws, when applicable;
E. all fees and expenses in connection with listing the Offered Securities on the Nasdaq Stock Market (“Nasdaq”), including DTC eligibility;
F. all reasonable travel expenses of the Company’s officers, directors and employees and any other expense of the Company incurred in connection with attending or hosting meetings with prospective purchasers of the Offered Securities;
G. any stock transfer taxes incurred in connection with this Agreement or the Offering;
H. the cost and charges of any transfer agent or registrar for the Offered Securities; and
I. Underwriters’ accountable out-of-pocket expenses in the aggregate amount of $255,000, including Underwriters’ counsel’s fees of up to $75,000 ($25,000 of which have been advanced by the Company to the Underwriter). In addition, the Company has advanced to the Underwriter approximately $72,000 for other expenses related to the Offering. Any such advances shall be applied against the aggregate out-of-pocket accountable expense allowance, which is capped at $255,000, and any unused portion of the advances will be returned to the Company to the extent not actually incurred.
In the event that this Agreement is terminated pursuant to Section 9 hereof, or subsequent to a Material Adverse Effect (as defined in Section 2(g)), the Company will pay all documented out-of-pocket and unreimbursed expenses of the Underwriters (including fees and disbursements of Underwriters’ counsel) incurred in connection herewith which shall be limited to expenses which are actually incurred as allowed under FINRA Rule 5110 and in any event, the aggregate amount of such expenses to be paid or reimbursed by the Company directly or indirectly to or on behalf of the Underwriters shall not exceed $75,000.
(b) Survival and Other Activities. Notwithstanding anything to the contrary contained herein, the Company’s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(g)(5)(A), will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Underwriters or their Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the Company. As used herein (i) “Persons” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind and (ii) “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.
Section 2. Representations, Warranties and Covenants of the Company. The Company hereby represents, warrants and covenants to the Underwriters, as of the date hereof, and as of the Closing Date, except as set out in the Registration Statement as follows:
(a) Securities Law Filings. The Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form F-1 (Registration File No. [*]) under the Securities Act and the rules and regulations of the Commission (the “Rules and Regulations”) promulgated thereunder and under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). At the time of the Effective Date, the Registration Statement and amendments met the requirements of Form F-1 under the Securities Act. The Company will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, a final prospectus included in such registration statement relating to the Offering and the underwriting thereof and has advised the Representative of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration statement, including the exhibits thereto, as amended at the date of this Agreement, is hereinafter called the “Registration Statement”; such prospectus in the form in which it appears in the Registration Statement as amended at the date of this Agreement is hereinafter called the “Prospectus.” If the Company has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term Registration Statement shall include such Rule 462 Registration Statement. Any preliminary prospectus included in the Registration Statement or filed with the Commission under the Securities Act is hereinafter called a “Preliminary Prospectus.” All references in this Agreement to financial statements and schedules and other information that is “contained,” “included,” “described,” “referenced,” “set forth” or “stated” in the Registration Statement, any Preliminary Prospectus or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is or is deemed to be incorporated by reference in the Registration Statement, any Preliminary Prospectus or the Prospectus, as the case may be. The Registration Statement has been declared effective on the date hereof. The Company shall, prior to the Closing Date, file with the Commission a Form 8-A providing for the registration under the Exchange Act of the Common Shares.
(b) Assurances. The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, at all other subsequent times until the Closing Date, complied in all material respects with the Securities Act and the applicable Rules and Regulations and did not and, as amended or supplemented, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations and warranties contained in this sentence shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Representative expressly for use therein, which information shall consist solely of (i) the names of the Underwriters appearing in the Prospectus, (ii) the statement regarding delivery of the Common Shares set forth on the cover page of the Prospectus, (iii) the securities dealer discount referred to in the second paragraph of the section of the Prospectus captioned “Underwriting”, (iv) the information set forth in the fourth paragraph of the section of the Prospectus captioned “Underwriting” and (v) the table showing the number of securities to be purchased by each Underwriter (the “Underwriter Information”). Each Preliminary Prospectus, as of its date, complies in all material respects with the Securities Act and the applicable Rules and Regulations. The Prospectus, as of its date, complies in all material respects with the Securities Act and the applicable Rules and Regulations. As of its date, each Preliminary Prospectus and the Prospectus did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a s fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations and warranties contained in this sentence shall not apply to any Underwriter Information). All post-effective amendments to the Registration Statement reflecting facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein have been so filed with the Commission. There are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. The Company is eligible to use “free writing prospectuses” in connection with the Offering pursuant to Rules 164 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable Rules and Regulations. Each such free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of the Securities Act and the applicable Rules and Regulations. The Company has not and will not, without the prior consent of the Representative, prepare, use or refer to, any free writing prospectus. Each such free writing prospectus shall be deemed to be included as part of the Registration Statement for purposes of this Agreement.
(c) Offering Materials. The Company has delivered, or will as promptly as practicable deliver, to the Underwriters complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies of the Registration Statement (without exhibits), any Preliminary Prospectus, any free writing prospectus and the Prospectus, as amended or supplemented, in such quantities and at such places as the Underwriters reasonably request. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering material in connection with the offering and sale of the Offered Securities other than the Prospectus, the Registration Statement, and any free writing prospectus authorized in advance by the Representative.
(d) Subsidiaries. All of the direct and indirect subsidiaries of the Company (the “Subsidiaries”) are described in the Registration Statement to the extent required by the Rules and Regulations. The Company owns, directly or indirectly, all of its capital stock or other equity interests of each Subsidiary free and clear of any liens, charges, security interests, encumbrances, rights of first refusal, preemptive rights or other restrictions (collectively, “Liens”) except as disclosed in the Registration Statement or the Prospectus, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive or similar rights to subscribe for or purchase securities.
(e) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing (where applicable) under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or material default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement, the Representative’s Warrant or any other agreement or instrument entered into between the Company and the Underwriters (“Transaction Documents”), (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement or the Offering (any of (i), (ii) or (iii), a “Material Adverse Effect”) and to the knowledge of the Company, no action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened (“Proceeding”) has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.
(f) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and the Offering and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company and each of the other Transaction Documents and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Company’s Board of Directors (the “Board of Directors”) or the Company’s shareholders in connection therewith other than in connection with the Required Approvals (as defined below). This Agreement and each other Transaction Document to which it is a party has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
(g) No Conflicts. The execution, delivery and performance by the Company of this Agreement, the other Transaction Documents to which it is a party and the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s memorandum and articles of association, certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such conflict, default or violation could not reasonably be expected to result in a Material Adverse Effect.
(h) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this Agreement, the other Transaction Documents to which it is a party and the transactions contemplated hereby where the failure to obtain any such consent, waiver, authorization or order of, give any notice to, or make any filing or registration would not, singularly or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, other than: (i) the filing with the Commission of the final Prospectus as required by Rule 424 under the Securities Act, (ii) application to the Nasdaq for the listing of the Offered Securities for trading thereon in the time and manner required thereby and (iii) such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).
(i) Issuance of the Securities. The Offered Securities are duly authorized and, when issued and paid for in accordance with this Agreement, the other Transaction Documents to which it is a party, and the terms of the Offering as described in the Prospectus, will be duly and validly issued, fully paid and non-assessable, and free and clear of all Liens. The Representative’s Warrant has been duly authorized for issuance, and the Warrant Shares, when issued, paid for and delivered upon due exercise of the Representative’s Warrant, will be duly authorized and validly issued, fully paid and nonassessable, free and clear of all Liens. The Company has sufficient authorized Common Shares for the issuance of the maximum number of Securities issuable pursuant to the Offering as described in the Prospectus.
(j) Capitalization. The capitalization of the Company is as set forth in the Registration Statement and the Prospectus. The Company has not issued any Common Shares since [*], 2021, other than (i) [*], (ii) pursuant to the Company’s equity incentive plans as described in the Registration Statement and the Prospectus (the “Company Incentive Plans”), and (iii) the issuance of Common Shares to employees, directors or consultants pursuant to the Company Incentive Plans and pursuant to the conversion and/or exercise of any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire Common Shares at any time, including, without limitation, any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares (“Ordinary Share Equivalents”) as described in the Registration Statement and the Prospectus. No Person has any right of first refusal, preemptive right or right of participation, or any similar right to participate in the transactions contemplated by this Agreement. Except as a result of the purchase and sale of the Offered Securities or as disclosed in the Registration Statement and the Prospectus, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any Common Shares or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional Common Shares or Common Share Equivalents or capital stock of any Subsidiary. Except as disclosed in the Registration statement or the Prospectus, the issuance and sale of the Offered Securities will not obligate the Company or any Subsidiary to issue Common Shares or other securities to any Person (other than the Underwriters) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. Except as disclosed in the Registration statement or the Prospectus, there are no securities of the Company or any Subsidiary that have any anti-dilution rights (other than adjustments for stock splits, recapitalizations, and the like) to the exercise or conversion price, have any exchange rights, or reset rights. Except as set forth in the Registration Statement, and the Prospectus, there are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any share appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement relating to rights in Common Shares. All of the outstanding Common Shares are duly authorized, validly issued, fully paid and non-assessable, have been issued in compliance in all material respects with all applicable securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of the Offered Securities. Except as disclosed in the Registration statement or the Prospectus, there are no shareholders agreements, voting agreements or other similar agreements with respect to the Common Shares or other securities of the Company to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders.
(k) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the Registration Statement, except as specifically disclosed in the Registration Statement and the Prospectus, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”), or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any Common Shares and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans, if any. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Offered Securities contemplated by the Prospectus or as disclosed in the Registration Statement, any Preliminary Prospectus or the Prospectus, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective business, prospects (as such prospects are described in the Prospectus), properties, operations, assets or financial condition that would be required to be disclosed by the Company under the Securities Act, the Exchange Act or the Rules and Regulations as of the date of this Agreement that has not been so disclosed under the Securities Act, the Exchange Act or the Rules and Regulations.
(l) Financial Statements. The financial statements of the Company, together with the related notes and schedules, included in the Registration Statement, any Preliminary Prospectus and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act and the Rules and Regulations, and fairly present, in all material respects, the financial condition of the Company as of the dates indicated and the results of operations and changes in cash flows for the periods therein specified in conformity with IFRS consistently applied throughout the periods involved. No other financial statements or schedules are required under the Securities Act, the Exchange Act, or the Rules and Regulations to be included in the Registration Statement, any Preliminary Prospectus and the Prospectus. The pro forma financial statements included in the Registration Statement, any Preliminary Prospectus and the Prospectus include assumptions that provide a reasonable basis for presenting the significant effects directly attributable to the transactions and events described therein, the related pro forma adjustments give appropriate effect to those assumptions, and the pro forma adjustments reflect the proper application of those adjustments to the historical financial statements amounts in the pro forma financial statements included in the Registration Statement, any Preliminary Prospectus and the Prospectus. The pro forma financial statements included in the Registration Statement, any Preliminary Prospectus and the Prospectus comply as to form in all material respects with the application requirements of Regulation S-X under the Exchange Act. No other pro forma financial information or schedules are required under the Securities Act, the Exchange Act, or the rules and regulations thereunder to be included in the Registration Statement, any Preliminary Prospectus and the Prospectus.
(m) Litigation. Except as disclosed in the Registration Statement, any Preliminary Prospectus or the Prospectus, there is no action, suit, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary, any of their respective properties or any of the Company’s officers or directors before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or any of the Transaction Documents or the Offering or the Securities or (ii) could, if there were an unfavorable decision, reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has within the last 10 years been the subject of any Action involving an order, judgment, decree, or finding of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.
(n) Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(o) Compliance. Except as set forth in the Registration Statement, any Preliminary Prospectus or the Prospectus , neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or governmental body or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not reasonably be expected to result in a Material Adverse Effect.
(p) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the Prospectus, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.
(q) Regulatory Matters. The tests conducted by or on behalf of or sponsored by the Company or its Subsidiaries that are described or referred to in the Registration Statement, any Preliminary Prospectus and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable. Neither the Company nor its Subsidiaries has received any notices or other correspondence from any foreign, federal, state or local governmental or regulatory authority with respect to any ongoing tests requiring the termination or suspension of such tests. Except as would not be reasonably expected to result in a Material Adverse Effect, neither the Company nor any of its Subsidiaries has failed to file with any foreign, federal, state or local governmental or the applicable regulatory authorities any filing, declaration, listing, registration, report or submission that is required to be so filed. All such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions.
(a) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens disclosed in the Registration Statement, any Preliminary Prospectus and the Prospectus, Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance except for any breach that could not reasonably be expected to result in a Material Adverse Effect.
(b) Patents and Trademarks. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the Registration Statement or the Prospectus and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or be abandoned, within two (2) years from the date of this Agreement, except where such action would not reasonably be expected to have a Material Adverse Effect. Except as disclosed in the Registration Statement or the Prospectus, neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the Registration Statement and the Prospectus, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.
(c) Transactions With Affiliates and Employees. Except as set forth in the Registration Statement, any Preliminary Prospectus and the Prospectus, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.
(d) No Undisclosed Contracts. There is no contract or document required by the Securities Act or by the Rules and Regulations to be described in the Registration Statement or in the Prospectus or to be filed as an exhibit to the Registration Statement which is not so described or filed therein as required. All descriptions of any such contracts or documents contained in the Registration Statement, any Preliminary Prospectus and in the Prospectus are accurate and complete descriptions of such documents in all material respects. Other than as described in the Registration Statement and the Prospectus, no such contract has been suspended or terminated for convenience or default by the Company or any Subsidiary party thereto or any of the other parties thereto, and neither the Company nor any of its Subsidiaries has received notice, and the Company has no knowledge, of any such pending or threatened suspension or termination, except for suspensions or terminations that are not reasonably likely to result in a Material Adverse Effect.
(e) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its Subsidiaries on the one hand, and the directors, officers, shareholders (or analogous interest holders), customers or suppliers of the Company or any of its Subsidiaries on the other hand, which is required to be described in or filed as an exhibit to the Registration Statement or the Prospectus and which is not so described or filed.
(f) Continued Business. No supplier, customer, distributor or sales agent of the Company or any Subsidiary has notified the Company or any Subsidiary that it intends to discontinue or decrease the rate of business done with the Company or any Subsidiary, except where such discontinuation or decrease has not resulted in and could not reasonably be expected to result in a Material Adverse Effect.
(g) Sarbanes-Oxley; Accounting and Disclosure Controls. Except as disclosed in the Registration Statement and in the Prospectus, the Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.
(h) Certain Fees, FINRA Affiliation. Except as set forth herein and in the Registration Statement and the Prospectus, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. Except as set forth in the Registration Statement, and the Prospectus, to the Company’s knowledge, there are no other arrangements, agreements or understandings of the Company or, to the Company’s knowledge, any of its stockholders that may affect the Underwriters’ compensation, as determined by FINRA. Except as already disclosed to the Representative, Company has not made any direct or indirect payments (in cash, securities or otherwise) to (i) any person, as a finder’s fee, investing fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who provided capital to the Company, (ii) any FINRA member, or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member within the 12-month period prior to the date on which the Registration Statement was filed with the Commission (the “Filing Date”) or thereafter. To the Company’s knowledge, no (i) officer or director of the Company or its subsidiaries, (ii) owner of 10% or more of the Company’s unregistered securities or that of its subsidiaries or (iii) owner of any amount of the Company’s unregistered securities acquired within the 180-day period prior to the Filing Date, has any direct or indirect affiliation or association with any FINRA member. The Company will advise the Representative if it becomes aware that any officer, director or stockholder of the Company or its Subsidiaries is or becomes an affiliate or associated person of a FINRA member participating in the Offering.
(i) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Offered Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
(j) Registration Rights. No Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company.
(k) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Offered Securities hereunder, the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, are sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). Except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. The Registration Statement and the Prospectus sets forth as of the date provided therein under the “Capitalization” section all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with IFRS. Except as set forth in the Registration Statement and the Prospectus, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.
(l) Tax Status. Except for matters that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, the Company and each Subsidiary (i) has made or filed all income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.
(m) Auditors. BF Borgers CPA PC (the “Auditor”) is the Company’s independent registered public accounting firm. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its opinion with respect to the financial statements of the Company and its subsidiaries for the periods filed with the Registration Statement or the Prospectus.
(n) Office of Foreign Assets Control. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any director or officer of the Company or any Subsidiary, or any employee, representative, agent or affiliate of the Company or any of its Subsidiaries or any other person acting on behalf of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), and the Company will not directly or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.
(o) Insurance. The Company and each of its Subsidiaries carries, or is covered by, insurance in such amounts and covering such risks as, in the Company’s reasonable belief, is adequate for the conduct of its business and the value of its properties.
(p) Company Not Ineligible Issuer. (i) At the time of filing the Registration Statement relating to the Offered Securities and (ii) as of the date of the execution and delivery of this Agreement (with such date being used as the determination date for purposes of this clause (ii)), the Company met all the requirements set forth in General Instruction I of Form F-1.
(q) Emerging Growth Company. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communications) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.
(r) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in either the Registration Statement, any Preliminary Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(s) Statistical or Market-Related Data. Any statistical, industry-related and market-related data included or incorporated by reference in the Registration Statement, any Preliminary Prospectus or the Prospectus, are based on or derived from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such data agree with the sources from which they are derived.
(t) Listing and Maintenance Requirements. The Securities are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Securities under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Offered Securities are currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of Nasdaq.
(u) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.
(v) Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Offered Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Offered Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Underwriters in connection with the Offering.
(w) Testing the Waters Communications. The Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (b) has not authorized anyone other than the Underwriters to engage in Testing-the-Waters Communications. The Company reconfirms that the Underwriters have been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications.
(x) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.
(y) Certificates. Any certificate signed by an officer of the Company and delivered to the Underwriters or to counsel for the Underwriters shall be deemed to be a representation and warranty by the Company to the Underwriters as to the matters set forth therein.
(z) Reliance. The Company acknowledges that the Underwriters will rely upon the accuracy and truthfulness of the foregoing representations and warranties and hereby consents to such reliance.
Section 3. Delivery and Payment.
(a) On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell the Firm Shares to the Underwriters, and the Underwriters agree to purchase the Firm Shares. The purchase price for each Firm Share shall be $[*] per share (the “Per Share Price”).
(b) The Company hereby grants to the Representative the option to purchase some or all of the Option Shares, and, upon the basis of the warranties and representations and subject to the terms and conditions herein set forth, the Underwriters shall have the right to purchase all or any portion of the Option Shares at the Per Share Price as may be necessary to cover over-allotments made in connection with the transactions contemplated hereby. This option may be exercised by the Representative at any time (but not more than once) on or before the forty-fifth (45th) day following the date of the Prospectus, by written notice to the Company (the “Option Notice”). The Option Notice shall set forth the aggregate number of Option Shares as to which the option is being exercised, and the date and time when the Option Shares are to be delivered (such date and time being herein referred to as the “Option Closing Date”); provided, however, that the Option Closing Date shall not be earlier than the Closing Date (as defined below) nor earlier than the first business day after the date on which the option shall have been exercised nor later than the fifth business day after the date on which the option shall have been exercised unless the Company and the Representative otherwise agree. Payment of the purchase price for and delivery of the Option Shares shall be made at the Option Closing Date in the same manner and at the same office as the payment for the Firm Shares as set forth in subparagraph (c) below.
(c) The Firm Shares will be delivered by the Company to the Representative against payment of the purchase price therefor by wire transfer of same day funds payable to the order of the Company’s offices, or such other location as may be mutually acceptable, at a mutually agreeable time, on the second (or if the Firm Shares are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m. Eastern Time, the third) full business day following the date hereof, or at such other time and date as the Representative and the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, or, in the case of the Option Shares, at such date and time set forth in the Option Notice. The time and date of delivery of the Firm Shares or the Option Shares, as applicable, is referred to herein as the “Closing Date.” If the Representative so elects, delivery of the Firm Shares and Option Shares may be made by credit through full fast transfer to the account at The Depository Trust Company designated by the Representative.
Section 4. Covenants and Agreements of the Company. The Company further covenants and agrees with the Underwriters as follows:
(a) Registration Statement Matters. The Registration Statement and any amendments thereto have been declared effective, and if Rule 430A is used or the filing of the Prospectus is otherwise required under Rule 424(b), the Company will file the Prospectus (properly completed if Rule 430A has been used) pursuant to Rule 424(b) within the prescribed time period and will provide evidence satisfactory to the Representative of such timely filing. The Company will advise the Representative promptly after they receive notice thereof of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement or amendment to the Prospectus has been filed and will furnish the Representative with copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Representative promptly after it receives notice thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement the Prospectus or for additional information, and (ii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any order preventing or suspending the use of the Prospectus or any amendment or supplement thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Offered Securities for offering or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, any Preliminary Prospectus or the Prospectus or for additional information. The Company shall use its commercially reasonable efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission shall enter any such stop order or order or notice of prevention or suspension at any time, the Company will use its commercially reasonable efforts to obtain the lifting of such order at the earliest possible moment, or will file a new registration statement and use commercially reasonable efforts to have such new registration statement declared effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder, and will use commercially reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission.
(b) Blue Sky Compliance. The Company will cooperate with the Representative in endeavoring to qualify the Offered Securities for sale under the securities laws of such jurisdictions (United States and foreign) as the Representative may reasonably request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose; provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction where it is not now so qualified or required to file such a consent; and provided further that the Company shall not be required to produce any new disclosure document other than the Prospectus. The Company will, from time to time, prepare and file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long a period as the Representative may reasonably request for distribution of the Offered Securities. The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its commercially reasonable efforts to obtain the withdrawal thereof at the earliest possible moment.
(c) Amendments and Supplements to the Prospectus and Other Matters. The Company will comply with the Securities Act and the Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Offered Securities as contemplated in this Agreement and the Prospectus. If during the period in which a prospectus is required by law to be delivered in connection with the distribution of Offered Securities contemplated by the Prospectus (the “Prospectus Delivery Period”), any event shall occur as a result of which, in the judgment of the Company or in the opinion of the Representative or counsel for the Underwriters, it becomes necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Prospectus to comply with any law, the Company will promptly prepare and file with the Commission, and furnish at its own expense to the Underwriters and to any dealers, an appropriate amendment to the Registration Statement or supplement to the Registration Statement, any Preliminary Prospectus or the Prospectus that is necessary in order to make the statements in the Prospectus as so amended or supplemented, in the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement, any Preliminary Prospectus or the Prospectus, as so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the Prospectus in connection with the Offering, the Company will furnish the Representative with a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the Representative reasonably objects; the Representative and its counsel shall have a reasonable amount of time to review and return any comments to the Company.
(d) Copies of any Amendments and Supplements to the Prospectus. The Company will furnish the Underwriter, without charge, during the period beginning on the date hereof and ending on the final Closing Date of the Offering, as many copies of the Prospectus and any amendments and supplements thereto as the Representative may reasonably request.
(e) Free Writing Prospectus. The Company covenants that it has not and will not, unless it has obtained or will obtain the prior consent of the Representative, make any offer relating to the Offered Securities that would constitute a “free writing prospectus” (as defined in Rule 405 of the Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 of the Securities Act. In the event that the Representative expressly consents in writing to any such free writing prospectus (a “Permitted Free Writing Prospectus”), the Company covenants that it shall (i) treat each Permitted Free Writing Prospectus as a Company Free Writing Prospectus, and (ii) comply with the requirements of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.
(f) Registration. The Company shall use commercially reasonable efforts to maintain the effectiveness of the Registration Statement and a current Prospectus relating thereto for as long as the Securities remain outstanding. During any period when the Company fails to have maintained an effective Registration Statement or a current Prospectus relating thereto and a holder of a Representative’s Warrant desires to exercise such warrants and, in the opinion of counsel to the holder, Rule 144 is not available as an exemption from registration for the resale of the Warrant Shares, the Company shall promptly file a registration statement registering the resale of the Warrant Shares and use commercially reasonable efforts to have it declared effective by the Commission within ninety (90) days.
(g) Transfer Agent. The Company will maintain, at its expense, a registrar and transfer agent for its Common Shares for so long as the Common Shares are publicly-traded.
(h) Earnings Statement. As soon as practicable and in accordance with applicable requirements under the Securities Act, but in any event not later than 18 months after the last Closing Date, the Company will make generally available to its security holders and to the Representative an earnings statement, covering a period of at least 12 consecutive months beginning after the last Closing Date, that satisfies the provisions of Section 11(a) and Rule 158 under the Securities Act.
(i) Periodic Reporting Obligations. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission all reports and documents required to be filed under the Exchange Act within the time periods and in the manner required by the Exchange Act.
(j) No Manipulation of Price. The Company has not taken and will not take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company.
(k) Company Lock-Up.
(i) The Company will not, without the prior written consent of the Representative, from the date of execution of this Agreement and continuing for a period of 12 months from the date on which the trading of the Common Shares the Nasdaq commences (the “Lock-Up Period”): (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating to, Common Shares or Ordinary Share Equivalents, or modify the terms of any existing securities, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or any Ordinary Share Equivalents, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Shares or any Ordinary Share Equivalents, in cash or otherwise, except to the Underwriters pursuant to this Agreement. The Company agrees not to accelerate the vesting of any option or warrant or the lapse of any repurchase right prior to the expiration of the Lock-Up Period.
(ii) The restrictions contained in Section 4(k)(i) hereof shall not apply to: (A) the Offered Securities, (B) any Common Shares previously issued under Company Incentive Plans as described as outstanding in the Registration Statement and the Prospectus, (C) any options and other awards granted under a Company Incentive Plan or Common Shares issued pursuant to an employee stock purchase plan, in each case, as described in the Registration Statement and the Prospectus, and (D) Common Shares or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity; provided that (x) the aggregate number of Common Shares issued pursuant to clause (D) shall not exceed five percent (5%) of the total number of outstanding Common Shares immediately following the issuance and sale of the Offered Securities pursuant to this Agreement and (y) the recipient of any such Common Shares or other securities issued or granted pursuant to clauses (B), (C) and (D) during the Lock-Up Period shall enter into an agreement substantially in the form of Exhibit A hereto.
(l) Acknowledgment. The Company acknowledges that any advice given by any of the Underwriters to the Company is solely for the benefit and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without such Underwriter’s prior written consent.
Section 5. Conditions of the Obligations of the Underwriters. The obligations of the Underwriters hereunder shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof and as of the Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the following additional conditions:
(a) Accountants’ Comfort Letter. On the date hereof, the Representative shall have received, and the Company shall have caused to be delivered to the Representative, a letter from the Auditor addressed to the Representative, dated as of the date hereof, in form and substance satisfactory to the Representative. The letter shall not disclose any change in the condition (financial or other), earnings, operations, business or prospects of the Company from that set forth in the Prospectus, which, in the Representative’s sole judgment, is material and adverse and that makes it, in the Representative’s sole judgment, impracticable or inadvisable to proceed with the Offering of the Offered Securities as contemplated by the Prospectus.
(b) Bring-down Comfort Letter. On the Closing Date, the Representative shall have received from the Auditor a letter dated as of such Closing Date, in form and substance satisfactory to the Representative, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (a) of this Section 5, except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to such Closing Date.
(c) Compliance with Registration Requirements; No Stop Order; No Objection from FINRA. The Registration Statement shall have become effective and all necessary regulatory and listing approvals shall have been received not later than 5:30 P.M., New York City time, on the date of this Agreement, or at such later time and date as shall have been consented to in writing by the Representative. The Prospectus (in accordance with Rule 424(b)) and any Permitted Free Writing Prospectus shall have been duly filed with the Commission in a timely fashion in accordance with the terms thereof. At or prior to the Closing Date and the actual time of the Closing, no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing or suspending the use of the Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Offered Securities or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the part of the Commission shall have been complied with; and the FINRA shall have raised no objections to the fairness and reasonableness of the placement terms and arrangements.
(d) Corporate Proceedings. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement and the Prospectus, and the registration, sale and delivery of the Offered Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Underwriters’ counsel.
(e) No Material Adverse Effect. Subsequent to the execution and delivery of this Agreement and prior to the Closing Date, in the Underwriter’s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect.
(f) Opinion of Counsel for the Company. The Representative shall have received on the Closing Date the favorable opinion and negative assurances statement of Rimon, P.C., counsel to the Company, dated as of such Closing Date, including, without limitation, a customary negative assurance letter, addressed to the Representative in customary form reasonably satisfactory to the Representative. The Underwriters and Rimon, P.C., shall be entitled to rely on the opinion of each of the Company’s Republic of Malta, United Kingdom, Kingdom of Lesotho, and Canadian counsel filed as Exhibit 5.1 to the Registration Statement, as to the due incorporation, validity of the Securities and due authorization, execution and delivery of the Agreement.
(g) Opinion of Canadian Counsel for the Company. The Representative shall have received on the Closing Date the favorable opinion of Dentons Canada LLP, Canadian counsel to the Company, dated as of such Closing Date, including, without limitation, a customary negative assurance letter, addressed to the Representative in customary form reasonably satisfactory to the Representative.
(h) Opinions of Other Counsels for the Company’s Subsidiaries. The Representative shall have received on the Closing Date the favorable opinions of each of [*], the Company’s Republic of Malta counsel,1 Dentons & Co., the Company’s United Kingdom counsel, and Kleingeld & Mayet, the Company’s Kingdom of Lesotho counsel, dated as of such Closing Date, for the Company’s subsidiaries, including, without limitation, a customary negative assurance letter, addressed to the Representative in customary form reasonably satisfactory to the Representative.
(i) Officers’ Certificate. The Representative shall have received on the Closing Date a certificate of the Company, dated as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Representative shall be satisfied that, the signers of such certificate have reviewed the Registration Statement and the Prospectus, and this Agreement and to the further effect that:
(i) The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date;
(ii) No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company’s knowledge, threatened under the Securities Act; no order having the effect of ceasing or suspending the distribution of the Offered Securities or any other securities of the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange in the United States;
(iii) Subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus, there has not been: (a) any Material Adverse Effect; (b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the exercise of outstanding options or warrants or conversion of outstanding indebtedness into Common Shares) or outstanding indebtedness of the Company or any Subsidiary (except for the conversion of such indebtedness into Common Shares); (e) any dividend or distribution of any kind declared, paid or made on Common Shares; or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been sustained or will have been sustained which has a Material Adverse Effect.
(j) Secretary’s Certificate. As of the Closing Date the Representative shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date, certifying: (i) that each of the Company’s articles of incorporation and bylaws attached to such certificate is true and complete, has not been modified and is in full force and effect; (ii) that each of the Subsidiaries articles of incorporation and bylaws or charter documents attached to such certificate is true and complete, has not been modified and is in full force and effect; (iii) that the resolutions of the Company’s Board of Directors relating to the Offering attached to such certificate are in full force and effect and have not been modified; and (iv) the good standing of the Company and each of the Subsidiaries, but only to the extent good standing is a concept applicable in the jurisdiction of formation of a Subsidiary. The documents referred to in such certificate shall be attached to such certificate.
1 To confirm who is the Malta counsel that has worked for the Malta entity.
(i) Additional Documents. On or before the Closing Date, the Representative and counsel for the Underwriters shall have received such customary information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained. If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by notice to the Company at any time on or prior to the Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution) and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.
(j) Subsequent to the execution and delivery of this Agreement or, if earlier, the dates as of which information is given in the Registration Statement (exclusive of any amendment thereof) and the Prospectus (exclusive of any supplement thereto), there shall not have been any change in the capital stock or long-term debt of the Company (other than as described in the Registration Statement, any Preliminary Prospectus or the Prospectus) or any change or development involving a change, whether or not arising from transactions in the ordinary course of business, in the business, condition (financial or otherwise), results of operations, shareholders’ equity, properties or prospects of the Company, taken as a whole, including but not limited to the occurrence of any fire, flood, storm, explosion, accident, act of war or terrorism or other calamity, the effect of which, in any such case described above, is, in the sole judgment of the Representative, so material and adverse as to make it impracticable or inadvisable to proceed with the sale of Offered Securities or Offering as contemplated hereby.
(k) Subsequent to the execution and delivery of this Agreement and up to a Closing Date, there shall not have occurred any of the following: (i) trading in securities generally on the Nasdaq or any of the New York Stock Exchange, the NYSE American, or any tier of the markets operated by OTC Markets Group, Inc. shall not have commenced, (ii) a banking moratorium shall have been declared by federal or state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States, (iii) the United States shall have become engaged in hostilities in which it is not currently engaged, the subject of an act of terrorism, there shall have been an escalation in hostilities involving the United States, or there shall have been a declaration of a national emergency or war by the United States, or (iv) there shall have occurred any other calamity or crisis or any actual or prospective change in general economic, political or financial conditions in the United States or elsewhere, if the effect of any such event in clause (ii) or (iv) makes it, in the sole judgment of the Representative, impracticable or inadvisable to proceed with the sale or delivery of the Offered Securities on the terms and in the manner contemplated by the Prospectus.
(l) The Representative shall have received a lock-up agreement from each person or entity set forth on Schedule A (each, a “Lock-Up Party”), duly executed by the applicable Lock-Up Party, in each case substantially in the form attached as Schedule B.
(m) No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Offered Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Offered Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company.
If any of the conditions specified in this Section 5 shall not have been fulfilled when and as required by this Agreement, or if any of the certificates, opinions, written statements or letters furnished to the Representative or to Underwriters’ counsel pursuant to this Section 5 shall not be reasonably satisfactory in form and substance to the Representative and to Underwriters’ counsel, all obligations of the Underwriters hereunder may be cancelled by the Representative at, or at any time prior to, the consummation of the Offering. Notice of such cancellation shall be given to the Company in writing.
Section 6. Payment of Company Expenses. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Offered Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Offered Securities; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Securities; (iv) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys’ fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country, and, if reasonably requested by the Representative, preparing and printing a “Blue Sky Survey,” an “International Blue Sky Survey” or other memorandum, and any supplements thereto, advising any of the Representative of such qualifications, registrations and exemptions; (vii) if applicable, the filing fees incident to the review and approval by the FINRA of the Underwriters’ participation in the offering and distribution of the Offered Securities; (viii) the fees and expenses associated with including the Offered Securities on the Nasdaq; and (ix) all costs and expenses incident to the travel and accommodation of the Company’s employees on the “roadshow,” as described in Section 1(a)(iv) of this Agreement.
Section 7. Indemnification and Contribution.
(a) The Company agrees to indemnify, defend and hold harmless the Underwriters, their respective affiliates, directors and officers and employees, and each person, if any, who controls the Underwriters within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (each an “Underwriter Indemnified Party”), from and against any losses, claims, damages or liabilities (including in settlement of any litigation if such settlement is effected with the prior written consent of the Company) arising out of (i) an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to Rules 430A and 430B of the Securities Act Regulations, or arise out of or are based upon the omission from the Registration Statement, or alleged omission to state therein, a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) an untrue statement or alleged untrue statement of a material fact contained in the Prospectus, or any amendment or supplement thereto, or in any other materials used in connection with the Offering, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and will reimburse such Underwriter Indemnified Party for any legal or other expenses reasonably incurred by it in connection with evaluating, investigating or defending against such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, or, in reliance upon and in conformity with the Underwriter Information. The indemnification obligations under this Section 7(a) are not exclusive and will be in addition to any liability which the Company might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Underwriter Indemnified Party.
(b) The Underwriters will indemnify, defend and hold harmless the Company, its affiliates, directors, officers and employees, and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (each a “Company Indemnified Party”), from and against any losses, claims, damages or liabilities to which such Company Indemnified Party may become subject, under the Securities Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Representative), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with the Underwriter Information, and will reimburse such Company Indemnified Party for any legal or other expenses reasonably incurred by it in connection with defending against any such loss, claim, damage, liability or action. The indemnification obligations under this Section 7(b) are not exclusive and will be in addition to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Company Indemnified Party.
(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof, but the failure to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure. In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of the indemnifying party’s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof; provided, however, that if (i) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (ii) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party), or (iii) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, the indemnified party shall have the right to employ a single counsel to represent it in any claim in respect of which indemnity may be sought under subsection (a) or (b) of this Section 7, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the indemnified party as incurred.
(d) The indemnifying party under this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is a party or could be named and indemnity was or would be sought hereunder by such indemnified party, unless such settlement, compromise or consent (i) includes an unconditional release of such indemnified party from all liability for claims that are the subject matter of such action, suit or proceeding and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Notwithstanding the foregoing, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel pursuant to Section 7(c), such indemnifying party agrees that it shall be liable for any settlement effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.
(e) If the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then the indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering and sale of the Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand shall be deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company bear to the total cash fees received by the Underwriters. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters and the parties’ relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection (e) were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in the first sentence of this subsection (e). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection (e) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim that is the subject of this subsection (e). No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
(f) For purposes of this Agreement, the Representative confirms, and the Company acknowledges, that there is no information concerning the Underwriters furnished in writing to the Company by the Underwriters specifically for preparation of or inclusion in the Registration Statement, any Preliminary Prospectus or the Prospectus other than the Underwriter Information.
Section 8. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company or any person controlling the Company, of its officers, and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Underwriters, the Company, or any of its or their respective affiliates, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement. A successor to the Underwriters, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement agreements contained in this Agreement.
Section 9. Termination.
(a) This Agreement shall become effective upon the mutual execution of this Agreement by the Company and the Representative. The Representative shall have the right to terminate this Agreement by giving written notice to the Company at any time prior to the Closing Date if: (i) any domestic or international event or act or occurrence has materially disrupted, or in the reasonable opinion of the Representative will in the immediate future materially disrupt, the market for the Company’s securities or securities in general; or (ii) trading on Nasdaq has been rejected by Nasdaq or made subject to material limitations, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices for securities have been required, on the Nasdaq or by order of the Commission, FINRA or any other governmental authority having jurisdiction; or (iii) a banking moratorium has been declared by any state or federal authority or any material disruption in commercial banking or securities settlement or clearance services has occurred; or (iv) (A) there has occurred any outbreak or escalation of hostilities or acts of terrorism involving the United States, Canada, Malta, the United Kingdom or the Kingdom of Lesotho or there is a declaration of a national emergency or war by the United States, Canada, Malta, the United Kingdom or the Kingdom of Lesotho or (B) there has been any other calamity or crisis or any change in political, financial or economic conditions, if the effect of any such event in (A) or (B), in the reasonable judgment of the Representative, is so material and adverse that such event makes it impracticable or inadvisable to proceed with the Offering, sale and delivery of the Securities on the terms and in the manner contemplated by the Prospectus.
(b) Any notice of termination pursuant to this Section 9 shall be in writing.
(c) If this Agreement shall be terminated pursuant to any of the provisions hereof, or if the sale of the Securities provided for herein is not consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof, the Company will, subject to demand by the Representative, reimburse the Underwriters for only the reasonable fees and expenses of their counsel actually incurred by the Underwriters in connection herewith as allowed under FINRA Rule 5110, less any amounts previously paid by the Company, subject to the cap on expenses set forth in Section 1(a)(iv) hereof. To the extent that the Underwriters’ out-of-pocket expenses are less than the sums already advanced by the Company to the Underwriter (“Advances”), the Underwriters will return to the Company that portion of the Advances not offset by actual expenses.
Section 10. Right of First Refusal. The Company hereby grants the Representative a right of first refusal (“Right of First Refusal”) for one (1) year from the date of consummation of the Offering or the termination or expiration of the Company’s engagement of the Representative, to act as underwriter, placement agent or financial advisor (or to act as joint underwriter, placement agent or financial advisor on at least equal economic terms) in connection with any public or private financings in the United States (debt or equity, and including self-underwritten offerings), merger, business combination, recapitalization or sale of some or all of the equity or assets of the Company or any of its Subsidiaries out of the ordinary course of business (collectively, “Future Services”); provided, however, that the Representative shall not be entitled to have such Right of First Refusal if no Offering is consummated. The Company shall notify the Representative in writing of its intention to pursue an activity that would enable the Representative to exercise its Right of First Refusal to provide Future Services. In the event the Company notifies the Representative of its intention to pursue an activity that would enable the Representative to exercise its Right of First Refusal to provide Future Services, the Representative shall notify the Company of its election to provide such Future Services, including notification of the compensation and other terms to which the Representative claims to be entitled, within thirty (30) days of written notice by the Company. In the event the Company engages the Representative to provide such Future Services, the Representative will be compensated consistent with Section 2 of that certain engagement letter between the Company and the Representative, dated September 8, 2020 (as amended, the “Engagement Letter”), unless mutually agreed otherwise by the Company and the Representative. To the extent the Company is approached by a third party (“Third Party Advisor”) to lead any public or private financing (debt or equity), merger, business combination, recapitalization or sale of some or all of the equity or assets of the Company, Boustead will be notified of the transaction and be granted the right to participate in such transaction under any syndicate formed by the Third Party Advisor.
Section 11. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered, delivered by reputable overnight courier (i.e., Federal Express) or delivered by facsimile or e-mail transmission to the parties hereto as follows:
If to the Representative, then to:
Boustead Securities, LLC
6 Venture, Suite 395
Irvine, CA 92618
Attn: Keith Moore
Email: keith@boustead1828.com
With a copy (which shall not constitute notice) to:
Bevilacqua PLLC
1050 Connecticut Avenue, NW, Suite 500
Washington, DC 20036
Attn: Louis A. Bevilacqua, Esq.
Email: lou@bevilacquapllc.com
If to the Company:
Akanda Corp.
1a, 1b Learoyd Road
New Romney TN28 8XU, United Kingdom Attn: Tejinder Virk
Email: tej@akandacorp.com
With copies (which shall not constitute notice) to:
Rimon, P.C.
423 Washington Street, Suite 600
San Francisco, CA 94111
Attn: Mark C. Lee
Email: mark.c.lee@rimonlaw.com
Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, Ontario M5K 0A1 Canada
Attn: Eric Foster
Email: eric.foster@dentons.com
Any party hereto may change the address for receipt of communications by giving written notice to the others.
Section 12. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal assigns, and no other person will have any right or obligation hereunder.
Section 13. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
Section 14. Governing Law; Venue; Agent for Service; Waiver of Jury Trial. This Agreement shall be deemed to have been made and delivered in New York and both this Agreement and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the Underwriters and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may now or hereafter have to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Underwriters and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified mail to the Company’s address shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon an Underwriter mailed by certified mail to such Underwriter’s address shall be deemed in every respect effective service process upon such Underwriter, in any such suit, action or proceeding. The Company hereby appoints C T Corporation System, as its authorized agent (the “Authorized Agent”) upon whom process may be served in any suit, action or proceeding arising out of or based upon the Transaction Documents or the transactions contemplated herein which may be instituted in any court referred to above. The Company hereby represents and warrants that the Authorized Agent (i) is validly existing and can lawfully accept such services of process and (ii) has accepted such appointment and has agreed to act as said agent for service of process, and the Company agrees to take any and all action, including the filing of any and all documents that may be necessary to continue such appointment in full force and effect as aforesaid. The Company hereby authorizes and directs the Authorized Agent to accept such service. Service of process upon the Authorized Agent shall be deemed, in every respect, effective service of process upon the Company. If the Authorized Agent shall cease to act as agent for service of process, the Company shall appoint, without unreasonable delay, another such agent in the United States, and notify the Representative of such appointment. This paragraph shall survive any termination of this Agreement, in whole or in part. The Company agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court shall be conclusive and binding upon the Company and may be enforced in any other courts to the jurisdiction of which the Company is or may be subject, by suit upon such judgment. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE AND AGREES NOT TO REQUEST A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE ARISING OUT OF OR RELATING TO THIS AGREEMENT.
Section 15. General Provisions.
(a) This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations solely with respect to the subject matters hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of the Engagement Letter shall remain in full force and effect. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Such counterparts may be executed and delivered by electronic means, which shall not impair such execution or delivery. This Agreement may not be amended or modified unless in writing and signed by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
(b) The Company acknowledges and agrees that in connection with the Offering of the Securities: (i) the Underwriters have acted at arm’s length, is not an agent of, and owes no fiduciary duties to the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations set forth in this Agreement and (iii) the Underwriters may have interests that differ from those of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Offered Securities.
[The remainder of this page has been intentionally left blank.]
If the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.
Very truly yours, | ||
AKANDA CORP. | ||
By: | ||
Name: Tejinder Virk | ||
Title: Chief Executive Officer |
The foregoing Underwriting Agreement is hereby confirmed and agreed to of the date first above written.
BOUSTEAD SECURITIES, LLC, in its | ||
own capacity and as representative of the Underwriters | ||
By: | ||
Name: Keith Moore | ||
Title: Chief Executive Officer |
Schedule I
Name |
Number
of Firm
Shares to be Purchased |
Number
of Option
Shares to be Purchased |
||
Boustead Securities, LLC | ||||
[*] | ||||
Total |
Schedule A
Lock-up Parties
Lock-up Parties | |
[*] |
Schedule B
Form of Lock-up Agreement
[_____________], 2021
Boustead Securities, LLC
6 Venture, Suite 395
Irvine, CA 92618
Re: Proposed Public Offering by Akanda Corp.
Ladies and Gentlemen:
The undersigned, a stockholder of Akanda Corp., a Canadian company (the “Company”), understands that Boustead Securities, LLC (the “Representative”) will act as the representative of the underwriters in carrying out an offering (the “Offering”) of the Company’s common shares (the “Securities”). In recognition of the benefit that the Offering will confer upon the undersigned, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Representative that, without the prior written consent of the Representative, during a period of up to 365 days from the date on which the trading of the Securities on the Nasdaq Stock Exchange commences (the “Lock-Up Period”), the undersigned will not, without the prior written consent of the Representative, directly or indirectly (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any securities of the Company (collectively, the “Lock-Up Securities”), whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition, or file, or cause to be filed, any registration statement under the Securities Act of 1933, as amended, with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of the Lock-Up Securities or such other securities, in cash or otherwise.
The Representative may in its sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the Lock-Up Period. When determining whether or not to release shares from the lock-up agreements, the Representative will consider, among other factors, the security holder’s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent of the Representative as follows, provided that (1) the Representative receives a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported in any public report or filing with the Securities and Exchange Commission, or otherwise and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers:
(i) as a bona fide gift or gifts (including but not limited to charitable gifts); or
(ii) to any member of the immediate family of the undersigned or to a trust or other entity for the direct or indirect benefit of, or wholly-owned by, the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); or
(iii) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (1) transfers to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (2) distributions of Common Shares or any security convertible into or exercisable for Common Shares to limited partners, limited liability company members or stockholders of the undersigned; or
(iv) if the undersigned is a trust, transfers to the beneficiary of such trust; or
(v) by will, other testamentary document or intestate succession; or
(vi) by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement.; or
(vii) pursuant to a trading plan established pursuant to Rule 10b5-1 of the Exchange Act.
Furthermore, no provision in this letter shall be deemed to restrict or prohibit (1) transactions relating to Securities purchased in the Offering or acquired in open market transactions after the completion of Offering; and (2) the exercise or exchange by the undersigned of any option or warrant to acquire any Common Shares or options to purchase Common Shares, in each case for cash or on a “cashless” or “net exercise” basis, pursuant to any share option, share bonus or other share plan or arrangement; provided, however, that the underlying Common Shares shall continue to be subject to the restrictions on transfer set forth in this letter.
The undersigned further agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during the Lock-Up Period, it will give notice thereof to the Representative and will not consummate such transaction or take any such action unless it has received written confirmation from the Company that the Lock-Up Period has expired.
The undersigned understands that, if the Offering shall terminate or be terminated prior to payment for and delivery of the Securities, the undersigned shall be released from all obligations set forth herein.
The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions.
The undersigned, whether or not participating in the Offering, understands that the Representative is proceeding with the Offering in reliance upon this lock-up agreement.
This lock-up agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.
Very truly yours, | |
(Name - Please Print) | |
(Signature) |
[Signature Page to Lock-Up Agreement]
Exhibit A
Form of Representative’s Warrant
Exhibit 2.1
EXECUTION VERSION
Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. This information is not material and disclosure of such information would constitute an unwarranted invasion of personal privacy. “[*]” indicates that information has been redacted.
SHARE PURCHASE AGREEMENT
THIS AGREEMENT is dated effective September 29, 2021.
AKANDA CORP.
(the "Purchaser")
- and -
HALO COLLECTIVE INC.
(the "Vendor")
RECITALS:
A. | the Vendor is the registered and beneficial owner of all of the issued and outstanding shares (the "Shares") in the capital of Cannahealth Limited ("Cannahealth"), a limited liability company incorporated and existing under the laws of Malta; |
B. | the Vendor is the parent company of each of: (i) Bophelo Holdings Ltd. ("Holdco"), a limited liability company incorporated and existing under the laws of the United Kingdom, (ii) Bophelo Bioscience & Wellness (pty) Ltd. ("Bophelo"), a limited liability company incorporated and existing under the laws of the Kingdom of Lesotho: and (iii) Canmart Ltd ("Canmart" and together with Cannahealth, Holdco and Bophelo, the "Corporations" and each a "Corporation"), a limited liability company incorporated and existing under the laws of the United Kingdom; |
C. | Holdco acquired its interest in Bophelo pursuant to a share purchase agreement, made among the Vendor, Louisa Maliako Mojela, Moira Granny Seape, Boiketlo Biomed (Pty) Ltd., GMG Financial Services Ltd., 1942 Capital Partners (Pty) Ltd. and Seedy Lette, dated November 27, 2019 and its interest in Canmart pursuant to a share purchase agreement, made among the Vendor, David Keith Dean and Darran William Quinn, dated October 1, 2020 (collectively, the "Pre-existing Purchase Agreements"); |
D. | the Vendor and each of the Corporations intend to undertake a re-organization such that, among other things, Cannahealth shall become the sole registered and beneficial owner of Holdco and Canmart and Holdco shall become the sole registered and beneficial owner of Bophelo (the "Reorganization"); |
E. | Canmart carries on the business of a licensed importer and distributor of cannabis-based products for medicinal use in the United Kingdom (the "Canmart Business") and Bophelo carries on the business of cultivating and producing bulk cannabis, as authorized by the Ministry of Health of Lesotho, intended for export (the "Bophelo Business" and together with the Canmart Business, the "Business"); and |
F. | the Purchaser wishes to purchase the Shares from the Vendor and the Vendor wishes to sell the Shares to the Purchaser upon the terms and conditions of this Agreement. |
2.
NOW THEREFORE, the parties agree as follows:
Article 1
INTERPRETATION
1.1 | Interpretation |
In this share purchase agreement ("Agreement") the following shall apply:
(a) | Taxes: In this Agreement, "Tax" or "Taxes" means all federal, provincial, territorial, county, municipal, local or foreign taxes, duties, imposts, levies, assessments, tariffs and other charges imposed, assessed or collected by a Governmental Authority (as defined herein) including, (i) any gross income, net income, gross receipts, business, royalty, capital, capital gains, goods and services, value added, severance, stamp, franchise, occupation, premium, capital stock, sales and use, real property, land transfer, personal property, ad valorem, transfer, licence, profits, windfall profits, environmental, payroll, employment, employer health, pension plan, anti-dumping, countervail, excise tax; (ii) all withholdings on amounts paid to or by the relevant person; (iii) all employment insurance premiums, and pension plan contributions or premiums; (iv) any fine, penalty, interest, or addition to tax, (v) any tax imposed, assessed, or collected or payable pursuant to any Tax-sharing agreement or any other contract relating to the sharing or payment of any such Tax, levy, assessment, tariff, duty, deficiency, or fee; and (vi) any liability for any of the foregoing as a transferee, successor, guarantor, or by contract or by operation of law. |
(b) | Currency: Unless otherwise specified, all dollar amounts in this Agreement, including the symbol "$", refer to Canadian currency. |
(c) | Headings: The division of this Agreement into Articles, Sections and other subdivisions and the inclusion of headings are provided for convenience only and do not affect the construction or interpretation of this Agreement. |
(d) | Including: In this Agreement, the words "include" or "including" mean "include (or including), without limitation," and the words following "include" or "including" are not to be considered an exhaustive list, unless expressly stated otherwise (e.g. including only). |
(e) | Performance on Holidays: If any act is required by the terms of this Agreement to be performed on a day which is not a Business Day, the act will be valid if performed on the next succeeding Business Day. In this Agreement "Business Day" means any day other than Saturday, Sunday or a statutory holiday in Ontario. |
(f) | References to Persons: Unless the context otherwise requires, any reference in this Agreement to a "person" includes any partnership, firm, trust, corporation, government entity, authority, or department, or other entity and their successors and permitted assigns. |
(g) | Statutory References: Unless otherwise specified, any reference in this Agreement to a statute includes all rules and regulations made under it and all applicable guidelines, bulletins or policies made in connection with it and which are legally binding, in each case as it or they may have been, or may from time to time be, amended or re-enacted. |
3.
(h) | Time: Time is of the essence of this Agreement, and no extension or variation of this Agreement will operate as a waiver of this provision. |
(i) | Time Periods: Unless otherwise specified, a period of days will be deemed to begin on the first day after the event which began the period and to end at 5:00 p.m. (Toronto Time) on the last day of the period. If a period of time is to expire on any day that is not a Business Day, the period will be deemed to expire at 5:00 p.m. (Toronto Time) on the next succeeding Business Day. |
(j) | Knowledge: in this Agreement, any reference to "knowledge" of the Vendor means the actual knowledge of Kiran Sidhu or Philip van den Berg and the knowledge that they would have had, had they made due and reasonable enquiry into the relevant matter. |
Article 2
PURCHASE AND SALE OF PURCHASED INTEREST
2.1 | Agreement to Purchase and Sell |
Subject to the terms and conditions of this Agreement, as of the Closing Time, the Vendor shall sell, transfer, convey and assign to the Purchaser and the Purchaser shall purchase and acquire from the Vendor, all of the Shares.
2.2 | Purchase Price |
The consideration payable by the Purchaser to the Vendor for the Shares (the "Purchase Price") will be US$13,129,212. The Purchase Price will be paid by way of issuance to the Vendor on the Closing Date of 13,129,212 common shares in the capital of the Purchaser (the "Consideration Shares") at a price per share of US$1.00, as fully paid and non-assessable common shares, free and clear of all encumbrances.
2.3 | Section 85 Election |
The Vendor shall be entitled to make an income tax election with the Purchaser pursuant to subsection 85(1) of the Income Tax Act (Canada) (“Tax Act”) and the analogous provisions of provincial income tax legislation to defer tax on the transfer of the Shares by the Vendor to the Purchaser in consideration for the Consideration Shares by providing two (2) signed copies of the necessary election forms to the Purchaser within ninety (90) days following the date of this Agreement, duly completed with the details of the Shares transferred and the applicable agreed amounts for the purposes of such elections. Thereafter, subject to the election forms complying with the provisions of the Tax Act (or applicable provincial income tax legislation), the forms will be signed by the Purchaser and returned to the Vendor within ninety (90) days after the receipt thereof by the Purchaser for filing with the Canada Revenue Agency (or the applicable provincial Governmental Entity). The Purchaser will not be responsible for the proper completion of any election form and, except for the obligation of the Purchaser to so sign and return duly completed election forms which are received by the Purchaser within ninety (90) days of the Closing Date, the Purchaser will not be responsible for any Taxes resulting from the failure by the Vendor to properly complete or file the election forms in the form and manner and within the time prescribed by the Tax Act (and any applicable provisions of provincial income tax legislation). In its sole discretion, the Purchaser may choose to sign and return an election form received by it more than ninety (90) days following the Closing Date but has no obligation to do so.
4.
Article 3
REPRESENTATIONS AND WARRANTIES
3.1 | Representations and Warranties of the Vendor |
The Vendor represents and warrants to the Purchaser as follows:
Authorization, Non-Contravention, etc.
(a) | the Vendor is a corporation formed and existing under the laws of Ontario; |
(b) | the Vendor has the corporate power to enter into and perform its obligations under this Agreement; |
(c) | the execution and delivery of, and performance by the Vendor of this Agreement and the sale of the Shares has been, or will at Closing be, duly authorized by all necessary action on behalf of the Vendor; |
(d) | this Agreement has been duly and validly executed by the Vendor and constitutes a legal, valid and binding agreement of the Vendor, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights and subject to general principles of equity; |
(e) | the execution, delivery and performance by the Vendor of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) violate, conflict with or result in the breach of any provision of the constating documents of the Vendor; (ii) conflict with or result in a violation or breach of any law or order applicable to the Vendor or the Corporations or any of their respective assets, properties or businesses, including the Business; (iii) conflict with, result in any breach of, constitute a default (or event which with the giving of notice or lapse of time, or both, would become a default) under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, any contract to which the Vendor or any of the Corporations is a party or the Vendor or any of the Corporations is bound or by which any of the Vendor's or any of the Corporations' properties or assets are subject; (iv) result in the creation of any lien or other encumbrance on any of the Vendor's or any of the Corporations' properties or assets; or (v) conflict with or result in a breach of any of the terms or requirements of, or give any Governmental Authority (as defined below) the right to revoke, withdraw, suspend, cancel, terminate or modify, any permit, licence or authorization that is held by or on behalf of the Vendor or any of the Corporations; |
(f) | except as disclosed in the disclosure schedule attached hereto as Schedule "A" (the "Disclosure Schedule"), no consent, approval, order or authorization of, or registration or declaration with, any applicable court, tribunal or government (federal, provincial, state, local or foreign) or any political subdivision thereof in Canada, the United Kingdom, the Kingdom of Lesotho, Malta, the United States or any other country, including any ministry, department, commission, board, bureau, agency or other regulatory, administrative or governmental authority (including stock exchanges) or instrumentality thereof (each, a "Governmental Authority") with jurisdiction over the Vendor or any of the Corporations is required to be obtained by the Vendor in connection with the execution and delivery of this Agreement or the consummation by the Vendor of the disposition of the Shares, except for those consents, orders, authorizations, declarations, registrations or approvals which have been obtained by the Vendor as of the date hereof or those consents, orders, authorizations, declarations, registrations or approvals that, if not obtained, would not prevent or materially delay the consummation of the disposition of the Shares or otherwise prevent the Vendor from performing its obligations under this Agreement; |
5.
(g) | all information with respect to the Corporations contained in the Vendor's prospectuses, annual reports, annual and interim Financial Statements, annual information forms, management's discussion and analysis of financial condition and results of operations, information circulars, material change reports, listing statements, press releases and all other information or documents required to be filed or furnished by the Vendor under applicable Canadian securities laws (the "Disclosure Record"), as of their respective filing dates, did not contain any misrepresentation (within the meaning of the Securities Act (Ontario)) other than any misrepresentation that was corrected and superseded by a subsequent document comprising the Disclosure Record; |
Financial Statements
(h) | complete copies of the audited annual financial statements of each of the Corporations for the years ended December 31, 2020 and 2019 and their unaudited interim financial statements for the three and six months ended June 30, 2021 and 2020, and, in each case, the related statements of income and retained earnings, stockholders' equity and cash flow for the years then ended (the "Financial Statements") have been delivered to the Purchaser. The Financial Statements have been prepared in accordance with IFRS applied on a consistent basis throughout the periods involved. The Financial Statements are based on the books and records of the Corporations, and fairly present the financial condition of the Corporations as of the respective dates they were prepared and the results of the operations of the Corporations for the periods indicated; |
(i) | except as disclosed in the Disclosure Schedule, no Corporation has any liabilities, except: |
(i) | those which are adequately reflected or reserved against in the Financial Statements as of the applicable date thereof, or |
(ii) | those which have been incurred in the ordinary course of business consistent with past practice since the date of the most recent Financial Statements and which are not, individually or in the aggregate, material in amount; |
(j) | since the date of the most recent Financial Statements, the business of the Corporations, including in particular the Business, has been conducted in the ordinary course, consistent with past practice and there has not been with respect to any Corporation any material adverse event; |
6.
Corporation, Capital, Shares
(k) | Cannahealth is a corporation validly existing and in good standing under the laws of Malta; |
(l) | Holdco is a corporation validly existing and in good standing under the laws of England and Wales; |
(m) | Canmart is a corporation validly existing and in good standing under the laws of England and Wales; |
(n) | Bophelo is a corporation validly existing and in good standing under the laws of the Kingdom of Lesotho; |
(o) | prior to the implementation of the Reorganization, each of the Corporations is a wholly owned subsidiary of the Vendor and Holdco is a wholly owned subsidiary of Cannahealth and, on completion of the Reorganization, Cannahealth is a wholly owned subsidiary of the Vendor, Holdco and Canmart are each a wholly owned subsidiary of Cannahealth, Bophelo is a wholly owned subsidiary of Holdco, and neither Canmart nor Bophelo have any subsidiaries; |
(p) | prior to the implementation of the Reorganization, except for Cannahealth, which owns all of the issued and outstanding shares in the capital of Holdco, none of the Corporations own any securities of (or other interest in) any other person and, on completion of the Reorganization, other than shares of Holdco and Canmart, Cannahealth does not own any securities of (or other interest in) any other person, and other than Bophelo, Holdco does not own any securities of (or other interest in) any other person, and neither Canmart nor Bophelo own any securities of (or other interest in) any other person; |
(q) | the authorized and issued capital of each of the Corporations, both as at the date of this Agreement and as of the Closing Date after taking account of the Reorganization respectively, is set forth in the Disclosure Schedule and the Shares represent all of the issued and outstanding shares of Cannahealth; |
(r) | the Vendor beneficially owns the Shares with good and valid title and has the full power and authority to sell the Shares to the Purchaser; |
(s) | the Shares are, or will at Closing be, free and clear of all liens, charges and encumbrances, other than those restrictions on transfer of the Shares, if any, stated in the memorandum of association of Cannahealth; |
(t) | the execution and delivery by the Vendor of this Agreement and the performance by the Vendor of its obligations hereunder will not result in (i) the breach or violation of any terms or conditions of: (1) the constating documents or by-laws of the Vendor or any of the Corporations; (2) any applicable law, regulation or order, or (3) any contract to which the Vendor or any of the Corporations is a party or by which any of the property or assets of the Vendor or any of the Corporations may be affected, or (ii) the creation of any lien, charge or encumbrance on any of the Shares or the property or assets of any of the Corporations; |
(u) | no person (other than the Purchaser under this Agreement) has any written or oral agreement, option, right or privilege capable of becoming an agreement or option to acquire any of the Shares or to cause to be issued any unissued securities of any of the Corporations; |
7.
Conduct, Material Contracts
(v) | neither Cannahealth nor Holdco carry on any activity or business, other than holding shares of Holdco and Canmart (in the case of Cannahealth) and holding shares of Bophelo (in the case of Holdco); |
(w) | Canmart has conducted and is conducting the Canmart Business and operates and maintains the properties and assets used in the Canmart Business in compliance with all applicable laws, rules and regulations, except as would otherwise not have a material adverse effect on the Canmart Business; |
(x) | Bophelo has conducted and is conducting the Bophelo Business and operates and maintains the properties and assets used in the Bophelo Business in compliance with all applicable laws, rules and regulations, except as would otherwise not have a material adverse effect on the Bophelo Business; |
(y) | neither Canmart, nor Bophelo, or any respective subsidiary thereof, have received any written or oral notice from a governmental body that alleges that it is not in compliance with any material legal requirement, and nor has any such entity been subject to any material adverse inspection, finding, investigation, penalty assessment, suspension, revocation, audit or other compliance or enforcement action. (A) Such entities have not received any written or oral notice from any governmental body having jurisdiction over its operations, activities, locations, or facilities, of (I) any material deficiencies or violations of, or (II) any material remedial or corrective actions required in connection with, any company permit or license or their renewal, and (B) no action is being or, to the knowledge of the Vendor, has been threatened or contemplated which (I) could reasonably be expected to result in the issuance of any notice referenced in the preceding clause (A) or (II) could prevent or materially impair the Canmart Business or Bophelo Business; |
(z) | Canmart has the corporate power to own or lease its property and to carry on the Canmart Business as now being conducted by it and is registered, licensed or otherwise qualified in all the jurisdictions where it owns or leases that property and carries on the Canmart Business; |
(aa) | Bophelo has the corporate power to own or lease its property and to carry on the Bophelo Business as now being conducted by it and is registered, licensed or otherwise qualified in all the jurisdictions where it owns or leases that property and carries on the Bophelo Business; |
(bb) | none of the Corporations is in default of any of its obligations under any material contract to which it is party (each a "Material Contract") and, to the knowledge of the Vendor, each other party to each Material Contract is not in default of its respective obligations under each such Material Contract; |
8.
(cc) | each of the Corporations holds all applicable licenses, permits, orders and related approvals authorizing it to conduct its business, in particular the Business, as applicable, including to: (i) import and distribute cannabis-based products into the United Kingdom for medicinal use; and (ii) cultivate and produce bulk cannabis for export from the Kingdom of the Lesotho (each a "Regulatory License"). Each Regulatory License is in full force and effect in all material respects and has not been revoked, suspended, cancelled, rescinded, terminated, modified and has not expired. There are no pending or, to the Vendor's knowledge, threatened actions by or before any Governmental Authority to revoke, suspend, cancel, rescind, terminate and/or materially adversely modify any Regulatory License. The Disclosure Schedule contains a complete and accurate list of all Regulatory Licenses, and true and correct copies of all of such Regulatory Licenses have been made available to the Purchaser; |
(dd) | all finished goods inventories, supplies and spare parts inventories owned by any of the Corporations, wherever located (the "Inventory"), whether or not reflected in the most recent Financial Statements, consist of a quality and quantity usable and salable in the ordinary course of business, except for obsolete, damaged, defective or slow-moving or other items required to be removed from inventory under applicable law, each of which have been written off or written down to fair market value or for which adequate reserves have been established. All Inventory is owned by the Corporations free and clear of all liens and encumbrances, and no Inventory is held on a consignment basis; |
Litigation
(ee) | there are no actions, suits, hearings, arbitrations, audits, charges, orders (draft or otherwise), judgments, injunctions, decrees, awards, writs, proceedings (public or private) or investigations that have been brought by or against any Governmental Authority or any other person (collectively, "Proceedings") pending or, to the knowledge of the Vendor, threatened, against or affecting the Shares or any of the Corporations or that seek to prevent, enjoin, alter or delay the transactions provided for by this Agreement; |
Insurance
(ff) | Each of the Corporations maintain insurance policies of the type and in the amounts customarily carried by prudent persons conducting a business similar to the Business and are sufficient for compliance with all Laws and Contracts to which the Corporations (or any of them) are a party or by which they are bound. |
(gg) | All insurance policies are in full force and effect. The Closing of the Transaction will not cause a modification, reduction or cancellation of any such insurance policy. The Corporation is not in default with respect to any of the provisions contained in any such insurance policies and has not failed to give any notice or pay any premium or present any claim under any such insurance policy in a timely manner. The Vendors have no reason to believe that any of the insurance policies will not be renewed by the insurer upon the scheduled expiry of the policy. There has been no significant change in relationship between any of the Corporations and their insurers, the premiums or availability of coverage, in the two (2) years preceding the date hereof. No Corporation has received notice from any of the insurers regarding cancellation of its insurance policies or denying any claims. There are no circumstances under which the Corporations would be required to or, in order to maintain its coverage, give any notice to the insurers under any such insurance policies which has not been given. No Corporation has experienced claims in excess of the current coverage of its insurance. There will be no retrospective insurance premiums or charges or any other similar adjustment on or with respect to any of the insurance policies for any period or occurrence from the date of this Agreement until the Closing Time. |
9.
Indebtedness & Liabilities
(hh) | except as disclosed in the Disclosure Schedule, no Corporation is indebted to any person and no Corporation is a party to, bound by, nor subject to any debt instrument or any agreement, contract or commitment to create, assume or issue any debt instrument or incur any indebtedness; |
(ii) | no Corporation has given nor agreed to give, nor is it a party to or bound by or subject to any guarantee or other financial assistance to any person; |
Assets, Property, Books and Records
(jj) | the assets owned, licensed or leased by each Corporation constitute all of the property and assets necessary to carry on such Corporation's business (including the Business) as currently carried on, are free of material defects and include all proprietary rights, Intellectual Property Rights and other property and assets, tangible and intangible, used in connection with the such business; |
(kk) | without limiting the foregoing, on acquisition of the shares of each of Bophelo and Canmart pursuant to the Pre-existing Purchase Agreements, the Vendor acquired good and valid title to, and has the full power and authority to transfer, such shares to Cannahealth pursuant to the Reorganisation and Cannahealth holds such shares free and clear of all liens, charges and encumbrances; |
(ll) | all material tangible assets used in the Business are in good operating condition and in a state of good repair and maintenance, except only for reasonable wear and tear; |
(mm) | except as disclosed in the Disclosure Schedule, no Corporation is a party to any real property lease; |
(nn) | except as disclosed in the Disclosure Schedule, none of the Corporations owns any real property; |
(oo) | the accounts receivables of the Business, together with any security or collateral therefor, arose from bona fide transactions in the ordinary course of the Business and are valid, enforceable and fully collectible accounts and are not subject to any defence, set-off or counterclaim; |
(pp) | the books and records of the Corporations (collectively, the "Books and Records") have, in all material respects, been duly maintained in accordance with all applicable legal requirements and contain full and accurate records of all material matters relating to the Corporations and the Business; |
10.
(qq) | the Disclosure Schedule contains a true and complete list of all deposit and disbursement accounts maintained by each of the Corporations with any bank, brokerage house or other financial institution, including for each such account the name and address of the financial institution, the nature of the account, the account number, and the name of the account holder, the names of each person with authority to draw on such account or to have access to such account, or to change the persons authorized to draw on the account. All such accounts, credit lines, safe deposit boxes and vaults are maintained by each of the Corporations for normal business purposes and no such proxy, power of attorney or other like instrument is irrevocable; |
Intellectual Property
(rr) | no Corporation has during the 2 years preceding the date of this Agreement been a party to any Proceedings, nor to the knowledge of the Vendor, are any Proceedings threatened as to which there is a reasonable possibility of a determination adverse to any Corporation, involving a claim of infringement by any person of any patent, patent application and invention, trademark, tradename, trademark or tradename registration or application, copyright or copyright registration or application for copyright registration, and each licence or licensing agreement, for any of the foregoing, relating to the Business or held by any Corporation (the "Intellectual Property Rights"). No Intellectual Property Right is subject to any outstanding order, judgment, decree, stipulation or agreement restricting the use thereof by the applicable Corporation or restricting the licensing thereof by such Corporation to any person. The Vendor does not have any knowledge that would cause such person to believe that the use of the Intellectual Property Rights or the conduct of the Business conflicts with, infringes upon or violates any patent, patent licence, patent application, trademark, tradename, trademark or tradename registration, copyright, copyright registration, service mark, brand mark or brand name or any pending application relating thereto, or any trade secret, know-how, programs or processes, or any similar rights, of any person; |
(ss) | Canmart either owns the entire right, title and interest in, to and under, or has acquired a licence to use, any and all patents, trademarks, tradenames, brand names and copyrights that are material to the conduct of the Canmart Business in the manner that the Canmart Business has been conducted prior to the date of this Agreement; |
(tt) | Bophelo either owns the entire right, title and interest in, to and under, or has acquired a licence to use, any and all patents, trademarks, tradenames, brand names and copyrights that are material to the conduct of the Bophelo Business in the manner that the Bophelo Business has been conducted prior to the date of this Agreement; |
Employees
(uu) | all salaries, wages, commissions and other compensation and benefits payable to each employee of the Corporations have been accrued and paid by the Corporations when due for all periods through the Closing Date. Except as set forth in the Disclosure Schedule, to the Vendor's knowledge, no current executive, key employee or group of employees has given notice of termination of employment or otherwise disclosed plans to terminate employment with any Corporation within the next 12 months; |
11.
(vv) | each applicable Corporation has complied and is currently complying, in respect of its employees, with all applicable laws respecting employment and employment practices and the protection of the health and safety of employees; |
(ww) | there is no trade union or association certified by competent authority or recognized by any Corporation as bargaining agent for its employees, and no Corporation is a party to or bound by any collective agreement with any labour union or association of employees and, to the Vendor's knowledge, no such certification process with any labour union or association of employees is presently contemplated by any such employees; |
(xx) | except as disclosed in the Disclosure Schedule, no Corporation has any outstanding contracts or agreements with any of its officers, directors, agents or employees, other than contracts of employment which have been entered into in the ordinary course; |
Tax Matters
(yy) | each Corporation has paid all Taxes due and payable by it, including all Taxes shown on its Tax Returns as being due and payable, and all Taxes payable under any assessment or reassessment; |
(zz) | each Corporation has prepared and filed all Tax Returns on time and in the prescribed manner with all appropriate Governmental Authorities which were required to be filed on or prior to the Closing Date. Each such Tax Return was correct and complete in all material respects and each Corporation has made complete and accurate disclosure in all material respects in its Tax Returns and in all materials accompanying those Tax Returns, except in respect of a particular Tax Return to the extent that it may have been modified in a subsequent Tax Return, as applicable; |
(aaa) | the Vendor is not a "non-resident" of Canada for the purpose of Section 116 of the Income Tax Act (Canada); |
(bbb) | there are no assessments or reassessments of Taxes that have been issued and are outstanding and no Corporation is negotiating any assessment or reassessment with any Governmental Authority; |
(ccc) | the Vendor is not aware of any liabilities of any Corporation for Taxes or any grounds for an action, suit, investigation, arbitration proceeding or other Proceedings, assessments, reassessment or requests for information outstanding or threatened against any Corporation with respect to Taxes, including aggressive treatment of income expenses, credits or other claims for deduction under any Tax Return; |
(ddd) | no Taxes shall accrue in respect of, or become payable by, or require the accelerated payment by, the Purchaser or relating to the Business, following the Closing as a result of the Reorganization (provided for clarity that the Vendor makes no representation under this Section 3.1(ddd) with respect to any Taxes that accrue, become payable or which payment is accelerated, to the extent such accrual, payment or acceleration was not caused or adversely impacted by the Reorganization); |
12.
Sanctions and Ethical Conduct
(eee) | Vendor does not engage (and has not engaged) in activities which are in violation of any country- or list- based economic and trade sanctions administered and enforced by Canada, the Office of Foreign Assets Control of the US Department of the Treasury, the US Department of State or other Governmental Authority in any jurisdiction in which the Business is conducted (a "Sanctions Authority") or is engaged, directly or indirectly, in any activity which is prohibited under Sanctions, including without limitation: (i) any direct or indirect dealings involving or benefitting: (A) a person or entity that is listed on, or owned or controlled by, or acting on behalf of a person or entity listed on any list administered by a Sanctions Authority or otherwise the target of Sanctions; (B) a person or entity that, is owned or controlled by, or acting for or on behalf of, or providing assistance, support or services of any kind to, or otherwise associated with any person or entity in (A); (ii) making or receiving any contribution of funds, goods or services to or for the benefit of any person or entity described in (A) or (B); (iii) any dealing in, or otherwise engaging in any transaction relating to any property or interests in, property subject to prohibitions under Sanctions; and (iv) any transaction that evades, avoids or attempts to violate any of the prohibitions set forth in the Sanctions or has such a purpose. For the purpose of this Agreement, "Sanctions" means economic or financial sanctions pursuant to all applicable laws regarding sanctions and export controls of the Sanctions Authority, specifically the United Nations Act, Special Economic Measures Act, Export and Import Permits Act, Freezing Assets of Foreign Corrupt Officials Act, Defense Production Act, Proceeds of Crime (Money Laundering) Terrorist Financing Act, Anti-Terrorism Act and any other similar statute or regulation that is enacted in any jurisdiction in which the Business is conducted; |
(fff) | the Vendor has not, directly or indirectly, in relation to the Business: (i) offered or given anything of value to any official or employee of any foreign government department or agency or instrumentality or government-owned entity, to any foreign political party or party official or political candidate or to any official or employee of a public international organization, or to anyone else acting in an official capacity (collectively, "Foreign Official"), in order to obtain, retain or direct business by: (A) influencing any act or decision of such Foreign Official in his official capacity; (B) inducing such Foreign Official to do or omit to do any act in violation of the lawful duty of such Foreign Official; (C) securing any improper advantage; or (D) inducing such Foreign Official to use his influence with a foreign government or instrumentality to affect or influence any act or decision of such government or instrumentality; (ii) to cause the Vendor to violate the US Foreign Corrupt Practices Act of 1977; or (iii) to cause the Vendor to violate any other anti-corruption law applicable to the Vendor; |
13.
Consideration Shares
(ggg) | the Vendor understands that the Consideration Shares are being offered and issued pursuant to an exemption from prospectus requirements of Canadian securities laws, and, as a consequence of acquiring the Consideration Shares pursuant to such exemptions, certain protections, rights and remedies provided by the applicable Canadian securities laws, including statutory rights of rescission or damages, will not be available to the Vendor. The Vendor acknowledges that Purchaser will rely on the Vendor's representations, warranties and certifications set forth below for purposes of confirming the availability of any exemption from such registration and prospectus requirements. The Vendor has not received a document purporting to describe the business and affairs of the Purchaser that has been prepared primarily for delivery to and review by prospective investors so as to assist those investors to make an investment decision in respect of Purchaser under the terms of this Agreement. The Vendor has such knowledge and experience in financial and business affairs as to be capable of evaluating the merits and risks of an investment in the Consideration Shares, and is able to, and agrees to, bear the economic risk of loss of its value of the Consideration Shares. The Vendor acknowledges that it is eligible to acquire the Consideration Shares pursuant to the exemption from the prospectus requirements of Canadian securities laws found in s. 2.12 Asset Acquisitions of National Instrument 45-106 - Prospectus Exemptions of the Canadian Securities Administrators. The Vendor acknowledges that the certificates representing the Consideration Shares, or ownership statements issued under a direct registration system or other electronic book-based or book entry system, will bear the following legends in accordance with Canadian securities laws: |
"UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS FOUR MONTHS AND A DAY AFTER THE LATER OF (I) [INSERT DISTRIBUTION DATE], AND (II) THE DATE THAT THE ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY.";
(hhh) | the Vendor acknowledges that (i) it has been provided with the opportunity to consult its own legal advisors with respect to the Consideration Shares issuable to it pursuant to this Agreement, and (ii) it is aware that no public market exists for the Consideration Shares and it may not be able to resell the Consideration Shares; and |
(iii) | the Vendor will execute and deliver within the applicable time periods all documentation as may be required by Canadian securities laws to permit the issuance of the Consideration Shares on the terms set forth herein and, if required by Canadian securities laws, will execute, deliver and file or assist Purchaser in obtaining and filing such reports, undertakings and other documents relating to the issuance of such Consideration Shares as may be required by any Canadian securities laws, securities regulator, stock exchange or other regulatory authority, which includes, without limitation, determining the eligibility of the Vendor to acquire the Consideration Shares under Canadian securities laws, preparing and registering certificates (if any) representing the Consideration Shares, and completing regulatory filings required by the applicable securities commissions. Accordingly, the Vendor consents to the collection, use and disclosure of certain personal information to Canadian securities regulatory authorities (including the Ontario Securities Commission (the "OSC")) and the Purchaser's advisors solely for and expressly limited to the purposes of meeting legal, regulatory, self-regulatory, security and audit requirements (including any applicable tax, securities, money laundering or antiterrorism legislation rules or regulations) in accordance with applicable Canadian securities law. The Vendor hereby acknowledges that it has been notified by the Purchaser: (i) of the requirement to deliver to the OSC the full name, address and telephone number of the party to whom the Consideration Shares are issued, the number of securities issued and the date of distribution; (ii) that this information is being collected indirectly by the OSC under the authority granted to it in Canadian securities legislation; (iii) that this information is being collected for the purposes of the administration and enforcement of the securities legislation of Ontario; and (iv) that the Administrative Support Clerk of the OSC can be contacted at Ontario Securities Commission, Suite 1903, Box 55, 20 Queen Street West, Toronto, Ontario M5H 3S8, or at (416) 593-3684, and can answer any questions about the OSC's indirect collection of this information. |
14.
3.2 | Representations and Warranties of the Purchaser |
The Purchaser represents and warrants to the Vendor as follows:
Authorization, Non-Contravention, etc. | ||
(a) | the Purchaser is a corporation validly existing and in good standing under the laws of Ontario; |
(b) | the Purchaser has the corporate power to enter into and perform its obligations under this Agreement; |
(c) | the execution and delivery of, and performance by the Purchaser of this Agreement and the purchase of the Shares has been duly authorized by all necessary corporate action on behalf of the Purchaser; |
(d) | this Agreement has been duly and validly executed by the Purchaser and constitutes a legal, valid and binding agreement of the Purchaser, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights and subject to general principles of equity; |
(e) | the Purchaser does not currently carry on any business other than as contemplated (expressly or implicitly) hereby and such business activities as are related thereto; |
(f) | no consent, approval, order or authorization of, or registration or declaration with, any applicable Governmental Authority with jurisdiction over the Purchaser is required to be obtained by the Purchaser in connection with the execution and delivery of this Agreement or the consummation by the Purchaser of the acquisition of the Shares, except for those consents, orders, authorizations, declarations, registrations or approvals which have been obtained by the Purchaser as of the date hereof or those consents, orders, authorizations, declarations, registrations or approvals that, if not obtained, would not prevent or materially delay the consummation of the acquisition of the Shares or otherwise prevent the Purchaser from performing its obligations under this Agreement; |
(g) | the authorized and issued capital of the Purchaser is set forth in Schedule "B"; |
(h) | there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any shares of the Purchaser other than those issued (or issuable) pursuant to: (i) the Company’s equity stock option plan; and (ii) those warrants (and underlying shares) to be granted to Boustead Securities Limited in connection with their acting as agents of the Company; |
(i) | the Consideration Shares, when issued, shall issued as fully paid and non assessable common shares of the Purchaser; |
(j) | the Consideration Shares are free and clear of all liens, charges and encumbrances, other than those restrictions on transfer of the Consideration Shares, if any, stated in the articles of the Purchaser; and |
15.
(k) | no person (other than the Vendor under this Agreement) has any written or oral agreement, option, right or privilege capable of becoming an agreement or option to acquire any of the Consideration Shares or to be caused to be issued any unissued securities of the Purchaser. |
3.3 | Survival |
(a) | The representations and warranties of the Vendor shall survive the Closing for twelve (12) months from the Closing Date and, notwithstanding such Closing or any investigation made by or on behalf of the Purchaser, shall continue in full force and effect for the benefit of the Purchaser during such period; provided that, any claim which is based upon or relates to the representations and warranties made in Sections 3.1(k) through 3.1(u) and 3.1(cc) or which is based upon intentional misrepresentation or fraud by the Vendor may be made or brought by the Purchaser at any time for the maximum period permitted by law. |
(b) | The representations and warranties of the Purchaser shall survive the Closing for twelve (12) months from the Closing Date and, notwithstanding such Closing or any investigation made by or on behalf of the Vendor, shall continue in full force and effect for the benefit of the Vendor during such period; any claim which is based upon or relates to the representations and warranties made in Sections 3.2(g) through 3.2(k) or which is based upon intentional misrepresentation or fraud by the Purchaser may be made or brought by the Vendor at any time for the maximum period permitted by law. |
3.4 | Known Breach |
In the event the Purchaser (including any director or officer thereof), prior to Closing, is aware of breach of a representation or warranty of the Vendor under this Agreement and nonetheless proceeds with Closing, then such representation or warranty will be deemed to be deleted from this Agreement and the Purchaser shall not be entitled to bring or assert any claim against the Vendor in respect of such breach.
Article
4
FLOW-THROUGH REPRESENTATIONS AND WARRANTIES
4.1 | Flow-through Representations and Warranties |
To the extent necessary to allow the Purchaser to pursue claims against the original vendors under the Pre-existing Purchase Agreements, and without incurring any liability itself, Vendor adopts those representations and warranties made to it under the Pre-existing Purchase Agreements, and makes each such representation and warranty to the Purchaser (the "Pre-existing Reps and Warranties"), as though it was the party first making such representations and warranties and as though the Purchaser was the in the place of the Vendor under such agreements, mutatis mutandis.
16.
4.2 | Subrogation and Limitation |
(a) | In the event of any breach of any of the Pre-existing Reps and Warranties that entitles the Vendor to claim damages against, or indemnification from, the person or entity originally making such representations and warranties under the Pre-existing Purchase Agreements, the Purchaser shall be subrogated to, and the Vendor shall assign to the Purchaser, all of the Vendor's rights in respect of any such claim or indemnification. If the Vendor is unable to assign such rights to the Purchaser, then instead of assigning such rights to the Purchaser, the Vendor shall allow the Purchaser to bring a suit in the name of the Vendor, at the Purchaser’s sole cost and expense; provided that, the Purchaser shall indemnify the Vendor for any losses, damages, costs and expenses (including legal expenses on a solicitor-client full indemnity basis) that the Vendor may, directly or indirectly, suffer or incur as result of or in connection with the Purchaser bringing any such suit. The Vendor shall execute all papers required and take all steps reasonable, necessary or advisable to secure and further such subrogation and assignment, at Purchaser’s sole cost and expense. In no event shall the Vendor waive any rights that could adversely affect any such subrogation or assignment. Any amounts recovered by the Purchaser whether directly or in connection with the exercise of such subrogation or assignment shall be applied to compensate the Purchaser for any loss suffered by it as a result of the breach of the Pre-existing Reps and Warranties and for any costs or expenses incurred in connection with such recovery; provided that, any amount received by the Purchaser in excess of the amount of any such loss, costs and expenses, shall be for the account of the Vendor and shall, upon receipt, be held by the Purchaser in trust for the Vendor and forthwith paid over to the Vendor or as the Vendor my direct in writing. |
(b) | Notwithstanding the foregoing, the Purchaser agrees and acknowledges that the rights granted to it under Section 4.2(a) shall be the sole and exclusive remedy available to the Purchaser in respect of a breach of the Pre-existing Reps and Warranties and the Purchaser shall not otherwise be entitled to other forms of recovery including through claims of indemnity, compensation, offset, contribution or otherwise, except to the extent such losses to the Purchaser were based upon or arose out of fraud by the Vendor. The foregoing sentence in this Section 4.2(b) shall not limit the right of the Purchaser to bring a direct action against the Vendor in connection with the enforcement of the terms of this Agreement, including with respect to any representations or warranties contained herein (with the exclusion of the Pre-existing Reps and Warranties). |
Article
5
CONDITION PRECEDENT; INTERIM PERIOD
5.1 | Conditions Precedent |
(a) | The obligations of the Purchaser to complete the purchase of the Shares is subject to: |
(i) | the Vendor delivering to the Purchaser, copies of all regulatory approvals required to be obtained by the Vendor to complete the within transaction; and |
(ii) | the Purchaser receiving, addressed to it, opinion(s) of duty qualified legal counsel in each relevant jurisdiction, in form acceptable to the Purchaser, acting reasonably, confirming that each of the respective Corporations: |
(A) | has been incorporated and existing under the applicable laws of their respective jurisdictions of incorporation; |
(B) | has corporate capacity and power to own and lease their properties and assets and to conduct their business as currently being conducted; |
(C) | as to the authorized and issued share capital of such Corporation and to the ownership thereof; and |
17.
(D) | is current with all corporate filings required to be made under their respective jurisdictions of incorporation and all other jurisdictions in which they exist or carry on any material business, and has all necessary licences, leases, permits, authorizations and other approvals necessary for the conduct of the Business as currently conducted, as applicable, and for the consummation of the transactions contemplated by this Agreement; and |
(iii) | the Vendor having completed the Reorganization, in a manner satisfactory to the Purchaser, acting reasonably, |
(collectively, the "Purchaser Conditions").
(b) | The obligations of the Vendor to complete the sale of the Shares is subject to: |
(i) | the Vendor having been provided with executed subscription agreements or other evidence satisfactory to the Vendor, acting reasonably, in respect of bona fide subscriptions for shares in the capital of the Purchaser for aggregate gross proceeds of not less than US$5,000,000 (or such lesser amount as may be determined by the Vendor); and |
(ii) | completion of the Reorganization, |
(collectively, the "Vendor Conditions", and together with the Purchaser Conditions, the "Conditions Precedent").
(c) | If, the Conditions Precedent have not been satisfied on or before December 31, 2021 (the "Condition Date"), then, in the event that a Purchaser Condition has not been met, at the election of the Purchaser and in the event that the Vendor Condition has not been met, at the election of the Vendor, this Agreement shall terminate and the parties shall have no further obligation to each other hereunder. |
(d) | Notwithstanding the foregoing, if, the Conditions Precedent have not been satisfied on or before the Condition Date, then, in the event that a Purchaser Condition has not been met, the Vendor, and in the event that the Vendor Condition has not been met, the Purchaser, shall be entitled to extend the Condition Date, in so far as it relates to the Purchaser Conditions or the Vendor Conditions, as applicable, by up to 30 days or such other period determined by them, acting reasonably, for the sole purpose of fulfilling the applicable condition, by providing written notice of such extension to the other party. |
Article 6
COVENANTS
6.1 | Conduct of Business During the Interim Period |
From the date of this Agreement up to the Closing Date, the Vendor covenants to the Purchaser that it will cause each Corporation to carry-on its business in the ordinary course, consistent with past practice and use its commercially reasonable efforts to preserve its assets and the existing contracts and goodwill of its customers, suppliers, vendors, service providers, personnel and others having business relations with it; provided that, in the event any Corporation desires to engage in any activity outside the ordinary course of its business for a bona fide reason, the Vendor shall obtain the Purchaser's prior written approval prior to any such Corporation engaging in any such activity, such approval not to be unreasonably withheld or delayed.
18.
6.2 Notice of Certain Events
From the date of this Agreement up to the Closing Date, the Vendor covenants to the Purchaser that it will promptly notify the Purchaser in writing of:
(a) | any events, circumstances, facts or occurrences which would result in a breach of a representation, warranty or covenant of the Vendor, or which would have the effect of making any representation or warranty of the Vendor untrue in any material respect, or would be reasonably likely to result in a material adverse effect as to any of the Corporations; and |
(b) | (i) the commencement or threat of any investigation, action or legal Proceedings by or before any Governmental Authority with respect to any Corporation, the Vendor, this Agreement or any of the other transactions contemplated by this Agreement and shall keep the Purchaser informed as to the status of any such investigation, action or legal Proceedings; and (ii) any communication to or from any Governmental Authority regarding any such investigation, threat or Proceedings and this Agreement or any of the other transactions contemplated by this Agreement. |
6.3 | Filings; Consents. |
(a) | The parties hereto will: (i) promptly make and effect all registrations, filings and submissions required to be made or effected by them under applicable law with respect to this Agreement and the transactions contemplated under this Agreement; and (ii) use commercially reasonable efforts to cause to be taken on a timely basis, all other actions necessary or appropriate for the purpose of consummating and effectuating the transactions contemplated by this Agreement, including the obtaining of all necessary consents, approvals or waivers from third parties. Each party will reasonably cooperate in efforts to obtain such consents, waivers and approvals. |
(b) | The Vendor shall use commercially reasonable efforts to (i) promptly provide all information requested by any Governmental Authority in connection with this Agreement or any of the other transactions contemplated by this Agreement, and (ii) promptly take all actions and steps necessary to obtain any acknowledgement to be obtained or clearance or approval required to be obtained from such Governmental Authority in connection with the transactions contemplated by this Agreement, if any. |
6.4 Further Assurances.
Subject to the terms and conditions hereof, each of the parties hereto shall use commercially reasonable efforts (without further consideration being payable) to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary, proper or advisable to consummate and give effect to the transactions contemplated by this Agreement as soon as possible.
6.5 Post-Closing Covenants
The Parties agree that, within 30 days of Bophelo issuing a new share certificate in connection with the Reorganization, the Vendor, the Purchaser and Bophelo shall work together to procure a non-resident endorsement of the share certificate from the Central Bank of Lesotho and shall use all commercially reasonable efforts to obtain the same in a prompt and timely manner.
19.
Article 7
CLOSING ARRANGEMENTS
7.1 | Date, Place and Time of Closing |
The closing of the sale and purchase of the Shares ("Closing") will take place at 12:00 p.m. (Toronto Time) (the "Closing Time") on the date that is two (2) Business Days following satisfaction or waiver of all Conditions Precedent (the "Closing Date"), electronically through the offices of Dentons Canada LLP and the offices of Aird & Berlis LLP, or in such other manner, and on such other date and time, as may be agreed upon in writing by the parties.
7.2 | Deliveries at Closing |
At the Closing Time:
(a) | the Purchaser shall issue the Consideration Shares to the Vendor and provide the Vendor with a copy of the share certificate representing the Consideration Shares and a copy of the securities' register of the Purchaser evidencing such issuance; |
(b) | the Vendor shall deliver to the Purchaser share certificates representing the Shares, duly endorsed in blank for transfer, or accompanied by irrevocable security transfer powers of attorney duly executed in blank; |
(c) | the Vendor shall deliver to the Purchaser the following (if applicable, in form and substance satisfactory to the Purchaser, acting reasonably): |
(i) | certified copies of the resolutions of the board of directors of the Vendor authorizing entering into and completion of the transactions contemplated by this Agreement; |
(ii) | certified copies of the resolutions of the board of directors of Cannahealth authorizing transfer of the Shares to the Purchaser; |
(iii) | a certificate of status (or equivalent) with respect to the Vendor and each Corporation, issued by the appropriate Governmental Authority in their respective jurisdictions of incorporation; |
(iv) | resignation of each director, officer, and employee (as applicable) of each of the Corporations, except to the extent such person is a director, officer, and employee of the Purchaser as of the date hereof; |
(v) | a release by the Vendor in favour of each of the Corporations for any and all claims that the Vendor may have against any of the Corporations; |
(vi) | the minute book for each of the Corporations; |
(vii) | an executed copy of the investor rights agreement, substantially in the form attached hereto as Schedule "C" (the "Investor Rights Agreement"); |
20.
(viii) | such other documents as may reasonably be requested by the Purchaser in order to complete the transactions contemplated herein. |
(d) | the Purchaser shall deliver to the Vendor the following (if applicable, in form and substance satisfactory to the Vendor, acting reasonably): |
(i) | certified copies of the resolutions of the board of directors of the Purchaser authorizing the entering into and completion of the transactions contemplated by this Agreement, including issuance of the Consideration Shares; |
(ii) | a certificate of status, compliance, good standing or like certificate with respect to the Purchaser, issued by the appropriate Governmental Authority in its jurisdiction of incorporation; |
(iii) | a release by each of the Corporations in favour of the Vendor for any and all claims that any of the Corporations may have against the Vendor as at the Closing Date; |
(iv) | an executed copy of the Investor Rights Agreement; and |
(v) | such other documents as may reasonably be requested by the Vendor in order to complete the transactions contemplated hereon. |
Article 8
TAX MATTERS
8.1 | Tax Returns |
(a) | The Vendor shall, at its cost, cause the Corporations to prepare and file in a timely fashion all Tax Returns required under any applicable Tax legislation (the "Tax Returns") to be filed by the Corporations for (i) any period ending on or before the Closing Date (including as a consequence of the Closing) and for which Tax Returns have not been filed as of that date; and (ii) any period beginning prior to the Closing Date and ending after the Closing Date (collectively, the "Stub Period Returns"). |
(b) | The Vendor and the Purchaser shall co-operate fully in good faith with each other and make available to each other in a timely fashion any information in their respective possession and that is reasonably required for the preparation and filing of the Stub Period Returns, and shall preserve that information in their respective possession until the expiration of any applicable limitation period under any applicable Tax legislation. The Vendor shall provide to the Purchaser (and its tax advisors) for its review and approval a copy of the Stub Period Returns and Tax Returns 30 days prior to filing and the Purchaser will have the opportunity to fully comment on those Stub Period Returns prior to filing. |
(c) | From and after the Closing Date, the Purchaser shall cause the Corporations to retain, until the expiration of any applicable limitation period under any applicable Tax legislation, all Books and Records relating to any period ending on or before the Closing Date (including as a consequence of Closing) and that are reasonably required for the purpose of the preparation and filing of the Stub Period Returns. So long as such Books and Records are retained by the Corporations, the Vendor may inspect the same for the purpose of the preparation and filing of the Stub Period Returns. |
21.
(d) | After Closing, the Purchaser shall cause the Corporations to co-operate in a reasonable manner with the Vendor and its representatives for the purposes of the preparation of the Vendor's accounts and the Tax Returns and in providing any information in the possession of the Corporations and that is reasonably required for those purposes. Without limiting the generality of the foregoing, the Purchaser shall, upon reasonable notice, cause the Corporations to provide the Vendor and its representatives reasonable access to those Books and Records in the possession of the Corporations that are reasonably required for the preparation of the Vendor's accounts and the Tax Returns together with the assistance of those employees of the Corporations that the Vendor may reasonably request. |
Article 9
MISCELLANEOUS
9.1 | Notices |
Any notice, direction or other communication (each a "Notice") regarding the matters contemplated by this Agreement must be in writing and must be delivered personally, sent by registered mail or courier, or transmitted electronically, as follows:
(a) | in the case of the Vendor, at: |
Halo Collective Inc.
504 - 100 Park Royal
West Vancouver, BC V7T 1A2
Attention: Kiranjit Sidhu
E-mail: [*]
with a copy to:
Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1
Attention: Eric Foster
E-mail: eric.foster@dentons.com
(b) | in the case of the Purchaser, at |
Akanda Corp.
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1
Attention: Tej Virk
Email [*]
22.
with a copy to:
Aird & Berlis LLP
181 Bay Street, Suite 1800, Brookfield Place
Toronto, ON M5J 2T9
Attention: Sherri Altshuler
Email: saltshuler@airdberlis.com
A Notice is deemed to be delivered and received (i) if delivered personally, on the date of delivery if delivered prior to 5:00 p.m. (recipient's time) on a Business Day and otherwise on the next Business Day; (ii) if sent by same-day courier, on the date of delivery if delivered prior to 5:00 p.m. (recipient's time) on a Business Day and otherwise on the next Business Day; (iii) if sent by overnight courier, on the next Business Day; (iv) if sent by registered mail, on the third Business Day after mailing, or (v) if transmitted electronically, on the date of transmission if received prior to 5:00 p.m. (recipient's time) on a Business Day and otherwise on the next Business Day. A party may change its Notice address from time to time by Notice given in accordance with the foregoing provisions.
9.2 | Further Assurances |
Each party shall from time to time, before or after the Closing Time, execute, acknowledge and deliver or cause to be executed, acknowledged and delivered all further acts, documents and instruments as may be reasonably necessary or desirable in order to give full effect to this Agreement or any provision of it.
9.3 | Costs and Expenses |
Unless otherwise specified, each party shall be responsible for all costs and expenses (including the fees and disbursements of legal counsel, bankers, investment bankers, accountants, brokers and other advisors) incurred by it in connection with this Agreement and the transactions contemplated by it.
9.4 | Waiver of Rights |
Any waiver of any of the provisions of this Agreement will be binding only if it is in writing and signed by the party to be bound by it, and only in the specific instance and for the specific purpose for which it has been given. The failure or delay of any party in exercising any right under this Agreement will not operate as a waiver of that right. No single or partial exercise of any right will preclude any other or further exercise of that right or the exercise of any other right, and no waiver of any of the provisions of this Agreement will constitute a waiver of any other provision (whether or not similar).
9.5 | Remedies Cumulative |
Unless otherwise specified, the rights and remedies of a party under this Agreement are cumulative and in addition to and without prejudice to any other rights or remedies available to that party at law, in equity or otherwise, and unless otherwise specified, no single or partial exercise by a party of any right or remedy precludes or otherwise affects the exercise of any other right or remedy to which that party may be entitled.
23.
9.6 | Public Disclosure |
The Vendor and the Purchaser shall cooperate with the other in releasing information concerning this Agreement and the transactions contemplated herein, and shall furnish to and discuss with the other drafts of all press and other releases prior to publication. No press release or other public announcement concerning the proposed transactions contemplated by this Agreement will be made by any party hereto without the prior consent of the other party, such consent not to be unreasonably withheld, delayed or conditioned; provided that nothing contained herein shall prevent any party hereto at any time from furnishing any information to any Governmental Authority or to the public if so required by applicable law.
9.7 | Severability |
If any provision of this Agreement or its application to any party or circumstance is determined by a court of competent jurisdiction to be illegal, invalid or unenforceable, it will be ineffective only to the extent of its illegality, invalidity or unenforceability without affecting the validity or the enforceability of the remaining provisions of this Agreement and without affecting its application to other parties or circumstances.
9.8 | Successors and Assignment |
This Agreement will enure to the benefit of and be binding upon the parties and their respective successors but neither this Agreement nor any of the rights or obligations under this Agreement is assignable or transferable by either the Purchaser or the Vendor without the prior written consent of the other party.
9.9 | Entire Agreement |
This Agreement constitutes the entire agreement between the parties with respect to the transactions contemplated by this Agreement. There are no representations, warranties, terms, conditions, covenants or other understandings, express or implied, collateral, statutory or otherwise, between the parties, except as expressly stated in this Agreement.
9.10 | No Contra Proferentem |
Unless otherwise expressly defined in this Agreement, the words used in this Agreement bear their natural meaning. The parties have had equal opportunity to take legal advice and the contra proferentem rule does not apply to the interpretation of this Agreement.
9.11 | Governing Law; Attornment |
This Agreement will be construed, interpreted and enforced in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein. Each party irrevocably attorns and submits to the exclusive jurisdiction of the courts of Ontario.
24.
9.12 | Counterparts and Delivery by Facsimile |
This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute but one and the same instrument. This Agreement will become effective when duly executed and delivered by each party. Counterpart signature pages to this Agreement may be delivered by electronic delivery (i.e., by email of a PDF signature page) and each such counterpart signature page will constitute an original for all purposes.
[Remainder of this page intentionally left blank. Signature page follows.]
25.
IN AGREEMENT WITH ITS TERMS, the parties have executed this Agreement.
HALO COLLECTIVE INC. | ||
Per: | /s/ Kiranjit Sidhu | |
Name: Kiranjit Sidhu | ||
Title: Chief Executive Officer | ||
AKANDA CORP. | ||
Per: | /s/ Tej Virk | |
Name: Tej Virk | ||
Title: Chief Executive Officer |
Schedule "A"
Vendor Disclosure Schedule
Agreement
Paragraph Reference |
Disclosure Item |
3.1(f) | An endorsement by the Central Bank of Lesotho of the share certificates held by any non-resident subsidiary of Cannahealth in relation to a shareholding in Bophelo Bio Science and Wellness (Pty) Ltd is required. |
3.1(i) | None. |
3.1(q) | Share Capital |
Corporation | Pre-Reorganization | Post-Reorganization | |||
Authorized Share Capital | Authorized Share Capital | ||||
Bophelo | [*] ordinary shares | [*] ordinary shares | |||
Canmart | [*] ordinary shares | [*] ordinary shares | |||
Cannahealth | [*] ordinary shares | [*] ordinary shares | |||
Holdco | [*] ordinary shares | [*] ordinary shares | |||
Issued Share Capital | Issued Share Capital | ||||
Bophelo | [*] shares | [*] shares | |||
Canmart | [*] ordinary shares | [*] ordinary shares | |||
Cannahealth | [*] ordinary shares | [*] ordinary shares | |||
Holdco | [*] ordinary shares | [*] ordinary shares |
3.1(cc) |
Regulatory Licenses
Bophelo holds an operator’s license issued by the Ministry of Health in the Kingdom of Lesotho in terms of the Drugs of Abuse Act and its Regulations thereto.
Canmart holds the following licenses issued by UK regulatory authorities:
§ Manufacturer’s “Specials” Licence § Wholesale Distribution Authorisation (Human) § Controlled Drugs Licence
|
3.1(hh) |
Indebtedness and Liabilities
Bophelo is party to a bridge financing arrangement with LM Mojela. Debt under the bridge financing arrangement will be settled through the issuance of 880,000 common shares of Akanda Corp.
|
27.
3.1(mm) |
Real Property Leases
Bophelo has entered into a lease agreement with the MMD Trust for the lease of its facilities at T’sakholo in the Kingdom of Lesotho. The lease is for a land area of approximately 200 hectares and for a 20 year period, with an option to renew for another 30-year term. Pursuant to the lease agreement, Bophelo will pay LSL 350,000 per month (approximately USD $25,000 per month) for the leased area utilized. The MMD Trust is controlled by Louisa Mojela, our Executive Chairman, and Granny Seape, a non-executive director of Bophelo.
Canmart has entered into a lease agreement with DND Investments Limited for the lease of 30,000 square foot warehouse in Somerset, United Kingdom. The lease period commenced on the date that Canmart fulfills the first 100 prescriptions for its clients for medical cannabis products (as certified by Canmart’s accountants or auditors) and terminates on 19 September 2024. Canmart has not yet fulfilled the first 100 prescriptions as contemplated in the lease agreement, and as such is not paying any rental fees. Pursuant to the lease agreement, Canmart will pay GBP 21,000 per annum once the lease payment arrangement described above is fulfilled and commences. |
3.1(nn) |
Owned Real Property
Nil |
3.1(qq) |
List of Deposit Accounts
Bophelo
Bophelo holds the following accounts:
Current Account (number [*]) held with [*] (address – [*]). Authorised signatories are [*] & [*].
Business Cheque Account (number [*]) held with [*] (address: [*]). Authorised signatories are [*] & [*].
Canmart
Canmart holds the following bank account:
Business Account (number [*]). held with [*] (address [*]). Authorised signatories are [*].
|
3.1(uu) |
Employees
Approximately [*] in arrear salary and directors fees are owing to Bophelo employees and directors.
No current executive, key employee or group of employees has given notice of termination of employment or otherwise disclosed plans to terminate employment with any Corporation within the next 12 months.
|
28.
3.1(xx) |
Contracts with officers, directors, agents and employees
Canmart is yet to conclude employment agreements with:
§ LM Mojela § T Scott § V Iyer
|
Schedule "B"
Purchaser Disclosure Schedule
Nil.
Schedule "C"
Investor Rights Agreement
Please see attached.
Exhibit 3.1
Request ID: 026453832 | Province of Ontario | Date Report Produced: 2021/07/16 |
Demande n°: | Province de l’Ontario | Document produit le: |
Transaction ID: 079982715 | Ministry of Government Services | Time Report Produced: 15:43:52 |
Transaction n°: | Ministère des Services gouvernementaux | Imprimé à: |
Category ID: CT | ||
Catégorie: |
Certificate of Incorporation
Certificat de constitution
This is to certify that | Ceci certifie que |
AKANDA CORP .
Ontario Corporation No. | Numéro matricule de la personne morale en Ontario |
002854618
is a corporation incorporated, | est une société constituée aux termes |
under the laws of the Province of Ontario. | des lois de la province de l’Ontario. |
These articles of incorporation | Les présents statuts constitutifs |
are effective on | entrent en vigueur le |
JULY 16 JUILLET, 2021
Director/Directeur
Business Corporations Act/Loi sur les sociétés par actions
Page: 1
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
FORM 1 | FORMULE NUMÉRO 1 | |
BUSINESS CORPORATIONS ACT | / | LOI SUR LES SOCIÉTÉS PAR ACTIONS |
ARTICLES OF INCORPORATION
STATUTS CONSTITUTIFS
1. | The name of the corporation is: | Dénomination sociale de la compagnie: |
AKANDA CORP. | ||
2. | The address of the registered office is: | Adresse du siège social: |
77 KING STREET WEST | Suite 400 | |
TORONTO-DOMINION CENTRE |
(Street & Number, or R.R. Number & if Multi-Office Building give Room No.)
(Rue et numéro, ou numéro de la R.R. et, s’il s’agit édifice à bureau, numéro du bureau)
TORONTO | ONTARIO | |
CANADA | M5K 0A1 | |
(Name of Municipality or Post Office) | (Postal Code/ Code postal) | |
(Nom de la municipalité ou du bureau de poste) | ||
3. | Number (or minimum and maximum number) of directors is: | Nombre (ou nombres minimal et maximal) |
Minimum 1 | d’administrateurs: | |
Maxium 10 | ||
4. | The first director(s) is/are: | Premier(s) administrateur(s): |
First name, initials and surname | Resident CanadianState Yes or No | |
Prénom, initiales et nom de famille | Résident Canadien Oui/Non | |
Address for service, giving Street & No. | Domicile élu, y compris la rue et le | |
or R.R. No., Municipality and Postal Code | numéro, le numéro de la R.R., ou le nom | |
de la municipalité et le code postal | ||
* | PHILIP | NO |
VAN DEN BERG | ||
77 KING STREET WEST Suite 400 | ||
TORONTO-DOMINION CENTRE | ||
TORONTO ONTARIO | ||
CANADA M5K 0A1 |
Page: 2
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
5. | Restrictions, if any, on business the corporation may carry on or on powers the corporation may exercise. |
Limites, s’il y a lieu, imposées aux activités commerciales ou aux pouvoirs de la compagnie.
None.
6. | The classes and any maximum number of shares that the corporation is authorized to issue: |
Catégories et nombre maximal, s’il y a lieu, d’actions que la compagnie est autorisée à émettre:
The Corporation is authorized to issue an unlimited number of preferred shares, issuable in series and an unlimited number of Common shares.
Page: 3
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
7. | Rights, privileges, restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series: Droits, privilèges, restrictions et conditions, s’il y a lieu, rattachés à chaque catégorie d’actions et pouvoirs des administrateurs relatifs à chaque catégorie d’actions que peut être émise en série: |
A. | PREFERRED SHARES |
The rights, privileges, restrictions and conditions attaching to the preferred shares, issuable in series, as a class, are as follows:
1. The preferred shares may at any time and from time to time be issued in one or more series, each series to consist of such number of shares as may, before the issue thereof, be determined by resolution of the board of directors of the Corporation.
2. The board of directors of the Corporation shall, subject as hereinafter provided, by resolution duly passed before the issue of the preferred shares of each series, fix the designation, rights, privileges, restrictions and conditions to be attached to the preferred shares of such series.
3. With respect to payment of dividends and priority in the distribution of assets in the event of the liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, or any other distribution of the assets of the Corporation among its shareholders for the purpose of winding-up its affairs, the preferred shares of each series shall be entitled to preference over the Common shares of the Corporation and over any other shares ranking junior to the preferred shares; and the preferred shares of each series may also be given such other preferences over the Common shares and any other shares ranking junior to the preferred shares as may be determined as to the respective series authorized to be issued.
4. The preferred shares of each series shall rank on a parity with the preferred shares of every other series with respect to priority in payment of dividends and in the distribution of assets in the event of the liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, or any other distribution of the assets of the Corporation among its shareholders for the purpose of winding-up its affairs.
B. | COMMON SHARES |
The rights, privileges, restrictions and conditions attaching to the Common shares, as a class, are as follows:
1. | Dividends |
Subject to the prior rights of the holders of the preferred shares of the Corporation, the board of directors of the Corporation may declare and cause to be paid dividends to the holders of the Common shares from any assets at the time properly applicable to the payment of dividends.
Page: 4
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
7. | Rights, privileges, restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series: Droits, privilèges, restrictions et conditions, s’il y a lieu, rattaches à chaque catégorie d’actions et pouvoirs des administrateurs relatifs à chaque catégorie d’actions que peut être émise en série: |
2. | Liquidation, Dissolution or Winding-Up |
In the event of the liquidation, dissolution or winding-up of the Corporation or other distribution of assets of the Corporation among shareholders for the purpose of winding-up its affairs, subject to the prior rights of the holders of the preferred shares of the Corporation, the holders of the Common shares shall be entitled to receive the remaining assets of the Corporation.
3. | Voting Rights |
The holders of the Common shares shall be entitled to receive notice of and to attend any meeting of the shareholders of the Corporation, and shall be entitled to one vote in respect of each Common share held at such meetings, except a meeting of holders of a particular class of shares other than the Common shares who are entitled to vote separately as a class at such meeting.
Page: 5
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
8. | The issue, transfer or ownership of shares is/is not restricted and the restrictions (if any) are as follows: |
L’émission, le transfert ou la propriété d’actions est/n’est pas restreinte. Les restrictions, s’il y a lieu, sont les suivantes:
Shares of the Corporation may not be transferred unless the restrictions on the transfer of securities of the Corporation contained in section 9 of the articles of the Corporation entitled “Other provisions, if any” are complied with.
Page: 6
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
9. | Other provisions, (if any, are): |
Autres dispositions, s’il y a lieu:
Securities of the Corporation, other than non-convertible debt securities, shall not be transferred without either:
(a) the approval of the directors of the Corporation, expressed by a resolution passed at a meeting of the directors or by an instrument or instruments in writing signed by a majority of the directors; or
(b) the approval of the holders of at least a majority of the shares of the Corporation entitling the holders thereof to vote in all circumstances (other than a separate class vote of the holders of another class of shares of the Corporation) outstanding at the time, expressed by a resolution passed at a meeting of the holders of those shares or by an instrument or instruments in writing signed by the holders of a majority of those shares.
Page: 7
Ontario Corporation Number | ||
Request ID / Demande n° | Numéro de la compagnie en Ontario | |
26453832 | 2854618 | |
10. | The names and addresses of the incorporators are |
Nom et adresse des fondateurs
First name, initials and last name | Prénom, initiale et nom de |
or corporate name | famille ou dénomination sociale |
Full address for service or address of registered office or of principal place of business giving street & No. or R.R. No., municipality and postal code Domicile élu, adresse du siège social au adresse de l’établissement principal, y compris la rue et le numéro, le numéro de la R.R., le nom de la municipalité et le code postal
* | PHILIP VAN DEN BERG |
77 KING STREET WEST Suite 400
TORONTO-DOMINION CENTRE
TORONTO ONTARIO
CANADA M5K 0A1
Exhibit 3.2
|
DocuSign Envelope ID: 8E513145-1 E8F-485E-9AEB-A94F00F1 E5F4 Form 3 Business Corporations Act Formule 3 Loi sur /es societes par actions For Ministry Use Only A l'usage exclusif du ministere Ontario Corporation Number Numero de la societe en Ontario f'\1-,, Ministry of Government t'f,? 3.ndConsumerServ1ces 1, Ontario CER'l'ftFIC/..\ TE This is to certify that 111ese articles are effective on Ministere des Services gouvernementaux P.t des Services aux consommateurs C.ERTRIFRCAT Cec, certifie que 1es presents statuts entrent en v1gueur le AUGUST· 3 0 AO0t 2021 , .. ; ................ ~;;;;7t;;;i.;;)J,'''''''@'·'' .Jirecror I Oirectnce Business Coroorations 1-\ct 11 .• 01 sur 1 es sociAtes oar actions 2854618 ARTICLES OF AMENDMENT STATUTS DE MODIFICATION 1. 2, 3, The name of the corporation is: (Set out in BLOCK CAPITAL LETTERS) Denomination sociale actuelle de la societe (ecrire en LETTRES MAJUSCULES SEULEMENT): A K A N D A C 0 R p The name of the corporation is changed to (if applicable ): (Set out in BLOCK CAPITAL LETTERS) Nouvelle denomination sociale de la societe (s'il ya lieu) (ecrire en LETTRES MAJUSCULES SEULEMENT): C------- Date of Incorporation/amalgamation: Date de la constitution ou de la fusion : 2021/07/16 (Year, Month, Day) (annee, mois, jour) 4. Complete only if there is a change In the number of directors or the minimum/ maximum number of directors. 5, II faut remplir cette partie seulement si le nombre d'administrateurs ou si le nombre minimal ou maximal d'administrateurs a change. Number of directors is/are: Nombre d'administrateurs : Number Nombre or OU minimum and maximum number of directors is/are: nombres minimum et maximum d'administrateurs : minimum and maKiln!Jm. minimum et maximum The articles of the corporation are amended as follows: Les statuts de la societe son! modifies de la fa9on suivante : See page 1 A attached. 07119 (2011/05) © Queen's Printer for Ontario, 2011 / © lmprimeur de la Reine pour !'Ontario, 2011 Page 1 of/de 2 |
|
DocuSign Envelope ID: 8E513145-1 E8F-485E-9AEB-A94F00F1 E5F4 SCHEDULE "A" TO ARTICLES OF AMENDMENT The Articles of the Corporation are amended as follows: 1. to remove the restriction on the transfer of shares set out in paragraph 8 of the articles of the Corporation by deleting the following provision in its entirety: "Shares of the Corporation may not be transferred unless the restrictions on the transfer of securities of the Corporation contained in section 9 of the articles of the Corporation entitled "Other provisions if any" are complied with." and to substitute therefore the following words: "No Restrictions." 2. to remove from paragraph 9 of the articles of the Corporation the following provisions in their entirety: "Securities of the Corporation, other than non-convertible debt securities, shall not be transferred without either: (a) (b) the approval of the directors of the Corporation, expressed by a resolution passed at a meeting of the directors or by an instrument or instruments in writing signed by a majority of the directors; or the approval of the holders of at least a majority of the shares of the Corporation entitling the holders thereof to vote in all circumstances (other than a separate class vote of the holders of another class of shares of the Corporation) outstanding at the time, expressed by a resolution passed at a meeting of the holders of those shares or by an instrument or instruments in writing signed by the holders of a majority of those shares." and to substitute therefore the following words: "None." NA TDOCS\57364938\V-1 1A |
|
DocuSign Envelope ID: 8E513145-1 E8F-485E-9AEB-A94F00F1 E5F4 07119 (2011/05) 6. The amendment has been duly authorized as required by sections 168 and 170 (as applicable) of the Business Corporations Act. La modification a ete d0ment autorisee conformement aux articles 168 et 170 (selon le cas) de la Loi sur /es societes par actions. 7. The resolution authorizing the amendment was approved by the shareholders/directors (as applicable) of the -corporation on Les actionnaires ou les adminlstrateurs (selon le cas) de la societe ont approuve la resolution autorisant la modification le 2021/08/30 (Year, Month, Day) (annee, mois, jour) These articles are signed in duplicate. Les presents statuts sont signes en double exemplaire. AKANDA CORP. (Print name of corporation from Article 1 on page 1) (Veuillez ecrir le nom de la societe de !'article un a la page une ). By/ Par: (Signature) (Signature) Director (Description of Office) (Fonction) Page 2 of/de 2 |
Exhibit 3.3 | |||
AKANDA CORP. | |||
BY-LAW NO. 1 | |||
TABLE OF CONTENTS | |||
ARTICLE 1 INTERPRETATION | 1 | ||
1.1 | Interpretation | 1 | |
1.2 | Conflicts with the Act | 1 | |
ARTICLE 2 BUSINESS OF THE CORPORATION | 2 | ||
2.1 | Registered Office | 2 | |
2.2 | Seal | 2 | |
2.3 | Financial Year | 2 | |
2.4 | Banking Arrangements | 2 | |
2.5 | Execution of Contracts, Documents and Instruments in Writing by the Corporation | 2 | |
2.6 | Execution of Documents in Counterparts or by Facsimile Signature | 2 | |
2.7 | Divisions | 3 | |
2.8 | Voting Rights in Other Bodies Corporate | 3 | |
ARTICLE 3 BORROWING | 3 | ||
3.1 | Borrowing | 3 | |
3.2 | Delegation of Borrowing Powers | 3 | |
ARTICLE 4 DIRECTORS | 4 | ||
4.1 | Powers and Duties of Directors | 4 | |
4.2 | Number of Directors | 4 | |
4.3 | Qualifications | 4 | |
4.4 | Election and Term | 4 | |
4.5 | Ceasing to Hold Office | 5 | |
4.6 | Removal of Directors | 5 | |
4.7 | Vacancies | 5 | |
4.8 | Remuneration of Directors | 5 | |
ARTICLE 5 MEETINGS OF DIRECTORS | 6 | ||
5.1 | Transaction of Business | 6 | |
5.2 | Quorum | 6 | |
5.3 | Place of Meetings | 6 | |
5.4 | Participation in Meeting by Electronic Means | 6 | |
5.5 | Calling of Meetings | 6 | |
5.6 | Notice of Meetings | 6 | |
5.7 | Waiver of Notice | 6 | |
5.8 | Omission of Notice | 7 | |
5.9 | Voting at Meetings | 7 | |
5.10 | Chair and Secretary | 7 | |
5.11 | Adjournment | 7 | |
5.12 | Conflicts of Interest | 7 | |
5.13 | Written Resolution In Lieu of Meeting | 8 | |
- ii - | |
ARTICLE 6 COMMITTEES OF THE BOARD | 8 |
10.8 | Certificated and Uncertificated Securities | 15 |
AKANDA CORP.
(the “Corporation”)
BY-LAW NO. 1
A by-law relating generally to the transaction of the business and affairs of the Corporation.
ARTICLE 1
INTERPRETATION
1.1 | Interpretation |
In this by-law:
(a) | “Act” means the Business Corporations Act (Ontario), R.S.O. 1990, c. B.16, and the regulations made thereunder, each as amended or re-enacted from time to time; |
(b) | “board” means the board of directors of the Corporation; |
(c) | “by-law” means any by-law of the Corporation in effect from time to time; |
(d) | “meeting of shareholders” means an annual or special meeting of shareholders of the Corporation; |
(e) | “STA” means the Securities Transfer Act, 2006 (Ontario), S.O. 2006, c. 8, as amended or re-enacted from time to time; |
(f) | unless otherwise specified, all words and expressions contained in this by-law and that are defined in the Act have the meanings given to them in the Act; |
(g) | any reference to gender includes all genders and words importing the singular number include the plural and vice versa; and |
(h) | the inclusion of headings and a table of contents are provided for convenience only and do not affect the construction or interpretation of this by-law. |
1.2 | Unanimous Shareholder Agreement |
If any provision in this by-law (or any other by-law) conflicts with any provision in a unanimous shareholder agreement, the provision in the unanimous shareholder agreement will govern to the extent permitted by the Act.
1.3 | Conflicts with the Act |
If any provision in this by-law (or any other by-law) contravenes any provision in the Act, the provision in the Act will govern.
- 2 -
ARTICLE 2
BUSINESS OF THE CORPORATION
2.1 | Registered Office |
The Corporation shall at all times have a registered office in Ontario. Unless changed in accordance with the Act, the registered office will be at the location specified in the articles.
2.2 | Seal |
The Corporation need not have a corporate seal, but any corporate seal adopted for the Corporation must be approved and may be changed by the board.
2.3 | Financial Year |
The financial year of the Corporation will be as determined by the board from time to time.
2.4 | Banking Arrangements |
Banking transactions will be made with the bank(s) or other financial institution(s) approved by the board from time to time, and banking transactions will be made on the Corporation’s behalf by the director(s), officer(s) or other person(s) designated, directed or authorized by the board from time to time and to the extent so designated, directed or authorized.
2.5 | Execution of Contracts, Documents and Instruments in Writing by the Corporation |
Contracts, documents or instruments in writing requiring the signature of the Corporation may be signed on behalf of the Corporation by any one officer or director of the Corporation. In addition, the board may from time to time authorize any officer or officers of the Corporation, any director or directors of the Corporation, or any other person or persons, either to sign contracts, documents and instruments in writing generally or to sign specific contracts, documents or instruments in writing and the manner in which those contracts, documents or instruments in writing may or will be signed.
2.6 | Execution of Documents in Counterparts or by Facsimile Signature |
Except as otherwise required by law:
(a) | any articles, notice, resolution, requisition, statement or other document required or permitted to be executed by more than one person for the purposes of the Act may be executed in several documents of like form each of which is executed by one or more of those persons, and those documents, when duly executed by all persons required or permitted, as the case may be, to do so, will be deemed to constitute one document for the purposes of the Act; |
(b) | the Corporation may accept delivery of any executed document, which is required or permitted to be executed by one or more persons for the purposes of the Act, by facsimile or by electronic transmission; and |
- 3 -
(c) | any document required or permitted to be executed by one or more persons for the purposes of the Act may be executed by means of electronic signature, and the Corporation may accept delivery of any document so executed. |
2.7 | Divisions |
The board may from time to time cause the business and operations of the Corporation or any part thereof to be divided into one or more divisions, further divide those divisions into sub-units, or consolidate the business and operations of divisions or sub-units.
2.8 | Voting Rights in Other Bodies Corporate |
Shares or other securities carrying voting rights of any body corporate or other entity held by the Corporation may be voted at any and all meetings of the holders of those shares or other securities in the manner and by the person(s) approved by the board from time to time. Persons authorized under paragraph 2.5 may also, for and on behalf of the Corporation and without the necessity of a resolution or other action by the board, execute and deliver proxies to vote any of those shares or other securities or arrange for the issue of security certificates or other evidence of the right to vote those shares or other securities.
ARTICLE 3
BORROWING
3.1 | Borrowing |
Without limiting the powers of the board as provided in the Act, unless the articles, by-laws or any unanimous shareholder agreement otherwise provide, the board may from time to time on behalf of the Corporation, without authorization of the shareholders:
(a) | borrow money upon the credit of the Corporation; |
(b) | issue, reissue, sell or pledge debt obligations of the Corporation; |
(c) | give a guarantee on behalf of the Corporation to secure performance of an obligation of any person; and |
(d) | mortgage, hypothecate, pledge or otherwise create a security interest in all or any property of the Corporation, owned or subsequently acquired, to secure any obligation of the Corporation. |
3.2 | Delegation of Borrowing Powers |
Unless the articles, by-laws or any unanimous shareholder agreement otherwise provide, the board may by resolution delegate any or all of the powers referred to in paragraph 3.1 to a director, a committee of the board or an officer of the Corporation.
- 4 -
ARTICLE 4
DIRECTORS
4.1 | Powers and Duties of Directors |
Subject to any unanimous shareholder agreement, the directors shall manage or supervise the management of the business and affairs of the Corporation. Every director of the Corporation in exercising his or her powers and discharging his or her duties to the Corporation shall act honestly and in good faith with a view to the best interests of the Corporation and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. Every director of the Corporation shall comply with the Act, the articles, the by-laws and any unanimous shareholder agreement.
4.2 | Number of Directors |
If the articles set out a fixed number of directors, the number of directors of the Corporation and the number of directors to be elected at an annual meeting of shareholders must be the number of directors set out in the articles. Where a minimum and maximum number of directors is provided for in the articles, the number of directors of the Corporation and the number of directors to be elected at an annual meeting of the shareholders must be that number as is determined from time to time by special resolution or, if a special resolution empowers the board to determine the number, by resolution of the board. Where no such resolution has been passed, the number of directors of the Corporation must be the number of directors named in the articles. The board must consist of at least one individual, but if the Corporation is an offering corporation, the board must consist of not fewer than three individuals.
4.3 | Qualifications |
If the Corporation is an offering corporation, at least one-third of the directors shall not be officers or employees of the Corporation or of any affiliate of the Corporation. No person may be a director if that person (i) is less than eighteen years of age, (ii) has been found under the Substitute Decisions Act, 1992 (Ontario) or under the Mental Health Act (Ontario) to be incapable of managing property or has been found to be incapable by a court in Canada or elsewhere, (iii) is not an individual, or (iv) has the status of bankrupt. Unless the articles otherwise provide, a director is not required to hold shares issued by the Corporation.
4.4 | Election and Term |
Subject to the Act, the shareholders of the Corporation shall elect, at the first meeting of shareholders and at each succeeding annual meeting at which an election of directors is required, directors to hold office for a term expiring not later than the close of the third annual meeting of shareholders following the election. A director not elected for an expressly stated term ceases to hold office at the close of the first annual meeting of shareholders following his or her election. A director who ceases to hold office upon the expiry of his or her term but who remains qualified to serve as a director is eligible for re-election. If directors are not elected at a meeting of shareholders at which an election of directors is required, the incumbent directors continue in office until their successors are elected.
- 5 -
4.5 | Ceasing to Hold Office |
A director ceases to hold office at the earliest of (i) his or her death, (ii) his or her removal from office by the shareholders of the Corporation in accordance with paragraph 4.6, (iii) his or her becoming disqualified for election as a director, (iv) his or her resignation, which resignation is effective when his or her written resignation is sent to the Corporation or, if a later time is specified in the resignation, at the later time, (v) the expiry of his or her term, if he or she is elected for an expressly stated term, or (vi) the close of the first annual meeting of shareholders following his or her election, if he or she is not elected for an expressly stated term.
4.6 | Removal of Directors |
Subject to the Act, the shareholders of the Corporation may by ordinary resolution at a meeting of shareholders remove any director or directors from office, and the vacancy or vacancies created by the removal of a director may be filled at that meeting, failing which the vacancy or vacancies may be filled by the board in accordance with the Act.
4.7 | Vacancies |
4.7.1 | Subject to the Act, a quorum of directors may fill a vacancy among the directors, except a vacancy resulting from: (i) an increase in the number of directors otherwise than in accordance with paragraph 4.7.2, or in the maximum number of directors, as the case may be, or (ii) a failure to elect the number of directors required to be elected at any meeting of shareholders. |
4.7.2 | Where a minimum and maximum number of directors is provided for in the articles, if a special resolution passed under paragraph 4.2 empowers the board to determine the number of directors, the directors may not, between meetings of shareholders, appoint an additional director if, after that appointment, the total number of directors would be greater than one and one-third times the number of directors required to have been elected at the last annual meeting of shareholders. |
4.7.3 | If there is not a quorum of directors, or if there has been a failure to elect the number of directors required by the articles or paragraph 4.2, the directors then in office shall forthwith call a special meeting of shareholders to fill the vacancy and, if they fail to call a meeting or if there are no directors then in office, the meeting may be called by any shareholder. |
4.7.4 | A director appointed or elected to fill a vacancy holds office for the unexpired term of the director’s predecessor. |
4.8 | Remuneration of Directors |
Subject to the articles and any unanimous shareholder agreement, the board may fix the remuneration of the directors of the Corporation.
- 6 -
ARTICLE 5
MEETINGS OF DIRECTORS
5.1 | Transaction of Business |
The powers of the board may be exercised at a meeting at which a quorum is present or by a resolution in writing signed by all the directors entitled to vote on that resolution at a meeting of the board. Where the Corporation has only one director, that director may constitute a meeting.
5.2 | Quorum |
Subject to the articles, a majority of the number of directors determined in accordance with paragraph 4.2 constitutes a quorum for the transaction of business at any meeting of the board and, notwithstanding any vacancies on the board, a quorum of directors may exercise all the powers of the board. Where the Corporation has fewer than three directors, all directors must be present at any meeting of the board to constitute a quorum.
5.3 | Place of Meetings |
Meetings of the board may be held at any place within or outside Ontario and it is not necessary in any financial year of the Corporation for a majority of the meetings of the board to be held at a place within Canada.
5.4 | Participation in Meeting by Electronic Means |
If all the directors of the Corporation present at or participating in the meeting consent, a meeting of the board may be held by means of telephone, electronic or other communication facilities that permit all persons participating in the meeting to communicate with each other simultaneously and instantaneously, and a director participating in that meeting by those means is deemed to be present at that meeting.
5.5 | Calling of Meetings |
Meetings of the board may be called at any time by the Chair of the board (if any), the President (if the President is a director), a Vice-President who is a director, or any two directors.
5.6 | Notice of Meetings |
Subject to paragraph 5.7, notice of the time and place of any meeting of the board must be sent to every director not less than 48 hours before the time when the meeting is to be held, but notice of an adjourned meeting need not be given if the time and place of the adjourned meeting is announced at the original meeting. A notice of a meeting of the board need not specify the purpose of or the business to be transacted at the meeting unless the Act requires that purpose or business or the general nature of the business to be specified. Provided a quorum of directors is present, each newly elected board may without notice hold its first meeting immediately following the meeting of shareholders at which that board is elected.
5.7 | Waiver of Notice |
A director may in any manner and at any time waive notice of a meeting of the board. Attendance of a director at a meeting of the board is a waiver of notice of the meeting, except where a director attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.
- 7 -
5.8 | Omission of Notice |
The accidental omission to give notice of any meeting of the board or any irregularity in the notice of any meeting or the non-receipt of any notice by any director will not invalidate any resolution passed or any proceeding taken at that meeting.
5.9 | Voting at Meetings |
Questions arising at any meeting of the board will be decided by a majority of the votes cast on the question. In case of an equality of votes the chair of the meeting will not be entitled to a second or casting vote.
5.10 | Chair and Secretary |
The Chair of the board (if any) will, when present, preside as chair at meetings of the board. If the Chair of the board is absent or unable or unwilling to preside as chair, the Vice-Chair of the board (if any) will, when present, preside as chair for that meeting. If the Vice-Chair of the board is absent or unable or unwilling to preside as chair, the President (if the President is a director) will, when present, preside as chair for that meeting. If none of these officers is present or able or willing to preside as chair, the directors present shall choose one from among them to preside as chair for that meeting. The Secretary of the Corporation (if any) will, when present, act as secretary at meetings of the board. If the Secretary is absent or unable or unwilling to act as secretary, the chair of the meeting shall appoint a person who need not be a director to act as secretary for that meeting.
5.11 | Adjournment |
The chair of a meeting of the board may, with the consent of the meeting, adjourn the meeting to a fixed time and place. If there is a quorum at the adjourned meeting, the meeting will be considered duly constituted and the board may deliberate and transact business in accordance with the procedures established at the original meeting. The directors constituting a quorum at the original meeting need not constitute the quorum at the adjourned meeting. If there is no quorum at the adjourned meeting, the meeting will be deemed to have ended at the original meeting at which the chair declared the adjournment.
5.12 | Conflicts of Interest |
A director of the Corporation who is a party to, or who is a director or an officer of or has a material interest in any person who is a party to, a material contract or transaction or proposed material contract or transaction with the Corporation shall disclose to the Corporation the nature and extent of that interest at the time and in the manner provided by the Act. No such director shall attend any part of a meeting of the board during which the contract or transaction is discussed or vote on any resolution to approve the contract or transaction except in accordance with the Act. If no quorum exists for the purpose of voting on a resolution to approve a contract or transaction only because a director is not permitted to be present at the meeting, the remaining directors will be deemed to constitute a quorum for the purposes of voting on the resolution.
- 8 -
5.13 | Written Resolution In Lieu of Meeting |
A resolution in writing, signed by all the directors entitled to vote on that resolution at a meeting of the board, is as valid as if it had been passed at a meeting of the board.
ARTICLE 6
COMMITTEES OF THE BOARD
6.1 | Committees of Directors |
Subject to the articles, the board may appoint from their number a managing director or one or more committees of directors, however designated, and delegate to the managing director or those committees any powers of the board except those that pertain to matters that, under the Act, a managing director or committee of the board has no authority to exercise.
6.2 | Transaction of Business |
The powers of a committee of the board may be exercised at a meeting at which a quorum is present or by a resolution in writing signed by all the directors entitled to vote on that resolution at a meeting of the committee. Meetings of committees of the board may be held at any place within or outside Ontario.
6.3 | Meetings by Electronic Means |
The provisions of paragraph 5.4 apply to meetings of committees of the board.
6.4 | Procedures |
Unless otherwise determined by the board, each committee of the board has the power to fix its quorum at not less than a majority of its members, to elect its chair and to regulate its procedure.
ARTICLE 7
OFFICERS
7.1 | Designation and Appointment |
Subject to the articles and any unanimous shareholder agreement, the board may designate the offices of the Corporation, appoint officers, specify their duties and, subject to the Act, delegate to them powers to manage the business and affairs of the Corporation. Subject to the articles and any unanimous shareholder agreement, a director may be appointed to any office of the Corporation and two or more offices of the Corporation may be held by the same person.
7.2 | Powers and Duties of Officers |
Every officer of the Corporation shall:
(a) | perform all powers and duties incident to his or her respective office and such other powers and duties respectively as may from time to time be assigned to him or her by the board; |
(b) | in exercising his or her powers and discharging his or her duties to the Corporation, act honestly and in good faith with a view to the best interests of the Corporation and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances; and |
(c) | comply with the Act, the articles, the by-laws and any unanimous shareholder agreement. |
- 9 -
7.3 | Term of Office |
An officer ceases to hold office at the earliest of (i) his or her death, (ii) his or her removal from office by the board, (iii) his or her ceasing to be a director if being a director is a necessary qualification of that officer’s appointment, (iv) his or her resignation, which resignation is effective when his or her written resignation is sent to the Corporation or, if a later time is specified in that resignation, at the later time, (v) the appointment of his or her successor, or (vi) the close of the first meeting following his or her appointment at which the board annually appoints the officers of the Corporation.
7.4 | Vacancies |
If the office of any officer of the Corporation becomes vacant for any reason, the board may appoint a person to fill that vacancy.
7.5 | Remuneration |
Subject to the articles and any unanimous shareholder agreement, the board may fix the remuneration of the officers of the Corporation.
7.6 | Conflicts of Interest |
An officer of the Corporation who is a party to, or who is a director or an officer of or has a material interest in any person who is a party to, a material contract or transaction or proposed material contract or transaction with the Corporation, shall disclose to the Corporation the nature and extent of that interest at the time and in the manner provided by the Act.
7.7 | Agents and Attorneys |
Subject to the Act, the Corporation may from time to time appoint agents or attorneys for the Corporation in or outside Canada, with such powers (including the power to sub-delegate) as may be thought fit.
7.8 | Divisional Officers |
Where the business and operations of the Corporation or any part thereof are divided into one or more divisions or sub-units, the board may designate and appoint divisional officers to those divisions or sub-units and determine their powers and duties.
- 10 -
ARTICLE 8
PROTECTION OF DIRECTORS AND OFFICERS
8.1 | Indemnity |
8.1.1 | Subject to the Act, the Corporation shall indemnify a director or officer of the Corporation, a former director or officer of the Corporation or another individual who acts or acted at the Corporation’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Corporation or other entity. |
8.1.2 | The Corporation shall not indemnify an individual under paragraph 8.1.1 unless the individual: |
(i) | acted honestly and in good faith with a view to the best interests of the Corporation or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the Corporation’s request; and |
(ii) | in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, had reasonable grounds for believing that the individual’s conduct was lawful. |
8.1.3 | The Corporation shall also indemnify an individual referred to in paragraph 8.1.1 in such other circumstances as the Act permits or requires. Nothing in this by-law limits the right of any individual entitled to indemnity to claim indemnity apart from the provisions of this by-law. |
8.2 | Insurance |
The Corporation may purchase and maintain insurance for the benefit of an individual referred to in paragraph 8.1.1 against any liability incurred by that individual, (i) in the individual’s capacity as a director or officer of the Corporation, or (ii) in the individual’s capacity as a director or officer, or a similar capacity, of another entity, if the individual acts or acted in that capacity at the Corporation’s request.
ARTICLE 9
MEETINGS OF SHAREHOLDERS
9.1 | Annual Meetings |
Subject to the Act, the board shall call an annual meeting of shareholders not later than eighteen months after the Corporation comes into existence and subsequently not later than fifteen months after holding the last preceding annual meeting, for the purpose of placing before the annual meeting the financial statements, reports and any further information required by the Act to be placed before the annual meeting, electing directors, appointing an auditor and transacting any other business that may be properly brought before the meeting.
9.2 | Special Meetings |
Subject to the Act, the board may at any time call a special meeting of shareholders, and a special meeting of shareholders may be held in conjunction with an annual meeting of shareholders.
9.3 | Place of Meetings |
Subject to the articles and any unanimous shareholder agreement, a meeting of shareholders will be held at such place in or outside Ontario as the board determines or, in the absence of such a determination, at the place where the registered office of the Corporation is located. A meeting of shareholders held under paragraph 9.6 will be deemed to be held at the place where the registered office of the Corporation is located.
- 11 -
9.4 | Quorum |
Subject to the Act and the articles, a quorum at any meeting of shareholders will be two persons present in person and holding or representing by proxy not less than 10% of the votes attached to all shares entitled to be voted at the meeting. If the Corporation has only one shareholder, or only one holder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting. No business may be transacted at any meeting of shareholders unless a quorum is present at the time of the transaction of the business.
9.5 | Written Resolution in Lieu of Meeting |
Subject to the Act, a resolution in writing signed by all the shareholders of the Corporation or their attorney authorized in writing entitled to vote on that resolution at a meeting of shareholders is as valid as if it had been passed at a meeting of shareholders.
9.6 | Meetings Held by Electronic Means |
Subject to the articles, a meeting of shareholders may be held by telephonic or electronic means and a shareholder of the Corporation who, through those means, votes at the meeting or establishes a communications link to the meeting will be deemed for the purposes of the Act to be present at the meeting.
9.7 | Notice of Meetings |
Subject to paragraph 9.8, notice of the time and place of any meeting of shareholders must be sent to each shareholder of the Corporation entitled to vote at the meeting, to each director and to the auditor of the Corporation as follows: if the Corporation is an offering corporation, not less than twenty-one days or, if the Corporation is not an offering corporation, not less than ten days, but, in either case, not more than fifty days, before the meeting. Notice of a meeting of shareholders at which special business (as defined in the Act) is to be transacted must state, or be accompanied by a statement of, the nature of that business in sufficient detail to permit the shareholder to form a reasoned judgment thereon and the text of any special resolution or by-law to be submitted to the meeting.
9.8 | Waiver of Notice |
A shareholder of the Corporation and any other person entitled to attend a meeting of shareholders may in any manner and at any time waive notice of a meeting of shareholders, and attendance of any such person at a meeting of shareholders is a waiver of notice of the meeting, except where that person attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called.
9.9 | Record Date for Notice |
For the purpose of determining shareholders entitled to receive notice of a meeting of shareholders, the board may fix in advance, as the record date for that determination, a date that is not less than 30 days and not more than 60 days before the date of the meeting or that is within such other period as may be prescribed by the Act.
- 12 -
9.10 | List of Shareholders Entitled to Receive Notice |
9.10.1 | For every meeting of shareholders, the Corporation shall prepare a list of shareholders entitled to receive notice of the meeting, arranged in alphabetical order and showing the number of shares held by each shareholder. |
9.10.2 | If a record date is fixed under paragraph 9.9, the shareholders listed will be those whose names are set out in the securities register of the Corporation at the close of business on that record date and the list must be prepared not later than ten days after that record date. |
9.10.3 | If no record date is fixed, the shareholders listed will be those whose names are set out in the securities register of the Corporation at the close of business on the day immediately preceding the day on which notice of the meeting is given and the list must be prepared on that date. However, where no notice of the meeting is given, the shareholders listed will be those whose names are set out in the securities register of the Corporation on the day on which the meeting is held and the list must be prepared on that date. |
9.10.4 | The list of shareholders must be made available for examination by any shareholder of the Corporation during usual business hours at the registered office of the Corporation or at the place where its central securities register is maintained and at the meeting of shareholders for which the list was prepared. |
9.11 | Shareholders Entitled to Vote |
A shareholder of the Corporation whose name appears on a list prepared under paragraph 9.10 is entitled to vote the shares shown opposite the shareholder’s name at the meeting of shareholders to which the list relates.
9.12 | Persons Entitled to Attend |
The only persons entitled to attend a meeting of shareholders are those entitled to vote at that meeting, the directors and the auditor of the Corporation and others who, although not entitled to vote, are entitled or required under the Act, the articles or the by-laws to be present at the meeting. Any other person may be admitted only with the consent of the chair of the meeting.
9.13 | Omission of Notice |
The accidental omission to give notice of any meeting of shareholders or any irregularity in the notice of any meeting or the non-receipt of any notice by any shareholder or director or the auditor of the Corporation will not invalidate any resolution passed or any proceeding taken at that meeting.
9.14 | Chair, Secretary and Scrutineers |
9.14.1 | Subject to the Act, the articles and any unanimous shareholder agreement, the Chair of the board (if any) will, when present, preside as chair at meetings of shareholders. If the Chair of the board is absent or unable or unwilling to preside as chair, the Vice-Chair of the board (if any) will, when present, preside as chair for that meeting. If the Vice-Chair of the board is absent or unable or unwilling to preside as chair, the President will, when present, preside as chair for that meeting. Subject to the Act, the articles and any unanimous shareholder agreement, if none of these officers is present within 15 minutes after the time appointed for holding the meeting, or if none of these officers is able or willing to preside as chair, the persons present and entitled to vote at the meeting shall choose a director present at the meeting to be the chair for that meeting, and if no director is present or if all the directors present decline to take the chair, then the persons present and entitled to vote shall choose one of their number to be the chair for that meeting. |
- 13 -
9.14.2 | The Secretary of the Corporation (if any) will, when present, act as secretary at meetings of shareholders, but if the Secretary is not present at a meeting, the chair of the meeting shall appoint a person who need not be a shareholder to act as secretary at that meeting. |
9.14.3 | One or more scrutineers, who need not be shareholders of the Corporation, may be appointed by ordinary resolution or by the chair of the meeting. |
9.15 | Proxies and Representatives |
Every shareholder entitled to vote at a meeting of shareholders may by means of a proxy appoint a proxyholder or one or more alternate proxyholders, who need not be shareholders, as the shareholder’s nominee to attend and act at the meeting in the manner, to the extent and with the authority conferred by the proxy. Subject to the Act, a proxy must be signed (i) in writing or by electronic signature by the shareholder or an attorney who is authorized by a document that is signed in writing or by electronic signature or, (ii) if the shareholder is a body corporate, by an officer or attorney of the body corporate duly authorized. If the Corporation is an offering corporation, a proxy appointing a proxyholder ceases to be valid one year from its date. A form of proxy must comply with the regulations under the Act.
9.16 | Voting at Meetings |
9.16.1 | Voting at a meeting of shareholders will be by show of hands, except where a ballot is demanded by a shareholder or proxyholder entitled to vote at the meeting or applicable law requires a ballot to be taken on a particular matter. A shareholder or proxyholder may demand a ballot either before or after any vote by show of hands. A demand for a ballot may be withdrawn. |
9.16.2 | On a show of hands, every person who is present and entitled to vote at the meeting will have one vote. Subject to the Act, if a ballot is taken on a question, every person who is present and entitled to vote at the meeting will, unless the articles otherwise provide, have one vote for each share which that person is entitled to vote at the meeting on the question. |
9.16.3 | If at any meeting a ballot is demanded on the election of a chair or on the question of adjournment, it will be taken immediately without adjournment. If at any meeting a ballot is demanded or required on any other question, including the election of directors, the vote will be taken by ballot in the manner and at the time (at once, later in the meeting or after adjournment) as the chair of the meeting directs. The result of a ballot on a question will be the decision of the shareholders on that question. |
9.16.4 | Unless a ballot is demanded, an entry in the minutes of a meeting of shareholders to the effect that the chair declared a motion to be carried is admissible in evidence as proof of the fact, in the absence of evidence to the contrary, without proof of the number or proportion of the votes recorded in favour of or against the motion. |
9.16.5 | Subject to the Act, the articles and any unanimous shareholder agreement, every question at any meeting of shareholders will be determined by a majority of the votes cast on the question. In case of an equality of votes, either on a show of hands or on a ballot, the chair of the meeting will not be entitled to a second or casting vote. |
- 14 -
9.17 | Joint Shareholders |
Where two or more persons hold shares jointly, one of those holders present at a meeting of shareholders may in the absence of the others vote the shares, but if two or more of those persons are present, in person or by proxy, they shall vote as one on the shares jointly held by them.
9.18 | Adjournment |
The chair of a meeting of shareholders may, with the consent of the meeting, adjourn the meeting to a fixed time and place. If a meeting is adjourned for less than 30 days, it is not necessary to give notice of the adjourned meeting other than by announcement at the earliest meeting that is adjourned. Subject to the Act, if a meeting is adjourned by one or more adjournments for an aggregate of 30 days or more, notice of the adjourned meeting must be given as for an original meeting. If a meeting is adjourned and no notice is required, any business that may have been brought before or dealt with at the original meeting in accordance with the notice calling that meeting may be brought before or dealt with at the adjourned meeting. Any adjourned meeting will be duly constituted if held in accordance with the terms of the adjournment and a quorum is present at that meeting. The persons constituting a quorum at the original meeting need not constitute the quorum at the adjourned meeting. If there is no quorum at the adjourned meeting, the original meeting will be deemed to have ended immediately after its adjournment.
9.19 | One Shareholder |
If the Corporation has only one shareholder, or only one holder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting.
ARTICLE 10
SECURITIES
10.1 | Issuance |
Subject to the Act, the articles and any unanimous shareholder agreement, shares in the capital of the Corporation may be issued at such time and to such persons and for such consideration as the board may determine. No share may be issued until the consideration for the share is fully paid as provided for in the Act.
10.2 | Commissions |
The board may authorize the Corporation to pay a reasonable commission to any person in consideration of the person’s purchasing or agreeing to purchase shares of the Corporation from the Corporation or from any other person, or procuring or agreeing to procure purchasers for any such shares.
10.3 | Lien on Shares |
The Corporation has a lien on shares registered in the name of a shareholder or the shareholder’s legal representative for a debt of that shareholder to the Corporation, but not on any class or series of shares listed and posted for trading on a stock exchange in or outside Canada. Subject to the articles and any unanimous shareholder agreement, the Corporation may enforce the lien by selling the shares affected by it or by any other means permitted by law.
- 15 -
10.4 | Securities Register |
The Corporation shall prepare and maintain at its registered office, or at any other place in Ontario designated by the board, a securities register in which it records the securities issued by it in registered form, showing with respect to each class or series of securities the information required by the Act. Branch registers, if any, may be kept at such offices of the Corporation or other places, either within or outside Ontario, designated by the board.
10.5 | Register of Transfers |
The Corporation shall cause to be kept, at its registered office or at any other place in Ontario designated by the board, a register of transfers in which all transfers of securities issued by the Corporation in registered form and the date and other particulars of each transfer as required by the Act will be set out. Branch registers of transfers, if any, may be kept at such offices of the Corporation or other places, either within or outside Ontario, designated by the board.
10.6 | Registrar and Transfer Agent |
For each class of securities and warrants issued by it, the Corporation may appoint, (i) a trustee, transfer agent or other agent to keep the securities register and the register of transfers and one or more persons or agents to keep branch registers; and (ii) a registrar, trustee or agent to maintain a record of issued security certificates and warrants, and, subject to the Act, one person may be appointed for the purposes of both clauses (i) and (ii) in respect of all securities and warrants of the Corporation or any class or classes thereof.
10.7 | Effect of Registration |
Subject to the Act, the Corporation may treat the registered owner of a security as the person exclusively entitled to vote, to receive notices, to receive any interest, dividend or other payments in respect of the security, and otherwise to exercise all the rights and powers of a holder of the security.
10.8 | Certificated and Uncertificated Securities |
A security issued by the Corporation may be represented by a security certificate or may be an uncertificated security. Unless otherwise provided by the articles, the board may provide by resolution that any or all classes and series of the Corporation’s shares or other securities will be uncertificated securities, but no such resolution will apply to securities represented by a certificate until that certificate is surrendered to the Corporation. Within a reasonable time after the issuance or transfer of an uncertificated security, the Corporation shall send to the registered owner of the uncertificated security a written notice containing the information required to be stated on a share certificate in accordance with the Act. The Corporation may charge a fee, not exceeding the amount prescribed by the Act, for a security certificate issued in respect of a transfer. Security certificates issued by the Corporation will be in such form as the board may from time to time approve and must be signed by at least one of the following persons:
(a) | a director or officer of the Corporation; |
- 16 -
(b) | a registrar, transfer agent or branch transfer agent of the Corporation, or an individual on their behalf; and |
(c) | a trustee who certifies it in accordance with a trust indenture. |
10.9 | Replacement of Certificates |
Subject to the Act and the STA, the Corporation shall issue a new security certificate in lieu of a security certificate claimed by its owner to have been lost, destroyed or wrongfully taken, on payment of a fee, not exceeding any amount prescribed by the Act, on such terms as to indemnity, reimbursement of expenses and evidence of loss and of title as the board may from time to time prescribe, whether generally or in any particular case, and upon satisfaction of any other reasonable requirements determined by the board. However, the Corporation will not be required to issue a new security certificate in lieu of a security certificate that has been lost, apparently destroyed or wrongfully taken if (i) the owner fails to give notice to the Corporation of that fact within a reasonable time after the owner has notice of it; and (ii) the Corporation registers a transfer of the security before receiving a notice of the loss, apparent destruction or wrongful taking of the security certificate.
10.10 | Joint Holders of Securities |
If the Corporation issues a security certificate in respect of securities, it will not be required to issue more than one security certificate in respect of securities held jointly by several persons, and delivery to one of several joint holders is sufficient delivery to all. Where a security of the Corporation is issued to several persons as joint holders, upon satisfactory proof of the death of one joint holder, the Corporation may treat the surviving joint holders as owner of the security.
ARTICLE 11
DIVIDENDS
11.1 | Dividends |
Subject to the Act, the articles and any unanimous shareholder agreement, the board may from time to time declare and the Corporation may pay dividends to the shareholders according to their respective rights and interests in the Corporation. Dividends may be paid in money or property or by issuing fully paid shares of the Corporation or options or rights to acquire fully paid shares of the Corporation.
11.2 | Record Date for Dividends |
For the purpose of determining shareholders entitled to receive payment of a dividend, the board may fix in advance, as the record date for that determination, a date that is not more than 50 days before the date for the payment of the dividend. If no record date is so fixed, the record date for the determination of shareholders entitled to receive payment of a dividend will be at the close of business on the day on which the resolution relating to that dividend is passed by the board.
11.3 | Dividend Cheques |
A dividend payable in cash may be paid by cheque to the order of each registered holder of shares of the class or series in respect of which it has been declared and mailed by prepaid ordinary mail to that registered holder at the holder’s recorded address, unless that holder otherwise directs. In the case of joint holders, the cheque will, unless such joint holders otherwise direct, be made payable to the order of all of those joint holders and mailed to them at their recorded address.
- 17 -
ARTICLE 12
NOTICES
12.1 | Method of Giving Notices |
12.1.1 | Any notice or document required by the Act, the articles or the by-laws to be sent to a shareholder or director may be sent by prepaid mail, delivered personally or, subject to paragraph 12.2, sent by electronic means, as follows: |
(i) | to a shareholder at the shareholder’s latest address as shown in the records of the Corporation or its transfer agent; and |
(ii) | to a director at the director’s latest address as shown in the records of the Corporation or in the most recent notice filed under the Corporations Information Act (Ontario), whichever is the more current. |
12.1.2 | A notice or document sent by prepaid mail to a shareholder in accordance with clause 12.1.1(i) or to a director in accordance with clause 12.1.1(ii) is deemed to be received by the addressee on the fifth day after mailing. |
12.2 | Sending Notices by Electronic Means |
A notice or document required or permitted to be sent by the Act to a shareholder or director of the Corporation may be sent by electronic means in accordance with the Electronic Commerce Act, 2000 (Ontario) or as otherwise permitted by law.
12.3 | Notice to Joint Shareholders |
If two or more persons are registered as joint holders of any share of the Corporation, any notice may be addressed to all of those joint holders, but notice addressed to one of them will be sufficient notice to all of them.
12.4 | Persons Entitled by Death or Operation of Law |
Subject to the Act, every person who by operation of law, transfer, death of a shareholder or any other means becomes entitled to any securities of the Corporation will be bound by every notice in respect of those securities that, prior to that person’s name and address being entered in the records of the Corporation, has been duly given to the registered holder of those securities.
12.5 | Undelivered Notices |
If any notice or document sent to a shareholder under clause 12.1.1(i) is returned on three consecutive occasions because the shareholder cannot be found, the Corporation is not required to send any further notices or documents to the shareholder until the shareholder informs the Corporation in writing of the shareholder’s new address.
- 18 -
12.6 | Waiver of Notice |
Where a notice or document is required to be sent, the notice may be waived or the time for the sending of the notice or document may be waived or abridged at any time with the consent in writing of the person entitled thereto, which consent may be sent by electronic means in accordance with the Electronic Commerce Act, 2000 (Ontario) or as otherwise permitted by law.
ARTICLE 13
ENACTMENT, AMENDMENT AND REPEAL OF BY-LAWS
13.1 | Approval and Confirmation |
Unless the articles, by-laws or any unanimous shareholder agreement otherwise provide, the board may, by resolution, make, amend or repeal any by-laws. Where the board so makes, amends or repeals a by-law, the board shall submit the by-law, amendment or repeal to the shareholders at the next meeting of shareholders, and the shareholders may by ordinary resolution confirm, reject or amend that by-law, amendment or repeal.
13.2 | Effective Date |
Subject to this Article 13, any by-law, amendment or repeal of a by-law is effective from the date of the resolution of the board and remains in force until it is confirmed, confirmed as amended or rejected by the shareholders at the next meeting of shareholders. If a by-law, amendment or repeal is rejected by the shareholders, or if the board does not submit it to the shareholders as required by the Act, the by-law, amendment or repeal ceases to be effective on the date of that rejection or on the date of the meeting of shareholders at which it should have been submitted, as the case may be, and no subsequent resolution of the board to make, amend or repeal a by-law having substantially the same purpose or effect is effective until it is confirmed or confirmed as amended by the shareholders.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
- 19 -
MADE by the board on the 16th day of July, 2021.
DocuSigned by: | DocuSigned by: | |||
/s/ Philip Van Den Berg | /s/ Tej Virk | |||
Name: | Philip van den Berg | Name: | Tej Virk | |
Title: | Director | Title: | Chief Executive Officer |
Exhibit 4.1
INVESTOR RIGHTS AGREEMENT
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of November 3, 2021 (the “Effective Date”), by and among AKANDA CORP., an Ontario corporation (the “Company”), and HALO COLLECTIVE INC., an Ontario corporation, as further identified on Schedule A hereto (the “Investor”).
RECITALS
WHEREAS, the Company and Investor have to entered into that certain Share Purchase Agreement between Company and Investor dated September 29, 2021(the “Share Purchase Agreement”), which contemplates the sale of all of the shares of Cannahealth Limited, a wholly owned subsidiary of Investor, to Company, upon the terms and conditions of the Share Purchase Agreement, resulting in Investor owning 13,129,212 Common Shares.
WHEREAS, in connection with the entering into of the Share Purchase Agreement , the Investor and the Company hereby agree that this Agreement shall govern the rights of the Investor, to receive certain information from the Company, to nominate an Investor Director, to exercise Board of Directors observer rights, and shall govern certain other matters as set forth in this Agreement;
NOW, THEREFORE, the parties hereby agree as follows:
1. | Definitions. For purposes of this Agreement: |
1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or other investment fund now or hereafter existing that is controlled by one (1) or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person.
1.2 “AGM” means the Company’s annual general meeting.
1.3 “Articles of Incorporation” means the Company’s Articles of Incorporation, as amended and/or restated from time to time.
1.4 “Board of Directors” means the board of directors of the Company.
1.5 “Common Shares” means the Company’s common shares, no par value.
1.6 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.
INVESTOR RIGHTS AGREEMENT
1
1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Shares, including options and warrants.
1.8 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
1.9 “FOIA Party” means a Person that, in the reasonable determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement.
1.10 “Form F-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC, as it relates to the Company, a corporation foreign to the United States.
1.11 “Form F-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC, as it relates to the Company, a corporation foreign to the United States.
1.12 “GAAP” means generally accepted accounting principles in the United States as in effect from time to time.
1.13 “Holder” means Investor.
1.14 “IFRS” means the international financial reporting standards, commonly called IFRS, the accounting standard in Canada as in effect from time to time.
1.15 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships of a natural person referred to herein.
1.16 “Investor Director” means an individual nominated to the Board of Directors by Investor.
1.17 “IPO” means the Company’s first underwritten public offering of its Common Shares under the Securities Act.
1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.
INVESTOR RIGHTS AGREEMENT
2
1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.
1.20 “SEC” means the Securities and Exchange Commission.
1.21 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.
1.22 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.
1.23 “Securities” means (i) any Common Shares, or any Common Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by a Holder of even date or after the date hereof, and (ii) any Common Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 5.1.
1.24 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
2. | Reports: “Lock-up”. |
2.1 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form F-3, the Company shall:
(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;
(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and
(c) furnish to any Holder, so long as the Holder owns any Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form F-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form F-3 (at any time after the Company so qualifies to use such form).
INVESTOR RIGHTS AGREEMENT
3
2.2 “Lock-Up” Agreement. The Holders agree hereby not to, and agree to execute and deliver a lock-up agreement with the underwriter(s) of the IPO restricting its right to, (a) offer, pledge, sell, contract to sell, sell any options or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any securities of the Company, or (b) enter into any swap or other arrangement or any transaction that transfers, in whole or in part, directly or indirectly, to another any of the economic consequences of ownership of such securities during the period of up to 270 days from the date on which the trading of the Securities on the Nasdaq Stock Exchange commences (the “Lock-Up Trigger Date”), in each case, excluding transfers pursuant to any carve-outs in the applicable lock-up agreement. The terms of such lock-up agreements shall be negotiated among the Investor, the Company and the underwriters in the IPO and shall include customary carve-outs from the restrictions on transfer set forth therein and shall permit that up to 50% of such securities may be transferred or sold from the 271st day through the 365th day following the Lock-Up Trigger Date; the remaining 50% of such securities will be entitled to be transferred without such lock-up restrictions beginning on the 366th day following the Lock-Up Trigger Date. Any such transfers remain subject to rules of the Securities and Exchange Commission applicable to securities held by Affiliates, provided that the Company agrees to cooperate with Investor to facilitate the transfer of Securities by Investor following the expiration of the lock-up restrictions as set forth herein, including with respect to the removal of restrictive legends from the Securities applicable to Affiliates, if Investor furnishes to the Company an opinion of counsel reasonably satisfactory to the Company that Investor is not an “affiliate” of the Company under the Securities Act. Notwithstanding the foregoing, nothing in this Section 2.2 shall prohibit the sale by the Investor of such number of Common Shares as is required in order for the Investor to comply with its covenants relating to control of the Company, found in that secured convertible debenture, dated the date here of, issued by the Company and acknowledged and agreed to by the Investor, evidencing indebtedness in the principal amount of USD$6,559,294.
3. | Information, Board Nominee and Observer Rights. |
3.1 Delivery of Financial Statements. Upon written request by Investor, the Company shall deliver the following to Investor:
(a) as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Section 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year;
INVESTOR RIGHTS AGREEMENT
4
(b) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with IFRS or GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with IFRS or GAAP);
(c) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Shares issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Shares and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit Investor to calculate its percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct;
(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company (such budget and business plan that is approved by the Board of Directors is collectively referred to herein as the “Budget”); and
(e) with respect to the financial statements called for in Section 3.1(a) and Section 3.1(b), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with IFRS or GAAP consistently applied with prior practice for earlier periods (except as otherwise set forth in Section 3.1(b) or as disclosed otherwise) and fairly present, in all material respects, the financial condition of the Company and its financial performance for the periods specified therein; and
(f) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.
INVESTOR RIGHTS AGREEMENT
5
Notwithstanding anything else in this Section 3.1 to the contrary, the Company shall have no obligation to provide any information requested pursuant to this Section 3.1 during (i) any period in which the Company has a public filing obligation to provide substantially similar information or (ii) the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.
3.2 Inspection. The Company shall permit Investor, at Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
3.3 Director Nominee Rights. Upon written notice of Investor, so long as Investor holds at least ten percent (10%) of the shares of Common Shares (subject to appropriate adjustment for any stock splits, stock dividends, combinations, recapitalizations and the like), Investor shall have the right, but not the obligation, to nominate an Investor Director to the Board of Directors of the Company at any election of the Board of Directors of the Company, at an AGM or otherwise, or within sixty (60) days of Investor’s notice to fill any vacancy. Any vacancies created by the resignation, removal or death of an Investor Director shall be filled by nomination of Investor, pursuant to the provisions of this Section 3.3.
3.4 Failure to Nominate an Investor Director. In the absence of any new nomination from the Investor as specified in Section 3.3 above, any Investor Director previously nominated by Investor and then serving shall be automatically re-nominated if willing to serve unless such individual has been removed by the Board of Directors, and otherwise such seat shall remain vacant until otherwise filled as provided in Section 3.4.
3.5 No Liability for Election of Nominated Directors. Investor, nor any Affiliate of any the same, shall have any liability as a result of nominating an individual for election as a director for any act or omission by such Investor Director in his or her capacity as a director of the Company, nor shall Investor or any Investor Affiliate have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement.
INVESTOR RIGHTS AGREEMENT
6
3.6 Observer Rights. Upon written notice of Investor, so long as Investor holds at least ten percent (10%) of the shares of the then issued and outstanding Common Shares (subject to appropriate adjustment for any stock splits, stock dividends, combinations, recapitalizations and the like) and the Investor Director is not a then-current member of the Board of Directors, the Company shall invite a representative of Investor to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company.
3.7 Termination of Information, Board Nominee and Observer Rights. The covenants set forth in Sections 3.1, 3.2, 4.3 and 4.6 shall terminate upon the date on which the Investor no longer holds any Securities or if the Investor receives information, nominee and observer rights from the acquiring company or other successor to the Company substantially similar to those set forth in Section 4.
3.8 Confidentiality. Investor agrees that it will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.8 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.8; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.
4. | Additional Covenants. |
4.1 Insurance. The Company shall obtain, within ninety (90) days of the effective date of this Agreement, from financially sound and reputable insurers, Directors and Officers liability insurance and term “key person” insurance, each in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. The key person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Board of Directors.
INVESTOR RIGHTS AGREEMENT
7
4.2 Board Matters. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors, if so approved by the Board of Directors. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors. Each non-employee director shall be entitled in such person’s discretion to be a member of all the audit and compensation committees of the Board of Directors.
4.3 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Articles of Incorporation, or elsewhere, as the case may be.
4.4 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the Investor Directors nominated to serve on the Board of Directors by one Investor may have certain rights to indemnification, advancement of expenses and/or insurance provided by the Investor (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by the Articles of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Section 4.4 and shall have the right, power and authority to enforce the provisions of this Section 4.4 as though they were a party to this Agreement.
INVESTOR RIGHTS AGREEMENT
8
4.5 FCPA. The Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any enforcement. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws.
4.6 Cybersecurity. The Company shall use commercially reasonable efforts to (a) identify and restrict access (including through physical and/or technical controls) to the Company’s confidential business information and trade secrets and any information about identified or identifiable natural persons maintained by or on behalf of the Company (collectively, “Protected Data”) to those individuals who have a need to access it and (b) implement reasonable physical, technical and administrative safeguards (“Cybersecurity Solutions”) designed to protect the confidentiality, integrity and availability of its technology and systems (including servers, laptops, desktops, cloud, containers, virtual environments and data centers) and all Protected Data. The Company shall use commercially reasonable efforts to ensure that the Cybersecurity Solutions (x) are up-to-date and include industry-standard protections (e.g., antivirus, endpoint detection and response and threat hunting), (y) to the extent determined necessary by the Company or the Board of Directors, are backed by a breach prevention warranty from the vendor certifying the effectiveness of such solutions, and (z) require the vendors to notify the Company of any security incidents posing a risk to the Company’s information (regardless of whether information was actually compromised). The Company shall evaluate on a periodic basis at least annually whether such safeguards should be updated to maintain a level of security appropriate to the risk posed to Company systems and Protected Data. The Company shall educate its employees about the proper use and storage of Protected Data, including periodic training as determined reasonably necessary by the Company or the Board of Directors.
INVESTOR RIGHTS AGREEMENT
9
5. | Miscellaneous. |
5.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Securities for no monetary consideration that (i) is an Affiliate of a Holder; or (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one (1) or more of such Holder’s Immediate Family Members; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.2. For the purposes of determining the number of shares of Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.
5.2 Governing Law. This Agreement shall be governed by the internal laws of the Province of Ontario, without regard to conflict of law principles that would result in the application of any law other than the laws of the Province of Ontario.
5.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
5.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.
5.5 Notices.
(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the Investor at its addresses as set forth on Schedule A, or (as to the Company) to the principal office of the Company and to the attention of the Chief Executive Officer, or in any case to such email address or address as subsequently modified by written notice given in accordance with this Section 5.5. If notice is given to the Company, a copy (which copy shall not constitute notice) shall also be sent to the Company’s legal counsel (Greenberg Traurig LLP) and if notice is given to Investor, a copy (which copy shall not constitute notice) shall also be given to Dentons Canada LLP.
INVESTOR RIGHTS AGREEMENT
10
5.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and Investor; provided that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
5.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
5.8 Aggregation of Stock; Apportionment. All shares of Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated Persons may apportion such rights as among themselves in any manner they deem appropriate.
5.9 Entire Agreement. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.
5.10 Dispute Resolution. The parties hereto irrevocably attorn and submit to the jurisdiction of the courts of the Province of Ontario, sitting in the City of Toronto, with respect to any dispute for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the courts of the Province of Ontario, sitting in the City of Toronto, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.
INVESTOR RIGHTS AGREEMENT
11
WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.
Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in any court of the Province of Ontario, sitting in the City of Toronto having subject matter jurisdiction.
5.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
[Signature page follows]
INVESTOR RIGHTS AGREEMENT
12
IN WITNESS WHEREOF, the parties have executed this Investor Rights Agreement as of the date first written above.
COMPANY: | ||
AKANDA CORP. | ||
By: | /s/ Tejinder Virk | |
Name: | Tejinder Virk | |
Title: | Chief Executive Officer | |
INVESTOR: | ||
HALO COLLECTIVE INC. | ||
By: | /s/ Kiran Sidhu | |
Name: | Kiran Sidhu | |
Title: | Chief Executive Officer |
INVESTOR RIGHTS AGREEMENT
13
SCHEDULE A
Investor
Name and Address |
HALO COLLECTIVE INC. Attn: Kiran Sidhu 504 - 100 Park Royal West Vancouver, BC V7T 1A2 Phone: 1-541-816-5410 Email: kiran@haloco.com
Copy to: DENTONS CANADA LLP Attn: Eric Foster 77 King Street West, Suite 400 Toronto-Dominion Centre Toronto, ON M5K 0A1 Phone: 1-416-558-3531 Email: eric.foster@dentons.com |
SCHEDULE A: INVESTOR RIGHTS AGREEMENT
Exhibit 4.2
Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. This information is not material and disclosure of such information would constitute an unwarranted invasion of personal privacy. “[*]” indicates that information has been redacted.
UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS FOUR (4) MONTHS AND ONE (1) DAY AFTER THE LATER OF: (I) November 3, 2021 AND (II) THE DATE THE ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY.
AKANDA CORP.
SECURED CONVERTIBLE DEBENTURE
CONVERTIBLE DEBENTURE
CERTIFICATE NUMBER: CD-2021-10 |
PRINCIPAL AMOUNT: $6,559,294 (USD) |
AKANDA CORP., a corporation incorporated under the laws of the Province of Ontario (the “Borrower”), for value received, hereby acknowledges itself indebted and promises to pay to or to the order of HALO COLLECTIVE INC. (hereinafter referred to as the “Lender” or the “Debentureholder”), the principal amount of $6,559,294 (the “Principal Amount”) in lawful money of the United States of America in the manner hereinafter provided at the foregoing address of the Lender, or at such other place or places as the Lender may designate by notice in writing to the Borrower, on November 2, 2022, or such other date as the Principal Amount may become due and payable (the “Maturity Date”) or upon a Triggering Event (as defined herein), and to pay interest to the Lender on the Principal Amount outstanding from time to time owing hereunder to the date of payment as hereinafter provided, both before and after maturity or demand, default and judgment.
Subject to automatic conversion upon the occurrence of a Triggering Event, the Borrower has the right, from time to time and at any time prior to 5:00 p.m. (Eastern Standard Time) on the Business Day (as defined herein) immediately preceding the Maturity Date at a price, with respect to the Principal Amount, equal to the Conversion Price (as defined herein), subject to adjustment in certain events, together with any accrued and unpaid interest owing thereon to the date of conversion, to convert such amount into Common Shares.
Unless (i) the Borrower exercises the Conversion Rights attached to this Debenture or (ii) a Triggering Event occurs, the Principal Amount owing, or the portion of the Principal Amount which has yet to be converted, together with any accrued and unpaid interest owing thereon and all other amounts now or hereafter payable hereunder (collectively, the “Obligations”) shall be due and payable on the Maturity Date in accordance with the terms hereof. This Debenture is issued subject to the terms and conditions appended hereto as Schedule A. The Borrower may satisfy the Obligations hereunder by converting, into Common Shares, all of the Principal Amount outstanding, subject to adjustment in certain events, together with any accrued and unpaid interest owing thereon under this Debenture at the Conversion Price on the Maturity Date.
IN WITNESS WHEREOF, the Borrower has caused this Debenture to be executed by a duly authorized officer.
DATED for reference this 3rd day of November, 2021.
- 2 -
AKANDA CORP. |
||
Per: | /s/ Tejinder Virk | |
Tej Virk, Chief Executive Officer | ||
Acknowledged and Agreed to by: | ||
HALO COLLECTIVE INC. | ||
/s/ Kiran Sidhu | ||
Kiranjit Sidhu, Chief Executive Officer |
(See terms and conditions attached hereto)
Schedule A – Terms and Conditions for Secured Convertible Debenture
Article 1 – Interpretation
Section 1.1 Definitions
In this Debenture, the following terms shall have the following meanings:
(1) “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any partner, managing member, officer, director or trustee of such Person, or any venture capital fund or investment fund now or hereafter existing that is controlled by one (1) or more general partners, managing members investment adviser of, or shares the same management company or investment adviser with, such Person;
(2) “Business Day” means a day other than a Saturday, Sunday or other day on which commercial banks in Toronto, Ontario are authorized by law to close;
(3) “Canadian Securities Laws” means the Securities Act (Ontario) and the securities laws of any other province or territory of Canada, if applicable, and the rules, regulations and policies of any Canadian securities regulatory authority administering such securities laws, as the same shall be in effect from time to time;
(4) “Change of Control” means:
(a) | any transaction (whether by purchase, Merger or otherwise) whereby a Person or Persons acting jointly or in concert directly or indirectly acquires the right to cast, at a general meeting of shareholders of the Borrower, more than 50% of the votes attached to the issued and outstanding Common Shares that may be ordinarily cast at a general meeting; |
(b) | the Borrower’s amalgamation, consolidation or Merger with or into any other Person, any Merger of another Person into the Borrower, unless the holders of voting securities of the Borrower immediately prior to such amalgamation, consolidation or Merger hold securities representing 50% or more of the voting control or direction in the Borrower or the successor entity upon completion of the amalgamation, consolidation or Merger; or |
(c) | any conveyance, transfer, sale lease or other disposition of all or substantially all of the Borrower’s and the Borrower’s subsidiaries’ assets and properties, taken as a whole, to another arm’s length Person; |
(5) “Common Shares” means the common shares in the capital of the Borrower or the common shares of the continuing corporation or other resulting issuer formed as a result of a Merger;
(6) “Conversion Price” means, subject to adjustment in certain events or the requirements of any applicable securities law or Exchange, the Current Market Price at the time of a Triggering Event (currently expected to be $5.00) or if no Triggering Event occurs then the price of the last private placement of the Borrower where it raises more than $1,000,000 USD prior to the conversion by the Borrower;
(7) “Conversion Right” means the right attached to this Debenture which permits the Borrower to convert the Principal Amount outstanding under this Debenture, or any portion thereof, into Common Shares in accordance with the provisions of Article 4;
(8) “Current Market Price” has the meaning attributed thereto in Section 4.3(2);
(9) “Debenture” means this secured convertible debenture;
(10) “Event of Default” has the meaning attributed thereto in Section 8.1;
-A 1-
(11) “Exchange” means the NYSE, NASDAQ, the Canadian Securities Exchange, the NEO Exchange, the TSX, the TSX Venture Exchange or if the Common Shares are not listed on either of those exchanges, then such other stock exchange on which the Common Shares are listed and where a majority of the trading volume occurs;
(12) “Free Trading Securities” means securities that are not subject to any restrictions on trading (other than in respect of resales by control persons or any escrow requirements of an applicable stock exchange);
(13) “Issue Date” has the meaning attributed thereto in Section 4.2;
(14) “Lien” means, with respect to any Person, any mortgage, lien, pledge, charge, security interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention agreement or capital lease, upon or with respect to any property of such Person;
(15) “Lock Up Trigger Date” has the meaning attributed thereto in Section 4.1;
(16) “Maturity Date” means November 2, 2022;
(17) “Merger” means any transaction (whether by way of consolidation, amalgamation, merger, transfer, sale or lease) whereby all or substantially all of the Borrower’s assets would become the property of any other Person, or, in the case of any such consolidation, amalgamation or merger, of the continuing corporation or other entity resulting therefrom;
(18) “Non-Control Covenant” has the meaning attributed thereto in Section 7.2(2);
(19) “Person” means an individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof;
(20) “Secured Debt” means, with respect to any Person, any obligation of such Person for borrowed money that is secured in any manner by any Lien on any real or personal property of such Person;
(21) “Subsidiary” means any Person, any corporation or other business entity in which such Person or one or more of its Subsidiaries owns, directly or indirectly, sufficient equity or voting interests to enable it or them (as a group) to elect a majority of the directors (or Persons performing similar functions) of such entity, and any partnership or joint venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries;
(22) “Taxes” means any present or future income and other taxes, levies, rates, royalties, deductions, withholdings, assessments, fees, dues, duties, imposts and other charges of any nature whatsoever, together with any interest and penalties, additions to tax and other additional amounts, levied, assessed or imposed by any governmental authority;
(23) “Trading Day” means a day on which the Exchange is open for trading (or if the Common Shares are not then listed on the Exchange, such other recognized stock exchange or quotation system on which the Common Shares may trade or be quoted);
-A 2-
(24) “Triggering Event” means the occurrence of any of the following that may occur during the Triggering Event Period:
(a) | an initial public offering of the Borrower’s securities or the qualification of a non-offering prospectus by the Borrower resulting, in either case, in the Borrower’s securities being listed for trading on a stock exchange and the Borrower becoming a “reporting issuer” (as that term or its equivalent is defined in applicable securities legislation) in any jurisdiction of Canada (or the equivalent in any other jurisdiction including the United States); | |
(b) | an amalgamation, arrangement, Merger, reverse takeover, reorganization or other similar transaction of the Borrower with or into any other person (provided that the other person is not an affiliate of the Borrower) whereby all of the issued and outstanding Common Shares are sold, transferred or exchanged for securities that are not subject to any restrictions on trading (other than in respect of resales by control persons or any escrow requirements of an applicable stock exchange) (the “Free Trading Securities”), or which results in all of the Common Shares (or the securities of a successor issuer) being listed on a stock exchange and not being not subject to any restricted period or hold period under applicable securities laws in Canada or any other jurisdiction (other than in respect of resales by control persons or any escrow requirements of an applicable stock exchange); |
(c) | a sale or conveyance of all or substantially all of the property and assets of the Borrower to any arm’s length third party for consideration consisting of Free Trading Securities and the subsequent distribution of all of such consideration to all of the holders of Common Shares, on a pro rata basis; |
(d) | the sale or exchange of all or substantially all of shares of the Borrower for Free Trading Securities; or | |
(e) | any combination of the events or circumstances described in subsections (a), (b), (c) or (d) above, such that all of the Common Shares shall be subject to one or more of (a), (b), (c) or (d) above. However, a Triggering Event conversion may only occur with respect to such number of Common Shares that would result in the Lender owing less than 50% of the issued and outstanding Common Shares; and |
-A 3-
(25) “Triggering Event Period” means six (6) months from the date hereof.
Section 1.2 Headings
The inclusion of headings in this Debenture is for convenience of reference only and shall not affect the construction or interpretation hereof.
Section 1.3 Currency
Unless otherwise indicated, all amounts in this Debenture are stated and shall be paid in the currency of the United States of America.
Section 1.4 Number, Gender and Persons
Unless the context otherwise requires, words importing the singular in number only shall include the plural and vice versa, words importing the use of gender shall include the masculine, feminine and neuter genders and words importing Persons shall include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities.
Section 1.5 Severability
If any provision of this Debenture is determined by a Court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each such provision shall be interpreted in such a manner as to render them valid, legal and enforceable to the greatest extent permitted by applicable law. Each provision of this Debenture is declared to be separate, severable and distinct.
Section 1.6 Entire Agreement
This Debenture, including any schedules attached hereto, constitutes the entire agreement between the Borrower and the Lender relating to the subject matter hereof, and supersedes all prior agreements, representations, warranties, statements, promises, information, arrangements, understandings, conditions or collateral agreements, whether oral or written, express or implied, with respect to the subject matter hereof.
-A 4-
Article 2 – Payment of Principal, Interest AND OTHER CONSIDERATIONS
Section 2.1 Repayment of Principal
Subject to the terms and conditions hereof, the Principal Amount outstanding on this Debenture, together with any accrued and unpaid interest owing thereon shall be repaid by the Borrower to the Lender on the Maturity Date. Subject to applicable regulatory approval, the Borrower shall satisfy its obligation to repay the Principal Amount outstanding under the Debenture upon a Triggering Event during the Triggering Event Period or at the election of Lender subsequent to the Triggering Event Period by issuing fully paid and non-assessable Common Shares at the Conversion Price.
Section 2.2 Interest Payable
Interest on the Principal Amount outstanding under this Debenture shall be at the rate of 1.00% per annum, calculated on a compounding basis, accrued and paid at the earlier of the Issue Date upon a Triggering Event or the Maturity Date. The Borrower shall satisfy its obligation to repay interest on the Principal Amount by issuing fully paid and non-assessable Common Shares at the applicable Conversion Price.
Section 2.3 Rank
This Debenture will constitute direct secured obligations of the Borrower. There is no other debt that ranks ahead of this Debenture without the express written consent of the Lender.
Article 3 – Purchase
Section 3.1 Purchases for Cancellation
The Borrower will have the right at any time and from time to time to purchase the Debentures and any accrued interest without any prepayment penalty.
Article 4 – Conversion
Section 4.1 Conversion Right
(1) Upon and subject to the terms and conditions hereinafter set forth (including, but not limited to, automatic conversion in the event of a Triggering Event as described in Section 4.1(3) below) and subject to the requirements of any applicable securities law or Exchange, the Borrower shall have the right (the “Conversion Right”), but not the obligation, at any time, and from time to time, up to and including the Business Day immediately preceding the Maturity Date to notify the Lender that it wishes to exchange or convert, for no additional consideration, all or any part of the Principal Amount of this Debenture (the “Converted Debenture Amount”) into Common Shares at the Conversion Price in effect on the Issue Date. If the Borrower is electing to convert all or a portion of the Principal Amount, then the applicable amount of accrued and unpaid interest on the Principal Amount being converted must be paid by the Borrower up to, but excluding, the applicable date of conversion in accordance with Section 2.2. A conversion of principal and interest hereunder into Common Shares may only occur in such amount as to ensure that the Lender does not own more than 50% of the issued and outstanding Common Shares.
-A 5-
(2) The Conversion Right shall extend only to the maximum number of whole Common Shares into which the Principal Amount of this Debenture or any part thereof may be converted in accordance with this Section 4.1. Fractional interests in Common Shares shall be adjusted in the manner provided in Section 4.4.
(3) Upon the occurrence of a Triggering Event that occurs prior to the end of the Triggering Event Period, the Principal Amount of this Debenture plus unpaid and accrued interest shall be converted into Common Shares at a price equal the Conversion Price
(4) The Lender agrees hereby not to, and agrees to execute and deliver a lock-up agreement restricting its right to, (a) offer, pledge, sell, contract to sell, sell any options or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any securities of the Borrower, or (b) enter into any swap or other arrangement or any transaction that transfers, in whole or in part, directly or indirectly, to another any of the economic consequences of ownership of such securities during the period of 270 days from the date on which the trading of the Common Shares on the Nasdaq Stock Exchange commences (the “Lock-Up Trigger Date”), in each case, excluding transfers pursuant to any carve-outs in the applicable lock-up agreement. The terms of such lock-up agreement shall be negotiated among the Lender, the Borrower and the Boustead Securities, LLC and shall include customary carve-outs from the restrictions on transfer set forth therein and shall permit that up to 50% of such securities may be transferred or sold from the 271st day through the 365th day following the Lock-Up Trigger Date; the remaining 50% of such securities will be entitled to be transferred without such lock-up restrictions beginning on the 366th day following the Lock-Up Trigger Date. Any such transfers remain subject to rules of the Securities and Exchange Commission applicable to securities of the Borrower held by Affiliates, provided that the Borrower agrees to cooperate with the Lender to facilitate the transfer of such securities by Lender following the expiration of the lock-up restrictions as set forth herein, including with respect to the removal of restrictive legends from such securities applicable to Affiliates, if Lender furnishes to the Borrower an opinion of counsel reasonably satisfactory to the Borrower that Lender is not an “affiliate” of the Borrower under the Securities Act of 1933. Notwithstanding the foregoing, nothing in this Section 4.1(4) shall prohibit the sale or transfer by the Lender of such number of Common Shares held by the Lender as is required in order for the Lender to comply with its covenants set forth in Section 7.2.
Section 4.2 Conversion Procedure
The Conversion Right may be exercised by the Borrower by completing and signing the notice of conversion (the “Conversion Notice”) attached hereto as Schedule B, and delivering the Conversion Notice and this Debenture to the Lender. The Conversion Notice shall provide that the Conversion Right is being exercised, shall specify the Converted Debenture Amount and shall set out the date (the “Issue Date”) on which Common Shares are to be issued upon the exercise of the Conversion Right (such date to be no earlier than five (5) Business Days and no later than ten (10) Business Days after the day on which the Conversion Notice is issued, subject in each case to applicable securities law, including Canadian Securities Laws or the requirements of any Exchange. The conversion shall be deemed to have been affected immediately prior to the close of business on the Issue Date and the Common Shares issuable upon conversion shall be deemed to be issued as fully paid and non-assessable at such time. Within ten (10) Business Days after the Issue Date, a certificate for the required number of Common Shares shall be issued to the Lender. If less than all of the Principal Amount of this Debenture is the subject of the Conversion Right, then within ten (10) Business Days after the Issue Date, the Borrower shall deliver to the Lender a replacement Debenture in the form hereof in the Principal Amount of the unconverted principal balance hereof, and this Debenture shall be cancelled. If the Conversion Right is being exercised in respect of the entire Principal Amount of this Debenture, this Debenture shall be cancelled. With the Conversion Notice, the Lender shall provide the Borrower with its written calculation of the amount of accrued and unpaid interest on the Principal Amount which is the subject of the Conversion Right pursuant to the Conversion Notice, up to the date of that Conversion Notice and a per diem amount thereon.
-A 6-
Section 4.3 Adjustment of Conversion Price
The Conversion Price in effect at any date shall be subject to adjustment from time to time as follows:
(1) If and whenever at any time prior to the Maturity Date, the Borrower shall:
(a) | subdivide or re-divide the outstanding Common Shares into a greater number of Common Shares; |
(b) | reduce, combine or consolidate the outstanding Common Shares into a smaller number of Common Shares; |
(c) | issue Common Shares (or securities convertible into or exchangeable for Common Shares) to the holders of all or substantially all of the outstanding Common Shares by way of stock dividend; or |
(d) | make a distribution on its outstanding Common Shares payable in Common Shares or securities exchangeable for or convertible into Common Shares, |
the Conversion Price in effect on the effective date of such subdivision, redivision, reduction, combination or consolidation or on the record date for such issue of Common Shares (or securities convertible into or exchangeable for Common Shares) by way of a stock dividend or other distribution, as the case may be, shall, in the case of the events referred to in Sections 4.3(1)(a), (c) and (d) above, be decreased in proportion to the increase in the number of outstanding Common Shares resulting from such subdivision, redivision or dividend (including, in the case where securities convertible into or exchangeable for Common Shares are issued, the number of Common Shares that would have been outstanding had such securities been converted into or exchanged for Common Shares on such effective or record date) or shall, in the case of the events referred to in Section 4.3(1)(b) above, be increased in proportion to the decrease in the number of outstanding Common Shares resulting from such reduction, combination or consolidation on such effective or record date. Such adjustment shall be made successively whenever any event referred to in this Section 4.3(1) shall occur. Any such issue of Common Shares (or securities convertible into or exchangeable for Common Shares) by way of a stock dividend or other distribution shall be deemed to have been made on the record date for the stock dividend or other distribution for the purpose of calculating the number of outstanding Common Shares under Sections 4.3(2) and (3); to the extent that any such securities are not converted into or exchanged for Common Shares prior to the expiration of the conversion or exchange right, the Conversion Price shall be readjusted effective as at the date of such expiration to the Conversion Price which would then be in effect based upon the number of Common Shares actually issued on the exercise of such conversion or exchange right.
(2) If and whenever at any time prior to the Maturity Date, the Borrower shall fix a record date for the issuance of rights, options or warrants to all or substantially all the holders of its outstanding Common Shares entitling them, for a period expiring not more than forty-five (45) days after such date of issue (such period from the record date to the date of expiry being referred to in this Section 4.3(2) as the “Rights Period”), to subscribe for or purchase Common Shares (or securities convertible into or exchangeable for Common Shares) (such subscription price per Common Share (inclusive of any cost of acquisition of securities exchangeable for or convertible into Common Shares in addition to any direct cost of Common Shares) being referred to in this Section 4.3(2) as the “Per Share Cost”), the Borrower shall give written notice to the Lender with respect thereto (any of such events herein referred to as a “Rights Offering”), and the Lender shall have fifteen (15) days after receipt of such notice to elect to convert any or all of the Principal Amount of this Debenture into Common Shares at the then applicable Conversion Price and otherwise on terms and conditions set out in this Debenture. If the Lender elects to convert any or all of the Principal Amount of this Debenture, such conversion shall occur immediately prior to the record date for the issuance of such rights, options or warrants. If the Lender elects not to convert any of the Principal Amount of this Debenture, there shall continue to be an adjustment to the Conversion Price as a result of the issuance of such rights, options or warrants, in the manner hereinafter provided. The Conversion Price will be adjusted effective immediately after the end of the Rights Period to a price determined by multiplying the Conversion Price in effect immediately prior to the end of the Rights Period by a fraction:
(a) | the numerator of which is the aggregate of: |
(i) | the number of Common Shares outstanding as of the record date for the Rights Offering; and |
(ii) | the number determined by dividing the product of the Per Share Cost and: |
(A) | where the event giving rise to the application of this Section 4.3(2) was the issue of rights, options or warrants to the holders of Common Shares under which such holders are entitled to subscribe for or purchase additional Common Shares, the number of Common Shares so subscribed for or purchased during the Rights Period, or |
-A 7-
(B) | where the event giving rise to the application of this Section 4.3(2) was the issue of rights, options or warrants to the holders of Common Shares under which such holders are entitled to subscribe for or purchase securities exchangeable for or convertible into Common Shares, the number of Common Shares for which those securities so subscribed for or purchased during the Rights Period could have been exchanged or into which they could have been converted during the Rights Period, |
by the Current Market Price (as hereinafter defined) of the Common Shares as of the record date for the Rights Offering; and
(b) | the denominator of which is |
(i) | in the case described in subparagraph 4.3(2)(a)(ii)(A), the number of Common Shares outstanding, or |
(ii) | in the case described in subparagraph 4.3(2)(a)(ii)(B), the number of Common Shares that would be outstanding if all the Common Shares described in subparagraph 4.3(2)(a)(ii)(B) had been issued, |
as at the end of the Rights Period.
“Current Market Price” of the Common Shares at any date, means the weighted average of the sale prices per Common Share at which the Common Shares have traded on the Exchange or, if the Common Shares are not listed on any stock exchange, then on the over-the-counter market, for any 20 consecutive Trading Days selected by the Borrower commencing not later than 45 Trading Days and ending no later than five (5) Trading Days before such date; provided, however, if such Common Shares are not traded during such 45 day period for at least 20 consecutive Trading Days, the simple average of the following prices established for each of 20 consecutive Trading Days selected by the Borrower commencing not later than 45 Trading Days before such date:
(a) | the average of the bid and ask prices for each day on which there was no trading, and |
(b) | the closing price of the Common Shares for each day that there was trading, |
or in the event that at any date the Common Shares are not listed on the Exchange or on the over-the-counter market, the current market price shall be as determined by the directors of the Borrower or such firm of independent chartered accountants as may be selected by the directors of the Borrower, acting reasonably, and in good faith in their sole discretion; for these purposes, the weighted average price for any period shall be determined by dividing the aggregate sale prices during such period by the total number of Common Shares sold during such period.
Any Common Shares owned by or held for the account of the Borrower or any subsidiary or affiliate (as defined in the Securities Act (Ontario)) of the Borrower will be deemed not to be outstanding for the purpose of any such computation.
If by the terms of the rights, options or warrants referred to in this Section 4.3(2), there is more than one purchase, conversion or exchange price per Common Share, the aggregate price of the total number of additional Common Shares offered for subscription or purchase, or the aggregate conversion or exchange price of the convertible securities so offered, will be calculated for purposes of the adjustment on the basis of
(c) | the lowest purchase, conversion or exchange price per Common Share, as the case may be, if such price is applicable to all Common Shares which are subject to the rights, options or warrants, and |
(d) | the average purchase, conversion or exchange price per Common Share, as the case may be, if the applicable price is determined by reference to the number of Common Shares acquired. |
-A 8-
To the extent that any adjustment in the Conversion Price occurs pursuant to this Section 4.3(2) as a result of the fixing by the Borrower of a record date for the distribution of rights, options or warrants referred to in this Section 4.3(2), the Conversion Price will be readjusted immediately after the expiration of any relevant exchange, conversion or exercise right to the Conversion Price which would then be in effect based upon the number of Common Shares actually issued and remaining issuable after such expiration, and will be further readjusted in such manner upon expiration of any further such right.
If the Lender has exercised its Conversion Right in accordance herewith during the Rights Period, the Lender will, in addition to the Common Shares to which it is otherwise entitled upon such exercise, be entitled to that number of additional Common Shares equal to the result obtained when the difference, if any, between the Conversion Price in effect immediately prior to, and the Conversion Price in effect immediately following the end of such Rights Offering pursuant to this Section 4.3(2), is multiplied by the number of Common Shares received upon the exercise of the Conversion Right during such period, and the resulting product is divided by the Conversion Price as adjusted for such
Rights Offering pursuant to this Section 4.3(2); provided that no fractional Common Shares will be issued. Such additional Common Shares will be deemed to have been issued to the Lender immediately following the end of the Rights Period and a certificate for such additional Common Shares will be delivered to the Lender within ten Business Days following the end of the Rights Period.
(3) If and whenever at any time prior to the Maturity Date, the Borrower shall fix a record date for the making of a distribution to all or substantially all the holders of its outstanding Common Shares of (i) shares of any class other than Common Shares (or other than securities convertible into or exchangeable for Common Shares), or (ii) rights, options or warrants (other than rights, options or warrants referred to in Section 4.3(2)), or (iii) evidences of its indebtedness, or (iv) assets (other than dividends paid in the ordinary course) then, in each such case, the Borrower shall give written notice to the Lender with respect thereto, and the Lender shall have fifteen (15) days after receipt of such notice to elect to convert any or all of the Principal Amount of this Debenture into Common Shares at the then applicable Conversion Price and otherwise on terms and conditions set out in this Debenture. If the Lender elects to convert any or all of the Principal Amount of this Debenture, such conversion shall occur immediately prior to the record date for the making of such distribution. If the Lender elects not to convert any of the Principal Amount of this Debenture, there shall continue to be an adjustment to the Conversion Price as a result of the making of such distribution, (herein referred to as a “Special Distribution”) determined in the manner hereafter set out. In this Section 4.3(3) the term “dividends paid in the ordinary course” shall include the value of any securities or other property or assets distributed in lieu of cash dividends paid in the ordinary course at the option of shareholders.
The Conversion Price will be adjusted effective immediately after such record date to a price determined by multiplying the Conversion Price in effect on such record date by a fraction:
(a) | the numerator of which is: |
(i) | the product of the number of Common Shares outstanding on such record date and the Current Market Price of the Common Shares on such record date; less |
(ii) | the aggregate fair market value (as determined by action by the directors of the Borrower, acting reasonably) to the holders of the Common Shares of such securities or property or other assets so issued or distributed in the Special Distribution; and |
(b) | the denominator of which is the number of Common Shares outstanding on such record date multiplied by the Current Market Price of the Common Shares on such record date. |
-A 9-
Any Common Shares owned by or held for the account of the Borrower or any subsidiary or affiliate (as defined in the Securities Act (Ontario)) of the Borrower will be deemed not to be outstanding for the purpose of any such computation.
(4) In the case of any reclassification of, or other change in, the outstanding Common Shares pursuant to a Change of Control, the Lender may elect, prior to the effective date of such Change of Control, to convert any or all of the Principal Amount of this Debenture into Common Shares at the then applicable Conversion Price and otherwise on terms and conditions set out in this Debenture. To exercise such right the Lender must provide a notice in writing to the Borrower no later than seven (7) days prior to the effective date of such Change of Control, failing which the Lender’s right to convert this Debenture as a consequence of such Change of Control shall cease. If the Lender elects to convert any or all of the Principal Amount of this Debenture, such conversion shall occur immediately prior to the effective date of such Change of Control. If the Lender elects not to convert any of the Principal Amount of this Debenture, the Conversion Price in effect after the effective date of such Change of Control shall be increased or decreased, as the case may be, in proportion to any decrease or increase in the number of outstanding Common Shares resulting from such Change of Control so that the Lender, upon exercising the Conversion Right after the effective date of such Change of Control, will be entitled to receive the aggregate number of Common Shares or other securities, if any, which the Lender would have been entitled to receive as a result of such Change of Control if, on the effective date thereof, the Lender had been the registered holder of the number of Common Shares to which the Lender was theretofore entitled upon exercise of the Conversion Right.
(5) In the case of any reclassification of, or other change in, the outstanding Common Shares (other than a change referred to in Section 4.3(1), Section 4.3(2), Section 4.3(3) or 4.3(4) hereof), the Conversion Price shall be adjusted in such manner, if any, and at such time, as the Board of Directors of the Borrower determines to be appropriate on a basis consistent with the intent of this Section 4.3; provided that if at any time a dispute arises with respect to adjustments provided for in this Article 4, such dispute will be conclusively determined by the auditors of the Borrower or if they are unable or unwilling to act, by such other firm of independent chartered accountants as may be selected by action by the directors of the Borrower, acting reasonably, and any such determination will be binding on the Borrower and the Lender. The Borrower will provide such auditors or accountants with access to all necessary records of the Borrower. If and whenever at any time after the date hereof there is a reclassification or redesignation of the Common Shares outstanding at any time or change of the Common Shares into other shares or into other securities (other than as set out in Section 4.3(1), (2), (3) or (4)), or a consolidation, amalgamation or Merger of the Borrower with or into any other corporation or other entity (other than a consolidation, amalgamation or Merger which does not result in any reclassification or redesignation of the outstanding Common Shares or a change of the Common Shares into other shares and other than as set forth in Section 4.3(4)), or a transfer of the undertaking or assets of the Borrower as an entirety or substantially as an entirety to another corporation or other entity (any of such events being called a “Capital Reorganization”), the Lender, upon the exercising the Conversion Right, after the effective date of such Capital Reorganization, will be entitled to receive in lieu of the number of Common Shares to which the Lender was theretofore entitled upon such exercise, the aggregate number of shares, other securities or other property, if any, which the Lender would have been entitled to receive as a result of such Capital Reorganization if, on the effective date thereof, the Lender had been the registered holder of the number of Common Shares to which such Lender was theretofore entitled upon exercise of the Conversion Right. If determined appropriate by action of the directors of the Borrower, appropriate adjustments will be made as a result of any such Capital Reorganization in the application of the provisions set forth in this Section 4.3 with respect to the rights and interests thereafter of the Lender to the end that the provisions set forth in this Section 4.3 will thereafter correspondingly be made applicable as nearly as may reasonably be in relation to any shares, other securities or other property thereafter deliverable upon the exercise of the Conversion Right. Any such adjustment must be made by and set forth in an amendment to this Debenture approved by action by the directors of the Borrower, acting reasonably, and will for all purposes be conclusively deemed to be an appropriate adjustment.
(6) In any case in which this Section 4.3 shall require that an adjustment shall become effective immediately after a record date for an event referred to herein, the Borrower may defer, until the occurrence of such event, issuing to the Lender before the occurrence of such event, the additional Common Shares issuable upon such conversion by reason of the adjustment required by such event before giving effect to such adjustment; provided, however, that the Borrower shall deliver to the Lender an appropriate instrument evidencing the Lender’s right to receive such additional Common Shares upon the occurrence of the event requiring such adjustment and the right to receive any distributions made on such additional Common Shares declared in favour of holders of record of Common Shares on and after the Issue Date or such later date as the Lender would, but for the provisions of this Section 4.3(6), have become the holder of such additional Common Shares pursuant to Section 4.3(2).
-A 10-
(7) The adjustments provided for in this Section 4.3 are cumulative and shall apply to successive subdivisions, redivisions, reductions, combinations, consolidations, distributions, issues or other event resulting in any adjustment under the provisions of this Section, provided that, notwithstanding any other provision of this Section, no adjustment of the Conversion Price shall be required unless such adjustment would require an increase or decrease of at least 1% in the Conversion Price then in effect; provided, however, that any adjustments which by reason of this Section 4.3(7) are not required to be made shall be carried forward and taken into account in any subsequent adjustment.
Section 4.4 No Requirement to Issue Fractional Common Shares
The Borrower shall not be required to issue fractional Common Shares upon the conversion of the Debenture pursuant to this Article 4. If any fractional interest in a Common Share, would, except for the provisions of this Section 4.4, be deliverable upon the conversion of any amount hereunder, the number of Common Shares to be issued shall be rounded down to the nearest whole Common Share.
Section 4.5 Borrower to Reserve Common Shares
The Borrower covenants with the Lender that it will at all times reserve and keep available out of its authorized Common Shares, solely for the purpose of issue upon exercise of the Conversion Right, and conditionally allot to the Lender, such number of Common Shares as shall then be issuable upon the conversion of this Debenture.
The Borrower covenants with the Lender that all Common Shares which shall be so issuable shall be duly and validly issued as fully paid and non-assessable.
Section 4.6 Certificate as to Adjustment
The Borrower shall from time to time, immediately after the occurrence of any event which requires an adjustment or readjustment as provided in Section 4.3, deliver an officer’s certificate to the Lender specifying the nature of the event requiring the same and the amount of the adjustment necessitated thereby and setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Subject to the dispute resolution procedure in subsection 4.3(5), such certificate shall be binding and determinative of the adjustment to be made, absent manifest error.
Section 4.7 Shareholder of Record
For all purposes, on the Issue Date or the applicable date specified in Section 4.2 the Lender shall be deemed to have become the holder of record of the Common Shares into which the Principal Amount of this Debenture (or a portion thereof) is converted in accordance with Section 4.2.
Section 4.8 Resale Restrictions, Legending and Disclosure
By its acceptance hereof the Lender acknowledges that this Debenture and the Common Shares issuable upon conversion hereof will be subject to certain resale restrictions under Canadian Securities Laws or the applicable securities laws of any other jurisdiction, and the Lender agrees to comply with all such restrictions and laws. The Lender further acknowledges and agrees that all Common Share certificates will bear the legend substantially in the form set forth on the face page hereof as well as any legends required by the Exchange, provided that such legend shall not be required on Common Share certificates issued at any time following four months plus one day after the date hereof. The Lender acknowledges that the Borrower will be required to provide to the applicable securities regulatory authorities the identity of the Lender and its principals and the Lender hereby agrees thereto.
-A 11-
Article 5 – RIGHTS OF DEBENTUREHOLDER
Section 5.1 Distribution on Dissolution, Etc.
Subject to applicable law and the rights of any holders of any Secured Debt or other indebtedness ranking in priority to the Lender, upon any sale, in one transaction or a series of transactions, of all, or substantially all, of the assets of the Borrower or distribution of the assets of the Borrower upon any dissolution or winding-up or total liquidation of the Borrower, whether in bankruptcy, liquidation, re-organization, insolvency, receivership or other similar proceedings or upon an assignment to or for the benefit of creditors of the Borrower or otherwise any payment or distribution of assets of the Borrower, whether in cash, property or security shall be paid or delivered by the trustee in bankruptcy, receiver, assignee of or for the benefit of creditors or other liquidating agent of the Borrower making such payment or distribution, directly to the holder of the Debentures or their representatives, to the extent necessary, to pay all obligations pursuant to the Debentures in full.
Section 5.2 Certificate Regarding Creditors
Upon any payment or distribution of assets of the Borrower referred to in this Section 5.2, the Debentureholder shall be entitled to rely upon a certificate of the trustee in bankruptcy, receiver, assignee of or for benefit of creditors or other liquidating agent of the Borrower making such payment or distribution, delivered to the Debentureholder, for the purpose of ascertaining the Persons entitled to participate in such distribution, and other indebtedness of the Borrower, the amount thereof or payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this Section 5.2.
Section 5.3 Rights of Debentureholder Reserved
Nothing contained in this Article 5 or elsewhere in this Debenture is intended to or shall impair, as between the Borrower and the Debentureholder, the obligation of the Borrower, which is absolute and unconditional, to pay to the Debentureholder the Principal Amount and interest on the Debenture, as and when the same shall become due and payable in accordance with their terms, nor shall anything herein prevent the Debentureholder from exercising all remedies otherwise permitted by applicable law upon default under this Debenture.
Section 5.4 Payment of Debenture Permitted
Nothing contained in this Debenture shall:
(a) | prevent the Borrower from making payments of the Principal Amount, interest and other amounts to the Debentureholder under this Debenture as herein provided; |
(b) | prevent the conversion of this Debenture into Common Shares as herein provided or as otherwise permitted according to law, including in connection with a bankruptcy, reorganization, insolvency, or other arrangement with creditors, of the Borrower; and |
(c) | prevent the redemption of this Debenture by the Borrower as herein provided or as otherwise permitted according to law. |
Section 5.5 Security
The undersigned acknowledges that the loan evidenced by this Debenture is secured, and the undersigned hereby grants a security interest, to and in favour of the Lender by and in all of the assets of the undersigned, except for any ownership interest or securities of Bophelo Bio Science and Wellness (Pty) Ltd., or the assets owned thereby which shall not be subject to any security interest by the Lender, in favour of the Lender pursuant to a general security agreement (the “Security”) dated the date hereof. The undersigned hereby consents and agrees to the loan, this Debenture and the Security.
The undersigned hereby acknowledges, confirms and agrees that the time for attachment has not been postponed and that the undersigned has received valuable consideration for the granting of the Security.
-A 12-
Article 6 – Covenants of the Borrower
Section 6.1 Covenants
The Borrower covenants and agrees, for as long this Debenture remains outstanding, that:
(1) Maintain Corporate Existence. Each of the Borrower and its material Subsidiaries shall maintain its corporate existence, and preserve its rights, powers, licenses and privileges which are necessary or material to the conduct of its business, and not materially change the nature of its business;
(2) Compliance with Laws. Each of the Borrower and its Subsidiaries shall comply in all material respects with all applicable laws, rules, governmental restrictions and regulations;
(3) Maintain Books and Records. The Borrower shall, and shall cause each of its Subsidiaries to, keep adequate and accurate records and books of account in which complete entries will be made reflecting all financial transactions and prepare its financial statements in accordance with generally accepted accounting principles;
(4) Payment of Taxes. Each of the Borrower and its Subsidiaries shall pay and discharge promptly all Taxes assessed or imposed upon it or its property as and when the same become due and payable save and except where it contests in good faith the validity thereof by proper legal proceedings;
(5) Payment of Obligations. The Borrower shall pay all principal, interest and other amounts owing to the Lender hereunder promptly when due;
(6) Performance of Covenants. The Borrower shall promptly perform and satisfy all covenants and obligations to be performed by it under this Debenture;
(7) Disposal of Assets. Neither the Borrower nor its Subsidiaries shall convey, sell, lease, assign, transfer or otherwise dispose of any of their respective material assets, other than in the ordinary course of business and for the purpose of carrying on the same, except for any inter-company reorganization where the Lender has been given 10 Business Days notice thereof and the Borrower has received the consent of the Lender acting reasonably but where security for the obligations hereof remain sufficient to cover any principal and interest outstanding thereon; and
(8) Notice of Event of Default. The Borrower shall promptly, and in any event within three (3) Business Days after the Borrower becoming aware, give notice to the Lender of the existence of any Event of Default.
-A 13-
Article 7 – REPRESENTATIONS, WARRANTIES AND Covenants of the LENDER
Section 7.1 Representations and Warranties
The Lender represents and warrants to the Borrower that, as of the date of this Debenture, the Principal Amount is an amount equal to the aggregate principal amount of that indebtedness owed to the Borrower (or any of its direct or indirect, wholly-owned subsidiaries) by Cannahealth Limited, Bophelo Holdings Ltd., Bophelo Bio Science & Wellness (Pty) Ltd. and Canmart Ltd., as a result of the purchase by the Borrower of all of the issued and outstanding shares in the capital of Cannahealth Limited, as well as funds expended by the Lender to operate the business, including but not limited to salaries, professional fees, capital expenditures, working capital, travel and other costs or the reorganization undertaken thereby in connection with such purchase.
Section 7.2 Covenants
(1) The Lender agrees that, within ten (10) Business Days of the signing of the Debenture by both the Lender and the Borrower, the Lender shall dispose of so many of the Common Shares that are held by the Lender that are necessary in order for the Lender to hold less than 50% of the issued and outstanding Common Shares. The Lender agrees to provide the Borrower with a written confirmation of the disposal within (3) three Business Days of such a disposal taking place. The Borrower agrees that any delays, on the part of the Borrower, in the issuance of share certificates, or the completion of any other applicable documentation, by the Borrower that are requisite to the disposal of any Common Shares held by the Lender pursuant to the covenants contemplated in this Section 7.2, shall not be taken into account when determining the ten (10) Business Days available to the Lender to complete the disposal.
(2) The Lender covenants and agrees, for as long this Debenture remains outstanding, that it shall not own 50% or more of the issued and outstanding Common Shares and shall not exercise any conversion rights of any convertible securities that would result in the Lender owning 50% or more of the issued and outstanding Common Shares (the “Non-Control Covenant”).
(3) In the event that the Lender is in breach of the Non-Control Covenant, the Borrower shall be entitled, at its election, to:
(a) | suspend repayment of the Principal Amount and any accrued interest thereon at the time of breach; |
(b) | suspend the charging of interest; and |
(c) | extend the Maturity Date by one day for each day that the Lender is in breach of the Non-Control Covenant. |
Article 8 – Events of Default
Section 8.1 Events of Default
(1) Any of the following shall constitute an Event of Default under this Debenture (each an “Event of Default”):
(a) | the Principal Amount owing hereunder shall not be paid when due; |
(b) | if the Borrower fails to pay when due any interest or other amount owing by the Borrower to the Lender and such breach or default shall continue for ten (10) Business Days of when it was due; |
-A 14-
(c) | if the Borrower breaches any representation contained herein, fails to make any payment or to observe, perform or comply with any term, covenant, condition or obligation of the Borrower contained herein or is otherwise in default of any of the provisions contained herein (other than referred in subparagraphs (a) and (b) of this Section 8.1) and such default, if capable of being remedied, is not remedied within thirty (30) days after the Borrower receives written notice of such default from the Lender; |
(d) | if the Borrower shall generally fail to pay, or admit in writing its inability or unwillingness to pay, debts as they become due or if a decree or order of a court having jurisdiction is entered adjudging the Borrower a bankrupt or insolvent; |
(e) | if the Borrower shall apply for, consent to or acquiesce in the appointment of a trustee, receiver, or other custodian for the Borrower or for a substantial part of the property thereof, or make a general assignment for the benefit of creditors; |
(f) | if the Borrower shall in the absence of such application, consent or acquiescence, become subject to the appointment of a trustee, receiver, or other custodian for the Borrower or for a substantial part of the property thereof, or have a distress, execution, attachment, sequestration or other legal process levied or enforced on or against a substantial part of the property of the Borrower; or, |
(g) | if the Borrower shall permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law, or any dissolution, winding up or liquidation proceeding, in respect of the Borrower and, if any such case or proceeding is not commenced by the Borrower, such case or proceeding, if contested by the Borrower is not dismissed within thirty (30) days. |
(2) If an Event of Default described in (e), (f) or (g) above shall occur, the entire unpaid principal of and accrued interest on this Debenture shall become immediately due and payable without any declaration or other act on the part of the Lender. Immediately upon the occurrence of any Event of Default described in (e), (f) or (g) above, or upon failure to pay this Debenture on the Maturity Date, the Lender, with or without notice to the Borrower, may proceed to protect, enforce, exercise and pursue any and all rights and remedies available to the Lender under this Debenture, or at law or in equity.
(3) If any other Event of Default shall occur for any reason, whether voluntary or involuntary, and be continuing, the Lender may, by notice to the Borrower, declare all or any portion of the outstanding Principal Amount of this Debenture to be due and payable, whereupon the full unpaid amount of this Debenture shall become immediately due and payable without further notice, demand, presentment, protest or other notice of any kind, all of which are expressly waived by the Borrower.
Article 9 – Mutilation, Loss, Theft or Destruction of Debenture Certificate
In case this Debenture certificate shall become mutilated or be lost, stolen or destroyed, the Borrower, shall issue and deliver, a new replacement debenture certificate upon surrender and cancellation of the mutilated Debenture certificate or, in the case of a lost, stolen or destroyed Debenture certificate, in lieu of and in substitution for the same. In the case of loss, theft or destruction, the applicant for a substituted debenture certificate shall furnish to the Borrower such evidence of the loss, theft or destruction of the Debenture certificate as shall be satisfactory to the Borrower in its discretion and shall also furnish an indemnity and surety bond satisfactory to the Borrower in its discretion. The applicant shall pay all reasonable expenses incidental to the issuance of any substituted debenture certificate.
-A 15-
Article 10 – General
Section 10.1 Notice
Any demand, notice, direction or other communication to be made or given hereunder (in each case, “Communication”) shall be in writing and shall be made or given by personal delivery, by courier, by facsimile or email transmission, or sent by registered mail, charges prepaid, addressed to the respective parties as follows:
(a) | if to the Borrower: |
AKANDA CORP.
Attention: Tej Virk
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1
Attention: Tej Virk
E-mail: [*]
with a copy to:
Aird Berlis LLP
Brookfield Place, 181 Bay Street, Suite 1800
Toronto, ON M5J 2T9
Attention: Sean Mason
E-mail: smason@airdberlis.com
(b) | if to the Lender: |
Halo Collective Inc.
504 - 100 Park Royal
West Vancouver, BC V7T 1A2
Attention: Kiranjit Sidhu
E-mail: kiran@halocanna.com
with a copy to:
Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1
Attention: Eric Foster
E-mail: eric.foster@dentons.com
or to such other address or email as any party may from time to time designate in accordance with this Section. Any Communication made by personal delivery or by courier shall be conclusively deemed to have been given and received on the day of actual delivery thereof or if such day is not a Business Day, on the first Business Day thereafter. Any Communication made or given by email on a Business Day before 4:00 p.m. (local time of the recipient) shall be conclusively deemed to have been given and received on such Business Day and otherwise shall be conclusively deemed to have been given and received on the first Business Day following the transmittal thereof. Any Communication that is mailed shall be conclusively deemed to have been given and received on the fifth Business Day following the date of mailing but if, at the time of mailing or within five Business Days thereafter, there is or occurs a labour dispute or other event that might reasonably be expected to disrupt delivery of documents by mail, any Communication shall be delivered or transmitted by any other means provided for in this Section.
-A 16-
Section 10.2 Change of Control of Borrower
By its acceptance hereof, each of the Borrower and the Lender acknowledges and agrees that in the event a Change of Control or Merger occurs, then all references herein to the Borrower shall extend to and include the entity resulting therefrom or which thereafter will carry on the business of the Borrower.
Section 10.3 Amendments
This Debenture may not be amended or otherwise modified except by an instrument in writing executed by the Borrower and the Lender.
Section 10.4 Waivers
The Lender shall not, by any act, delay, omission or otherwise, be deemed to have expressly or impliedly waived any of its rights, powers and/or remedies unless such waiver shall be in writing and executed by an authorized officer of the Lender. Any such waiver shall be enforceable only to the extent specifically set forth therein. A waiver by the Lender of any right, power and/or remedy on any one occasion shall not be construed as a bar to or waiver of any such right, power and/or remedy which the Lender would otherwise have on any future occasion, whether similar in kind or otherwise.
Section 10.5 Registration of Debenture
The Borrower shall cause to be kept at the head office of the Borrower in the City of Toronto, Ontario a register in which shall be entered the name and latest known address of the Lender and any other holders of Debentures. Such register shall at all reasonable times during regular business hours of the Borrower be open for inspection by the Lender and any such holder. The Borrower shall not be charged with notice of or be bound to see to the performance of any trust, whether express, implied, or constructive, in respect of this Debenture and may act on the direction of the Lender, whether named as trustee or otherwise, as though the Lender were the beneficial owner of this Debenture.
Section 10.6 No Transfer of Debenture
No transfer of this Debenture shall be permitted.
Section 10.7 Release and Discharge
If the Lender exercises all conversion rights attached to this Debenture pursuant to Article 4 hereof or if the Borrower pays all of the Obligations in full to the Lender, the Lender shall release this Debenture and the Borrower shall be, and shall be deemed to have, discharged of all its obligations under this Debenture.
Section 10.8 Successors and Assigns
This Debenture shall enure to the benefit of the Lender and its successors and assigns and shall be binding upon the Borrower and its successors and permitted assigns.
Section 10.9 Time
Time shall be of the essence of this Debenture.
-A 17-
Section 10.10 Governing Law
This Debenture shall be governed by and interpreted in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein. The Borrower and, by its acceptance hereof, the Lender each hereby irrevocably submit and attorn to the nonexclusive jurisdiction of the courts of the Province of Ontario in connection with this Debenture.
Section 10.11 Further Assurances
The Borrower shall forthwith, at its own expense and from time to time, do or file, or cause to be done or filed, all such things and shall execute and deliver all such documents, agreements, opinions, certificates and instruments reasonably requested by the Lender or its counsel as may be necessary or desirable to complete the transactions contemplated by this Debenture and carry out its provisions and intention.
Schedule B – Conversion Notice
TO: HALO COLLECTIVE INC. (the “Lender”)
Pursuant to the Secured Convertible Debenture (the “Debenture”) of the Borrower issued to the undersigned on November 3, 2021, the Borrower hereby notifies you that $ of the principal amount outstanding and $ of interest thereon under the Debenture shall be converted into common shares in the capital of the Borrower at a price per Common Share of $ .
[Describe the reason for the conversion – if it is a Triggering Event, etc.]
Please confirm the registration instructions for the certificates representing the Common Shares to be issued in the following format within five (5) Business Days hereof:
Name | Address for Delivery | # of Common Shares |
(Print name as name is to appear on share certificate) | ||
DATED this _____ day of ___________________, 20 .
AKANDA CORP. | ||
By: | ||
Name: | ||
Title: |
-B 1-
Exhibit 4.3
Form of Warrant Agreement
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE Effective DATE OF THE REGISTRATION STATEMENT (AS DEFINED BELOW): (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT TO ANYONE OTHER THAN OFFICERS OR PARTNERS OF BOUSTEAD securities, llc, EACH OF WHOM SHALL HAVE AGREED TO THE RESTRICTIONS CONTAINED HEREIN, IN ACCORDANCE WITH FINRA CONDUCT RULE 5110(E)(1), OR (B) CAUSE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [*], 2022 (THE DATE OF ISSUANCE). VOID AFTER 5:00 P.M., EASTERN TIME, [*], 2027 (THE DATE THAT IS FIVE YEARS FROM THE DATE ON WHICH THE REGISTRATION STATEMENT IS DECLARED EFFECTIVE).
COMMON SHARES PURCHASE WARRANT
For the Purchase of [*] Common Shares
Of
AKANDA CORP.
1. Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between Akanda Corp., a company incorporated in the Province of Ontario (the “Company”) and Boustead Securities, LLC (“Boustead”), dated [*], 2022 (the “Underwriting Agreement”), Boustead (in such capacity with its permitted successors or assigns, the “Holder”), as registered owner of this Purchase Warrant, is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or from time to time from [*], 2022 (the “Issuance Date”), and at or before 5:00 p.m., Eastern time, [*], 2027 (the “Expiration Date,”) which such date is five (5) years from the effective date of the registration statement on Form F-1 (Registration No. 333-[*]) of the Company (the “Registration Statement”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [*] Common Shares of the Company, without par value (the “Shares”), subject to adjustment as provided in Section 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day that is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[*] per Share (125% of the price of the Shares sold in the Offering); provided, however, that upon the occurrence of any of the events specified in Section 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.
2. Exercise.
2.1 Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto as Exhibit A (the “Exercise Form”) must be duly executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank check to the order of the Company. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.
2.2 Cashless Exercise. In lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the Exercise Form, in which event the Company shall issue to Holder, Shares in accordance with the following formula:
X = | Y(A – B) |
A |
Where, | X = The number of Shares to be issued to Holder; | |
Y = The number of Shares for which the Purchase Warrant is being exercised; | ||
A = The fair market value of one Share; and | ||
B = The Exercise Price. |
For purposes of this Section 2.2, the fair market value means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Eligible Market, the value shall be deemed to be the highest intra-day or closing price on any trading day on such Eligible Market during the five trading days preceding the exercise, (b) if OTCQB or OTCQX is not an Eligible Market, the value shall be deemed to be the highest intra-day or closing price on any trading day on the OTCQB or OTCQX on which the Common Shares are then quoted during the five trading days preceding the exercise, as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the “OTC Markets Group”, the value shall be deemed to be the highest intra-day or closing price on any trading day on the Pink Sheets on which the Common Shares are then quoted during the five trading days preceding the exercise, or (d) in all other cases, the fair market value of a Common Share as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company.
2.3 Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities have been registered under the Securities Act of 1933, as amended (the “Securities Act”):
“The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities Act and applicable state law which, in the opinion of counsel to the Company, is available.”
3. Transfer.
3.1 General Restrictions. The Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder (or permitted assignees under FINRA Rule 5110(e)(1)) will not for a period of one hundred eighty (180) days following the date the Registration Statement is declared effective (the “Effective Date”) by the Securities and Exchange Commission (the “Commission”): (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant to anyone other than: (i) Boustead or an underwriter, placement agent, or a selected dealer participating in the initial public offering (the “Offering”) contemplated by the Underwriting Agreement, or (ii) officers or partners of Boustead or of any such underwriter, placement agent or selected dealer, each of whom in (i) and (ii) shall have agreed to the restrictions contained herein, in accordance with FINRA Conduct Rule 5110(e)(1), or (b) cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). On and after that date that is one hundred eighty (180) days after the effective date of the Registration Statement, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto as Exhibit B duly executed and completed, together with this Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) business days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.
3.2 Restrictions Imposed by the Securities Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) if required by law, the Company has received the opinion of counsel for the Company that the securities may be transferred pursuant to an exemption from registration under Securities Act and applicable state securities laws, or (ii) a registration statement or post-effective amendment to the Registration Statement relating to the offer and sale of such securities that includes a current prospectus has been filed and declared effective by the Commission and compliance with applicable state securities law has been established.
4. New Purchase Warrants to be Issued.
4.1 Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereof, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.
4.2 Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.
5. Adjustments.
5.1 Adjustments to Exercise Price and Number of Shares. The Exercise Price and the number of Shares underlying this Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth:
5.1.1 Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 5.1.3 below, the number of outstanding Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding shares, and the Exercise Price shall be proportionately decreased.
5.1.2 Aggregation of Shares. If, after the date hereof, and subject to the provisions of Section 5.1.3 below, the number of outstanding Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares, and the Exercise Price shall be proportionately increased.
5.1.3 Replacement of Shares upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding Shares other than a change covered by Section 5.1.1 or Section 5.1.2 hereof or that solely affects the par value of such Shares, or in the case of any share reconstruction or amalgamation or merger or consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation or merger, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change in Shares covered by Section 5.1.1 or Section 5.1.2, then such adjustment shall be made pursuant to Section 5.1.1, Section 5.1.2 and this Section 5.1.3. The provisions of this Section 5.1.3 shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, mergers or consolidations, sales or other transfers.
5.1.4 Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 5.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the date hereof or the computation thereof.
5.2 Substitute Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation or merger of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation or merger which does not result in any reclassification or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation or merger shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation or merger, by a holder of the number of Shares of the Company for which such Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation or merger, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 5. The above provision of this Section 5 shall similarly apply to successive consolidations or share reconstructions or amalgamations or mergers.
5.3 Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number of Shares or other securities, properties or rights.
6. Reservation and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise of this Purchase Warrant, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of this Purchase Warrant and payment of the Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company further covenants and agrees that upon exercise of this Purchase Warrant and payment of the exercise price therefor, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. As long as this Purchase Warrant shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable upon exercise of this Purchase Warrant to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market) on which the Shares issued to the public in the Offering may then be listed and/or quoted.
7. Registration. The issuance of the Warrant and the Warrant Shares has been registered on the Registration Statement. The Company shall file periodic filings with the Commission during the term of this Purchase Warrant as required by the rules and regulations issued by the Commission. To the extent the Company does not maintain an effective registration statement for the Shares, during the term of this Purchase Warrant and for a period of no more than seven (7) years from the commencement of sales of the Offering in accordance with FINRA Rule 5110(g)(8)(D), whenever the Company proposes to register any of its securities under the Securities Act, whether for its own account or for the account of another shareholder (except for the registration of securities (A) to be offered pursuant to an employee benefit plan on Form S-8 or (B) pursuant to a registration made on Form F-4, or any successor forms then in effect) at any time and the registration form to be used may be used for the registration of the Shares, it will so notify in writing the Holder (a “Piggyback Notice”) as soon as practicable but in no event less than five (5) business days before the anticipated filing date and offer to the Holder the opportunity to register the sale of such number of Shares as such Holder may request in writing within three (3) business days after receipt of such Piggyback Notice (a “Piggyback Registration”). Notwithstanding the foregoing, the Company may delay any such notice to the Holder, including until after filing a registration statement, so long as the Holder has the same amount of time to determine whether to participate in an offering as it would have had if such notice had not been so delayed. The Company shall cause such Shares to be included in such registration and shall use commercially reasonable efforts to cause the managing underwriter or underwriters of a proposed underwritten offering to permit the Shares requested to be included in a Piggyback Registration on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of such Shares in accordance with the intended method(s) of distribution thereof; provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of Common Shares which may be included in the registration statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Shares with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Holder shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggyback Registration.
8. Certain Notice Requirements.
8.1 Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books (the “Notice Date”) for the determination of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is given to the shareholders.
8.2 Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation or merger) or a sale of all or substantially all of its property, assets and business shall be proposed.
8.3 Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section 5 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s Chief Financial Officer.
8.4 Transmittal of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been duly made (1) when hand delivered, (2) when mailed by express mail or private courier service or (3) when the event requiring notice is disclosed in all material respects and filed in a current report on Form 8-K (or similar report of the Company required of foreign private issuers) or in a definitive proxy statement on Schedule 14A prior to the Notice Date: (i) if to the registered Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address or to such other address as the Company may designate by notice to the Holders:
If to the Holder:
Boustead Securities, LLC
6 Venture, Suite 395
Irvine, CA 92618
Fax: (815) 301-8099
Attention: Keith Moore, CEO
with a copy (which shall not constitute notice) to:
BEVILACQUA PLLC
1050 Connecticut Avenue, Suite 500
Washington, DC 20036
Fax: (202) 869-0889
Attn: Louis A. Bevilacqua, Esq.
If to the Company:
Akanda Corp.
1a, 1b Learoyd Road
New Romney TN28 8XU, United Kingdom
Fax: [*]
Attention: Tejinder Virk, CEO
with copies (which shall not constitute notice) to:
Rimon, P.C.
423 Washington Street, Suite 600
San Francisco, California 94111
Fax: [*]
Attn: Mark C. Lee
Eric Foster Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1 Canada
Fax: [*]
Attn: [*]
9. Miscellaneous.
9.1 Amendments. The Company and Boustead may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and Boustead may deem necessary or desirable and that the Company and Boustead deem shall not adversely affect the interest of the Holders. All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification or amendment is sought.
9.2 Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.
9.3 Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
9.4 Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective successors, legal representatives and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.
9.5 Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of California, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the courts located in Los Angeles, California, or in the United States District Court located in Los Angeles, California, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
9.6 Waiver, etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.
9.7 Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Boustead enter into an agreement (“Exchange Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.
9.8 Execution in Counterparts. This Purchase Warrant may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
[Remainder of page intentionally left blank.]
IN WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of [*], 2022.
AKANDA CORP. | ||
By: | ||
Name: Tejinder Virk | ||
Title: Chief Executive Officer |
EXHIBIT A
Form to be used to exercise Purchase Warrant:
Date: __________, 20___
The undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ Shares of Akanda Corp., a company incorporated in the Province of Ontario (the “Company”) and hereby makes payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.
or
The undersigned hereby elects irrevocably to convert its right to purchase ___ Shares under the Purchase Warrant for ______ Shares, as determined in accordance with the following formula:
X | = | Y(A-B) |
A |
Where, | X = The number of Shares to be issued to Holder; | |
Y = The number of Shares for which the Purchase Warrant is being exercised; | ||
A = The fair market value (defined in Section 2.2 of the Purchase Warrant) of one Share which is equal to $_____; and | ||
B = The Exercise Price which is equal to $______ per share |
The undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation shall be resolved by the Company in its sole discretion.
Please issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.
Signature | |
Name/Title |
INSTRUCTIONS FOR REGISTRATION OF SECURITIES
Delivery of Warrant Shares. The Company shall deliver to Holder, or its designee or agent as specified below, __________ Warrant Shares in accordance with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, as follows:
__ Check here if requesting delivery as a certificate to the following name and to the following address:
Issue to: | |
__ Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:
DTC Participant: | ||
DTC Number: | ||
Account Number: | ||
Date: _____________ __,
|
|
Name of Registered Holder |
By: | ||
Name: | ||
Title: |
Tax ID: |
Electronic Mail : |
EXHIBIT B
Form to be used to assign Purchase Warrant:
(To be executed by the registered Holder to effect a transfer of the within Purchase Warrant):
FOR VALUE RECEIVED, does hereby sell, assign and transfer unto the right to purchase shares of Akanda Corp., a company incorporated in the Province of Ontario (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company.
Dated: ____________, 20__
Signature
NOTICE: The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever.
Exhibit 5.1
Dentons Canada LLP
20th Floor, 250 Howe Street
dentons.com |
January [XX], 2022 |
File No.: 587987-1
|
Akanda Corp.
Toronto, ON M5K 0A1 |
Dear Sirs/Mesdames:
Re: | Akanda Corp. – Registration Statement on Form F-1 |
We have acted as Canadian counsel to Akanda Corp., a corporation organized under the laws of the Province of Ontario, Canada (the "Corporation"), in connection with the Corporation’s filing of a Registration Statement on Form F-1 (File No. [●]) (the "Registration Statement") filed by the Corporation under the U.S. Securities Act of 1933 (the "Securities Act") with the Securities and Exchange Commission (the "Commission") relating to the initial public offering (the "Offering") by the Corporation of up to 4,000,000 common shares, without par value, of the Corporation (including the up to 600,000 common shares that the underwriters have the option to purchase to cover any over-allotments) (such common shares generally the "Common Shares" and the Common Shares being issued pursuant to the Offering specifically, the "Offered Shares") pursuant to an underwriting agreement to be entered into on or prior to the closing date of the Offering (the "Underwriting Agreement") between the Corporation and Boustead Securities, LLC, as representative, and the other several underwriters to be named therein.
A. | Documents Reviewed and Relied Upon |
As Canadian counsel to the Corporation, we have participated in the preparation of and examined original executed or electronically delivered copies, which have been certified or otherwise identified to our satisfaction, of:
1. | the Registration Statement; and |
2. | resolutions of an officer of the Corporation approving Offering, and authorizing and approving the issuance of the Offered Shares (the "Authorizing Resolutions"). |
We have also made such investigations and examined originals or copies, certified or otherwise identified to our satisfaction, of such certificates of public officials and of such other certificates, documents and records as we considered necessary or relevant for purposes of the opinions expressed below, including:
1. | a certificate of status (the "Certificate of Status") dated [●], 2022 issued by the Ministry of Government and Consumer Services (Ontario) in respect of the Corporation; and |
Rattagan Macchiavello Arocena ► Jiménez de Aréchaga, Viana & Brause ► Lee International ► Kensington Swan ► Bingham Greenebaum ► Cohen & Grigsby ► Sayarh & Menjra ► Larraín Rencoret ► Hamilton Harrison & Mathews ► Mardemootoo Balgobin ► HPRP ► Zain & Co. ► Delany Law ► Dinner Martin ► For more information on the firms that have come together to form Dentons, go to dentons.com/legacyfirms |
January [XX], 2022 Page 2 |
dentons.com |
2. | a certificate of certain officers of the Corporation dated the date hereof, as to certain factual matters and certifying the constating documents of the Corporation and resolutions of the board of directors of the Corporation passed in connection with the Offering (the "Officer's Certificate"). |
As to various questions of fact material to the opinions provided herein, we have relied upon the Officer’s Certificate.
B. | Laws Addressed |
We are qualified to practice law in the Province of Ontario and our opinion herein is restricted to the laws of the Province of Ontario and the federal laws of Canada applicable therein (the "Applicable Laws").
C. | Assumptions |
For the purposes of the opinions expressed herein, we have assumed, without independent investigation, the following:
1. | with respect to all documents examined by us, the genuineness of all signatures, the authenticity, completeness and accuracy of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified, conformed, telecopied, PDF or photocopied copies of originals and the legal capacity of individuals signing any documents; |
2. | the completeness, accuracy and currency of the indices and filing systems maintained at the public offices where we have searched or made relevant inquiries and of other documents and certificates supplied by public officials; |
3. | the Officer’s Certificate continues to be accurate on the date hereof; |
4. | the minute books and corporate records of the Corporation made available to us are the original minute books and records of the Corporation and contain all of the articles and constating documents of the Corporation and any amendments thereto and all of the respective minutes, or copies thereof, of all proceedings of the shareholders and directors; |
5. | at the time of offer, issuance and sale of any Offered Shares, the Registration Statement will have been declared effective under the Securities Act, and no stop order suspending its effectiveness will have been issued and remain in effect; |
6. | the Offered Shares will be delivered against payment of valid consideration therefor and in accordance with the terms of the Authorizing Resolutions authorizing such sale and the Underwriting Agreement and as contemplated by the Registration Statement; and |
7. | that if any obligation under any document is required to be performed in a jurisdiction outside of the Province of Ontario, the performance of that obligation will not be illegal under the laws of that jurisdiction. |
January [XX], 2022 Page 3 |
dentons.com |
D. | Reliance |
For the purposes of expressing the opinions set forth herein, in connection with certain factual matters pertaining to this opinion, we have relied exclusively and without independent investigation upon the Officer’s Certificate.
In giving the opinion expressed in paragraph 1 below as it pertains to the Corporation being an existing corporation under the laws of the Province of Ontario, we have relied solely on the Certificate of Status, which we have assumed continues to be accurate as of the date hereof.
E. | Opinions |
Based upon and relying on the foregoing and the qualifications hereinafter expressed, we are of the opinion that:
1. | The Corporation is an existing corporation under the Business Corporations Act (Ontario) and has not been dissolved. |
2. | The Offered Shares have been authorized for issuance and when issued in accordance with the terms of the Underwriting Agreement and the Authorizing Resolutions will be validly issued, fully paid and non-assessable Common Shares in the capital of the Corporation. |
3. | The statements concerning tax matters set forth in the Registration Statement under the subheading "Certain Material Canadian Federal Income Tax Considerations" under the heading “Certain Tax Considerations” insofar as they purport to describe the provisions of the laws referred to therein represent our opinion with respect to the matters discussed therein subject to the qualifications, assumptions and limitations set out under such heading. |
F. | Qualifications |
Whenever our opinion refers to securities of the Corporation, whether issued or to be issued, as being "fully-paid and non-assessable", such phrase means that the holders of such securities will not, after the issuance to them of such securities, be liable to pay further amounts to the Corporation in respect of the issue price payable for such securities, and no opinion is expressed as to the adequacy of any consideration received by the Corporation therefor.
For greater certainty, a specific assumption, limitation or qualification in this opinion is not to be interpreted to restrict the generality of any other assumption, limitation or qualification expressed in general terms in this opinion that includes the subject matter of the specific assumption, limitation or qualification.
We hereby consent to the reference to us under the heading "Legal Matters" and under the subheading "Certain Material Canadian Federal Income Tax Considerations" under the heading “Certain Tax Considerations” in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 or Section 11 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
January [XX], 2022 Page 4 |
dentons.com |
The opinions are given as at the date hereof and as of the effective date of the Registration Statement, and we disclaim any obligation or undertaking to advise any person of any change in law or fact that may come to our attention after the effective date of the Registration Statement. Our opinions do not take into account any proposed rules, policies or legislative changes that may come into force following the date hereof.
Very truly yours, |
Dentons Canada LLP |
Exhibit 10.1
AKANDA CORP.
2021 EQUITY INCENTIVE PLAN
ADOPTED BY THE BOARD OF DIRECTORS: August 6, 2021
1. | GENERAL. |
(a) Eligible Award Recipients. Employees, Officers, Directors and Consultants are eligible to receive Awards.
(b) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Stock Options, and (ii) Restricted Share Unit Awards.
(c) Purpose. The Plan, through the grant of Awards, is intended to help the Corporation secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Corporation and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Shares.
2. | ADMINISTRATION. |
(a) Administration by the Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).
(b) Powers of the Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:
(i) To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Shares under the Award; (E) the number of Common Shares subject to, or the cash value of, an Award.
(ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.
(iii) To settle all controversies regarding the Plan and Awards granted under it.
(iv) To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or Common Shares may be issued in settlement thereof).
(v) To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under the Participant’s then-outstanding Award without the Participant’s written consent except as provided in subsection (viii) below.
- 2 -
(vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Awards granted under the Plan into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Corporation will seek shareholder approval of any amendment of the Plan that (A) materially increases the number of Common Shares available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which Common Shares may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Award without the Participant’s written consent.
(vii) To submit any amendment to the Plan for shareholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 422 of the Code regarding Incentive Stock Options.
(viii) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that a Participant’s rights under any Award will not be impaired by any such amendment unless (A) the Corporation requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s consent (A) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.
(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Corporation and that are not in conflict with the provisions of the Plan or Awards.
(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Officers, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).
(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike price of any outstanding Award; (B) the cancellation of any outstanding Award and the grant in substitution therefor of a new (1) Option, (2) Restricted Share Unit Award, and/or (3) Other Award, determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of Common Shares as the cancelled Award and (y) granted under the Plan or another equity or compensatory plan of the Corporation; or (C) any other action that is treated as a repricing under generally accepted accounting principles.
- 3 -
(c) Delegation to Committee.
(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.
(d) Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of Common Shares to be subject to such Awards granted to such Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of Common Shares that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Market Value pursuant to Section 14(w)(i)B below.
(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.
3. | SHARES SUBJECT TO THE PLAN. |
(a) Share Reserve. Subject to Section 9(a) relating to Capitalization Adjustments and any subsequent amendment to this Plan, the aggregate number of shares reserved for issuance pursuant to Awards granted under this Plan, including any options granted under previous stock option plans outstanding as of the date of this Plan, shall not exceed [20%] of the Corporation’s total issued and outstanding Common Shares from time to time. This Plan is considered an “evergreen” plan, since the shares covered by Awards which have been exercised or terminated shall be available for subsequent grants under the Plan and the number of Awards available to grant increases as the number of issued and outstanding Shares increases.
(b) To the extent any Awards (or portion(s) thereof) under this Plan are exercised, terminate or are cancelled for any reason prior to exercise in full, any shares subject to such Awards (or portion(s) thereof) shall be added back to the number of shares reserved for issuance under this Plan and will again become available for issuance pursuant to the exercise of Awards granted under this Plan.
(c) Any shares issued by the Corporation through the assumption or substitution of outstanding stock options or other equity-based awards from an acquired company shall not reduce the number of Shares available for issuance pursuant to the exercise of Awards granted under this Plan.
- 4 -
(d) For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of Common Shares that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of SAR Awards or any Other Award not involving, whether by election or otherwise, the issuance of Common Shares to the Participant.
(e) Reversion of Shares to the Share Reserve. If an Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of Common Shares that may be available for issuance under the Plan. If any Common Shares issued pursuant to an Award are forfeited back to or repurchased by the Corporation because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Corporation in satisfaction of tax withholding obligations on an Award or as consideration for the exercise or purchase price of an Award will again become available for issuance under the Plan.
(f) Source of Shares. The shares issuable under the Plan will be shares of authorized but unissued Common Shares.
4. | ELIGIBILITY. |
(a) Eligibility for Specific Awards. Incentive Stock Options may be granted only to applicable employees of the Corporation or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Awards other than Incentive Stock Options may be granted to Employees, Officers, Directors and Consultants.
(b) Ten Percent Shareholders. A Ten Percent Shareholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.
5. | PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS. |
Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Non-Incentive Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for Common Shares purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Non-Incentive Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:
(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders, no Option or SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Award Agreement.
(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Market Value of the Common Shares subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Market Value of the Common Shares subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction; provided that such grant is permitted under applicable Securities Laws and Stock Exchange Rules and, to the extent relevant to the Participant, is made in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in Common Share equivalents.
- 5 -
(c) Purchase Price for Options. The purchase price of Common Shares acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Corporation to use a particular method of payment. The permitted methods of payment are as follows:
(i) by cash, certified cheque, bank draft or money order payable to the Corporation;
(ii) if an Option is a Non-Incentive Stock Option, by a “net exercise” arrangement pursuant to which the Corporation will reduce the number of Common Shares issuable upon exercise by the largest whole number of shares with a Market Value that does not exceed the aggregate exercise price; provided, however, that the Corporation will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Common Shares will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or
(iii) in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.
(d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Corporation in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Market Value (on the date of the exercise of the SAR) of a number of Common Shares equal to the number of Common Share equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Share equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Shares, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.
(e) Transferability of Options and SARs. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Corporation or as otherwise expressly consented to by the Board, Options and SARs shall not be assignable, transferable or negotiable (whether by operation of law or otherwise) and may not be assigned or transferred other than by will or the laws of descent and distribution.
(f) Vesting Generally. The total number of Common Shares subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of Common Shares as to which an Option or SAR may be exercised.
- 6 -
(g) Termination of Continuous Service. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Corporation, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date ninety (90) days following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement, which period will not be less than 30 days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.
(h) Disability of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Corporation, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.
(i) Death of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Corporation, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date 12 months following the date of death (or such longer or shorter period specified in the Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.
(j) Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Corporation or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service.
- 7 -
(k) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any Common Shares until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement, in another agreement between the Participant and the Corporation, or, if no such definition, in accordance with the Corporation’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the employee’s regular rate of pay, the provisions of this Section will apply to all Awards and are hereby incorporated by reference into such Award Agreements.
(l) Right of Repurchase. Subject to the “Repurchase Limitation” and any applicable Securities Laws and Stock Exchange Rules, the Option or SAR may include a provision whereby the Corporation may elect to repurchase all or any part of the vested Common Shares acquired by the Participant pursuant to the exercise of the Option or SAR.
(m) Right of First Refusal. Subject to any applicable Securities Laws and Stock Exchange Rules, the Option or SAR may include a provision whereby the Corporation may elect to exercise a right of first refusal following receipt of notice from the Participant of the intent to transfer all or any part of the Common Shares received upon the exercise of the Option. Such right of first refusal will be subject to the “Repurchase Limitation”. Except as expressly provided in this Section or in the Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of the Corporation.
6. | PROVISIONS OF AWARDS OTHER THAN OPTIONS AND SARS. |
(a) Restricted Share Unit Awards. Each Restricted Share Unit Award Agreement will be in such form and will contain such terms and conditions as the will Board deem appropriate. The terms and conditions of Restricted Share Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Share Unit Award Agreements need not be identical. Each Restricted Share Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:
(i) Consideration. At the time of grant of a Restricted Share Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each Common Share subject to the Restricted Share Unit Award. The consideration to be paid (if any) by the Participant for each Common Share subject to a Restricted Share Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.
(ii) Vesting. At the time of the grant of a Restricted Share Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Share Unit Award as it, in its sole discretion, deems appropriate.
(iii) Payment. A Restricted Share Unit Award may be settled by the delivery of Common Shares, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Share Unit Award Agreement.
- 8 -
(iv) Additional Restrictions. At the time of the grant of a Restricted Share Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the Common Shares (or their cash equivalent) subject to a Restricted Share Unit Award to a time after the vesting of such Restricted Share Unit Award.
(v) Dividend Equivalents. Dividend equivalents may be credited in respect of Common Shares covered by a Restricted Share Unit Award, as determined by the Board and contained in the Restricted Share Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional Common Shares covered by the Restricted Share Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Share Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Share Unit Award Agreement to which they relate.
(vi) Termination of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Share Unit Award Agreement, such portion of the Restricted Share Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.
(vii) Compliance with Section 409A of the Code. Notwithstanding anything to the contrary set forth herein, any Restricted Share Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code shall contain such provisions so that such Restricted Share Unit Award will comply with the requirements of Section 409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Restricted Share Unit Award Agreement evidencing such Restricted Share Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Share that is to be issued in a year following the year in which the Restricted Share Unit Award vests must be issued in accordance with a fixed pre-determined schedule.
(b) Other Awards. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Shares, including the appreciation in value thereof may be granted either alone or in addition to Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of Common Shares (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.
7. | COVENANTS OF THE COMPANY. |
(a) Availability of Shares. The Corporation will keep available at all times the number of Common Shares reasonably required to satisfy then-outstanding Awards.
(b) Securities Law Compliance. The Corporation will seek to obtain from each securities commission or other regulatory body having jurisdiction over the Plan, as necessary, such authority as may be required to grant Awards and to issue and sell Common Shares upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Corporation to register or qualify by prospectus under applicable Securities Laws, the Plan, any Award or any Common Shares issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Corporation is unable to obtain from any such regulatory commission or agency the authority that counsel for the Corporation deems necessary or advisable for the lawful issuance and sale of Common Shares under the Plan, the Corporation will be relieved from any liability for failure to issue and sell Common Shares upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Shares pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.
- 9 -
(c) No Obligation to Notify or Minimize Taxes. The Corporation will have no duty or obligation to any Participant to advise such holder as to the tax treatment or time or manner of exercising such Award. Furthermore, the Corporation will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Corporation has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.
8. | MISCELLANEOUS. |
(a) Use of Proceeds from Sales of Common Shares. Proceeds from the sale of Common Shares pursuant to Awards will constitute general funds of the Corporation.
(b) Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Corporation of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.
(c) Shareholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Common Shares subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of Common Shares under, the Award pursuant to its terms, and (ii) the issuance of the Common Shares subject to the Award has been entered into the books and records of the Corporation.
(d) No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Corporation or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Corporation or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Corporation or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Corporation or an Affiliate, and any applicable provisions of the corporate law of the state of foreign jurisdiction in which the Corporation or the Affiliate is domiciled or incorporated, as the case may be.
(e) Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Corporation and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Corporation and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.
- 10 -
(f) Incentive Stock Option Limitations. To the extent that the aggregate Market Value (determined at the time of grant) of Common Shares with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Corporation and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Non-Incentive Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).
(g) Investment Assurances. The Corporation may require a Participant, as a condition of exercising or acquiring Common Shares under any Award, (i) to give written assurances satisfactory to the Corporation as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Corporation who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Corporation stating that the Participant is acquiring Common Shares subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Shares. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if as to any particular requirement, a determination is made by counsel for the Corporation that such requirement need not be met in the circumstances under the then applicable Securities Laws. The Corporation may, upon advice of counsel to the Corporation, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable Securities Laws, including, but not limited to, legends restricting the transfer of the Common Shares.
(h) Withholding Obligations. Unless prohibited by the terms of an Award Agreement, the Corporation may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding Common Shares from the Common Shares issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no Common Shares are withheld with a value exceeding the maximum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.
(i) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Shares or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Corporation. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.
- 11 -
(j) Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Corporation is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Corporation’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired Common Shares or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntary terminate employment upon a “resignation for good reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Corporation.
(k) Compliance with Section 409A of the Code. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the Common Shares are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump-sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.
(l) Repurchase Limitation. The terms of any repurchase right will be specified in the Award Agreement. Subject to any applicable Securities Laws and Stock Exchange Rules, the repurchase price for vested Common Shares will be the Market Value of the Common Shares on the date of repurchase. Subject to any applicable Securities Laws and Stock Exchange Rules, the repurchase price for unvested Common Shares will be the lower of (i) the Market Value of the Common Shares on the date of repurchase or (ii) their original purchase price. However, the Corporation will not exercise its repurchase right until at least six months (or such longer or shorter period of time necessary to avoid classification of the Award as a liability for financial accounting purposes) have elapsed following delivery of Common Shares subject to the Award, unless otherwise specifically provided by the Board.
9. | ADJUSTMENTS UPON CHANGES IN COMMON SHARES; OTHER CORPORATE EVENTS. |
(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), and (ii) the class(es) and number of securities and price per share subject to outstanding Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.
(b) Dissolution or Liquidation. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Corporation, all outstanding Awards (other than Awards consisting of vested and outstanding Common Shares not subject to a forfeiture condition or the Corporation’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the Common Shares subject to the Corporation’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Corporation notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.
- 12 -
(c) Corporate Transaction. The following provisions will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Corporation or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Awards, contingent upon the closing or completion of the Corporate Transaction:
(i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to assume or continue the Award or to substitute a similar stock award for the Award (including, but not limited to, an award to acquire the same consideration paid to the shareholders of the Corporation pursuant to the Corporate Transaction);
(ii) arrange for the assignment of any reacquisition or repurchase rights held by the Corporation in respect of Common Shares issued pursuant to the Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company);
(iii) accelerate the vesting, in whole or in part, of the Award (and, if applicable, the time at which the Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Corporate Transaction), with such Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; provided, however, that the Board may require Participants to complete and deliver to the Corporation a notice of exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction;
(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Corporation with respect to the Award;
(v) cancel or arrange for the cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration (including no consideration) as the Board, in its sole discretion, may consider appropriate; and
(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Corporation’s Common Shares in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.
The Board need not take the same action or actions with respect to all Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of an Award.
(d) Change in Control. An Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Award Agreement for such Award or as may be provided in any other written agreement between the Corporation or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.
- 13 -
10. | PLAN TERM; EARLIER TERMINATION OR SUSPENSION OF THE PLAN. |
(a) Plan Term. The Board may suspend or terminate the Plan at any time. No Incentive Stock Option will be granted after the tenth anniversary of the earlier of (i) the Adoption Date, or (ii) the date the Plan is approved by the shareholders of the Corporation. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.
(b) No Impairment of Rights. Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.
11. | ASSIGNMENT OF RIGHTS. |
Any and all rights under Awards and Award Agreements shall not be assignable, transferable or negotiable (whether by operation of law or otherwise) by the Participant and may not be assigned or transferred other than by transmission by will or the laws of descent and distribution.
12. | EFFECTIVE DATE OF PLAN. |
This Plan, as amended and restated, will become effective on the Effective Date.
13. | CHOICE OF LAW. |
The laws of the Province of Ontario will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that province's conflict of laws rules.
14. | DEFINITIONS. |
As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
(a) “Adoption Date” means July ___, 2021, which is the date the Plan was adopted by the Board.
(b) “Affiliate” means, at the time of determination, any “affiliate” of the Corporation, as such term is defined in the Business Corporations Act (Ontario).
(c) “Award” means any right to receive Common Shares granted under the Plan, including an Incentive Stock Option, a Non-Incentive Stock Option, a Restricted Share Unit Award or any Other Award.
(d) “Award Agreement” means a written agreement between the Corporation and a Participant evidencing the terms and conditions of an Award.
(e) “Award Agreement” means a written agreement between the Corporation and a Participant evidencing the terms and conditions of an Award grant. Each Award Agreement will be subject to the terms and conditions of the Plan.
(f) “Board” means the Board of Directors of the Corporation.
(g) “Capital Stock” means each and every class of common stock of the Corporation, regardless of the number of votes per share.
- 14 -
(h) “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Shares subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Corporation through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Corporation will not be treated as a Capitalization Adjustment.
(i) “Cause” will have the meaning ascribed to such term in any written agreement between the Participant and the Corporation defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of Canada, the United States or any province or state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Corporation; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Corporation or of any statutory duty owed to the Corporation; (iv) such Participant’s unauthorized use or disclosure of the Corporation’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Corporation, in its sole discretion. Any determination by the Corporation that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Corporation or such Participant for any other purpose.
(j) “Change of Control” means the occurrence of one or more of the following events:
(i) any change in the holding, direct or indirect, of shares in the capital of the Company as a result of which a person or group of persons acting jointly or in concert, or person associated or affiliated with any such person or group within the meaning of the Securities Act (Ontario), becomes the beneficial owner, directly or indirectly, of shares and/or other securities in excess of the number which, directly or following conversion thereof, would entitle the holders thereof to cast more than 50% of the votes attaching to all shares of the Company which may be cast to elect directors of the Company (the “Company Voting Securities”); provided, however, that the event described in this paragraph (ii) shall not be deemed to be a Change of Control by virtue of any of the following acquisitions of Company Voting Securities:
A. by the Company or any subsidiary;
B. by any employee benefit plan sponsored or maintained by the Company or any subsidiary;
C. by any underwriter temporarily holding securities pursuant to an offering of such securities;
D. pursuant to a Non-Qualifying Transaction (as defined in paragraph (ii)); or
E. from the Company pursuant to a transaction (other than one described in paragraph (iii)), if a majority of the directors approve a resolution providing expressly that the acquisition pursuant to this clause E shall not constitute a Change of Control under this paragraph (ii);
- 15 -
(ii) the consummation of a merger, consolidation, share exchange or similar form of corporate transaction involving the Company or any of its subsidiaries (a “Business Combination”), unless immediately following such Business Combination:
A. Company Voting Securities that were outstanding immediately prior to the consummation of such Business Combination (or, if applicable, securities into or for which such Company Voting Securities were converted or exchanged pursuant to such Business Combination) represent more than 50% of the combined voting power of the then outstanding securities eligible to vote for the election of directors or trustees (“voting power”) of (1) the entity resulting from such Business Combination (the “Surviving Entity”), or (2) if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of 100% of the voting securities eligible to elect directors of the Surviving Entity (the “Parent Entity”); or
B. no person (other than any employee benefit plan sponsored or maintained by the Surviving Entity or the Parent Entity) is the beneficial owner, directly or indirectly, of 50% or more of the voting power of the Parent Entity (or, if there is no Parent Entity, the Surviving Entity);
(any Business Combination which satisfies all of the criteria specified in A, B and C above shall be deemed to be a “Non-Qualifying Transaction”);
(iii) the approval by the Board or shareholders of the Company of a complete liquidation or dissolution of the Company; or
(iv) a sale or other disposition of all or substantially all of the property or assets of the Company, other than to an affiliate within the meaning of the Securities Act (Ontario) or pursuant to a Non-Qualifying Transaction.
(k) “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(l) “Committee” means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).
(m) “Common Shares” means the class of Common Shares of the Corporation.
(n) “Consultant” means any person, including an advisor, who is engaged by the Corporation or an Affiliate to render consulting or advisory services pursuant to a written consulting agreement, and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.
(o) “Continuous Service” means that the Participant’s service with the Corporation or an Affiliate, whether as an Employee, Officer, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Corporation or an Affiliate as an Employee, Officer, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Corporation or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Corporation, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Corporation, an Affiliate, or their successors. In addition, to the extent required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of “separation from service” as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).
- 16 -
(p) “Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:
(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Corporation and its Subsidiaries;
(ii) a sale or other disposition of more than 50% of the outstanding securities of the Corporation;
(iii) a merger, consolidation or similar transaction following which the Corporation is not the surviving corporation; or
(iv) a merger, consolidation or similar transaction following which the Corporation is the surviving corporation but the Common Shares outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.
(q) “Corporation” means Akanda Corp., an Ontario business corporation.
(r) “Director” means a member of the Board.
(s) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months, and will be determined by the Board on the basis of such medical evidence as the Board deems reasonable under the circumstances.
(t) “Effective Date” means the effective date of this Plan, which is the earlier of (i) the date that this Plan is first approved by the Corporation’s shareholders, and (ii) the date this Plan is adopted by the Board.
(u) “Employee” means any person employed by the Corporation or an Affiliate.
(v) “Entity” means a corporation, partnership, limited liability company or other entity.
(w) “Market Value” means,
(i) as of the date of grant of an Award, the value of the Common Shares determined as follows:
A. If the Common Shares are listed on the Stock Exchange or traded on any other established market, the Market Value of a Common Share will be, unless otherwise determined by the Board, the greater of the closing market prices of the underlying securities on (a) the trading day prior to the date of grant of the Award; and (b) the date of grant of the stock options, and
- 17 -
B. In the absence of such markets for the Common Shares, the Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code or, in the case of Incentive Stock Options, in compliance with Section 422 of the Code; and
(ii) as of any other relevant date, the value of the Common Shares determined as follows:
A. If the Common Shares are listed on the Stock Exchange or traded on any other established market, the Market Value of a Common Share will be, unless otherwise determined by the Board, the closing market price of the underlying securities on the trading day prior to such relevant date, and
B. In the absence of such markets for the Common Shares, the Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code or, in the case of Incentive Stock Options, in compliance with Section 422 of the Code.
(x) “Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.
(y) “Insider” has the meaning given to such term in the Stock Exchange Rules, or if the Common Shares are not listed or posted for trading on the Stock Exchange, the meaning given under Securities Laws.
(z) “Non-Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option, including an Incentive Stock Option granted to a person not subject to taxation on income under the laws of the United States.
(aa) “Officer” means a person who is an officer of the Corporation.
(bb) “Option” means an Incentive Stock Option or a Non-Incentive Stock Option to purchase Common Shares granted pursuant to the Plan.
(cc) “Option Agreement” means a written agreement between the Corporation and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.
(dd) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
(ee) “Other Award” means an award based in whole or in part by reference to the Common Shares which is granted pursuant to the terms and conditions of Section 6(b).
(ff) “Other Award Agreement” means a written agreement between the Corporation and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.
(gg) “Own,” “Owned,” “Owner,” “Ownership” A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
- 18 -
(hh) “Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.
(ii) “Plan” means this Akanda Corp. 2021 Equity Incentive Plan.
(jj) “Restricted Share Unit Award” means a right to receive Common Shares which is granted pursuant to the terms and conditions of Section 11.
(kk) “Restricted Share Unit Award Agreement” means a written agreement between the Corporation and a holder of a Restricted Share Unit Award evidencing the terms and conditions of a Restricted Share Unit Award grant. Each Restricted Share Unit Award Agreement will be subject to the terms and conditions of the Plan.
(ll) “Securities Laws” means securities legislation, securities regulation and securities rules, as amended, and the policies, notices, instruments and blanket orders in force from time to time that govern or are applicable to the Corporation or to which it is subject;
(mm) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Shares that is granted pursuant to the terms and conditions of Section 5.
(nn) “Stock Appreciation Right Agreement” means a written agreement between the Corporation and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.
(oo) “Stock Exchange” means the Nasdaq Stock Market.
(pp) “Stock Exchange Rules” means the applicable rules and policies of the Stock Exchange, as such rules and policies may be amended, supplemented or replaced from time to time
(qq) “Subsidiary” has the meaning given to it under the Business Corporations Act (Ontario).
(rr) “Ten Percent Shareholder” means a person, who is subject to taxation on income under the laws of the United States, and who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of shares of the Corporation or any Affiliate.
Exhibit 10.2
AGREEMENT OF SUBLEASE
2
AGREEMENT OF SUBLEASE
MEMORANDUM OF AGREEMENT OF SUBLEASE
Concluded by and between
Mophuthi Matsoso Development Trust (Reg No:TD2015/0015)
(Hereinafter referred to as the “Sub-lessor”)
Makhemeng Ts’akholo, Mafetengand
Bophelo Bioscience and Wellness Proprietary Limited (Reg No: 2018/62924)(Hereinafter referred to as the “Sub-lessee”)
Makhemeng Ts’akholo, Mafeteng.
WHEREAS
The Sub-lessor hereby agrees to sublet to Sub-lessee, who agrees to hire certain properties held by; A Form C
(Certificate of Allocation) in terms of Section 23(1) of Land Act 2010
NOW THEREFORE THE PARTIES AGREE AS FOLOWS ON THE TERMS AND CONDITIONS OF THEAFORESAID AGREEMENT
1 INTERPRETATION
In this agreement -
1.1 | clause headings are for the purposes of convenience and reference only and shall not be used in the interpretation of this agreement; |
1.2 | unless the context clearly indicates a contrary intention an expression which denotes - |
1.2.1 | any gender includes the other genders; |
1.2.2 | a natural person includes an artificial person and vice versa; |
1.2.3 | the singular includes the plural and vice versa; |
1.3 | the following expressions shall, unless the context clearly indicates a contrary intention, bear the following meanings and related expressions shall bear corresponding meanings- |
1.3.1 | “agreement” -this agreement of lease and all annexes hereto; |
1.3.2 | “buildings” - at any relevant time, the greenhouses, sheds and other building/s on the leased premises and all other improvements of every nature whatever situate on the leased premises; |
1.3.3 | “commencement date” - notwithstanding the signature date, 1 April 2019; |
3
1.3.4 | “initial period” - the period commencing on the commencement date and terminating on the 20th anniversary thereof; |
1.3.5 | “leased premises” subject to the provisions of clause 4, the 68834 sq msituated on the properties indicated on Annex A; |
1.3.6 | “parties” - collectively the Sub-lessor and the Sub-lessee and any reference to“party” shall be deemed to be reference to either one of them as the context may require; |
1.3.7 | “permitted business” –the activities described in clause 12.1 |
1.3.8 | “prime rate” - the rate publicly quoted by The Standard Bank of South Africa Limited, from time to time, as being its prime rate of interest (expressed as a nominal annual compounded monthly in arrear rate), calculated on a 365 day a year basis, irrespective of whether or not the year is a leap year and prima facie proved, in the event of there being a dispute in relation thereto, by a certificate signed by any manager of the aforesaid bank (whose appointment, qualification or authority need not be proved); |
1.3.9 | “properties” - collectively the properties described as South = 1345m, East = 954m, North = 4231m, West = 1397m, East-North = 1510m; |
1.3.10 | “signature date” – the last date on which the parties sign this agreement; |
1.3.11 | “Sub-lessee” - Bophelo Bioscience and Wellness Proprietary Limited (registration number 2018/62924), a company incorporated in accordance with the laws of The Kingdom of Lesotho; |
1.3.12 | “Sub-lessor” - Mophuthi Matsoso Development Trust (Reg No: TD2015/0015)established in accordance with the laws of The Kingdom of Lesotho; |
1.3.13 | “termination date”- the date on which this agreement is terminated for any reason whatsoever; |
1.3.14 | “VAT” - Value-added Tax as defined in the Vat Act at the prescribed rate onthe date of supply to which it relates; |
1.3.15 | “VAT Act”-the Value-added Tax Act of 2001; |
1.4 | where any term is defined within the context of any particular clause, the term so defined, unless it is clear from the clause in question that the term so defined has limited application to the relevant clause, shall bear the meaning ascribed to it in terms of the particular clause for all purposes in terms of this agreement, notwithstanding that the term has not been defined in this interpretation clause; |
1.5 | should any provision contained in a definition be a substantive provision conferring any right or imposing any obligation on any party, then notwithstanding that it is only contained in this interpretation clause effect shall be given to it as if it were a substantive provision in this agreement; |
4
1.6 | when any number of days is prescribed such number shall exclude the first and include the last day unless the last day falls on a day which is not a business day, in which case the last day shall be the next succeeding business day; |
1.7 | the use of a specific example (whether or not after the word “including” or “such as”) shall not be construed as limiting the meaning of the general wording preceding it and the eiusdem generis rule shall not be applied in the interpretation of such general wording or such specific example/s. Accordingly, without limiting the generality of the aforegoing, wherever the words “includes” or “including” are used in this agreement, the words “without limitation” shall be deemed to follow them; |
1.8 | the rule of construction that the contract shall be interpreted against the party responsible for the drafting or preparation of the agreement. |
1.9 | all of the annexes, if any, hereto are deemed to be incorporated herein and shall havethe same force and effect as if they were contained in the body of this agreement; |
1.10 | words and/or expressions defined in this agreement shall bear the same meanings when used in the annexes, if any, hereto; |
1.11 | a reference to any statutory body or court shall be construed as a reference to that statutory body or court as at the signature date and as substituted from time to time thereafter by successor statutory bodies or courts, as the case may be; |
1.12 | the expiration or termination of this agreement shall not affect such of its provisions as expressly provide that they shall continue to apply after such expiration or termination or which of necessity must continue to apply after such expiration ortermination; |
1.13 | a reference to - |
1.13.1 | “business day” shall be construed as being any day other than a Saturday,Sunday or public holiday in Lesotho; |
1.13.2 | day/s, month/s or year/s shall be construed as day/s, month/s or year/s in the Gregorian calendar; |
1.13.3 | any written agreement shall be a reference to that agreement as amended,substituted or replaced from time to time in accordance with its terms; |
1.14 | no provision of this agreement shall, unless otherwise stipulated, constitute a stipulation for the benefit of any person (stipulation alteri) who is not a party to this agreement. |
2 INTRODUCTION
It is recorded that the parties agree that the Sub-lessee shall let from the Sub-lessor the leased premises, upon the terms and conditions set out in this agreement.
3 SUB-LEASE
The Sub-lessor hereby lets the leased premises to the Sub-lessee on the terms and conditions set out in this agreement.
5
4 EXTENSION OF LEASED PREMISES
4.1 | The Sub-lessee shall have the right to increase the area of the leased premises, at anytime and on one occasion or on more than one occasion, by notice in writing to the Sub-lessor so as to include any portion of the properties depicted on annex B as part of the leased premises, provided that the maximum increase in extent of the leased premises shall not pursuant to the exercise of the aforesaid right/s exceed an additional 192 hectares. |
4.2 | Should the Sub-lessee exercise its rights in terms of clause 4.1 the extended area to be comprised in the leased premises shall be at the discretion of the Sub-lessee but shall be selected from the area shown in annex B and the leased premises shall be extended with effect from the last day of the month in which such right is exercised by the Sub-lessee in terms of clause 4.1. |
4.3 | After the area of the leased premises has been extended by an additional 194 hectares pursuant to the exercise by the Sub-lessee of the rights granted to it in terms of clause 4.1, the Sub-lessee shall have the right to further increase the area of the leased premises, at any time and on one occasion or on more than one occasion, by notice in writing to the Sub-lessor so as to include any portion of the properties depicted on annex C as part of the leased premises, provided that the maximum increase in extent of the leased premises shall not pursuant to the exercise of the aforesaid right/s exceed an additional 1 000 hectares. |
4.4 | Should the Sub-lessee exercise its rights in terms of clause 4.3 the extended area to be comprised in the leased premises shall be at the discretion of the Sub-lessee but shall be selected from the area shown in annex C and the leased premises shall be extended with effect from the last day of the month in which such right is exercised by the Sub-lessee in terms of clause 4.3. |
4.5 | The Sub-lessor undertakes to ensure that the Sub-lessee, its employees, contractors, agents and invitees are at all times given free and unrestricted access to all parts of the leased premises including the right to traverse the other parts of the properties if necessary to gain access to any portion of the leased premises. |
5 REGISTRATION OF SUBLEASE
The Sub-lessor undertakes to procure that-
5.1 | it obtains the requisite consent in terms of section 36 of the Land Act 2010 for the Sub-lessor to sublet the leased premises to the Sub-lessee; and |
5.2 | after obtaining the consent referred to in clause 5.1 that the lease is registered (as soon as possible after the aforesaid consent is obtained but in any event within3 month from the date thereof) in terms of the Deeds Registry Act of 1969. Refer to Annex A. |
6 DURATION
6.1 | This agreement shall commence on the commencement date and shall terminate on the 20th anniversary of the commencement date subject to such other rights as are vested in the parties in terms of this agreement or in terms of law. |
6
6.2 | The Sub-lessee shall have an option (“the first option”) to renew this lease for a period of 30 years (“the first option period”) from the termination of the initial period. |
6.3 | The Sub-lessee shall be entitled to exercise the first option by written notice to the Sub-lessor, not less than 60 days prior to the termination of the initial period, failing which, the first option shall lapse. |
6.4 | The first option shall be on the same terms as set out in this lease applicable to the initial period. |
6.5 | The Sub-lessee shall have an option (“the second option”) to renew this lease for a period of 30 years (“the second option period”) from the termination of the first option period. |
6.6 | The Sub-lessee shall be entitled to exercise the second option by written notice to the Sub-lessor, not less than 60 days prior to the termination of the first option period, failing which, the second option shall lapse. |
6.7 | The second option shall be on the same terms as set out in this lease applicable to the initial period. |
7 RENTAL
7.1 | The monthly rental payable by the Sub-lessee to the Sub-lessor in respect of the hire of the leased premises for the period commencing on the commencement date and terminating on the termination date shall be 350,000 Malotis per month. |
7.2 | The monthly rental referred to in clause 7.1 shall escalate on each anniversary of the commencement date (including during any option period if the relevant option is exercised) at the rate of 10% on a compound basis. |
8 PAYMENT
8.1 | The Sub-lessee shall pay the basic monthly rental to the Sub-lessor in Maloti free of any deduction and/or set-off whatever and free of bank charges and/or commission no later than the 7th of every following month |
8.2 | Unless expressly notified in writing to the Sub-lessee to the contrary, all amounts payable to the Sub-lessor in terms of this agreement shall be paid by means of electronic transfer of funds into the Sub-lessor’s banking account referred to below - |
Account holder | Mophuthi Matsoso Development Trust | |
Bank | Nedbank Lesotho | |
Branch | Mafeteng | |
Branch code | - | [*] |
Account number | [*] | |
Reference | Bophelo Rent |
or such other banking account in Lesotho as the Sub-lessor may from time to time, inwriting, direct.
7
8.3 | Any rent falling due for payment by the Sub-lessee under this agreement which is not paid on its due date for payment, shall bear interest at the prime rate, calculated from the due date for payment thereof. |
8.4 | All amounts payable by the Sub-lessee to the Sub-lessor in terms of this agreement are expressed to be exclusive of VAT on the basis that the Sub-lessee shall pay the Sub-lessor VAT thereon at the applicable rate as determined in accordance with the provisions of the Vat Act from time to time. |
9 DELIVERY OF KEYS AND REMOTES
The Sub-lessee shall deliver all keys to the buildings to the Sub-lessor not later than 16:30 on the termination date. The Sub-lessee shall be responsible for all costs incurred by the Sub-lessor in obtaining new keys should the Sub-lessee fail to deliver the keys as aforesaid.
10 ELECTRICITY, WATER, GAS AND OTHER OUTGOINGS
10.1 | The Sub-lessee shall with effect from the commencement date be liable for and pay forthwith on demand to the Sub-lessor all costs for water, electricity, gas, sanitary fees, refuse removal fees, and any other services consumed by the Sub-lessee at the leased premises. |
10.2 | Should the leased premises, or part of the leased premises, be served by specific sub-meters in respect of electricity, water and/or gas, then the Sub-lessee shall pay to the Sub-lessor, the cost of all electricity, water and/or gas used in and/or on the leased premises as metered by such sub-meters. |
10.3 | Should no separate sub meter be installed in respect of any of the services contemplated in terms of clause 10.1 or should a common sub meter exist for more than the leased premises, such service charges shall be calculated by the Sub-lessor on a pro rata basis based on the percentage which the hectares comprised in the leased premises bears to the hectares comprised in the property/ies served by the common sub meter or in respect of which the charges are levied, as the case may be. |
11 RATES AND TAXES
11.1 | The Sub-lessee shall be liable for and shall pay to the Sub-lessor all rates and taxes, including assessment rates, business or city improvement district fees, park levies and municipal fees and charges, levied by any competent local authority in respect of the leased premises in respect of any period during this agreement. |
11.2 | Should any of the rates, taxes, fees and/or charges contemplated in clause 11.1 be levied in respect of any area greater than just the leased premises, then the portion payable by the Sub-lessee shall be calculated on a pro rata basis based on the percentage which the hectares comprised in the leased premises bears to the hectares comprised in the property/ies in respect of which such amounts are levied. |
12 PURPOSE FOR WHICH LEASED PREMISES ARE
12.1 | The leased premises are let to the Sub-lessee for the purposes of(i) planting, growing, cultivating, farming and manufacturing cannabis and all associated and ancillary activities; (ii) use as offices; and (iii) the provision of administration services. The lessee shall not use the leased premises for any other purpose whatsoever without the prior written consent of the Sub-lessor, which consent shall not be unreasonably withheld or delayed. |
8
12.2 | The Sub-lessee undertakes to make timeous application for any licences and any renewals thereof necessary for the conduct of the permitted business in the leased premises and to proceed with any such applications without delay. |
13 MAINTENANCE
13.1 | The Sub-lessee shall - |
13.1.1 | at its own cost, keep and maintain in a clean, good order and condition the buildings and replace or repair same, as the case may be, which, without derogating from the generality hereof, shall include all fixtures and fittings, electrical installations, plumbing, geysers and sanitary works, appliances, fire fighting equipment, air-conditioners, doors, roller shutter doors, door handles, locks, keys, entrances, doors, glass and windows in or serving the leased premises and on termination of this agreement shall deliver the buildings to the Sub-lessor in the same good order and condition as existed at the commencement date, fair wear and tear excepted; |
13.1.2 | prevent any blockage of sewerage or water pipes or septic tanks or drains in or used in connection with the leased premises and shall remove at its cost any obstruction or blockage in any sewer or water pipe or septic tanks or drains serving the leased premises and, where necessary, repair the sewer pipe or drain concerned. |
13.2 | Should the Sub-lessee fail or refuse to maintain or repair the buildings as provided for in terms of this agreement and remain in default for a period of 30 days after receipt of a written notice calling on the Sub-lessee to rectify such default, then the Sub-lessor shall be entitled, without prejudice to its other rights in law or in terms of this agreement, to effect the necessary maintenance or repairs and to claim the costs so incurred from the Sub-lessee. |
13.3 | The Sub-lessee shall notify the Sub-lessor in writing within 30 business days after the signature date of any patent defects in the buildings, particularly in respect of taps, toilets, electrical plug points, lighting, locks, keys, doors, glass and windows. The Sub-lessor undertakes to remedy such defects within a period of 14 days after receipt of the written notice from the Sub-lessee, or such longer period as may be required in the circumstances. |
14 CONTRAVENTION OF LAWS
14.1 | The Sub-lessee shall not contravene or permit the contravention of any law, by-law or statutory regulation or the conditions of any licence relating to or affecting the occupation of the leased premises or the carrying on of the Sub-lessee’s permitted business therein, which may expose the Sub-lessor to any claim, action or prosecution. |
14.2 | The Sub-lessee shall not contravene any of the conditions of title as set out in the title deed of the properties on which the leased premises are situated and under which the Sub-lessor holds title, nor any laws which the Sub-lessor is required to observe, by reason of its ownership of the leased premises. |
9
14.3 | Should the Sub-lessee contravene any law and the Sub-lessor be penalised in any way as a result thereof, the Sub-lessor shall be entitled to recover any loss or damageeither incurred or to be incurred in the future, from the Sub-lessee. |
15 ALTERATIONS, ADDITIONS, FIXTURES AND FITTINGS
15.1 | The Sub-lessor shall not be under any obligation or liability to make any applications in respect of, do any work or make any alterations or repairs to the buildings in order to comply with the requirements of any local authority or other applicable laws and regulations. |
15.2 | The Sub-lessee shall be entitled to - |
15.2.1 | effect or cause to allow to be effected to the leased premises and/or to any buildings, any alterations or additions or improvements or renovations (collectively “the improvements”), whether external, internal, structural, non-structural or of any other nature whatsoever, without the prior consent of the Sub-lessor; and/or |
15.2.2 | erect any other buildings or structures of any nature whatever on the leased premises, without the prior consent of the Sub-lessor. |
15.3 | The Sub-lessee shall be entitled to exercise its rights in terms of clause 15.2 provided that the - |
15.3.1 | plans and specifications for the works shall be prepared by an architect approved by the Sub-lessor and submitted to the Sub-lessor for approval, which approval shall not be unreasonably withheld or delayed; |
15.3.2 | work shall be carried out by a contractor(s) reasonably approved by the Sub-lessor under the supervision of the Sub-lessor’s architect and/or other professional consultant(s) nominated by the Sub-lessor for such purpose; |
15.3.3 | reasonable professional fees and charges of the Sub-lessor’s architect, quantity surveyor, consulting engineer and/or other professional consultant(s) shall be borne by the Sub-lessee. |
15.4 | Upon the termination of this agreement for any reason whatever the Sub-lessee shall have no claim of whatever nature against the Sub-lessor for the value and/or cost of any improvements effected to the leased premises and/or the buildings, whether or not such improvements were effected at the cost of the Sub-lessee, and the Sub-lessor shall be deemed to have become the owner of such improvements upon the installation thereof. |
15.5 | The Sub-lessee shall be entitled from time to time without the Sub-lessor’s consent, to erect on the buildings such fixtures and fittings as may be required or necessary for the carrying on of the permitted business therein, provided that should this agreement be terminated for any reason whatever - |
15.5.1 | all such fixtures and fittings erected by the Sub-lessee in the buildings shall, only if the Sub-lessee elects, be removed by the Sub-lessee upon the termination of this agreement, failing which such fixtures and fittings shall become the Sub-lessor’s property; |
10
15.5.2 | any damage caused to the buildings as a result of any removal by the Sub-lessee of fixtures and fittings, in respect of which the Sub-lessee haselected to remove, shall be made good at the Sub-lessee’s expense; |
15.5.3 | the Sub-lessee shall not be entitled to any compensation from the Sub-lessor for any improvements made. |
16 SUB-LESSEE’S GENERAL OBLIGATIONS AND RESTRICTIONS
The Sub-lessee shall be-
16.1 | liable to repair and/or replace, at its cost, all damage of whatever nature caused to the buildings; |
16.2 | entitled to modify the electrical installations of the buildings on the basis that the Sub-lessee shall be liable for all costs of such modification/s; |
16.3 | responsible for ensuring the safety, safe use and maintenance of the electrical installations in the buildings. |
17 SUBLETTING
The Sub-lessee shall not-
17.1 | cede, assign, transfer, alienate, hypothecate or otherwise dispose of any rights and/or obligations under this agreement; and/or |
17.2 | sub-let the leased premises or any part thereof; and/or |
17.3 | give up occupation or possession of the leased premises or any part thereof, to any person; |
without the Sub-lessor’s prior written consent, which consent shall not be unreasonablywithheld or delayed.
18 RIGHT OF FIRST REFUSAL
18.1 | The Sub-lessor hereby agrees that should it wish to sell any of the properties and/or any portion thereof and/or any right in and to any such properties held by the Sub-lessor (collectively “the sale property”), the Sub-lessor shall be obliged to first offer the sale property for sale to the Sub-lessee upon the following terms and conditions - |
18.1.1 | the offer shall be made in writing to the Sub-lessee and shall contain the price which the Sub-lessor requires for the sale property and all other terms and conditions upon which the Sub-lessor is prepared to sell the sale property(“the offer”); |
18.1.2 | the Sub-lessee shall be afforded 30 days from receipt of the offer to accept the offer by furnishing the Sub-lessor with a written acceptance to that effect. Should the Sub-lessee accept the offer as aforesaid, the Sub-lessee shall be obliged to furnish the Sub-lessor, within 45 days of such written acceptance, |
11
with a guarantee/s issued by a registered bank or financial institution, which guarantee/s shall secure payment of the purchase price of the sale property and shall be in such form as may be reasonably approved by the Sub-lessor and be expressed to be payable free of exchange by electronic transfer in favour of the Sub-lessor or the Sub-lessor’s nominee on the date of transferof the sale property to the Sub-lessee;
18.1.3 | should the Sub-lessee refuse or fail to accept the offer timeously, the Sub-lessor shall be entitled forthwith upon the date of expiry of the offer period or the date of such refusal, whichever is the earlier, to sell the sale property to any bona fide third party, provided that such sale shall be at a price not less than and on terms and conditions no less onerous than the price and terms and conditions contained in the offer to the Sub-lessee. |
18.2 | The Sub-lessee hereby acknowledges and agrees that the Sub-lessee’s right of first refusal as set out in shall automatically terminate and cease to be of any force or effect should this agreement be cancelled for any reason whatever. |
18.3 | The Sub-lessor agrees that it shall only be entitled to sell the sale property to another party as envisaged in terms of clause 18.1.3, if such purchaser agrees in writing, in favour of the Sub-lessee, to be bound by the provisions of this agreement. |
19 | WARRANTIES |
19.1 | The Sub-lessor gives the Sub-lessee the warranties in (“the warranties”) on the basisthat this agreement is entered into by the Sub-lessee relying on the warranties, each of which is deemed to be a material warranty inducing the Sub-lessee to enter into this agreement. |
19.2 | Each warranty shall be a separate warranty and shall in no way be limited to or restricted by reference to or by inference from the terms of any other warranty. |
19.3 | The Sub-lessor warrants to the Sub-lessee that - |
19.3.1 | it has the lawful right to occupy the properties; |
19.3.2 | it is not precluded in any way from entering into this agreement and giving the Sub-lessee the rights granted to the Sub-lessee in terms of this agreement; |
19.3.3 | no other person has the right to occupy the properties; |
19.3.4 | no person has any pre-emptive right, right of first refusal, option or other right of any nature whatever to buy any of the properties; and |
19.3.5 | the properties are unencumbered. |
19.4 | It is agreed that, the Sub-lessee shall be entitled, without prejudice to its other rights in law or in terms hereof, to cancel this agreement as a consequence of any breach by the Sub-lessor of any of the warranties. |
12
20 | BREACH |
Save as otherwise provided herein should the -
20.1 | Sub-lessee commit a breach of any provision of this agreement and fail to remedy such breach within 14 days after receiving written notice from the Sub-lessor requiring the Sub-lessee to remedy such breach, then the Sub-lessor shall be entitled, without prejudice to the Sub-lessor’s other rights in law, to cancel this agreement, or to claim immediate specific performance of all of the Sub-lessee’s obligations then due for performance, in either event without prejudice to the Sub-lessor’s right to claim damages; or |
20.2 | Sub-lessor commit a breach of any provision of this agreement and fail to remedy such breach within 14 days after receiving written notice from the Sub-lessee requiring the Sub-lessor to remedy such breach, then the Sub-lessee shall be entitled, without prejudice to its other rights in law, to cancel this agreement or to claim immediate specific performance of all of the Sub-lessor’s obligations then due for performance, in either event without prejudice to the Sub-lessee’s right to claim damages. |
21 | DOMICILIA AND NOTICES |
21.1 | The parties choose domicilium citandi et executandi for all purposes of the giving ofany notice, the payment of any sum, the serving of any process and for any other purpose arising from this agreement, as follows - |
21.2 | Each of the parties shall be entitled from time to time, by written notice to the others, to vary its domicilium to any other physical address within Lesotho. |
21.3 | Any notice given and any payment made by any party to any other which is delivered by hand during the normal business hours of the addressee at the addressee’s domicilium for the time being shall be presumed to have been received by the addressee at the time of delivery. |
21.4 | Notwithstanding anything to the contrary contained in this clause written notice or other communication actually received by a party shall be adequate written notice or communication to it notwithstanding that the notice was not sent or delivered to itschosen address or electronic mail address. |
22 | APPLICABLE LAW |
This agreement (including its validity, existence and implementation, the interpretation and application of its provisions, the respective rights and obligations of the parties in terms of and arising out of the conclusion, and termination of the provisions of this agreement), shall be interpreted and governed in all respects by the laws of The Kingdom of Lesotho.
13
23 | JURISDICTION |
Save as otherwise provided herein, the parties hereby consent to the non-exclusive jurisdiction of the Courts of The Kingdom Lesotho Commercial Division in respect of any action or legal proceedings which may arise out of or in connection with this agreement, its interpretation, validity or termination.
24 | ARBITRATION |
24.1 | Save for those provisions in this agreement which provide for their own remedies and for the purposes of this a “dispute” shall mean any dispute which arises between the parties in connection with - |
24.1.1 | the formation or existence; |
24.1.2 | the implementation; |
24.1.3 | the interpretation or application of the provisions; |
24.1.4 | the parties’ respective rights and obligations in terms of or arising out of theconclusion, breach or termination; |
24.1.5 | the validity, enforceability, rectification, termination or cancellation, whetherin whole or in part; |
24.1.6 | any documents furnished by the parties pursuant to the provisions, |
of this agreement or which relates in any way to any matter affecting the interests of the parties in terms of this agreement. The parties agree that any dispute shall, unless resolved amongst the parties to the dispute, be referred to and be determined by arbitration.
24.2 | The parties hereby consent to the arbitration being dealt with in terms of the laws of The Kingdom of Lesotho. |
24.3 | Any party to this agreement may demand that a dispute be determined in terms of this clause 24 by written notice given to the other parties. |
24.4 | This clause 24 shall not preclude any party from obtaining interim relief by way of motion proceedings (including on an urgent basis) from a court of law pending the decision of the arbitrator. |
24.5 | Only the parties and their representatives (including legal representatives) shall be entitled to attend the arbitration hearing. |
24.6 | The parties agree to keep the arbitration including the subject-matter of the arbitration and the evidence heard during the arbitration confidential and not to disclose it to anyone except for purposes of a court order to be made in terms of clause 24.4. |
24.7 | The award of the arbitrator shall be final and binding on the parties to the dispute and may be made an order of the court at the instance of any of the parties to the dispute. |
14
The parties agree that as between them the arbitral award shall be final and bindingand have the effect of a court order.
24.8 | Any arbitral award shall not be subject to a right of appeal. |
24.9 | The provisions of this clause - |
24.9.1 | constitute an irrevocable consent by the parties to any proceedings in terms hereof and no party shall be entitled to withdraw therefrom or claim at any such proceedings that it is not bound by such provisions; and |
24.9.2 | are severable from the rest of this agreement and shall remain in effect despite the termination of or invalidity for any reason of this agreement. |
24.10 | The parties agree that the written demand by any party in terms of that the dispute be submitted to arbitration, shall be deemed to be a legal process for the purpose ofinterruption of extinctive prescription in terms of the Prescription Act of Lesotho |
25 | COSTS |
Each party shall pay its own costs and charges in connection with and incidental to the negotiation, drafting and execution of this agreement.
26 | GENERAL |
26.1 | This document constitutes the sole record of the agreement between the parties inrelation to the subject matter hereof. |
26.2 | Neither party shall be bound by any representation, warranty, promise or the like not recorded herein. |
26.3 | No addition to, variation, or agreed cancellation of this agreement shall be of any force or effect unless recorded in a written document and signed by or on behalf of the parties. |
26.4 | No indulgence which either party (“the grantor”) may grant to the other (“the grantee”) shall constitute a waiver of any of the rights of the grantor, who shall not thereby be precluded from exercising any rights against the grantee which may have arisen in the past or which might arise in the future. |
26.5 | The parties shall at all times act in good faith towards each other and shall not bringany of the other parties into disrepute. |
26.6 | Each of the parties undertakes at all times to do all such things, perform all such acts and take all such steps and to procure the doing of all such things, within his/her power and control, as may be open to and is necessary for and incidental to the putting into effect or maintenance of the terms, conditions and import of this agreement. |
15
THUS DONE AND SIGNED AT MAKHEMENG, TSAKHOLO ON THIS 20
AS WITNESSES
1 | /s/ [ILLEGIBLE] | ||
/s/ [ILLEGIBLE] | |||
2 | /s/ [ILLEGIBLE] | SUB- LESSOR |
THUS DONE AND SIGNED AT MASERU ON THIS day of 2018
AS WITNESSES
1 | /s/ [ILLEGIBLE] | /s/ [ILLEGIBLE] | |
2 | /s/ [ILLEGIBLE] | SUB-LESSEE |
ANNEX A
AS PER BELOW REGISTERED SUB LEASE
04412-10001
07-03-2019
LEASE
under
The Land Act
2010
Land Administration Authority
P.O. Box 11856
MASERU 100
Lesotho
Lease Number: 04412-10001
LEASE
(In terms of The Land Act 2010)
TO WHOM IT MAY CONCERN
THAT: MOPHUTHI MATSOSO DEVELOPMENT TRUST – REGISTERED UNDER
DEEDS REGISTRY ACT 1967
OF: SEA POINT
MASERU
Hereinafter referred to as the Lessee, has been granted, accepts and holds title in land known as:
Plot Number: 04412-10001
Situated at: METSI MAHOLO MAFETENG DISTRICT
Approximate area: 68834 Square metres more or less
As shown on plan number 04412 as held by the Chief Surveyor.
Under a Lease issued by the Land Administration Authority pursuant to the Land Administration Authority Act 2010 and the Land Act 2010, on behalf of and with the authority of:
HIS MAJESTY THE KING
Subject to the statutory conditions as prescribed in the Land Regulations and any and all of the following terms and special conditions and general provisions:
1. | Ground rent: |
1.01 | Annual ground rent shall mean M16 520.16 per year or such other amount as may be reassessed. |
2. | Duration: |
2.01 | This lease shall come into operation on the 20 February 2019 and shall expire at the end of a sixty (60) Year term on 19 February 2079 |
Land Administration Authority | Page 1 of 4 | PO Box 11856, Maseru 100, Lesotho |
3. Special conditions:
3.1 The permitted use in respect of which this lease is granted or issued is: COMMERCIAL
3.2 Other special conditions:
4. General provisions
4.1 | That this title is inheritable subject to the provisions of Section 35 of the Act and any other law which may be applicable. |
4.2 | That this lease shall only be terminated by: |
(i) the expiry of its period; or | |
(ii) the surrender thereof under the provisions of Section 35; or | |
(iii)its determination pursuant to the provisions of the Act. |
4.3 | The Act shall mean the Land Act 2010 and all regulations made there under. |
4.04 | This lease shall be governed by revisions of the Act and all Acts and Regulations now or hereafter applicable to the land. |
Thus done, granted and executed on this 20 February 2019 at Maseru.
/s/ [ILLEGIBLE] | /s/ [ILLEGIBLE] | ||
Director General | Lessee | (signature) | |
Land Administration Authority |
/s/ [ILLEGIBLE] | |||
Witness | (signature) | ||
Name: | Papali Tsunyane |
Where the lessee is legal entity the capacity of the signatory is: representative in exercise of the powers conferred on him/her by a Power of Attorney No - / resolution of the Board of Directors of the Lessee / - dated the 20th day of February 2019 a certified copy of which is attached hereto.
Seal affixed in the presence of the witness.
Lease number: 04412-10001
Registration number: 04412-10001
Registration date: 07-03-2019
Registration fee: M 100.00
Stamp duty: M 360.00
Land Administration Authority | Page 3 of 4 | PO Box 11856, Maseru 100, Lesotho |
Land Regulations 2011 | Regulation 10 |
Statutory conditions
1. | Unless the Minister directs otherwise the Lessee shall fence the boundaries of the land within 6 (six) months of the date of the grant and the Lessee shall maintain the fence to the satisfaction of the Director General. |
2. | Unless special written authority is given by the Commissioner of Lands, the Lessee shall commence development of the land within 5 years of the date of the granting of a lease. This shall also apply to further development of the land held under a lease during the term of the lease. |
3. | Within a period of the time to be fixed by the planning authority, the Lessee shall provide at his own expense main drainage or main sewerage connections from the building erected on the land as the planning authority may require. |
4. | In the event of any main building erected on the land being dismantled, destroyed, demolished or removed, the Lessee shall replace the building within a period specified by the planning authority and sub-regulations (2) and (3) of the Land Regulations 2011 shall apply where applicable. |
5. | The Lessee shall use the land comprised in the lease only for the purpose specified in the lease or in any variation made to the original lease. |
6. | The Lessee shall permit entry on land at any reasonable period of the day by any duly empowered employee, officer or agent of the: |
(i)Land Administration Authority;
(ii)Government of Lesotho; or
(iii)any statutory corporation or parastatal organisation established to provide and maintain public utility services.
7. | Save with the written authority of the planning authority, no electrical power or telephone pole or line or water, drainage or sewer pipe being upon or passing through, over or under the land and no replacement thereof, shall be moved or in any way be interfered with and reasonable access thereto shall be preserved to allow for inspection, maintenance, repair, renewal and replacement. |
8. | Full right and liberty reserved unto the Government of Lesotho freely to exercise or have, or unto the Minister to grant to a statutory corporation or parastatal organisation, the right freely to exercise or have a public servitude over the land for the purpose of providing and maintaining public utility services and more particularly for the purpose of erecting telephone or electric power poles, installing electric or telephone wires and cables, laying down drains, sewers or water pipes and maintaining the same. |
9. | The interior and exterior of any building erected on the land and all building additions thereto and all other buildings at any time erected or standing on the land and walls, drains and other appurtenances, shall be kept by the Lessee in good repair and tenantable condition to the satisfaction of the planning authority. |
10. | No act, matter or thing, whatever, shall be done or permitted to be done upon the land or any part of such land which may cause or lead to pollution of the environment or result in the creation of any hazard to the health of other persons, or become a nuisance or annoyance to or damage or in any way interfere with the peace and comfort of adjoining Lessees or the occupiers of adjoining or other land in the neighbourhood. |
11. | The Lessee shall not subdivide the land or part with the possession of any part thereof without the written prior approval of the planning authority. |
12. | A Lessee shall, unless exempted under Section 77(1) or qualifies under Section 77(5), pay a prescribed annual ground rent in advance not later than the 31st day of March in each year provided that on execution of the lease, the Lessee shall pay any ground rent due for the period ending the 31st day of March which shall be calculated as follows: |
(i)where the lease begins to subsist on any day in the month of April in any calendar year, one whole year’s rent;
(ii)in any other case, one whole year’s rent less one- twelfth thereof for each complete month of that rental year that has elapsed prior to the date of the grant.
13. | Annual ground rent reserved in the lease shall be subject to revision every three (3) years of the term of the lease and consequent upon any revision, the amount shall be fair and reasonable having regard to general values and no account shall be taken of any improvements made by the Lessee to or on the land subsequent to the date of such revision. |
14. | Upon application by the Lessee made not later than 6 (six) months before expiry of the term of the lease the Lessee shall be entitled to the grant of a new lease of the land on terms set by the Director General provided the land or part thereof is not required for any public purpose. |
14. | Upon application by the Lessee made not later than 6 (six) months before expiry of the term of the lease the Lessee shall be entitled to the grant of a new lease of the land on terms set by the Director General provided the land or part thereof is not required for any public purpose. |
Land Administration Authority | Page 4 of 4 | PO Box 11856, Maseru 100, Lesotho |
Exhibit 10.3
DATED: 29 September 2020
LOUISA MADIAKO MOJELA
(‘the Lender”)
AND
BOPHELO BIO SCIENCE & WELLNESS PTY LTD
(“the Borrower”)
LOAN AGREEMENT | ||
1
This loan agreement dated the 28th September 2020 is made between the following parties:
1. | Louisa Madiako Mojela, an individual of legal age, holder of a South African Passport bearing the number M00181072 and residing at 2 & 3 West Road, South Estate, Farringdon street, Morningside, West Road South, Morningside 2146, South Africa (Lender) and |
2. | Bophelo Bio Science and Wellness Pty Ltd, a company incorporated and registered in the Kingdom of Lesotho with registration number 62924 whose registered office is at Ts’Akholo, Mafeteng 900, Lesotho (Borrower). |
Background
The Lender has agreed to provide the Borrower with a short term facility in an aggregate amount of upto ZAR 2,000,000 (two million rands) which shall be provided either in one lumpsum amount or in parts in accordance with the terms of this agreement.
Now it is agreed as follows:
1. | Definitions & Interpretations |
1.1 | The definitions and rules of interpretation in this clause apply in this agreement. |
Business day | a day (other than Saturday or a Sunday) on which financial institutions are open for general business in South Africa and the Kingdom of Lesotho; |
Loan | means the principal amount of the loan made or to be made by the lender to the borrower under this agreement or the principal amount outstanding for the time being of that loan; |
Total Facility amount | means the maximum principal amount of the facility referred to in clause 2; |
ZAR | means the lawful currency of South Africa. |
1.2 | Clauses, schedules and paragraph headings shall not affect the interpretation of this agreement. |
1.3 | A reference to this agreement (or any provision of it) or any other document shall be construed as a reference to this agreement, that provision or that document as it is in force for the time being and as amended, varied or supplemented from time to time in accordance with its terms or with the agreement of the relevant parties. |
1.4 | A reference to a person shall include a reference to an individual, firm, company, corporation, unincorporated body of persons, or any state or any agency of any person. |
2
1.5 | A reference to a statute, statutory provision or subordinate legislation is a reference to it as it is in force for the time being, taking into account of any amendment, extension or re-enactment and includes any former statute, statutory provision or subordinate legislation which it amends or re-enacts. |
1.6 | A reference to writing or written includes fax and email. |
1.7 | Unless the context otherwise requires, a reference to one gender shall include a reference to the other genders. |
1.8 | Unless the context otherwise requires, words in the singular include the plural and, in the plural, include the singular. |
1.9 | A reference to an amendment includes a novation, re-enactment, supplement or variation (and amended shall be construed accordingly). |
1.10 | A reference to the Borrower and the Lender shall include their respective successors, permitted transferees and permitted assigns. |
1.11 | A reference to continuing in relation to an Event of Default means an Event of Default which has not been remedied or waived. |
2. | The Facility |
The Lender grants to the Borrower a ZAR short term loan facility of a total principal amount not exceeding ZAR 2,000,000.00 (two million rands only) on the terms, and subject to the conditions, of this Agreement.
3. | Drawing |
Subject to clause 7, the Borrower may utilise the Loan in a single amount on any Business Day during the term of the Loan or may utilize it in parts as and when faced with a cash crunch. To do this, the Borrower should provide the Lender with at least one (1) Business Day’s prior notice of the date on which the Borrower intends to draw down the Loan, specifying the amount of the Loan, the Business Day on which it is to be made and the bank account to which payment is to be made. The amount of the Loan shall not exceed the Total Facility Amount.
4. | Repayment |
The Borrower shall repay the loan in full within 30 days of the payment being received by the borrower including the interest for the period of the loan.
5. | Interest |
The Lender shall charge interest at the prevailing bank interest rate in South Africa.
3
6. | Entire Agreement |
Except as otherwise provided for in this Agreement, this Agreement constitutes the entire understanding of the rights and obligations of the Lender and the Borrower with respect to the subject matter hereof. This Agreement may not be modified or amended except by a written agreement signed by the parties.
7. | Notices |
All notices required or permitted by this Agreement shall be in writing and delivered by hand or sent by prepaid post to:
Lender: | Louisa Madiako Mojela |
Address: | 2 & 3 West Road South Estate, Farringdon Street, Morningside, West Road, South Morning Side 2146, South Africa |
Borrower: | Bophelo Bio Science and Wellness Pty Ltd |
Address: | Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng, Lesotho 900 |
or at such other address of which the addressee may from time to time have notified the addressor. A notice shall be deemed to have been sent and received on the day, if it is delivered by hand, or, if it is sent by prepaid post, at the expiration of 72 hours after the same was posted, or on the day on which transmission is confirmed, if sent by facsimile transmission. If such day is not a Business Day or if the notice is received after ordinary office hours (time of place of receipt), the notice shall be deemed to have been sent and received on the next Business Day. In proving service by post of any such notice it shall be sufficient to prove that the envelope containing the same was properly addressed stamped and posted.
8. | Remedies, Waivers, Amendments & Consents |
8.1 | Any amendment to this Agreement shall be in writing and signed by, or on behalf of, each party. |
8.2 | No waiver of any provision of this Agreement shall be binding unless it is in writing. |
8.3 | No indulgence or forbearance by a party shall constitute a waiver of such party’s right to insist on performance in full and in a timely manner of all covenants in this Agreement. Waiver of any provision shall not be deemed to waive the same provision thereafter, or any other provision of this Agreement at any time. |
4
9. | Severance |
If any provision of this Agreement is invalid or unenforceable, such provision shall be severed and the remainder of this Agreement shall be unaffected thereby and shall continue to be valid and enforceable to the fullest extent permitted by law.
10. | Assiqnment & Transfer |
Neither party may assign or transfer any of its rights or obligations under this Agreement without the prior written agreement of the other party.
11. | Counterparts |
This Agreement may be executed in any number of counterparts, each of which is an original and which, together, have the same effect as if each party had signed the same document.
12. | Governing Law and Jurisdiction |
This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws of South Africa and is irrevocably agreed by the parties to this agreement.
This agreement has been entered into on the date stated at the beginning of it.
Executed by Louisa Madiako Mojela
/s/ [ILLEGIBLE] | |
Executed by |
/s/ [ILLEGIBLE] | |
Director |
On behalf of Bophelo Bio Science and Wellness Pty Ltd
5
Exhibit 10.4
Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. This information is not material and disclosure of such information would constitute an unwarranted invasion of personal privacy. “[*]” indicates that information has been redacted.
AKANDA CORP.
UP TO $10,000,000 (or 4,000,000 SHARES) of COMMON SHARES
Investor Package dated as of August 26, 2021
This Investor Package (the “Investor Package”) contains the documents listed below in connection with an offering by Akanda Corp., a Province of Ontario, Canada corporation (“we” or the “Company”), of up to $10,000,000, or 4,000,000 shares of the Company’s common shares (the “Shares”). The offering of the Shares is known as the “Offering.”
The Shares under this Offering will only be offered and sold to “accredited investors” (“Accredited Investors”), as that term is defined in Rule 501(a) of Regulation D promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) or, as defined under applicable Canadian laws, pursuant to Section 4(a)(2) of the Securities Act, Rule 506(b) of Regulation D promulgated thereunder, Regulation S promulgated thereunder and applicable foreign or state laws. The price of the Shares has been determined by us and such price does not necessarily bear any relation to the book value or other recognized criteria of value of the Company.
The Offering will commence on the date of this Investor Package and continue until the earlier of the sale of all 4,000,000 Shares or September 30, 2021, unless extended by the Company in its sole discretion.
The Company was only recently incorporated, has not commenced commercial operations and has no assets other than cash. The Company expects to acquire all the issued and outstanding equity interests of Canmart Limited, Bophelo Bio Science and Wellness (Pty) Ltd., Bophelo Holdings Limited and Cannahealth Limited from Halo Collective Inc. immediately prior to the closing of this Offering. See “The Proposed Acquisition” in the Business Summary of the Company on Exhibit B for more detailed information. The closing of the Offering will be subject to the completion of this acquisition.
Under our engagement letter with Boustead, originally entered into on June 17, 2021 (the “Engagement Letter”), Boustead has been engaged as our exclusive financial advisor for an initial 12 month term, which may be extended pursuant to the Engagement Letter, in connection with the Company’s intention to pursue corporate finance activities including private placements. The Shares are being offered in this Offering by Boustead Securities, LLC (“Boustead”) which will be paid a commission of 7% of the gross proceeds from the sale of Common Shares sold in the Offering and an additional non-accountable expense allowance of 1% of the gross proceeds from the sale of Common Shares in the Offering.
This Investor Package consists of (a) Subscription Agreement to be executed by the Company and each subscriber to the Shares, and an Investor Representation and Suitability Questionnaire to be completed by each subscriber to the Shares1, (b) Exhibit A – Terms of the Offering, (c) Exhibit B – Business Summary of the Company, (d) Exhibit C – Risk Factors to be considered by potential subscribers to the Shares, (d) Exhibit D – Company Investor Presentation, (e) Exhibit E – a Lock-Up Agreement to be executed by each subscriber to the Shares (collectively, the “Offering Documents”).
1 Investors other than Canadian Investors shall complete the “Investor Representation and Suitability Questionnaire (for non-Canadian Subscribers)”. Canadian investors shall complete the “Investor Representation and Suitability Questionnaire (for Canadian Subscribers)”.
1
SUBSCRIPTION PROCEDURE (FOR NON-CANADIAN SUBSCRIBERS):
To subscribe to purchase the Shares, an investor must pay the applicable subscription price and email a duly executed Subscription Agreement and a completed and duly executed Investor Representation and Suitability Questionnaire to offerings@boustead1828.com.
Alternatively, investors may mail or deliver a duly executed Subscription Agreement and a completed and duly executed Investor Representation and Suitability Questionnaire to:
Sutter Securities Clearing, LLC
6 Venture, Suite 395
Irvine, CA 92618
For: Akanda Corp.
The subscription price may be paid by wire transfer as follows:
Bank Name: | [*] |
Bank Address: | [*] |
SWIFT Code: | [*] |
Routing #: | [*] |
Account Name: | [*] |
Account #: | [*] |
REF / Notes: | Akanda Corp. – [Investor Name] |
Subscription Agreement and Investor Representation and Suitability Questionnaire
Exhibit A - Term Sheet
Exhibit B - Business Summary
Exhibit C - Risk Factors
Exhibit D - Akanda Corp. Investor Presentation
Exhibit E - Lockup Agreement
2
SUBSCRIPTION PROCEDURE (FOR CANADIAN SUBSCRIBERS):
(Attached under separate cover)
3
IMPORTANT INVESTOR NOTICES
NO OFFERING LITERATURE OR ADVERTISEMENT IN ANY FORM MAY BE RELIED UPON IN THE OFFERING OF THE SHARES EXCEPT FOR THIS INVESTOR PACKAGE AND ANY EXHIBITS AND SUPPLEMENTS HERETO, AND NO PERSON HAS BEEN AUTHORIZED TO MAKE ANY REPRESENTATIONS EXCEPT THOSE CONTAINED HEREIN.
THIS INVESTOR PACKAGE IS CONFIDENTIAL AND THE CONTENTS HEREOF MAY NOT BE REPRODUCED, DISTRIBUTED OR DIVULGED BY OR TO ANY PERSONS OTHER THAN THE RECIPIENT OR ITS REPRESENTATIVE, ACCOUNTANT OR LEGAL COUNSEL, WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY. EACH PERSON WHO ACCEPTS DELIVERY OF THIS INVESTOR PACKAGE, ACKNOWLEDGES AND AGREES TO THE FOREGOING RESTRICTIONS.
THIS INVESTOR PACKAGE DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION THAT YOU MAY DESIRE IN EVALUATING THE COMPANY, OR AN INVESTMENT IN THE OFFERING. THIS INVESTOR PACKAGE DOES NOT CONTAIN ALL OF THE INFORMATION THAT WOULD NORMALLY APPEAR IN A PROSPECTUS FOR AN OFFERING REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR CANADIAN SECURITIES LAWS. YOU MUST CONDUCT AND RELY ON YOUR OWN EVALUATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, IN DECIDING WHETHER TO INVEST IN THE OFFERING.
THIS INVESTOR PACKAGE DOES NOT CONSTITUTE AN OFFER OR SOLICITATION OF AN OFFER TO ANY PERSON OR IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION IS UNLAWFUL OR NOT AUTHORIZED. EACH PERSON WHO ACCEPTS DELIVERY OF THIS INVESTOR PACKAGE AGREES TO DELETE OR OTHERWISE DESTROY IT AND ALL RELATED DOCUMENTS IF SUCH PERSON DOES NOT PURCHASE ANY OF THE SECURITIES DESCRIBED HEREIN.
NEITHER THE DELIVERY OF THIS INVESTOR PACKAGE AT ANY TIME NOR ANY SALE OF SECURITIES HEREUNDER SHALL IMPLY THAT INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE. THE COMPANY WILL EXTEND TO EACH PROSPECTIVE INVESTOR (AND TO ITS REPRESENTATIVE, ACCOUNTANT OR LEGAL COUNSEL, IF ANY) THE OPPORTUNITY, PRIOR TO ITS PURCHASE OF SECURITIES, TO ASK QUESTIONS OF AND RECEIVE ANSWERS FROM THE COMPANY CONCERNING THE OFFERING AND TO OBTAIN ADDITIONAL INFORMATION, TO THE EXTENT THE COMPANY POSSESSES THE SAME OR CAN ACQUIRE IT WITHOUT UNREASONABLE EFFORT OR EXPENSE, IN ORDER TO VERIFY THE ACCURACY OF THE INFORMATION SET FORTH HEREIN. ALL SUCH ADDITIONAL INFORMATION SHALL ONLY BE PROVIDED IN WRITING AND IDENTIFIED AS SUCH BY THE COMPANY THROUGH ITS DULY AUTHORIZED OFFICERS AND/OR DIRECTORS ALONE; NO ORAL INFORMATION OR INFORMATION PROVIDED BY ANY BROKER OR THIRD PARTY MAY BE RELIED UPON.
NO REPRESENTATIONS, WARRANTIES OR ASSURANCES OF ANY KIND ARE MADE OR SHOULD BE INFERRED WITH RESPECT TO THE ECONOMIC RETURN, IF ANY, THAT MAY ACCRUE TO AN INVESTOR IN THE COMPANY. THIS INVESTOR PACKAGE CONTAINS FORWARD-LOOKING STATEMENTS REGARDING THE COMPANY’S PERFORMANCE, STRATEGY, PLANS, OBJECTIVES, EXPECTATIONS, BELIEFS AND INTENTIONS. THE OUTCOME OF THE EVENTS DESCRIBED IN THESE FORWARD-LOOKING STATEMENTS IS SUBJECT TO SUBSTANTIAL RISKS, AND ACTUAL RESULTS COULD DIFFER MATERIALLY.
THE OFFERING PRICE OF THE SECURITIES HAS BEEN DETERMINED ARBITRARILY. THE PRICE OF THE SECURITIES DOES NOT NECESSARILY BEAR ANY RELATIONSHIP TO THE ASSETS, EARNINGS OR BOOK VALUE OF THE COMPANY, OR TO POTENTIAL ASSETS, EARNINGS, OR BOOK VALUE OF THE COMPANY. THE PRICE OF COMMON SHARES MAY BE IMPACTED BY A LACK OF LIQUIDITY OR AVAILABILITY OF COMMON SHARES FOR PUBLIC SALE AND ALSO WILL NOT NECESSARILY BEAR ANY RELATIONSHIP TO THE ASSETS, EARNINGS, BOOK VALUE OR POTENTIAL PROSPECTS OF THE COMPANY OR APPLICABLE QUOTED OR TRADING PRICES THAT MAY EXIST FOLLOWING REGISTRATION OR THE LAPSE OF RESTRICTIONS ON THE SECURITIES SOLD PURSUANT TO THE OFFERING OR OTHER RESTRICTIONS. SUCH PRICES SHOULD NOT BE CONSIDERED ACCURATE INDICATORS OF FUTURE QUOTED OR TRADING PRICES THAT MAY SUBSEQUENTLY EXIST FOLLOWING THE OFFERING.
4
THIS OFFERING IS MADE AS A PRIVATE PLACEMENT PURSUANT TO APPLICABLE Canadian Securities laws, SECTION 4(A)(2) OF THE SECURITIES ACT AND RULE 506(B) OF REGULATION D PROMULGATED THEREUNDER, AND ONLY TO PARTIES THAT ARE “ACCREDITED INVESTORS” AS DEFINED under canadian securities laws AND IN RULE 501(A) OF REGULATION D UNDER THE SECURITIES ACT, as applicable. OUTSIDE THE UNITED STATES and canada, THIS OFFERING IS ALSO MADE PURSUANT TO REGULATION S UNDER THE SECURITIES ACT ONLY TO PARTIES THAT ARE NOT “U.S. PERSONS” AS DEFINED IN SUCH REGULATION, AND PURSUANT TO EXEMPTIONS FROM APPLICABLE SECURITIES LAWS OF OTHER COUNTRIES (THE “FOREIGN SECURITIES LAWS”).
THIS OFFERING IS MADE IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND FOREIGN SECURITIES LAWS AS DESCRIBED ABOVE. the COMPANY WILL NOT BE OBLIGATED TO REGISTER THE SHARES UNDER THE SECURITIES ACT OR ANY FOREIGN SECURITIES LAWS IN THE FUTURE. ALL THE SHARES, WHETHER ACQUIRED WITHIN THE UNITED STATES OR OUTSIDE THE UNITED STATES, WILL BE “RESTRICTED SECURITIES” WITHIN THE MEANING OF RULE 144 UNDER THE SECURITIES ACT AND, THEREFORE, MAY NOT BE TRANSFERRED BY A HOLDER THEREOF WITHIN THE UNITED STATES OR TO A “U.S. PERSON” UNLESS SUCH TRANSFER IS MADE PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, PURSUANT TO AN EXEMPTION THEREFROM, OR IN A TRANSACTION OUTSIDE THE UNITED STATES PURSUANT TO THE RESALE PROVISIONS OF REGULATION S. MOREOVER, THE SHARES WILL BE SUBJECT TO LOCK-UP RESTRICTIONS SET FORTH IN THE OFFERING DOCUMENTS. HEDGING TRANSACTIONS INVOLVING THE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. YOU MAY BE REQUIRED TO BEAR INDEFINITELY THE FINANCIAL RISKS OF ANY INVESTMENT YOU MAKE IN THE SHARES.
this offering is made on a private placement basis in canada and there are restrictions with respect to trading in, and the restricted period or statutory hold period applicable to the Securities imposed by canadian securities legislation and regulations of, and the instruments, policies, rules, orders, codes, notices and interpretation notes of the Canadian securities regulatory authorities in each of the provinces AND TERRITORIES of Canada, as applicable.
THE COMPANY MAY REJECT ANY SUBSCRIPTION, IN WHOLE OR IN PART, IN ANY ORDER AND FOR ANY OR NO REASON, IN OUR SOLE DISCRETION. IN THE EVENT THAT THIS OFFERING IS OVER-SUBSCRIBED, THE COMPANY MAY REDUCE (OR REJECT) THE SUBSCRIPTIONS BASED ON EACH INVESTOR’S PRO RATA PARTICIPATION IN THIS OFFERING OR IN ANY OTHER MANNER THAT THE COMPANY TOGETHER WITH THE PLACEMENT AGENT MAY DETERMINE, OR THE COMPANY MAY INCREASE THE SIZE OF THE OFFERING.
THE SECURITIES OFFERED HEREBY HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THIS INVESTOR PACKAGE. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
PROSPECTIVE INVESTORS SHOULD NOT CONSTRUE THE CONTENTS OF THIS INVESTOR PACKAGE AS INVESTMENT, LEGAL, BUSINESS, OR TAX ADVICE. EACH INVESTOR SHOULD CONTACT HIS, HER OR ITS OWN ADVISORS REGARDING THE APPROPRIATENESS OF THIS INVESTMENT AND THE TAX CONSEQUENCES THEREOF, WHICH MAY DIFFER DEPENDING ON AN INVESTOR’S PARTICULAR FINANCIAL SITUATION. IN NO EVENT SHOULD THIS INVESTOR PACKAGE BE DEEMED OR CONSIDERED TO BE TAX ADVICE PROVIDED BY THE COMPANY.
5
THIS INVESTOR PACKAGE WAS PREPARED BY REPRESENTATIVES OF THE COMPANY. BOUSTEAD SECURITIES LLC, AND ITS OFFICERS, DIRECTORS, PARTNERS, SHAREHOLDERS, MANAGERS, MEMBERS AND EMPLOYEES, ACTING AS PLACEMENT AGENT, EXPRESSLY DISCLAIM ANY REPRESENTATION OR WARRANTY REGARDING INVOLVEMENT IN OR RESPONSIBILITY FOR ANY INFORMATION OR FORWARD-LOOKING STATEMENTS CONTAINED IN THIS MEMORANDUM. BOUSTEAD IS ACTING AS PLACEMENT AGENT FOR THE COMPANY, AND, IN THAT CAPACITY, IS NOT ACTING AS INVESTMENT ADVISOR TO PROSPECTIVE INVESTORS IN CONNECTION WITH THE SECURITIES BEING OFFERED IN THIS MEMORANDUM. PROSPECTIVE INVESTORS MUST MAKE THEIR OWN INVESTMENT DECISIONS. IN MAKING THOSE DECISIONS, PROSPECTIVE INVESTORS SHOULD BE AWARE THAT BOUSTEAD WILL RECEIVE A PLACEMENT FEE AND OTHER COMPENSATION AS DESCRIBED ELSEWHERE IN THIS INVESTOR PACKAGE.
CONFIDENTIALITY
By accepting delivery of this Investor Package, you acknowledge and agree that all of the information contained herein is of a confidential nature and that this Investor Package has been furnished to you for the sole purpose of enabling you to consider and evaluate an investment in the Shares. You agree that you will treat such information in a confidential manner, will not use such information for any purpose other than evaluating an investment in the Shares, and will not, directly or indirectly, disclose or permit your agents, representatives or affiliates to disclose any of such information without the prior written consent of the Company.
You also agree to make your agents, affiliates and representatives aware of the confidential nature of the information contained herein and the terms of this paragraph including your agreement to not disclose such information and to be responsible for any disclosure or other improper use of such information by such agents, affiliates or representatives. Likewise, without the prior written consent of the Company, you agree that you will not, directly or indirectly, make any statements, public announcements, or other release or provision of information in any form to any trade publication, to the press or to any other person or entity whose primary business is or includes the publication or dissemination of information related to the subject matter of this Investor Package. If you decide not to pursue further investigation or evaluation of the Company or to not participate in the Offering, you agree to promptly delete or otherwise destroy this Investor Package and any accompanying documentation (and all copies thereof).
6
THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR ANY OTHER APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS REGISTERED THEREUNDER OR UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.
THE SECURITIES TO BE ISSUED PURSUANT TO THIS AGREEMENT HAVE NOT BEEN QUALIFIED BY A PROSPECTUS IN CANADA AND THERE ARE RESTRICTIONS WITH RESPECT TO TRADING IN, AND THE RESTRICTED PERIOD OR STATUTORY HOLD PERIOD APPLICABLE TO THE SECURITIES IMPOSED BY CANADIAN SECURITIES LEGISLATION AND REGULATIONS OF, AND THE INSTRUMENTS, POLICIES, RULES, ORDERS, CODES, NOTICES AND INTERPRETATION NOTES OF THE CANADIAN SECURITIES REGULATORY AUTHORITIES IN EACH OF THE PROVINCES AND TERRITORIES OF CANADA, AS APPLICABLE.
SUBSCRIPTION AGREEMENT
Akanda Corp.
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, Ontario M5K 0A1
Ladies and Gentlemen:
Subscription. I (sometimes referred to herein as the “Investor” or “Subscriber”) hereby subscribe for and agree to purchase the Securities (as defined below) for the purchase price (the “Purchase Price”) set forth on the signature page hereto of Akanda Corp., a Province of Ontario, Canada corporation (the “Company”), on the terms and conditions described herein and in Exhibits A, B, C, D and E hereto (collectively, the “Offering Documents”). Terms not defined herein are as defined in the Offering Documents. The Company seeks to raise a minimum of $5,000,000 or, 2,000,000 shares (the “Minimum Offering Amount”) and maximum of $10,000,000 or 4,000,000 shares (the “Maximum Offering Amount”) in this Offering. The minimum amount of investment required from any one subscriber to participate in this Offering is $50,000 or 20,000 shares, subject to the Company’s discretion to access a smaller amount. All references to $ means United States dollars.
1. | Description of Securities; Description of Company and Risk Factors; Lock-Up. |
a. Description of Securities. The Company is offering (the “Offering”) to the Investor common shares of the Company (“Shares” or “Securities”) at a purchase price of $2.50 per share. For a more detailed description of the Securities see the Term Sheet attached as Exhibit A.
b. Risks Related to the Investment in the Securities. Investing in the Securities involves a high degree of risk. Before investing, Investors should carefully consider the description of our business and the risks related to our business, as set forth in Exhibits B and C and the investor deck set forth in Exhibit D, together with the other information contained in Offering Documents.
c. Lock-Up. In connection with this Offering, the Investor agrees to enter into the Lock-up Agreement attached as Exhibit E (the “Lock-up Agreement”) and be subject to the transfer restrictions set forth therein.
2. | Purchase. |
a. | I hereby agree to tender to Sutter Securities Clearing, LLC (the “Escrow Agent”), by certified check or wire transfer of immediately available funds (to the bank account and related wire instructions set forth on page 2 of this Investor Package) made payable to “Akanda Corp.” for such number of Shares indicated on the signature page hereto, an executed copy of this Subscription Agreement, an executed copy of my Investor Representation and Suitability Questionnaire2 (“Investor Questionnaire”) attached hereto and an executed copy of the Lock-up Agreement. Funds will be held in escrow, as set forth in more detail below (the “Escrow Account”), pending the Initial Closing. |
7
b. | This Offering will continue until the earlier of (a) the sale of 4,000,000 Shares for $10,000,000 of gross proceeds of the Maximum Offering Amount or (b) September 30, 2021, subject to extension or early termination by mutual agreement of the Company and the Placement Agent (either, the “Termination Date”). Upon the earlier of a Closing (defined below) on my subscription or completion of the Offering, I will be notified promptly by the Company as to whether my subscription has been accepted by the Company. |
3. | Acceptance or Rejection of Subscription. |
a. | I understand and agree that the Company reserves the right to reject this subscription for the Securities, in whole or in part, for any reason and at any time prior to the Closing (defined below) of my subscription. |
b. | In the event the Company rejects this subscription, my subscription payment will be promptly returned to me without interest or deduction and this Subscription Agreement shall be of no force or effect. In the event my subscription is accepted and the Offering is completed, the subscription funds submitted by me shall be released to the Company. |
4. Closing. The closing (“Closing”) of this Offering may occur at any time and from time to time on or before the Termination Date. The Company must achieve the Minimum Offering Amount and complete the proposed Acquisition described under “The Proposed Acquisition” in the Business Summary of the Company on Exhibit B (the “Acquisition”) prior to conducting an initial Closing (the “Initial Closing”). Upon receipt of the Minimum Offering Amount, an Initial Closing will be held and all funds will be released from the Escrow Account and paid to the Company, less professional fees and compensation paid to the Placement Agent and syndicate members. Thereafter additional Closings will be held as funds are received up to the earlier to occur of receipt of the $10,000,000 Maximum Offering Amount or the Termination Date. Pending receipt of the Minimum Offering Amount, all subscriptions will be placed in escrow with the Escrow Agent. If, for any reason, the Minimum Offering Amount of subscriptions are not received by the Termination Date, all escrowed funds will be returned to subscribers, without interest or deduction. The Securities subscribed for herein shall not be deemed issued to or owned by me until one copy of this Subscription Agreement has been executed by me and countersigned by the Company and the Closing with respect to such Securities has occurred.
5. Disclosure. The Shares under this Offering will only be offered and sold to “accredited investors”, as that term is defined in Rule 501(a) of Regulation D promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), or as defined under applicable Canadian law, and pursuant to Section 4(a)(2) of the Securities Act, Rule 506(b) of Regulation D promulgated thereunder, Regulation S promulgated thereunder and applicable foreign or state laws. The Securities are being sold without registration under the Securities Act or qualification by a prospectus under Canadian Securities Laws (as defined below). I acknowledge receipt of the Offering Documents and represent that I have carefully reviewed and understand the Offering Documents, including all exhibits attached hereto. I have received all information and materials regarding the Company that I have requested. I fully understand that each of the Company and the subsidiaries it contemplates acquiring under the Acquisition has a limited financial and operating history and that the Securities are speculative investments which involve a high degree of risk, including the potential loss of my entire investment. I fully understand the nature of the risks involved in purchasing the Securities and I am qualified to make such investment based on my knowledge of and experience in investing in securities of this type. I have carefully considered the potential risks relating to the Company and purchase of its Securities and have, in particular, reviewed each of the risks set forth in the Offering Documents including the those discussed on Exhibit C. Both my advisors and I have had the opportunity to ask questions of and receive answers from representatives of the Company or persons acting on its behalf concerning the Company and the terms and conditions of a proposed investment in the Company and my advisors and I have also had the opportunity to obtain additional information necessary to verify the accuracy of information furnished about the Company. Accordingly, I have independently evaluated the risks of purchasing the Securities.
2 Investors other than Canadian Investors shall complete the “Investor Representation and Suitability Questionnaire (for non-Canadian Subscribers)”. Canadian investors shall complete the “Investor Representation and Suitability Questionnaire (for Canadian Subscribers)”.
8
6. Investor Representations and Warranties. I acknowledge, represent and warrant to, and agree with, the Company as follows:
a. | I am aware that my investment involves a high degree of risk as disclosed in the Offering Documents and have read carefully the Offering Documents, and I understand that by signing this Subscription Agreement I am agreeing to be bound by all of the terms and conditions of the Offering Documents. |
b. | I acknowledge and am aware that there is no assurance as to the future performance of the Company. |
c. | I acknowledge that there may be certain adverse tax consequences to me in connection with my purchase of Securities, and the Company has advised me to seek the advice of experts in such areas prior to making this investment. |
d. | I am purchasing the Securities for my own account for investment purposes only and not with a view to or for sale in connection with the distribution of the Securities, nor with any present intention of selling or otherwise disposing of all or any part of the foregoing securities. I agree that I must bear the entire economic risk of my investment for an indefinite period of time because, among other reasons, the Securities have not been registered under the Securities Act or under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Securities Act and under applicable securities laws of certain states or an exemption from such registration is available. I hereby authorize the Company to place a restrictive legend on the Securities that are issued to me. |
e. | I recognize that the Securities, as an investment, involve a high degree of risk including, but not limited to, the risk of economic losses from operations of the Company and the total loss of my investment. I believe that the investment in the Securities is suitable for me based upon my investment objectives and financial needs, and I have adequate means for providing for my current financial needs and contingencies and have no need for liquidity with respect to my investment in the Company. |
f. | I have been given access to full and complete information regarding the Company and have utilized such access to my satisfaction for the purpose of obtaining information in addition to, or verifying information included in, the Offering Documents, and I have either met with or been given reasonable opportunity to meet with officers of the Company for the purpose of asking questions of, and receiving answers from, such officers concerning the terms and conditions of the offering of the Securities and the business and operations of the Company and to obtain any additional information, to the extent reasonably available. |
g. | I have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Securities and have obtained, in my judgment, sufficient information from the Company to evaluate the merits and risks of an investment in the Company. I have not utilized any person as my purchaser representative as defined in Regulation D under the Securities Act in connection with evaluating such merits and risks. |
h. | I have relied solely upon my own investigation in making a decision to invest in the Company. |
9
i. | I have received no representation or warranty from the Company or any of its officers, directors, employees or agents in respect of my investment in the Company and I have received no information (written or otherwise) from them relating to the Company or its business other than as set forth in the Offering Documents. I am not participating in the offer as a result of or subsequent to: (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio or (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising. |
j. | I have had full opportunity to ask questions and to receive satisfactory answers concerning the offering and other matters pertaining to my investment and all such questions have been answered to my full satisfaction. |
k. | I have been provided an opportunity to obtain any additional information concerning the offering and the Company and all other information to the extent the Company possesses such information or can acquire it without unreasonable effort or expense. |
l. | I am an “accredited investor” as defined in Section 2(15) of the Securities Act and in Rule 501(a) promulgated thereunder or under applicable Canadian law and have attached the applicable completed Investor Questionnaire to indicate my “accredited investor” status. I can bear the entire economic risk of the investment in the Securities for an indefinite period of time and I am knowledgeable about and experienced in making investments in the equity securities of non-publicly traded companies, including early stage companies. I am not acting as an underwriter or a conduit for sale to the public or to others of unregistered securities, directly or indirectly, on behalf of the Company or any person with respect to such securities. |
m. | I understand that (1) the Securities have not been registered under the Securities Act, or the securities laws of certain states, in reliance on specific exemptions from registration, (2) no securities administrator of any state or the federal government has recommended or endorsed this offering or made any finding or determination relating to the fairness of an investment in the Company, and (3) the Company is relying on my representations and agreements for the purpose of determining whether this transaction meets the requirements of certain exemptions from registration afforded by the Securities Act and certain state securities laws. |
n. | I understand that the sale of the Securities by the Company to me is conditional upon such sale being exempt from the requirements as to the filing of a prospectus and as to the preparation of an offering memorandum or similar document prescribed in any statute, regulation, instrument, rule or policy applicable to the sale of the Securities in any jurisdiction where the Securities are offered or upon the issue of such orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus or delivering an offering memorandum or similar document. |
o. | I understand that since neither the offer nor sale of the Securities has been registered under the Securities Act or the securities laws of any state, the Securities may not be sold, assigned, pledged or otherwise disposed of unless they are so registered or an exemption from such registration is available. |
p. | I have had the opportunity to seek independent advice from my professional advisors relating to the suitability of an investment in the Company in view of my overall financial needs and with respect to the legal and tax implications of such investment. |
q. | If the Investor is a corporation, company, trust, employee benefit plan, individual retirement account, Keogh Plan, or other tax-exempt entity, it is authorized and qualified to become an Investor in the Company and the person signing this Subscription Agreement on behalf of such entity has been duly authorized by such entity to do so. |
10
r. | To the extent the undersigned Subscriber is not a “U.S. Person,” as such term is defined in Rule 902(k) of Regulation S, the undersigned has initialed the following representation (please initial below if applicable) and made the following representations below: |
_____ The undersigned Subscriber is not a “U.S. Person,” as such term is defined in Rule 902(k) of Regulation S.3
i. | The undersigned is not acquiring the Securities for the account or benefit of a U.S. Person. |
ii. | If the undersigned is a legal entity, it has not been formed specifically for the purpose of investing in the Company. |
iii. | The undersigned hereby represents that he, she or it has satisfied and fully observed the laws of the jurisdiction in which he, she or it is located or domiciled, in connection with the acquisition of the Securities, including (i) the legal requirements of the undersigned’s jurisdiction for the acquisition of the Securities, (ii) any foreign exchange restrictions applicable to such acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, which may be relevant to the holding, redemption, sale, or transfer of the Securities; and further, the undersigned agrees to continue to comply with such laws as long as he, she or it shall hold the Securities. |
3 Regulation S provides in part as follows:
1. “U.S. person” means: (i) any natural person resident in the United States; (ii) any partnership or corporation organized or incorporated under the laws of the United States; (iii) any estate of which any executor or administrator is a U.S. person; (iv) any trust of which any trustee is a U.S. person; (v) any agency or branch of a foreign entity located in the United States; (vi) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (vii) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (viii) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act of 1933, as amended, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.
2. The following are not “U.S. persons”: (i) any discretionary account or similar account (other than an estate or trust) held for the benefit or account of a non-U.S. person by a dealer or other professional fiduciary organized, incorporated, or (if an individual) resident in the United States; (ii) any estate of which any professional fiduciary acting as executor or administrator is a U.S. person if: (A) an executor or administrator of the estate who is not a U.S. person has sole or shared investment discretion with respect to the assets of the estate; and (B) the estate is governed by foreign law; (iii) any trust of which any professional fiduciary acting as trustee is a U.S. person, if a trustee who is not a U.S. person has sole or shared investment discretion with respect to the trust assets, and no beneficiary of the trust (and no settlor if the trust is revocable) is a U.S. person; (iv) an employee benefit plan established and administered in accordance with the law of a country other than the United States and customary practices and documentation of such country; (v) any agency or branch of a U.S. person located outside the United States if: (A) the agency or branch operates for valid business reasons; and (B) the agency or branch is engaged in the business of insurance or banking and is subject to substantive insurance or banking regulation, respectively, in the jurisdiction where located; and (vi) the International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American Development Bank, the Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension plans, and any other similar international organizations, their agencies, affiliates and pension plans.
11
iv. | To the knowledge of the undersigned, without having made any independent investigation, neither the Company nor any person acting for the Company, has conducted any “directed selling efforts” in the United States as the term “directed selling efforts” is defined in Rule 902 of Regulation S, which, in general, means any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the marketing in the United States for any of the Securities being offered. Such activity includes, without limitation, the mailing of printed material to investors residing in the United States, the holding of promotional seminars in the United States, and the placement of advertisements with radio or television stations broadcasting in the United States or in publications with a general circulation in the United States, which discuss the offering of the Securities. To the knowledge of the undersigned, the Securities were not offered to the undersigned through, and the undersigned is not aware of, any form of general solicitation or general advertising, including without limitation, (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising. |
v. | The undersigned will offer, sell or otherwise transfer the Securities, only (A) pursuant to a registration statement that has been declared effective under the Securities Act, (B) pursuant to offers and sales that occur outside the United States within the meaning of Regulation S in a transaction meeting the requirements of Rule 904 (or other applicable Rule) under the Securities Act, or (C) pursuant to another available exemption from the registration requirements of the Securities Act, subject to the Company’s right prior to any offer, sale or transfer pursuant to clauses (B) or (C) to require the delivery of an opinion of counsel, certificates or other information reasonably satisfactory to the Company for the purpose of determining the availability of an exemption. |
vi. | The undersigned will not engage in hedging transactions involving the Securities unless such transactions are in compliance with the Securities Act. |
vii. | The undersigned represents and warrants that the undersigned is not a citizen of the United States and is not, and has no present intention of becoming, a resident of the United States (defined as being any natural person physically present within the United States for at least 183 days in a 12-month consecutive period or any entity who maintained an office in the United States at any time during a 12-month consecutive period). The undersigned understands that the Company may rely upon the representations and warranty of this paragraph as a basis for an exemption from registration of the Securities under the Securities Act of 1933, as amended, and the provisions of relevant state securities laws. |
12
s. | I, or others for whom I am contracting hereunder, am aware that the Company is not now a “reporting issuer” under Canadian Securities Laws and there is no guarantee that it will become a reporting issuer in the future and have been independently advised as to or am aware of the restrictions with respect to trading in, and the restricted period or statutory hold period applicable to the Securities imposed by securities legislation in Canada and the regulations of, and the instruments, policies, rules, orders, codes, notices and interpretation notes of the Canadian securities regulatory authorities in each of the provinces and territories of Canada, as applicable (collectively the “Canadian Securities Laws”), that a suitable legend or legends will be placed on the certificates representing the Securities to reflect the applicable restricted period and hold period to which the Securities are subject, and I, or others for whom I am contracting hereunder, are solely responsible (and the Company is in no way responsible) for compliance with applicable resale restrictions. |
t. | I acknowledge and agree that the certificates representing the Securities may bear the following legend: |
“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE LATER OF (i) [DATE OF DISTRIBUTION], AND (ii) THE DATE THE ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY.”
u. | I, or others for whom I am contracting hereunder, am basing my investment decision solely on the Offering Documents and other publicly available information concerning the Company and not on any other information concerning the Company. |
v. | I, or others for whom I am contracting hereunder, acknowledge that the Company is a private company and does not have any of its securities listed on a stock exchange, and there is no assurance that its securities will ever become publicly listed and that there is currently no market for the Securities and no market may ever develop. |
w. | I, or others for whom I am contracting hereunder, acknowledge that as a consequence of the sale being exempt from the prospectus requirements of Canadian Securities Laws: (A) certain protections, rights and remedies provided by Canadian Securities Laws, including statutory rights of rescission and certain statutory remedies against an issuer, underwriters, auditors, directors and officers that are available to investors who acquire securities offered by a prospectus, will not be available to me, or, if applicable, others for whom I am contracting hereunder; (B) the common law may not provide investors with an adequate remedy in the event that they suffer investment losses in connection with securities acquired in a private placement; (C) I, or, if applicable, others for whom I am contracting hereunder, may not receive information that would otherwise be required to be given under Canadian Securities Laws; and (D) the Company is relieved from certain obligations that would otherwise apply under Canadian Securities Laws. |
x. | I, or others for whom I am contracting hereunder, represent and warrant that no person has made any written or oral representation: (A) that any person will resell or repurchase any of the Securities; (B) that any person will refund the purchase price for the Securities; or (C) as to the future price or value of the Securities. |
y. | I, or others for whom I am contracting hereunder, acknowledge that there is no government or other insurance covering the Securities. |
13
z. | I, or others for whom I am contracting hereunder, represent and warrant that the funds representing the aggregate purchase price in respect of the Securities which will be advanced by me or on my behalf to the Company hereunder will not represent proceeds of crime for the purposes of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada) (for the purposes of this paragraph the “PCMLTFA”) and I acknowledge that the Company may in the future be required by law to disclose my name and other information relating to this Agreement and the subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. (a) None of the subscription funds provided by me: (i) have been or will be derived directly or indirectly from or related to any activity that is deemed criminal under the laws of Canada, the United States of America, or any other jurisdiction; or (ii) are being tendered on behalf of a person or entity who has not been identified to me; and (b) I will promptly notify the Company if I discover that any of such representations cease to be true, and to provide the Company with appropriate information in connection therewith. |
aa. | I, and, if applicable, others for whom I am contracting hereunder, acknowledge that we have not received, nor have we requested nor had any need to receive, or been provided with a prospectus, offering memorandum (within the meaning of Canadian Securities Laws) or any document purporting to describe the business and affairs of the Company which has been prepared for review by prospective purchasers to assist in making an investment decision in respect of the Securities, other than the Offering Documents and that my decision, or, if applicable, the decision of others for whom I am contracting hereunder, to enter into this Agreement and to purchase the Securities from the Company is based entirely upon the Offering Documents and not upon any other verbal or written representation as to fact or otherwise made by or on behalf of the Company. |
bb. | I agree not to sell the Securities except in accordance with any applicable Canadian resale restrictions. |
cc. | If required by applicable securities laws or stock exchange rules, I will execute, deliver and file or assist the Company in obtaining and filing such reports, undertakings and other documents relating to the purchase of the Securities as may be required by applicable securities law, any securities commission, stock exchange or other regulatory authority. |
dd. | I acknowledge that I have consented to and requested that all documents evidencing or relating in any way to the sale of the Securities be drawn up in the English language only. Le souscripteur reconnaît par les présentes avoir consenti et exigé que tous les documents faisant foi ou se rapportant de quelque manière à la vente des bons de unités soient rédigés en anglais seulement. |
ee. | The information contained in my Investor Questionnaire, as well as any information which I have furnished to the Company with respect to my financial position and business experience, is correct and complete as of the date of this Subscription Agreement and, if there should be any material change in such information prior to the Closing of the offering, I will furnish such revised or corrected information to the Company. I hereby acknowledge and am aware that except for any rescission rights that may be provided under applicable laws, I am not entitled to cancel, terminate or revoke this subscription and any agreements made in connection herewith shall survive my death or disability. |
7. Placement Agent. The Company has engaged Boustead Securities LLC, a broker-dealer licensed with FINRA (the “Placement Agent”), as placement agent for the Offering on a reasonable best efforts basis. The Company anticipates that the Placement Agent and its sub-agents or syndicate members will be paid at each Closing from the proceeds in the Escrow Account, fees including and not to exceed: a cash commission of seven percent (7%) of the gross Purchase Price paid by subscribers in the Offering; and a non-accountable expense allowance of one percent (1%) of the gross Purchase Price paid by subscribers in the Offering. Any sub-agent or syndicate member of the Placement Agent that introduces investors to the Offering will be entitled to share in the cash fees attributable to those investors as described above, pursuant to the terms of an executed sub-agent, finder or selected dealer agreement). The Company will also pay certain expenses of the Placement Agent.
14
8. Representations and Warranties of the Company. The Company hereby represents and warrants to the Subscriber, as of the date hereof and on each Closing Date, (it being understood that these representations and warranties are given as of immediately following the closing of the Acquisition such that they are made with respect to the Company and each of the entities acquired directly and indirectly through the Acquisition), the following:
a. Organization and Qualification. The Company and each of its subsidiaries is a corporation or other business entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation, and has the requisite corporate power to own its properties and to carry on its business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the assets, business, financial condition, results of operations or future prospects of the Company and its subsidiaries taken as a whole (a “Material Adverse Effect”).
b. Authorization, Enforcement, Compliance with Other Instruments. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, and each of the other agreements and documents that are exhibits hereto or thereto or are contemplated hereby or thereby or necessary or desirable to effect the transactions contemplated hereby or thereby (the “Transaction Documents”) and to issue the Securities in accordance with the terms hereof, (ii) the execution and delivery by the Company of each of the Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Securities have been, or will be at the time of execution of such Transaction Document, duly authorized by the Company’s Board of Directors, and no further consent or authorization is, or will be at the time of execution of such Transaction Document, required by the Company, its respective Board of Directors or its shareholders, (iii) each of the Transaction Documents will be duly executed and delivered by the Company, (iv) the Transaction Documents when executed and delivered by the Company and each other party thereto will constitute the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.
c. Capitalization. The authorized capital stock of the Company consists of an unlimited number of common shares and preferred shares. Immediately prior to the Initial Closing, the Company will have no more than 20,137,740 common shares outstanding on a “fully diluted” basis, and no preferred shares issued and outstanding. Such “fully diluted” shares outstanding will not include the Company’s right at any time, upon the approval of its Board of Directors or the compensation committee thereof, to award stock options and/or restricted share unit awards to qualified participants pursuant to the terms of the Company’s Employee Stock Option Plan. All of the outstanding shares of capital stock or other equity interests of each of the Company’s subsidiaries have been or will be, as of the Initial Closing, duly authorized, validly issued and are fully paid and nonassessable. (i) No shares of capital stock or other equity interests of the Company or any of its subsidiaries will be subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) there will be no agreements or arrangements under which the Company or any of its subsidiaries is obligated to register the sale of any of their securities under the Securities Act, and (iii) there are no securities or instruments of the Company or any of its subsidiaries containing anti-dilution or similar provisions, including the right to adjust the exercise, exchange or reset price under such securities, that will be triggered by the issuance of the Securities as described in this Agreement. Upon request, the Company will make available to the Subscriber true and correct copies of the Company’s articles of incorporation, and as in effect on the date hereof (the “Articles of Incorporation”), and the Company’s by-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities exercisable for common shares and the material rights of the holders thereof in respect thereto other than stock options issued to officers, directors, employees and consultants.
15
d. Subsidiaries. Upon the completion of the contemplated Acquisition and prior to the Initial Closing, the Company will own, directly or indirectly, 100% of Canmart Limited, Bophelo Bio Science and Wellness (Pty) Ltd., Bophelo Holdings Limited and Cannahealth Limited. The Company will have no other direct or indirect subsidiaries as of each Closing.
e. Issuance of Securities. The Securities are duly authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and are free and clear of all taxes, liens and charges with respect to the issue thereof.
f. No Conflicts. The execution, delivery and performance of each of the Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Articles of Incorporation or the By-laws (or equivalent constitutive document) of the Company or any of its subsidiaries or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any subsidiary is a party, except for those which would not reasonably be expected to have a Material Adverse Effect, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws and regulations) applicable to the Company or any subsidiary or by which any property or asset of the Company or any subsidiary is bound or affected except for those which could not reasonably be expected to have a Material Adverse Effect. Except those which could not reasonably be expected to have a Material Adverse Effect, neither the Company nor any subsidiary is in violation of any term of or in default under its constitutive documents. Except those which could not reasonably be expected to have a Material Adverse Effect, neither the Company nor any subsidiary is in violation of any term of or in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or any subsidiary. The business of the Company and its subsidiaries is not being conducted, and shall not be conducted in violation of any law, ordinance, or regulation of any governmental entity, except for any violation which could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act, Canadian Securities Laws and any applicable state or foreign securities laws, neither the Company nor any of its subsidiaries is required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement or the other Transaction Documents in accordance with the terms hereof or thereof. Neither the execution and delivery by the Company of the Transaction Documents, nor the consummation by the Company of the transactions contemplated hereby or thereby, will require any notice, consent or waiver under any contract or instrument to which the Company or any subsidiary is a party or by which the Company or any subsidiary is bound or to which any of their assets is subject, except for any notice, consent or waiver the absence of which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect and would not adversely affect the consummation of the transactions contemplated hereby or thereby. All consents, authorizations, orders, filings and registrations which the Company or any of its subsidiaries is required to obtain pursuant to the preceding two sentences have been or will be obtained or effected on or prior to the Closing.
16
g. Absence of Litigation. There is no action, suit, claim, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation before or by any court, public board, governmental or administrative agency, self-regulatory organization, arbitrator, regulatory authority, stock market, stock exchange or trading facility (an “Action”) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, wherein an unfavorable decision, ruling or finding would (i) adversely affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under this Agreement or any of the other Transaction Documents, or (ii) have a Material Adverse Effect.
h. Acknowledgment Regarding Subscriber’s Purchase of the Securities. The Company acknowledges and agrees that each Subscriber is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that each Subscriber is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by such Subscriber or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Subscriber’s purchase of the Securities.
i. No General Solicitation. Neither the Company, nor any of its “affiliates” (as defined in Rule 144 under the Securities Act), nor, to the knowledge of the Company, any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities.
j. No Integrated Offering. Neither the Company, nor any of its affiliates, nor to the knowledge of the Company, any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the Securities under the Securities Act or cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act.
k. Employee Relations. Neither the Company nor any subsidiary is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened. Neither the Company nor any subsidiary is party to any collective bargaining agreement. The Company’s and/or its subsidiaries’ employees are not members of any union, and the Company believes that its and its subsidiaries’ relationship with their respective employees is good.
l. Permits. The Company and its subsidiaries have all authorizations, approvals, clearances, licenses, permits, certificates or exemptions (including manufacturing approvals and authorizations, pricing and reimbursement approvals, labeling approvals, registration notifications or their foreign equivalent) issued by any regulatory authority or governmental agency (collectively, “Permits”) required to conduct their respective businesses as currently conducted and as will be conducted immediately following the Acquisition, except to the extent that the failure to have such Permits would not have a Material Adverse Effect. The Company or its subsidiaries have fulfilled and performed in all material respects their obligations under each Permit, and, as of the date hereof, to the knowledge of the Company, no event has occurred or condition or state of facts exists which would constitute a breach or default or would cause revocation or termination of any such Permit except to the extent that such breach, default, revocation or termination would not have a Material Adverse Effect.
m. Title. Each of the Company and its subsidiaries has good and marketable title to all of its real and personal property and assets, free and clear of any material restriction, mortgage, deed of trust, pledge, lien, security interest or other charge, claim or encumbrance which would have a Material Adverse Effect. With respect to properties and assets it leases, each of the Company and its subsidiaries is in material compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances which would have a Material Adverse Effect.
17
n. Rights of First Refusal. The Company is not obligated to offer the securities offered hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former shareholders of the Company, underwriters, brokers, agents or other third parties.
o. Reliance. The Company acknowledges that the Subscriber is relying on the representations and warranties made by the Company hereunder and that such representations and warranties are a material inducement to the Subscriber purchasing the Securities. The Company further acknowledges that without such representations and warranties of the Company made hereunder, the Subscriber would not enter into this Agreement.
p. Brokers’ Fees. The Company does not have any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions contemplated by this Agreement, except for the payment of fees to the Placement Agent as described above.
q. Off-Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any subsidiary and an unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in its financial statements and is not so disclosed or that otherwise would have a Material Adverse Effect.
r. Investment Company. The Company is not required to be registered as, and is not an affiliate of, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
s. Reliance. The Company acknowledges that the Purchaser is relying on the representations and warranties made by the Company hereunder and that such representations and warranties are a material inducement to the Purchaser purchasing the Shares. The Company further acknowledges that without such representations and warranties of the Company made hereunder, the Purchaser would not enter into this Agreement.
9. Indemnification.
a. Investor Indemnification. I hereby agree to indemnify and hold harmless the Company and its officers, directors, shareholders, employees, agents, advisors and counsel, and Boustead Securities, LLC and its officers, directors, shareholders, employees, agents, advisors and counsel, against any and all losses, claims, demands, liabilities and expenses (including reasonable legal or other expenses, including reasonable attorneys’ fees) incurred by each such person in connection with defending or investigating any such claims or liabilities, whether or not resulting in any liability to such person, to which any such indemnified party may become subject under the Securities Act, under any other statute, at common law or otherwise, insofar as such losses, claims, demands, liabilities and expenses (a) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact made by me and contained in this Subscription Agreement or my Investor Questionnaire, or (b) arise out of or are based upon any breach by me of any representation, warranty, or agreement made by me contained herein or therein.
b. Company Indemnification. The Company agrees to indemnify and hold harmless each Subscriber, the Placement Agent and their respective affiliates and their respective directors, officers, employees and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Offering Documents, and will reimburse any such person for all such amounts as they are incurred by such person.
18
10. Transfer Restrictions. None of the Shares have been registered under the Securities Act. As such, any Shares purchased pursuant to this Subscription Agreement constitute “restricted securities” under the Securities Act. Such Shares may not be sold or otherwise transferred unless they are registered under the Securities Act and applicable foreign or state laws or unless exemptions from registration are available under such laws. Any certificates evidencing the Shares will bear a legend restricting the distribution, resale, transfer, pledge, hypothecation or other disposition of such securities unless and until such securities are registered under the Securities Act or an opinion of counsel acceptable to the Company is received concluding that registration is not required under the Securities Act. The Company is also not a reporting issuer in any jurisdiction of Canada and the Shares are not currently listed on any stock exchange. Accordingly, pursuant to Canadian securities laws, the Shares will be subject to a statutory hold period in Canada expiring on the date which is four months and a day after the later of (i) the issuance date, and (ii) the date that the Company becomes a reporting issuer in any province or territory of Canada.
11. Collection of Personal Information. I, on my own behalf and, if applicable, on behalf of each beneficial purchaser for whom I am contracting hereunder, acknowledge and consent to the fact that the Company is collecting our personal information (as that term is defined under applicable privacy legislation, including, without limitation, the Personal Information Protection and Electronic Documents Act (Canada) and any other applicable similar, replacement or supplemental provincial or federal legislation or laws in effect from time to time), and, if applicable, that of each beneficial purchaser for whom I am contracting hereunder, for the purpose of completing this Agreement and the transaction contemplated herein. I, on my own behalf, and, if applicable, on behalf of each beneficial purchaser for whom I am contracting hereunder, acknowledge and consent to the Company retaining such personal information for as long as permitted or required by law or business practices. I, on my own behalf, and, if applicable, on behalf of each beneficial purchaser for whom I am contracting hereunder, further acknowledge and consent to the fact that the Company may be required by Canadian Securities Laws, the rules and policies of any stock exchange or the rules of the Investment Industry Regulatory Organization of Canada or otherwise by applicable law to provide regulatory authorities with any personal information provided under this Agreement. I represent and warrant, as applicable, that I have the authority to provide the consents and acknowledgements set out in this paragraph on behalf of each beneficial purchaser for whom I am contracting hereunder. In addition to the foregoing, I agree and acknowledge that the Company may use and disclose my personal information, or that of each beneficial purchaser for whom I am contracting hereunder, as follows:
· | for internal use with respect to managing the relationships between and contractual obligations of the Company and me or any beneficial purchaser for whom I am contracting hereunder; |
· | for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada Revenue Agency; |
· | for disclosure to stock exchanges, securities regulatory authorities and other regulatory bodies with jurisdiction with respect to reports of trades and similar regulatory filings; |
· | for disclosure to a governmental or other authority to which the disclosure is required by court order or subpoena compelling such disclosure and where there is no reasonable alternative to such disclosure; |
· | for disclosure to professional advisers of the Corporation in connection with the performance of their professional services; |
· | for disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with my prior written consent; |
· | for disclosure to a court determining the rights of the parties under this Agreement; or |
· | for use and disclosure as otherwise required or permitted by law. |
19
The information provided by me in this Agreement identifying my name, address, and telephone number, the number of Securities being purchased hereunder, the aggregate purchase price and the closing date, will be disclosed to the securities regulatory authority or regulator in each of the provinces and territories of Canada in which Securities are distributed by the Company, and such information is being collected by such securities regulatory authorities and regulators under the authority granted to each of them under securities legislation. This information is being collected for the purposes of the administration and enforcement of the securities legislation of such selling jurisdictions. I hereby authorize the indirect collection of such information by such securities regulatory authorities and regulators. In the event I have any questions with respect to the indirect collection of such information by such securities regulatory authorities and regulators, I should contact the applicable securities regulatory authority or regulator using the contact information set out below:
· British Columbia Securities Commission, P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia V7Y 1L2, Inquiries: (604) 899-6854, Toll free in Canada: 1-800-373-6393, Facsimile: (604) 899-6581, Email: inquiries@bcsc.bc.ca;
· Alberta Securities Commission, Suite 600, 250 – 5th Street, SW Calgary, Alberta T2P 0R4, Telephone: (403) 297-6454, Toll free in Canada: 1-877-355-0585, Facsimile: (403) 297-2082;
· Financial and Consumer Affairs Authority of Saskatchewan, Suite 601 - 1919 Saskatchewan Drive, Regina, Saskatchewan S4P 4H2, Telephone: (306) 787-5879, Facsimile: (306) 787-5899;
· The Manitoba Securities Commission, 500 – 400 St. Mary Avenue, Winnipeg, Manitoba R3C 4K5, Telephone: (204) 945-2548, Toll free in Manitoba 1-800-655-5244, Facsimile: (204) 945-0330;
· Ontario Securities Commission, 20 Queen Street West, 22nd Floor Toronto, Ontario M5H 3S8, Telephone: (416) 593- 8314, Toll free in Canada: 1-877-785-1555, Facsimile: (416) 593-8122, Email: exemptmarketfilings@osc.gov.on.ca, Public official contact regarding indirect collection of information: Inquiries Officer;
· Autorité des marchés financiers, 800, Square Victoria, 22e étage, C.P. 246, Tour de la Bourse, Montréal, Québec H4Z 1G3, Telephone: (514) 395-0337 or 1-877-525-0337, Facsimile: (514) 873-6155 (For filing purposes only), Facsimile: (514) 864-6381 (For privacy requests only), Email: financementdessocietes@lautorite.qc.ca (For corporate finance issuers); fonds_dinvestissement@lautorite.qc.ca (For investment fund issuers);
· Financial and Consumer Services Commission (New Brunswick), 85 Charlotte Street,, Suite 300 Saint John, New Brunswick E2L 2J2, Telephone: (506) 658-3060, Toll free in Canada: 1-866-933-2222, Facsimile: (506) 658-3059, Email: info@fcnb.ca
· Nova Scotia Securities Commission, Suite 400, 5251 Duke Street, Duke Tower, P.O. Box 458 Halifax, Nova Scotia B3J 2P8, Telephone: (902) 424-7768, Facsimile: (902) 424-4625;
· Prince Edward Island Securities Office, 95 Rochford Street, 4th Floor Shaw Building, P.O. Box 2000 Charlottetown, Prince Edward Island C1A 7N8, Telephone: (902) 368-4569, Facsimile: (902) 368-5283;
· Government of Newfoundland and Labrador, Financial Services Regulation Division, P.O. Box 8700, Confederation Building 2nd Floor, West Block, Prince Philip Drive, St. John's, Newfoundland and Labrador A1B 4J6, Attention: Director of Securities, Telephone: (709) 729-4189, Facsimile: (709) 729-6187;
· Government of Yukon, Department of Community Services Law Centre, 3rd Floor, 2130 Second Avenue, Whitehorse, Yukon Y1A 5H6, Telephone: (867) 667-5314, Facsimile: (867) 393-6251;
· Government of the Northwest Territories, Office of the Superintendent of Securities, P.O. Box 1320 Yellowknife, Northwest Territories X1A 2L9 Attention: Deputy Superintendent, Legal & Enforcement, Telephone: (867) 920-8984, Facsimile: (867) 873-0243; and
· Government of Nunavut, Department of Justice, Legal Registries Division, P.O. Box 1000, Station 570, 1st Floor, Brown Building, Iqaluit, Nunavut X0A 0H0, Telephone: (867) 975-6590, Facsimile: (867) 975-6594.
12. Severability. In the event any parts of this Subscription Agreement are found to be void, the remaining provisions of this Subscription Agreement shall nevertheless be binding with the same effect as though the void parts were deleted.
20
13. No Third-Party Beneficiaries Other than Placement Agent. Except for the Placement Agent, who is an intended third-party beneficiary of this Agreement, including the representations and warranties and indemnities made in this Agreement, this Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person
14. Choice of Law and Jurisdiction. This Subscription Agreement shall be governed by the laws of the Province of Ontario, Canada. Any action arising out of this Subscription Agreement shall be brought exclusively in a court of competent jurisdiction in the Province of Ontario, and the parties hereby irrevocably attorn to the courts of such Province.
15. Counterparts. This Subscription Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. The execution of this Subscription Agreement may be by actual or facsimile signature.
16. Assignability. Neither this Subscription Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the undersigned without the prior written consent of the Company. This Subscription Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.
17. Notices and Addresses. All notices, offers, acceptance and any other acts under this Subscription Agreement (except payment) shall be in writing, and shall be sufficiently given if delivered to the addresses in person, by Federal Express or similar receipted delivery, or by email delivery, as follows:
Investor:
At the address designated on the signature
page of this Subscription Agreement.
The Company:
Akanda Corp.
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, Ontario M5K 0A1
Attn: Trevor Scott
Email: trevor@akandacorp.com
With a copy to:
Greenberg Traurig, P.A.
1201 K Street, Suite 1100
Sacramento, CA 95814
Attn: Mark Lee, Esq.
Email: leema@gtlaw.com
Dentons Canada LLP
77 King Street West, Suite 400
Toronto-Dominion Centre
Toronto, ON M5K 0A1 Canada
Attn: Eric Foster
Email: eric.foster@dentons.com
or to such other address as any of them, by notice to the others may designate from time to time. The transmission confirmation receipt from the sender's email service provider shall be conclusive evidence of successful email delivery. Time shall be counted to, or from, as the case may be, the delivery in person or by mailing.
18. Entire Agreement. This Subscription Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior oral and written agreements between the parties hereto with respect to the subject matter hereof. This Subscription Agreement may not be changed, waived, discharged, or terminated orally but, rather, only by a statement in writing signed by the party or parties against which enforcement or the change, waiver, discharge or termination is sought.
21
19. Section Headings. Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part, any of the terms or provisions of this Subscription Agreement.
20. Survival of Representations, Warranties and Agreements. The representations, warranties and agreements contained herein shall survive the delivery of, and the payment for, the Securities.
21. Acceptance of Subscription. The Company may accept this Subscription Agreement at any time for all or any portion of the Securities subscribed for by executing a copy hereof as provided and notifying me within a reasonable time thereafter.
United States Disclaimers
RESIDENTS OF ALL STATES: THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE OFFERING DOCUMENTS. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
FOR FLORIDA RESIDENTS: THE SECURITIES OFFERED HEREBY WILL BE SOLD, AND ACQUIRED, IN A TRANSACTION EXEMPT UNDER SECTION 517.061(11) OF THE FLORIDA SECURITIES AND INVESTOR PROTECTION ACT. THE SECURITIES HAVE NOT BEEN REGISTERED UNDER SAID ACT IN THE STATE OF FLORIDA. PURSUANT TO SECTION 517.061(11) OF THE FLORIDA SECURITIES AND INVESTOR PROTECTION ACT, WHEN SALES ARE MADE TO FIVE (5) OR MORE PERSONS (EXCLUDING ACCREDITED INVESTORS) IN THE STATE OF FLORIDA, ANY SALE IN THE STATE OF FLORIDA MADE PURSUANT TO SECTION 517.061(11) OF SUCH ACT IS VOIDABLE BY THE PURCHASER IN SUCH SALE (WITHOUT INCURRING ANY LIABILITY TO THE COMPANY OR TO ANY OTHER PERSON OR ENTITY) EITHER WITHIN THREE (3) DAYS AFTER THE FIRST TENDER OF CONSIDERATION IS MADE BY SUCH PURCHASER TO THE ISSUER, AN AGENT OF THE ISSUER, OR AN ESCROW AGENT OR WITHIN THREE (3) DAYS AFTER THE AVAILABILITY OF THAT PRIVILEGE IS COMMUNICATED TO SUCH PURCHASER, WHICHEVER OCCURS LATER. TO VOID HIS OR HER PURCHASE, THE PURCHASER NEED ONLY SEND A LETTER OR TELEGRAM TO THE COMPANY AT THE ADDRESS INDICATED HEREIN. ANY SUCH LETTER OR TELEGRAM SHOULD BE SENT AND POSTMARKED PRIOR TO THE END OF THE AFOREMENTIONED THREE (3) DAY PERIOD. IT IS PRUDENT TO SEND ANY SUCH LETTER BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO ASSURE THAT IT IS RECEIVED AND ALSO TO HAVE EVIDENCE OF THE TIME THAT IT WAS MAILED. SHOULD A PURCHASER MAKE THIS REQUEST ORALLY, THAT PURCHASER MUST ASK FOR WRITTEN CONFIRMATION THAT THE REQUEST HAS BEEN RECEIVED. IF NOTICE IS NOT RECEIVED WITHIN THE TIME LIMIT SPECIFIED HEREIN, THE FOREGOING RIGHT TO VOID THE PURCHASE SHALL BE NULL AND VOID.
22
Canadian Disclaimers
The Offering Documents may constitute an offering memorandum under Canadian Securities Laws. Securities legislation in certain of the provinces of Canada provides purchasers with rights of rescission or damages, or both, where an offering memorandum or any amendment to it contains a misrepresentation. A “misrepresentation” is an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading or false in the light of the circumstances in which it was made.
These remedies must be commenced by the purchaser within the time limits prescribed and are subject to the defences contained in the applicable securities legislation. Each purchaser should refer to the provisions of the applicable securities laws for the particulars of these rights or consult with a legal advisor.
The following rights will only apply to a purchaser of securities of the Company in the event that the Offering Documents are deemed to be an offering memorandum pursuant to applicable securities legislation in certain provinces of Canada and are in addition to and without derogation from any other right or remedy which purchasers may have at law and are intended to correspond to the provisions of the relevant Canadian Securities Laws and are subject to the defences contained therein. The following summaries are subject to the express provisions of the applicable securities statutes and instruments in the below-referenced provinces and the regulations, rules and policy statements thereunder and reference is made thereto for the complete text of such provisions.
FOR ONTARIO RESIDENTS: UNDER ONTARIO SECURITIES LEGISLATION, CERTAIN PURCHASERS WHO PURCHASE SECURITIES OFFERED BY AN OFFERING MEMORANDUM DURING THE PERIOD OF DISTRIBUTION WILL HAVE A STATUTORY RIGHT OF ACTION FOR DAMAGES, OR WHILE STILL THE OWNER OF THE SECURITIES, FOR RESCISSION AGAINST THE ISSUER OR ANY SELLING SECURITY HOLDER IF THE OFFERING MEMORANDUM CONTAINS A MISREPRESENTATION WITHOUT REGARD TO WHETHER THE PURCHASERS RELIED ON THE MISREPRESENTATION. THE RIGHT OF ACTION FOR DAMAGES IS EXERCISABLE NOT LATER THAN THE EARLIER OF 180 DAYS FROM THE DATE THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION AND THREE YEARS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. THE RIGHT OF ACTION FOR RESCISSION IS EXERCISABLE NOT LATER THAN 180 DAYS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. IF A PURCHASER ELECTS TO EXERCISE THE RIGHT OF ACTION FOR RESCISSION, THE PURCHASER WILL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER OR ANY SELLING SECURITY HOLDER. IN NO CASE WILL THE AMOUNT RECOVERABLE IN ANY ACTION EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED TO THE PURCHASER AND IF THE PURCHASER IS SHOWN TO HAVE PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION, THE ISSUER AND ANY SELLING SECURITY HOLDER WILL HAVE NO LIABILITY. IN THE CASE OF AN ACTION FOR DAMAGES, THE ISSUER AND ANY SELLING SECURITY HOLDER WILL NOT BE LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT ARE PROVEN TO NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON. THESE RIGHTS ARE NOT AVAILABLE FOR A PURCHASER THAT IS (A) A CANADIAN FINANCIAL INSTITUTION OR A SCHEDULE III BANK (EACH AS DEFINED IN NATIONAL INSTRUMENT 45-106 – PROSPECTUS EXEMPTIONS), (B) THE BUSINESS DEVELOPMENT BANK OF CANADA INCORPORATED UNDER THE BUSINESS DEVELOPMENT BANK OF CANADA ACT (CANADA), OR (C) A SUBSIDIARY OF ANY PERSON REFERRED TO IN PARAGRAPHS (A) AND (B), IF THE PERSON OWNS ALL OF THE VOTING SECURITIES OF THE SUBSIDIARY, EXCEPT THE VOTING SECURITIES REQUIRED BY LAW TO BE OWNED BY DIRECTORS OF THAT SUBSIDIARY. THESE RIGHTS ARE IN ADDITION TO, AND WITHOUT DEROGATION FROM, ANY OTHER RIGHTS OR REMEDIES AVAILABLE AT LAW TO AN ONTARIO PURCHASER. THE FOREGOING IS A SUMMARY OF THE RIGHTS AVAILABLE TO AN ONTARIO PURCHASER. NOT ALL DEFENCES UPON WHICH AN ISSUER, SELLING SECURITY HOLDER OR OTHERS MAY RELY ARE DESCRIBED HEREIN. ONTARIO PURCHASERS SHOULD REFER TO THE COMPLETE TEXT OF THE RELEVANT STATUTORY PROVISIONS.
23
FOR ALBERTA AND BRITISH COLUMBIA RESIDENTS: BY PURCHASING SECURITIES OF THE COMPANY, PURCHASERS IN ALBERTA AND BRITISH COLUMBIA ARE NOT ENTITLED TO THE STATUTORY RIGHTS DESCRIBED ABOVE. IN CONSIDERATION OF THEIR PURCHASE OF SECURITIES IN THE COMPANY AND UPON ACCEPTING A PURCHASE CONFIRMATION IN RESPECT THEREOF, THESE PURCHASERS ARE HEREBY GRANTED BY THE COMPANY, A CONTRACTUAL RIGHT OF ACTION FOR DAMAGES OR RESCISSION THAT IS SUBSTANTIALLY THE SAME AS THE STATUTORY RIGHT OF ACTION PROVIDED TO RESIDENTS OF ONTARIO WHO PURCHASE SECURITIES.
FOR SASKATCHEWAN RESIDENTS: UNDER SASKATCHEWAN SECURITIES LEGISLATION, CERTAIN PURCHASERS WHO PURCHASE SECURITIES OFFERED BY AN OFFERING MEMORANDUM DURING THE PERIOD OF DISTRIBUTION WILL HAVE A STATUTORY RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER, EVERY DIRECTOR AND PROMOTER OF THE ISSUER OR ANY SELLING SECURITY HOLDER AS OF THE DATE OF THE OFFERING MEMORANDUM, EVERY PERSON OR COMPANY WHOSE CONSENT HAS BEEN FILED UNDER THE OFFERING MEMORANDUM, EVERY PERSON OR COMPANY THAT SIGNED THE OFFERING MEMORANDUM OR THE AMENDMENT TO THE OFFERING MEMORANDUM AND EVERY PERSON OR COMPANY WHO SELLS THE SECURITIES ON BEHALF OF THE ISSUER OR SELLING SECURITY HOLDER UNDER THE OFFERING MEMORANDUM, OR WHILE STILL THE OWNER OF THE SECURITIES, FOR RESCISSION AGAINST THE ISSUER OR SELLING SECURITY HOLDER IF THE OFFERING MEMORANDUM CONTAINS A MISREPRESENTATION WITHOUT REGARD TO WHETHER THE PURCHASERS RELIED ON THE MISREPRESENTATION. THE RIGHT OF ACTION FOR DAMAGES IS EXERCISABLE NOT LATER THAN THE EARLIER OF ONE YEAR FROM THE DATE THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION AND SIX YEARS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. THE RIGHT OF ACTION FOR RESCISSION IS EXERCISABLE NOT LATER THAN 180 DAYS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. IF A PURCHASER ELECTS TO EXERCISE THE RIGHT OF ACTION FOR RESCISSION, THE PURCHASER WILL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER OR THE OTHERS LISTED ABOVE. IN NO CASE WILL THE AMOUNT RECOVERABLE IN ANY ACTION EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED TO THE PURCHASER AND IF THE PURCHASER IS SHOWN TO HAVE PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION, THE ISSUER AND THE OTHERS LISTED ABOVE WILL HAVE NO LIABILITY. IN THE CASE OF AN ACTION FOR DAMAGES, THE ISSUER AND THE OTHERS LISTED ABOVE WILL NOT BE LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT ARE PROVEN TO NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON.
OTHER DEFENCES IN SASKATCHEWAN LEGISLATION INCLUDE THAT NO PERSON OR COMPANY, OTHER THAN THE ISSUER, WILL BE LIABLE IF THE PERSON OR COMPANY PROVES THAT (A) THE OFFERING MEMORANDUM OR ANY AMENDMENT TO IT WAS SENT OR DELIVERED WITHOUT THE PERSON’S OR COMPANY’S KNOWLEDGE OR CONSENT AND THAT, ON BECOMING AWARE OF IT BEING SENT OR DELIVERED, THAT PERSON OR COMPANY IMMEDIATELY GAVE REASONABLE GENERAL NOTICE THAT IT WAS SO SENT OR DELIVERED, OR (B) WITH RESPECT TO ANY PART OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO IT PURPORTING TO BE MADE ON THE AUTHORITY OF AN EXPERT, OR PURPORTING TO BE A COPY OF, OR AN EXTRACT FROM, A REPORT, AN OPINION OR A STATEMENT OF AN EXPERT, THAT PERSON OR COMPANY HAD NO REASONABLE GROUNDS TO BELIEVE AND DID NOT BELIEVE THAT THERE HAD BEEN A MISREPRESENTATION, THE PART OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO IT DID NOT FAIRLY REPRESENT THE REPORT, OPINION OR STATEMENT OF THE EXPERT.
NO PERSON OR COMPANY, OTHER THAN THE ISSUER, IS LIABLE FOR ANY PART OF THE OFFERING MEMORANDUM OR THE AMENDMENT TO THE OFFERING MEMORANDUM NOT PURPORTING TO BE MADE ON THE AUTHORITY OF AN EXPERT AND NOT PURPORTING TO BE A COPY OF OR AN EXTRACT FROM A REPORT, OPINION OR STATEMENT OF AN EXPERT, UNLESS THE PERSON OR COMPANY (A) FAILED TO CONDUCT A REASONABLE INVESTIGATION SUFFICIENT TO PROVIDE REASONABLE GROUNDS FOR A BELIEF THAT THERE HAD BEEN NO MISREPRESENTATION, OR (B) BELIEVED THERE HAD BEEN A MISREPRESENTATION.
24
SIMILAR RIGHTS OF ACTION FOR DAMAGES AND RESCISSION ARE PROVIDED IN SASKATCHEWAN LEGISLATION IN RESPECT OF A MISREPRESENTATION IN ADVERTISING AND SALES LITERATURE DISSEMINATED IN CONNECTION WITH AN OFFERING OF SECURITIES.
SASKATCHEWAN LEGISLATION ALSO PROVIDES THAT WHERE AN INDIVIDUAL MAKES A VERBAL STATEMENT TO A PROSPECTIVE PURCHASER THAT CONTAINS A MISREPRESENTATION RELATING TO THE SECURITY PURCHASED AND THE VERBAL STATEMENT IS MADE EITHER BEFORE OR CONTEMPORANEOUSLY WITH THE PURCHASE OF THE SECURITY, THE PURCHASER HAS, WITHOUT REGARD TO WHETHER THE PURCHASER RELIED ON THE MISREPRESENTATION, A RIGHT OF ACTION FOR DAMAGES AGAINST THE INDIVIDUAL WHO MADE THE VERBAL STATEMENT.
IN ADDITION, SASKATCHEWAN LEGISLATION PROVIDES A PURCHASER WITH THE RIGHT TO VOID THE PURCHASE AGREEMENT AND TO RECOVER ALL MONEY AND OTHER CONSIDERATION PAID BY THE PURCHASER FOR THE SECURITIES IF THE SECURITIES ARE SOLD BY A VENDOR WHO IS TRADING IN SASKATCHEWAN IN CONTRAVENTION OF SASKATCHEWAN SECURITIES LEGISLATION, REGULATIONS OR A DECISION OF THE FINANCIAL AND CONSUMER AFFAIRS AUTHORITY OF SASKATCHEWAN.
THE SASKATCHEWAN LEGISLATION ALSO PROVIDES A RIGHT OF ACTION FOR RESCISSION OR DAMAGES TO A PURCHASER OF SECURITIES TO WHOM AN OFFERING MEMORANDUM OR ANY AMENDMENT TO IT WAS NOT SENT OR DELIVERED PRIOR TO OR AT THE SAME TIME AS THE PURCHASER ENTERS INTO AN AGREEMENT TO PURCHASE THE SECURITIES, AS REQUIRED BY THE SASKATCHEWAN LEGISLATION.
A PURCHASER WHO RECEIVES AN AMENDED OFFERING MEMORANDUM HAS THE RIGHT TO WITHDRAW FROM THE AGREEMENT TO PURCHASE THE SECURITIES BY DELIVERING A NOTICE TO THE ISSUER OR SELLING SECURITY HOLDER WITHIN TWO BUSINESS DAYS OF RECEIVING THE AMENDED OFFERING MEMORANDUM.
THESE RIGHTS ARE IN ADDITION TO, AND WITHOUT DEROGATION FROM, ANY OTHER RIGHTS OR REMEDIES AVAILABLE AT LAW TO A SASKATCHEWAN PURCHASER. THE FOREGOING IS A SUMMARY OF THE RIGHTS AVAILABLE TO A SASKATCHEWAN PURCHASER. NOT ALL DEFENCES UPON WHICH AN ISSUER OR OTHERS MAY RELY ARE DESCRIBED HEREIN. SASKATCHEWAN PURCHASERS SHOULD REFER TO THE COMPLETE TEXT OF THE RELEVANT STATUTORY PROVISIONS.
FOR MANITOBA RESIDENTS: IF AN OFFERING MEMORANDUM OR ANY AMENDMENT THERETO, SENT OR DELIVERED TO A PURCHASER CONTAINS A MISREPRESENTATION, THE PURCHASER WHO PURCHASES THE SECURITY IS DEEMED TO HAVE RELIED ON THE MISREPRESENTATION IF IT WAS A MISREPRESENTATION AT THE TIME OF THE PURCHASE AND HAS A STATUTORY RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER, EVERY DIRECTOR OF THE ISSUER AT THE DATE OF THE OFFERING MEMORANDUM, AND EVERY PERSON OR COMPANY WHO SIGNED THE OFFERING MEMORANDUM. ALTERNATIVELY, THE PURCHASER MAY ELECT TO EXERCISE A STATUTORY RIGHT OF RESCISSION AGAINST THE ISSUER, IN WHICH CASE THE PURCHASER WILL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST ANY OF THE AFOREMENTIONED PERSONS.
UNLESS OTHERWISE PROVIDED UNDER APPLICABLE SECURITIES LEGISLATION, NO ACTION SHALL BE COMMENCED TO ENFORCE ANY OF THE FOREGOING RIGHTS MORE THAN: (A) IN THE CASE OF AN ACTION FOR RESCISSION, 180 DAYS FROM THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION, OR (B) IN THE CASE OF AN ACTION FOR DAMAGES, THE EARLIER OF (I) 180 DAYS AFTER THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION, OR (II) TWO YEARS AFTER THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION.
25
A PURCHASER TO WHOM THE OFFERING MEMORANDUM IS REQUIRED TO BE SENT MAY RESCIND THE CONTRACT TO PURCHASE THE SECURITIES BY SENDING A WRITTEN NOTICE OF RESCISSION TO THE ISSUER NOT LATER THAN MIDNIGHT ON THE SECOND DAY, EXCLUDING SATURDAYS, SUNDAY AND HOLIDAYS, AFTER THE PURCHASER SIGNS THE AGREEMENT TO PURCHASE THE SECURITIES.
SECURITIES LEGISLATION IN MANITOBA PROVIDES A NUMBER OF LIMITATIONS AND DEFENCES TO SUCH ACTIONS, INCLUDING:
A) IN AN ACTION FOR RESCISSION OR DAMAGES, NO PERSON OR COMPANY WILL BE LIABLE IF IT PROVES THAT THE PURCHASER PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION;
B) IN AN ACTION FOR DAMAGES, NO PERSON OR COMPANY WILL BE LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT IT PROVES DO NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON; AND
C) IN NO CASE WILL THE AMOUNT RECOVERABLE UNDER THE RIGHT OF ACTION DESCRIBED ABOVE EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED UNDER THE OFFERING MEMORANDUM.
FOR NEW BRUNSWICK RESIDENTS: UNDER NEW BRUNSWICK SECURITIES LEGISLATION, CERTAIN PURCHASERS WHO PURCHASE SECURITIES OFFERED BY AN OFFERING MEMORANDUM DURING THE PERIOD OF DISTRIBUTION WILL HAVE A STATUTORY RIGHT OF ACTION FOR DAMAGES, OR WHILE STILL THE OWNER OF THE SECURITIES, FOR RESCISSION AGAINST THE ISSUER AND ANY SELLING SECURITY HOLDER IN THE EVENT THAT THE OFFERING MEMORANDUM, OR A DOCUMENT INCORPORATED BY REFERENCE IN OR DEEMED INCORPORATED INTO THE OFFERING MEMORANDUM, CONTAINS A MISREPRESENTATION WITHOUT REGARD TO WHETHER THE PURCHASERS RELIED ON THE MISREPRESENTATION. THE RIGHT OF ACTION FOR DAMAGES IS EXERCISABLE NOT LATER THAN THE EARLIER OF ONE YEAR FROM THE DATE THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION AND SIX YEARS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. THE RIGHT OF ACTION FOR RESCISSION IS EXERCISABLE NOT LATER THAN 180 DAYS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES. IF A PURCHASER ELECTS TO EXERCISE THE RIGHT OF ACTION FOR RESCISSION, THE PURCHASER WILL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER OR ANY SELLING SECURITY HOLDER. IN NO CASE WILL THE AMOUNT RECOVERABLE IN ANY ACTION EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED TO THE PURCHASER AND IF THE PURCHASER IS SHOWN TO HAVE PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION, THE ISSUER AND ANY SELLING SECURITY HOLDER WILL HAVE NO LIABILITY. IN THE CASE OF AN ACTION FOR DAMAGES, THE ISSUER AND ANY SELLING SECURITY HOLDER WILL NOT BE LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT ARE PROVEN TO NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON.
THESE RIGHTS ARE IN ADDITION TO, AND WITHOUT DEROGATION FROM, ANY OTHER RIGHTS OR REMEDIES AVAILABLE AT LAW TO A NEW BRUNSWICK PURCHASER. THE FOREGOING IS A SUMMARY OF THE RIGHTS AVAILABLE TO A NEW BRUNSWICK PURCHASER. NOT ALL DEFENCES UPON WHICH AN ISSUER, SELLING SECURITY HOLDER OR OTHERS MAY RELY ARE DESCRIBED HEREIN. NEW BRUNSWICK PURCHASERS SHOULD REFER TO THE COMPLETE TEXT OF THE RELEVANT STATUTORY PROVISIONS.
26
FOR NOVA SCOTIA RESIDENTS: UNDER NOVA SCOTIA SECURITIES LEGISLATION, CERTAIN PURCHASERS WHO PURCHASE SECURITIES OFFERED BY AN OFFERING MEMORANDUM DURING THE PERIOD OF DISTRIBUTION WILL HAVE A STATUTORY RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER OR OTHER SELLER AND THE DIRECTORS OF THE ISSUER AS OF THE DATE THE OFFERING MEMORANDUM, OR WHILE STILL THE OWNER OF THE SECURITIES, FOR RESCISSION AGAINST THE ISSUER OR OTHER SELLER IF THE OFFERING MEMORANDUM, OR A DOCUMENT INCORPORATED BY REFERENCE IN OR DEEMED INCORPORATED INTO THE OFFERING MEMORANDUM, CONTAINS A MISREPRESENTATION WITHOUT REGARD TO WHETHER THE PURCHASERS RELIED ON THE MISREPRESENTATION. THE RIGHT OF ACTION FOR DAMAGES OR RESCISSION IS EXERCISABLE NOT LATER THAN 120 DAYS FROM THE DATE ON WHICH PAYMENT IS MADE FOR THE SECURITIES OR AFTER THE DATE ON WHICH THE INITIAL PAYMENT FOR THE SECURITIES WAS MADE WHERE PAYMENTS SUBSEQUENT TO THE INITIAL PAYMENT ARE MADE PURSUANT TO A CONTRACTUAL COMMITMENT ASSUMED PRIOR TO, OR CONCURRENTLY WITH, THE INITIAL PAYMENT. IF A PURCHASER ELECTS TO EXERCISE THE RIGHT OF ACTION FOR RESCISSION, THE PURCHASER WILL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE ISSUER OR OTHER SELLER OR THE DIRECTORS OF THE ISSUER. IN NO CASE WILL THE AMOUNT RECOVERABLE IN ANY ACTION EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED TO THE PURCHASER AND IF THE PURCHASER IS SHOWN TO HAVE PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION, THE ISSUER OR OTHER SELLER AND THE DIRECTORS OF THE ISSUER WILL HAVE NO LIABILITY. IN THE CASE OF AN ACTION FOR DAMAGES, THE ISSUER OR OTHER SELLER AND THE DIRECTORS OF THE ISSUER WILL NOT BE LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT ARE PROVEN TO NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON.
IN ADDITION, A PERSON OR COMPANY, OTHER THAN THE ISSUER, IS NOT LIABLE WITH RESPECT TO ANY PART OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM NOT PURPORTING (A) TO BE MADE ON THE AUTHORITY OF AN EXPERT OR (B) TO BE A COPY OF, OR AN EXTRACT FROM, A REPORT, OPINION OR STATEMENT OF AN EXPERT, UNLESS THE PERSON OR COMPANY (I) FAILED TO CONDUCT A REASONABLE INVESTIGATION TO PROVIDE REASONABLE GROUNDS FOR A BELIEF THAT THERE HAD BEEN NO MISREPRESENTATION OR (II) BELIEVED THAT THERE HAD BEEN A MISREPRESENTATION.
A PERSON OR COMPANY, OTHER THAN THE ISSUER, WILL NOT BE LIABLE IF THAT PERSON OR COMPANY PROVES THAT (A) THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM WAS SENT OR DELIVERED TO THE PURCHASER WITHOUT THE PERSON’S OR COMPANY’S KNOWLEDGE OR CONSENT AND THAT, ON BECOMING AWARE OF ITS DELIVERY, THE PERSON OR COMPANY GAVE REASONABLE GENERAL NOTICE THAT IT WAS DELIVERED WITHOUT THE PERSON’S OR COMPANY’S KNOWLEDGE OR CONSENT, (B) AFTER DELIVERY OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM AND BEFORE THE PURCHASE OF THE SECURITIES BY THE PURCHASER, ON BECOMING AWARE OF ANY MISREPRESENTATION IN THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM, THE PERSON OR COMPANY WITHDREW THE PERSON’S OR COMPANY’S CONSENT TO THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM, AND GAVE REASONABLE GENERAL NOTICE OF THE WITHDRAWAL AND THE REASON FOR IT, OR (C) WITH RESPECT TO ANY PART OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM PURPORTING (I) TO BE MADE ON THE AUTHORITY OF AN EXPERT, OR (II) TO BE A COPY OF, OR AN EXTRACT FROM, A REPORT, AN OPINION OR A STATEMENT OF AN EXPERT, THE PERSON OR COMPANY HAD NO REASONABLE GROUNDS TO BELIEVE AND DID NOT BELIEVE THAT (A) THERE HAD BEEN A MISREPRESENTATION, OR (B) THE RELEVANT PART OF THE OFFERING MEMORANDUM OR ANY AMENDMENT TO THE OFFERING MEMORANDUM DID NOT FAIRLY REPRESENT THE REPORT, OPINION OR STATEMENT OF THE EXPERT, OR WAS NOT A FAIR COPY OF, OR AN EXTRACT FROM, THE REPORT, OPINION OR STATEMENT OF THE EXPERT.
THESE RIGHTS ARE IN ADDITION TO, AND WITHOUT DEROGATION FROM, ANY OTHER RIGHTS OR REMEDIES AVAILABLE AT LAW TO A NOVA SCOTIA PURCHASER. THE FOREGOING IS A SUMMARY OF THE RIGHTS AVAILABLE TO A NOVA SCOTIA PURCHASER. NOT ALL DEFENCES UPON WHICH AN ISSUER OR OTHER SELLER OR OTHERS MAY RELY ARE DESCRIBED HEREIN. NOVA SCOTIA PURCHASERS SHOULD REFER TO THE COMPLETE TEXT OF THE RELEVANT STATUTORY PROVISIONS.
27
FOR PRINCE EDWARD ISLAND RESIDENTS: IF AN OFFERING MEMORANDUM, TOGETHER WITH ANY AMENDMENT THERETO, IS DELIVERED TO A PURCHASER AND THE OFFERING MEMORANDUM, OR ANY AMENDMENT THERETO, CONTAINS A MISREPRESENTATION, A PURCHASER HAS, WITHOUT REGARD TO WHETHER THE PURCHASER RELIED ON THE MISREPRESENTATION, A STATUTORY RIGHT OF ACTION FOR DAMAGES AGAINST (A) THE ISSUER, (B) SUBJECT TO CERTAIN ADDITIONAL DEFENCES, AGAINST EVERY DIRECTOR OF THE ISSUER AT THE DATE OF THE OFFERING MEMORANDUM AND (C) EVERY PERSON OR COMPANY WHO SIGNED THE OFFERING MEMORANDUM, BUT MAY ELECT TO EXERCISE THE RIGHT OF RESCISSION AGAINST THE ISSUER (IN WHICH CASE THE PURCHASER SHALL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE AFOREMENTIONED PERSONS OR COMPANY).
NO ACTION SHALL BE COMMENCED TO ENFORCE THE RIGHT OF ACTION DISCUSSED ABOVE MORE THAN: (A) IN THE CASE OF AN ACTION FOR RESCISSION, 180 DAYS AFTER THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION; OR (B) IN THE CASE OF ANY ACTION FOR DAMAGES, THE EARLIER OF: (I) 180 DAYS AFTER THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION; OR (II) THREE YEARS AFTER THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION.
SECURITIES LEGISLATION IN PRINCE EDWARD ISLAND PROVIDES A NUMBER OF LIMITATIONS AND DEFENCES TO SUCH ACTIONS, INCLUDING:
A) NO PERSON OR COMPANY WILL BE LIABLE IF IT PROVES THAT THE PURCHASER PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION;
B) IN AN ACTION FOR DAMAGES, THE DEFENDANT IS NOT LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT IT PROVES DOES NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON; AND
C) IN NO CASE SHALL THE AMOUNT RECOVERABLE UNDER THE RIGHT OF ACTION DESCRIBED HEREIN EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED UNDER THE OFFERING MEMORANDUM, OR ANY AMENDMENT THERETO.
FOR NEWFOUNDLAND AND LABRADOR RESIDENTS: IF AN OFFERING MEMORANDUM, TOGETHER WITH ANY AMENDMENT THERETO, CONTAINS A MISREPRESENTATION, A PURCHASER HAS, WITHOUT REGARD TO WHETHER THE PURCHASER RELIED ON THE MISREPRESENTATION, A STATUTORY RIGHT OF ACTION FOR DAMAGES AGAINST (A) THE ISSUER, (B) SUBJECT TO CERTAIN ADDITIONAL DEFENCES, AGAINST EVERY DIRECTOR OF THE ISSUER AT THE DATE OF THE OFFERING MEMORANDUM AND (C) EVERY PERSON WHO SIGNED THE OFFERING MEMORANDUM, BUT MAY ELECT TO EXERCISE THE RIGHT OF RESCISSION AGAINST THE ISSUER (IN WHICH CASE THE PURCHASER SHALL HAVE NO RIGHT OF ACTION FOR DAMAGES AGAINST THE AFOREMENTIONED PERSONS).
NO ACTION SHALL BE COMMENCED TO ENFORCE THE RIGHT OF ACTION DISCUSSED ABOVE MORE THAN: (A) IN THE CASE OF AN ACTION FOR RESCISSION, 180 DAYS AFTER THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION; OR (B) IN THE CASE OF ANY ACTION FOR DAMAGES, THE EARLIER OF: (I) 180 DAYS AFTER THE PURCHASER FIRST HAD KNOWLEDGE OF THE FACTS GIVING RISE TO THE CAUSE OF ACTION; OR (II) THREE YEARS AFTER THE DATE OF THE TRANSACTION THAT GAVE RISE TO THE CAUSE OF ACTION. SECURITIES LEGISLATION IN NEWFOUNDLAND AND LABRADOR PROVIDES A NUMBER OF LIMITATIONS AND DEFENCES TO SUCH ACTIONS, INCLUDING:
A) NO PERSON WILL BE LIABLE IF IT PROVES THAT THE PURCHASER PURCHASED THE SECURITIES WITH KNOWLEDGE OF THE MISREPRESENTATION;
28
B) IN AN ACTION FOR DAMAGES, THE DEFENDANT IS NOT LIABLE FOR ALL OR ANY PORTION OF THE DAMAGES THAT IT PROVES DOES NOT REPRESENT THE DEPRECIATION IN VALUE OF THE SECURITIES AS A RESULT OF THE MISREPRESENTATION RELIED UPON; AND
C) IN NO CASE SHALL THE AMOUNT RECOVERABLE UNDER THE RIGHT OF ACTION DESCRIBED HEREIN EXCEED THE PRICE AT WHICH THE SECURITIES WERE OFFERED UNDER THE OFFERING MEMORANDUM, OR ANY AMENDMENT THERETO.
29
THE AGGREGATE AMOUNT SUBSCRIBED FOR HEREBY IS:
_______________ shares for a total purchase price of $_______________
Manner in Which Title is to be Held. (check one)
¨ | Individual Ownership | ¨ | Community Property | |
¨ | Joint Tenant with Right of Survivorship (both parties must sign) | |||
¨ | Partnership | ¨ | Tenants in common | |
¨ | Corporation Trust | ¨ | IRA or Keogh | |
¨ | Other (please indicate) |
INDIVIDUAL INVESTORS | ENTITY INVESTORS | |||
Name of entity, if any | ||||
Signature (Individual) | By: | |||
*Signature | ||||
Its: | ||||
Signature (Joint) | Title: | |||
(all record holders must sign) | ||||
Name(s) Typed or Printed | Name Typed or Printed | |||
Address to Which Correspondence
Should be Directed |
Address to Which Correspondence
Should be Directed |
|||
City, Country, State and Zip Code/Postal Code | City, Country, State and Zip Code/Postal Code | |||
Tel: | Tel: | |||
Email: | Email: | |||
Tax Identification or
Social Security Number |
Tax Identification or
|
|||
State whether the Subscriber is a Registrant1: Yes ¨ No ¨ |
State whether the Subscriber is an Insider2 of the Corporation: Yes ¨ No ¨
Number and kind of securities of the Company held, directly or indirectly, if any:
|
(1) | “Registrant” means a dealer, adviser, investment fund management, ultimate designated person or chief compliance officer as those terms are used pursuant to the Canadian Securities Laws, or a person registered or otherwise required to be registered under Canadian Securities Laws |
30
(2) | “Insider” means (i) a director or officer of the Company (or a subsidiary of the Company), (ii) any person who beneficially owns, directly or indirectly, voting securities of the Company or who exercises control or direction over, directly or indirectly, voting securities of the Company or a combination of both carrying more than 10% of the voting rights attached to all voting securities of the Company for the time being outstanding, or (iii) a director or officer of an Insider of the Company. |
* | If Securities are being subscribed for by any entity, the Certificate of Signatory on the next page must also be completed |
31
The foregoing subscription is accepted and the Company hereby agrees to be bound by its terms on _____ day of ___________________, 2021.
Akanda Corp. | |||
Dated: | By: | ||
Name: Tejinder Virk | |||
Its: Chief Executive Officer |
32
CERTIFICATE OF SIGNATORY
(To be completed if Securities are being subscribed for by an entity)
I, ____________________________, the __________________________________
(name of signatory) (title)
of ________________________________________ (“Entity”), a ________________________
(name of entity) (type of entity)
Organized under the laws of ______________, hereby certify that I am empowered and duly authorized by the Entity to execute the Subscription Agreement and to purchase the Securities, and certify further that the Subscription Agreement has been duly and validly executed on behalf of the Entity and constitutes a legal and binding obligation of the Entity.
IN WITNESS WHEREOF, I have set my hand this ______ day of ____________, 2021.
(Signature) |
33
INSTRUCTIONS FOR COMPLETION OF
INVESTOR REPRESENTATION
AND SUITABILITY QUESTIONNAIRE
(FOR NON-CANADIAN SUBSCRIBERS)
Item I: | Name and address information must be provided. Securities will be issued in the name(s) set forth in this Item and delivered to the address set forth in this Item. If two people are subscribing jointly, both people must provide their names and social security numbers. A telephone number must also be provided. |
Item II: | If the securities are to be held in a different name than the investor and sent to a different address (i.e., an IRA or other account held at a brokerage firm), this Item must be completed. If the securities are to be issued and delivered directly to the entity listed in Item I, this Item need not be completed. |
Item III: | This Item needs to be read by the investor, but nothing needs to be written here. The Securities are suitable for investment only by prospective investors who are “Accredited Investors.” |
Item IV: | A. Only complete this Item by checking the appropriate line if you are an individual investor. |
B. Only complete this Item if you are an entity investor.
C. Only complete this Item if you are a trust investor.
Item V: | This Item needs to be read by the investor, but nothing needs to be written here. |
Item VI: | The USA Freedom Act requires us to collect information on the sources of funds. Please complete section 1, add the documents requested in section 2 only if funds did not come from an approved country (U.S. is approved), and complete section 3. |
Item VII: | You must thoroughly complete the Suitability Questionnaire, in order for the Company and the Managing Dealer to make a determination whether this is a suitable investment for you. |
Item VIII: | You and must sign and date here. |
34
INSTRUCTIONS FOR PAYMENT
Review and complete the Investor Representation & Suitability Questionnaire and deliver it to the email or address below along with payment for your investment.
Email: | offerings@boustead1828.com |
Subject: | Akanda Corp. – [Investor Name] |
Address: | Boustead Securities, LLC |
6 Venture, Suite 395 | |
Irvine, CA 92618 | |
WIRE INSTRUCTIONS | |
Bank Name: | [*] |
Bank Address: | [*] |
SWIFT Code: | [*] |
Routing #: | [*] |
Account Name: | [*] |
Account #: | [*] |
REF / Notes: | Akanda Corp. – [Investor Name] |
If you need assistance, please contact: | |
Email: | offerings@boustead1828.com |
Phone: | (949)-502-4408 |
35
INVESTOR REPRESENTATION & SUITABILITY QUESTIONNAIRE (For Non-Canadian Subscribers) |
Please read all instructions of this Investor Representation and Suitability Questionnaire (this “Questionnaire”) carefully before filling out this Questionnaire. This is a legally binding document. If you need assistance, please call 949-502-4408 or by email at offerings@boustead1828.com.
|
I. | ACCOUNT REGISTRATION |
¨ Individual Account | ¨ Trust |
¨ Corporation, Partnership, LLC, |
¨ Joint Registration * If no box below is checked, we will issue the securities as JTWROS. |
¨ Individual Retirement Account (IRA) |
Pension or Profit-Sharing Plan. Association, or other Entity |
¨ Joint Tenants with Rights of Survivorship * |
||
¨ Tenants in Common |
||
¨ Tenants in Entirety |
||
¨ Community Property |
||
PLEASE PUT A CHECK NEXT TO EACH SOCIAL SECURITY NUMBER OR TAX ID NUMBER THAT IS RESPONSIBLE FOR TAXES. WE WILL REPORT THIS NUMBER TO THE IRS. |
¨ | ||||
Name of INVESTOR (Individual, Entity, Custodian, Trust or Beneficiary) | Date of Birth | Soc. Sec. / Tax ID # | ||
¨ | ||||
Name of SIGNER (Signer for Entity, Trust. Name of IRA Participant) | Date of Birth | Soc. Sec. / Tax ID # | ||
¨ | ||||
Name of JOINT INVESTOR or CO- TRUSTEE (if applicable) | Date of Birth | Soc. Sec. / Tax ID # | ||
Marital Status (please check one): | ¨ Single | ¨ Married | ¨ Other |
$ _____________________Total Investment Amount |
HOME ADDRESS ¨ USE THIS ADDRESS FOR MAILING | ||||
Street Address | Apt / Suite / Unit # | |||
City | State | Zip | ||
Home Phone | Fax | |||
BUSINESS ADDRESS ¨ USE THIS ADDRESS FOR MAILING | ||||
Street Address | Apt / Suite / Unit # | |||
City | State | Zip | ||
Business Phone | Fax | |||
36
II. | ALTERNATIVE DISTRIBUTION INFORMATION |
To direct distributions to a party other than the registered owner, complete the information below. YOU MUST COMPLETE THIS ITEM IF THIS IS AN IRA INVESTMENT.
Name of Firm (Bank or Brokerage): |
Account Name: | Account #: | |||
Address: |
III. | INVESTOR REPRESENTATIONS & AUTHORIZATIONS |
You as an individual or you on behalf of the subscribing entity are being asked to complete this Investor Representation and Suitability Questionnaire so a determination can be made as to whether or not you are qualified to purchase securities under applicable federal and state securities laws. Your answers to the questions contained herein must be true and correct in all respects, and a false representation by you may constitute a violation of law for which a claim for damages may be made against you.
Your answers will be kept strictly confidential; however, by signing this Questionnaire, you will be authorizing release of this Questionnaire to make certain that the offer and sale of the securities will not result in a violation of the Securities Act of 1933, as amended (the “Act”) or of the securities laws of any state.
This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy securities or any other security. All questions must be answered. If the appropriate answer is “None” or “Not Applicable,” please state so. Please print or type your answers to all questions and attach additional sheets if necessary to complete your answers to any item. Please initial any correction.
INDIVIDUAL SUBSCRIBERS:
If the securities subscribed for are to be owned by more than one person, you and the other co-subscriber must each complete separate Questionnaires (except if the co-subscriber is your spouse or spousal equivalent) and sign the Signature Page annexed hereto. If your spouse or spousal equivalent is a co-subscriber, you must indicate their name and social security number.
CORPORATIONS, PARTNERSHIPS, PENSION PLANS AND TRUSTS:
The information requested herein relates to the subscribing entity and not to you personally (unless otherwise determined in the Item IV. Accredited Investor Status).
IV. | ACCREDITED INVESTOR STATUS |
TO BE AN ACCREDITED INVESTOR, YOU MUST MEET ONE OF THE FOLLOWING TESTS, PLEASE CHECK THE APPROPRIATE SPACES BELOW.
A. | INDIVIDUAL ACCOUNTS: |
I certify that I am an “accredited investor” because:
(a) ___ I had an individual income of more than $200,000 in each of the two most recent calendar years, and I reasonably expect to have an individual income in excess of $200,000 in the current calendar year; or my spouse or spousal equivalent and I had joint income in excess of $300,000 in each of the two most recent calendar years, and we reasonably expect to have a joint income in excess of $300,000 in the current calendar year (please complete “Item V. Income Statement”); or
(b) I have an individual net worth, or my spouse or spousal equivalent and I have a joint net worth, in excess of $1,000,000 (excluding my (our) primary residence); or
37
(c) I hold in good standing the FINRA Series 7, Series 65, or Series 82 licenses, and/or other such certain professional certifications, designations or credentials or other credentials issued by an accredited educational institution, which the SEC may designate from time to time by order; or
(d) I am a knowledgeable employee of the fund. (This should only be answered with respect to investments in a private fund); or
(e) I am a director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer.
For purposes of this Questionnaire “individual income” means “adjusted gross income” as reported for Federal income tax purposes, exclusive of any income attributable to a spouse or spousal equivalent or to property owned by a spouse or spousal equivalent, and increased by the following amounts:
(i) the amount of any interest income received which is tax-exempt under Section 103 of the Internal Revenue Code of 1986, as amended, (the “Code”); (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of form 1040); (iii) any deduction claimed for depletion under Section 611 et seq. of the Code; and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Sections 1202 of the Code as it was in effect prior to enactment of the Tax Reform Act of 1986.
For purposes of this Questionnaire, “joint income” means “adjusted gross income” as reported for federal income tax purposes, including any income attributable to a spouse or spousal equivalent or to property owned by a spouse or spousal equivalent and increased by the following amounts:
(i) the amount of any interest income received which is tax-exempt under Section 103 of the Code; (ii) the amount of losses claimed as a limited partner in a limited partnership (as reported on Schedule E of Form 1040); (iii) any deduction claimed for depletion under Section 611 et seq. of the Code; and (iv) any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Code as it was in effect prior to enactment of the Tax Reform Act of 1986.
For the purposes of this Questionnaire, “net worth” means (except as otherwise specifically defined) the excess of total assets at fair market value over total liabilities, excluding your primary residence and the related amount of indebtedness secured by the primary residence up to its fair market value; provided, however, that indebtedness secured by the primary residence should be considered a liability and deducted from net worth to the extent that (i) the amount of such indebtedness outstanding at the time of completion of this Questionnaire exceeds the amount outstanding 60 calendar days before such time, other than as a result of the acquisition of the primary residence; and (ii) the amount of the indebtedness exceeds the estimated fair market value of the primary residence at the time of completion of this Questionnaire.
For the purposes of this Questionnaire, “spousal equivalent” means a cohabitant occupying a relationship generally equivalent to that of a spouse or spousal equivalent.
B. CORPORATIONS, PARTNERSHIPS, LIMITED LIABILITY COMPANIES, EMPLOYEE BENEFIT PLANS, OR OTHER ENTITIES (Please provide a copy of the Corporate Resolution authorizing this investment, Partnership Agreement, Limited Liability Company Operating Agreement, Employee Benefit Plan, or other entity documentation as applicable.)
Has the subscribing entity been formed for the specific purpose of investing in the securities? ¨ Yes ¨ No
If your answer to the question above is “No,” CHECK whichever of the following statements (a-e) is applicable to the subscribing entity. If your answer to the question above is “Yes,” the subscribing entity must be able to certify to statement (c) below in order to qualify as an “accredited investor.”
The undersigned certifies that:
(a) ___ the undersigned entity is an “accredited investor,” because it is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974 (“ERISA”), provided that the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, and the plan fiduciary is a bank, savings and loan association, insurance company or registered investment adviser; or
38
(b) ___ the undersigned entity is an “accredited investor,” because it is an employee benefit plan within the meaning of ERISA, Title I that has total assets in excess of $5,000,000; or
(c) ___ Any private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended; or
(d) ___ the undersigned entity is an “accredited investor because it is an entity whose shareholders, partners, beneficiaries or equity owners are all accredited investors (If you are checking this option, please submit a list of all owners; EACH owner of the entity must complete Item IV and, complete Item V, if applicable, and Item VI. Make copies of this Item IV, Item VI (and V if applicable) to do this and note each owner’s name on each copy); I am one of its equity owners; and I meet at least one of the conditions described below (Please also CHECK the appropriate space below):
¨ I had an individual income of more than $200,000 in each of the two most recent calendar years, and I reasonably expect to have an individual income in excess of $200,000 in the current calendar year; or my spouse or spousal equivalent and I had joint income in excess of $300,000 in each of the two most recent calendar years, and we reasonably expect to have a joint income in excess of $300,000 in the current calendar year (please complete “Item V. Income Statement”); or
¨ I have an individual net worth, or my spouse or spousal equivalent and I have a joint net worth, in excess of $1,000,000 (excluding my (our) primary residence); or
¨ I hold in good standing the FINRA Series 7, Series 65, or Series 82 licenses, and/or other such certain professional certifications, designations or credentials or other credentials issued by an accredited educational institution, which the SEC may designate from time to time by order; or
¨ I am a knowledgeable employee of the fund; or
¨ I am a director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer.
(e) ___ the undersigned entity is an “accredited investor,” because it is a self-directed employee benefit plan; I solely make its investment decisions; and I meet at least one of the conditions described below (Please also CHECK the appropriate space below):
¨ I had an individual income of more than $200,000 in each of the two most recent calendar years, and I reasonably expect to have an individual income in excess of $200,000 in the current calendar year; or my spouse or spousal equivalent and I had joint income in excess of $300,000 in each of the two most recent calendar years, and we reasonably expect to have a joint income in excess of $300,000 in the current calendar year (please complete “Item V. Income Statement”); or
¨ I have an individual net worth, or my spouse or spousal equivalent and I have a joint net worth, in excess of $1,000,000 (excluding my (our) primary residence); or
¨ I hold in good standing the FINRA Series 7, Series 65, or Series 82 licenses, and/or other such certain professional certifications, designations or credentials or other credentials issued by an accredited educational institution, which the SEC may designate from time to time by order; or
¨ I am a knowledgeable employee of the fund; or
¨ I am a director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer. or
39
(f) ___ the undersigned entity is an “accredited investor,” because it is an organization described in section 501(c)3 of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; or
(g) ___ the undersigned entity is an “accredited investor,” because it is a limited liability company, SEC or state -registered Investment Adviser, Exempt Reporting Adviser, or a rural business investment company (RBIC) with $5,000,000 in assets; or
(h) ___ the undersigned entity is an “accredited investor,” because it is an Indian tribe, governmental body, fund, or any entity organized under the laws of foreign countries, that own “investments,” as defined in Rule 2a51-1(b) under the Investment Company Act, in excess of $5,000,000 and that was not formed for the specific purpose of investing in the securities offered; or
(i) ___ the undersigned entity is an “accredited investor,” because it is a family office with at least $5,000,000 in assets under management and their “family clients,” as each term is defined under the Investment Advisers Act.
C. | TRUST ACCOUNTS (Please provide a complete copy of the Trust document.) |
Has the subscribing entity been formed for the specific purpose of investing in the securities? ¨ Yes ¨ No
If your answer to the question above is “No,” CHECK whichever of the following statements (a-c) is applicable to the subscribing entity. If your answer to the question above is “Yes,” the subscribing entity must be able to certify to the statement (c) below in order to qualify as an “accredited investor.”
The undersigned trustee certifies that the trust is an “accredited investor” because:
(a) ___ the trust has total assets in excess of $5,000,000 and the investment decision has been made by a “sophisticated person,” as described in Rule 506(b)(ii) promulgated under the Act; or
(b) ___ the trustee making the investment decision on its behalf is a bank (as defined in Section 3(a)(2) of the Act), a saving and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, acting in its fiduciary capacity; or
(c) ___ the grantor(s) of the trust may revoke the trust at any time and regain title to the trust assets and has (have) retained sole investment control over the assets of the trust and the (each) grantor(s) meets at least one of the conditions described below. Each grantor must also INITIAL the appropriate space below.
¨ I had an individual income of more than $200,000 in each of the two most recent calendar years, and I reasonably expect to have an individual income in excess of $200,000 in the current calendar year; or my spouse or spousal equivalent and I had joint income in excess of $300,000 in each of the two most recent calendar years, and we reasonably expect to have a joint income in excess of $300,000 in the current calendar year (please complete “Item V. Income Statement”); or
¨ I have an individual net worth, or my spouse or spousal equivalent and I have a joint net worth, in excess of $1,000,000 (excluding my (our) primary residence); or
¨ I hold in good standing the FINRA Series 7, Series 65, or Series 82 licenses, and/or other such certain professional certifications, designations or credentials or other credentials issued by an accredited educational institution, which the SEC may designate from time to time by order; or
¨ I am a knowledgeable employee of the fund; or
¨ I am a director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer.
40
V. | CERTIFICATIONS |
I understand that investment in the securities is an illiquid investment. In particular, I recognize that I must bear the economic risk of investment in the securities for an indefinite period of time since the securities have not been registered under the Act and therefore cannot be sold unless either they are subsequently registered under the Act or an exemption from such registration is available and a favorable opinion of counsel for the Company to that effect is obtained if requested by the Company. I consent to the affixing by the Company of such legends on certificates representing the securities as any applicable federal or state securities law may require from time to time.
I represent and warrant to the Company that: (i) all information provided in this Questionnaire is complete, true and correct; (ii) I and my investment managers, if any, have carefully reviewed and understand the risks of, and other considerations relating to, a purchase of these securities, including, but not limited to, the risks set forth in the risk factor disclosure document and other Offering Materials provided to me; (iii) I and my investment managers, if any, have been afforded the opportunity to obtain all information necessary to verify the accuracy of any representations or information in the transaction documents for this offering and other information provided to the undersigned and have had all inquiries to the Company answered, and have been furnished all requested materials relating to the Company and the offering and sale of the securities; (iv) I have such knowledge and experience in financial and investment matters, either alone or with my investment managers, that I am capable of evaluating the merits and risks of this investment; (v) neither I nor my investment managers, if any, have been furnished any offering literature by the Company or any of its affiliates, associates or agents other than the transaction documents, the term sheet, the Business Summary, the Risk Factor Disclosure Document, and the investor presentation provided to the undersigned by the Company related to this investment (collectively, the “Offering Materials”) relating to this investment, and the documents referenced therein; and (vi) I am acquiring the securities for which I am subscribing for my own account, as principal, for investment and not with a view to the resale or distribution of all or any part of the securities. By my completion of this Questionnaire and execution of other transaction documents, I confirm and agree that I have reviewed and understand the provisions of each such transaction document and, should my subscription be accepted by the Company, agree to be bound thereby.
The undersigned, if a corporation, partnership, trust or other form of business entity: (i) is authorized and otherwise duly qualified to purchase and hold the securities; (ii) has obtained such additional tax and other advice that it has deemed necessary; (iii) has its principal place of business at its address set forth in this Questionnaire; and (iv) has not been formed for the specific purpose of acquiring the securities (although this may not necessarily disqualify the subscriber as a purchaser). The persons completing this Questionnaire and executing all other documents related to the offering, represent that they are duly authorized to complete or execute all such documents on behalf of the entity. (If the undersigned is one of the aforementioned entities, it agrees to supply any additional written information that may be required.
All of the information which I have furnished to the Company, and which is set forth in this Questionnaire is correct and complete as of the date of this Questionnaire. If any material change in this information should occur prior to my subscription being accepted, I will immediately furnish the revised or corrected information. I further agree to be bound by all of the terms and conditions of the Offering Materials. I am the only person with a direct or indirect interest in the securities subscribed for hereby.
I agree to indemnify and hold harmless the Company and its Officers, Directors, employees, affiliates, and agents as well as the brokerage firm through which I am subscribing (if any) and all of its officers, directors, employees, affiliates, and agents from and against all damages, losses, costs and expenses (including reasonable attorneys’ fees) they may incur by reason of the failure of the undersigned to fulfill any of the terms or conditions set forth in the transaction documents. This subscription is not transferable or assignable by me without the written consent of the Company. If more than one person is completing this Questionnaire, the obligations of each shall be joint and several, and the representations contained in this Questionnaire shall be deemed to be made by, and be binding upon, each of these persons and his or her heirs, executors, administrators, successors, and assigns. This subscription, upon acceptance by the Company, shall be binding upon my heirs, executors, administrators, successors, and assigns.
This Questionnaire and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed, and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.
Under penalties of perjury, by signing below I certify that (i) my taxpayer identification number shown in this Questionnaire is correct; and (ii) I am not subject to backup withholding because: (a) I have not been notified that I am subject to backup withholding as a result of a failure to report all interest and dividends; or (b) the Internal Revenue Service has notified me that I am no longer subject to backup withholding. (If you have been notified that you are subject to backup withholding and the Internal Revenue Service has not advised you that backup withholding has been terminated, strike out item (ii)).
VI. | INFORMATION REQUIRED BY FEDERAL LAW |
The USA Freedom Act requires us to obtain the following information from you to detect and prevent misuse of the world financial system.
1. In the space provided below, please provide details of where monies were transferred from to the Company in relation to your subscription for the securities.
41
Country | Name of Bank / Financial Institution | Name of Account Holder | Account Number |
If the country from which the monies were transferred appears in the Approved Country List below, please skip to section 3. If the country does not appear, please go to section 2.
*Vision Financial Markets will require enhanced due diligence as applicable.
2. | If subscription monies were transferred to the Company from any country other than on the "Approved Country List" (see above), please provide the following documentation to the Company (all copies should be in English and certified as being "true and correct copies of the original" by a notary public of the jurisdiction of which you are resident). |
(a) | For Individuals: |
(i) | evidence of name, signature, date of birth and photographic identification; |
(ii) | evidence of permanent address; and |
(iii) | where possible, a reference from a bank with whom the individual maintains a current relationship and has maintained such relationship for at least two years. |
(b) | For Companies: |
(i) | a copy of its certificate of incorporation and any change of name certificate; |
(ii) | a certificate of good standing; |
(iii) | a register or other acceptable list of directors and officers; |
(iv) | a properly authorized mandate of the company to subscribe in the form, for example, of a certified resolution which includes naming authorized signatories; |
(v) | a description of the nature of the business of the company; |
(vi) | identification, as described above for individuals, for at least two directors and authorized signatories; |
(vii) | a register of members or list of shareholders holding a controlling interest; and |
(viii) | identification, as described above, for individuals who are beneficial owners of corporate shareholders which hold 10% or more of the capital share of the company. |
(c) | For Partnerships and Unincorporated Businesses: |
(i) | a copy of any certificate of registration and a certificate of good standing, if registered; |
(ii) | identification, as described above, for individuals and, where relevant, companies constituting a majority of the partners, owners or managers and authorized signatories; |
(iii) | a copy of the mandate from the partnership or business authorizing the subscription in the form, for example, of a certified resolution which includes naming authorized signatories; and |
(iv) | a copy of constitutional documents (formation and partnership agreements). |
(d) | For Trusts: |
(i) | identification, as described above, for individuals or companies (as the case may be) in respect of the trustees; |
(ii) | identification, as described above for individuals, of beneficiaries, any person on whose instructions or in accordance with those wishes the trustee/nominee is prepared or accustomed to act and the settlor of the trust; and |
(iii) | evidence of the nature of the duties or capacity of the trustee. |
42
3. | The Company is also required to verify the source of funds. To this end, summarize the underlying source of the funds remitted to us (for example, where subscription monies were the profits of business (and if so, please specify type of business), investment income, savings, etc.). |
Source of Funds: | |||
VII. | SUITABILITY QUESTIONNAIRE |
This is a speculative investment (Each responding individual must complete his/her own Suitability Questionnaire)
Name of Individual Investor OR Name of Person Answering Questions on behalf of an Entity/Trust/IRA Investor:
A. | Please provide the below Identification information: |
ID Number: ____________________________________ | |
Place of Issuance: _______________________________ | |
Issue Date: ____________________________________ | |
Expiration Date: _________________________________ |
Are you a U.S. Citizen? ¨ Yes ¨ No |
Please provide a copy of the photo page of your government-issued identification.
B. | Please provide your present employment status. If currently retired or unemployed, please provide your last/most recent employment history: |
Current Employment Status Latest Role/Occupation Latest Employer Name
C. | Please provide the following information concerning your financial experience: |
C-1. | Risk Tolerance (select one): |
¨ Speculative – You are willing to accept substantial risk. May endure extensive volatility and very limited or no liquidity. You value the potential for maximizing long-term returns over principal preservation.
¨ Aggressive – You are willing to accept considerable risk. You may endure high volatility and limited or very limited liquidity. You value long-term appreciation over principal preservation.
¨ Moderate – You are willing to accept limited risk. You may endure some volatility and illiquidity. You value enhancing returns and principal preservation equally. You are willing to risk losing a substantial amount of your investment.
¨ Conservative – You are willing to accept low risk for greater stability and liquidity. You value minimizing risk and maximizing principal preservation.
C-2. | What is your primary investment objective? (select one): |
¨ Investment speculation
¨ Steadily accumulate wealth over the long term
¨ Partially fund my retirement
¨ Other
43
C-3. | What are your time horizon and liquidity needs? |
(a) | Time Horizon (select one): | (b) | Liquidity Needs (select one): |
¨ 10 years or more | ¨ Low | ||
¨ 5 –10 years | ¨ Medium | ||
¨ 2 – 5 years | ¨ High | ||
¨ Under 2 years |
C-4. | How much investment experience do you have? (select one): |
¨ Extensive
¨ Substantial
¨ Moderate
¨ Limited
¨ None
C-5. | Please state the approximate number and total dollar amount of your prior investments in restricted securities (e.g., private placements): |
No. of Investments: ______________________ | Total Amount: ______________________ |
C-6. | Please indicate your Annual Income and Net Worth: |
(a) | Annual Income | (b) | Net Worth | (c) | Liquid Net Worth | |
¨ Under $25,000 | ¨ Under $25,000 | ¨ Under $25,000 | ||||
¨ $25,000 – $50,000 | ¨ $25,000 – $50,000 | ¨ $25,000 – $50,000 | ||||
¨ $50,000 – $75,000 | ¨ $50,000 – $75,000 | ¨ $50,000 – $75,000 | ||||
¨ $75,000 – $100,000 | ¨ $75,000 – $100,000 | ¨ $75,000 – $100,000 | ||||
¨ $100,000 – $200,000 | ¨ $100,000 – $150,000 | ¨ $100,000 – $150,000 | ||||
¨ $200,000 – $300,000 | ¨ $150,000 – $200,000 | ¨ $150,000 – $200,000 | ||||
¨ $300,000 – $500,000 | ¨ $200,000 – $250,000 | ¨ $200,000 – $250,000 | ||||
¨ $500,000 – $1,200,000 | ¨ $250,000 – $500,000 | ¨ $250,000 – $500,000 | ||||
¨ Over $1,200,000 | ¨ $500,000 – $1,000,000 | ¨ $500,000 – $1,000,000 | ||||
¨ $1,000,000 – $5,000,000 | ¨ $1,000,000 – $5,000,000 | |||||
¨ Over $5,000,000 | ¨ Over $5,000,000 |
C-7. Please provide in the space below any additional information which would indicate that you have sufficient knowledge and experience in financial and business matters so that you are capable of evaluating the merits and risks of investing in restricted securities of private or thinly traded enterprise.
D. | Please provide the following information concerning your industry and other affiliations. |
D-1. Are you, your spouse or spousal equivalent, or any other immediate family members, including parents, in-laws, and siblings that are dependents, an officer, director or greater than ten percent (10%) shareholder of the Company offering securities?
¨ Yes ¨ No
D-2. Are you, your spouse or spousal equivalent, or any other immediate family members, including parents, in-laws, and siblings that are dependents, employed by or associated with the securities industry (for example, investment advisor, sole proprietor, partner, officer, director, branch manager or broker at a broker-dealer firm or municipal securities dealer) or a financial regulatory agency, such as FINRA or the New York Stock Exchange?
¨ Yes ¨ No
If yes, please provide the name and contact information for such firm.
44
D-3. Are you a senior military, governmental or political official in a non-US country?
¨ Yes ¨ No
If yes, please provide the name of the country.
E. | Did anyone at Boustead Securities, LLC recommend the investment to you? |
¨ Yes ¨ No
If yes, please provide the name of the individual.
F. | Trusted Contact. If you are over 65 years old, please provide the name and contact phone number of a trusted contact: |
Name | Relationship | Contact Number |
45
VIII. SIGNATURES |
This Questionnaire contains various statements and representations by subscribers and should be carefully reviewed in its entirety before executing this signature page. I hereby certify that I have reviewed and am familiar with the instructions of this Questionnaire.
¨ | (check if applicable) I hereby certify that I previously invested in the Company and that, unless otherwise indicated in this Questionnaire, the information I provided in the Questionnaire dated for my previous investment continues to be true and correct and is incorporated by reference into this Questionnaire. |
Dated: ____________
Print name of individual subscriber, custodian, corporation, trust: | Signature of individual subscriber, authorized person, Trustee: | |
Print name of co-subscriber, authorized person, co-trustee if required by trust instrument: | Signature of co-subscriber, authorized person, co-trustee if required by trust instrument: | |
Investment Authorization. The undersigned corporation, partnership, limited liability company, benefit plan, or IRA has all requisite authority to acquire the securities hereby subscribed for and to complete the Questionnaire, and further, the undersigned officer, partner, manager, or fiduciary of the subscribing entity has been duly authorized by all requisite action on the part of such entity to execute these documents on its behalf. Such authorization has not been revoked and is still in full force and effect.
Check Box: ¨ Yes ¨ No ¨ Not Applicable
CAPACITY CLAIMED BY SIGNER: (select one)
¨ Individual(s) | ¨ Attorney-In-Fact | ||||
¨ Partner(s) | ¨ Trustee(s) | ||||
¨ Corporate Officer: | ¨ Other: | ||||
Title | Title |
46
INSTRUCTIONS FOR COMPLETION OF
INVESTOR REPRESENTATION
AND SUITABILITY QUESTIONNAIRE
(FOR CANADIAN SUBSCRIBERS)
(Attached under separate cover)
47
INVESTOR REPRESENTATION & SUITABILITY QUESTIONNAIRE
(For Canadian Subscribers)
TO BE COMPLETED BY ACCREDITED INVESTORS RESIDENT IN OR SUBJECT TO THE LAWS OF A JURISDICTION OF CANADA
The categories listed herein contain certain specifically defined terms, some of which are defined below the following list of categories. If you are unsure as to the meanings of any term, or are unsure as to the applicability of any category below, please contact your broker and/or legal advisor before completing this certificate.
TO: | Akanda Corp. (the "Company") |
In connection with the purchase of the Securities by the undersigned subscriber, on its own behalf and on behalf of each disclosed principal for whom the subscriber is acting (together referred to as the "Subscriber" for the purposes of this Investor Representation & Suitability Questionnaire), the Subscriber hereby represents, warrants, covenants and certifies to the Company (and acknowledges that the Company and its counsel are relying thereon) that:
(a) | the Subscriber is resident in or otherwise subject to the securities laws of one of the jurisdictions of Canada; |
(b) | the Subscriber is purchasing the Securities as principal for its own account and not for the benefit of any other person (unless the Subscriber is an accredited investor pursuant to paragraphs (p) and (q) below); |
(c) | the Subscriber is (and will be at the closing time) an "accredited investor" within the meaning of National Instrument 45-106 – Prospectus Exemptions or, in Ontario, section 73.3 of the Securities Act (Ontario), on the basis that the Subscriber fits within the category of an "accredited investor" reproduced below beside which the undersigned has indicated the undersigned belongs to such category; |
(d) | the Subscriber was not created and is not used solely to purchase or hold securities as an accredited investor as described in paragraph (m) of the definition of "accredited investor" below; and |
(e) | upon execution of this Investor Representation & Suitability Questionnaire by the Subscriber, this Investor Representation & Suitability Questionnaire and, if applicable, Appendix 1 to Investor Representation & Suitability Questionnaire, will be incorporated into and form a part of the Agreement. |
Terms used herein and not otherwise defined find their meaning in the accompanying Agreement.
(CHECK THE BOX OF THE APPLICABLE CATEGORY OF ACCREDITED INVESTOR ON THE FOLLOWING PAGE AND PROVIDE ANY OTHER INFORMATION REQUIRED AS NOTED BELOW SUCH CATEGORY)
THE COMPANY MAY FOLLOW UP WITH THE SUBSCRIBER AT THE TELEPHONE NUMBER PROVIDED IN ORDER TO VERIFY THEIR ACCREDITED INVESTOR STATUS BY OBTAINING FURTHER INFORMATION IN ORDER SATISFY THE COMPANY'S OBLIGATIONS UNDER APPLICABLE SECURITIES LAWS.
Accredited Investor means:
¨ | (a) | a Canadian financial institution, or a Schedule III bank; |
¨ | (b) | the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada); |
¨ | (c) | a subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary; |
48
¨ | (d) |
a person registered under the securities legislatio of a jurisdiction of Canada as an adviser or dealer;
Jurisdiction(s) registered ____________________________________
Category/ies of registration: __________________________________ |
¨ | (e) | an individual registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred to in paragraph (d); |
¨ | (e.1) |
an individual formerly registered under the securities legislation of a jurisdiction of Canada, other than an individual formerly registered solely as a representative of a limited market dealer under one or both of the Securities Act (Ontario) or the Securities Act (Newfoundland and abrador);
Person with whom Subscriber is or was registered:________________________
Jurisdiction(s) registered: ____________________________________
Category/ies of registration: __________________________________ |
¨ | (f) | the Government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the Government of Canada or a jurisdiction of Canada; |
¨ | (g) | a municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion de la taxe scolaire de l'île de Montréal or an intermunicipal management board in Québec; |
¨ | (h) | any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government; |
¨ | (i) |
a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a jurisdiction of Canada;
Jurisdiction(s) registered: ____________________________________
Registration number(s): __________________________________ |
¨ | (j) |
an individual who, either alone or with a spouse, beneficially owns, directly or indirectly, financial assets having an aggregate realizable value that before taxes, but net of any related liabilities, exceeds $1,000,000;
A subscriber under this category must complete Appendix 1 to this Investor Representation & Suitability Questionnaire – Form 45-106F9 Risk Acknowledgement Form for Certain Accredited Investors |
¨ | (j.1) | an individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related liabilities, exceeds $5,000,000; |
¨ | (k) |
an individual whose net income before taxes exceeded $200,000 in each of the two most recent calendar years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the two most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year;
A subscriber under this category must complete Appendix 1 to this Investor Representation & Suitability Questionnaire – Form 45-106F9 Risk Acknowledgement Form for Certain Accredited Investors |
¨ | (l) |
an individual who, either alone or with a spouse, has net assets of at least $5,000,000;
A subscriber under this category must complete Appendix 1 to this Investor Representation & Suitability Questionnaire – Form 45-106F9 Risk Acknowledgement Form for Certain Accredited Investors |
49
¨ | (m) |
a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements;
Type of entity: ____________________________________
Jurisdiction and date of formation: ____________________________________ |
¨ | (m) |
(n)an investment fund that distributes or has distributed its securities only to
(i) a person that is or was an accredited investor at the time of the distribution;
(ii) a person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment] and 2.19 [Additional investment in investment funds] of NI 45-106, or
(iii) a person described in subparagraph (i) or (ii) that acquires or acquired securities under section 2.18 [Investment fund reinvestment] of NI 45-106; |
¨ | (o) | an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt; |
¨ | (p) |
a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or (subject to paragraph (p.1)) under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case ma be;
Jurisdiction(s) registered: ____________________________________
Registration number(s): ____________________________________ |
¨ | (p.1) |
a trust company or trust corporation registered under the laws of Prince Edward Island and not registered under the Trust and Loan Companies Act (Canada) or under comparable legislation in another jurisdiction of Canada, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be;
Registration number(s): ______________________________________ |
¨ | (q) |
a person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction;
Jurisdiction(s) registered or authorized: __________________________
Category/ies of registration: ___________________________________________ |
¨ | (r) |
a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded;
Registration number(s) of subscriber: __________________________
Name of eligibility adviser or registered adviser: ____________________
Jurisdiction(s) registered: ____________________________________
Category/ies of registration: __________________________________ |
¨ | (s) |
an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) or paragraph (i) in for and function;
Jurisdiction organized: ______________________________
Type of entity: __________________________ |
50
¨ | (t) |
a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors;
Each owner must complete and submit its own copy of this Accredited Investor Status Certificate;
Name(s) of owner(s): ___________________________________
Category/ies of accredited investor: ______________________________ |
¨ | (u) |
an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser;
Name of adviser: _____________________________________
Jurisdiction(s) registered: ______________________________
Category/ies of registration (if applicable): ________________________
Basis of exemption (if applicable): _______________________________ |
¨ | (v) |
a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Québec, the regulator as an accredited investor; or
Jurisdiction(s) recognized or designated: _________________________ |
¨ | (w) |
a trust established by an accredited investor for the benefit of the accredited investor's family members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor's spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor's spouse or of that accredited investor's former spouse.
Name(s) of settlor: ________________________________
Name(s) of trustees: ________________________________
Categories of accredited investor: _______________________________
Categories of beneficiaries: ___________________________________ |
For the purposes hereof, the following definitions are included for convenience:
"Canadian financial institution" means: (i) an association governed by the Cooperative Credit Associations Act (Canada) or a central cooperative credit society for which an order has been made under section 473(1) of that Act; or (ii) a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services cooperative, or league that, in each case, is authorized by an enactment of Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction of Canada;
"entity" means a company, syndicate, partnership, trust or unincorporated organization;
"financial assets" means cash, securities, or any a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation;
"founder" means, in respect of the Company, a person who: (i) acting alone, in conjunction, or in concert with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the Company; and (ii) at the time of the trade is actively involved in the business of the Company;
"fully managed account" means an account of a client for which a person makes the investment decisions if that person has full discretion to trade in securities for the account without requiring the client's express consent to a transaction;
"investment fund" means a mutual fund or a non-redeemable investment fund;
"mutual fund" means an issuer whose primary purpose is to invest money provided by its security holders and whose securities entitle the holder to receive on demand, or within a specified period after demand, an amount computed by reference to the value of a proportionate interest in the whole or in part of the net assets, including a separate fund or trust account, of the issuer;
51
"non-redeemable investment fund" means an issuer,
(i) | whose primary purpose is to invest money provided by its securityholders, |
(ii) | that does not invest: |
(A) | for the purpose of exercising or seeking to exercise control of an issuer, other than an issuer that is a mutual fund or a non-redeemable investment fund; or |
(B) | for the purpose of being actively involved in the management of any issuer in which it invests, other than an issuer that is a mutual fund or a non-redeemable investment fund; and |
(iii) | that is not a mutual fund; |
"related liabilities" means liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial assets and liabilities that are secured by financial assets;
"Schedule III bank" means an authorized foreign bank named in Schedule III of the Bank Act (Canada);
"spouse" means an individual who: (i) is married to another individual and is not living separate and apart within the meaning of the Divorce Act (Canada), from the other individual; (ii) is living with another individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender; or (iii) in Alberta, is an individual referred to in subparagraph (i) or (ii), or is an adult interdependent partner within the meaning of the Adult Interdependent Relationships Act (Alberta); and
"subsidiary" means an issuer that is controlled directly or indirectly by another issuer and includes a subsidiary of that subsidiary.
Affiliate: An issuer is considered to be an affiliate of another issuer if one is a subsidiary of the other, or if both are subsidiaries of the same issuer, or if each of them is controlled by the same issuer.
Control: A person (first person) is considered to control another person (second person) if: (i) the first person, directly or indirectly, beneficially owns or exercises control or direction over securities of the second person carrying votes which, if exercised, would entitle the first person to elect a majority of the directors of the second person, unless that first person holds the voting securities only to secure an obligation; (ii) the second person is a partnership, other than a limited partnership, and the first person holds more than 50% of the interests of the partnership; or (iii) the second person is a limited partnership and the general partner of the limited partnership is the first person.
Beneficial Ownership: The following is an excerpt from Companion Policy 45-106CP which provides guidance as to the meaning of beneficial ownership of financial assets:
Paragraphs (j) and (j.1) of the "accredited investor" definition refer to the beneficial ownership of financial assets. As a general matter, it should not be difficult to determine whether financial assets are beneficially owned by an individual, an individual's spouse, or both, in any particular instance. However, in the case where financial assets are held in a trust or in another type of investment vehicle for the benefit of an individual there may be questions as to whether the individual beneficially owns the financial assets. The following factors are indicative of beneficial ownership of financial assets:
(a) physical or constructive possession of evidence of ownership of the financial asset;
(b) entitlement to receipt of any income generated by the financial asset;
(c) risk of loss of the value of the financial asset; and
(d) the ability to dispose of the financial asset or otherwise deal with it as the individual sees fit.
For example, securities held in a self-directed RRSP, for the sole benefit of an individual, are beneficially owned by that individual. In general, financial assets in a spousal RRSP would also be included for the purposes of the $1,000, 000 financial asset test in paragraph (j) because it takes into account financial assets owned beneficially by a spouse. However, financial assets in a spousal RRSP would not be included for purposes of the $5,000,000 financial asset test in paragraph (j.1). Financial assets held in a group RRSP under which the individual does not have the ability to acquire the financial assets and deal with them directly would not meet the beneficial ownership requirements in either paragraph (j) or paragraph (j.1).
[The rest of this page is intentionally left blank.]
52
SIGNATURE PAGE TO INVESTOR REPRESENTATION &
SUITABILITY QUESTIONNAIRE
(FOR CANADIAN SUBSCRIBERS)
The foregoing representations contained in this Investor Representation & Suitability Questionnaire are true and accurate as of the date of this certificate and will be true and accurate as of the closing time of the Offering. If any such representation ceases to be true and accurate prior to the closing time of the Offering, the undersigned will give immediate written notice of such fact to the Company prior to such closing time.
Dated: | Signed: | |||
Witness (If Subscriber is an Individual) | Print the name of Subscriber | |||
Print Name of Witness | If Subscriber is a corporation, print name and title of Authorized Signing Officer |
53
APPENDIX 1 TO INVESTOR REPRESENTATION & SUITABILITY QUESTIONNAIRE
RISK ACKNOWLEDGEMENT FORM (FORM 45-106F9) FOR CERTAIN ACCREDITED INVESTORS
This form must be completed by "accredited investors" who have checked boxes (j), (k) or (l) of Exhibit B, and by any other accredited investors that the Company directs to complete this form.
WARNING!
This investment is risky. Do not invest unless you can afford to lose all the money you pay for this investment |
Section 1 – TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER | |||
1. About your investment | |||
Type of Securities: Common Shares | Issuer: Akanda Corp. (the "Issuer") | ||
Purchased from: The Issuer | |||
Sections 2 to 4 – TO BE COMPLETED BY THE PURCHASER | |||
2. Risk acknowledgement | |||
This investment is risky. Initial that you understand that: | Your Initials | ||
Risk of loss – You could lose your entire investment of $ ___________ [Insert total dollar amount of the Investment] | |||
Liquidity risk – You may not be able to sell your investments quickly – or at all. | |||
Lack of information – You may receive little or no information about your investment. | |||
Lack of advice – You will not receive advice from the salesperson about whether this investment is suitable for you unless the salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investment. To check whether the salesperson is registered, go to www.aretheyregistered.ca. | |||
3. Accredited investor status | |||
You must meet at least one of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria. |
Your Initials |
||
· | Your net income before taxes was more than $200,000 in each of the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.) | ||
· | Your net income before taxes combined with your spouse's was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year. | ||
· | Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the cash and securities. | ||
54
· | Either alone or with your spouse, you have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.) |
4. Your name and signature | |
By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form. | |
First and Last Name (please print): | |
Signature: | |
Date: | |
Section 5 – TO BE COMPLETED BY THE SALESPERSON | |
5. Salesperson information | |
[Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement.] | |
First and Last Name of Salesperson (please print): Tej Virk | |
Telephone: | Email: tej@akandacorp.com |
Name of Firm (if registered): N/A | |
Section 6 – TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER |
6. For more information about this investment |
For more information about this investment / the Issuer:
Akanda Corp. 77 King Street West, Suite 400 Toronto, ON M5K 0A1
Attention: Chief Executive Officer Email: tej@akandacorp.com
For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at www.securities-administrators.ca. |
Form instructions:
1. | The information in sections 1, 5 and 6 must be completed before the purchaser completes and signs the form. |
2. | The purchaser must sign this form. Each of the purchaser and the issuer or selling security holder must receive a copy of this form signed by the purchaser. The issuer or selling security holder is required to keep a copy of this form for 8 years after the distribution. |
55
Exhibit A
AKANDA CORP.
TERM SHEET SUMMARY
August 26, 2021
This Term Sheet Summary (the “Term Sheet”) summarizes the terms on which you and other qualified accredited investors (the “Investors”) are invited to make an investment (the “Investment”) in Akanda Corp. (“we,” “us,” “our” or the “Company”). This Term Sheet is merely a summary of the terms and provisions of the Subscription Agreement (the “Subscription Agreement”), the form of which has been provided to you. Accordingly, this Term Sheet is qualified in its entirety by reference, and is subject in all instances, to the terms and provisions of the Subscription Agreement. You are advised to carefully review the terms and provisions of the Subscription Agreement, as well as the risk factors attached thereto, before making a decision concerning the Investment.
Issuer: | Akanda Corp., a Province of Ontario, Canada corporation (“Akanda” or the “Company”). |
Business: | The Company is a cannabis cultivation, manufacturing, and distribution company with proposed operations in the Kingdom of Lesotho and the United Kingdom. For more information about the Company and its current and intended operations, see the Business Summary attached as Exhibit B to the Subscription Agreement and the investor deck attached as Exhibit D to the Subscription Agreement. |
Placement Agent: | Boustead Securities, LLC (the “Placement Agent”), a California-based investment bank and Broker/Dealer regulated by the U.S. Financial Industry Regulatory Association and a Member of the Securities Investor Protection Corporation and other licensed brokers who may become part of the selling syndicate. |
Securities Being Offered: | Subject to the terms of this Term Sheet, the Company is offering (the “Offering”) in the aggregate a minimum of USD$5,000,000 or 2,000,000 common shares (the “Minimum Amount”) and up to a maximum of USD$10,000,000 (the “Maximum Amount”) or 4,000,000 common shares (the “Shares”) of the Company, at a purchase price of USD$2.50 per Share (subject to adjustment). |
Minimum Investment: | USD$50,000. The Company may accept investments for less than the minimum investment amount in its sole discretion. |
Offering Size: |
Minimum Amount: USD$5,000,000 or 2,000,000 Shares
Maximum Amount: USD$10,000,000 or 4,000,000 Shares |
Plan of Offering: |
The Shares are being offered through the Placement Agent and selling syndicate on a “best efforts, all or none” basis as to the Minimum Amount and, thereafter, the remaining Shares will be offered on a “best efforts” basis. The Offering will continue until September 30, 2021 (the “Expiration Date”), subject to extension or termination of the Offering prior to the Expiration Date by the Company and the Placement Agent.
The Placement Agent and selling syndicate will receive a success fee not to exceed seven percent (7%) of the gross purchase price of the Shares sold at each closing, payable in cash. In addition, the Placement Agent and selling syndicate will receive a non-accountable expense allowance of one percent (1%) of the gross purchase price of Shares sold. |
56
Affiliates of the Placement Agent and the Company (including their respective officers, directors, employees and affiliates) may purchase Shares in this Offering. Any of such purchases may be used to satisfy the Minimum Amount. | |
Payment and Escrow; Offering Period: | The purchase price for the Shares is payable in U.S. dollars upon delivery of the completed Subscription Agreement and Investor Questionnaire. All subscription funds will be held in a non-interest-bearing escrow account, for the benefit of the investors, in the Company’s name with the Placement Agent’s affiliate Sutter Securities Clearing, LLC, or with such other escrow agent as may be appointed by the Placement Agent and the Company. In the event that the Company does not receive and accept subscriptions for at least the Minimum Amount on or before September 30, 2021, subject to extension, in the discretion of the Placement Agent and the Company, the Company will refund all subscription funds, without interest thereon, and will return to each investor the subscription documents completed by each such investor. If the Company rejects a subscription, either in whole or in part (which decision is in the sole discretion of the Company), the rejected subscription funds, or the rejected portion thereof, will be returned promptly to such investor without interest thereon. After the closing of the Minimum Amount and until the Company has offered in an aggregate the Maximum Amount of Shares in the offering, subsequent closings may occur at any date mutually agreed by the Company and the Placement Agent but no later than September 30, 2021, subject to extension, in the discretion of the Placement Agent and the Company. |
Eligible Investors: | The Shares which are offered by this Term Sheet will be sold to an unlimited number of “accredited investors” in the United States and Canada, including qualified institutional buyers as such term is defined in Rule 501(a) of Regulation D as promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The Shares may also be offered and sold to purchasers outside the United States or Canada in accordance with the rules of Regulation S promulgated under the Securities Act, applicable Canadian securities laws and/or such other rules and regulations, as may be applicable under the circumstances. Investors will be required to make certain representations with respect to their status and business experience and to represent, among other things, that they have received a copy of this Term Sheet, that they understand the terms and risks of this Offering, and that they are capable of withstanding a loss of their entire investment in the Shares. |
Authorized and Issued Capital of the Company: | The authorized capital of the Company consists of an unlimited number of common shares and preferred shares, of which no more than 20,137,740 common shares will be outstanding on a “fully diluted” basis immediately prior to the initial closing of this Offering (“Fully-Diluted Shares Outstanding”). Fully-Diluted Shares Outstanding does not include the Company’s right at any time, upon the approval of its Compensation Committee, to award stock options and / or restricted share unit awards underlying the issuance of up to 20% of issued and outstanding shares to employees under the terms of the Company’s Employee Stock Option Plan (“ESOP”). The shares underlying the initial award of stock options and / or restricted share unit awards shall not exceed 10% of the fully-diluted shares outstanding prior to the Company’s planned initial public offering (“IPO”). |
57
Description of Shares: | The holders of common shares are entitled to one vote for each such share and shall be entitled to notice of any shareholders’ meeting. The Shares are not redeemable at the option of the holder and not convertible into shares of any other class. |
Lock-Up: |
In connection with this Offering, the Investor agrees to the following lock-up agreement with respect to the purchased Shares:
i. From and after the date hereof and until the 180th day after the date the Company’s Common Shares are first listed for trading on a national securities exchange (such first trading day, the “Lock-Up Trigger Date”), the Investor agrees not to sell, transfer or otherwise dispose of the Shares.
ii. Between the 181st and 270th day after the Lock-Up Trigger Date, the Investor agrees not to sell, transfer or otherwise dispose of more than one-third of the Shares purchased pursuant to the Subscription Agreement, subject to a maximum sale on any trading day of 3% of the daily volume.
iii. Between the 271st and 365th day after the Lock-Up Trigger Date, the Investor agrees not to sell, transfer or otherwise dispose of more than one-third of the Shares purchased pursuant to the Subscription Agreement, subject to a maximum sale on any trading day of 3% of the daily volume.
iv. After the 365th day after the Lock-Up Trigger Date, the Investor will be entitled to sell the remaining Shares purchased hereunder without restriction.
Notwithstanding the above, commencing 90 days after the Lock-Up Trigger Date, if the Company’s common share price is at least 50% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Investor may sell one-third of its shares subject to a maximum sale on any trading day of 3% of the daily volume; and if the Company’s common share price is at least 100% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Investor may sell up to an additional one-third of its shares subject to a maximum sale on any trading day of 3% of the daily volume; and if the Company common share price is at least 150% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Investor may sell an additional one-third constituting a maximum total of all of its shares subject to a maximum sale on any trading day of 3% of the daily volume. For purpose of this term, the “IPO price” shall mean the price the Company’s common shares are first sold to the public pursuant to an underwritten registered offering resulting in a listing of its common shares on the NASDAQ Stock Market or another national stock exchange. |
Use of Proceeds: | The Company intends to use the net proceeds from the Offering to: expand its existing operations, fund working capital requirements and potential acquisitions, and fund the cost of the IPO. |
Representations and Warranties: | The Company will make the representations and warranties contained in the Subscription Agreement. |
58
Covenants: | The Subscription Agreement contains certain affirmative and negative covenants of the Company which are customary in a transaction of this nature. |
Conditions Precedent: | The Company will have taken such corporate and shareholder actions as are necessary to approve the definitive agreements and any other transactions contemplated thereby. |
Governing Law: | Province of Ontario, Canada. |
Private Placement: | The Shares offered hereby are not being registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D promulgated thereunder, and pursuant to certain state securities laws. The Company is also offering the Shares in “offshore transactions” to non-U.S. persons made in compliance with the provisions of Regulation S promulgated under the Securities Act. Accordingly, the sale, transfer or other disposition of any of our securities, which are purchased pursuant hereto, may be restricted by applicable federal securities laws and/or the securities laws of one or more non-U.S. countries (depending on the residency of the Investor) and by the provisions of the Subscription Agreement executed by such Investor. See also “Lock-Up” above. |
Restrictions on Transferability: |
None of the Shares have been registered under the Securities Act. As such, they constitute “restricted securities” under the Securities Act. Such Shares may not be sold or otherwise transferred unless they are registered under the Securities Act and applicable foreign or state laws or unless exemptions from registration are available under such laws. Any certificates evidencing the Shares will bear a legend restricting the distribution, resale, transfer, pledge, hypothecation or other disposition of such securities unless and until such securities are registered under the Securities Act or an opinion of counsel acceptable to the Company is received concluding that registration is not required under the Securities Act.
The Company is also not a reporting issuer in any jurisdiction of Canada and the Shares are not currently listed on any stock exchange. Accordingly, pursuant to Canadian securities laws, the Shares will be subject to a statutory hold period in Canada expiring on the date which is four months and a day after the later of (i) the issuance date, and (ii) the date that the Company becomes a reporting issuer in any province or territory of Canada. |
Documentation: | The Shares being offered hereby involve a high degree of risk and should be considered only by persons who can afford the loss of their entire investment. See the Risk Factors attached as Appendix B to the Subscription Agreement. |
Confidentiality: |
You are requested to keep the Offering and the terms thereof, including but not limited to the provisions of this Term Sheet, in the strictest of confidence. Neither this Term Sheet nor any other information regarding the Offering should be disclosed by you other than to your advisors who need to know such information for purposes of evaluating an investment. |
Contact: |
Boustead Securities, LLC 6 Venture, Suite 395 Irvine, California 92618 USA offerings@boustead1828.com |
59
Exhibit B
THIS IS A PRIVATE OFFERING OF SECURITIES OF AKANDA CORP. THAT IS BEING MADE PURSUANT TO RULE 506(B) OF REGULATION D AND REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED AND WITHIN THE UNITED STATES, IS BEING OFFERED ONLY TO ACCREDITED INVESTORS AS DEFINED IN RULE 501 UNDER THE ACT. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
NEITHER THIS BUSINESS SUMMARY NOR THE ACCOMPANYING INVESTOR PRESENTATION MAY BE SHOWN OR GIVEN TO ANY PERSON OTHER THAN THE PERSON TO WHOM IT WAS DIRECTLY PROVIDED BY THE COMPANY AND MAY NOT BE PRINTED, REPRODUCED OR DISSEMINATED IN ANY MANNER WHATSOEVER. FAILURE TO COMPLY WITH THIS DIRECTIVE CAN RESULT IN A VIOLATION OF APPLICABLE LAWS, INCLUDING THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND/OR ANY APPLICABLE FOREIGN LAWS. ANY FURTHER DISTRIBUTION OR REPRODUCTION OF THESE MATERIALS, IN WHOLE OR IN PART, OR THE DIVULGENCE OF ANY OF THE CONTENTS BY AN INVESTOR IS UNAUTHORIZED AND STRICTLY PROHIBITED.
CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: regulatory or political change such as changes in applicable laws and regulations, the ability to obtain and maintain required licenses, the complex and evolving regulatory environment for the cannabis industry, changes in public perception of the cannabis industry, the Company having a limited operating history and negative cash flow from operations, operational risks, the impact of the COVID-19 pandemic, the effect of capital market conditions and other factors on capital availability and general economic, market and business conditions. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including but not limited to assumptions that legal, licensing and regulatory regimes globally in the industry in which the Company operates will become increasingly favorable, that after the Acquisition the Company will experience financial growth and profitability, and that intended expansion of its business and operations and negotiations with strategic third parties to access additional markets will be successful. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.
BUSINESS SUMMARY
Unless otherwise indicated or the context requires otherwise, the words “we,” “us,” “our,” the “Company,” “our Company,” or “Akanda” refer to Akanda Corp., a Province of Ontario, Canada corporation.
The Company
We are a cannabis cultivation, manufacturing and distribution company. We are an early stage, emerging growth company incorporated in the Province of Ontario, Canada and headquartered in London, the United Kingdom.
60
The Proposed Acquisition
During July 2021, Halo Collective Inc. (“Halo”), a publicly-traded, vertically integrated multinational cannabis company (NEO: HALO) (OTCQX: HCANF) (Germany: A9KN), resolved to reorganize its non-U.S. operations to consolidate them under Akanda whose mission is to provide high-quality and ethically sourced medical cannabis products to patients worldwide. In connection with this contemplated reorganization, Akanda intends to acquire all the issued and outstanding equity interests of Cannahealth Limited, a Republic of Malta company (“Cannahealth”), from Halo (the “Acquisition”). Immediately prior to the closing of the Acquisition, Cannahealth will own all the issued and outstanding equity interests of Canmart Limited, an England and Wales company (“Canmart”) and Bophelo Holdings Limited., an England and Wales company, which will own all the issued and outstanding equity interests of Bophelo Bio Science and Wellness (Pty) Ltd., a Kingdom of Lesotho company (“Bophelo”). As a result of this Acquisition, we will operate and control all of Canmart and Bophelo’s respective businesses and affairs. As consideration for this Acquisition, we will issue Common Shares to Halo, which is expected to own approximately 62.06% of all our outstanding Common Shares at the closing of this Acquisition. The Acquisition is expected to close immediately prior to the closing of the Offering.
The following diagram summarizes our legal entity structure at the closing of the proposed Acquisition above and prior to the closing of the Offering.
61
Our Business
We have not commenced commercial operations and currently have no assets other than cash. Upon the completion of the Acquisition, we will operate and control all of Canmart and Bophelo’s respective businesses and affairs, and continue to expand their local operations and develop sales channels of our medicinal-grade cannabis products and cannabis based medical and wellness products in international markets and in particular, in Africa and Europe.
Bophelo
Bophelo’s business focuses on the cultivation of cannabis, the production of medical cannabis products including dried flower, oils, and other concentrates and the supply of such medical cannabis products to wholesalers in international markets. Its operations are based in the Kingdom of Lesotho in the Mafeteng Region of Southern Africa. Bophelo is the holder of one of a limited number of operational licenses issued in Lesotho for the production and export of medicinal cannabis products. On July 27, 2018, the Ministry of Health in Lesotho issued a prohibited drug operator license to Bophelo. This license allows the following activities in respect of cannabis and cannabis resin: cultivate, manufacture, supply, hold, import, export and transit. This license will remain effective for 8 years, with an option for further renewal.
Bophelo commenced operations including establishing sites and first phase construction and starting site preparation activities in 2018. As of August 2021, Bophelo has completed a few harvests and obtained its Good Agricultural and Collection Practices (“GACP”) certification. Furthermore, manufacturing plans are on track to build out an on-site extraction facility at Bophelo of approximately 80 square meters (800 square feet). This extraction room and the accompanying lab will be built to EU GMP specifications, which is expected to allow for export of oils and concentrates worldwide where allowed.
In January 2020, Bophelo entered into a strategic alliance and seed purchase agreement with OG DNA Genetics Inc. (“DNA Genetics”), which provides Bophelo with exclusive rights to develop new and existing DNA Genetics’ strains of medical cannabis in Lesotho for worldwide exportation. The initial period of the strategic alliance is five years, with successive five-year renewal options in place. In addition, Bophelo and DNA Genetics entered into an exclusive seed purchase agreement. This seed purchase agreement will enable Bophelo to commence imports to Lesotho of cannabis seeds for cultivation from DNA Genetics.
On August 7, 2020, Bophelo entered into a C$30,000,000 offtake agreement with Medcan Ltd. for the sale of bulk cannabis biomass, primarily into the European market. The contract specifies initial deliveries of up to 10,000 kilograms. The term of the agreement is for a period commencing on August 3, 2020, and ended on the earlier of: (i) the date on which Medcan has purchased the full specified volume biomass from Bophelo; or (ii) the seventh anniversary of the effective date.
Canmart
Canmart is a licensed importer and distributor of cannabis-based products for medicinal use (“CBPMs”) in the United Kingdom. Canmart holds one of a limited number of Controlled Drug Licenses issued by the Home Office to possess and supply CBPMs in the United Kingdom. This license is due to expire on February 3, 2022 and needs to be reapplied for on a yearly basis. Canmart is required to apply for an import license issued by the Home Office for every specific shipment of CBPMs and Canmart has successfully been granted such import licenses. Canmart holds both a Manufacturer’s Specials License for importation of CBPMs and a Wholesale Distribution Authorization from the Medicines and Healthcare Products Regulatory Agency. In addition, Canmart operates a licensed 25,000 square foot third-party logistics warehouse in the southeast of England.
Canmart commenced importing and distributing CBPMs in 2020. Under the current controlled drugs regulatory regime, Canmart is only able to supply to dispensing pharmacists, clinics and other wholesale distributors. However, Canmart’s intention is to establish direct sales channels to patients through Canmart owned and operated clinics and pharmacies. Canmart’s strategy is to grow the medical cannabis market by identifying patients with specific conditions and needs and providing easy to access education and consultations to patients about medical benefits of CBPMs based on observational clinical studies from international studies. We believe this direct sales model will enable Canmart to expand its market share effectively and efficiently.
62
Our Opportunity, Competitive Strengths and Growth Strategies
We are targeting what we believe to be the lucrative international medical cannabis market, which is estimated to be worth approximately $47 billion by 2027, according to Emergen Research. There has been a growing demand for medical cannabis around the world as a result of the increased legalization of cannabis for medical purposes as well as the rise in cannabis-related medical research activities.
We believe that upon the completion of the Acquisition, the following competitive strengths will contribute to our success and differentiate us from our competitors:
· | Lesotho Cultivation Advantage. Through Bophelo’s cultivation operations, we have the ability to cultivate high yielding strains of cannabis for medical purposes at a comparatively low cost. Conditions at Bophelo’s site of operations near T’sakholo in the Mafeteng District of Lesotho are conductive for the cultivation of medical-grade cannabis including favorable environmental conditions, abundant supply of semi-skilled and unskilled labor, world-class road and air infrastructure network and favorable tax treatments. |
· | Significant Potential to Scale Up Production. Bophelo is one of the largest licensed landholders engaging in cannabis cultivation in Lesotho. Bophelo is cultivating cannabis over a 5 hectare area under greenhouse or indoor conditions, with conditional government approval to expand our cultivation footprint up to 200 hectares once it has fully utilized the first 5 hectares of our licensed cultivation area, which gives us the potential ability to significantly scale up production. Bophelo has leased a 200-hectare land package in an emerging Special Economic Zone in Lesotho which is intended to be dedicated to the cannabis cultivation and related operations. |
· | Possession of Licenses. Canmart possesses a collection of regulatory licenses, of which only a limited number have been issued, for the import and distribution of medical cannabis to patients in the United Kingdom. Bophelo is the holder of one of a limited number of operational licenses issued in Lesotho for the import, cultivation, production and export of medicinal cannabis products. |
· | Pursuit for ESG Goals and Strong Partnership with Local Communities. We focus on environmental, social and governance (“ESG”) initiatives and aim to empower women and vulnerable persons. To this end, Bophelo has partnered and we will continue to partner with Mophuthi Matsoso Development Trust, a Lesotho non-profit organization, to provide for the construction of a learning center, a place of worship, feeding programs and other public good initiatives for the local community of T’sakholo. We believe a commitment to ESG initiatives and building a strong partnership with the local African community will promote goodwill towards our local operations and brands and benefit our long-term business growth. |
· | Experienced Management Team. Our management is experienced and has an extensive knowledge of the international cannabis industry as well as local conditions in Lesotho and the United Kingdom. |
Our goal after the Acquisition is completed is to become a market leader in the cultivation, processing and supply of ethically sourced, medicinal-grade cannabis products and cannabis based medical and wellness products for international markets. Our primary strategies to achieve our goals include:
· | Expanding our production capacity. In the near term, our primary strategy is to expand our production capacity as quickly as possible at Bophelo. We plan to take advantage of the favorable cultivation conditions in Lesotho to achieve economies of scale in our production of premium quality cannabis products. |
· | Expanding our geographic footprint. Our current focus is on selling third-party CBPMs in the United Kingdom in the short term, with plan to expand sales of such products in the United Kingdom and sales of cannabis products produced by Bophelo to international markets, subject to regulatory conditions in such countries. |
63
· | Pursuing accretive acquisitions. We believe that our deal-making capabilities and experience will allow us to successfully identify, consummate and integrate acquisitions. |
· | Ethical sourcing. We are committed to ESG performance in our operations, with a particular focus on empowering women and vulnerable persons in local communities. We believe our ESG commitments and practices will enable us to build strong partnerships with the communities in which we operate, enhance the reputation of our brands and benefit our long-term growth. |
Our Management Team
Louisa Mojela serves as Executive Chairman and director of Akanda and is one of Southern Africa’s most influential and successful business leaders. Ms. Mojela is the Group CEO of Wiphold (Women Investment Portfolio Holdings), one of the largest African-based ESG funds to empower black African women, which she co-founded in 1994. She has led capital raises and held directorships at companies such as Sasol Mining (a subsidiary of Sasol Holdings listed on the New York Exchange), Distell, Ixia Coal, South African Airways, Ericsson SA, Adcorp, and Sun International (SJ: SUI), amongst others. In addition to her business dealings, Ms. Mojela is focused on various social development initiatives in Lesotho in line with the Sustainable Development Goals of the Government of Lesotho. She has received numerous accolades for her leadership. Among these, in 2000 she was selected as one of 40 women for the “Leading Women Entrepreneur of the World”; in 2015 she was named one of three “Business Women of the Year – Southern Africa” at the All Africa Business Leaders Awards in partnership with CNBC Africa; and in 2016, she won the European Business Assembly’s “Best Manager of the Year” award at an event held in Switzerland.
Tej Virk, an accomplished cannabis and corporate finance and banking industry executive, serves as Akanda’s founding Chief Executive Officer and director. He joins Akanda from Khiron Life Sciences (TSX-V: KHRN) (OTC: KHRNF) (“Khiron”), where he was President and Managing Director, Europe, establishing Khiron’s medical and consumer packaged goods business in the region. Prior to Khiron, Mr. Virk was Managing Director, Europe, for Canopy Growth Corporation (NASDAQ: CGC) (TSE: WEED) (“Canopy”), where he was responsible for driving the multinational expansion of Canopy's European operations. Working with top research doctors in the UK, Spain, and Germany, he has overseen the launch of multiple medical cannabis products in Europe, including flower for inhalation and oils. Mr. Virk has extensive cannabis sector M&A experience and has transacted on numerous IPOs and follow-on capital raises for global cannabis companies, including Canopy and Tilray (NASDAQ: TLRY). At the beginning of his career, Virk spent 15 years in investment banking and capital markets at BMO Financial Group (NYSE: BMO).
Charles Kie will serve as the Lead Independent Director of Akanda. As the Co-Founder and CEO of New African Capital Partners and former Managing Director and CEO of Ecobank Nigeria, Mr. Kie brings a wealth of financial and operational expertise to the Akanda. Mr. Kie also currently serves as a non-executive board member at Empower Families for Innovative Philanthropy (ERFIP) – Edmond de Rothschild Foundations – Switzerland.
Philip van den Berg serves as director of Akanda and brings an extensive 30-year career in finance, principally in the equities divisions at Goldman Sachs and Deutsche Morgan Grenfell in London, as well as on the buy-side as co-founder of both Olympus Capital Management, one of the first European hedge funds and Taler Asset Management, a wealth management company based in Gibraltar. Since 2014, Mr. van den Berg has been an active investor in various start-up companies in Europe and the U.S. where he has held positions as director and CFO of several public companies. Mr. van den Berg is currently a director and Chief Financial Officer of Halo. He has implemented corporate governance and administrative systems, has been involved in a number of capital market transactions, oversaw a public listing, and has been involved in mergers and acquisitions.
Trevor Scott serves as Akanda’s Chief Financial Officer and Corporate Secretary. Trevor has, since 2009, held several positions as director and CFO of a number of public, stock exchange listed companies and has significant experience in the international cannabis industry. Trevor was involved in the formation of Bophelo in 2018 and has served as its CFO since its inception. Trevor is a chartered accountant by profession, and has experience with regards to fundraising, accounting, investor relations, internal controls and mergers and acquisition related matters.
64
Corporate Structure
Akanda was incorporated on July 16, 2021 in the Province of Ontario, Canada under the Business Corporations Act (Ontario) and is headquartered in London, the United Kingdom.
65
Exhibit C
RISK FACTORS
An investment in the Shares involves a high degree of risk. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition and operating results. If any of the following risks, or any other risks not described below, actually occur, it is likely that business, financial condition and operating results could be seriously harmed. As a result you could lose part or all of your investment.
Risks Related to our Business and Industry
We are an early-stage company with limited operating history and may never become profitable.
The Company was only recently incorporated, has not commenced commercial operations and has no assets other than cash. Each of Bophelo and Canmart has a very limited operating history and has generated minimal revenue. Upon the completion of the Acquisition, we will remain an early-stage company and will have limited financial resources and minimal operating cash flow. If we cannot successfully develop, manufacture and distribute our products, or if we experience difficulties in the development process, such as capacity constraints, quality control problems or other disruptions, we may not be able to develop or offer market-ready commercial products at acceptable costs, which would adversely affect our ability to effectively enter the market or expand our market share. A failure by us to achieve a low-cost structure through economies of scale or improvements in cultivation, manufacturing or distribution processes would have a material adverse effect on our commercialization plans and our business, prospects, results of operations and financial condition.
We will require adequate proceeds generated from this Offering and additional funding to maintain and expand our operations and develop our sales and distribution channels. There can be no assurance that additional funding will be available to us for the development of our business, which will require the commitment of substantial resources. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development. Potential investors should carefully consider the risks and uncertainties that an early stage company with a very limited operating history will face. In particular, potential investors should consider that we may be unable to:
• | successfully implement or execute our business plan, or that our business plan is sound; |
• | effectively pursue business opportunities, including potential acquisitions; |
• | adjust to changing conditions or keep pace with increased demand; |
• | attract and retain an experienced management team; or |
• | raise sufficient funds in the capital markets to effectuate our business plan, including expanding production capacity, licensing and approvals. |
Our financial situation creates doubt as to whether we will continue as a going concern.
Each of Akanda, Bophelo and Canmart has generated no revenue or, only minimal revenue, since inception, and after the completion of the Acquisition, we expect to incur a net loss for the fiscal year ending December 31, 2021 and thereafter, primarily as a result of increased operating expenses to execute our business plan and growth strategy. There can be no assurances that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations or obtain funding from this Offering or additional financing through private placements, public offerings and/or bank financing necessary to support our working capital requirements. To the extent that funds generated from any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire investment.
66
The closing of the Acquisition will be subject to the satisfaction or waiver of certain closing conditions, and there is a risk that the closing will not occur timely if those conditions are not satisfied or waived.
We plan to enter into a share purchase agreement (the “Purchase Agreement”) with Halo to acquire all the issued and outstanding equity interests in Cannahealth. Pursuant to the Purchase Agreement, as consideration for the Acquisition, we will issue 13,129,212 Common Shares at the closing, which is expected to occur immediately prior to the closing of this Offering. The closing of the Acquisition will be subject to the satisfaction or waiver of certain closing conditions, including: (i) the accuracy of the representations and warranties of the parties set forth in the Purchase Agreement as of the closing; (ii) the performance by the parties of all covenants and obligations set forth in the agreement which are required to be performed or complied with at or prior to the closing; (iii) the receipt of all necessary third party consents, waivers and releases required to be obtained in connection with the Acquisition; and (iv) Halo’s completion of certain reorganization transactions to consolidate Bophelo and Canmart’s equity ownership interests under Cannahealth as shown in the diagram on Exhibit B “Business Summary”. Accordingly, if either we or Halo is unable to meet all closing conditions, as required by the Purchase Agreement, we may not be able to close the Acquisition and acquire Bophelo and Canmart.
The Company cannot be certain when or if the conditions for the Acquisition will be satisfied or, if permissible under applicable law, waived, or if or when the Acquisition will be completed. Any failure to complete the Acquisition could negatively impact the Company’s ongoing business, financial condition and results of operations.
Future acquisitions and strategic investments could be difficult to integrate, divert the attention of key management personnel, disrupt our business, dilute shareholder value, and harm our results of operations and financial condition.
We expect to complete the Acquisition by acquiring Bophelo and Canmart from Halo prior to the closing of the Offering and we may in the future seek to acquire or invest in, businesses, products, or technologies that we believe could complement our operations or expand our breadth, enhance our capabilities, or otherwise offer growth opportunities. While our growth strategy includes broadening our product offerings, implementing an aggressive marketing plan and employing product diversification, there can be no assurance that our systems, procedures and controls will be adequate to support our operations as they expand. We cannot assure you that our personnel, systems, procedures or controls will be adequate to support our operations in the future or that we will be able to successfully implement appropriate measures consistent with our growth strategy. As part of our planned growth and diversified product offerings, we may have to implement new operational and financial systems, procedures and controls to expand, train and manage our employee base, and maintain close coordination among our staff. We cannot guarantee that we will be able to do so, or that if we are able to do so, we will be able to effectively integrate them into our existing staff and systems. Additionally, the integration of our acquisitions and pursuit of potential future acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. Any acquisition, investment or business relationship may result in unforeseen operating difficulties and expenditures. In addition, we have limited experience in acquiring other businesses. Specifically, we may not successfully evaluate or utilize the acquired products, assets or personnel, or accurately forecast the financial impact of an acquisition transaction, including accounting charges. Moreover, the anticipated benefits of any acquisition, investment, or business relationship may not be realized, or we may be exposed to unknown risks or liabilities associated with our acquisitions.
We may not be able to find and identify desirable acquisition targets or we may not be successful in entering into an agreement with any one target. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could harm our results of operations. In addition, if an acquired business fails to meet our expectations, our business, results of operations, and financial condition may suffer. In some cases, minority shareholders may exist in certain of our non-wholly-owned acquisitions (for businesses we do not purchase as an 100% owned subsidiary) and may retain minority shareholder rights which could make a future change of control or necessary corporate approvals for actions more difficult to achieve and/or more costly.
We may also make strategic investments in early-stage companies developing products or technologies that we believe could complement our business or expand our breadth, enhance our technical capabilities, or otherwise offer growth opportunities. These investments may be in early-stage private companies for restricted stock. Such investments are generally illiquid and may never generate value. Further, the companies in which we invest may not succeed, and our investments could lose their value.
67
Demand for cannabis and its derivative products could be adversely affected and significantly influenced by scientific research or findings, regulatory proceedings, litigation, or media attention.
The legal cannabis industry in the United Kingdom, the Kingdom of Lesotho and in many other potential international markets for us is at an early stage of its development. Consumer perceptions regarding legality, morality, consumption, safety, efficacy and quality of medicinal cannabis are mixed and evolving and can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medicinal cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medicinal cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity, could have a material adverse effect on the demand for medicinal cannabis and on our business, results of operations, financial condition and cash flows. Public opinion and support for medicinal cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. Our ability to gain and increase market acceptance of our business may require substantial expenditures on investor relations, strategic relationships and marketing initiatives. There can be no assurance that such initiatives will be successful, and their failure to materialize into significant demand may have an adverse effect on our financial condition.
Our success will depend, in part, on our ability to continue to enhance our product offerings to respond to technological and regulatory changes and emerging industry standards and practices.
Rapidly changing markets, technology, emerging industry and regulatory standards and frequent introduction of new products characterize our business. The process of cultivating and processing our cannabis products to meet applicable standards and successfully marketing such products and obtaining necessary licenses requires significant continuing costs, marketing efforts, third-party commitments and regulatory approvals. We may not be successful in timely expanding our production capacity, or obtaining any required regulatory approvals or licenses, which, together with any capital expenditures made in our operations, may have a material adverse effect on our business, financial condition and operating results.
We are subject to the inherent risk of exposure to product liability claims.
As a cultivator and distributor of products designed to be ingested by humans, we face an inherent risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused bodily harm or injury. In addition, the sale of our products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of our products alone or in combination with other medications or substances could occur. We may be subject to various product liability claims, including, among others, that our products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances. Product liability claims or regulatory actions against us could result in increased costs, could adversely affect our reputation with our clients and consumers generally, and could have a material adverse effect on our results of operations and financial condition. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our products.
68
We are subject to the inherent risks involved with product recalls.
Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of our products are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection therewith. There can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if our products are subject to recall, our reputation could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses, and increased legal fees and other expenses.
Research regarding the medical benefits, viability, safety, efficacy, use and social acceptance of cannabis or isolated cannabinoids (such as cannabidiol and tetrahydrocannabinol) remains in early stages.
There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as cannabidiol and tetrahydrocannabinol. Although we believe that the articles, reports and studies support our beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, investors should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions to those stated herein or reach negative conclusions related to medical cannabis, which could have a material adverse effect on the demand for our products and could result in a material adverse effect on our business, financial condition and results of operations or prospects.
We may not be able to maintain effective quality control systems.
We may not be able to maintain an effective quality control system. The effectiveness of our quality control system and our ability to obtain or maintain EU GMP and GACP certifications with respect to our manufacturing, processing and testing facilities depend on a number of factors, including the design of our quality control procedures, training programs, and the ability to ensure that our employees adhere to our policies and procedures. We also may depend on third party service providers to manufacture, process or test our products, that are subject to EU GMP and GACP requirements.
We expect that regulatory agencies will periodically inspect our and our service providers’ facilities to evaluate compliance with applicable EU GMP and GACP requirements. Failure to comply with these requirements may subject us or our service providers to possible regulatory enforcement actions. Any failure or deterioration of our or our service providers’ quality control systems, including loss of EU GMP and GACP certifications, may have a material adverse effect on our business, results of operations and financial condition.
The cannabis and cannabinoid industries face strong opposition.
Many political and social organizations oppose hemp and cannabis and their legalization, and many people, even those who support legalization, oppose the sale of hemp, cannabis and their derivatives in their geographies. Our business will need support from local governments, industry participants, consumers and residents to be successful. Additionally, there are large, well-funded businesses and industry groups that may have a strong opposition to the cannabis industry. For example, the pharmaceutical and alcohol industries have traditionally opposed cannabis legalization. Any efforts by these or other industries opposed to cannabis to halt or impede the cannabis industry could have detrimental effects on our business.
We are subject to the risks inherent in an agricultural business.
Upon the completion of the Acquisition, our business will involve the growing of cannabis, which is an agricultural product. The occurrence of severe adverse weather conditions, especially droughts, fires, storms or floods is unpredictable and may have a potentially devastating impact on agricultural production and may otherwise adversely affect the supply of cannabis. Adverse weather conditions may be exacerbated by the effects of climate change and may result in the introduction and increased frequency of pests and diseases. The effects of severe adverse weather conditions may reduce our yields or require us to increase our level of investment to maintain yields. Additionally, higher than average temperatures and rainfall can contribute to an increased presence of insects and pests, which could negatively affect cannabis crops. Future droughts could reduce the yield and quality of our cannabis production, which could materially and adversely affect our business, financial condition and results of operations.
69
The occurrence and effects of plant disease, insects and pests can be unpredictable and devastating to agricultural production, potentially rendering all or a substantial portion of the affected harvests unsuitable for sale. Even when only a portion of the production is damaged, our results of operations could be adversely affected because all or a substantial portion of the production costs may have been incurred. Although some plant diseases are treatable, the cost of treatment can be high and such events could adversely affect our operating results and financial condition. Furthermore, if we fail to control a given plant disease and the production is threatened, we may be unable to adequately supply our customers, which could adversely affect our business, financial condition and results of operations. There can be no assurance that natural elements will not have a material adverse effect on production.
Our business will be reliant upon third party suppliers, service providers and distributors.
As our business grows, we will need a supply chain for certain material portions of the production and distribution process of our products. Our suppliers, service providers and distributors may elect, at any time, to breach or otherwise cease to participate in supply, service or distribution agreements, or other relationships, on which our operations rely. Loss of our suppliers, service providers or distributors would have a material adverse effect on our business and operational results.
Bophelo currently depends on OG DNA Genetics Inc. for the supply of quality cannabis seeds. Upon the completion of the Acquisition, if for any reason the supply of cannabis seeds is ceased or delayed, we would have to seek alternate suppliers and obtain all necessary authorization for the new seeds. If replacement seeds cannot be obtained at comparable prices, or at all, or if the necessary authorizations are not obtained, our business, financial condition and results of operations would be materially and adversely affected. Our operations could be materially and adversely affected if the supply of cannabis seeds is ceased or delayed and we do not find replacement suppliers and obtain all necessary authorizations.
Part of our strategy is to enter into and maintain arrangements with third parties related to the development, testing, marketing, manufacturing, distribution and commercialization of our products. Our revenues are dependent on the successful efforts of these third parties, including the efforts of our distribution partners. Entering into strategic relationships can be a complex process and the interests of our distribution partners may not be or remain aligned with our interests. Some of our current and future distribution partners may decide to compete with us, refuse or be unable to fulfill or honor their contractual obligations to us, or change their plans to reduce their commitment to, or even abandon, their relationships with us. There can be no assurance that our distribution partners will market our products successfully or that any such third-party collaboration will be on favorable terms.
Our profit margins and the timely delivery of our products are dependent upon the ability of our outside suppliers and manufacturers to supply us with products in a timely and cost-efficient manner. Our ability to develop our business and enter new markets and sustain satisfactory levels of sales in each market depends upon the ability of its outside suppliers and manufacturers to produce the ingredients and products and to comply with all applicable regulations. The failure of our primary suppliers or manufacturers to supply ingredients or produce its products could adversely affect our business operations.
There is no assurance that our sales and promotional activities will be successful.
Our future growth and profitability will depend on the effectiveness and efficiency of sales and promotional expenditures, including our ability to (i) create greater awareness of our products, (ii) determine the appropriate creative message and media mix for future marketing expenditures and (iii) effectively manage sales and promotional costs in order to maintain acceptable operating margins. Upon completion of the Acquisition, we plan to continue to develop the direct sale model of Canmart, which may require us to establish our own clinics and pharmacies. There can be no assurance that our sales and promotional expenditures will result in revenues in the future or will generate awareness of our products and services. In addition, no assurance can be given that we will be able to manage our sales and promotional expenditures on a cost-effective basis.
70
We believe that maintaining and promoting our brand is critical to expanding our customer base. Maintaining and promoting our brand will depend largely on our ability to continue to provide quality, reliable and innovative products, which we may not do successfully. We may introduce new products or services that our customers do not like, which may negatively affect our brand and reputation. Maintaining and enhancing our brand may require us to make substantial investments, and these investments may not achieve the desired goals. If we fail to successfully promote and maintain our brand or if we incur excessive expenses in this effort, our business and financial results from operations could be materially adversely affected.
We may be unable to sustain its pricing model.
Significant price fluctuations or shortages in the cost of materials may increase our cost of goods sold and cause its results of operations and financial condition to suffer. If we are unable to secure materials at a reasonable price, we may have to alter or discontinue selling some of our products or attempt to pass along the cost to its customers, any of which could adversely affect our results of operations and financial condition.
Additionally, increasing costs of labor, freight and energy could increase our and our suppliers’ cost of goods. If our suppliers are affected by increases in their costs of labor, freight and energy, they may attempt to pass these cost increases on to us. If we pay such increases, we may not be able to offset them through increases in its pricing, which could adversely affect our results of operations and financial condition.
We may be unable to effectively manage future growth.
We may be subject to growth-related risks, including capacity constraints and pressure on our internal systems and controls. Our ability to manage growth effectively will require us to continue to implement and improve our operational and financial systems and to expand, train and manage our employee base. Rapid growth of our business may significantly strain our management, operations and technical resources. If we are successful in obtaining large orders for its products, we will be required to deliver large volumes of products to our customers on a timely basis and at a reasonable cost. We may not obtain large-scale orders for our products and if we do, we may not be able to satisfy large-scale production requirements on a timely and cost-effective basis. Our inability to deal with this growth may have a material adverse effect on our business, financial condition, results of operations and prospects.
We are subject to significant competition by new and existing competitors in the cannabis industry.
The industry in which we operate is subject to intense and increasing competition. Many of our competitors have greater resources that may enable them to compete more effectively than us in the cannabis industry, or they have a longer operating history and greater capital resources and facilities, which may enable them to compete more effectively in this market. We expect to face additional competition from existing licensees and new market entrants who are granted licenses in the jurisdictions in which we expect to operate, including the United Kingdom and the Kingdom of Lesotho, and other jurisdictions in which we intend to expand our operations. If a significant number of new licenses are granted in the near term, we may experience increased competition for market share and may experience downward pricing pressure on our products as new entrants increase production. Such competition may cause us to encounter difficulties in generating revenues and market share, and in positioning our products in the market. If we are unable to successfully compete with existing companies and new entrants to the market, our lack of competitive advantage will have a negative effect on our business and financial condition.
The legalization of adult-use, recreational cannabis may reduce sales of medical cannabis.
Legalization of the sale to adults of recreational, non-medical cannabis in any country may increase competition in the medical cannabis market. We currently do not plan to sell recreational, non-medical cannabis products. We may not be able to achieve our business plan in a highly competitive market where recreational, adult-use cannabis is legal, or the market may experience a drop in the price of cannabis and cannabis products over time, decreasing our profit margins.
71
We are dependent upon our management and key employees, and the loss of any member of our management team or any key employee could have a material adverse effect on our operations.
Our success is dependent upon the ability, expertise, judgment, discretion and good faith of our senior management and key employees, including, without limitation, Louisa Mojela, our Executive Chairman, and Tejinder Virk, our Chief Executive Officer. The loss of any member of our management team or any of our key employees could have a material adverse effect on our business and results of operations. While employment agreements and incentive programs are customarily used as primary methods of retaining the services of key employees, these agreements and incentive programs cannot assure the continued services of such employees. Any loss of the services of such individuals, or an inability to attract other suitably qualified persons when needed, could have a material adverse effect on our business, operating results or financial condition. We do not currently maintain key-person insurance on the lives of any of our key employees or members of management. Competition for qualified technical, sales and marketing staff, as well as officers and directors can be intense, and no assurance can be provided that we will be able to attract or retain such qualified individuals in the future, which may adversely affect our operations.
Our directors and officers may have conflicts of interest in conducting their duties.
We may be subject to various potential conflicts of interest because of the fact that some of our officers and directors may be engaged in a range of business activities. In addition, our executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to us. In some cases, our executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to our business and affairs and that could adversely affect our operations. These business interests could require significant time and attention of our executive officers and directors.
The recent Coronavirus (“COVID-19”) outbreak and similar disease outbreaks or public health emergencies could adversely affect our future operations.
Our operations could be significantly and adversely affected by the effects of a widespread global outbreak of a contagious disease and other unforeseen events, including the recent outbreak of a respiratory illness caused by COVID-19 and the related economic repercussions. We cannot accurately predict the effects COVID-19 will have on our operations and the ability of others to meet their obligations with us, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In light of the recent COVID-19 pandemic, upon the completion of the Acquisition, there could be a negative impact on sourcing medical cannabis products for our distribution in the United Kingdom or, the continued buildout and optimization of our cultivation and manufacturing facilities in Lesotho in accordance with the requirement of EU GMP. Additionally, COVID-19 has caused significant disruptions to the global financial markets, which could impact our ability to raise additional capital. The ultimate impact on us and our significant suppliers and prospective customers is unknown, but our operations and financial condition could suffer in the event of any of these types of unpredictable events. Further, any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash flows.
At Bophelo and Canmart’s offices and operations facilities in the United Kingdom and the Kingdom of Lesotho, all employees wear masks and practice social distancing. There are strict protocols on screening of employees and visitors; which include temperature checks and the requirement to complete detailed questionnaires concerning, among other things, possible exposure to COVID-19. Hand sanitizer is provided and hand washing protocols are in place. Signage has been put in place at our operations reminding visitors and staff of COVID-19 protocols. Both the UK and Lesotho governments have commenced the roll-out of COVID-19 vaccines to the population of each of those countries. The UK population has reached a significant level of vaccination, while Lesotho’s rate of vaccination is still in its early stages. Bophelo and Canmart have encouraged all of their employees to be vaccinated. Despite these measures taken, there is no guarantee that the continued development of COVID-19 will not affect their operations negatively.
We could be subject to a security breach that could result in significant damage or theft of products and equipment.
Breaches of security at our facilities may occur and could result in damage to or theft of products and equipment. A security breach at our facilities could result in a significant loss of inventory or work in process, expose us to liability under applicable regulations and increase expenses relating to the investigation of the breach and implementation of additional preventative security measures, any of which could have an adverse effect on our business, financial condition and results of operations.
72
We may incur significant costs to defend our intellectual property and other proprietary rights.
The ownership and protection of trademarks, patents, trade secrets and intellectual property rights are significant aspects of our future success. Unauthorized parties may attempt to replicate or otherwise obtain and use our products and technology. Policing the unauthorized use of our current or future trademarks, patents, trade secrets or intellectual property rights could be difficult, expensive, time-consuming and unpredictable, as may be enforcing these rights against unauthorized use by others.
In addition, other parties may claim that our products infringe on their proprietary rights such as trade secrets. Such claims, regardless of their merit, may result in the expenditure of significant financial and managerial resources, legal fees, injunctions, temporary restraining orders and/or require the payment of damages. Additionally, we may need to obtain licenses from third parties who allege that we have infringed on their lawful rights. Such licenses may not be available on terms acceptable to us or at all. In addition, we may not be able to obtain or utilize on terms that are favorable to us, or at all, licenses or other rights with respect to intellectual property that we do not own.
Risks Related to Our Expected International Operations and Operations in Emerging Markets
As a company based outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations.
Our business is subject to risks associated with conducting business outside of the United States. Upon the completion of the Acquisition, our operations will be based primarily in the United Kingdom and the Kingdom of Lesotho. Our principal office and Canmart’s operations are located in the United Kingdom, and Bophelo’s cultivation operations are located in Lesotho. Accordingly, our future results could be harmed by a variety of factors, including, without limitation, the following:
· | economic weakness, including inflation, or political instability in non-U.S. economies and markets; |
· | differing and changing regulatory requirements for product licenses and approvals; |
· | differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; |
· | difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; |
· | changes in applicable non-U.S. regulations and customs, tariffs and trade barriers; |
· | changes in applicable non-U.S. currency exchange rates and currency controls; |
· | changes in a specific country’s or region’s political or economic environment, including the implications of the recent decision of the United Kingdom to withdraw from the European Union; |
· | trade protection measures, import or export licensing requirements or other restrictive actions by governments; |
· | differing reimbursement regimes and price controls in certain non-U.S. markets; |
· | negative consequences from changes in tax laws; |
· | compliance with applicable tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment in different jurisdictions of options granted under our share option schemes or equity incentive plans; |
· | workforce uncertainty in countries where labor unrest is more common than in the United States; |
· | difficulties associated with staffing and managing international operations, including differing labor relations; |
· | production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and |
73
· | business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes, typhoons, floods and fires. |
Our business could suffer as a result of the United Kingdom’s withdrawal from the European Union.
While we are incorporated in the Province of Ontario in Canada, our principal office, a number of our executive officers and key employees, and Canmart’s operations and assets are primarily located in the United Kingdom. The United Kingdom formally exited the European Union, commonly referred to as Brexit, on January 31, 2020. Under the terms of its departure, the United Kingdom entered into a transition period during which it continued to follow all European Union rules, and the trading relationship remained the same, until December 31, 2020. On December 24, 2020, the European Union and the United Kingdom entered into a new trade agreement to govern their relationship following Brexit. However, substantial uncertainty remains concerning which EU laws and regulations will continue to be implemented in the United Kingdom after Brexit (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data protection laws, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws).
The uncertainty concerning the United Kingdom’s legal, political and economic relationship with the European Union after Brexit may negatively impact direct foreign investment in the United Kingdom, increase costs, depress economic activity and restrict access to capital. It may also be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border cooperation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit. We may also face new regulatory costs and challenges that could have an adverse effect on our operations.
The United Kingdom’s withdrawal from the European Union could lead to increased market volatility, which could make it more difficult for us to do business in Europe or have other adverse effects on our business.
As a result of the United Kingdom’s withdrawal from the European Union, the United Kingdom now has third country status outside of the European Union. Before the end of 2020, the United Kingdom and the European concluded a Trade and Cooperation Agreement (“TCA”) which took effect January 1, 2021. The terms of the TCA allow for tariff-free and quota-free access to the EU market for the United Kingdom so long as the United Kingdom does not diverge from EU laws. To the extent the United Kingdom does diverge from EU laws, access to EU markets may be made more restricted than it currently is. In addition, the TCA does not allow U.K. institutions access to EU markets, so it is possible that there will be a period of considerable uncertainty, particularly in relation to U.K. financial and banking markets, as well as in relation to the regulatory process in Europe. As a result of this uncertainty, financial markets could experience volatility. We may also face new regulatory costs and challenges that could have a material adverse effect on our operations. In this regard, the European Medicines Agency has already issued a notice reminding marketing authorization holders of centrally authorized medicinal products for human and veterinary use of certain legal requirements that need to be considered as part of Brexit, such as the requirement for the marketing authorization holder of a product centrally approved by the European Commission to be established in the European Union, and the requirement for some activities relating to centrally approved products to be performed in the European Union. As a third country, the United Kingdom will lose the benefits of global trade agreements negotiated by the European Union on behalf of its members, which may result in increased trade barriers which could make our doing business worldwide more difficult. In addition, currency exchange rates in the pound sterling and the euro with respect to each other and the U.S. dollar have already been adversely affected by Brexit. Should this foreign exchange volatility continue, it could cause volatility in our financial results.
We expect to increase our international sales in the future, and such sales may be subject to unexpected exchange rate fluctuations, regulatory requirements and other barriers.
We currently expect that our sales will be denominated in U.S. Dollars and Euro and that we may, in the future, have sales denominated in the currencies of additional countries in which we establish operations or distribution. In addition, upon the completion of the Acquisition, we expect to incur the majority of our operating expenses in U.S. Dollars, Euro, South African Rands and Lesotho Maloti. Our international sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively affect our business, financial condition and results of operations. We have not previously engaged in foreign currency hedging. If we decide to hedge our foreign currency exposure, we may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets. In addition, those activities may be limited in the protection they provide from foreign currency fluctuations and can themselves result in losses.
74
A change in our tax residence could have a negative effect on our future profitability.
Although we are incorporated in the Province of Ontario in Canada, we are a resident in the United Kingdom for tax purposes. It is possible that in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the conduct of our affairs following a review by our directors or for any other reason, we could become, or be regarded as having become, a resident in a jurisdiction other than the United Kingdom. Should we cease to be tax resident in the United Kingdom, we may have exposure related to unexpected tax liabilities, such as a charge of United Kingdom, capital gains tax on a deemed disposal at market value of our assets and of unexpected tax charges in other jurisdictions on our income. Similarly, if the tax residency of any of our future subsidiaries were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge of local capital gains tax on the assets.
Tax regulations and challenges by tax authorities could have a material adverse effect on our business.
We expect to operate in a number of countries and will therefore be regularly examined by and remain subject to numerous tax regulations. Changes in our global mix of earnings could affect our effective tax rate. Furthermore, changes in tax laws could result in higher tax-related expenses and payments. Legislative changes in any of the countries in which we operate could materially impact our tax receivables and liabilities as well as deferred tax assets and deferred tax liabilities. Additionally, the uncertain tax environment in some regions in which we operate may limit our ability to successfully challenge adverse determination by any local tax authorities. We expect to operate in countries with complex tax rules, which may be interpreted in a variety of ways and could affect our effective tax rate. Future interpretations or developments of tax regimes or a higher than anticipated effective tax rate could have a material adverse effect on our tax liability, return on investments and business operations.
In addition, we and our future subsidiaries operate in, are incorporated in and are tax residents of, various jurisdictions. The tax authorities in the various jurisdictions in which we and our subsidiaries operate, or are incorporated, may disagree with and challenge our assessments of our transactions, tax position, deductions, exemptions, where we or our subsidiaries are tax resident, or other matters. If we are unsuccessful in responding to any such challenge from a tax authority, we may be required to pay additional taxes, interest, fines or penalties, we may be subject to taxes for the same business in more than one jurisdiction or may also be subject to higher tax rates, withholding or other taxes. A successful challenge could potentially result in payments to the relevant tax authority of substantial amounts that could have a material adverse effect on our financial condition and results of operations.
Even if we are successful in responding to challenges by taxing authorities, responding to such challenges may be expensive, consume time and other resources, or divert management’s time and focus from our business operations. Therefore, a challenge as to our tax position or status or transactions, even if unsuccessful, may have a material adverse effect on our business, financial condition, results of operations or liquidity or the business, financial condition, and results of operations.
We may be subject to emerging market risks.
Emerging market investment generally poses a greater degree of risk than investment in more mature market economies because the economies in the developing world are more susceptible to destabilization resulting from domestic and international developments.
The Kingdom of Lesotho has a history of economic instability and crises, as well as political instability. Laws and regulations applicable to our cultivation operations in the Kingdom of Lesotho are subject to change in the future and could adversely affect our business, financial condition and results of operations. In particular, fluctuations in the economy in Southern Africa and actions adopted by the government have had and may continue to have a significant impact on companies operating in Southern Africa, including in the Kingdom of Lesotho. Specifically, Bophelo may be impacted by inflation, foreign currency fluctuations, regulatory policies, business and tax regulations and, in general, by the political, social and economic scenarios in the Kingdom of Lesotho and other countries in which we may do business.
75
Global or regional economic crises could negatively affect investor confidence in emerging markets or the economies of the countries in Southern Africa, including the Kingdom of Lesotho. A significant decline in economic growth or a sustained economic downturn for any of Lesotho’s major trading partners (in particular, the United Kingdom, the United States and China) could have a material adverse impact on the balance of trade and remittances, resulting in lower economic growth. Deterioration in the economic and political situation in South Africa, which surrounds the Kingdom of Lesotho entirely, could adversely affect the local economy and cause instability by disrupting diplomatic or commercial relationships with other nearby countries. Any future tensions may cause political and economic uncertainty, instability, market volatility, low confidence levels and higher risk aversion by investors and market participants that may negatively affect economic activity generally in Southern Africa, including in the Kingdom of Lesotho. Such events could materially and adversely affect Bophelo’s business, financial condition and results of operations.
Exchange controls may restrict our ability to convert or transfer sums in foreign currencies.
Companies operating in Southern Africa are subject to exchange control limitations. Exchange controls in Lesotho are administered by the Central Bank of Lesotho. While exchange controls have been relaxed in recent years and may continue to be relaxed, companies operating in Southern Africa remain subject to restrictions on their ability to export capital outside of the Common Monetary Area, which includes South Africa, Namibia, Lesotho and Eswatini. In addition, as the cash flows of certain countries are highly dependent on the export of certain raw materials, the ability to convert such currencies can be limited by the timing of payments for such exports, which may require us to organize our currency conversions around such constraints. These restrictions may affect the manner in which we finance our transactions outside Southern Africa and the geographic distribution of our debt.
We can offer no assurance that additional restrictions on currency exchange will not be implemented in the future or that these restrictions will not limit our ability to transfer cash, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
The markets in which we may operate are exposed to high inflation and interest rates which could increase our operating costs and reduce our profitability.
The economies of the countries in which we may operate, including the Kingdom of Lesotho, in the past have been, and in the future may continue to be, characterized by rates of inflation and interest rates that are substantially higher than those prevailing in the United States and other highly developed economies. High rates of inflation could increase our costs in such regions and decrease our operating margins. Inflation in Southern African countries generally results in an increase in our operational costs. Higher and sustained inflation in the future, with a consequent increase in operational costs, could have a material adverse effect on our results of operations and our financial condition and could result in operations being discontinued or reduced or rationalized, which could have a material adverse effect on our business, financial condition and results of operations.
Although higher interest rates would increase the amount of income we earn on our cash balances, they would also adversely affect our ability to obtain cost-effective debt financing in certain countries in which we may operate.
Operating in emerging markets may subject us to greater political, economic and market risks than those we would face if we only operated in more developed markets, which could increase our operating costs.
Emerging markets, including the Kingdom of Lesotho in Southern Africa, are subject to greater risks than more developed markets. The political, economic and market conditions in many emerging markets present risks that could make it more difficult to operate our business successfully. These risks include:
· | the strength of emerging market economies; |
· | fluctuations in interest rates; |
· | political and economic instability, including higher rates of inflation and currency fluctuations; |
· | high levels of crime and unemployment; |
· | higher levels of corruption, including bribery of public officials; |
· | loss due to civil strife, acts of war or terrorism, guerrilla activities and insurrection; |
76
· | lack of well-developed legal systems which could make it difficult for us to enforce our intellectual property and contractual rights; |
· | potential adverse changes in laws and regulatory practices, including import and export license requirements and restrictions, tariffs, taxation and other laws or policies affecting foreign trade or investment; |
· | restrictions on the right to convert or repatriate currency or export assets; |
· | introduction or changes to indigenization and empowerment programs; |
· | logistical and communications challenges; |
· | difficulties in staffing and managing operations and ensuring the safety of our employees; |
· | greater risk of uncollectible accounts and longer collection cycles; and |
· | future downgrades of the debt ratings of the countries in which we operate. |
If we are unable to effectively manage these risks, it could have a material adverse effect on our business, financial condition and results of operations.
Governments in Africa have in the past intervened in the economies of their respective countries and occasionally made significant changes in policy and regulations. Governmental actions have often involved, among other measures, nationalizations and expropriations, price controls, currency devaluations, mandatory increases on wages and employee benefits, capital controls, limits on imports and arbitrary interference with private ownership of contract rights. Our business, financial condition and results of operations may be adversely affected by changes in government policies or regulations, including such factors as exchange rate and exchange control policies, inflation control policies, price control policies, consumer protection policies, import duties and restrictions, liquidity of domestic capital and lending markets, electricity rationing, tax policies, including tax increases and retroactive tax claims, and other political, diplomatic, social and economic developments in or affecting the countries where we operate. In the future, the level of intervention by African governments may continue to increase. It is difficult to predict the future political, economic and market environment in these countries, and these or other measures could have a material adverse effect on the economy of the countries in which we may operate and, consequently, could have a material adverse effect on our business, financial condition and results of operations.
We face the risk of disruption from labor disputes and changes to labor laws, which could result in significant additional operating costs or alter our relationship with our employees.
We are required to comply with extensive labor regulations in each of the countries in which we will have employees, including with respect to wages, social security benefits and termination payments. For example, Lesotho laws relating to labor regulate work time, provide for mandatory compensation in the event of termination of employment for operational reasons, and impose monetary penalties for non-compliance with administrative and reporting requirements in respect of affirmative action policies, which could result in significant costs.
In addition, future changes to Lesotho legislation and regulations relating to labor may increase our costs or alter our relationship with our employees. Resulting disruptions could have a material adverse effect on our business, results of operations and financial condition.
Risks Related to our Regulatory Framework
The medicinal cannabis regulatory regime is very restrictive and new in the United Kingdom, and laws and enforcement could rapidly change again.
There are significant legal restrictions and regulations that govern the cannabis industry in the United Kingdom. The legislative changes recently made to allow for the prescription and possession of medicinal cannabis without Home Office licenses were very narrow. “Cannabis” remains a Class B controlled drug under the Misuse of Drugs Act 1973 and remains a Schedule 1 drug under the Misuse of Drugs Regulation 2001 (“MDR 2001”). Schedule 1 contains drugs which are not used medically. Cultivation, distribution and possession of Schedule 1 controlled drug is illegal without appropriate licenses. It is only cannabis based products for medicinal use (“CBPMs”) that have been moved to various other schedules under the MDR 2001, which then allows for the prescription and possession of CBPMs without a license.
77
However, there are also strict requirements that need to be met for the supply of CBPMs to patients to be compliant with the regulations. Despite the demand for CBPMs, there has been great reluctance from the medical establishment in general to prescribe “medicinal products” for which there are no official prescribing guidelines and a lack of clinical data. In particular, the Royal College of Physicians and NHS England have issued guidelines for medical practitioners stating that there is currently limited evidence of the effectiveness of CBPMs, except in very limited cases. This appears to have made specialist doctors loathe to prescribe CBPMs against this explicit guidance. As the medical establishment and regulators are still firming up their approaches to guidance and enforcement, this can create a level of operating uncertainty.
Our activities are, and will continue to be, subject to evolving regulation by governmental authorities. Due to the current regulatory environment in the United Kingdom, new risks may emerge; management may not be able to predict all such risks.
UK based companies also need to be aware of the potential difficulties posed by the UK Proceeds of Crime Act 2002 (“POCA”). POCA prohibits dealing with any benefit (directly or indirectly) arising from criminal conduct. Conduct is criminal if it:
· | constitutes an offence in any part of the United Kingdom, or |
· | would constitute an offence in part of the United Kingdom if it occurred there. |
This principle of “dual criminality” means that measures to legalize cannabis overseas can be potentially irrelevant when it comes to investing in the United Kingdom, and medicinal cannabis companies operating in the United Kingdom.
Although the risk of action being taken against a UK investor by law enforcement may be considered low when dealing with the indirect proceeds of cannabis, UK companies and investors should be sure to understand the precise nature of their investments or transactions and to keep in mind that investing in, or doing business with, companies involved in recreational cannabis, even where their activity is legal under the laws applicable to them, may nonetheless cause the UK-based investor or counterparty to violate UK money laundering laws.
Cannabis laws, regulations, and guidelines are dynamic and subject to changes.
Cannabis laws and regulations are dynamic and subject to evolving interpretations which could require us to incur substantial costs associated with compliance or alter certain aspects of our business plan. It is also possible that regulations may be enacted in the future that will be directly applicable to certain aspects of our businesses. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. Management expects that the legislative and regulatory environment in the cannabis industry in the United Kingdom, the Kingdom of Lesotho and internationally will continue to be dynamic and will require innovative solutions to try to comply with this changing legal landscape in this nascent industry for the foreseeable future. Failure to comply with any such legislation may have a material adverse effect on our business, financial condition and results of operations.
Public opinion can also exert a significant influence over the regulation of the cannabis industry. A negative shift in the public’s perception of the cannabis industry could affect future legislation or regulation in different jurisdictions.
There are risks associated with the regulatory regime and permitting requirements of our operations.
Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the cultivation, processing and sale of our products. Bophelo and Canmart currently holds the licenses required to conduct their respective operations. We may not be able to obtain or maintain the necessary licenses, permits, quotas, authorizations or accreditations to operate our business going forward, or may only be able to do so at great cost. We cannot predict the time required to secure all appropriate regulatory approvals for our products, or the extent of testing and documentation that may be required by local governmental authorities.
78
Our officers and directors must rely, to a great extent, on our local legal counsel and local consultants retained in the United Kingdom and Lesotho in order to keep abreast of material legal, regulatory and governmental developments as they pertain to and affect our business operations, and to assist us with governmental relations. Upon the completion of the Acquisition, we must rely, to some extent, on those members of management and the Board who have previous experience working and conducting business in the United Kingdom or the Kingdom of Lesotho in order to enhance our understanding of and appreciation for the local business culture and practices in such jurisdictions.
We also rely on the advice of local experts and professionals in connection with any current and new regulations that develop in respect of banking, financing and tax matters in the jurisdictions in which we operate. Any developments or changes in such legal, regulatory or governmental requirements or in local business practices in such jurisdictions are beyond our control and may adversely affect our business.
We will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. We may be required to compensate those suffering loss or damage by reason of our operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on our business, results of operations and financial condition.
Any failure on our part to comply with applicable regulations or to obtain and maintain the necessary licenses and certifications could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.
Our business activities are heavily regulated in all jurisdictions where we do business. Our operations are subject to various laws, regulations and guidelines by governmental authorities relating to the cultivation, processing, manufacture, marketing, management, distribution, transportation, storage, sale, packaging, labelling, pricing and disposal of cannabis and cannabis products. In addition, we are subject to laws and regulations relating to employee health and safety, insurance coverage and the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services.
Any failure by us to comply with applicable regulatory requirements could:
• | require extensive changes to our operations; |
• | result in regulatory or agency proceedings or investigations; |
• | result in the revocation of our licenses and permits, the imposition of additional conditions on licenses to operate our business, and increased compliance costs; |
• | result in product recalls or seizures; |
• | result in damage awards, civil or criminal fines or penalties; |
• | result in the suspension or expulsion from a particular market or jurisdiction of our key personnel; |
• |
result in restrictions on our operations or the imposition of additional or more stringent inspection, testing and reporting requirements; |
• | harm our reputation; or |
79
• | give rise to material liabilities. |
There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management’s attention and resources or other adverse consequences to our business.
In addition, changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities or a revocation of our licenses and other permits. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely affect our ongoing regulatory compliance costs. There is no assurance that we will be able to comply or continue to comply with applicable regulations.
The legal cannabis market is a relatively new industry. As a result, the size of our target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.
Because the cannabis industry is in a nascent stage, there is a lack of information about comparable companies available for potential investors to review in deciding whether to invest in us and, few, if any, established companies whose business model we can follow or upon whose success we can build. Accordingly, investors should rely on their own estimates regarding the potential size, economics and risks of the cannabis market in deciding whether to invest in our Common Shares. We are an early-stage company that has not generated net income. There can be no assurance that our growth estimates are accurate or that the cannabis market will be large enough for our business to grow as projected.
Although we are committed to researching and developing new markets and products and improving existing products, there can be no assurances that such research and market development activities will prove profitable or that the resulting markets or products, if any, will be commercially viable or successfully produced and marketed. We must rely largely on our own market research to forecast sales and design products as detailed forecasts and consumer research are not generally obtainable from reliable third-party sources in the United Kingdom, the European market, Southern Africa, Canada and in other international jurisdictions.
In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management’s expectations and assumptions. We could also be subject to other events or circumstances that adversely affect the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets.
Marijuana remains illegal under U.S. federal law, and the enforcement of U.S. cannabis laws could change.
There are significant legal restrictions and regulations that govern the cannabis industry in the United States. Marijuana remains a Schedule I drug under the Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. In those states in which the use of marijuana has been legalized, its use remains a violation of federal law pursuant to the Controlled Substances Act. The Controlled Substances Act classifies marijuana as a Schedule I controlled substance, and as such, medical and adult use cannabis use is illegal under U.S. federal law. Unless and until the U.S. Congress amends the Controlled Substances Act with respect to marijuana (and the President approves such amendment), there is a risk that federal authorities may enforce current federal law. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis regulatory programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve us of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against us should we expand our operations into the U.S. Since U.S. federal law criminalizing the use of marijuana pre-empts state laws that legalize its use, enforcement of federal law regarding marijuana may be a significant risk and could greatly harm our business, prospects, revenue, results of operation and financial condition if we were to expand our operations into the United States. We currently have no operations in the United States and no plans to expand our operations into the United States in the foreseeable future.
80
Our activities are, and will continue to be, subject to evolving regulation by governmental authorities. The legality of the production, cultivation, extraction, distribution, retail sales, transportation and use of cannabis differs among states in the United States. Due to the current regulatory environment in the United States, new risks may emerge; management may not be able to predict all such risks. Due to the conflicting views between state legislatures and the federal government regarding cannabis, cannabis businesses are subject to inconsistent laws and regulations. There can be no assurance that the federal government will not enforce federal laws relating to marijuana and seek to prosecute cases involving marijuana businesses that are otherwise compliant with state laws in the future. To date, federal enforcement agencies have taken little or no action against state-compliant cannabis businesses in the United States. However, the DOJ may change its enforcement policies at any time, with or without advance notice. The uncertainty of U.S. federal enforcement practices going forward and the inconsistency between U.S. federal and state laws and regulations may present risks for us if we expand our operations into the United States in the future.
Risks Related to Financials and Accounting
There are tax risks we may be subject to in carrying out our business in multiple jurisdictions.
We will operate and, accordingly, will be subject to income tax and other forms of taxation in multiple jurisdictions. We may be subject to income taxes and non-income taxes in a variety of jurisdictions and our tax structure may be subject to review by both domestic and foreign taxation authorities. Those tax authorities may disagree with our interpretation and/or application of relevant tax rules. A challenge by a tax authority in these circumstances might require us to incur costs in connection with litigation against the relevant tax authority or reaching a settlement with the tax authority and, if the tax authority’s challenge is successful, could result in additional taxes (perhaps together with interest and penalties) being assessed on us, and as a result an increase in the amount of tax payable by us. In addition, we may be subject to different taxes imposed by the local governments in the jurisdictions where we operate, and changes within such tax, legal and regulatory framework may have an adverse effect on our financial results.
Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates are also subject to change. Therefore, our earnings may be affected by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The determination of our provision for income taxes and other tax liabilities will require significant judgment (including based on external advice) as to the interpretation and application of these rules. We may have exposure to greater than anticipated tax liabilities or expenses.
There is a risk that we will be a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes for the current or any future taxable year, which could result in material adverse U.S. federal income tax consequences if you are a U.S. Holder.
If we (or any of our non-U.S. subsidiaries) are a PFIC for any taxable year during which a U.S. Holder owns Common Shares, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder. The determination of whether a corporation is a PFIC for a taxable year depends, in part, on the application of complex U.S. federal income tax rules that are subject to differing interpretations. In addition, the determination of whether a corporation will be a PFIC for any taxable year generally can only be made after the close of such taxable year. Therefore, it is possible that we could be classified as a PFIC for our initial taxable year or in future years due to changes in the nature of our business, composition of our assets or income, as well as changes in our market capitalization. In particular, our PFIC status will depend, in part, on the amount of cash that we raise in this offering and how quickly we utilize the cash in our business. Based upon the foregoing, it is uncertain whether we will be a PFIC for our current taxable year or any future taxable year. We have not determined, if we (or any of our non-U.S. subsidiaries) were to be classified as a PFIC for a taxable year, whether we will provide information necessary for a U.S. Holder to make a “qualified electing fund” election which, if available, would result in tax treatment different from (and generally less adverse than) the general tax treatment for PFICs. Accordingly, U.S. Holders should assume that they will not be able to make a qualified electing fund election with respect to our Common Shares. The PFIC rules are complex, and each U.S. Holder should consult his, her or its own tax advisor regarding the PFIC rules, the elections which may be available, and how the PFIC rules may affect the U.S. federal income tax consequences relating to the ownership and disposition of our Common Shares.
81
Failure to develop our internal controls over financial reporting as we grow could have an adverse effect on our operations.
As we mature, we will need to continue to develop and improve our current internal control systems and procedures to manage our growth. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls, or any failure of those controls once established, could adversely affect our public disclosures regarding our business, financial condition or results of operations. In addition, management’s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors.
Risks Related to our Common Shares and this Offering
Although a minimum offering amount is required, there will be multiple closings in the Offering which will increase the risk that investors, especially earlier investors, could lose their entire investment.
Although a minimum offering amount is required for the initial closing of this Offering, once the minimum offering amount is achieved, proceeds from the Offering will be released then and thereafter as the Company receives additional subscriptions for Shares. If the Company raises less than the maximum offering amount, it may lack the working capital and to fully implement its business plans. No assurance can be given that the Company will raise any funds after the initial closing and the allowance for the Company to have multiple closings increases the chance that investors, particularly early investors, may lose their entire investment.
Affiliates of our Company and the Placement Agent, including officers, directors and existing stockholders of our Company, may invest in this offering and their funds will be counted toward our achievement of the Minimum Amount.
There is no restriction on affiliates of our Company or of the placement agent, including its officers, directors and existing stockholder, investing in the offering. As a result, it is possible that if we raise some funds, but have not reached the minimum amount, affiliates can contribute the balance so that there will be a closing. The minimum amount is typically intended to be a protection for investors and give investors confidence that other investors, along with them, are sufficiently interested in the offering and the company, and its prospects to receive investments of at least the minimum amount. By permitting affiliates to invest in the offering and make up any shortfall between what non-affiliate investors have invested and the minimum amount, this protection is largely eliminated. Investors should be aware that no funds other than their own and those of affiliates investing along with them may be invested in this offering.
We have no significant sources of revenue and limited capitalization and may require additional financing after the Offering, which may not be available.
We are in the development stage and have not generated any revenue. We have limited capitalization, which increases our vulnerability to general adverse economic and industry conditions, limits our flexibility in planning for, or reacting to changes in our business and industry and may place us at a competitive disadvantage to competitors with sufficient or excess capitalization. After the completion of the Acquisition, to develop our business, we will require additional cash in the form of equity or debt following completion of the Offering in order to meet our working capital requirements. If we are unable to obtain sufficient additional financing on satisfactory terms and conditions, we may be forced to curtail our plans or operations. Our ability to obtain additional financing will depend upon a number of factors, many of which are beyond our control. We have no current arrangements with respect to, or sources of, financing other than the proposed Offering. Should we be unable to raise additional capital, investors could lose their entire investment.
82
We have a limited operating history upon which investors may base their investment decision, and as a result any potential investment is highly speculative.
Although we believe our management team has extensive knowledge of the cannabis product industry and closely monitors changes in legislation with regards to recreational cannabis laws worldwide, we operate in an evolving industry that may not develop as expected and we may not be able to adapt as needed to stay competitive in such industry. Furthermore, we were incorporated in July 2021 and Bophelo and Canmart, which we intend to acquire, also each have a limited operating history. We are, and upon the completion of the Acquisition, will continue to subject to all of the business risks and uncertainties associated with any new business, including the risk that we will not achieve any investment objectives as described in the Offering Documents. Our financial condition and results of operations will depend on many factors, including our ability to bring our products to commercial production, marketing success and obtaining and maintaining the necessary licenses and certifications.
An investment in our Shares carries a high degree of risk and should be considered as a speculative investment by purchasers. Akanda, Bophelo and Canmart each have a limited history of earnings, limited cash reserves, a limited operating history, have not paid dividends, and are unlikely to pay dividends in the immediate or near future. We are, and upon the completion of the Acquisition, will continue to be in the development and planning phases of our business. Operations are not yet sufficiently established such that we can mitigate the risks associated with planned activities.
We may be presumed to be insolvent from time to time.
In the future, the Company may not be able to pay its debts as they become due. Therefore, the Company may be deemed to be insolvent until the Company receives sufficient proceeds from debt or equity financings, including the Offering, or until it generates sufficient revenues from operations. No assurance can be given that the Company will raise sufficient funds in equity financings, generate sufficient revenues from operations or that the Company will become solvent should a period of insolvency be experienced.
The purchase price of the Shares has been arbitrarily set and does not bear any relationship to our assets, financial condition or our actual or projected performance or on any other criteria of market value.
As a development stage company we lack operating history or other metrics to provide a valuation of the Shares and we arbitrarily set the price and number of offering Shares to reflect our goals of having a balanced ownership between management and the private investors and our consideration of certain market factors. As a result of this arbitrarily defined initial selling price for the Shares offered hereby, such price does not necessarily bear any relationship to our assets, book value, net worth, financial condition, current or anticipated revenue, cash flow, earnings, shareholders’ equity or any other recognized criteria of market value and is not indicative of the price of the Common Shares that may be realized upon disposition of such Common Shares. Purchasers of our equity securities may not be able to resell their shares at or above their purchase price.
We do not expect to pay dividends on any shares of our capital stock in the near future.
It is not expected that we will pay any cash dividends on any shares of our capital stock in the near future. Initially, it is expected that we will retain virtually any and all profit to fund our business and growth plans. Future dividend declarations and payments will be made at the discretion of our board of directors and will depend on, among other things, the capital needed to satisfy current and projected business opportunities, as well as applicable contractual and regulatory requirements. No assurance can be given that our operations will result in sufficient revenues to enable us to operate at profitable levels or to generate positive cash flows. Furthermore, no assurance can be given that our board of directors will declare dividends even if we are profitable.
There may be no public market for our securities and investors may be unable to liquidate their purchased Shares if they need money.
There is no public market for any of our securities. There is no guarantee that an active market for any of our securities will develop or be sustained after the Offering or in the foreseeable future. Therefore, investors may not be able to sell any securities they acquire in connection with the Offering until a public market develops.
83
There are restrictions on the transfer of our securities.
None of our Shares will be registered with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), or registered or qualified with any state or foreign securities regulatory agency. Until any such registration occurs, investors will not be able to sell, transfer or otherwise dispose of these securities, even if a public market develops for the securities, unless the disposition is exempt from registration under any applicable federal, state or foreign laws. We cannot guarantee that any exemption from registration or qualification will be available subsequent to the Offering. As result, the investors may have to hold the purchased Shares for an indefinite period.
The Company may not be able to achieve its financial projections.
The operating and financial information contained in any projected financial data furnished to investors have been prepared by management of the Company based upon its goals and objectives for the future performance and various assumptions concerning future phenomena. In addition, the Company’s projected results are dependent on the successful implementation of management’s growth and operating strategies and are based on hypothetical assumptions and events over which the Company has only partial or no control. While management believes that its goals and objectives are reasonable and achievable, no assurance can be given that they will be realized. The selection of assumptions underlying the projected information required the exercise of judgment by, and represent the opinions and beliefs of, the Company’s management. Others may have different opinions and beliefs. In addition, the projections have not been compiled, reviewed or examined by any independent public accountants and were not prepared with a view to public disclosure or compliance with published guidelines of the Securities and Exchange Commission or with the guidelines established by the American Institute of Certified Public Accountants regarding projections. Moreover, the Company’s projections are subject to uncertainty due to the effects that economic, legislative, political or other changes may have on future events. Changes in the facts or circumstances underlying such assumptions could materially and adversely affect the projections. To the extent assumed events do not materialize, actual results may vary substantially from the projected results. As a result, no assurance can be given that the Company will achieve the operating or financial results set forth in its financial projections and, accordingly, investors are cautioned about placing undue reliance thereon.
We have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations.
We will have considerable discretion in the application of the net proceeds of this Offering. We intend to use the net proceeds from this offering for operating capacity, potential acquisitions, working capital and general corporate purposes. As a result, investors will be relying upon management’s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this Offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our shareholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.
We have a significant shareholder, which may limit your ability to influence corporate matters and may give rise to conflicts of interest.
We have a significant shareholder, Halo, and certain of our directors and officers including our Executive Chairman, Louisa Mojela, are former directors or officers of Halo. Following this Offering, assuming all of the Shares offered hereby are sold, we anticipate that Halo will own approximately 47.41% of our outstanding Common Shares. Accordingly, Halo exerts and may continue to exert significant influence over us and any action requiring the approval of the holders of our Common Shares, such as election of directors, amendments to our organizational documents, and approval of significant corporate transactions. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our Common Shares that you may feel are in your best interest as one of our shareholders. Furthermore, the interests of Halo may not always coincide with your interests or the interests of other shareholders and Halo may act in a manner that advances its best interests and not necessarily those of other shareholders.
84
Investors may be unable to enforce judgments against our directors and officers because our directors and officers reside outside of the United States.
We are incorporated under the laws of the Province of Ontario, Canada and most of our assets are located outside of the United States. Furthermore, most of our directors and officers reside outside of the United States in Canada, the Kingdom of Lesotho and the United Kingdom. As a result, investors may not be able to effect service of process within the United States upon our directors or officers or enforce against them in U.S. courts, judgments predicated on U.S. securities laws. Likewise, it may also be difficult for an investor to enforce in U.S. courts, judgments obtained against these persons in courts located in jurisdictions outside of the United States.
As a result of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a U.S. based company.
Investing in private placements like this offering involves significant risks not present in investments in public offerings.
Investing in private placements involves a high degree of risk. Securities sold through private placements are typically not publicly traded and, therefore, are less liquid. Additionally, investors will receive restricted securities that are subject to holding period requirements. Companies seeking private placement investments tend to be in earlier stages of development and have not yet been fully tested in the public marketplace. Investing in private placements requires high risk tolerance, low liquidity concerns, and long-term commitments. Investors must be able to afford to lose their entire investment. Investment products are not Federal Deposit Insurance Corporation insured, may lose value, and there is no bank guarantee.
85
Exhibit D
Akanda Corp. Investor Presentation
(Attached under separate cover)
86
Exhibit E
August 26, 2021
Akanda Corp.
77 King Street West, Suite 400
Toronto-Dominion
Centre
Toronto, Ontario M5K 0A1
Attention: Trevor Scott, Chief Financial Officer
Re: Lock-Up Agreement
Ladies and Gentlemen:
This letter (this “Letter Agreement”) is being delivered to Akanda Corp. (the “Company”) in accordance with the subscription agreement signed and delivered by the undersigned to the Company. In order to induce the Company to proceed with the sale and issuance of Common Shares of the Company (“Common Shares”) to the undersigned pursuant to the subscription agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned (the “Securityholder”) hereby agrees with the Company as follows:
1. | Subject to the exceptions set forth herein, the Securityholder agrees not to, without the prior written consent of the Company and the managing underwriter, during the periods specified under (a), (b) and (c) below (the entire period from the date when the period under (a) commences and until the date when the period under (c) expires, the “Lock-up Period”), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Shares or other securities, in cash, or otherwise (the actions specified in clauses (i)-(ii), collectively, “Transfer”) as required below: |
(a) | From the date when the subscription agreement is signed by both the Securityholder and the Company to the 180th day after the closing of the Company’s initial public offering of Common Shares which results in a listing of the Company’s Common Shares on the NASDAQ Stock Market or another national stock exchange (such first trading day, the “Lock-Up Trigger Date”), the Securityholder shall not Transfer the Purchased Shares. |
(b) | Between the 181st and 270th day after the Lock-up Trigger Date, the Securityholder shall not Transfer more than one-third of the Purchased Shares, subject to a maximum sale on any trading day of 3% of the daily volume. |
(c) | Between the 271st and 365th day after the Lock-Up Trigger Date, the Securityholder shall not Transfer more than one-third of the Purchased Shares, subject to a maximum sale on any trading day of 3% of the daily volume. |
(d) | After the 365th day after the Lock-Up Trigger Date, the Securityholder will be entitled to Transfer the remaining Purchased Shares without restriction. |
87
Notwithstanding the foregoing, commencing 90 days after the Lock-Up Trigger Date, if the Company’s Common Share price is at least 50% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Securityholder may sell up to one-third of its Purchased Shares subject to a maximum sale on any trading day of 3% of the daily volume; and if the Company’s Common Share price is at least 100% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Securityholder may sell up to an additional one-third of its Purchased Shares subject to a maximum sale on any trading day of 3% of the daily volume; and if the Company Common Share price is at least 150% higher than the IPO price per share and trades at least 100,000 shares daily, both for ten (10) consecutive trading days, the Securityholder may sell up to an additional one-third of its Purchased Shares constituting a maximum total of all of its Purchased Shares subject to a maximum sale on any trading day of 3% of the daily volume. For purpose of this term, the “IPO price” shall mean the price the Company’s Common Shares are first sold to the public pursuant to an underwritten registered offering resulting in a listing of its Common Shares on the NASDAQ Stock Market or another national stock exchange.
2. | The restrictions set forth in paragraph 1 shall not apply to: |
(a) | in the case of a corporation, limited liability company, partnership, trust or other entity, Transfers to its shareholders, members, partners or trust beneficiaries as part of a distribution, including Transfers by virtue of the laws of the state of the entity’s organization and the entity’s organizational documents upon dissolution of the entity, or to any corporation, partnership or other entity that is its affiliate. |
(b) | in the case of an individual, Transfers by gift to members of the individual’s immediate family (as defined below) or to a trust, the beneficiary of which is a member of one of the individual’s immediate family, an affiliate of such person or to a charitable organization. |
(c) | in the case of an individual, Transfers by virtue of laws of descent and distribution upon death of the individual. |
(d) | in the case of an individual, Transfers pursuant to a qualified domestic relations order. |
provided, however, that (A) in the case of clauses (a) through (d), these permitted transferees must enter into a written agreement, in substantially the form of this Letter Agreement (it being understood that any references to “immediate family” in the agreement executed by such transferee shall expressly refer only to the immediate family of the Securityholder and not to the immediate family of the transferee), agreeing to be bound by these Transfer restrictions. For purposes of this paragraph, “immediate family” shall mean a spouse, domestic partner, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned; and “affiliate” shall have the meaning set forth in Rule 405 under the Securities Act of 1933, as amended.
3. | This Letter Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto. |
4. | No party hereto may assign either this Letter Agreement or any of its rights, interests or obligations hereunder without the prior written consent of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Securityholder and each of its respective successors, heirs and assigns and permitted transferees. |
5. | This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the Province of Ontario, Canada and the federal laws of Canada applicable therein, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in a court of competent jurisdiction in the Province of Ontario, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum. |
88
6. | This Letter Agreement shall terminate on the expiration of the Lock-up Period. In addition to the restrictions agreed upon herein, the Securityholder acknowledges and agrees that it shall comply with any Transfer restrictions imposed by the subscription agreement and the applicable law whether within or beyond the Lock-up Period. |
7. | The undersigned acknowledges and agrees that Boustead Securities, LLC is an intended, third-party beneficiary of this Agreement and may enforce the Company’s rights hereunder directly against the undersigned as if Boustead Securities, LLC were a party to this Agreement. |
The undersigned understands that the Company and the underwriters for the Company’s initial public offering are relying on this Letter Agreement in proceeding toward consummation of the public offering. This Letter Agreement is irrevocable and shall be binding upon the undersigned and the heirs, personal representatives, successors and assigns of the undersigned.
Very truly yours,
|
|
[SECURITYHOLDER NAME] |
89
Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. This information is not material and disclosure of such information would constitute an unwarranted invasion of personal privacy. “[*]” indicates that information has been redacted.
SUPPLEMENT
NUMBER 1
to
INVESTOR PACKAGE
Dated August 26, 2021
with respect to the offering by
AKANDA CORP.
Offering of a
Minimum of 2,000,000 Shares at $2.50 per Share ($5,000,000)
up to a
Maximum of 4,000,000 Shares at $2.50 per Share ($10,000,000)
The information contained herein corrects and supplements certain information contained in the Confidential Private Placement Investor Package that was previously distributed to you in September 2021 (the “September Investor Package”). Each prospective investor should carefully review and consider the information contained herein before deciding whether to invest in the Shares referred to in the September Investor Package. From and after the date hereof, all references in the September Investor Package to “this Investor Package” (or similar expressions) shall be deemed to refer the September Investor Package as corrected and supplemented by the information contained in this Supplement. Capitalized terms used herein, unless otherwise defined or noted in this Supplement, shall have the meanings set forth in the September Investor Package.
1. This Supplement extends the offering period to November 29, 2021. The Company may, in its sole discretion, extend the Offering up to an additional 60 days beyond November 29, 2021. The offering period was previously set to expire on September 30, 2021.
Should you have any questions regarding the extension of the offering period or if you have already placed your funds in escrow but no longer desire to go forward with your investment as a result of this change to the offering period, please contact your representative at the placement agent or contact Trevor Scott, Chief Financial Officer of the Company, at [*] or by email at [*].
The date of this Supplement is September 28, 2021
RECONFIRMATION OFFER
The undersigned (“you” or the “Investor”) has subscribed to purchase $_________ (the “Subscription Amount”) of securities of Akanda Corp., a Province of Ontario, Canada corporation (the “Company”), in connection with the Company’s private placement (the “Original Offering”) as described in the Company’s Confidential Private Placement Investor Package, dated August 26, 2021 (the “Investor Package”). The Investor has executed subscription documents and placed the Subscription Amount in an escrow account maintained through Sutter Securities Clearing, LLC.
Following your execution of the subscription documents and payment of the Subscription Amount, the Company and Boustead Securities LLC (the “Placement Agent”) have agreed to extend the last day of the offering period from September 30, 2021 to November 29, 2021. The Company may, in its sole discretion, extend the offering up to an additional 60 days.
The Investor Package has been supplemented as of September 28, 2021, which supplement reflects the fact that the offering period has been extended to November 29, 2021. The Investor Package, as so supplemented, was made available to the Investor by the Placement Agent.
By signing this Reconfirmation Offer in the space provided below, the Investor reconfirms the Investor’s desire to participate in the Offering, acknowledges and agrees to the extended Offering period (to November 29, 2021), and acknowledges and agrees that the Investor has been provided with the Investor Package, updated as described herein, and reconfirms the Investor’s desire to invest the existing Subscription Amount already delivered to escrow into the Offering. If you do not reconfirm on or before September 30, 2021, then the Subscription Amount will be promptly returned to you without interest.
ACKNOWLEDGED AND AGREED TO
AS OF SEPTEMBER ___, 2021
FOR INDIVIDUALS | FOR ENTITIES: | ||
Print Name | Print Name | ||
By: | |||
Signature | Signature of Authorized Signatory | ||
Print Name of Joint Member, if any | Printed Name of Authorized Signatory | ||
Print Title of Authorized Signatory | |||
Exhibit 10.5
Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. This information is not material and disclosure of such information would constitute an unwarranted invasion of personal privacy. “[*]” indicates that information has been redacted.
AKANDA Corp.
SUBSCRIPTION AGREEMENT FOR COMMON SHARES
The following items in this Subscription Agreement must be completed as directed. Please initial or mark "N/A" in each box, as applicable: |
All Subscribers:
□ All Subscriber information in the boxes on pages 1 and 2. □ A certified cheque, money order, bank draft, wire or other applicable means in the amount of the aggregate subscription price set forth on the face page of this Subscription Agreement made payable to Dentons Canada LLP in Trust
Canadian Purchasers:
□ For Canadian residents purchasing the Common Shares as an "accredited investor" as defined in NI 45-106, a duly completed and executed copy of Schedule "A" (including the applicable schedules attached thereto).
United States Purchasers:
□ For Subscribers resident in the United States, a duly completed and executed copy of Schedule "B".
|
Delivery of Subscription Agreement:
A completed and originally executed copy of this Subscription Agreement and all applicable schedules and exhibits hereto must be delivered by no later than 4:00 p.m. (Toronto time) on the date that is two business days prior to the Closing Time to the Company at:
Akanda Corp.
Address: 77 King Street West, Suite 400, Toronto, Ontario
M5K 0A1
Payment:
A certified cheque, money order, bank draft, wire or other applicable means in the amount of the aggregate subscription price set forth on the face page of this Subscription Agreement made payable to Dentons Canada LLP in Trust. Payment may be made by wire in accordance with the instructions in Schedule "C". Please reference "Akanda Corp." when making payment by wire.
|
-1-
AKANDA Corp.
SUBSCRIPTION AGREEMENT FOR COMMON SHARES
TO: | Akanda Corp. (the "Company") |
The undersigned (the "Subscriber"), on its own behalf and, if applicable, on behalf of those for whom the Subscriber is contracting hereunder, hereby irrevocably subscribes for and agrees to purchase the number of common shares ("Common Shares") in the capital of the Company set forth below for the aggregate subscription price set forth below, representing a subscription price of USD$0.533162238 per Common Share, upon and subject to the terms and conditions set forth in the "Terms and Conditions of Subscription for Common Shares of Akanda Corp." attached to and forming a part of this subscription agreement (this "Subscription Agreement"). In addition to this face page, the Subscriber must also complete the applicable schedules attached hereto.
PART A – DETAILS OF SECURITIES PURCHASED:
Number of Securities:
|
Aggregate Subscription Price: | ||
PART B – LEGAL NAME OF SUBSCRIBER:
|
|||
Non-Individual Subscriber Signature
___________________________________________________ (Name of Subscriber - please print)
By: ________________________________________________ (Authorized Signature)
___________________________________________________ (Official Capacity or Title - please print)
___________________________________________________ Please print name of individual whose signature appears above on behalf of the non-individual subscriber. |
Individual Subscriber Signature
___________________________________________________ (Family Name - please print)
___________________________________________________ (First Name - please print)
___________________________________________________ (Secondary Given Name(s) - please print)
By: _________________________________________________ (Signature) |
||
OTHER: |
|||
[CHECK IF APPROPRIATE] | |||
The Subscriber is a registrant: | |||
The Subscriber is an insider of the issuer: |
[Subscriber Information Continues on Next Page]
-2-
PART C – CONTACT INFORMATION OF SUBSCRIBER:
Subscriber Information
___________________________________________________ (Subscriber’s Residential Address)
___________________________________________________ (Municipality) (Province/State)
___________________________________________________ (Postal Code/Zip Code) (Country)
___________________________________________________ (Telephone Number)
___________________________________________________ (Email Address)
Number of Securities of the Company currently owned:
___________________________________________________ |
Disclosed Beneficial Subscriber: If the Subscriber is signing as agent for a principal and is not a trust company, trust corporation, or registered adviser described in paragraph (p) or (q) of the definition of "accredited investor" in section 1.1 of National Instrument 45-106 Prospectus Exemptions, each purchasing on behalf of a fully managed account, complete the following and ensure that each of the Schedules, as applicable, are completed on behalf of such principal:
___________________________________________________ (Name of Principal)
___________________________________________________ (Municipality) (Province/State)
___________________________________________________ (Postal Code/Zip Code) (Country)
___________________________________________________ (Telephone Number)
___________________________________________________ (Email Address) |
Register the Securities as set forth below: ¨ Same as Subscriber Information (otherwise complete below)
___________________________________________________ (Name)
___________________________________________________ (Account reference, if applicable)
___________________________________________________ (Address)
___________________________________________________
|
Deliver the Securities as set forth below: ¨ Same as Registered Address (otherwise complete below)
___________________________________________________ (Name)
___________________________________________________ (Account reference, if applicable)
___________________________________________________ (Contact Name)
___________________________________________________ (Address)
___________________________________________________ |
-3-
TO BE COMPLETED BY THE COMPANY ONLY |
The Company accepts the subscription on the terms and conditions of this Subscription Agreement, including the attached "Terms and Conditions of Subscription for Common Shares of Akanda Corp." |
Date:________________________ |
AKANDA Corp. |
By: _________________________ |
Authorized Signing Officer |
-4-
TERMS AND CONDITIONS OF SUBSCRIPTION FOR
Common Shares OF AKANDA Corp.
Details of the Offering
The Subscriber acknowledges that the Common Shares subscribed for by the Subscriber hereunder form part of a private placement by the Company of an aggregate of up to 468,900 Common Shares in the capital of the Company at a subscription price of USD$0.533162238 per Common Share for aggregate gross proceeds of up to USD$250,000 (the "Offering") and that Boustead Securities LLC (the “Placement Agent”), a broker-dealer that is registered with the U.S. Securities And Exchange Commission and a member of the Financial Industry Regulatory Authority in the United States, is acting as the exclusive placement agent. The amount to be raised in the Offering is subject to adjustment by the mutual agreement of the Company and the Placement Agent.
Representations, Warranties and Covenants by Subscriber
1. | The Subscriber represents, warrants and covenants (on its own behalf and on behalf of any beneficial purchaser for whom it is acting) to the Company (and acknowledges that the Company and its counsel are relying thereon) as at the date hereof and as at the completion of the purchase and sale of the Common Shares contemplated hereby that: |
(a) | it has been independently advised as to restrictions with respect to trading in the Common Shares imposed by applicable securities legislation in the jurisdiction in which it resides, confirms that no representation has been made to it by or on behalf of the Company with respect thereto, acknowledges that it is aware of the characteristics of the Common Shares, the risks relating to an investment therein and of the fact that it may not be able to resell the Common Shares except in accordance with limited exemptions under applicable securities legislation and regulatory policies until expiry of the applicable hold period (which hold period may be indefinite) and in compliance with the other requirements of applicable law; |
(b) | it understands that the Company is not a "reporting issuer" as that term is defined in the Securities Act (Ontario), in Ontario, or in any other jurisdiction, and, therefore, the Common Shares will be subject to an indefinite hold period and may not be resold except in accordance with limited exemptions under applicable securities legislation and regulatory policies; |
(c) | it understands that any share certificate or replacement certificate representing the Common Shares will bear a legend or legends, substantially in the following form: |
UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THESE SECURITIES MUST NOT TRADE THE SECURITIES BEFORE THE DATE THAT IS FOUR MONTHS AND ONE DAY AFTER THE LATER OF: (I) THE DATE OF ISSUE, AND (II) THE DATE THE ISSUER BECOMES A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY IN CANADA.
[IF APPLICABLE] THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"), OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING THESE SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ENCUMBERED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S ("REGULATION S") UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C) WITHIN THE UNITED STATES IN ACCORDANCE WITH (1) RULE 144A UNDER THE U.S. SECURITIES ACT OR (2) RULE 144 UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, PROVIDED THAT IN THE CASE OF TRANSFERS PURSUANT TO (C)(2) OR (D) ABOVE, A LEGAL OPINION SATISFACTORY TO THE COMPANY MUST FIRST BE PROVIDED TO THE COMPANY OR THE TRANSFER AGENT, IF ANY, OF THE COMPANY.
-5-
[IF APPLICABLE] THE SALE OF THE SECURITIES REPRESENTED HEREBY HAS NOT BEEN QUALIFIED WITH ANY STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE.
[IF APPLICABLE] THESE SECURITIES MAY NOT CONSTITUTE "GOOD DELIVERY" IN SETTLEMENT OF TRANSACTIONS ON CANADIAN STOCK EXCHANGES. IF THE COMPANY IS A "FOREIGN ISSUER" WITHIN THE MEANING OF REGULATION S AT THE TIME OF TRANSFER, A NEW CERTIFICATE, BEARING NO LEGEND, MAY BE OBTAINED FROM THE TRANSFER AGENT, IF ANY, OF THE COMPANY, UPON DELIVERY OF THIS CERTIFICATE AND A DULY EXECUTED DECLARATION, IN A FORM SATISFACTORY TO THE COMPANY AND THE TRANSFER AGENT OF THE COMPANY AND, IF SO REQUIRED BY THE TRANSFER AGENT OF THE COMPANY, AN OPINION OF COUNSEL, TO THE EFFECT THAT THE SALE OF THE SECURITIES REPRESENTED HEREBY IS BEING MADE IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT.
(d) | it understands that in the event that the Common Shares held by the Subscriber are ever listed on any stock exchange such securities may be subject to restrictive hold periods or escrow provisions and it hereby agrees to accept such hold periods and/or escrow provisions and in furtherance of this covenant, the Subscriber hereby irrevocably appoints the Chief Executive Officer of the Company as his, her, or its attorney-in-fact and authorizes him as his, her, or its attorney-in-fact to approve and sign an escrow agreement on behalf of the Subscriber to provide for escrow of the Common Shares; |
(e) | the delivery of this subscription, the acceptance hereof by the Company and the issuance of Common Shares to the Subscriber complies with all applicable laws of the Subscriber’s jurisdiction of residence and domicile and will not cause the Company or any of its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement to which the Company is not currently subject; |
(f) | it is aware that it is not purchasing the Common Shares hereunder pursuant to a prospectus and as a result: |
(i) | there is no government or other insurance covering the Common Shares; |
(ii) | it is restricted from using most of the civil remedies available under applicable securities legislation; |
(iii) | it will not receive information that would otherwise be required to be provided to it under applicable securities legislation; |
-6-
(iv) | the Company is relieved of certain obligations that would otherwise apply under applicable securities legislation; and |
(v) | no securities commission or similar regulatory authority has reviewed or passed on the merits of the Common Shares or the Offering; |
(g) | it understands that the Company is relying on an exemption from the requirement to provide the Subscriber with a prospectus under applicable Canadian securities laws and, as a consequence of acquiring the Common Shares pursuant to such exemption: |
(i) | certain protections, rights and remedies provided by applicable Canadian securities laws, including statutory rights of rescission, or damages and certain statutory remedies against an issuer, underwriters, auditors, directors and officers that are available to investors who acquire securities offered by a prospectus, will not be available to the Subscriber, |
(ii) | the common law may not provide investors with an adequate remedy in the event that they suffer investment losses in connection with securities acquired in a private placement, and |
(iii) | the Subscriber may not receive information that would otherwise be required to be given under the applicable Canadian securities laws, and the Company is relieved from certain obligations that would otherwise apply under applicable Canadian securities laws; |
(h) | it understands that the sale and delivery of the Common Shares is conditional upon such sale being exempt from the requirements of applicable securities legislation as to the filing of a prospectus or upon the issuance of such orders, consents or approvals as may be required to permit such sale without the requirement of filing a prospectus; |
(i) | no representation has been made to it regarding the present or future value of the Common Shares; |
(j) | it has not received nor has it requested, nor does it have any need to receive, any document describing the business and affairs of the Company and it has not become aware of any advertisement with respect to the Offering or the distribution of the Common Shares by the Company; |
(k) | the Common Shares are not being purchased by the Subscriber as a result of any material information concerning the Company that has not been publicly disclosed and the Subscriber’s decision to tender this offer and acquire the Common Shares has not been made as a result of any oral or written representation as to fact or otherwise made by or on behalf of the Company or any other person and is based entirely upon currently available public information concerning the Company; |
(l) | if the Subscriber is resident in Canada, |
(i) | it is purchasing the Common Shares as principal for its own account and not for the benefit of any other person, (or is deemed to be purchasing as principal under subsection 2.3(5) of National Instrument 45-106 – Prospectus Exemptions ("NI 45-106")) and not with a view to the resale or distribution of all or any of the Common Shares subscribed for hereunder; |
(ii) | it is resident in the jurisdiction set out as the "Subscriber’s Residential Address" on page two hereof; and |
(iii) | it fully complies with a prospectus exemption set forth in Schedule "A" to this Subscription Agreement; |
-7-
(m) | it has not received or been provided with a prospectus, offering memorandum (within the meaning of applicable Canadian securities laws) or any sales or advertising literature in connection with this Subscription Agreement or any document purporting to describe the business and affairs of the Company which has been prepared for review by prospective purchasers to assist in making an investment decision in respect of the Common Shares; |
(n) | if the Subscriber is a resident of the United States, |
(i) | it is resident in the jurisdiction set out as the "Subscriber’s Residential Address" on page two hereof; |
(ii) | it qualifies as an "accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the U.S. Securities Act, and one or more of the categories set forth in Schedule "B" attached hereto and incorporated herein correctly and in all respects describes the Subscriber; |
(iii) | it has been advised that the Common Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the U.S., and that the offer and sale of the Common Shares to it are being made in reliance upon Section 4(a)(2) of the US. Securities Act and Rule 506(b) of Regulation D under the ("Regulation D"); |
(iv) | it acknowledges that it has not purchased the Common Shares as a result of any "directed selling efforts" (as defined in Regulation S under the U.S. Securities Act) or any "general solicitation" or "general advertising" (as those terms are used in Regulation D), including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or on the Internet, or broadcast over radio or television, or any seminar or meeting whose attendees have been invited by general solicitation or general advertising; and |
(v) | Neither Subscriber nor, to its knowledge, any beneficial owner of the Company’s voting equity securities (in accordance with Rule 506(d) of the U.S. Securities Act) held by such Subscriber is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the U.S. Securities Act, (“Disqualification Events”), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the U.S. Securities Act, and disclosed reasonably in advance of the Closing Time in writing in reasonable detail to the Company. |
(o) | it undertakes and agrees that it will not offer or sell the Common Shares in the United States unless such securities are registered under the 1933 Act and the securities laws of all applicable states of the United States or an exemption from such registration requirements is available, and further that it will not resell the Common Shares, except in accordance with the provisions of applicable securities legislation, regulations, rules, policies and orders and stock exchange rules; |
(p) | if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all action pursuant hereto; |
(q) | if a company, body corporate, partnership, incorporated association or other entity, it is a valid and subsisting entity, has the necessary legal capacity and authority to execute and deliver this Subscription Agreement and to take all actions required pursuant thereto, was not created or is not being used solely to purchase or hold the Common Shares and certifies that all necessary approvals by its directors, shareholders, partners, members or otherwise has been given; |
(r) | this Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding and enforceable obligation of the undersigned; |
-8-
(s) | the Subscriber has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment in this company and it is able to bear the economic risk of loss of its investment; |
(t) | if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock exchange or other regulatory authority, the undersigned will execute, deliver, file and otherwise assist the Company in filing, such reports, undertakings and other documents with respect to the issue or continued ownership of the Common Shares as may be required; |
(u) | it will comply with all applicable securities legislation, regulations, rules, orders, policies or other laws concerning the purchasing, holding and resale or other disposition of the Common Shares, including the execution and filing of any required private placement reports. In particular, the Subscriber will not resell or otherwise transfer or dispose of any of the Common Shares except in accordance with the provisions of all applicable securities laws; |
(v) | it will keep confidential all information provided to the Subscriber from time to time relating to the business and affairs of the Company and will not distribute or otherwise make available any such information to any other person or otherwise exploit any such information; |
(w) | none of the funds the Subscriber is using to purchase the Common Shares are, to the knowledge of the Subscriber, proceeds obtained or derived, directly or indirectly, as a result of illegal activities; and |
(x) | the representations and warranties of the Subscriber stated or referred to herein will be true and correct, both as of the execution of this Subscription Agreement and as of the Closing Time (as such term is defined below) as if repeated at such time and shall survive the completion of the issuance of the Common Shares. |
Acknowledgements by Subscriber
2. | The Subscriber acknowledges (on its own behalf and on behalf of any beneficial purchaser for whom it is acting) to the Company (and further acknowledges that the Company and its counsel are relying thereon) that: |
(a) | this subscription represents "seed" or "risk" capital as the Company currently has no business and may not be successful in future efforts to acquire businesses and non-cash assets; |
(b) | the Company was only recently incorporated, has not commenced commercial operations and has no assets other than cash. It has no history of earnings, and may not generate earnings or pay dividends; |
(c) | the directors and officers of the Company will only devote a portion of their time to the business and affairs of the Company and some of them are or will be engaged in other projects or businesses such that conflicts of interest may arise from time to time; |
(d) | assuming completion of the Offering, the Subscriber will suffer an immediate dilution to its investment; |
(e) | the Company may issue additional securities subsequent to this Offering and this may result in further dilution to the Subscriber, which dilution may be significant and which may also result in a change of control of the Company; |
(f) | there can be no assurance that an active and liquid market for the Company's Common Shares will ever develop and an investor may find it difficult to resell its Common Shares; |
-9-
(g) | the Company has only limited funds with which to identify and evaluate potential businesses and assets to acquire and there can be no assurance that the Company will be able to identify any suitable businesses and assets; |
(h) | the Company may never become a "reporting issuer" as that term is defined in the Securities Act (Ontario), in Ontario or in any other jurisdiction; |
(i) | in the event that management of the Company resides outside of Canada or the Company identifies a foreign business for acquisition, investors may find it difficult or impossible to effect service or notice to commence legal proceedings upon any management resident outside of Canada or upon the foreign business and may find it difficult or impossible to enforce against such persons, judgments obtained in Canadian courts; |
(j) | the Subscriber is not entitled to be paid any commission in relation to its participation in the Offering; |
(k) | there is no person acting or purporting to act in connection with the transactions contemplated herein who is entitled to any brokerage or finder’s fee; |
(l) | the Company’s counsel is acting solely as counsel to the Company and not as counsel to the Subscriber; |
(m) | the Placement Agent has entered into an agreement with the Company that provides the Placement Agent with the right to receive certain fees, reimbursement of expenses, rights to act as the Company’s intermediary in the future, and indemnification rights, including the right to receive a success fee payable (i) in cash, equal to seven percent (7%) of the gross amount to be distributed to the Company at the closing of this Offering, plus (ii) a non-accountable expense allowance equal to one percent (1%) of the gross amount to be disbursed to the Company at the closing of this Offering, plus (iii) warrants equal to seven percent (7%) of the gross amount to be disbursed to the Company at the closing of this Offering. |
Representations, Warranties and Covenants by Company
3. | The Company represents, warrants and covenants to the Subscriber that: |
(a) | the Company is a valid and subsisting Ontario company, duly incorporated and in good standing, and has all requisite corporate power and authority to carry on its business as now conducted, to own, lease and operate its properties and assets and to carry out the provisions hereof; and |
(b) | upon their issuance at the Closing Time, the Common Shares will be validly issued and outstanding as fully paid and non-assessable securities of the Company |
(c) | Immediately prior to the Closing Time, the authorized equity of the Company consists of [*] Common Shares, of which [*] Common Shares are issued and outstanding, and [*] preferred shares of which no preferred shares are issued and outstanding. All outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable and have been issued in compliance with all applicable U.S., Canadian and other applicable securities laws. There are no outstanding options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any person any right to subscribe for or acquire, any Common Shares of the Company, or contracts, commitments, understandings or arrangements by which the Company or any subsidiary is or may become bound to issue additional Common Shares, or securities or rights convertible or exchangeable into Common Shares. There are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders) other than as provided herein and the issue and sale of the securities hereunder will not obligate the Company to issue Common Shares or other securities to any person (other than the Subscriber) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under such securities. |
-10-
(d) | Based in part on the representations made by the Subscriber made herein, the offer and sale of the Common Shares hereunder in accordance with this Agreement is exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”) and the securities registration and qualification requirements of the currently effective provisions of the securities laws of the state in which the Subscriber is resident based upon the Subscriber’s address set forth on the signature pages attached hereto. |
(e) | The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the Company. |
(f) | This Agreement has been, or will be, duly executed and delivered by the Company and constitutes, or will constitute, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. |
(g) | The execution and delivery by the Company of this Agreement and the performance and consummation of the transactions contemplated hereby do not and will not (i) violate the Company’s constitutional and organizational documents or any material judgment, order, writ, decree, statute, rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the giving of notice or lapse of time or both), any material mortgage, indenture, agreement, instrument or contract to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any security interest, mortgage, pledge, lien, claim, charge or other encumbrance (“Lien”) upon any property, asset or revenue of the Company (other than any Lien arising under this Agreement) or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations, or any of its assets or properties. |
(h) | No consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other person (including, without limitation, the shareholders of any Person) is required in connection with the execution and delivery of this Agreement and the performance and consummation of the transactions contemplated hereby, other than such as have been obtained and remain in full force and effect and other than such qualifications or filings under applicable securities laws as may be required in connection with the transactions contemplated by this Agreement. |
(i) | There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its subsidiaries that could, individually or in the aggregate, reasonably be expected to have a material adverse effect on the assets, properties, condition (financial or otherwise), operations of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”). |
(j) | Except for brokerage fees payable to the Placement Agent, which have been separately disclosed to the Subscriber, there are no brokerage or finder’s fees or commissions which are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by this Agreement, and the Company has not taken any action that would cause any Subscriber to be liable for any such fees or commissions. |
-11-
(k) | The Company and its subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other similar rights that are necessary or material for use in connection with their respective businesses and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Neither the Company nor any subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any subsidiary violates or infringes upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. |
Closing
4. | The Subscriber agrees to deliver to the Company on or before the Closing Time: |
(a) | this duly completed and executed Subscription Agreement together with the applicable schedules attached hereto; |
(b) | a certified cheque, money order, bank draft, wire or other applicable means in the amount of the aggregate subscription price set forth on the face page of this Subscription Agreement made payable to Dentons Canada LLP in Trust; and |
(d) | such other documents as may be required by counsel to the Company. |
5. | The sale and issuance of the Common Shares will be completed at the offices of the Company at such place, time or date as the Company may determine (the "Closing Time") on an individual basis, provided that the Company shall not be required to complete the sale and issuance of the Common Shares unless the Subscriber shall have complied with Section 4 hereof and the conditions set forth in Section 8 hereof have been met or waived. The certificates for the Common Shares shall be stored at the offices of counsel to the Company, unless a Subscriber specifically requests otherwise, and copies shall be delivered to each individual Subscriber by email subsequent to the Closing Time. |
6. | The Subscriber hereby irrevocably authorizes the Company to complete or correct any errors or omissions in any form or document provided by the undersigned and to register and deliver certificates representing the Common Shares purchased under this subscription in the name and to the address provided on the face page of this Subscription Agreement. |
7. | The Company shall be entitled to rely on delivery of a facsimile or electronic copy of executed subscriptions, and acceptance by the Company of such facsimile or electronic subscriptions shall be legally effective to create a valid and binding agreement between the Subscriber and the Company in accordance with the terms hereof. |
8. | The obligations of the Subscriber and the Company to complete the purchase and sale of the Common Shares as contemplated hereby shall be conditional upon receipt of all regulatory approvals necessary to the purchase and sale of the Common Shares on or before the Closing Time. In the event that this condition has not been met or waived by the Company, the Subscriber shall not be required to purchase, and the Company shall not be required to issue and sell, any Common Shares, and any subscription funds received by the Company will be returned to the Subscriber without interest thereon or deduction therefrom. |
General
9. | The Company has the unconditional right to accept or reject any subscriptions in its sole discretion. If the Company rejects this subscription it will, in a timely manner, cause the return to the Subscriber of the funds tendered herewith, without interest thereon or deduction therefrom. |
10. | The representations, warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Company in determining the suitability of a purchaser of Common Shares and the Subscriber agrees to indemnify the Company against all losses, claims, costs, expenses and damages or liabilities which the Company may suffer or incur caused or arising from reliance thereon. The Subscriber undertakes to immediately notify the Company of any change in any statement or other information relating to the Subscriber set forth herein which takes place after execution hereof and prior to completion of the purchase and sale of the Common Shares contemplated hereby. |
-12-
11. | This Subscription Agreement, any amendment, schedule, exhibit, addendum, attachment or supplement hereto, and all other documents relating hereto shall be governed by and construed in accordance with the internal laws of the Province of Ontario governing contracts made and to be performed wholly therein, and without reference to its principles governing the choice or conflict of laws. The parties hereto irrevocably attorn and submit to the jurisdiction of the courts of the Province of Ontario, sitting in the City of Toronto, with respect to any dispute related to or arising from this Subscription Agreement. Time shall be of the essence hereof. |
12. | This Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations, covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. |
13. | If any provision of this Subscription Agreement is determined to be void or unenforceable in whole or in part, it shall be deemed not to affect or impair the validity of any other provision of this agreement and such void or unenforceable provision shall be severable from this agreement. |
14. | The covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby. |
15. | This Subscription Agreement is not transferable or assignable. |
16. | The Subscriber: |
(a) | acknowledges, consents and authorizes the Company to collect the Subscriber’s personal information (such as full names, residential address and telephone number) for the purpose of completing the Subscriber’s subscription; |
(b) | acknowledges, consents and authorizes the Company to retain the personal information for as long as permitted or required by applicable law or business practices; |
(c) | acknowledges, consents and authorizes the Company to deliver the personal information pertaining to the Subscriber to the applicable regulatory authorities to comply with applicable securities legislation, stock exchanges, revenue or taxing authorities, and any other parties involved in the Offering or future transactions of the Company; and |
(d) | agrees that by executing this Subscription Agreement, the Subscriber is deemed to be consenting to the foregoing collection, use, and disclosure of personal information. |
[Schedule "A" and Schedule "B" follow on next page]
A-1
Schedule "A"
CANADIAN ACCREDITED INVESTOR CERTIFICATE
TO: | AKANDA Corp. (the "Issuer") |
RE: | Purchase of Common Shares of the Issuer |
Representations and Warranties
In connection with the purchase by the undersigned (the "Subscriber") of the Common Shares (as defined in the attached Subscription Agreement), the Subscriber hereby represents, warrants and certifies (on its own behalf and on behalf of any beneficial purchaser for whom it is acting) to the Issuer (and further acknowledges that the Issuer and its counsel are relying thereon) that the Subscriber:
(i) | is purchasing the Common Shares as principal for its own account and not for the benefit of any other person or is deemed to be purchasing as principal pursuant to National Instrument 45-106 – Prospectus Exemptions ("NI 45-106"); |
(ii) | has read and understands the indicated criterion of an accredited investor as set out in Annex "1" to this Schedule "A"; |
(iii) | is (and will be at the Closing Time (as defined in the Subscription Agreement)) an "accredited investor" (as defined in NI 45-106) or Section 73.3 of the Securities Act (Ontario), as applicable, by virtue of satisfying the indicated criterion on Annex "1" to this Schedule "A"; |
(iv) | was not created or used solely to purchase or hold securities as an accredited investor as described in paragraph (m) of the definition of "accredited investor" in NI 45-106; |
(v) | if the Subscriber is an accredited investor by virtue of satisfying paragraph (j), (k) or (l) of Annex "1" to this certificate, it has reviewed and understands the definitions of "financial assets" and "related liabilities", as applicable, contained herein and it acknowledges that it needs to complete Appendix "2" to this Schedule "A"; |
(vi) | has not been provided with any offering memorandum (as such term is defined in Annex "1" to this Schedule "A") in connection with the purchase of the Common Shares; and |
(vii) | upon execution of this Schedule "A" by the Subscriber, this Schedule "A" (and all annexes attached hereto) shall be incorporated into and form a part of the Subscription Agreement. |
By completing this Schedule "A", the Subscriber authorizes the indirect collection of this information by each applicable securities regulatory authority or regulator and acknowledges that such information is made available to the public under applicable securities legislation.
A-2
Certified ________________________:
(Name of Subscriber - please print) | |
By: | |
(Authorized Signature) | |
(Official Capacity or Title - please print) | |
Please print name of individual whose signature appears above if different than the name of the Subscriber printed above. |
A-3
ANNEX "1" (APPLICABLE CATEGORY)
TO CANADIAN ACCREDITED INVESTOR CERTIFICATE (SCHEDULE "A")
(All underlined words have the meanings set forth at the end of this Annex "1").
***Please note that if the Investor qualifies as an "accredited investor" under paragraphs (j), (k) or (l), below, a completed and executed Form 45-106F9 must also be obtained (see Annex "2") ***
Please check the appropriate box:
A-4
¨ | (k) | an individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the 2 most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year, |
¨ | (l) | an individual who, either alone or with a spouse, has net assets of at least $5,000,000, |
¨ | (m) | a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements and that has not been created or used solely to purchase or hold securities as an accredited investor as defined in this paragraph (m), |
¨ | (n) |
an investment fund that distributes or has distributed its securities only to
(i) a person that is or was an accredited investor at the time of the distribution,
(ii) a person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment] of NI 45-106, or 2.19 [Additional investment in investment funds] of NI 45-106, or
(iii) a person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 [Investment fund reinvestment] of NI 45-106, |
¨ | (o) | an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt, |
¨ | (p) | a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be, |
¨ | (q) | a person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction, |
¨ | (r) | a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded, |
¨ | (s) | an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) or paragraph (i) in form and function, |
¨ | (t) | a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors, |
¨ | (u) | an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser, |
A-5
¨ | (v) | a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Québec, the regulator as an accredited investor, |
¨ | (w) | a trust established by an accredited investor for the benefit of the accredited investor’s family members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor’s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor’s spouse or of that accredited investor’s former spouse. |
As used in this ACCREDITED INVESTOR CERTIFICATE, the following terms have the following meanings:
"control person" means
in Ontario, Alberta, Newfoundland and Labrador, Nova Scotia and Saskatchewan:
(a) | a person or company who holds a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, and, if a person or company holds more than 20 per cent of the voting rights attached to all outstanding voting securities of an issuer, the person or company is deemed, in the absence of evidence to the contrary, to hold a sufficient number of the voting rights to affect materially the control of the issuer, or |
(b) | each person or company in a combination of persons or companies, acting in concert by virtue of an agreement, arrangement, commitment or understanding, which holds in total a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, and, if a combination of persons or companies holds more than 20 per cent of the voting rights attached to all outstanding voting securities of an issuer, the combination of persons or companies is deemed, in the absence of evidence to the contrary, to hold a sufficient number of the voting rights to affect materially the control of the issuer; |
in British Columbia and New Brunswick:
(a) | a person who holds a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, or |
(b) | each person in a combination of persons, acting in concert by virtue of an agreement, arrangement, commitment or understanding, which holds in total a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, |
and, if a person or combination of persons holds more than 20% of the voting rights attached to all outstanding voting securities of an issuer, the person or combination of persons is deemed, in the absence of evidence to the contrary, to hold a sufficient number of the voting rights to affect materially the control of the issuer;
in Prince Edward Island, Northwest Territories, Nunavut and the Yukon:
(a) | a person who holds a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, and if a person holds more than 20% of the voting rights attached to all outstanding voting securities of an issuer, the person is deemed, in the absence of evidence to the contrary, to hold a sufficient number of the voting rights to affect materially the control of the issuer, or |
A-6
(b) | each person in a combination of persons acting in concert by virtue of an agreement, arrangement, commitment or understanding, who holds in total a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, and if a combination of persons holds more than 20% of the voting rights attached to all outstanding voting securities of an issuer, the combination of persons is deemed, in the absence of evidence to the contrary, to hold a sufficient number of the voting rights to affect materially the control of the issuer; |
in Quebec:
(a) | a person that, alone or with other persons acting in concert by virtue of an agreement, holds a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer. If the person, alone or with other persons acting in concert by virtue of an agreement, holds more than 20% of those voting rights, the person is presumed to hold a sufficient number of the voting rights to affect materially the control of the issuer; and |
in Manitoba
(a) | a person or company who holds a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, |
(b) | each person or company, or combination of persons or companies acting in concert by virtue of an agreement, arrangement, commitment or understanding, that holds in total a sufficient number of the voting rights attached to all outstanding voting securities of an issuer to affect materially the control of the issuer, or |
(c) | a person or company, or combination of persons or companies, that holds more than 20% of the voting rights attached to all outstanding voting securities of an issuer, unless there is evidence that the holding does not affect materially the control of the issuer; |
"director" means
(a) | a member of the board of directors of a company or an individual who performs similar functions for a company, and |
(b) | with respect to a person that is not a company, an individual who performs functions similar to those of a director of a company; |
"eligibility adviser" means
(c) | a person that is registered as an investment dealer and authorized to give advice with respect to the type of security being distributed, and |
(d) | in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association of chartered accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided that the lawyer or public accountant must not |
(i) | have a professional, business or personal relationship with the issuer, or any of its directors, executive officers, founders, or control persons (as such term is defined in applicable securities legislation), and |
(ii) | have acted for or been retained personally or otherwise as an employee, executive officer, director, associate or partner of a person that has acted for or been retained by the issuer or any of its directors, executive officers, founders or control persons (as such term is defined in applicable securities legislation) within the previous 12 months; |
A-7
"executive officer" means, for an issuer, an individual who is
(a) | a chair, vice-chair or president, |
(b) | a vice-president in charge of a principal business unit, division or function including sales, finance or production, or |
(c) | performing a policy-making function in respect of the issuer; |
"financial assets" means
(a) | cash, |
(b) | securities, or |
(c) | a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation; |
"financial institution" means,
(a) | other than in Ontario, |
(i) | an association governed by the Cooperative Credit Associations Act (Canada) or a central cooperative credit society for which an order has been made under section 473(1) of that Act, |
(ii) | a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services cooperative, or league that, in each case, is authorized by an enactment of Canada or a jurisdiction of Canada to carry on business in Canada or a jurisdiction of Canada; or |
(iii) | a Schedule III bank, |
(b) | and in Ontario, |
(i) | a bank listed in Schedule I, II or III to the Bank Act (Canada); |
(ii) | an association to which the Cooperative Credit Association Act (Canada) applies or a central cooperative credit society for which an order has been made under subsection 473(1) of that Act; or |
(iii) | a loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services cooperative or credit union league or federation that is authorized by a statute of Canada or Ontario to carry on business in Canada or Ontario, as the case may be. |
"founder" means, in respect of an issuer, a person who,
(a) | acting alone, in conjunction, or in concert with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the issuer, and |
(b) | at the time of the distribution or trade is actively involved in the business of the issuer; |
A-8
"fully managed account" means an account of a client for which a person makes the investment decisions if that person has full discretion to trade in securities for the account without requiring the client’s express consent to a transaction;
"investment fund" has the same meaning as in National Instrument 81-106 Investment Fund Continuous Disclosure;
"offering memorandum" means a document, together with any amendments to that document, purporting to describe the business and affairs of an issuer that has been prepared primarily for delivery to and review by a prospective purchaser so as to assist the prospective purchaser to make an investment decision in respect of securities being sold in a distribution to which section 53 of the Securities Act (Ontario) would apply but for the availability of one or more exemptions contained in Ontario securities laws, but does not include a document setting out current information about an issuer for the benefit of a prospective purchaser familiar with the issuer through prior investment or business contacts,
"person" includes
(a) | an individual, |
(b) | a corporation, |
(c) | a partnership, trust, fund and an association, syndicate, organization or other organized group of persons, whether incorporated or not, and |
(d) | an individual or other person in that person’s capacity as a trustee, executor, administrator or personal or other legal representative; |
"related liabilities" means
(a) | liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial assets, or |
(b) | liabilities that are secured by financial assets; |
"Schedule III bank" means an authorized foreign bank named in Schedule III of the Bank Act (Canada);
"spouse" means, an individual who,
(a) | is married to another individual and is not living separate and apart within the meaning of the Divorce Act (Canada), from the other individual, |
(b) | is living with another individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender, or |
(c) | in Alberta, is an individual referred to in paragraph (a) or (b), or is an adult interdependent partner within the meaning of the Adult Interdependent Relationships Act (Alberta); |
"subsidiary" means an issuer that is controlled directly or indirectly by another issuer and includes a subsidiary of that subsidiary.
A-9
Interpretation
In this Schedule "A", a person (first person) is considered to control another person (second person) if
(a) | the first person, directly or indirectly, beneficially owns or exercises control or direction over securities of the second person carrying votes which, if exercised, would entitle the first person to elect a majority of the directors of the second person, unless that first person holds the voting securities only to secure an obligation, |
(b) | the second person is a partnership, other than a limited partnership, and the first person holds more than 50% of the interests of the partnership, or |
(c) | the second person is a limited partnership and the general partner of the limited partnership is the first person. |
A-10
ANNEX "2" (RISK ACKNOWLEDGEMENT FORM)
TO CANADIAN ACCREDITED INVESTOR CERTIFICATE (SCHEDULE "A")
Form 45-106F9
Form for Individual Accredited Investors
WARNING!
This
investment is risky.
Don’t invest unless you can afford to lose all the money you pay for this investment.
SECTION 1 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER | ||||
1. About your investment | ||||
Type of securities: Common Shares | Issuer: Akanda Corp. | |||
Purchased from: the Issuer | ||||
SECTIONS 2 TO 4 TO BE COMPLETED BY THE INVESTOR | ||||
2. Risk acknowledgement | ||||
This investment is risky. Initial that you understand that: | Your initials | |||
Risk of loss – You could lose your entire investment of $____________________.
[Instruction: Insert the total dollar amount of the investment.] |
||||
Liquidity risk – You may not be able to sell your investment quickly – or at all. | ||||
Lack of information – You may receive little or no information about your investment. | ||||
Lack of advice – You will not receive advice from the salesperson about whether this investment is suitable for you unless the salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investment. To check whether the salesperson is registered, go to www.aretheyregistered.ca. | ||||
3. Accredited investor status | ||||
You must meet at least one of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria. | Your initials | |||
· Your net income before taxes was more than $200,000 in each of the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.) | ||||
· Your net income before taxes combined with your spouse’s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year. | ||||
· Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the cash and securities. | ||||
· Either alone or with your spouse, you have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.) | ||||
A-11 |
4. Your name and signature | ||||
By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form. | ||||
First and last name (please print): _____________________________ | ||||
Signature: _____________________________ | Date: _______________ | |||
SECTION 5 TO BE COMPLETED BY THE SALESPERSON | ||||
5. Salesperson information | ||||
[Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement.] | ||||
First and last name of salesperson (please print): ___________________________________________ | ||||
Telephone: ______________________________ | Email: ______________________________ | |||
Name of firm (if registered): _____________________________________ | ||||
SECTION 6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER | ||||
6. For more information about this investment | ||||
Akanda Corp.
Address: 77 King Street West, Suite 400, Toronto, Ontario M5K
0A1
For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at www.securities-administrators.ca. |
||||
Form instructions:
1. | This form does not mandate the use of a specific font size or style but the font must be legible. |
2. | The information in sections 1, 5 and 6 must be completed before the purchaser completes and signs the form. |
3. | The purchaser must sign this form. Each of the purchaser and the issuer or selling security holder must receive a copy of this form signed by the purchaser. The issuer or selling security holder is required to keep a copy of this form for 8 years after the distribution. |
B-1 |
Schedule “B”
U.S. ACCREDITED INVESTOR CERTIFICATE
TO: | AKANDA Corp. (the “Issuer”) |
RE: | Purchase of Common Shares of the Issuer |
The Subscriber hereby represents and warrants (on its own behalf and on behalf of any beneficial purchaser for whom it is acting) to the Issuer (and further acknowledges that the Company and its counsel are relying thereon), pursuant to the attached Subscription Agreement that it is correctly and in all respects described by the category or categories set forth below directly under which the Subscriber or its authorized representative has checked.
The Subscriber acknowledges that upon execution of this Schedule "B" by the Subscriber, this Schedule "B" shall be incorporated into and form a part of the Subscription Agreement.
(Capitalized terms not specifically defined in this Schedule "B" have the meaning ascribed to them in the Subscription Agreement to which this Schedule "B" is attached. All monetary references in this Schedule "B" are in United States Dollars.)
CHECK THE CATEGORY OR CATEGORIES WHICH DESCRIBES THE SUBSCRIBER
¨ | Any bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section 15 of the Exchange Act; any insurance company as defined in Section 2(13) of the Act; any investment company registered under the 1940 Act or a business development company as defined in Section 2(a)(48) of the 1940 Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any Plan (as defined above under "Certain ERISA Considerations") within the meaning of ERISA if the investment decision is made by a Plan fiduciary that is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the Plan has total assets in excess of $5,000,000 or, if a self-directed Plan, with investment decisions made solely by persons that are accredited investors; |
¨ | Any private business development company as defined in Section 202(a)(22) of the Advisers Act; |
¨ | Any organization described in Section 501(c)(3) of the Code, corporation, or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; |
¨ | Any director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer; |
¨ | Any natural person whose individual net worth or joint net worth with that person’s spouse, at the time of his or her purchase exceeds $1,000,0001; |
1 | For purposes of calculating his or her net worth, an investor may include equity in personal property, cash, short term investments, stock, securities and real estate, but must exclude the value of his or her primary residence. Indebtedness secured by a primary residence may also be excluded up to the fair market value of the primary residence, while any excess above the fair market value of the primary residence should be considered a liability and deducted from net worth. Equity in other real estate and in any personal property should be based on the fair market value of such property minus any debt secured by such property. |
B-2 |
¨ | Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; |
¨ | Any trust with total assets in excess of $5,000,000 not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii); |
¨ | Any entity in which all of the equity owners are accredited investors; |
¨ | A person who holds one of the following licenses in good standing: General Securities Representative license (Series 7), the Private Securities Offerings Representative license (Series 82), or the Investment Adviser Representative license (Series 65); |
¨ | A “family office,” as defined in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)-1): (i) with assets under management in excess of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment; and |
¨ | A “family client,” as defined in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)-1)), of a family office meeting the requirements in paragraph (16) above and whose prospective investment in the issuer is directed by such family office pursuant to the immediately preceding clause. |
Dated as of _________________________, 201_
Print name of Subscriber | ||
By: | ||
Signature | ||
Print name of Signatory (if different from Subscriber) | ||
Title |
C-1 |
SCHEDULE “C”
WIRE INSTRUCTIONS
For all trust accounts the Beneficiary Name and Address is as follows:
Dentons Canada LLP in Trust
77 King Street West, Suite 400
Toronto, ON M5K 0A1
Please reference "Akanda Corp.".
If being wired from within Canada in CAD or USD or in CAD from the U.S.
Exhibit 10.6
/RA/65218.1/65871948.5
Service agreement
Dated 2 June 2021
Canmart Limited
(Company)
Halo Labs Inc.
(Guarantor)
Tejinder Virk
(Executive)
Contents
32 | General | 27 |
33 | Entire agreement | 27 |
34 | Counterparts | 27 |
35 | Third party rights | 27 |
36 | Governing law | 27 |
37 | Jurisdiction | 28 |
This agreement is dated | 2 June 2021 |
Between
(1) | Canmart Ltd a company incorporated and registered in England and Wales with registered company number 11741517 and whose registered office is at Units 1a/1b Learoyd Road, New Romney, Kent TN28 8XU (the Company); |
(2) | Halo Labs Inc. a company incorporated in Canada whose registered office is 77 King Street West, Suite 400, Toronto-Dominion Centre, Toronto, Ontario, Canada (the Guarantor); and |
(3) | Tejinder Virk of 39 Landau, 72 Farm Lane, London SW6 1QA (the Executive). |
It is agreed:
1 | Interpretation |
1.1 | In this agreement the following terms and expressions shall have the following meanings: |
Appointment means the employment of the Executive by the Company on the terms of this agreement.
Board means the board of directors of the Company and any committees duly constituted by the board.
Capacity means as agent, consultant, director, the holder of any office, employee, worker, owner, partner, Shareholder or in any other capacity.
Cash Shell Company means any undertaking (including a special purpose acquisition company) (a) which is listed/quoted or becomes listed/quoted on a Recognised Investment Exchange and (b) of which the Company is or becomes a wholly-owned subsidiary, but excluding for the avoidance of doubt Halo Labs Inc.
Control means in relation to a body corporate, the power of a person to secure that the affairs of the body corporate are conducted in accordance with the wishes of that person:
(a) | by means of the holding of shares, or the possession of voting power, in or in relation to that or any other body corporate; or |
(b) | as a result of any powers conferred by the articles of association or any other document regulating that or any other body corporate. |
Change of Control occurs if a person (whether alone or together with any person acting in concert with that person) who controls any body corporate ceases to do so or if another person acquires Control of it.
Commencement Date means such date as agreed by the parties in writing.
Competitor means a business concern which is, or intends to be, in competition with any Restricted Business.
Page 1
Confidential Information means information of a confidential nature (in any form) concerning the business, affairs and/or finances of the Company or any Group Company or their respective customers, clients, suppliers, agents, distributors, investors and shareholders which the Executive receives, obtains, creates or develops at any time by reason of or in connection with the Executive's service with the Company or any Group Company (whether or not marked as confidential). This includes: trade secrets; technical information, data, research and development; customer, client and supplier lists, contact details of customers, clients and suppliers and individuals within those organisations; inventions and patent applications in the course of preparation and all other Intellectual Property Rights; financial projections, target details and accounts; details of funding and resource allocation; fee levels, pricing policies, commissions and commission charges; budgets, forecasts, reports, records and corporate and business plans; planned or potential products and services; marketing and advertising plans, requirements and materials, marketing surveys and research reports; market share and pricing statistics; disputes (whether existing, threatened or prior), settlement discussions and terms; details of employees, workers, officers and consultants including their roles and responsibilities, remuneration, benefits and organisational structures, legally privileged material; computer software and passwords.
Copies means copies or records of any Confidential Information in whatever form (including in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) including extracts, analysis, studies, plans, compilations or any other way of representing or recording and recalling information which contains, reflects or is derived or generated from Confidential Information.
Executive Equity has the meaning given to it in Clause 13.
Executive Equity Rights means the rights to be granted to the Executive as set out and materially on the terms described in Schedule 1.
Garden Leave means any period during which the Company has exercised its rights under Clause 23.
Group Company means any company which is from time to time a subsidiary or holding company of the Company and any subsidiary of any holding company of the Company (and references to the Group shall be construed accordingly). The words "subsidiary" and "holding company" have the meanings given to them in section 1159 of the Companies Act 2006 and a person shall be treated, for the purposes only of the membership requirement contained in subsections 1159(1)(b) and (c) of that Act, as a member of another company even if its shares in that other company are registered in the name of: (i) another person (or its nominee), whether by way of security or in connection with the taking of security, or (ii) a nominee.
Holiday Year means 1 January to 31 December or such other period as the Company notifies the Executive in writing.
Incapacity means any sickness, injury or other incapacity or medical disorder or condition which prevents the Executive from carrying out his duties.
Intellectual Property Rights means patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.
Page 2
Invention means any invention, idea, discovery, development, improvement or innovation, whether or not patentable or capable of registration, and whether or not recorded in any medium.
Investor means any person, firm, company or other entity who or which is an investor in the Company or any Group Company at the Termination Date or who or which invested in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible investment in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Lender means any person, firm, company or other entity who or which is a lender of funds to the Company or any Group Company at the Termination Date or who or which lent funds to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible lending to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Listing means the admission, approved by the Board, of the entire issued share capital of the Company or a Cash Shell Company, or securities representing those shares (including without limitation depositary interests, American depositary receipts, American depositary shares and/or other instruments) on a Recognised Investment Exchange.
Long Stop Date means the date falling 12 months from the date of this agreement.
Personal Data means personal data about or relating to the Executive including his name, date of birth, home address, telephone number, driver's licence number, passport number, family information (such as marital status and dependant details), emergency contact information, education and training details (such as qualifications and professional expertise), employment details (such as employment status, employee type, performance and evaluation information, work phone number and email, intranet user log in and department and supervisor details), financial information (such as compensation, benefits, bank account information and pensions information) and hiring information (such as CV, prior employment history and personal references).
Policies and Procedures means the policies and procedures of the Company applicable to employees and officers of the Company as amended from time to time.
Prospective Customer means any firm, company or person who, during the 12 months before the Termination Date, was in negotiations with the Company or any Group Company about becoming a customer of the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of his duties or responsibilities, about whom he became aware or informed to a material extent in the course of the Appointment.
Qualifying Equity Finance means a bona fide transaction (or series of transactions, provided that the type of share issued and the price paid per share is consistent across the series of transactions), approved by the Board, with the principal purpose of raising capital, pursuant to which the Company (or a Cash Shell Company) issues equity shares (but excluding any equity shares issued on conversion of any convertible securities or any equity securities issued to Halo, Inc) with an aggregate subscription price of not less than £10,000,000.
Page 3
Recognised Investment Exchange means NASDAQ, the New York Stock Exchange, the Official List of the United Kingdom Listing Authority, the AIM Market operated by the London Stock Exchange Group Plc, the Toronto Stock Exchange, the NEO Exchange or the TSX Venture Exchange or any other recognised investment exchange (as defined in section 285 of the Financial Services and Markets Act 2000).
Regulatory Requirements means all legal and regulatory obligations, codes of practice and recommendations and similar which apply to the Executive, the Company or any Group Company, including:
(a) | in relation to transactions in securities, related party transactions and inside information (including any share dealing policy of the Company); |
(b) | pursuant to the Financial Services and Markets Act 2000 and the Criminal Justice Act 1993; and |
(c) | any other laws, rules and regulations of, or applicable to companies admitted to, a Recognised Investment Exchange on which the Company (or a Cash Shell Company) is Listed, |
Restricted Business means those parts of the business of the Company and any Group Company with which the Executive was involved to a material extent in the 12 months before the Termination Date.
Restricted Customer means any firm, company or person who, during the 12 months before the Termination Date, was a customer of or in the habit of dealing with the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of his duties or responsibilities, about whom he became aware or informed to a material extent in the course of the Appointment.
Restricted Person means anyone employed or engaged by the Company or any Group Company with whom the Executive dealt in the 12 months before the Termination Date in the course of the Appointment.
Restricted Supplier means any person, firm or company which at any time during the 12 months prior to the Termination Date was a supplier of any goods, products or services (other than utilities and goods or services supplied for administrative purposes) to the Company or any Group Company and with whom or which the Executive had personal dealings during that period other than in a de minimis way and where such entities remain suppliers of the Company and/or the Group Company at or immediately before the Termination Date.
Shareholder means holding an investment by way of shares or other securities of over 5% of the total issued share capital of any company, other than a Cash Shell Company, whether or not it is listed or dealt in on a recognised stock exchange.
Termination Date means the date on which the Executive's employment with the Company terminates however caused.
1.2 | The headings in this agreement are inserted for convenience only and shall not affect its construction. |
Page 4
1.3 | A reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension or re-enactment and includes any subordinate legislation for the time being in force made under it. |
1.4 | Unless the context otherwise requires: |
1.4.1 | a reference to one gender shall include a reference to the other genders; and |
1.4.2 | words in the singular include the plural and in the plural include the singular. |
1.5 | References to a "person" include any individual, company, any other body corporate, partnership or unincorporated association (whether or not having separate legal personality). |
1.6 | The words "including", "include", "in particular", "for example" and words of similar effect shall not limit the general effect of the words that precede them. |
2 | Employment |
2.1 | The Executive agrees to serve the Company as Chief Executive on and subject to the terms and conditions of this agreement. It is envisaged that the Company will be subject to a reverse takeover and there will be a Listing. Accordingly, the terms of this agreement may require amendments to comply with any applicable Regulatory Requirements and if so, the Executive will be paid a cash sum equivalent to any amounts (including benefits) that he is entitled to under this agreement that are not included in the amended agreement. |
2.2 | The Executive's employment will commence on the Commencement Date and shall continue, subject to the remaining terms of this agreement, until terminated by either party giving the other not less than 6 months prior written notice, save that the Company can only give notice after 18 months following the Commencement Date (except that this limitation shall not apply in respect of termination rights under Clause 22.1(a), (c) or (g)). If the Company does give notice sooner, the amount of Basic Salary and contractual benefits that the Executive would otherwise have been entitled to up to the first day on which termination could have been effective in accordance with this clause will be paid to the Executive as a lump sum within 28 days of the Termination Date. For the avoidance of doubt, nothing in this Clause 2.2 shall prevent or limit the Company's right to terminate this agreement without notice and without payment for any Basic Salary and contractual benefits for any reason that falls within Clause 22.1(a), (c) or (g). |
2.3 | No period of employment with the Company or any other employer counts towards the period of continuous employment between the Executive and the Company which therefore will begin on the Commencement Date |
2.4 | The parties acknowledge and agree that the Company intends to pursue a Listing, either directly or via a Cash Shell Company, and that as part of that process the Company's advisers (including its brokers) may require certain terms of this Agreement to be varied, amended or deleted. The parties agree that they will act reasonably in agreeing any such variations, amendments or deletions and the Executive agrees that (without limitation) the following provisions, amendments or variations, if required or reasonably requested by the Company (on the advice of its brokers) pursuant to such Listing, will be acceptable: |
(a) | any lock-in and/or orderly market restrictions on market-standard terms (where, in respect of the length of any such restriction, "market-standard" means no longer than two years in respect of each of any lock-in and any orderly market restriction); |
Page 5
(b) | the Executive ceasing to be entitled to any or all of the Executive Equity Rights; and |
(c) | a vesting, or reverse vesting, period of up to four years and otherwise on market-standard terms, |
and the Executive agrees that he will take all action reasonably necessary to give effect to any such amendments, variations or deletions. For the avoidance of doubt, under no circumstances shall the Executive be required to surrender or otherwise lose the ownership of whole or any part of the Executive Equity pursuant to this Clause 2.4.
3 | Conditions to employment |
Conditions Precedent
3.1 | The Executive's employment under this agreement is conditional upon: |
(a) | receipt by the Company of such references, pre-employment background checks and medical checks as it considers necessary or appropriate; and |
(b) | the results of each reference and check being satisfactory to the Company in its absolute discretion. |
Conditions Subsequent
3.2 | The Company shall take appropriate professional advice as to the best way in which to achieve the proposed Listing of the business operated or proposed to be operated by it. If, following such advice, the Board decides that it would be in the best interests of the Company and its members as a whole to achieve a Listing via a Cash Shall Company then, before the Long Stop Date, the Company will: |
(a) | establish or acquire or be acquired by a Cash Shell Company; |
(b) | in respect thereof and subject always to Clause 2.4, grant the Executive the Executive Equity; and |
(c) | transfer his engagement as Chief Executive to the Cash Shell Company, |
(together, the Conditions Subsequent).
3.3 | In the event that the Conditions Subsequent have not been satisfied by the Long Stop Date and such non-satisfaction is predominantly or primarily the result of either or both of (a) some action or inaction by or on behalf of Halo and/or (b) another factor or factors beyond the reasonable control of the Executive, the parties shall, in good faith, use reasonable endeavours to grant equity interests in the Guarantor (or the Company if it is directly subject to a Listing) to the Executive that give the Executive an approximately equivalent monetary valuation as would have been held by him in a Cash Shell Company that held the businesses of Cannahealth, Canmart and Bophelo only, pursuant to the terms of this Agreement. |
4 | Fundamental terms and warranties |
4.1 | The Executive represents and warrants to the Company that (in each case as a fundamental term of this agreement): |
(a) | the Executive is not subject to any restrictions which prevent the Executive from holding office as a director; |
Page 6
(b) | by entering into this agreement or fully performing any of the Executive's obligations under it, the Executive will not be in breach of any court order or any express or implied terms of any contract or other obligation binding on the Executive; and |
(c) | the Executive has not used or disclosed to the Company or any Group Company any confidential information belonging to any previous employer or any other person; and |
(d) | the Executive has the right to work in the United Kingdom and, if his right to work in the United Kingdom is time limited, the Executive’s visa permits him to be employed by the Company and carry out his duties under this agreement (without hindrance). |
4.2 | The Executive must notify the Company immediately of any change to the Executive's immigration status and must produce to the Company the documents proving the Executive's right to work within five working days of any request to do so. If the Executive has time limited immigration permission which is due to expire at any time during the Executive's employment, the Executive's ongoing employment will be subject to the Company being satisfied that the Executive has submitted an application to extend the Executive's United Kingdom immigration permission prior to the date it is due to expire and that the application has not been rejected. |
4.3 | Notwithstanding (and without prejudice to) any other provision of this agreement, the Company may terminate this agreement summarily if the Executive is in breach of any of the terms and/or warranties in this Clause 4. |
5 | Appointment as a director |
5.1 | The Executive will be appointed as a director of the Company subject to the remaining provisions of this agreement and the Company's articles of association. |
5.2 | The Executive will not be entitled to any director's or other fees from the Company or any Group Company or to any fees in respect of any office the Executive may hold as nominee or representative. |
5.3 | The Executive's appointment as a director of the Company or any Group Company, at any time, is a term of the Executive's employment. If the Executive ceases for any reason (except as provided in Clause 22.1(a)) to be a director, the Executive's employment under this agreement will continue in such other position as the Company may reasonably require and all provisions of this agreement not relating to the Executive's directorship will continue to apply. The Executive agrees that in such circumstances any such termination of office will not be in repudiation of this agreement and the Executive will have no claims in respect of such cessation of office. |
5.4 | The Executive will at all times: |
(a) | comply with the articles of association of the Company and any Group Company of which the Executive is a director; |
(b) | abide by all statutory, fiduciary and common-law duties to any Company and Group Company of which the Executive is a director; |
Page 7
(c) | comply with all rules regarding conduct as an officer and executive under the Companies Act 2006; and |
(d) | not do anything that would cause the Executive to be disqualified from acting as a director. |
5.5 | The Executive must disclose to the Company, on reasonable request, any information which the Company requires in order to enable it to fulfil its obligations under any Regulatory Requirements and the Executive shall endeavour to ensure that this information is kept up to date at all times. |
5.6 | Except with the prior approval of the Board, the Executive shall not resign as a director of the Company or any Group Company. |
6 | Duties |
6.1 | The Executive acknowledges that he will be a fiduciary in a position of seniority and trust. |
6.2 | At all times during the course of employment the Executive will: |
(a) | faithfully and diligently serve the Company and the Group and exercise such powers and perform such duties as may from time to time be assigned to the Executive by the Board or perform such other duties as the Company may reasonably require; |
(b) | devote the whole of the Executive's working time, attention and abilities to the business and affairs of the Company and the Group; |
(c) | comply with all reasonable directions of and regulations made by the Company and the Board; |
(d) | promptly make such reports to the Board in connection with the affairs of the Company and of any Group Company on such matters and at such times as are reasonably required, and otherwise keep the Board fully informed of all matters relating to the business and affairs of the Company and the Group; |
(e) | immediately upon becoming aware, report: |
(i) | any wrongdoing (including the Executive's own wrongdoing) whether committed, contemplated or discussed by any person employed or engaged by the Company or any Group Company irrespective of whether this would or may involve self-incrimination; |
(ii) | any plans or proposals or discussions by any person employed or engaged by the Company or any Group Company to leave the employment or engagement of the Company or Group Company, whether alone or in concert with any other person and whether to join a competitor or any other business; and |
(iii) | any misuse of Confidential Information by any person (including the Executive) irrespective of whether this would or may involve self-incrimination; |
(f) | use all reasonable endeavours to promote, protect, develop and extend the business of the Company and Group Companies; |
Page 8
(g) | comply with all Policies and Procedures; |
(h) | comply with all Regulatory Requirements and promptly provide the Company with all information that it requires or may require to comply with the Regulatory Requirements; and |
(i) | not: |
(i) | offer, promise or provide any bribe, inducement or reward to any third party in order to gain any commercial, contractual, regulatory or personal advantage; |
(ii) | receive or accept any bribe, inducement or reward from any third party in order to gain any commercial, contractual, regulatory or personal advantage; or |
(iii) | receive any gifts, goods, service, rebates or commission from any third party other than in accordance with Company policy from time to time in force. |
6.3 | The Executive agrees and accepts that: |
(a) | the Policies and Procedures do not form part of this agreement or the terms of the Executive's employment and the Company may amend the Policies and Procedures at any time; and |
(b) | a breach of the Regulatory Requirements may lead to civil or criminal liability for the Executive, action being taken against the Executive by any relevant regulatory authority and/or disciplinary action by the Company up to and including summary dismissal if the Executive's conduct falls within the categories in Clause 22.1. |
7 | Place of work |
7.1 | The normal place of work of the Executive is London (or such other place as agreed by the parties) or any other place as the Company may reasonably require for the proper performance and exercise of the Executive's duties. |
7.2 | The Executive will be required to travel in appropriate circumstances on the business of the Company and the Group (within the United Kingdom and/or abroad). |
8 | Hours of work |
8.1 | The Executive's normal hours of work are from 8.30am to 5:30pm Monday to Friday, inclusive of one hour for lunch daily, and such additional hours as may be necessary for the proper performance of the Executive's duties. The Executive is not entitled to any further remuneration for additional hours outside normal office hours. |
8.2 | The parties agree that the nature of the Executive's position is such that the Executive's working time cannot be measured and, accordingly, the Executive's employment falls within the scope of regulation 20 of the Working Time Regulations 1998. |
9 | Salary |
9.1 | The Executive will be paid an annual salary of £500,000 (Basic Salary) subject to applicable deductions as required by law including for tax and national insurance. |
Page 9
9.2 | The Basic Salary will be paid in equal monthly instalments (or pro rata where the Executive is only employed during part of a month) in arrears. For convenience, payment will usually be slightly in advance of the end of the calendar month to which the payment relates. |
9.3 | The Executive authorises the Company to deduct (and retain) from the Basic Salary, or any other sum due to the Executive at any time, any sum due to the Company or any Group Company from the Executive. |
10 | Pension |
The Company will comply with the employer pension duties in accordance with Part 1 of the Pension Act 2008.
11 | Expenses |
Subject to any Company policy in operation from time to time and to production of VAT receipts or other appropriate evidence to the reasonable satisfaction of the Company, the Company will reimburse (or procure the reimbursement of) all reasonable expenses wholly, properly and necessarily incurred by the Executive in the performance of the Executive's duties.
12 | Incentive payments & bonus |
12.1 | Subject to Clause 12.7, on a Listing, the Executive shall be entitled to receive an incentive payment of £250,000, which shall be paid on or around the payroll in the subsequent month following the Listing. |
12.2 | Subject to Clause 12.7, on completion of a Qualifying Equity Finance, the Executive shall be entitled to receive an incentive payment of £250,000, which shall be paid on or around the payroll in the month following receipt by the Company of the Qualifying Equity Finance. |
12.3 | The Executive is entitled to participate in the Company's bonus scheme with an annual bonus opportunity of: |
(a) | up to 100% of Basic Salary based on meeting achievable KPIs as determined by the Board using its reasonable discretion on or around the beginning of each financial year; and |
(b) | an additional bonus opportunity based on achievable stretch targets which is to be determined by the Board using its reasonable discretion. |
12.4 | The Board may award any such bonus in cash, equity or such other instrument or arrangement with the Company undertaking that it will act reasonably in making any such award in a way which is tax efficient and cost effective for the Executive. |
12.5 | Any bonus made pursuant to Clause 12.3 may, at the Board's absolute discretion, be reduced pro rata by reference to any period for which the Executive has been absent from work for any reason during the period to which the bonus relates. |
12.6 | The Executive will not be entitled to compensation for loss of bonus (whether pursuant to this Clause 12 or otherwise) on termination of employment. Payment of a bonus in one year will not entitle the Executive to a bonus in any other year. |
Page 10
12.7 | Payment of any incentive payment or bonus under this Clause 12 will be conditional on: |
(a) | notice not having been served by the Executive; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct (in which case payment of any incentive or bonus will be postponed pending the final outcome of that disciplinary procedure save where the procedure results in dismissal in which case no incentive or bonus shall be payable); and/or |
(c) | the Executive not having committed a repudiatory breach of this agreement; |
in each case, as at the payment date.
12.8 | If any payment or other obligation under this agreement or any related benefit or remuneration plan does not comply with any applicable Regulatory Requirement, the Company may in its sole discretion amend the terms of the payment or other obligation (including by reducing, revoking, cancelling or recovering any payment or award) to make it compliant. |
12.9 | Any payments under this Clause 12 will be subject to applicable deductions for tax and National Insurance (excluding employer National Insurance contributions) and will not be pensionable. |
13 | Shares |
13.1 | If the Board considers it likely that a Cash Shell Company will acquire Control of the Company, the Company shall procure that the Executive is granted an award of an equity interest in the Cash Shell Company (which could be a subscription/award of shares or share options, depending on the taxation implications for both the Company and the Executive, with the Company undertaking that it will act reasonably in procuring the offer of an incentive structure which is tax efficient and cost effective for the Executive provided there are no adverse consequences for the Company or the Cash Shell Company) (the Executive Equity). |
13.2 | The Executive Equity is intended to represent 10% of the issued share capital of the Cash Shell Company before the Cash Shell Company acquires the Company or any other company or business, and/or issues equity to participants in a placing or public offering to occur on or around the date of Listing, when, pursuant to each of such events, the percentage equity interest held by the Executive will be diluted in accordance with the terms of such transactions. |
13.3 | Subject always to Clause 2.4, the Executive Equity will be subject to monthly vesting (or reverse vesting if shares are awarded) over a three year period, with a one year vesting cliff (33.3% vesting 12 months after date of grant of the award), and will be subject to customary good leaver, intermediate leaver and bad leaver conditions. |
13.4 | In the event that there is a Change of Control of the Company or Cash Shell Company (other than as part of the fundraising on or around the date of Listing or an internal re-organisation) after the date falling 12 months after the date of the grant of Executive Equity and before the end of the three year vesting period (or such other period as required in accordance with Clause 2.4), and the Executive is an employee of the Company (or the Cash Shell Company as the case may be) at such time, it is agreed that vesting of the Executive Equity will automatically be accelerated immediately prior to such Change of Control. |
Page 11
13.5 | The Executive's participation in the Executive Equity shall be determined by the applicable rules (or other documents) of the scheme to be implemented. |
13.6 | In the event a Cash Shell Company does not acquire Control of the Company, the Company and the Executive will both act in good faith to agree an alternative incentive arrangement to that referred to in Clause 13.1 above and, if applicable, Clause 3.3. |
14 | Other benefits and paid leave |
14.1 | The Company will endeavour to put in place a private medical insurance scheme as soon as reasonably practicable after the Commencement Date. The Executive, his spouse and dependents shall be entitled to participate in such scheme. |
14.2 | The Executive's rights and entitlements and the Company's obligations to pay premiums for the private medical insurance scheme shall be subject always to: |
(a) | the rules and terms of such scheme from time to time in force; |
(b) | the Company's absolute discretion to change scheme and/or scheme provider and/or to discontinue providing the benefit at any time; |
(c) | the Executive satisfying any underwriting or other requirements of the relevant scheme provider; and |
(d) | the Executive co-operating with the Company and the relevant scheme provider when making any claim. |
14.3 | The Executive agrees that: |
(a) | the Company shall have no obligation to pursue any claim for benefits on behalf of the Executive or the Executive's spouse or dependants or any other beneficiaries or potential beneficiaries if it is not accepted by the scheme provider; |
(b) | the Company will have no liability to the Executive or the Executive's spouse or dependants for failure or refusal by the scheme provider for whatever reason to pay benefits or for cessation of benefits on the termination of the Executive's employment and the Company is entitled to terminate the Executive's employment notwithstanding the fact that the Executive may lose entitlement to benefits under these arrangements as a result; |
(c) | The Executive is not contractually entitled to any benefit he receives which is not expressly referred to in this agreement (whether payment of insurance scheme premiums or otherwise). |
14.4 | The Executive may be eligible to take the following types of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules applicable to each type of leave in force from time to time: |
(a) | statutory paternity leave; |
(b) | statutory adoption leave; |
Page 12
(c) | shared parental leave; and |
(d) | parental bereavement leave. |
14.5 | The Company will pay up to a total of £30,000 towards the Executive's legal and tax fees he reasonably incurs through his appointed professional advisors and which arises directly from the corporate restructuring referred to in this agreement. Any such payment will be made directly to his appointed advisers subject to production of satisfactory invoices confirming the fees incurred and shall exclude any success fee or uplift on standard hourly rates. |
15 | Training |
In addition to general training the Company provides during the Executive's induction and throughout his employment, the Company will specify certain mandatory training modules from time to time. These cover matters that are essential for working for the Company, or for the Executive's role. The subject matter will vary from time to time and the Company will update the Executive on the requirements. Details of the current compliance training that is mandatory for all employees are available on the intranet.
16 | Holidays |
16.1 | The Executive will be entitled to 30 days' paid holiday in each Holiday Year in addition to the usual public holidays in England and Wales. The first 28 days of holiday (including any public holidays) taken in any Holiday Year will be the Executive's statutory holiday for the purpose of both the Working Time Regulations 1998 and Clause 16.6 below. |
16.2 | If the Executive's employment commences or terminates part way through a Holiday Year, the entitlement of the Executive during that Holiday Year shall be calculated on a pro rata basis rounded up to the nearest half day. |
16.3 | Holidays shall be taken at such time or times as shall be approved in advance by the Company. The Company may require the Executive to take holiday on particular dates. |
16.4 | The Executive will be entitled to carry over up to 5 days' holiday at the end of each Holiday Year provided that the Executive uses that holiday by 31 March in the following Holiday Year (all other holiday remaining at the end of the Holiday Year will lapse). Any carried over holiday not used by that date will lapse. |
16.5 | The Executive shall have no entitlement to any payment in lieu of accrued but untaken holiday except on termination of the Executive's employment. Subject to Clause 16.6, the amount of any payment in lieu will be 1/260th of the Executive’s Basic Salary for each untaken day of holiday entitlement for the Holiday Year in which termination takes place. |
16.6 | If: |
(a) | the Company has terminated or would have been entitled to terminate the Executive's employment under Clause 22; or |
(b) | the Executive terminates in breach of this agreement, |
any payment due under Clause 16.5 will be limited to the statutory entitlement of the Executive under the Working Time Regulations 1998 (and any holiday (including public holidays) taken shall be deemed first to have been taken in satisfaction of that statutory entitlement as set out in Clause 16.1).
Page 13
16.7 | If on termination of the Executive's employment the Executive has taken in excess of his accrued holiday entitlement, the Company shall be entitled to recover from the Executive, by way of deduction from any payments due to the Executive or otherwise, one day's pay calculated at 1/260th of the Basic Salary of the Executive for each excess day. |
16.8 | If either party has served notice to terminate the Executive's employment, the Company may require the Executive to take any accrued but unused holiday entitlement during the notice period. Any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave. |
16.9 | During any continuous period of absence due to Incapacity of one month or more the Executive shall not accrue holiday under this contract and the entitlement of the Executive under Clause 16.1 for the Holiday Year(s) in which such absence takes place shall be reduced pro rata save that it shall not fall below the entitlement of the Executive under the Working Time Regulations 1998. |
17 | Incapacity |
17.1 | If the Executive is absent from work due to Incapacity, the Executive shall notify the Company of the reason for the absence as soon as possible on the first day of absence. |
17.2 | Immediately following the Executive's return to work after a period of absence due to Incapacity of seven days or less the Executive must complete a self-certification form. For periods of absence of more than seven consecutive days the Executive must produce a doctor's fit note verifying that the absence is due to Incapacity. |
17.3 | Subject to complying with the Company’s absence requirements above and to the remaining provisions of this Clause 17, the Executive shall be entitled to receive full Basic Salary and contractual benefits during any periods of absence due to Incapacity up to a maximum of 12 weeks in aggregate in any rolling 52-week period. Any such payments shall be inclusive of any statutory sick pay. The Executive's qualifying days for statutory sick pay purposes are Monday to Friday. |
17.4 | The Executive agrees to consent to medical examinations (at the Company's expense) by a doctor or clinic nominated by the Company should the Company so require. The Executive agrees that any report produced in connection with any such examination may be disclosed to the Company and the Company may discuss the contents of the report with the relevant doctor. |
17.5 | If the Incapacity is or appears to be occasioned by actionable negligence, nuisance or breach of any statutory duty on the part of a third party in respect of which damages are or may be recoverable, the Executive shall immediately notify the Company of that fact and of any claim, settlement or judgment made or awarded in connection with it and provide all relevant particulars that the Company may reasonably require. The Executive shall, if required by the Company, co-operate in any related legal proceedings and refund to the Company that part of any damages or compensation recovered by the Executive relating to the loss of earnings for the period of the Incapacity as the Company may reasonably determine less any costs borne by the Executive in connection with the recovery of such damages or compensation, provided that the amount to be refunded to the Company shall not exceed the total amount paid to the Executive by the Company in respect of the period of Incapacity. |
Page 14
17.6 | The Company is entitled to terminate the Executive's employment under the terms of this agreement notwithstanding that any such termination would or might cause the Executive to forfeit any entitlement to sick pay or other benefits. |
17.7 | The payment of the Executive's Basic Salary and other contractual benefits during absence due to Incapacity is conditional on: |
(a) | notice not having been served by either party; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct; and |
(c) | the Executive not being under a performance improvement plan. |
18 | Outside interests |
18.1 | Subject to Clause 18.2, the Executive shall not at any time during employment (including during any period of notice) save with the prior written approval of the Company: |
(a) | be directly or indirectly engaged, concerned or have any financial interest in any Capacity in any other business, trade, profession or occupation (or the setting up of any business, trade, profession or occupation) other than that of the Company and the Group, whether paid or unpaid; or |
(b) | hold any directorship (or other office) of any company other than that of the Company and any Group Company, whether paid or unpaid. |
18.2 | Notwithstanding Clause 18.1, the Executive: |
(a) | may hold an investment by way of shares or other securities of not more than 5% of the total issued share capital of any company (whether or not it is listed or dealt in on a recognised stock exchange) provided that such company does not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company; |
(b) | has disclosed to the Company the external interests and activities listed in schedule 2 including the Executive's Capacity with regard to each such interest and activity. The Company consents to the Executive continuing these activities on the strict condition that it reserves the right to require (at any time) the Executive to cease any or all of such interests or activities to the extent that, in the opinion of the Company, they interfere, may be likely to interfere or could be perceived to interfere with the discharge of the Executive's obligations to the Company or Group or create or may be likely to create a conflict of interest or perceived conflict of interest; and |
(c) | may engage in external interests and activities provided that such companies do not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company and such interests or activities do not interfere with the Executive's performance of his duties for the Company, and any board level appointments shall require prior written approval of the governance committee of the Company, not to be unreasonably withheld, and subject to being permitted by the rules of any applicable regulatory framework. |
Page 15
18.3 | Without prejudice to the Executive's obligations above, the Executive must promptly disclose to the Company any matter relating to the Executive's spouse, civil partner, partner, children, parents or other immediate family and/or any entity whose affairs the Executive or any such person controls which may (or may be perceived to) interfere, conflict or compete with the proper performance of the obligations of the Executive under this agreement. |
19 | Confidential information |
19.1 | Without prejudice to the Executive's common law duties, the Executive shall not (except in the proper course of the Executive's duties, as authorised or required by law or as authorised in advance by the Company), either during the Executive's employment or at any time after termination of employment (howsoever arising): |
(a) | use any Confidential Information; |
(b) | make or use any Copies; or |
(c) | disclose any Confidential Information to any person whatsoever. |
19.2 | The Executive shall be responsible for protecting the confidentiality of the Confidential Information and shall: |
(a) | use best endeavours to prevent the use or communication of any Confidential Information by any person (except in the proper course of that person’s duties, as required by law or as authorised in advance by the Company); and |
(b) | inform the Company immediately upon becoming aware, or suspecting, that any unauthorised person knows, has access to, has been provided with or has used any Confidential Information. |
19.3 | All Confidential Information and Copies are and shall remain at all times the property of the Company and on termination of the Executive's employment (or at the request of the Company at any time during employment), the Executive shall: |
(a) | hand over all Copies to such person as is nominated by the Company; |
(b) | irretrievably delete any Confidential Information (including any Copies) stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in the Executive's possession or under the Executive's control; and |
(c) | on the request of the Company, provide a signed statement that the Executive has complied fully with all obligations under this Clause 19.3 together with such evidence of compliance as the Company may reasonably request . |
19.4 | Clause 19 shall not apply to any Confidential Information which the Executive can demonstrate: |
(a) | is already in the public domain at the time of disclosure; |
(b) | is identifiable without requiring significant expenditure of time, skill or money; and |
(c) | came into the public domain other than by reason of or as a direct or indirect result of the disclosure by the Executive of any Confidential Information. |
Page 16
19.5 | Nothing in this Clause 19 shall prevent the Executive from: |
(a) | making a protected disclosure within the meaning of Part 4A of the Employment Rights Act 1996 (this includes protected disclosures made about matters previously disclosed to another recipient); |
(b) | making a disclosure to a regulator regarding any misconduct, wrongdoing or serious breach of a Regulatory Requirement; |
(c) | reporting a criminal offence to the police or a law enforcement agency; or |
(d) | co-operating with the police or a law enforcement agency regarding any criminal investigation or prosecution or with a regulator regarding any investigation by that regulator. |
20 | Intellectual property |
20.1 | All Intellectual Property Rights made, discovered, originated, produced or developed by the Executive during the course of employment with the Company (whether or not during working hours or using the premises or resources of the Company or the Group) shall immediately be disclosed in writing to the Company by the Executive and shall automatically, on creation, vest absolutely in the Company or such Group Company as the Company may nominate for that purpose to the fullest extent permitted by law. |
20.2 | The Executive: |
(a) | acknowledges for the purposes of section 39 of the Patents Act 1977 that because of the nature of the Executive's duties, and the particular responsibilities arising from those duties, the Executive has, and at all times during employment will have, a special obligation to further the interests of the business of the Company and the Group; |
(b) | undertakes to promptly, whenever requested by the Company, and in any event upon the termination of employment, deliver up to the Company all such Intellectual Property Rights and all related correspondence, documents, papers and records and all copies of any such Intellectual Property Rights in the Executive's possession or control; |
(c) | undertakes to hold upon trust for the benefit of the Company (or its nominee) all Intellectual Property Rights in respect of all Intellectual Property Rights made, originated or developed by the Executive during employment by the Company (whether or not during working hours or using the premises or resources of the Company or the Group) to the extent that they do no vest automatically in the Company, until the same are vested absolutely in the Company (or its nominee); |
(d) | assigns absolutely with full title guarantee by way of present assignment of present and future rights, all Intellectual Property Rights made, originated or developed by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group); |
(e) | acknowledges that, other than as required by law, no further remuneration or compensation other than that set out in this agreement is or may become due to the Executive in respect of the performance of the Executive's obligations under this Clause 20; |
Page 17
(f) | undertakes, at the reasonable expense of the Company, to execute all such documents, make such applications, give such assistance and do all such acts and things as may in the opinion of the Company be necessary or desirable to vest, register or obtain any Intellectual Property in the name of the Company (or its nominee), and otherwise to protect and maintain any Intellectual Property Rights made, originated or developed by the Executive and all related Intellectual Property Rights; |
(g) | waives any moral rights (as provided for by Chapter IV of the Copyright Designs & Patents Act 1988 (the 1988 Act) or any similar provisions of law in any jurisdiction) in any Intellectual Property Rights created, made, originated, developed or produced by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group) and agrees to grant all necessary consents and further agrees not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such Intellectual Property Rights infringes the Executive's moral rights, including the right to be identified, the right of integrity and the right against false attribution provided for in the 1988 Act; |
(h) | will not, except in the proper performance of the Executive's duties, disclose any Intellectual Property Rights (or any related correspondence, documents, papers and records and copies) belonging to the Company (or its nominee) without the prior written consent of the Company; and |
(i) | will give all necessary assistance to the Company (or its nominee) to enable the Company (or its nominee) to enforce its Intellectual Property Rights against third parties and/or to defend claims for infringement of third party Intellectual Property Rights. |
20.3 | The Executive irrevocably appoints the Company to be the Executive's attorney in the Executive's name and on the Executive's behalf to execute and/or sign all such instruments, and/or do all such things and generally to use the Executive's name for the purpose of giving to the Company (or its nominee) the full benefit of the provisions of this Clause 20. With respect to any third party, a certificate in writing signed by any director of the Company or the company secretary of the Company that any instrument or act falls within the authority conferred by this Clause 20.3 shall be conclusive evidence that such is the case. |
21 | Payment in lieu of notice |
21.1 | Notwithstanding any other provision of this agreement, the Company may, in its sole and absolute discretion, terminate the Executive's employment under this agreement summarily by giving the Executive written notice that it is exercising its discretion under this Clause 21.1. In such circumstances the Company shall pay the Executive his Basic Salary and contractual benefits in lieu of the notice period referred to in Clause 2.2 or any unexpired part of it. Payment will be made subject to such deductions as are required by law, including for tax and national insurance. The Company's right to make a payment under this Clause 21.1 does not give the Executive any right to demand such payment. |
21.2 | The Executive shall not be entitled to any payment in lieu of notice if the Company would otherwise have been entitled to terminate the Executive's employment without notice in accordance with Clause 22 and the Company shall be entitled to recover from the Executive any payment in lieu of notice already made. |
Page 18
22 | Termination without notice |
22.1 | The Company may terminate the Executive's employment with immediate effect without notice (and with no liability to make any further payment to the Executive) if the Executive: |
(a) | is disqualified from acting as a director; |
(b) | commits, in the reasonable opinion of the Board, an act of gross misconduct; |
(c) | commits, in the reasonable opinion of the Board, any serious or repeated breach or failure to observe of any of the provisions of this agreement or the Policies and Procedures or the Regulatory Requirements or any anti-bribery and corruption policies and the Executive has previously been given written notice of such and a reasonable opportunity to improve or comply as the case may be; |
(d) | refuses to comply with any reasonable and lawful direction of the Board; |
(e) | is declared bankrupt or makes any arrangement with or for the benefit of his creditors or has a county court administration order made against the Executive under the County Court Act 1984; |
(f) | is convicted of any criminal offence (other than an offence under any road traffic legislation in the United Kingdom or elsewhere for which a fine or non-custodial penalty is imposed); |
(g) | is guilty of fraud or dishonesty or acts in any manner which, in the reasonable opinion of the Board, brings or is likely to bring the Executive, the Company or any Group Company into disrepute or is materially adverse to the interests of the Company or any Group Company (in each case whether or not in the course of employment); or |
(h) | ceases to hold any qualification, approval, registration or authorisation required for the proper performance of the Executive's duties. |
22.2 | The rights of the Company under Clause 22.1 are without prejudice to any other rights that it may have at law to terminate the Executive's employment or to accept any breach of this agreement by the Executive as having brought the agreement to an end. Any delay by the Company in exercising any right to terminate shall not constitute a waiver of that right. |
22.3 | If the Executive's employment is terminated at any time by reason of any reconstruction or amalgamation of the Company or any Group Company, whether by winding up or otherwise, and the Executive is offered employment with any concern or undertaking involved in or resulting from the reconstruction or amalgamation on terms which (considered in their entirety) are no less favourable to any material extent than the terms of this agreement, the Executive shall have no claim against the Company, any Group Company or the undertaking arising out of or in connection with such termination. |
Page 19
22.4 | This Clause 22.4 applies if the Executive subscribes for or is awarded shares in the Company or any Group Company or participates in any share option, restricted share, restricted share unit, long term incentive, carried interest or co-invest, or any other form of profit sharing, incentive, bonus or equity plan or arrangement (each an Incentive) or may do so. Upon termination of the Executive's employment (whether lawful or unlawful), the Executive's rights (if any) in respect of each Incentive shall be solely determined by the applicable rules or other documents governing each Incentive and the Executive hereby irrevocably waives any other claims or rights in respect of the loss of any rights or benefits under or in respect of any Incentive granted or not yet granted to the Executive (including any loss relating to the lapse of, or the Executive's ineligibility to exercise, any share options, the value of any shares, the operation of any compulsory transfer provisions or the operation of any vesting criteria). |
23 | Garden leave |
23.1 | Following service of notice to terminate the Executive's employment by either party, or if the Executive purports to terminate his employment in breach of contract and/or without serving the period of notice required by Clause 2.2, the Company may in its absolute discretion place the Executive on garden leave for the whole or part of the Executive's notice period (Garden Leave). |
23.2 | During any period of Garden Leave the Company: |
(a) | shall be under no obligation to provide any work to the Executive and may revoke any powers he holds on behalf of the Company or any Group Company; |
(b) | may exclude the Executive from any premises of the Company or any Group Company; |
(c) | may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser, investor or other business contact of the Company or any Group Company; |
(d) | may require the Executive to resign as a director of the Company or any Group Company; |
(e) | may cease to provide the Executive with access to the Company and Group Company information systems; |
(f) | may appoint another person(s) to perform the Executive's responsibilities jointly with the Executive or in the Executive's place; and/or |
(g) | may require the Executive to take any accrued holiday due to the Executive. |
23.3 | During any period of Garden Leave the Executive: |
(a) | will continue to receive Basic Salary and all contractual benefits including the incentives in Clauses 12.1 and 12.2 in the usual way and subject to the terms of any benefit arrangement; |
(b) | will remain an employee of the Company and bound by the terms of this agreement (including his fiduciary duties and duties of good faith and fidelity); and |
(c) | must ensure that the Board knows where the Executive will be and how the Executive can be contacted during each working day (except during any periods taken as holiday in the usual way); |
23.4 | The Executive agrees that he shall have no claim against the Company in respect of any action set out in this Clause 23. |
Page 20
24 | Obligations upon termination |
24.1 | On termination of the Executive's employment (however arising) or, if the Company so requires, at any time following the service of notice by either party or purported notice of termination by the Executive, the Executive shall: |
(a) | resign immediately from any directorship held by him in or on behalf of the Company or any Group Company and from any other offices he may hold as nominee or representative of the Company or any Group Company; |
(b) | immediately deliver to the Company all property of the Company or any Group Company or any of its or their respective customers, clients, suppliers, investors and other business contacts (including documents, books, materials, records, correspondence, papers and information on whatever media and wherever located relating to the business or affairs of the Company or any Group Company or their respective customers, clients, investors, suppliers and other business contacts), which is in his possession or under his control and he/ shall not retain any Copies; |
(c) | irretrievably delete any information relating to the business or affairs of the Company or any Group Company stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in his possession or under his control; |
(d) | deliver to the Company on request any computer or other device in his possession or control to allow the Company to remove all Confidential Information and any software of the Company; and |
(e) | on the request of the Company, provide a signed statement that he has complied fully with his obligations under this Clause 24.1 together with such reasonable evidence of compliance as the Company may require. |
24.2 | The Executive hereby irrevocably appoints the Company to be his attorney to appoint any director of the Company as his attorney to execute such instrument or do any such thing and generally to use his name for the purpose of giving effect to and providing to the Company or its nominee the full benefit of Clause 24.1(a). |
24.3 | The obligations in Clause 24.1 shall not be affected by the fact that any document or device may include the Executive's Personal Data. It shall be the Executive's responsibility to notify the Company of any Personal Data that may exist so that the Company can make proper arrangements for its disposal. |
24.4 | The Executive will, on the Company's reasonable request, co-operate with and assist the Company or any Group Company in any internal investigation, administrative, regulatory, quasi-judicial proceedings or any threatened or actual litigation concerning it or them. The Company will only make such a request where the Executive has in his possession or knowledge any facts or other matters which the Company or any Group Company reasonably considers is relevant to such process or legal proceedings. This assistance may include giving statements/affidavits, meeting with the Company or any Group Company's legal and other professional advisers, attending any legal hearing and giving evidence. The Company or relevant Group Company will pay the Executive's reasonable expenses and loss of income incurred in providing such assistance provided that the Executive notifies the Company or relevant Group Company of the amount of any expenses or anticipated loss of income in advance. |
Page 21
25 | Post-termination restrictions |
25.1 | In order to protect the Confidential Information and business connections of the Company and each Group Company to which he has access as a result of the Appointment , the Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that he shall not: |
25.1.1 | for 12 months after the Termination Date, solicit or endeavour to entice away from the Company or any Group Company the business or custom of a Restricted Customer with a view to providing goods or services to that Restricted Customer in competition with any Restricted Business; |
25.1.2 | for 12 months after the Termination Date in the course of any business concern which is in competition, or intends to compete, with the Company or any Group Company, offer to employ or engage or otherwise endeavour to entice away from the Company or any Group Company any Restricted Person who could damage the interests of the Company or any Group Company as a result of any such employment, engagement or enticement; |
25.1.3 | for 12 months after the Termination Date in the course of any business concern which is in competition, or which intends to compete, with any Restricted Business, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person who could damage the interests of the Company or any Group Company as a result of that employment or engagement, whether or not such person would be in breach of contract as a result of such employment or engagement; |
25.1.4 | for six months after the Termination Date, be involved in any Capacity with any business concern which is (or intends to be) in competition with any Restricted Business; |
25.1.5 | for 12 months after the Termination Date, be involved with the provision of goods or services to (or otherwise have any business dealings with) any Restricted Customer or Prospective Customer in the course of any business concern which is in competition with any Restricted Business; |
25.1.6 | for 12 months after the Termination Date damage (or attempt to do so) any relationship between the Company or any Group Company and the Restricted Supplier; or |
25.1.7 | at any time after the Termination Date, represent himself as connected with the Company or any Group Company in any capacity, other than as a former employee, director or shareholder, or use any registered names or trading names associated with the Company or any Group Company. |
25.1.8 | at any time after the Termination Date, make any comments or statements of any nature that are derogatory to or disparaging of, or have the effect of lowering the reputation of the Company or any Group Company or any of its or their directors, officers, employees or agents; and/or take part in any conduct which may bring into disrepute the Company, any Group Company or any of its or their directors, officers, employees or agents. |
Page 22
25.2 | None of the restrictions in Clause 25.1 shall prevent the Executive from: |
25.2.1 | being engaged or concerned in any business concern insofar as the Executive's duties or work shall relate solely to geographical areas where the business concern is not in competition with any Restricted Business; or |
25.2.2 | being engaged or concerned in any business concern, provided that the Executive's duties or work shall relate solely to services or activities of a kind with which the Executive was not concerned to a material extent in the 12 months before the Termination Date. |
25.3 | The restrictions imposed on the Executive by this Clause 25 apply to him acting: |
25.3.1 directly or indirectly; and
25.3.2 | on his own behalf or on behalf of, or in conjunction with, any firm, company or person. |
25.4 | Subject to Clause 25.12, the Executive agrees that the Board may review the Prospective Customer, Restricted Business, Restricted Customer, Restricted Person and Restricted Supplier definitions and revise, delete and amend these (to include but not be limited to adding new customers, persons and suppliers or deleting or revising named customers, persons and suppliers) from time to time. |
25.5 | The periods for which the restrictions in Clause 25 apply shall be reduced by any period that the Executive spends on Garden Leave immediately before the Termination Date. |
25.6 | If the Executive receives an offer to be involved in a business concern in any Capacity during the Appointment, or before the expiry of the last of the covenants in this Clause 25, the Executive shall give the person making the offer a copy of this Clause 25 and shall tell the Company the identity of that person as soon as possible after accepting the offer. |
25.7 | This Clause 25.7 applies if, at any time during the Executive's employment, two or more Restricted Persons have left their employment, appointment or engagement with the Company and have subsequently performed work for a Competitor. Where this clause applies, the Executive will not, at any time during the six months following the last date on which any of those Restricted Persons were employed or engaged by the Company, be employed or engaged in any way by the Competitor if the Executive would perform work for or on behalf of the Competitor that is competitive with the Restricted Business. |
25.8 | The Executive has had the opportunity to take legal advice on the restrictions in this Clause 25. |
25.9 | Each of the restrictions in this Clause 25 is intended to be separate and severable. If any of the restrictions shall be held to be void but would be valid if part of their wording were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective. |
25.10 | If the Executive's employment is transferred to any firm, company, person or entity other than a Group Company (the "New Employer") pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, the Executive will, if required, enter into an agreement with the New Employer containing post-termination restrictions corresponding to those restrictions in this Clause 25, protecting the Confidential Information, trade secrets and business connections of the New Employer. |
25.11 | The Executive will, at the request and expense of the Company, enter into a separate agreement with any Group Company in which he agrees to be bound by restrictions corresponding to those restrictions in this Clause 25 (or such of those restrictions as may be appropriate) in relation to that Group Company. |
Page 23
25.12 | No variation of this Clause 25 will be effective unless it is in writing and signed by the parties. |
25.13 | The Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that he shall not for 12 months after the Termination Date: |
25.13.1 | interfere or take such steps as may be likely to interfere with the continuance of investment or funding to the Company (or the terms relating to such investment or funding) from any Investor or Lender; or |
25.13.2 | seek to damage the relationship between any Investor or Lender and the Company. |
26 | Disciplinary and grievance procedures |
26.1 | The Executive is subject to the disciplinary and grievance procedures of the Company, copies of which are available on the Company's intranet. These procedures do not form part of this agreement or the terms and conditions of the Executive's employment. |
26.2 | The Executive should refer: |
(a) | any appeal the Executive wishes to make against a disciplinary sanction/decision to a member of the Board (or such other person as the Company may specify from time to time); or |
(b) | any grievance the Executive wishes to raise to a member of the Board (or such other person as the Company may specify from time to time), |
in accordance with the Company's disciplinary and grievance procedures.
26.3 | The Company may suspend the Executive from any or all of his duties during any period in which the Company is investigating any disciplinary matter involving the Executive or until the conclusion of any disciplinary procedure (including any appeal). During any period of suspension: |
(a) | subject to Clause 12.5, the Executive will continue to receive Basic Salary and all contractual benefits in the usual way; |
(b) | the Company may suspend the Executive's access to the Company's and Group's systems and internal communications; |
(c) | the Company may require the Executive to return temporarily any Company or Group IT equipment and communication devices (including any smartphones, tablets, laptops and hard drives); |
(d) | the Executive shall remain an employee of the Company and bound by the terms of this agreement; |
(e) | the Executive shall ensure that the Company knows where he will be and how he can be contacted during each working day (except during any periods taken as holiday in the usual way); |
Page 24
(f) | the Company may exclude the Executive from his place of work or any other premises of the Company or any Group Company; and |
(g) | the Company may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company or any Group Company. |
27 | Change of Control |
27.1 | In the event that there is a Change of Control of the Company or the Cash Shell Company (other than as part of the Listing, the fundraising on or around the date of Listing or an internal re-organisation) and, within 365 days of the Change of Control, the Appointment is terminated by the Company (other than where the Company is entitled to terminate the Appointment without notice or payment in lieu of notice in accordance with Clause 22.1) the Company shall, within one month of the date of the Termination Date, pay or provide the Prescribed Sum to him as provided by this Clause. |
27.2 | The Prescribed Sum shall be an amount equal to one year's Basic Salary in accordance with Clause 9.1 as adjusted in accordance with Clause 27.3. |
27.3 | If the Company or the Cash Shell Company (as the case may be) terminates the Appointment by giving a period of notice whether under Clause 2.2 or otherwise, or terminates the Appointment under Clause 21, the Prescribed Sum shall be reduced pro rata by the number of complete months of service for which the Executive remains employed following notice being given to him or shall be reduced by the amount paid to the Executive under Clause 21. |
27.4 | The payment or provision of the Prescribed Sum shall be conditional upon and in consideration of: |
(a) | the Executive having complied with Clause 24; and |
(b) | the Executive having complied with and continuing to comply with his obligations relating to confidentiality and intellectual property in Clauses 19 and 20 respectively. |
27.5 | For the avoidance of doubt, the payment or provision of the Prescribed Sum shall not affect the Executive's entitlement as at the Termination Date to any of the following: |
(a) | any accrued but unpaid Basic Salary; |
(b) | any payment in lieu of accrued but unused holiday; or |
(c) | the reimbursement of his expenses, provided that all claims for reimbursement are submitted within four weeks of the Termination Date. |
27.6 | To the extent that the Prescribed Sum is damages (which is not admitted), the parties agree that the terms of this Clause 27 represent a genuine pre-estimate of the loss to the Executive that would arise on termination of the Appointment in the circumstances described and does not constitute a penalty. |
Page 25
28 | Guarantee |
28.1 | The Guarantor guarantees to the Executive that, if the Company does not comply with its obligations to pay any amount due to the Executive under this agreement (Guaranteed Amounts), the Guarantor shall pay on demand the Guaranteed Amounts to the Executive. |
28.2 | The Guarantor as principal obligor and as a separate and independent obligation and liability from its obligations under Clause 28.1 agrees to indemnify and keep indemnified the Executive in full and on demand from and against all and any losses, costs and expenses suffered or incurred by the Executive arising out of, or in connection with, any failure of the Company to pay the Guaranteed Amounts except where the Company's failure to pay the Guaranteed Amounts results from the Executive's failure to comply with his obligations under this agreement. |
28.3 | The liability of the Guarantor under this Clause shall not be reduced, discharged or otherwise adversely affected by any act, omission, matter or thing which would not have discharged or affected the liability of the Guarantor had it been a principal obligor instead of a guarantor. |
28.4 | All sums payable by the Guarantor under this agreement shall be paid in full to the Executive in the currency in which the Guaranteed Amounts are payable, free and clear of any deductions or withholdings of any kind, except for those as required under the terms of this agreement or by any law binding on the Guarantor. |
28.5 | The Guarantor represents and warrants to the Executive that it is has all requisite power and authority, and has taken all necessary action, to enable it to enter into, deliver and perform its obligations under this agreement. |
29 | Data protection |
29.1 | The Company will collect and process Personal Data in accordance with the data privacy notice which is annexed to this agreement and which is also available on the Company intranet. The Executive shall sign and date the privacy notice and return it to the Company within five working days of the date of this agreement. |
29.2 | The Executive shall comply with the Policies and Procedures in relation to privacy and data protection when handling personal data in the course of employment including personal data relating to any employee, worker, contractor, customer, client, supplier, agent or other contact of the Company or any Group Company. |
30 | Collective agreements |
There is no collective agreement applicable to the Company or to the Executive's employment with the Company.
31 | Notices |
31.1 | A notice given to a party under this agreement shall be in writing in the English language and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the party at the address given in this agreement or as otherwise notified in writing to the other party. |
Page 26
31.2 | Any such notice shall be deemed to have been received: |
(a) | if delivered by hand, at the time the notice is left at the address or given to the addressee; |
(b) | in the case of pre-paid first class UK post or other next working day delivery service, at 9.00 a.m. on the second business day after posting or at the time recorded by the delivery service; |
(c) | in the case of email, at the time of transmission. |
31.3 | A notice shall have effect from the earlier of its actual or deemed receipt by the addressee. For the purpose of calculating deemed receipt: |
(a) | all references to time are to local time in the place of deemed receipt; and |
(b) | if deemed receipt would occur on a Saturday or Sunday or a public holiday when banks are not open for business, deemed receipt is at 9.00 a.m. on the next business day. |
31.4 | This Clause does not apply to the service of any proceedings or other documents in any legal action. |
32 | General |
32.1 | No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives). |
33 | Entire agreement |
This agreement contains the entire and only agreement between the parties, and both parties acknowledge that, on entering into this agreement, they have not relied on any written or oral representation or undertaking other than as expressly stated in this agreement, and that this agreement supersedes any previous contract or arrangement between the parties.
34 | Counterparts |
This agreement may be executed in any number of counterparts, each of which, when executed, shall be an original, and all the counterparts together shall constitute one and the same instrument.
35 | Third party rights |
Except as expressly provided elsewhere in this agreement, no person other than the Executive and the Company or any Group Company shall have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.
36 | Governing law |
This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.
Page 27
37 | Jurisdiction |
Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).
Page 28
EXECUTED as a DEED by Tejinder Virk | /s/ ILLEGIBLE | |
at | ||
on 2021 2 June 2021 | ||
before the following witness: | ||
Witness Signature: | ||
/s/ Mouhssine Sebbar | ||
Full name: | ||
MOUHSSINE SEBBAR | ||
Address: | ||
245 West Hampstead | ||
NW6 1XN | ||
EXECUTED as a DEED for and on behalf of Canmart Ltd | /s/ ILLEGIBLE | |
at | Director/Authorised Signatory | |
on 2021 2 June 2021 | ||
before the following witness: | ||
Witness Signature: | ||
/s/ Mouhssine Sebbar | ||
Full name: | ||
MOUHSSINE SEBBAR | ||
Address: | ||
245 West Hampstead | ||
NW6 1XN |
Page 29
EXECUTED as a DEED for and on behalf of Halo Labs Inc | /s/ ILLEGIBLE | |
at | Director/Authorised Signatory | |
on 2021 2 June 2021 | ||
before the following witness: | ||
Witness Signature: | ||
/s/ Mouhssine Sebbar | ||
Full name: | ||
MOUHSSINE SEBBAR | ||
Address: | ||
245 West Hampstead | ||
NW6 1XN |
Page 30
Schedule 1
Executive Equity Rights
• | Board seat for so long as the Executive is appointed as the Chief Executive of the Company |
• | Up to 5% of the options available for grant pursuant to a share option pool to be created which constitutes, in aggregate, 15% of the fully diluted share capital of the Company (i.e. up to 0.75% of the aggregate fully diluted equity), subject always to approval by a remuneration or compensation committee to be established by the Company |
• | Market standard pre-emption rights on a new issuance of shares for cash in the Company except where such rights are not held by another minority shareholder of the Company with an equivalent percentage shareholding to the Executive or greater |
• | Tag rights (on a fully diluted basis) except where such rights are not held by another minority shareholder of the Company with an equivalent percentage shareholding to the Executive or greater |
• | Prior to a Listing, a right of consent in respect of the following matters: |
o | passing any resolution or presenting any petition for the Company's winding up or administration (unless the Company is insolvent) |
o | proposing any amendment to the Articles of Association of the Company that would prejudice the rights of the shares held by the Executive, other than with respect to administrative matters or approved by the Board (acting reasonably) in contemplation of a Listing |
o | reducing the capital of the Company or undertaking a purchase by the Company of any of its own shares |
o | changing the Company's accounting reference date or accounting standards falling outside of either UK GAAP, IAS or IFRS |
o | transferring the whole or any material part of the assets or undertaking of the Company |
• | Information rights, on and subject to the same terms as agreed with other shareholders of the Company with an equivalent percentage shareholding to the Executive |
Page 31
Schedule 2
Outside Interests
Windy Apple Ventures Limited – Board Advisor, soon to be Non-Executive Director
Page 32
Exhibit 10.7
CONTRACT OF EMPLOYMENT
Between
NewCo
(“Employer” or “Company” or “NewCo”)
and
Dr. Aslihan Akkar-Schenkl
(“Employee”)
§ 1 Commencement of the Employment Relationship
The employment relationship begins effectively as of October 1, 2021, subject to the condition precedent that NewCo is established and that the termination of any employment agreement with the former employer is effective, and is made for an indefinite period of time. In the event that the condition precedent is not met by October 1, 2021, the employment contract begins effectively as of the date of the occurrence of the conditions precedent. The Employee and the Employer shall cooperate and work diligently to ensure the establishment of NewCo.
§ 2 Place of Work
Place of work is Munich,- Germany.
§ 3 Activities
3.1
The Employee shall be employed as Managing Director, Europe. The Employee’s business title will be President, Akanda Corp. A brief description of the Employees duties are set out in Annexure 1 to this Agreement.
3.2
Notwithstanding the above, the Employer is entitled, if necessary, to assign other equivalent tasks to the Employee which correspond to her educational background and abilities. This reservation also applies to a transfer to another work place. In each case of assignment or transfer, the interests of both parties must be taken into consideration appropriately.
3.3
The Employee acknowledges that it is a requirement of the position that the Employee may be requested by the Employer to travel regularly to work with other members of the Employer’s management team and advisors, including without limitation, travel to Toronto, Ontario, Maseru, Kingdom of Lesotho„ London, United Kingdom, Johannesburg, South Africa and other locations where the Employer or its related companies may operate from time to time. When undertaking business class travel on behalf of the Employer, the Employee may book business class travel for flights and first class rail travel, where such class of travel is available.
Page 1 of 13
§ 4 Working Time
4.1
The Employee’s regular weekly working time without breaks currently amounts to 40 hours.
4.2
The beginning and the end of the daily working time and breaks shall be determined by the Employer.
4.3
The Employee undertakes to work overtime as well as on Sundays and public holidays to the extent permissible by law (currently regulated by the German Working Hours Act).
§ 5 Remuneration
5.1
As remuneration for her work, the Employee shall receive an annual gross salary of
EUR 154,000.00
(in words: One Hundred Fifty Four Thousand Euros),
which shall be paid in 12 equal instalments of EUR 12,833.33 gross each.
In addition, a fixed annual bonus of EUR 46,000.00 will be paid. The bonus payout takes place every twelve months in January of each year, with each 12 month measurement period commencing on 1 January and ending on 31 December of each year. Should the Employee have completed less than 12 months of service prior to the first 12 month period ending 31 December, then the fixed annual bonus shall be pro-rated in accordance with the duration of service in that 12 month measurement period.
5.2
Remuneration shall be due on the last calendar day of each month and transferred in cash to a German account to be named by the Employee by no later than the 5th calendar day of the following month.
5.3
Salary claims shall neither be pledged nor assigned. In case of attachment of salary, the company is entitled to deduct the specific processing fee.
5.4
Other employees or third parties shall not be given knowledge of the amount and composition of the remuneration by the Employee. However, the Employee acknowledges that the Employer’s affiliated company is a listed issuer and details of her compensation, including any equity-based compensation provided in connection with this Agreement or under any other arrangement with the Employer or its affiliated companies, will be required to be disclosed under applicable securities laws.
Page 2 of 13
5.5
Until such time that NewCo is formed and properly registered with German authorities in such a manner to facilitate the processing and payment of remuneration in accordance with applicable regulations and tax requirements, the Employee shall prepare and submit a tax invoice; which shall include all basic remuneration due to the Employee as well as any applicable statutory social security and retirement funding deductions, to the Employer (or it’s designated nominee) by no later than the 25th of each month.
5.6
For the duration of this contract, the Employer shall grant the Employee a subsidy for health insurance in the amount of the employer’s contribution as it would have been if the Employee had been obliged to take out health insurance, but not exceeding half of the amount which the Employee has to spend on her health insurance.
§ 6 Inability to attend work
6.1
The Employer shall, without undue delay, be notified of any inability of the Employee to attend work, indicating the reason and the anticipated duration. The same applies if the duration of the inability to attend work is extended.
6.2
Any incapacity for work due to sickness shall be immediately, however, no later than by the beginning of work on the relevant working day, be reported to the superior, indicating the reason and anticipated duration. In case that the incapacity for work exceeds three calendar days, the Employee shall furthermore submit a medical certificate on the inability to work and its anticipated duration before the end of the third calendar day. These obligations to notify and submit a certificate will also apply after the end of any continued payment of remuneration during illness.
6.3
The Employer is entitled at any time to request earlier submission of the medical certificate.
6.4
If the incapacity for work exceeds the period indicated in the certificate, notwithstanding the duration of incapacity for work and also after the period of sick pay, the Employee shall immediately notify the Employer of the continued incapacity for work and submit a new medical certificate, or the payment slip from the health insurance company.
6.5
In the event of a temporary prevention of the Employee’s activities clue to illness, incapacity or other circumstances for which she is not responsible, the Employee shall be entitled to the difference between net remuneration and payments from his statutory and/or private health insurance for a period of three months.
6.6
The Employee subrogates herewith all claims for compensation to the Employer in the amount of the abovementioned payments to which the Employee is entitled as a result of the third-party event that caused the work inability.
Page 3 of 13
6.7
If the Employee dies during the term of the employment contract, her dependants are jointly entitled to continued payment of her fixed salary for the month of death and the two following months. The dependants shall agree among themselves what percentage of the Employee’s monthly salary they are entitled to. If the Employer is not notified by all the dependants in agreement to whose attention the maximum of three months’ salary is to be paid for the benefit of all the dependants, the Employer shall be entitled to deposit the payments with the depository of the competent local court or to pay them into the escrow account of a lawyer or a notary public with discharging effect.
§ 7 Insurances
7.1
The Employee is entitled to take out a D&O insurance policy for herself in Germany with a current insured sum of EUR 5.000.000,- (Five Million Euro) per claim and year. She will pay the insurance premiums initially herself and then invoices them to the Employer. The Employer safeguards that the amount of the insured sum is checked at regular intervals to ensure that it is appropriate. The D&O insurance also covers all claims against the Employee after she has left the company, as long as these claims have not yet become time-barred. The insurance shall also cover or become part of an insurance encompassing any activity of the Employee as a member of a governing body of affiliated companies outside of Germany.
7.2
The Employer shall take out legal expenses insurance for the Employee, which shall include at least criminal law protection, as well as legal protection against financial loss and legal protection for the employment contract. The policyholder is the Employee. The insurance obligation ends when the Employee leaves the company.
7.3
The Employer shall insure the Employee against accidents within the usual scope, but at least in the amount of € 250,000.00 in case of disability and € 150,000.00 in case of accidental death. The persons entitled to benefit from the insurance in the event of disability are the Employee, in the event of death the persons named by her, in the absence of such a provision or if the named persons are deceased, the heirs of the Employee. Coverage is provided for accidents of any kind, regardless of whether they are work-related or private. The insurance shall expire on the date of termination of this contract.
§ 8 Liability and Discharge of the Employee
8.1
The Employee shall be liable to the Employer only for compensation for such damage as is caused by gross negligence or willful misconduct. Article 43, section 3, sentence 3 GmbHG remains unaffected.
Page 4 of 13
8.2
In the event of a breach of such duties which are imposed on the Employee for the protection of the company’s creditors, the limitation of liability pursuant to subsection 1 shall cease to apply upon the opening of the company’s insolvency proceedings or their rejection for lack of assets.
8.3
All claims of the Employer against the Employee shall become statute-barred after two years, unless the breach of duty of the Employee consists in the fact that she participated in the disbursement of tied capital of the GmbH to shareholders contrary to section 43, subsection 3 GmbHG. The limitation of liability due to intent remains unaffected.
8.4
Deviating from the distribution of the burden of proof according to the case law of the Federal Court of Justice (BGH), the Employer bears the full burden of presentation and proof for all preconditions for a claim, following general principles.
8.5
The Employee has a claim against the Employer for discharge. If the discharge is refused, the Employee shall be informed of the reasons for this refusal in writing by the general meeting.
§ 9 Term and Termination
9.1
The first 6 (six) months of the employment agreement shall be agreed as probationary period, at most for the duration of this six months, the employment relationship may be terminated with a notice period of 2 (two) weeks.
9.2
After the probationary period, the employment relationship may be terminated by either party with three months’ notice to the end of the quarter.
9.3
The right to termination without notice for a compelling reason shall remain unaffected (Sec. 626 BGB (German Civil Code)).
9.4
Any notice of termination requires the written form.
9.5
The Employer may release the Employee from the duty to work if there is a factual ground (including, without limitation, notice of termination by the Employee or the Employer, shortage of orders, misconduct by the Employee, a risk of the Employee to join a competitor company). Remaining days of vacation are set off against an irrevocably determined release period. After such set-off, the remuneration that remains to be payable to the Employee is subject to deduction of what the Employee saves by not performing the employment hereunder or what the Employee acquires by using her services for other purposes or what the Employee maliciously fails to acquire.
Page 5 of 13
9.6
The employment relationship shall end without requiring notice of termination when the Employee reaches the regular retirement age for old-age pension. It terminates before that date upon expiry of the month in which the Employee begins receiving a statutory pension provider determines that the Employee is entitled to a pension based on complete inability to engage in gainful activities, then the employment terminates upon the expiry of the day prior to the commencement of the pension payments. If the pension based on complete inability to engage in gainful activities will be accorded only for a temporary period, the employment will suspend as of the expiry of the day preceding the commencement of the pension payments until expiry of the day until which the temporary pension is authorized, but no later than until expiry of the day in which the employment terminates.
§ 10 Reimbursement of Travelling Costs
The Employer shall reimburse the Employee for documented travel expenses that the Employee incurs in the context of performing her duties, at least up to the amount of the German tax law guidelines as amended from time to time or in accordance with the internal guidelines and policies of the Employer, as amended by the Employer from time to time.
§ 11 Holiday
11.1
The Employee is entitled to annual recreational leave of 30 working days per calendar year based on 5 working days per calendar week (the statutory vacation entitlement comprises 20 days per calendar year, the additional voluntary vacation comprises 10 vacation days per calendar year). Employee taken vacation days are primarily deducted from the statutory vacation days. Once all statutory vacation days have been taken, vacation days are deducted from the voluntarily granted vacation days.
The vacation entitlement will be adapted accordingly if the Employee regularly works more or less than five days per week.
11.2
Vacation shall be taken in agreement with the superior and, as far as possible, on consecutive days. The entire vacation must be taken in the current calendar year. Vacation can only be carried forward to the next calendar year if justified by urgent operational reasons or personal reasons of the employee. Vacation entitlements so carried forward shall expire if not taken within the first three months of the following year (carry-forward period). If the Employee is unable to take the carried forward vacation during the carry-forward period due to incapacity for work due to sickness, the vacation entitlements shall continue to exist, however, only up to the amount of the statutory vacation entitlement (including additional vacation for severely disabled persons). In such case, the statutory vacation entitlement shall expire 15 months after the end of the calendar year, in which the vacation entitlement arose, at the latest.
11.3
The Employer always grants the statutory minimum vacation first (and, if applicable, statutory additional vacation, such as under the laws regarding severely disabled persons). If the employment relationship is terminated, any compensation for vacation shall only be paid up to the amount of the statutory minimum vacation.
Page 6 of 13
§ 12 Side-Line Employment
12.1
The Employee may not take up any paid or unpaid secondary activity unless the Employee prior notifies the secondary activity in text form. The Employer shall give its approval, if so required, if and as far as the intended secondary activity is not in conflict with the timing of the Employee’s duties hereunder and does not affect any other legitimate interests of the Employer. The Company shall be notified in text-form prior to the beginning of any additional occupation.
12.2
Any lectures and publications of the Employee, insofar as they concern her scope of duties or the company’s general area of interests, require the management’s consent.
§ 13 Confidentiality, Return of Property,
13.1
The Employee agrees to keep confidential all trade and business secrets (“Secrets”). Furthermore, the Employee agrees to keep confidential all business matters that a superior has designated as confidential or that are obviously of a confidential nature (“Confidential Matters”).
13.2
The duty of confidentiality also applies to employees of the Employer as far as they are not entitled to learn about the Secret or Confidential Matters by reason of their position.
13.3
The duty of confidentiality also applies to Secrets and Confidential Matters of other companies of the group. The same applies to Secrets and Confidential Matters of companies that are economically or organizationally associated with the Employer.
13.4
The Employee’s duty of confidentiality survives the termination of this Employment Agreement. As far as the post-contractual duty of confidentiality hinders the occupational advancement of the Employee inadequately, she is entitled to be released from this duty by the Employer.
13.5
The betrayal of trade and business secrets is a criminal offence and can be punished with imprisonment of up to three years or by payment of a fine. Furthermore, the infringement of the duty to confidentiality can justify the termination of the employment and / or claims for damages of the Employer.
13.6
Any kind of business items and business records, including personal notes and (electronically) copies respectively concerning business affairs and activities must only be used for business purposes. There are to be carefully retained and handed over at any time to the Employer at its request and upon the termination of the employment in the absence of such request. The Employee has no rights of retention.
Page 7 of 13
§ 14 Inventions Assignment
14.1
The Employee transfers to the Employer the exclusive, perpetual, worldwide and unlimited right of use and exploitation of all results produced by the Employee during the term of this Employment Agreement whether on or off duty as long as such results are associated with the Employee’s contractual duties and capable of being protected by intellectual property law, design patent law, utility patent law, trademark law or other law.
14.2
The Employee’s transfer of rights under section 12.1 above includes, without limitation, permission of adaptation and licensing.
14.3
The Employee waives all other rights arising to the Employee as creator of or other holder of proprietary rights to work results, in particular the right of having the Employee named as the author of a work result, the right of adaptation and the right of making a work accessible to the public.
14.4
The Employee’s grant and waiver of rights under this section 12.1 is fully settled by the remuneration payable in accordance with this employment agreement.
14.5
The German Employee Inventions Act and Section 69b German Copyright Act remain unaffected.
§ 15 Collecting, Processing and Use of Personal Data
15.1
The Employer is authorized to collect process and use her personal data of the Employee for the purpose of establishing, implementing and terminating the employment relationship.
15.2
The Employer is authorized to the transfer the Employee’s personal data by the Employer to third parties, for purposes in the framework of this employment relationship and in accordance with applicable laws.
15.3
Other statutory rights of the Employer for the collecting, processing and use of personal data shall remain unaffected.
§ 16 IT Clause, Forbidden private use of Internet
16.1
The parties undertake to strictly adhere to the provisions of the copyright law.
Page 8 of 13
16.2
The Employer informs the Employee of the following:
To comply with the requirements under data protection law it is necessary that the connection data to the internet be recorded and controlled. This also extends to the private use of the internet connection, i.e. also to privately received e-mails.
In this context, it is explicitly pointed out to the Employee that, for the purpose of data protection and security, spam filters and virus scanners are or may be used.
It can therefore not be ruled out that such filter mechanisms sort out e-mails (also of a private nature) even though they neither classify as spam nor contain viruses. The Employee also gives its consent hereto.
This is expressly not an authorization to use the internet and business email account privately; private use is forbidden.
§ 17 Non-Competition, Non-Solicitation
17.1
During the term of this Employment Agreement, the Employee is prohibited from working on a self-employed or employed basis or otherwise for any business that is in direct or indirect competition with the Employer. Likewise, during the term of this Employment Agreement, the Employee is prohibited from forming, acquiring or directly or indirectly participating in such companies. The Employee may hold any shares or other securities of any competitor that is listed on any securities exchange or recognized securities market anywhere to the extent that she does not hold more than 1 of the share capital.
17.2
During the term of her employment relationship and following the end of this employment relationship, the Employee may not, whether in person or through others, whether directly or indirectly, — for the benefit of another employer — poach staff from the Employer. She may also not cause any staff of the Employer to terminate their employment contracts with the Employer.
§ 18 Forfeiture of Claims
18.1
Forfeiture clauses are not applicable to claims based on the Minimum Wage Act. The respective statutory limitations periods will apply instead.
Accordingly, forfeiture clauses do not apply to liability caused by premeditation or gross negligence. The before said applies accordingly to all claims which cannot be subject to forfeiture clauses.
18.2
All other claims that result from or in connection with the Agreement should be claimed in text form by the contractors within 3 months after the claim has emerged and the claimant has known about the claim circumstances or should have known about them without gross negligence. Otherwise, the claim will expire.
Page 9 of 13
§ 19 Certificate of good conduct
The Employee is obliged to present to the Employer a current certificate of good conduct (not older than 3 months) no later than at the beginning of the contractual commencement date.
§ 20 Policy
The Employee is obliged to act in compliance with all policies of the Employer and / or of the affiliated entities with the Employer and / or of the mother company of the Employer that may be applicable to her employment agreement.
§ 21 Miscellaneous
21.1
Amendments and/or supplements to this Agreement as well as collateral agreements require the written form in order to be effective. This shall also apply to the cancellation of this written form requirement. This shall not apply to amendments due to verbal individual agreements.
21.2
If individual current or future provisions of this Agreement are or become ineffective, entirely or in part, the remaining provisions shall remain unaffected. In such case, the parties shall replace the ineffective provision with a new provision that comes as close as possible to the economic intent of the ineffective provision.
21.3
If any claims are commenced by third parties against the Employee arising out of non-compete or other agreements that would preclude him from carrying out her obligations under this Agreement, the Employee shall be solely liable to such third parties, and shall pay her own costs and expenses in relation to such claims, provided that the Employee shall have no liability to the Employer for damages or other losses resulting from such claims by third parties.
21.4
This Agreement is made in English language only and the Employee expressly acknowledges and confirms it understand all provisions.
21.5
This Agreement shall be governed by the laws of the Federal Republic of Germany. Any disputes under or in connection with this Agreement (including those regarding it validity) shall be exclusively settled in the labour courts. The labour court in Munich shall have first instance jurisdiction.
Page 10 of 13
SIGNATURES | |
September 28, 2021, Johannesburg | |
Date, Place | |
NewCo | |
Employer | |
September 23, 2021, Munich | |
Date, Place | |
/s/ Aslihan Akkar-Schenkl | |
Employee / Dr. Aslihan Akkar-Schenkl |
Page 11 of 13
Annexure 1
JOB OVERVIEW | |
COMPANY | NewCo TBD |
JOB TITLE | President, Akanda Corp. |
GENERAL
DESCRIPTION |
The Employee shall serve as, and the hold the title of, President: Akanda Corp.
The position of President: Akanda Corp. is a senior executive position and the Employee shall fulfil a variety of duties commensurate with that role, and as shall be determined by the Chief Executive Officer from time-to-time.
|
JOB LOCATION | Munich, Germany |
EMPLOYEE | Dr. Aslihan Akkar-Schenkl |
REPORTS TO | The Group Chief Executive Officer - Tejinder Virk |
EMPLOYMENT TYPE | Full time |
RESPONSIBILITIES |
● Ensuring that Lesotho medical cannabis products are compliant and EU GMP quality standards (or equivalent depending on jurisdiction), either through direct company efforts or via third party processing, for commercial sale in all possible international markets.
● Working with the Lesotho government to create a framework for medical cannabis product registrations domestically and associated dispensation.
● Leading implementation of Global Compliance Management at corporate level including all sites.
● Lead and implementation of Corporate Quality Management as well as responsible for ground operations in Quality Assurance at all sites, which includes arranging internal and external audits by relevant government authorities/representatives
● Attend to the incorporation of Akanda Deutschland GmbH (including company formation and registration, opening of bank accounts and other matters necessary for the formation of a new company in Germany), and be appointed Managing Director and hold related responsibility at operational, financial and strategic levels.
● Oversee Akanda Deutschland GmbH hiring of local staff and consultants; the positioning of Akanda’s brands and establishing medical programmes with the clinics.
|
Page 12 of 13
● Develop and manage Akanda Deutschland GmbH occasional public communications and media engagements, in coordination with global communications strategy.
● Serve as a member of the Akanda group’s strategic management committee overseeing global mergers and acquisitions, new Global Product development and geographic expansion, spanning all business lines including pharmaceutical, medical and wellness such as Consumer Healthcare; for example - pharmaceutical cannabis lines, medical cannabis, Cosmeceuticals with Cannabinoids.
● Oversight of any scientific, research and development activities, as well as intellectual property portfolio establishment and management for market exclusivity in strategic relevant markets activities at the company.
● Global supply chain oversight.
● Serve as the head of global medical and pharmaceutical operations.
● Serve as the head of Legal & Regulatory affairs.
● Bridge external and internal Legal affairs with the CEO and the Board of Directors.
|
Page 13 of 13
Exhibit 10.8
INDEMNITY AGREEMENT
DATED effective as of the day of August, 2021.
BETWEEN:
Akanda Corp. a corporation incorporated under the Business Corporations Act (Ontario) (hereinafter called the "Corporation")
– and –
[●]
(hereinafter called the "Indemnified Party")
WHEREAS Section 136(1) of the Business Corporations Act (Ontario) (the "Act"), under which the Corporation is continued, provides that a corporation may indemnify a director or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation or other entity.
AND WHEREAS in addition, Section 136(2) of the Act provides that a corporation may advance money to a director, officer or other individual for the costs, charges and expenses of a proceeding referred to in subsection (1), but the individual shall repay the money if the individual does not fulfil the conditions set out in subsection (3).
AND WHEREAS in addition, Section 136(3) of the Act provides that a corporation shall not indemnify an individual under subsection (1) unless the individual acted honestly and in good faith with a view to the best interests of the corporation or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the corporation’s request.
AND WHEREAS in addition, Section 136(4) of the Act provides that in addition to the conditions set out in subsection (3), if the matter is a criminal or administrative action or proceeding that is enforced by a monetary penalty, the corporation shall not indemnify an individual under subsection (1) unless the individual had reasonable grounds for believing that the individual’s conduct was lawful.
AND WHEREAS in addition, Section 136(4.1) of the Act provides that a corporation may, with the approval of a court, indemnify an individual referred to in subsection (1), or advance moneys under subsection (2), in respect of an action by or on behalf of the corporation or other entity to obtain a judgment in its favour, to which the individual is made a party because of the individual’s association with the corporation or other entity as described in subsection (1), against all costs, charges and expenses reasonably incurred by the individual in connection with such action, if the individual fulfils the conditions set out in subsection (3).
AND WHEREAS in addition, Section 136(4.2) of the Act provides despite subsection (1), an individual referred to in that subsection is entitled to indemnity from the corporation in respect of all costs, charges and expenses reasonably incurred by the individual in connection with the defence of any civil, criminal, administrative, investigative or other proceeding to which the individual is subject because of the individual’s association with the corporation or other entity as described in subsection (1), if the individual seeking an indemnity, (a) was not judged by a court or other competent authority to have committed any fault or omitted to do anything that the individual ought to have done; and (b) fulfils the conditions set out in subsections (3) and (4).
-2-
AND WHEREAS in addition, Section 136(4.3) of the Act empowers a corporation to purchase and maintain insurance for the benefit of any such persons referred to in subsection 124(1) of the Act against any liability incurred by him (a) in his capacity as a director or officer of the corporation; or (b) in his capacity as a director or officer of another body corporate when he acts or acted in that capacity at the corporation's request.
AND WHEREAS the Corporation desires to have the Indemnified Party serve or continue to serve as a director or officer of the Corporation, or as a director or officer of any subsidiary or affiliate of the Corporation or any entity of which the Corporation is or was a shareholder or creditor (each an "Affiliate") of which he has been or is serving, or will serve at the request of the Corporation, free from undue concern for unpredictable, inappropriate or unreasonable claims for damages by reason of his being, or having been, a director or officer of the Corporation or a director of officer of an Affiliate or by reason of his decisions or actions on their behalf.
AND WHEREAS the Indemnified Party is willing to serve, or to continue to serve, or to take on additional service for, the Corporation or the Affiliates in such aforesaid capacities on the condition that he be indemnified as provided for herein.
NOW THEREFORE, IN CONSIDERATION OF the premises and mutual covenants herein contained, and in consideration of the sum of One ($1.00) Dollar paid by the Indemnified Party to the Corporation (the receipt of which is hereby acknowledged) and the Indemnified Party acting and/or agreeing to continue to act as a director and/or officer of the Corporation or as a director and/or officer of an Affiliate, the Corporation and the Indemnified Party do hereby covenant and agree as follows:
1. | Agreement to Serve |
The Indemnified Party agrees to serve or continue to serve as a director or officer of the Corporation or as a director or officer of an Affiliate (in the case of an officer of the Corporation or Affiliate officer, at the will of the Corporation or Affiliate, as applicable, or under a separate contract, if any such contract exists or shall hereafter exist), honestly and in good faith with a view to the best interests of the Corporation or an Affiliate so long as he is duly elected and qualified in accordance with the provisions of the Act, the by-laws or any other governing documents of the Corporation or Affiliate, as applicable, provided, however, that (i) the Indemnified Party may at any time and for any reason resign from such position (subject to any contractual obligations which the Indemnified Party shall have assumed apart from this Agreement), and (ii) neither the Corporation nor any Affiliate shall have any obligation under this Agreement to continue the Indemnified Party in any such position.
2. | Indemnification |
(a) | To the full extent allowed by law, the Corporation agrees to indemnify and save harmless the Indemnified Party, his estate, executors, administrators, legal representatives and lawful heirs, from and against any and all costs, charges or expenses (including, but not limited to, an amount paid to settle any action or to satisfy any judgment, legal fees on a solicitor and client basis, other professional fees, out-of-pocket expenses for attending proceedings including discoveries, trials, hearings and meetings, and any amount for which he is liable by reason of any statutory provision whether civil, criminal or otherwise) (collectively, hereinafter referred to as "Costs, Charges and Expenses"), suffered or incurred by the Indemnified Party, his estate, executors, administrators, legal representatives and lawful heirs, directly or indirectly, as a result or by reason of the Indemnified Party being or having been a director or officer of the Corporation or Affiliate or by reason of any action taken by the Indemnified Party in his capacity as a director or officer of the Corporation or Affiliate, provided that such costs, charges or expenses were not suffered or incurred as a result of the Indemnified Party's own fraud, dishonesty, wilful neglect or wilful default. |
(b) | In addition to and without limitation of Section 2(a) of this Agreement, the Corporation agrees: |
-3-
(i) | except in respect of an action by or on behalf of the Corporation or an Affiliate to procure a judgment in its favour, to indemnify the Indemnified Party, his estate, executors, administrators, legal representatives and lawful heirs, from and against all Costs, Charges and Expenses reasonably incurred by him in respect of any civil, criminal or administrative action or proceeding to which he is made a party (including actions, proceedings, investigations, inquiries or hearings in which the Indemnified Party is compelled by the authorities or requested by the Corporation or Affiliate to participate, whether or not charges have been laid against the Corporation, Affiliate or Indemnified Party), by reason of being or having been a director or officer of the Corporation or Affiliate, if: |
(A) | he acted honestly and in good faith with a view to the best interests of the Corporation or the Affiliate, as the case may be; and |
(B) | in the case of a criminal or administrative action, proceeding, investigation, inquiry or hearing that is enforced by monetary penalty, he had reasonable grounds for believing that his conduct was lawful; |
(ii) | to indemnify the Indemnified Party and his estate, executors, administrators, legal representatives and lawful heirs from and against all Costs, Charges and Expenses of any action by or on behalf of the Corporation or Affiliate to procure a judgment in its favour, to which he is made a party by reason of being or having been a director or officer of the Corporation or Affiliate, if the Indemnified Party has fulfilled the conditions set forth in Subsections 2(b)(i)(A) and (B) of this Agreement and if the Corporation or the Affiliate, as the case may be, obtains the approval of the Court (as defined in the Act) to grant such indemnity; |
(iii) | in the event that the approval of the Court is required to effect any indemnification granted hereunder, the Corporation agrees to make application for and use its best effort to obtain the Court's approval to such indemnification provided that the Indemnified Party has fulfilled the conditions set forth in Subsections 2(b)(i)(A) and (B) of this Agreement; |
(iv) | in addition to and without limitation of Subsections 2(b)(i) and (ii) of this Agreement, to indemnify the Indemnified Party and his estate, executors, administrators, legal representatives and lawful heirs against all Costs, Charges and Expenses reasonably incurred by him in respect of the defence of any actual or threatened civil, criminal or administrative action or proceeding to which he is made a party or threatened to be made a party, (including actions, proceedings, investigations, inquiries or hearings in which the Indemnified Party is compelled by the authorities or requested by the Corporation or Affiliate to participate, whether or not charges have been laid against the Corporation, Affiliate or Indemnified Party), by reason of being or having been a director or officer of the Corporation or Affiliate if the Indemnified Party: |
(A) | was substantially successful on the merits in his defence of the action, proceeding, investigation, inquiry or hearing; |
(B) | fulfils the conditions set out in Subsections 2(b)(i) (A) and (B) of this Agreement; and |
(C) | is fairly and reasonably entitled to indemnity; and |
(v) | for the purposes of this Agreement including, without limitation, Section 2 hereof, the termination of any such civil, criminal or administrative action, proceeding, investigation, inquiry or hearing, by judgment, order, settlement, conviction or similar or other result, shall not, of itself, create a presumption either that the Indemnified Party did not act honestly or in good faith with a view to the best interests of the Corporation or Affiliate or that, in the case of a criminal or administrative action, proceeding, investigation, inquiry or hearing that is enforced by a monetary penalty, the Indemnified Party did not have reasonable grounds for believing that his conduct was lawful. |
-4-
(c) | The intention of this Agreement is to provide the Indemnified Party indemnification to the fullest extent permitted by law and without limiting the generality of the foregoing and notwithstanding anything contained herein: |
(i) | nothing in this Agreement shall be interpreted, by implication or otherwise, in limitation of the scope of the indemnification provided in Subsections 2(a) and (b) hereof; and |
(ii) | Subsection 2(b) is intended to provide indemnification to the Indemnified Party that is not specifically prohibited by a court of competent jurisdiction and to the fullest extent permitted by the Act, as applicable, and, in the event that the Act, as applicable, is amended to permit a broader scope of indemnification (including, without limitation, the deletion or limiting of one or more of the provisos to the applicability of indemnification), Subsection 2(b) shall be deemed to be amended concurrently with the amendment to the Act, as applicable, so as to provide such broader indemnification. |
3. | Prepaid Expenses |
All Costs, Charges and Expenses reasonably incurred by the Indemnified Party and covered hereunder shall, if requested by the Indemnified Party within a reasonable time, be paid by the Corporation immediately, with the understanding and agreement being herein made that, in the event it is ultimately determined as provided hereunder that the Indemnified Party was not entitled to be so indemnified, or was not entitled to be fully so indemnified, the Indemnified Party shall indemnify and hold harmless the Corporation, and pay to the Corporation forthwith after such ultimate determination, such amount or the appropriate portion thereof, so paid. In the event of dispute, the Corporation or Indemnified Party, at the Corporation's expense, shall make application to the Court to approve the indemnity.
4. | Other Rights and Remedies |
Indemnification and immediate payment of incurred Costs, Charges and Expenses as provided by this Agreement shall not be deemed to derogate from or exclude any other rights to which the Indemnified Party may be entitled under any provision of the Act or otherwise at law, the articles or by-laws or other governing documents of the Corporation or Affiliate, this Agreement, any vote of shareholders, unitholders or partners, as the case may be, of the Corporation or Affiliate, or otherwise, both as to matters arising out of his capacity as a director or officer of the Corporation or Affiliate, or as to matters arising out of another capacity with the Corporation or Affiliate while being a director or officer of the Corporation or Affiliate, and shall continue after the Indemnified Party has ceased to be a director or officer of the Corporation or Affiliate.
5. | Limitation of Actions and Release of Claims |
No legal action shall be brought and no cause of action shall be asserted by or on behalf of the Corporation against the Indemnified Party, his estate, executors, administrators, legal representatives or lawful heirs after the expiration of two years from the date the Indemnified Party ceased (for any reason) to be a director or officer of the Corporation or Affiliate and the Corporation agrees that any claim or cause of action of the Corporation shall be extinguished and the Indemnified Party, his estate, executors, administrators, legal representatives and lawful heirs deemed released therefrom absolutely unless asserted by the commencement of legal action in a court of competent jurisdiction within such two-year period.
-5-
6. | No Presumption as to Absence of Good Faith |
(a) | In respect of any claim for indemnification pursuant to this Agreement, the Indemnified Party shall be presumed to have acted honestly and in good faith and with a view to the best interests of the Corporation or Affiliate, as applicable, and in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, to have had reasonable grounds for believing that his conduct was lawful, unless proven otherwise. |
(b) | Determination of any civil, criminal or administrative action or proceeding by judgment, order, settlement or conviction, or upon a plea of "nolo contendere" or its equivalent, shall not, of itself, create any presumption for the purposes of this Agreement that the Indemnified Party did not act honestly and in good faith with a view to the best interests of the Corporation or Affiliate, as applicable, and in the case of a criminal or administrative action or proceeding that is enforced by monetary penalty, that he did not have reasonable grounds for believing that his conduct was lawful, unless the judgment or order of the court shall specifically find otherwise. |
7. | Notice of Proceedings |
The Indemnified Party agrees to give notice to the Corporation as soon as is reasonably practical after being served with any statement of claim, writ, notice of motion, indictment or other document commencing or continuing any civil, criminal or administrative action, proceeding, investigation, inquiry or hearing to which the Indemnified Party, is a party, whether or not charges have been laid against the Corporation, an Affiliate or the Indemnified Party, by reason of being or having been a director or officer of the Corporation or Affiliate and the Corporation agrees to give notice to the Indemnified Party in writing as soon as is reasonably practical after:
(a) | being served with any such statement of claim, writ, notice of motion, indictment or other document commencing or continuing any civil, criminal or administrative action, proceeding, investigation, inquiry or hearing to which the Indemnified Party is a party; whether or not charges have been laid against the Corporation, an Affiliate or the Indemnified Party, or |
(b) | receiving notice of any such civil, criminal or administrative action, proceeding, investigation, inquiry or hearing to which the Indemnified Party is a party, whether or not charges have been laid against the Corporation, an Affiliate or the Indemnified Party, |
provided, however, that the failure of the Indemnified Party to give such notice to the Corporation shall not adversely affect the Indemnified Party's rights under this Agreement except to the extent that the Corporation or Affiliate shall have been materially prejudiced as a direct result of such failure.
8. | Right to Retain Counsel |
The Corporation agrees to promptly retain counsel who shall be reasonably satisfactory to the Indemnified Party to represent the Indemnified Party.
In any such matter the Indemnified Party shall have the right to retain other counsel to act on his behalf, provided that the fees and disbursements of such other counsel shall be paid by the Indemnified Party unless:
(a) | the Indemnified Party and the Corporation shall have mutually agreed to the retention of such other counsel, or |
(b) | the parties to any such civil, criminal or administrative action, proceeding, investigation, inquiry or hearing (including any added third, or interpleaded parties) include the Corporation and the Indemnified Party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them (including the availability of different defences) in which event the Corporation and Affiliate, jointly and severally agree to pay the fees and disbursements of such counsel. |
-6-
9. | Investigation by Corporation and Affiliate |
The Corporation and/or Affiliate may conduct any investigation it considers appropriate of any proceedings, including discoveries, trials, hearings and meetings, and will pay all costs of that investigation.
10. | Indemnified Party to Cooperate |
The Indemnified Party agrees to give the Corporation and Affiliate such information and cooperation as the Corporation and Affiliate may reasonably require from time to time in respect of all matters hereunder.
11. | Settlement |
The parties will act reasonably in pursuing the settlement of any Proceeding. The Corporation and/or an Affiliate may not negotiate or effect a settlement of claims against the Indemnified Party without the consent of the Indemnified Party, acting reasonably. The Indemnified Party may negotiate and effect a settlement without the consent of the Corporation and/or an Affiliate but the Corporation and/or an Affiliate will not be liable for indemnification under this Agreement with respect to any settlement negotiated without its prior written consent, which consent will not be unreasonably withheld or delayed.
12. | Insurance |
(a) | The Corporation agrees to purchase and maintain or cause to be purchased and maintained, while the Indemnified Party remains a director or officer of the Corporation or an Affiliate and for a minimum of six years thereafter, insurance for the benefit of the Indemnified Party against any liability incurred by him in his capacity as a director and/or officer of the Corporation or Affiliate on terms no less favourable in terms of coverage and amounts, to the extent permitted by law and available on reasonable commercial terms, than such insurance maintained by the Corporation or any other entity on the Corporation's behalf on the date hereof; provided that such insurance shall not apply where the liability relates to his failure to act honestly and in good faith with a view to the best interests of the Corporation or Affiliate, as the case may be. |
(b) | The Corporation agrees to provide evidence to the Indemnified Party on an annual basis (on the anniversary date of this Agreement) during the term for which the Corporation is obligated to maintain such insurance under the terms hereof, that it has the insurance required under the terms of this Agreement and that it has paid the applicable premium(s) for such insurance and shall, upon request of the Indemnified Party, provide the Indemnified Party with a copy of the relevant insurance policy within 14 days of such request. If the Indemnified Party is not provided with evidence that the Corporation has such insurance or that it has paid the applicable premium, the Indemnified Party shall be entitled to purchase the required insurance and the Corporation agrees to indemnify and save harmless the Indemnified Party, his estate, executors, administrators and lawful heirs for all expenses incurred by or on behalf of the Indemnified Party to obtain such insurance coverage. |
(c) | In the event an insurable event occurs, the Indemnified Party will be indemnified promptly as agreed hereto regardless of whether the Corporation has received the insurance proceeds. The Indemnified Party is entitled to full indemnification as agreed hereto notwithstanding any deductible amounts or policy limits contained in any such insurance policy. |
-7-
13. | Arbitration |
All disputes, disagreements, controversies or claims arising out of or relating to this Agreement, including, without limitation, with respect to its formation, execution, validity, application, interpretation, performance, breach, termination or enforcement will be determined by arbitration before a single arbitrator under the Arbitration Act, 1991 (Ontario). The arbitrator will determine, based on the outcome of the arbitration, the breakdown between the Corporation and/or Affiliate and the Indemnified Party of the costs for conducting the arbitration.
14. | Taxes Payable |
The Corporation agrees to reimburse the Indemnified Party for the net amount of tax payable by the Indemnified Party under the taxing laws of any jurisdiction provided that such net taxes payable are directly a result of the payment or reimbursement of the Costs, Charges and Expenses under this Agreement, including this clause, constituting a taxable benefit to the Indemnified Party.
15. | Effective Time |
This Agreement shall be effective as and from the first day that the Indemnified Party became or becomes a director and/or officer of the Corporation or commenced or commences to serve as an officer or director of an Affiliate.
16. | Notices |
Unless otherwise permitted by this Agreement, all notices or other communications to be given hereunder shall be delivered by hand, courier, ordinary prepaid mail, facsimile or electronic mail; and, if delivered by hand, shall be deemed to have been given on the delivery date, if delivered by ordinary prepaid mail shall be deemed to have been given on the fifth day following the delivery date and, if sent by facsimile or electronic mail, on the date of transmission if sent before 5:00 p.m. (local time where the notice is received) on a business day or, if such day is not a business day, on the first business day following the date of transmission:
(a) | if to the Indemnified Party, at: |
[●]
[●]
(b) | if to the Corporation, at: |
Akanda Corp.
77 King Street West, Suite 400
Toronto, ON M5K 0A1
Attention: Chief Executive Officer
Email:
or to such other address as each party may from time to time notify the other of in writing.
If the Corporation receives notice from any other source of any matter which the Indemnified Party would otherwise be obligated hereunder to give notice of to the Corporation, then the Indemnified Party shall be relieved of his obligation hereunder to give notice to the Corporation, provided the Corporation has not suffered any material damage from the failure of the Indemnified Party to give notice as herein required.
-8-
17. | Severability |
If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever:
(a) | the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, all portions of any paragraph of this Agreement containing such provisions held to be invalid, illegal or unenforceable, that are not of themselves in whole invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and |
(b) | to the fullest possible extent, the provisions of this Agreement (including, without limitations, all portions of any paragraphs of this Agreement containing any such provisions held to be invalid, illegal or unenforceable, that are not of themselves in whole invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision which is held to be invalid, illegal or unenforceable. |
18. | Governing Law |
The parties hereto agree that this agreement shall be construed and enforced in accordance with the laws in force in the Province of Ontario.
19. | Modification and Waiver |
No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.
20. | Entire Agreement |
This Agreement shall supersede and replace any and all prior agreements (except any written agreement of employment between the Corporation and the Indemnified Party, which shall remain in full force and effect, except to the extent augmented or amended hereby), between the parties hereto respecting the matters set forth herein, and shall constitute the entire agreement between the parties hereto in respect of the matters set forth herein.
21. | Successors and Assigns |
This Agreement shall be binding upon and enure to the benefit of the Corporation and their respective successors and assigns and to the Indemnified Party and his estate, executors, administrators, legal representatives and lawful heirs.
22. | Counterparts |
This Agreement may be executed and delivered by the parties in one or more counterparts, each of which when so executed and delivered will be an original, and those counterparts will together constitute one and the same instrument.
23. | Successor Legislation |
Any references herein to any enactment shall be deemed to be references to such enactment as the same may be amended or replaced from time to time and, in the event that the Corporation is continued, incorporated, amalgamated, arranged under or otherwise becomes governed by an enactment other than the Act, then all references herein to the Act shall be deemed to be references to such enactment as the same may be amended or replaced from time to time.
IN WITNESS WHEREOF the parties hereto have executed this Agreement as at the date first above written.
AKANDA CORP. | ||
Per: | ||
Name: | ||
Title: | Chief Executive Officer | |
[●] |
Signature Page – Akanda Corp. (D&O Indemnity)
Exhibit 10.9
OFF-TAKE AGREEMENT
THIS OFF-TAKE AGREEMENT (this “Agreement”), dated 3rd August 2020, (the “Effective Date”) is made and entered into by and between Medcan Ltd,a company incorporate in the Republic of Malta with registration number C 73431 (“Medcan”) and Bophelo Bio Science and Wellness Pty Ltd, a company incorporated in the Kingdom of Lesotho with the registration number 2018/62924 (“BOPHELO”), both of whom are hereinafter collectively referred to as the “Parties” and any one of which shall be referred to as a “Party” as the context may require. This Agreement shall apply to each and every delivery and sale of Bulk Extract (defined in “DEFINITIONS” below) by BOPHELO to Medcan and shall constitute the entire agreement between the Parties with respect to the purchase and sale of Bulk Biomass.
DEFINITIONS:
In this Agreement, unless the context clearly indicates a contrary intention, the following expressions shall bear the following meanings and related expressions shall bear corresponding meanings:
“Bophelo’s nominated account” – [Account Name - Bophelo Bio Science & Wellness; Account No. - l l 990043908; Nedbank Mafeteng Branch; Branch Code - 390461; Swift Code - NEDLLSMX], or such other bank account as BOPHELO may nominate on written notice of not less than 7 days to Medcan;
“Bulk Biomass” – means both Flower and Trimmings, each of various grades (of potency, strains and other qualities) to be purchased by Medcan hereunder;
“business day” – means any day other than a Saturday, Sunday or official public holiday in Lesotho;
“Commencement of Bulk Biomass Processing” – means the commencement of drying, trimming, and processing operations;
“Cultivation Facility” – mean the greenhouses, hoop-houses and/or other indoor or outdoor cannabis cultivation facilities designed, built and operated by BOPHELO for the cultivation of cannabis and production of cannabis crops by or on behalf of BOPHELO in compliance with such standards for the cultivation and collection of cannabis crops as may be imposed in terms of the requirements of the various markets to which the products produced by BOP HELO are to be exported (the relevant standards hereinafter collectively referred to as “Agricultural Practices Standards” );
“EFT” – electronic funds transfer, being a transfer of funds between bank accounts on the internet (free of set off, bank charges levied by the paying party’s bank or deductions of any nature whatever);
“Flower” – dried cannabis flower harvested from female cannabis plants, packed in 1 kilogram bags ready for sale;
Page 1 of 14
“Prime Rate” – the rate of interest publicly quoted by Nedbank Lesotho, from time to time, as being its prime rate of interest (expressed as a nominal annual compounded monthly in arrear rate), calculated on a 365 day a year basis, irrespective of whether or not the year is a leap year and prima facie proved, in the event of there being a dispute in relation thereto, by a certificate signed by any manager of the aforesaid bank (whose appointment, qualification or authority need not be proved);
“Property” – the land situated at Ts'akholo, Mafeteng, Kingdom of Lesotho and having the GPS co-ordinates latitude 29°39’ 46.28”S and longitude 27°9’ 36.01”E;
“Specified Volume” – 10,000 kilograms of Bulk Biomass;
“Trimmings” – any extraneous plant matter harvested as a by-product of trimming cannabis flower, packed in 1 kilogram bags available for sale;
Where any term is defined within the context of any particular clause of this Agreement, the term so defined, unless it is clear from the clause in question that the term so defined has limited application to the relevant clause, shall bear the meaning ascribed to it in terms of the particular clause for all purposes in terms of this Agreement, notwithstanding that the term has not been defined in this Definitions clause.
RECITALS:
WHEREAS, Medcan is a private limited liability company with registered address at Level 4, the Penthouse, Suite 2, Ewropa Business Centre, Triq Dun Karm, Birkirkara, BKR 9034, Malta and with the objects of the company including, inter alia, the importation, preparation and distribution of marijuana for medical use by patients in Malta and to this end, Medcan intends on importing the Bulk Biomass purchased from BOPHELO under this Agreement;
WHEREAS, BOPHELO holds a Prohibited Drug Operator license authorizing it to engage in the business of cannabis cultivation, manufacturing of cannabis products and export of cannabis and cannabis products, and is in good standing with all relevant and necessary local and national licensing authorities in the Kingdom of Lesotho;
NOW, THEREFORE, in consideration of the foregoing recitals, which said recitals are incorporated herein by this reference, and the mutual covenants and conditions hereinafter contained, the Parties agree as follows:
BOPHELO agrees to sell, and Medcan agrees to buy Bulk Biomass that BOPHELO produces from the cannabis cultivated on the initial 5 hectares of the Property in the Cultivation Facility;
l. Contract Term: The term of this Agreement shall, subject to any termination in terms of section 8, be for a period commencing on the Effective Date and ending on the date being the earlier of (i) the date on which Medcan has purchased the full Specified Volume from BOPHELO; or (ii) the 7th anniversary of the Effective Date (“the Final Date”).
2. | Delivery: |
2.1 | BOPHELO agrees to deliver to Medcan the Specified Volume, unless otherwise agreed in writing by both Parties, of Bulk Biomass each week, beginning one (1) week after Commencement of Bulk Biomass Processing (the “First Delivery Date”). BOPHELO shall thereafter give Medcan not less than 5 days’written notice in advance each time that a delivery will be ready for collection in terms of section 2.2. |
Page 2 of 14
2.2 | The Bulk Biomass shall be delivered Ex Works (as such term is defined in INCOTERMS 2010) and Medcan will take delivery of the Bulk Biomass Ex Works subsequent to customs clearance in a port in Malta (“Clearance”) and BOPHELO will, procure the transport of the Bulk Biomass by a cannabis transport operator licensed as such in terms of the Drugs of Abuse Act, 2008 of Lesotho to an international airport in Lesotho or South Africa, or a seaport in South Africa (each such location, a “Port”) as agreed upon by both Parties and shall take such steps as may be required for clearing the Bulk Biomass for export, subject to Medcan having, with at least 30 (thirty) days advance notice, provided (i) correct and comprehensive instructions to BOPHELO as regards any requirements (including, but not limited to approved strains, packing and labelling specifications and correct licenses in respect of the country of import) which the Bulk Biomass or any particular Batch (as such term is defined in section 2.4) need to comply with; and (ii) a copy of all relevant documentation, including specifically documentary proof of the country of import's consent to importation as required for purposes of BOPHELO obtaining the relevant export permit, in order to enable the Batch to be legally and validly exported via the designated Port to the port of destination. Notwithstanding anything herein contained, BOPHELO shall not incur any liability of any nature whatsoever, whether to Medcan or any third party, for any failure to have the Bulk Biomass or any particular Batch cleared for export due to incorrect instructions having been provided to BOPHELO by Medcan willingly and knowingly in this regard or the Bulk Biomass or any particular Batch not meeting the legal requirements for import and Clearance and Medcan hereby indemnifies and holds BOPHELO harmless against any claim made against BOPHELO in this regard. Medcan shall be responsible for (i) all other tasks through clearing the Bulk Biomass through customs in the importing country; and (ii) receiving and transporting the Bulk Biomass after it has been so transported for Clearance. Medcan may perform the foregoing actions, or appoint a properly licensed third party to do so on Medcan’s behalf. All Bulk Biomass will be free and clear of any liens, claims and encumbrances. |
2.3 | Notwithstanding the terms of delivery being Ex Works, BOPHELO agrees to pay an amount equal to 50% of the actual costs incurred by Medcan in the process of landing a Batch at the import destination, including, inter alia, transport costs, export and import duties, customs and handling fees, but excluding costs of insurance (“landing costs”), provided that BOPHELO’s contribution to landing costs shall never exceed an amount equal to 5% of the total amount paid by Medcan to BOPHELO for the Batch in terms of section 6.l. BOPHELO shall pay such costs to Medcan upon presentation of an invoice setting forth the costs incurred as line items and shall, if so required by BOPHELO, furnish documentary proof of the costs so incurred. |
2.4 | Risk of loss of the Bulk Biomass shall pass to Medcan upon completion of delivery, namely, Clearance, by BOPHELO Ex Works at the Extraction Facility. Title to and ownership of the Bulk Biomass shall pass from BOPHELO to Medcan against payment by Medcan to BOPHELO in terms of section 6. BOPHELO will deliver each batch of Bulk Biomass with a Certificate of Analysis, including residual, pesticide and potency results, from an independent, properly licensed and credentialed cannabis analytical testing laboratory (“Compliant Laboratory”) in Lesotho or South Africa (a “COA”), indicating that each batch of Bulk Extract meets the Specifications (as such term is defined below). All Bulk Biomass packaged under the same COA is hereinafter referred to as a “Batch”. Medcan shall at any time and from time to time, at its cost, be entitled to submit the Bulk Biomass to any compliant laboratory outside Lesotho or South Africa for analysis. |
Page 3 of 14
2.5 | If BOPHELO has notified Medcan in accordance with section 2.1 that a Batch is ready for delivery and Medcan has for any reason whatsoever (other than Medcan’s legitimate rejection of the relevant Batch in accordance with the provisions of section 3(b)) failed to take delivery of such Batch Ex Works within 15 days from the date of the notice contemplated in section 2.1, Medcan shall be liable to make payment to BOPHELO for such Batch in accordance with the provisions of section 6 as if Medcan had taken title to and delivery thereof. BOPHELO shall, at Medcan’s risk, store such Batch in a secured, temperature-controlled storage area for Clearance, provided that – |
2.5.1 | if Medcan fails to make payment for the relevant batch within the 15 day period aforementioned, BOPHELO shall be entitled to dispose of or destroy the Batch as it deems fit; |
2.5.2 | if Medcan has made payment to BOPHELO for the relevant Batch, but has failed to accept delivery thereof within a period of 6 months from the date of the notice contemplated in section 2.1, BOPHELO shall be entitled to dispose of or destroy the Batch as it deems fit, and BOPHELO shall, if it has sold any Batch as contemplated above, pay to Medcan the proceeds received from such sale, less reasonable storage costs and any costs incurred by BOPHELO in the course of selling and delivering the relevant Batch to the purchaser in question. BOPHELO shall promptly return any payments made by Medcan for such Batches as are subsequently found at delivery not to be accompanied by a valid COA, or for which the accompanying COA indicates a failure to satisfy the Specifications. |
2.6 | If by the Final Date Medcan has not purchased the total Specified Volume from BOPHELO under this Agreement, Medcan undertakes to pay to BOPHELO within 7 business days of the Final Date an amount equal to Z calculated in accordance with the following formula – |
Z = (A-B) x P
where
Z represents the amount payable;
A represents the Specified Volume;
B represents the actual volume of Bulk Biomass which Medcan has purchased from Bophelo as at the Final Date; and
P represents the then prevailing market rate per gram of Bulk Biomass as determined in accordance with section 6.1.
Page 4 of 14
For the avoidance of doubt it is recorded that if sufficient Bulk Biomass has not been produced to meet the Specified Volume by the Final Date, save where such failure is as a result of a breach or negligence by BOPHELO of this Agreement, BOPHELO shall have no liability of any nature whatsoever arising from such failure and Medcan hereby indemnifies and holds BOPHELO harmless against any claim made against BOPHELO in this regard.
2.7 | As holder of the Prohibited Drug Operator license under the Drugs of Abuse Act, 2008, BOPHELO shall be responsible to procure and import all cannabis seeds required for purposes of cultivating cannabis at the Cultivation Facility. Medcan shall at all times and from time to time during the term of this Agreement give BOPHELO written instructions as to the strains of the seeds to be purchased by BOPHELO for this purpose. BOPHELO shall not incur any liability of any nature whatsoever, whether to Medcan or any third party, if it has procured seeds on the instructions of Medcan and such seeds turn out to be seeds of a strain(/s) of cannabis plant not permitted under the import authorisations of the territories to which Medcan intends to sell the Bulk Biomass produced from plants cultivated from the seeds. Medcan hereby indemnifies and holds BOPHELO harmless against any claim made against BOPHELO in this regard and all loss and damages which BOPHELO may suffer as a result of Medcan having provided incorrect instructions for the seeds to be procured and imported by BOPHELO. |
3. Packaging of Bulk Biomass:
(a) | BOPHELO will deliver Bulk Biomass to Medcan in containers complying with the applicable Agricultural Practices Standards (“Containers”) or as otherwise agreed in writing between the Parties; BOPHELO shall not co-mingle different Batches in the same Containers. BOPHELO will pre-fill each Container with up to 1000 grams of Bulk Biomass, before further packaging each Batch in accordance with the applicable Agricultural Practices Standards for delivery to Medcan. Each Batch will be packaged, labelled, marked and shipped in its own set of Containers, segregated from other Batches, in a commercially reasonable manner, and in accordance with the applicable Agricultural Practices Standards and all applicable laws, rules and regulations of the importing territory timely identified to BOPHELO by Medcan in writing. Medcan shall be responsible for communicating to BOPHELO, in writing, all requirements and specifications with which a Batch needs to comply in order to ensure it is cleared for export and is capable of being imported to the relevant importing territory. BOPHELO shall not incur any liability of any nature whatsoever, whether to Medcan or any third party, for any failure to have a Batch cleared for export due to incorrect requirements and/or specifications having been communicated to BOPHELO by Medcan in this regard and a Batch accordingly not meeting the legal requirements for importation into the importing territory, and Medcan hereby indemnifies and holds BOPHELO harmless against any claim made against BOPHELO in this regard. BOPHELO will weigh each empty Container independently before filling and include the exact weight of the empty Container on its label. |
Page 5 of 14
(b) | All Bulk Biomass supplied by BOPHELO is subject to Medcan’s inspection and acceptance or rejection at the Cultivation Facility prior to BOPHELO’s delivery Ex Works. A Compliant Laboratory shall conduct an inspection of each Batch before it is loaded into the relevant transport vehicle. If this inspection reveals that the Batches being delivered do not conform to the requirements set forth in sections 2, 3 or 4, Medcan will forthwith advise BOPHELO of such non-compliance in writing and shall be entitled to reject any Batch which it considers non-compliant. If a batch is rejected, BOPHELO shall at its election be entitled to remediate such Batch or otherwise dispose of it as it deems fit. Any Batch so rejected (and not remediated) shall be retained by BOPHELO and excluded for purposes of determining the weight of the relevant delivery made. All Bulk Biomass shall be weighed upon delivery, prior to being loaded on the relevant vehicle for transport, and the weight (hereinafter “the Delivery Weight”) shall be recorded, a copy of which recording shall be given to BOPHELO and an original shall be retained by Medcan. For the sake of clarity, the Parties agree that the weight of the empty Containers will not be included in the weight of the Bulk Biomass. |
4. Procured Cannabis Specifications: BOPHELO shall ensure that all Bulk Extract delivered to Medcan complies with the Specifications set forth in subparagraphs (a) and (b) of this section 4 as follows:
(a) | The levels of residual pesticide, microbes, foreign material, mycotoxins, heavy metals and other impermissible chemicals in each Batch must be at or below the maximum levels set forth in the applicable Agricultural Practices Standards of the importing territory identified by Medcan, as the same may be amended from time-to-time by agreement in writing between the Parties (“Chemical Specifications”). |
(b) | Each Batch must provide a total THC concentration at least twelve percent (12%) (its “Total THC Concentration”). Total THC Concentration shall be verified be ensuring that each one gram of Bulk Extract would yield a combined total of at least 120 milligrams of THC and THCA, using the following formula: Total THC Concentration (mg/g) = (THCA concentration (mg/g) x 0.877) + THC concentration (mg/g) (“Potency Specifications”, and together with the Chemical Specifications, the "Specifications"). |
5. | Pricing and Payment Terms: |
5.1 | Medcan will pay BOPHELO prevailing market rates (the “Price”) calculated on the basis of a Price per gram based on the Delivery Weight, which Price shall be payable upon delivery of the Bulk Biomass Ex Works as set forth in section 2. The Price for each Batch shall be determined as follows – |
a) | the Price shall always be determined on the basis that Medcan shall seek to sell the Batch at the highest value achievable in the market, the average price for Bulk Biomass for 2020 and 2021 will be $3.00 USD per gram; |
b) | within 3 days of the date of the notice from BOPHELO as contemplated in section 2.1, the Parties shall endeavour to agree on the Price for the relevant Batch, and shall record such price in writing between them; |
Page 6 of 14
c) | if the Parties fail to agree on the Price in the period contemplated in section 6.1(b), the Price (always subject to the principle in section 6.1(a)) shall be obtained from referencing the price per gram for such product as reflected in the most as published by Canaccord Genuity Group Inc (“Cannacord”); provided that if Canaccord no longer publishes such report or index publicly and the parties are unable to instruct Canaccord to prepare or provide such a report for their specific purpose, the Price shall be equal to the average of the wholesale price per gram as applied by the 5 biggest international cannabis trading companies by market capitalisation (“average wholesale price”). If for any reason the parties are unable to obtain the necessary information to determine the average wholesale price at any point in time, the parties agree that the price will be determined by an independent expert in international cannabis trading (“the expert”), such expert to be a person as nominated by the head of the cannabis practice cluster of the firm of Aird & Berlis LLP, Toronto. The expert shall be instructed to determine the average wholesale price based on his/her industry knowledge and expertise and such information as he/she is able to obtain in respect of the current market and to provide his/her determination within 5 days of being requested to do so. The expert's determination shall be final and binding on the parties. |
5.2 | Such payment shall be made by Medcan by way of EFT to BOPHELO's nominated account forthwith against presentation by BOPHELO of the relevant invoice to Medcan, which invoice shall be presented to Medcan upon delivery of the relevant Batch Ex Works. |
5.3 | Notwithstanding the aforegoing, the parties agree that to the extent that Medcan, or any of Medcan's associates or subsidiaries, sells a Batch at a price which is more than the Price paid to BOPHELO in terms of section 6.1 in respect of such Batch, Medcan shall forthwith pay to BOPHELO the difference between the price paid by Medcan in terms of section 6.1 and the actual price at which the Batch has been sold by Medcan, the principle being that Medcan is not entitled to the benefit of any margin on the sale by Medcan of any Batch. Medcan shall at the end of each 3 months for the term of this Agreement provide to BOPHELO a certificate from Medcan’s auditors confirming the prices at which all Batches obtained from BOPHELO were sold by Medcan. |
6. National and Local Cannabis Taxes, Fees and Regulations: BOPHELO shall collect, pay and remit any and all local and national cannabis-related fees (including but not limited to licensing, renewal and inspection fees due pursuant to the Drugs of Abuse Act of 2008, the Medicines Control and Medical Devices Control Bill 2018 Act No. 5, and the Drugs of Abuse (Cannabis) Regulations, 2018 Act (collectively, the “Acts”)) and any applicable taxes that are owed on the cannabis and cannabis products cultivated, manufactured, sold and exported by BOPHELO, or are instituted by the Kingdom of Lesotho at any time. Furthermore, the Parties agree to comply with the Acts and all applicable regulations set forth by the relevant local and national agencies, including but not limited to the Kingdom of Lesotho’s Ministry of Health and Social Welfare and the Lesotho Narcotics Bureau.
Page 7 of 14
7. Termination Rights:
(a) | Notwithstanding section 1 of this Agreement, Medcan may terminate this Agreement, subject to any applicable notice and cure periods set forth below, immediately upon delivery of written notice by Medcan to BOPHELO: |
(1) in the event of an order for the liquidation of BOPHELO, whether voluntarily or involuntarily winding-up of BOPHELO or the placing of BOPHELO under judicial management or administration and such order has not been dismissed or rescinded within 120 business days after granting thereof, or the execution by BOPHELO of an assignment for the benefit of its creditors generally;
(2) for the loss or suspension of BOPHELO’s national and/or local licenses to cultivate, store, supply and/or export cannabis for a period of more than 60 consecutive days, provided that such loss or suspension has not been occasioned by a breach by Medcan of its obligations under this Agreement; or
(3) for the occurrence of a material breach of this Agreement by BOPHELO that remains uncured for 60 days after the date of receipt by BOPHELO of written notice of the alleged breach, provided that such breach has not been occasioned by a breach by Medcan of its obligations under this Agreement,
in each instance without prejudice to Medcan’s right to claim damages from BOPHELO, provided however, that where a termination arising from BOPHELO’s loss of licensure is occasioned by Medcan’s breach of this Agreement as described in section 8(a)(2), Medcan shall have no remedy.
(b) | Notwithstanding section 1 of this Agreement, BOPHELO may terminate this Agreement, subject to any applicable notice and cure periods set forth below, immediately upon delivery of written notice by BOPHELO to Medcan: |
(1) for the passing of an extraordinary resolution for the dissolution of the Medcan, in accordance with the Companies Act, Chapter 386 of the laws of Malta, an involuntary bankruptcy filing against Medcan that has not been dismissed 120 business days after filing, or the execution by Medcan of an assignment for benefit of creditors;
(2) for the loss or suspension of any of Medcan’s applicable licenses required to perform its obligations under this Agreement for a period of more than 60 consecutive days; and
(3) for the occurrence of a breach of this Agreement, by Medcan that remains uncured for 60 days after the date of receipt by Medcan of written notice of the alleged breach, provided that such breach has not been occasioned by a breach by BOPHELO of its obligations under this Agreement,
Page 8 of 14
in each instance without prejudice to BOPHELO’s right to claim damages from Medcan. If consequent upon an unremedied breach by Medcan, BOPHELO elects to terminate this Agreement, BOPHELO shall be entitled to require Medcan, which shall be obliged to pay to BOPHELO, as a genuine pre-estimate of the liquidated damages which BOPHELO shall be deemed to have suffered as a result of Medcan’S breach and without prejudice to BOPHELO’S right to recover from Medcan the actual damages suffered by BOPHELO as a result thereof and its other rights in law or in terms of this Agreement, an amount equal to D as calculated in accordance with the following forrnula -
D = (A-B) x P
where
D represents the amount payable;
A represents the Specified Volume;
B represents the actual volume of Bulk Biomass which Medcan has purchased from BOPHELO at the date on which the breach occurs; and
P represents the then prevailing Price per gram of Bulk Extract as determined in accordance with section 6.1.
Notwithstanding the aforegoing, the Parties agree that all amounts which BOPHELO realises from selling any stock of Bulk Biomass in its possession as at the date of termination less the costs incurred in respect thereof, shall be set off against D.
8. Effect of Termination or Expiration.
All amounts then due and payable by Medcan to BOPHELO or by BOPHELO to Medcan will be accelerated and immediately become due upon termination or expiration, unless such termination results from the other's breach of this Agreement and the delivery of payment is at issue as a result of such breach.
9. Warranties.
Medcan hereby warrants to BOPHELO that Medcan –
9.1 | is and will for the duration of this Agreement remain duly registered with all such regulatory authorities and or bodies and is and will remain in possession for the duration of this Agreement of all such licenses and other regulatory approvals, as may be required for Medcan to lawfully perform all aspects falling within or being implicit in the scope of its obligations in terms hereof, including its ability to lawfully purchase the Bulk Biomass from BOPHELO in terms hereof; |
9.2 | will not act in breach of any law or regulation which it is required to comply with in performing its obligations in terms hereof; |
9.3 | is duly incorporated and validly exists as a company in accordance with the laws of Malta; |
9.4 | has the power to enter into, deliver and perform, and has taken all necessary action to authorise its entry into, delivery and performance of, this Agreement and that its entry into, delivery and performance of this Agreement does not contravene or conflict with any of its constitutional documents nor any law or regulation or judicial or administrative order which applies to Medcan. |
BOPHELO hereby warrants to Medcan that BOPHELO –
9.5 | is and will for the duration of this Agreement remain duly registered with all such regulatory authorities and or bodies and is and will remain in possession for the duration of this Agreement of all such licenses and other regulatory approvals, as may be required for BOPHELO to lawfully perform all aspects falling within or being implicit in the scope of its obligations in terms hereof, including its ability to lawfully supply the Bulk Extract to Medcan in terms hereof, including delivery of the Bulk Extract Ex Works for Clearance; |
Page 9 of 14
9.6 | will not act in breach of any law or regulation which it is required to comply with in performing its obligations in terms hereof; |
9.7 | is duly incorporated and validly exists as a company in accordance with the laws of the Kingdom of Lesotho; |
9.8 | has the power to enter into, deliver and perform, and has taken all necessary action to authorise its entry into, delivery and performance of, this Agreement and that its entry into, delivery and performance of this Agreement do not contravene or conflict with any of its constitutional documents nor any law or regulation or judicial or administrative order which applies to BOPHELO. |
10. Miscellaneous.
a) Time is of the Essence.
The Parties acknowledge and agree that time is of the essence in performing the obligations set forth in this Agreement.
b) Mediation and Arbitration.
For the purposes of this section l0(b) a “dispute” shall mean any dispute which arises between the Parties in connection with -
i. | the formation or existence; |
ii. | the implementation; |
iii. | the interpretation or application of the provisions; |
iv. | the Parties’ respective rights and obligations in terms of or arising out of the conclusion, breach or termination; |
v. | the validity, enforceability, rectification, termination or cancellation, whether in whole or in part; |
vi. | any documents furnished by the Parties pursuant to the provisions, of this Agreement or which relates in any way to any matter affecting the interests of the Parties in terms of this Agreement. Save for those provisions in this Agreement which provide for their own remedies, the Parties agree that any dispute shall, unless resolved amongst the Parties to the dispute, be referred to and be determined by arbitration. |
While the Parties shall attempt amicable conflict resolution and negotiation, the Parties hereto submit to the exclusive jurisdiction of the Malta Arbitration Centre, of Palazzo Laparelli, 33 South Street, Valletta, VLT 1100, Malta, should such amicable solutions prove fruitless.
The Parties hereby confirm that any dispute, matter or interpretation of the Malta Arbitration Centre shall be final and binding on the Parties and that the arbitral award shall be final and binding and have the effect of a court order.
Page 10 of 14
The arbitration shall be heard by an arbitration tribunal which shall consist of 3 arbitrators and in accordance with the procedure laid out in the Malta Arbitration Act, Chapter 387 of the laws of Malta.
c) Governing Law.
This Agreement and all rights and obligations hereunder, including matters of validity and performance shall be governed and construed in accordance with the Laws of Malta.
d) Amendments.
These terms cannot be amended, modified or changed in any manner, except by a written amendment designated as such and signed by an authorized representative of each Party hereto.
e) Independent Contractor.
The relationship between Medcan and BOPHELO is that of independent contractors. Nothing contained herein shall be construed to create a principal-agent or employer-employee relationship between the Parties. Neither Party shall represent to others that it is the agent of the other.
f) | Notices. |
(1) The Parties choose domicilium citandi et executandi (“Domicilium”) for all purposes of the giving of any notice, the payment of any sum, the serving of any process and for any other purpose arising from this Agreement, as follows
BOPHELO:
T’ sakholo, Ha-Mojela
Mafeteng District
Kingdom of Lesotho
Attorneys for BOPHELO
Ira Epstein
Fluxmans Inc
30 Jellicoe Avenue, Rosebank
Johannesburg, South Africa
iepstein@fluxrnans.com
MEDCAN:
Level 4, the Penthouse, Suite 2,
Ewropa Business Centre
Triq Dun Karm
Attorneys for Medcan:
Dr. Jonathan Corrieri
Level 4, the Penthouse, Suite 2,
Ewropa Business Centre
Triq Dun Karm
Birkirkara
BKR 9034
Malta
Jonathan@corriericilia.com
Page 11 of 14
(2) | Each of the Parties shall be entitled from time to time, by written notice to the other, to vary its domicilium to any other physical address and/or its email address. |
(3) | Any notice given and any payment made by any Party (“the sender”) to the other (“the addressee”) shall be in writing and if - |
(i) | delivered by hand during the normal business hours of the addressee at the addressee’s domicilium for the time being shall be presumed to have been received by the addressee at the time of delivery; |
(ii) | delivered by way of courier service shall be presumed to have been received by the addressee on the 7th business day following the date on which the courier service was placed in possession of such notice; |
(4) | Any notice given by the sender to the addressee which is transmitted by email to the addressee at the addressee’s email address, for the time being shall be presumed to have been received by the addressee when (i) the email enters an information system designated or used for that purpose by the addressee and is capable of being retrieved by the addressee; and (ii) the sender has received a return email from the addressee of the email acknowledging receipt by the addressee of that email (it being the responsibility of the sender of that email to obtain such acknowledgment). |
(5) | Notwithstanding anything to the contrary contained in this section 10(f), written notice or other communication actually received by a party shall be adequate written notice or communication to it notwithstanding that the notice was not sent or delivered to its chosen address or email address. |
g) | Severability. |
In the event that any one or more of these provisions is held invalid, illegal or unenforceable in any respect by a court with jurisdiction, the validity, legality and enforceability of the remaining provisions contained herein shall not be in any way impaired thereby. In the event the provisions of any such applicable law may be waived, they are hereby waived by BOPHELO and Medcan to the full extent permitted by law, and these terms shall be deemed to be valid, binding and enforceable.
h) Waiver.
No omission or delay by either party at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof at any time designated, shall be a waiver of any such right or remedy to which either Party is entitled, nor shall it in any way affect the right of either Party to enforce such provisions thereafter. No waiver of any rights or obligations shall be effective unless in writing and signed by an officer or other authorized representative of the Party holding such rights or to whom such obligations are owed, and any such waiver shall be effective only in the specific instance and for the specific purpose stated in such writing.
Page 12 of 14
i) Survival.
All terms that by their nature would be intended to survive expiration or termination of this Agreement shall so survive, and in particular, it is expressly agreed by the Parties that the obligations regarding confidentiality shall so survive.
j) No Third-Party Beneficiaries.
All of these terms are for the sole and exclusive benefit of the Parties.
k) Interpretation.
The Parties agree that the rule of construction that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of these terms. Each Party has had the opportunity to consult the legal counsel of its choice. Unless otherwise required by the context in which the term appears, the words include, includes and including will be deemed to be followed by the phrase “without limitation” and will not be construed to mean that the examples given are an exclusive list of the topics covered. All defined terms apply to both singular and plural forms, and all references to any gender include all other genders. The captions are for convenience only, and in no way limit or amplify the provisions hereof.
l) Integration.
These terms constitute the entire agreement between the Parties in respect of the subject matter hereof and shall replace and supersede all prior and/or contemporaneous agreements, negotiations or representations between the Parties with respect to the subject matter hereof, whether written or oral. To the extent there is any inconsistency between these terms and any invoice or similar document produced by Medcan, these terms shall govern. No subsequent acceptance, acknowledgment or other document submitted by one Party to the other shall vary these terms unless confirmed in writing by the other Party.
m) Interest.
Any amount falling due for payment by Medcan to BOPHELO in terms of this Agreement shall bear interest at the prime rate, calculated from the due date for payment (or, in the case of any amount payable by way of damages, with effect from the date upon which those damages are sustained) to the actual date of payment thereof, both dates inclusive.
n) Confidentiality.
The Parties acknowledge that, as a result of this agreement, information not generally available to members of the public and/or of a proprietary, confidential or commercially-sensitive nature (“Confidential Information”) may or will be disclosed to either Party. Accordingly, the Parties irrevocably and unconditionally undertake to maintain all and any Confidential Information disclosed to and/or obtained in the strictest confidence and not at any time to disclose any such Confidential Information to any person whatsoever, including (without limitation) to professional advisers, consultants, employees, servants or agents.
Page 13 of 14
This OFF-TAKE AGREEMENT is entered into on this 3rd day of August, 2020.
In WITNESS WHEREOF, the parties have set their hands on the date above written.
BOPHELO: | ||
/s/ Louisa Mojela | ||
Bophelo Bio Science and Wellness Pty Ltd | ||
By: Louisa Mojela | ||
Title: Director | ||
MEDCAN: | ||
/s/ Dr. Jonathan Corrieri and /s/ Mr. Michael Zammit Taboona | ||
Medcan | ||
By: Dr. Jonathan Corrieri and Mr. Michael Zammit Taboona | ||
Title: “A” Class Director and “C” Class Director |
Page 14 of 14
Exhibit 10.10
Bophelo - Cantourage
SERVICE, REFINEMENT AND DISTRIBUTION AGREEMENT
between
1. | Cantourage GmbH, |
represented by its CEO Philip Schetter
Heinrich-Mann-Str. 12, 14532 Kleinmachnow, Germany
- hereinafter “CANTOURAGE” -
and
2. | Bophelo Bio Science and Wellness (Pty) Ltd |
represented by its Chief Financial Officer & Director Trevor Scott
Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng, Lesotho
- hereinafter “BOPHELO” -
The terms “CANTOURAGE” and “BOPHELO” include the respective affiliated companies of CANTOURAGE or BOPHELO pursuant to Sections 15 AktG et seqq. [Aktiengesetz - Stock Corporations Act]. Those companies in which CANTOURAGE holds a share of at least 50 % are also deemed to be affiliated companies of CANTOURAGE.
CANTOURAGE and BOPHELO are hereinafter respectively designated individually as “Party” and together as “Parties”.
Bophelo - Cantourage
TABLE OF CONTENTS
Page 2 of 53
Bophelo - Cantourage
30. | FORM | 16 |
31. | Applicable law | 17 |
32. | VENUE | 17 |
33. | Integral parts of the AGREEMENT | 17 |
34. | Final provisions | 18 |
Page 3 of 53
Bophelo - Cantourage
PREAMBLE
Whereas
(A) | CANTOURAGE is a Manufacturer and Pharmacy Wholesaler of cannabis for medicinal use. |
(B) | BOPHELO is a producer/cultivator of medicinal cannabis incorporated in the Kingdom of Lesotho with the registration number 2018/62924. |
(C) | The Parties intend to establish a cooperation which enables BOPHELO with CANTOURAGE’s assistance to market its products within the European Union, especially within Germany; |
Now, the Parties agree to enter into the following
SERVICE, REFINEMENT AND DISTRIBUTION AGREEMENT
1. | Definitions |
Headings are for reference purposes only and shall in no way define, limit, construe or describe the scope or extent of an article.
The Annexes are integral part of this Agreement and a reference to this Agreement shall always be interpreted as including the Annexes.
Unless the context otherwise requires words importing one gender include all other genders and words incorporating a verb include the respective noun and the single include the plural, and vice versa.
For the purpose of this Agreement, the Parties agree on the meaning of the following definitions:
1.1 | “AGREEMENT” means this Agreement including its Annexes. |
1.2 | “ALLIANCE COMMITTEE” shall have the meaning described in Clause 25. |
1.3 | “AVERAGE SELLING PRICE” means the average of the weighted SELLING PRICES over the RELEVANT PERIOD. |
1.4 | “BACKGROUND RIGHTS” means all intellectual property rights (in particular industrial property rights, copyrights and comparable rights, including know-how) held by BOPHELO which are necessary for the manufacture of END PRODUCTS. |
1.5 | “CONFIDENTIAL INFORMATION” means all information disclosed (whether in writing, orally or by another means and whether directly or indirectly) with respect to the subject matter hereof by one Party (the “DISCLOSING PARTY”) to the other Party (the “RECEIVING PARTY”) whether before or after the date of this AGREEMENT including, without limitation, information relating to the DISCLOSING PARTY’s products, operations, processes, plans or intentions, product information, know-how, design rights, trade secrets, market opportunities and business affairs. |
Page 4 of 53
Bophelo - Cantourage
1.6 | “CONSIGNMENT STOCK” means the stock of CONTRACTUAL PRODUCTS and END PRODUCTS established and maintained by CANTOURAGE for BOPHELO. |
1.7 | “CONSUMER” is any end user of the END PRODUCTS. |
1.8 | “CONTRACTUAL PRODUCTS” means the products specified in ANNEX 2. |
1.9 | “DEFECT” means any deviation of a CONTRACTUAL PRODUCT from the agreed quality. |
1.10 | “DELIVERY” means the delivery of CONTRACTUAL PRODUCTS in accordance with Incoterms® 2020 DAP at the first port of entry in Germany. |
1.11 | “DISTRIBUTOR” means any third party which is supplied with END PRODUCTS and not a CONSUMER. |
1.12 | “END PRODUCTS” means all CONTRACTUAL PRODUCTS which have been successfully REFINED by CANTOURAGE. |
1.13 | “FORECAST” shall mean, with respect to any twelve (12) month period, a rolling projection or estimate of the demand for CONTRACTUAL PRODUCTS during such twelve month period which is updated and amended by CANTOURAGE on a quarterly basis, which approximates, as nearly as possible, based on information available at the relevant time to CANTOURAGE. For the avoidance of doubt, it is possible that the amount of CONTRACTUAL PRODUCTS in any given month can equal a zero. |
1.14 | “FORCE MAJEURE” means any unforeseeable and exceptional occurrence, cause or condition beyond the respective PARTY’s reasonable control and shall include fire; explosion; flood; earthquake; tsunami; extreme adverse weather conditions; act of God; riot; war or threat of war; civil commotion; pandemic; change in approval or applicable law; regulation or directive having the force of law; non-availability, interruptions to or shortage of electricity, fuel or raw materials; failure of a Party’s supplier to supply or manufacturer to manufacture due to any event or circumstance which would constitute FORCE MAJEURE under this Agreement; and strike, labour dispute or lock-out. However no occurence, cause or condition shall be considered to be an event of Force Majeure if |
(i) | and to the extent the Party seeking to invoke the Force Majeure has caused or contributed to the applicable occurence, cause or condition by its fault or negligence or has failed to use commercially reasonable efforts to prevent or remedy or mitigate the risks resulting from such occurence, cause or condition, and so far as possible and within a reasonable time period, remove it; |
(ii) | the occurence, cause or condition is the result of a breach of any applicable law by the Party seeking to invoke the Force Majeure; or |
Page 5 of 53
Bophelo - Cantourage
(iii) | the occurence, cause or condition was caused by a lack of funds or other financial cause. |
1.15 | “FOREGROUND RIGHTS” means all intellectual property rights conceived or developed by either Party or its employees or agents during the term of, and in connection with, the respective Party’s performance under this Agreement. |
1.16 | “GACP” means the “Guideline on good agricultural and collection practice for starting materials of herbal origin” (EMEA/HMPC/246816/2005) issued by the European Medicines Agency, as being amended from time to time. |
1.17 | “MINIMUM PURCHASE PRICE” means the minimum price to be paid by CANTOURAGE to BOPHELO for the CONTRACTUAL PRODUCTS as further specified in ANNEX 3. |
1.18 | “MINIMUM QUANTITY” means the minimum quantity of CONTRACTUAL PRODUCTS and END PRODUCTS stored in the CONSIGNMENT STOCK which shall be determined by the Parties from time to time. |
1.19 | “PRICE” means the SELLING PRICE and/or PURCHASE PRICE and/or RAP SERVICE PRICE and/or RAP PLUS SERVICE PRICE and/or AVERAGE SELLING PRICE and/or MINIMUM PURCHASE PRICE as the case may require. |
1.20 | “PURCHASE PRICE” means the price for the sale of CONTRACTUAL PRODUCTS by BOPHELO to CANTOURAGE calculated as specified in ANNEX 3. |
1.21 | “RELEVANT PERIOD” means a period of every month, the first RELEVANT PERIOD starts on first sale of END PRODUCTS at the date of payment for the END PRODUCTS. |
1.22 | “REFINE” or “REFINEMENT” means CANTOURAGE’s activities with regard to the conversion of CONTRACTUAL PRODUCTS into END PRODUCTS as specified in ANNEX 1. |
1.23 | “SELLING PRICE” means the prices for the sale of END PRODUCTS by CANTOURAGE to DISTRIBUTORS as specified in ANNEX 3 and amended by the Parties from time to time. |
1.24 | “RAP SERVICES” means the mandatory services to be provided by CANTOURAGE as specified in ANNEX 1. |
1.25 | “RAP PLUS SERVICES” means the optional services to be provided by CANTOURAGE as specified in ANNEX 6 and to the extent these services have been ordered by BOPHELO and accepted by CANTOURAGE. |
1.26 | “RAP SERVICE PRICE” means the price to be paid by BOPHELO to CANTOURAGE for the RAP SERVICES as specified in ANNEX 3. |
1.27 | “RAP PLUS SERVICE PRICE” means the price to be paid by BOPHELO to CANTOURAGE for the RAP PLUS SERVICES as specified in ANNEX 3. |
Page 6 of 53
Bophelo - Cantourage
1.28 | “TERRITORY” means the territory of the European Union, especially of the Federal Republic of Germany. |
2. | SCOPE of the AGREEMENT |
2.1 | The object of the AGREEMENT is the provision of the RAP SERVICES, and if agreed, the RAP PLUS SERVICES by CANTOURAGE to BOPHELO, the REFINEMENT of CONTRACTUAL PRODUCTS by CANTOURAGE for BOPHELO, and distribution of END PRODUCTS within the TERRITORY. |
2.2 | For that purpose, |
2.2.1 | CANTOURAGE shall provide the RAP SERVICES and RAP PLUS SERVICES to BOPHELO, |
2.2.2 | BOPHELO shall deliver CONTRACTUAL PRODUCTS to the CONSIGNMENT STOCK, |
2.2.3 | CANTOURAGE shall REFINE certain quantities of CONTRACTUAL PRODUCTS within the CONSIGNMENT STOCK, |
2.2.4 | CANTOURAGE shall market and distribute END PRODUCTS within the TERRITORY. |
3. | Term and termination |
3.1 | This AGREEMENT comes into effect upon signature of both Parties and its initial term shall be 5 years. The term shall be extended each time for further period of 1 years unless the AGREEMENT has been duly terminated prior to the expiration of the term. |
3.2 | The notice period for a termination by CANTOURAGE is 60 days and for a termination by BOPHELO 60 days. |
3.3 | BOPHELO can terminate the AGREEMENT before the initial term expires. CANTOURAGE is not allowed to terminate the AGREEMENT before the initial term expires. |
3.4 | The right of termination for good cause remains unaffected. Good cause shall be, inter alia, if (i) CANTOURAGE does not dutifully provide the RAP SERVICES; or (ii) the REFINEMENT is not carried out in accordance with applicable law; or (iii) the END PRODUCTS do not conform to specifications as set out in ANNEX 5 for reasons not referring to the CONTRACTUAL PRODUCT. BOPHELO has to notify CANTOURAGE in writing and provide 30 days to remedy the situation. Afterwards if the situation is not remedied, BOPHELO can terminate the AGREEMENT with immediate effect subject to all further requirements for a termination for good cause as stipulated by applicable law. |
3.5 | The termination notice has to be in writing. |
Page 7 of 53
Bophelo - Cantourage
4. | Title and risk of loss |
4.1 | Upon DELIVERY, CANTOURAGE shall become the sole owner of the CONTRACTUAL PRODUCTS. CANTOURAGE shall keep all CONTRACTUAL PRODUCTS derived therefrom free of liens, security interests and encumbrances. |
4.2 | Upon DELIVERY, CANTOURAGE will assume the risk of loss of the CONTRACTUAL PRODUCTS. CANTOURAGE assumes the risk of loss of all END PRODUCTS. CANTOURAGE shall maintain an adequate insurance up to an amount of minimum EUR 1,500,000 to cover such potential losses. |
5. | SERVICES |
5.1 | During the term of this AGREEMENT, CANTOURAGE shall provide to BOPHELO the RAP SERVICES and RAP PLUS SERVICES in accordance with the due diligence of a professional expert. |
5.2 | The provision of RAP PLUS SERVICES is conditional upon BOPHELO and CANTOURAGE entering into a separate service agreement further detailing the respective obligations of either Party. |
6. | CONSIGNMENT STOCK |
6.1 | BOPHELO shall be responsible for the DELIVERY of the CONTRACTUAL PRODUCTS . BOPHELO shall not pay for taxes and duties for the importation. |
6.2 | CANTOURAGE shall inform BOPHELO in due course whenever the quantity of CONTRACTUAL PRODUCTS and END PRODUCTS stored in the CONSIGNMENT STOCK falls below the MINIMUM QUANTITY. |
6.3 | CANTOURAGE shall provide to BOPHELO a FORECAST for the period beginning on 1 January 2022 or beginning no later then three weeks of recieving the expansion of the narcotics license which ever is the later. |
No later than ten (10) days prior to the first day of each subsequent calendar quarter, CANTOURAGE shall deliver to BOPHELO a FORECAST for the period beginning with the first day of such calendar quarter. FORECASTS are subject to RAP PLUS SERVICES and for informational purposes only. They do not create any binding obligations on behalf of either PARTY; provided, however, that BOPHELO shall not be required to manufacture and sell to CANTOURAGE any quantity of CONTRACTUAL PRODUCTS that is unreasonably disproportionate to any FORECAST for the period covered by such FORECAST.
6.4 | Upon expiration or termination of this AGREEMENT without cause, CANTOURAGE shall destroy and dispose all remaining CONTRACTUAL PRODUCTS and END PRODUCTS from the CONSIGNMENT STOCK. BOPHELO shall bear all reasonable costs and expense incurred by CANTOURAGE for the distruction or disposal up to a maximum amount equaling an average cost of EUR 0,20 per gram. For each destroyed and disposed END PRODUCT, BOPHELO shall pay to CANTOURAGE the difference between the agreed PURCHASE PRICE and the AVERAGE SELLING PRICE plus statutory value added tax (if applicable). |
Page 8 of 53
Bophelo - Cantourage
6.5 | Upon termination of this AGREEMENT for cause, CANTOURAGE shall destroy and dispose all remaining CONTRACTUAL PRODUCTS and END PRODUCTS from the CONSIGNMENT STOCK at costs and expense of CANTOURAGE. For each detroyed and disposed END PRODUCT, BOPHELO shall pay to CANTOURAGE only the costs of REFINEMENT. |
7. | REFINEMENT |
7.1 | CANTOURAGE shall REFINE CONTRACTUAL PRODUCTS, which are stored in the CONSIGNMENT STOCK on behalf of BOPHELO in such quantities as CANTOURAGE considers reasonably necessary in order to meet DISTRIBUTOR’s demands for END PRODUCTS. |
7.2 | The specifications of the END PRODUCTS are set out in ANNEX 5. |
7.3 | CANTOURAGE shall within 7 days after receiving the testing results for the END PRODUCTS report to BOPHELO on the REFINEMENT results and provide BOPHELO with the respective CoA (Certificate of analysis). |
7.4 | CANTOURAGE shall ensure in its contractual relationship with the DISTRIBUTOR that the ownership of the END PRODUCTS shall only transfer to the DISTRIBUTOR once the SELLING PRICE is paid in full to CANTOURAGE. |
8. | BRANDS, LABELLING |
CANTOURAGE shall distribute and sell the END PRODUCTS with the brands and labelling specified in ANNEX 7.
9. | Distribution, sales activities |
9.1 | CANTOURAGE shall use commercially reasonable efforts to market, distribute and promote the END PRODUCTS within the TERRITORY within the scope of RAP PLUS SERVICES described under ANNEX 6. CANTOURAGE is obliged to make sure that the DISTRIBUTOR has all the required approvals, permits and licences to handle the END PRODUCTS. |
9.2 | The PARTIES shall agree on an ANNUAL MARKETING PLAN that will include at least the sales forecasts and extent of the RAP PLUS SERVICES. The ANNUAL MARKETING PLAN is subject to RAP PLUS SERVICES and can be amended from time to time by a mutual agreement of the PARTIES. |
Page 9 of 53
Bophelo - Cantourage
10. | Order Fulfilment |
10.1 | Upon respective orders of DISTRIBUTORS, CANTOURAGE shall deliver the ordered END PRODUCTS from the CONSIGNMEMT STOCK to the respective DISTRIBUTOR. |
10.2 | For each delivery of END PRODUCTS to the respective DISTRIBUTOR, CANTOURAGE shall invoice to the respective DISTRIBUTORS the respective SELLING PRICE plus statutory value added tax and costs and expenses. |
10.3 | In the event a DISTRIBUTOR fails to pay invoiced amounts in a timely manner, CANTOURAGE shall submit at least two payment reminder notices to the respective DISTRIBUTOR and take commercially reasonable measures to enforce the claim at their own costs. |
11. | Deliveries |
BOPHELO shall effect DELIVERY of CONTRACTUAL PRODUCTS in a timely manner as agreed between BOPHELO and CANTOURAGE from time to time.
12. | PRICE, INVOICES |
12.1 | For RAP SERVICES and RAP PLUS SERVICES, BOPHELO shall pay to CANTOURAGE the PRICES at the dates specified in ANNEX 3 plus statutory value added tax (if applicable). |
12.2 | For each END PRODUCT delivered to and paid by a DISTRIBUTOR, BOPHELO shall invoice CANTOURAGE and CANTOURAGE shall pay to BOPHELO the MINIMUM PURCHASE PRICE plus statutory value added tax (if applicable). For the avoidance of doubt, the MINIMUM PURCHASE PRICE and the PURCHASE PRICE shall not become payable to the extent CANTOURAGE has not received payment of the SELLING PRICE for the respective END PRODUCTS. |
For each CONTRACTUAL PRODUCT that cannot be refined into an END PRODUCT due to loss of the CONTRACTUAL PRODUCT, BOPHELO shall invoice CANTOURAGE and CANTOURAGE shall pay to BOPHELO the cost price. The same applies in case of loss of the END PRODUCT.
12.3 | CANTOURAGE shall not be obliged to make payment if the delivered CONTRACTUAL PRODUCTS contains a DEFECT. |
12.4 | CANTOURAGE has to calculate the PURCHASE PRICE within 14 days following the end of each RELEVANT PERIOD and notify it to BOPHELO. In case the PURCHASE PRICE exceeds the MINIMUM PURCHASE PRICE, BOPHELO shall invoice the PURCHASE PRICE minus the already paid MINIMUM PURCHASE PRICE plus statutory value added tax (if applicable). |
12.5 | All PRICES are to be paid in Euro and payable within 14 days after receipt of a respective invoice. Either Party may invoice a PRICE as soon as the PRICE has become payable. |
Page 10 of 53
Bophelo - Cantourage
12.6 | CANTOURAGE shall be entitled to request an adjustment of PRICES if market conditions require a PRICE adjustment. |
13. | Release of CONTRACTUAL PRODUCT |
13.1 | Prior to the first DELIVERY, CANTOURAGE will audit BOPHELO with regard to its GACP compliance, BOPHELO shall only deliver CONTRACTUAL PRODUCT which has been produced with same production equipment, production materials and production processes at the same production place as audited by CANTOURAGE. |
13.2 | Prior to the first DELIVERY, BOPHELO shall, at the request of CANTOURAGE, produce proof of the conformity of the CONTRACTUAL PRODUCTS with the agreed specification (ANNEX 2) by submitting a CoA (Certificate of analysis) by an independent third party. |
13.3 | Each change in the production equipment, the production materials, location or processes used for the production of CONTRACTUAL PRODUCTS (including the production equipment, production materials, location or processes of sub-contractors and sub-suppliers) shall require a new sign-off. BOPHELO shall inform CANTOURAGE of any forthcoming or impending changes at the earliest possible date. In addition, the provisions of Clause 19 apply. |
14. | Quality; Inspection |
14.1 | Prior to DELIVERY, BOPHELO shall inspect the quality of the CONTRACTUAL PRODUCTS and ensure that no CONTRACTUAL PRODUCTS containing a DEFECT are delivered. In addition, BOPHELO shall send CoA (Certificate of analysis) by an independent third party for each delivered batch to CANTOURAGE. |
14.2 | CANTOURAGE shall test samples of each shipment of CONTRACTUAL PRODUCTS in due course. The time limit for notifying evident DEFECTS or any DEFECTS discovered shall be three weeks as from DELIVERY or discovery of the DEFECT. |
15. | Warranty |
15.1 | Each CONTRACTUAL PRODUCT delivered must have the following quality: |
15.1.1 | The CONTRACTUAL PRODUCT must conform with the specification agreed in this AGREEMENT. |
15.1.2 | The CONTRACTUAL PRODUCT must conform with the quality of the Certificate of Analysis delivered by BOPHELO. |
15.2 | With regard to each DEFECT, CANTOURAGE shall be entitled to the statutory warranty rights. |
15.3 | In deviation from the statutory provisions, CANTOURAGE may, in respect of any CONTRACTUAL PRODUCT containing a DEFECT, at any time request to send back or destroy the CONTRACTUAL PRODUCT at costs of BOPHELO. |
Page 11 of 53
Bophelo - Cantourage
16. | Analysis costs |
Without prejudice to all further claims, CANTOURAGE shall be entitled for each CONTRACTUAL PRODUCT containing a DEFECT to claim fifty (50) % of the effective analysis costs incurred in connection with the analysis and elimination of the DEFECT and its consequences. BOPHELO shall be enabled to challenge such test with a retest. If the retest does not confirm the adverse result brought by the previous test, CANTOURAGE will bear hundred (100) % of the cost of the retest. If the retest does confirm the adverse result brought by the previous test, BOPHELO will bear hundred (100) % of the cost of both the previous test and the retest. Parties commit to revisit in good faith this provision in case the practicalities of the first twelve (12) months of shipments prove to make this stipulation an unexpected burden to any of the Parties.
17. | RECALL |
17.1 | CANTOURAGE shall be entitled to recall END PRODUCTS supplied to DISTRIBUTORS if such a recall is necessary under applicable law. |
17.2 | In case of a recall caused by the CONTRACTUAL PRODUCTS, BOPHELO shall, without prejudice to all further claims by CANTOURAGE, indemnify CANTOURAGE for the reasonable costs of all measures taken by CANTOURAGE to eliminate or minimise the risks which have arisen for CANTOURAGE, unless the recall has arisen out of any breach of the AGREEMENT by CANTOURAGE or any negligence in the sale or promotion of the END PRODUCTS. These include in particular the following measures: |
17.2.1 | the notification of known or the public notification of unknown owners of the products; |
17.2.2 | the removal and transport - including packaging, insurance, temporary storage and customs duties - of the products from the owner to CANTOURAGE or to the nearest suitable location at which the fault in the products can be rectified, the products disposed of, destroyed, temporarily stored or replaced; |
17.2.3 | the disposal or destruction of the products; |
17.2.4 | the examination of products which demonstrably belong to any series containing a DEFECT at the premises of the owner or at the nearest suitable location. |
17.3 | In case a recall is caused by the REFINEMENT or as a condition in the END PRODUCT and not caused by the CONTRACTUAL PRODUCT, CANTOURAGE shall, without prejudice to all further claims by BOPHELO, indemnify BOPHELO for the reasonable costs of all measures taken by BOPHELO to eliminate or minimise the risks, which have arisen for BOPHELO. |
Page 12 of 53
Bophelo - Cantourage
18. | Product liability |
18.1 | Should any product liability claims be asserted against CANTOURAGE which are based on a fault or DEFECT in a CONTRACTUAL PRODUCT, BOPHELO shall indemnify CANTOURAGE from these claims and from all costs incurred by CANTOURAGE by reason of the claims asserted, including any costs of legal defence and costs for corrective measures to mitigate the risk. |
18.2 | Should any product liability claims be asserted against BOPHELO which are based on a fault in an END PRODUCT or caused by REFINEMENT, CANTOURAGE shall indemnify BOPHELO from these claims and from all costs incurred by BOPHELO by reason of the claims asserted, including any costs of legal defence and costs for corrective measures to mitigate the risk. |
19. | Insurance |
Either Party shall be obliged to maintain business liability insurance and extended product liability insurance with coverage of at least EUR 1 (one) million per claim for damage.
20. | Change management |
In case of a change in regulation affecting the distribution of END PRODUCTS within the TERRITORY, the PARTIES shall mutually agree on necessary measures.
21. | Obsolescence |
PARTIES shall inform each other at the earliest possible date of any anticipated or impending restrictions concerning manufacture or delivery of the CONTRACTUAL PRODUCTS or END PRODUCTS.
22. | Provision of materials and assistance by CANTOURAGE |
CANTOURAGE shall only be obliged to provide such services, assistance and cooperation if and to the extent explicitly provided in this AGREEMENT.
23. | Intellectual property |
Any FOREGROUND RIGHTS created by CANTOURAGE shall be deemed the sole property of CANTOURAGE as they relate exclusively to the END PRODUCTS.
24. | CERTIFICATIONS, PERMISSIONS |
The Parties agree that CANTOURAGE alone shall be the sole owner of all certifications or permissions regarding the END PRODUCTS in so far as these relate exclusively to the END PRODUCTS and the TERRITORY.
Page 13 of 53
Bophelo - Cantourage
25. | Rights of third parties |
25.1 | BOPHELO shall be liable for ensuring that no rights of third parties are infringed through the manufacture and supply of CONTRACTUAL PRODUCTS. |
25.2 | CANTOURAGE shall be liable for ensuring that no rights of third parties are infringed through the manufacture and supply of END PRODUCTS. |
26. | Duties to inform; Inspection rights |
26.1 | BOPHELO shall without undue delay provide to CANTOURAGE the information required by applicable law relating to the manufacture and supply of CONTRACTUAL PRODUCTS and also in regard to compliance with the duties of BOPHELO agreed in this AGREEMENT. |
26.2 | BOPHELO shall be obliged to inform CANTOURAGE at the earliest possible date of pending or announced changes in the manufacturing location and process, statutory provisions, in particular applicable accident prevention, occupational safety, environment and similar provisions, the applicable technical standards and the latest recognised rules of science and technology in so far as these concern or may concern the CONTRACTUAL PRODUCTS. |
26.3 | Each Party shall be entitled to check the other Party’s compliance with the obligations agreed in this AGREEMENT (Audit). The audit is to be announced with a reasonable period of advance notice and to be carried out within the usual business hours of the Party. |
26.4 | BOPHELO shall retain all information, documents and data concerning the manufacture and supply of CONTRACTUAL PRODUCTS for a period of at least [10] years from the manufacture of the last CONTRACTUAL PRODUCT and deliver the same to CANTOURAGE if required by applicable law. |
27. | Alliance Committee |
The Parties shall establish an ALLIANCE COMMITTEE that shall manage the fulfilment of this AGREEMENT, in particular, but not limited to the regulatory matters, supply arrangements, adoption and implementation of the ANNUAL MARKETING PLAN etc. The ALLIANCE COMMITTEE shall consist of at least one member of each Party and shall meet at least once a month by teleconference or more regularly as required to fulfil the AGREEMENT.
28. | Export/Import regulations |
28.1 | BOPHELO must comply at its own cost and expense with all export control, customs and foreign trade regulations applicable in the export countries for the CONTRACTUAL PRODUCTS and obtain all necessary permits unless CANTOURAGE or any third party are obliged to apply for such permits. |
Page 14 of 53
Bophelo - Cantourage
28.2 | CANTOURAGE must comply at its own cost and expense with all import, customs and foreign trade regulations applicable in Germany and obtain all necessary permits in Germany. CANTOURAGE shall be solely liable for any damage in case CANTOURAGE does not obtain all necessary import permits. |
28.3 | BOPHELO must provide CANTOURAGE in writing as early as possible with all information and data which CANTOURAGE requires for the application of the import permits - especially the Certificate of Analysis. |
28.4 | BOPHELO must provide CANTOURAGE in writing upon DELIVERY with all information and data which CANTOURAGE requires for the import / customs clearance. With each shipment, BOPHELO must send the following documents: |
• | Certificate of Analysis |
• | Delivery Note with the actual amount of CONTRACTUAL PRODUCT declared |
• | Pro Forma Invoice with the actual amount of CONTRACTUAL PRODUCT declared |
• | Export Permit |
28.5 | In the case of any changes in the origin and/or of features of the products or services sold to CANTOURAGE and/or the relevant regulations, BOPHELO must update the information specified in Clause 26.2 or any further information which may have become necessary as early as possible but no later than two (2) weeks following the date when these changes came into force and in any event prior to the planned DELIVERY date. BOPHELO shall be liable for all expenses and/or damage suffered by CANTOURAGE by reason of any incorrectness or inaccuracy of the information provided by the supplier unless BOPHELO was not responsible for the breach of duty. |
28.6 | Neither Party shall be obliged to perform this Agreement if and in so far as relevant regulations, embargos or any other sanctions preclude their performance. |
28.7 | BOPHELO guarantees the security of its own supply chain and observes corresponding legal requirements. BOPHELO undertakes at the request of CANTOURAGE to provide corresponding proof through certificates or declarations. |
28.8 | Neither Party shall be responsible for any failure of or delay in performance hereunder which may be due, in whole or in part to any event of FORCE MAJEURE. The Party claiming the existence of a FORCE MAJEURE event shall use commercially reasonable efforts to resume performance under this AGREEMENT as soon as possible, and if it has not performed under this AGREEMENT due to a FORCE MAJEURE event for more than thirty (30) days, the other Party may terminate this AGREEMENT without further cost or liability in addition to any other applicable termination rights. |
Page 15 of 53
Bophelo - Cantourage
29. | Confidentiality |
29.1 | During the term of this AGREEMENT and after termination or expiration of this AGREEMENT for any reason, the RECEIVING PARTY: |
29.1.1 | shall keep the CONFIDENTIAL INFORMATION confidential; |
29.1.2 | may not disclose the CONFIDENTIAL INFORMATION to another person except with the prior written consent of the DISCLOSING PARTY or in accordance with Clause 27.2 and 27.3; and |
29.1.3 | may not use the CONFIDENTIAL INFORMATION for a purpose other than the performance of its obligations under this AGREEMENT. |
29.2 | During the term of this Agreement or thereafter the RECEIVING PARTY may disclose the CONFIDENTIAL INFORMATION to its employees, sub-contractors and customers only to the extent that it is reasonably necessary for the purposes of this AGREEMENT. |
29.3 | The RECEIVING PARTY shall ensure that each recipient is made aware of and complies with all the RECEIVING PARTY’s obligations of confidentiality under this AGREEMENT as if the recipient was a party to this AGREEMENT. |
29.4 | Clause 27.1 to 27.3 do not apply to CONFIDENTIAL INFORMATION which: |
29.4.1 | is at the date of this AGREEMENT or at any time after the date of this AGREEMENT comes into the public domain other than due to breach of this AGREEMENT by the RECEIVING PARTY; |
29.4.2 | to the extent such information has to be disclosed by the RECEIVING PARTY to public authorities or courts pursuant to statute or applicable law rules; |
29.4.3 | can be shown by the RECEIVING PARTY to have been known by the RECEIVING PARTY before disclosure by the DISCLOSING PARTY to the RECEIVING PARTY; or |
29.4.4 | subsequently comes lawfully into the possession of the RECEIVING PARTY from another source not under obligation of confidentiality to the DISCLOSING PARTY. |
30. | FORM |
30.1 | BOPHELO shall make any legally relevant statement, declaration or notice under this AGREEMENT to Cantourage GmbH, Schloßstr. 112, 12163 Berlin, Germany in text form. |
30.2 | CANTOURAGE shall make any legally relevant statement, declaration or notice under this AGREEMENT to BOPHELO Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng, Lesotho and in parallel to vidya@akandacorp.com in text form. |
Page 16 of 53
Bophelo - Cantourage
31. | Applicable law |
This AGREEMENT and the performance of the same shall be governed exclusively by the law of the Federal Republic of Germany (to the exclusion of its conflict of law provisions). The application of the United Nations Convention on Contracts for the International Sale of Goods (CISG) is excluded.
32. | VENUE |
32.1 | The exclusive court venue for all disputes arising from or in connection with this AGREEMENT shall be Hamburg, Germany. |
32.2 | CANTOURAGE has the right to sue BOPHELO also at its place of general jurisdiction. |
33. | Integral parts of the AGREEMENT |
33.1 | Integral parts of this AGREEMENT are: |
Annex 1: RAP SERVICES
Annex 2: CONTRACTUAL PRODUCTS
Annex 3: PRICES
Annex 4: Quality Assurance Agreement
Annex 5: END PRODUCTS
Annex 6: RAP PLUS SERVICES
Annex 7: Brands, Labelling
33.2 | In the case of ambiguities or inconsistencies, the integral parts of the AGREEMENT shall apply in the following order of precedence: |
33.2.1 | Prior-ranking, the text of this AGREEMENT shall apply; thereafter the Annexes in the order of their numbering. |
33.2.2 | Provisions of higher rank shall have precedence in the case of inconsistencies with provisions of lower rank. |
33.2.3 | Terms and conditions deviating from this AGREEMENT shall have no validity unless the Parties have agreed the deviation in a contractual document signed by both sides with express reference to the contrary provisions of this AGREEMENT. |
33.2.4 | Should inconsistencies or ambiguities arise which cannot be unequivocally dispelled through the foregoing order of priority, BOPHELO shall be obliged to inform CANTOURAGE in writing without delay. |
Page 17 of 53
Bophelo - Cantourage
34. | Final provisions |
34.1 | No ancillary agreements have been made. |
34.2 | In so far as any earlier agreements between the Parties exist in regard to the CONTRACTUAL PRODUCTS and their supply, these agreements lose their validity upon signature to this AGREEMENT. |
34.3 | General terms and conditions of either Party shall not apply even if a Party has referred to such terms and conditions. |
34.4 | This AGREEMENT is executed in duplicate. Each Party hereto receives one signed copy. |
34.5 | Any amendments or supplements need to be made in written form in order to be effective. This also applies for the revocation or amendment of the requirement of the written form. |
34.6 | Should individual provisions of this AGREEMENT be or become ineffective or incapable of performance, either in whole or in part, or should this AGREEMENT contain any gap in its provisions, the effectiveness of the remaining provisions shall not be thereby affected. In place of the ineffective provision or provision incapable of performance or for the purpose of filling any gap in the contractual provisions, such arrangement shall be deemed to be agreed as most closely reflects that which the Parties hereto intended or, in accordance with the intent and purpose of the AGREEMENT, would have intended had they given consideration to the point. |
Berlin, the 9/15/2021 | Johannesburg, the 9/15/2021 | |
/s/ Patrick Hoffman | /s/ Trevor Scott | |
Cantourage GmbH | Bophelo Bio Science and Wellness (Pty) Ltd |
Page 18 of 53
Bophelo - Cantourage
ANNEX 1
(RAP SERVICES and REFINEMENT)
A. | RAP SERVICES |
Initial setup to secure an initial Import Permit
Paper Audit:
Checking the following documents and comparing them with own specifications to decide whether BOPHELO; is eligible for the program or not:
• | valid cultivation license | |
• | representative certificates of analysis (CoAs) | |
• | self-disclosure about products | |
• | basic statement on the use of pesticides and fertilizers |
Audit by Cantourage:
• | Auditing BOPHELO; on site to check the conformity of BOPHELO; with the GACP guidelines (in certain cases with support of qualified third-party experts) | |
• | Using checklists, which are based on the WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants: | |
▪ | Quality assurance | |
▪ | Propagation | |
▪ | Cultivation | |
▪ | Harvest | |
▪ | Primary processing | |
▪ | Packaging |
Product Definition:
• | Definition and check of the product quality in consideration of the DAB monography (e.g. heavy metals, microbiology, pesticides) | |
• | Working with the guidelines that are also specified by the European medicinal book for herbals & drugs | |
• | Checking in the German market whether END PRODUCT name may be used or not and checking the END PRODUCT names for trademark violations |
Registration:
• | Inclusion of BOPHELO; in the narcotic license and manufacturing authorization | |
• | Narcotic registration of all necessary third parties (e.g. logistic providers) | |
• | Expanding Cantourage’s BTM-license to include the END PRODUCTS |
Page 19 of 53
Bophelo - Cantourage
Product Registration:
Registration of various END PRODUCTS including the product central number (PZN) at the “Informationsstelle für Arzneispezialitäten” (IFA).
Import Permit:
• | Applying the Import Permit “Einfuhrgenehmigung” at the “Bundesopiumstelle” | |
• | Sending the 2 originals to BOPHELO |
Export Permit:
• | Helping BOPHELO; with the application and the fulfillment of the export if necessary |
Manufacturing Process
Import Management:
• | Arranging a pickup at a German airport | |
• | Fulfillment of all relevant aspects for customs clearance | |
• | Responsibility for the CONTRACTUAL PRODUCTS from the German Airport on | |
• | Carrying and shipping under GDP conditions, which means that the temperature is between 15-25 degrees, the shipment is always safe & secure and also traceable at any time |
Quality Management:
As part of the quality management of Cantourage, the following procedures take place with every import:
• | Incoming goods inspection (transport documentation e.g. temperature) | |
• | Comparing quantities with delivery note | |
• | Taking a representative sample | |
• | Carrying out a quality control of the sample | |
• | Checking the client’s certificate of analysis (CoA) with the DAB monography | |
• | prompt identification of any defects in accordance with the Agreement |
Batch Labeling:
• | Creating a label that is conform with the European drug law consisting two parts (product-specific level and presentation of the analysis certificate) | |
• | In other European countries, the label is created in coordination with local representatives of the individual states |
Page 20 of 53
Bophelo - Cantourage
Testing and Release:
After the CONTRACTUAL PRODUCT is transformed to END PRODUCTS, it will be tested and released by Cantourage before it can be sold:
• | Taking a representative sample |
• | Carrying out the quality control |
• | Releasing batch if all quality assurance parameters match |
• | taking all other steps to ensure compliance with EU GMP standards |
Order & fulfillment
Storage of CONTRACTUAL PRODUCTS and END PRODUCTS:
The CONTRACTUAL PRODUCTS and END PRODUCTS are always stored in an anesthetic warehouse under GMP conditions and the requirements of the relevant German and EU guidelines:
• | Temperature is between 15-25 degrees |
• | Humidity and air quality are continuously monitored |
• | Product is always kept safe & secure |
• | Product is stored on one or more pallets in an assigned storage location |
Order Management & Fulfillment:
To ensure that all processes run smoothly, Cantourage is setting up an own module in a proven virtual Enterprise resource planning system (ERP system) for BOPHELO:
• | Introducing all CONTRACTUAL PRODUCTS and END PRODUCTS into the system |
• | Handling the entire order acceptance via phone, fax, email and the shop with an experienced team of salespeople |
• | Introducing the entire DISTRIBUTOR data into the ERP in order to do the shipping and the billing with BOPHELO; and our logistic providers |
• | Shipping the END PRODUCT within the TERRITORY under GDP conditions |
• | Fulfilling the entire narcotic documentation within the shipping process |
Return handling & reclamation:
Cantourage does the return handling & reclamation. Within the process, each complaint is first checked and assessed by Cantourage’s quality assurance.
• | Fulfilling a detailed determination and an evaluation of the cause |
• | Tracking the process and e.g. testing a batch if necessary |
• | Taking care of the narcotic documentation and the physical transport management within the reclamation process |
• | Fulfilling any payments of refunds that might be required |
Page 21 of 53
Bophelo - Cantourage
Payment Fulfillment:
• | Fulfilling the cash flow management including the posting of the receivable |
• | Checking and posting of incoming payments for the individual orders |
• | Sending out payment reminders within the reminder management when the payment target is exceeded |
• | CANTOURAGE will undertake all necessary measures to ensure payments due for the delivery of END PRODUCTS are paid on time and in full |
Documentation:
• | Providing monthly KPIs to BOPHELO; |
• | Summarizing the sales and presenting them in Euro amounts and product quantities |
• | Documenting the inventories (incoming and outgoing goods), as well as the gross margin analysis |
• | Sharing monthly documentation with the client, in order to discuss future approaches. |
B. | REFINEMENT |
Product Transformation:
Transforming the CONTRACTUAL PRODUCTS into an END PRODUCT by an EU GMP compliant manufacturer in accordance with the relevant EU guidelines thereby producing EU GMP compliant product that can be sold as such in Germany and will be palatable and appealing to consumers. The activities CANTOURAGE will undertake to do this include but are not limited to:
• | Trimming |
• | Post treatment (if necessary) |
• | Drying (if necessary) |
• | Packing |
• | Labeling according to defined manufacturing regulations |
• | Testing and Release |
In the course of the REFINEMENT there will be trimming and drying losses as well as retentions and testing provisions that will not be included into the END PRODUCT. Cantourage will keep a record of these losses and retentions, but also of the yield, and will disclose them to BOPHELO; immediately after the REFINEMENT process.
CANTOURAGE will make the best endeavors to sell the trimming loses and any profits will be split between the 2 parties as per a normal sale of product outlined in this contract. At all times, BOPHELO owns the trimming losses and has the right to request CANTOURAGE ship such product to another party at BOPHELOS’s cost.
Page 22 of 53
Bophelo - Cantourage
ANNEX 2
(CONTRACTUAL PRODUCTS)
The CONTRACTUAL PRODUCTS must comply with the following parameters and specification:
Page 23 of 53
Bophelo - Cantourage
ANNEX 3
(PRICES)
A. | RAP SERVICE PRICE |
The price for the RAP SERVICE is 420.000 EUR and is payable as followed:
• | 20.000 EUR, due 10 days after signing of this Agreement and receipt of a proper invoice |
• | 200.000 EUR, due 10 days after REFINEMENT and the first sale of END PRODUCTS to a DISTRIBUTOR |
• | Upon IPO, Bophelo will issue 200,000 EUR of IPO stock to Cantourage. Stock will be held in escrow until first sale obligation is met. Equity would vest immediately on that first sales event. |
B. | RAP PLUS SERVICE PRICES |
PLUS Service | One time fee | Recurring / monthly fee |
Homepage | 10.000 € (*) | 500 € |
Direct HCP access | 10.000 € (*) | 500 € |
Listing at wholesales | 7.500 € / wholesale (*) | 150 € / wholesale |
Info material | 10.000 € (*) / 20.000 € / 40.000 € | Printing costs |
Pharma representatives | 5.000 € / pharma rep | 7.000 € / pharma rep |
Press announcements | 2.000 € + placement costs | - |
Advertisements | Real costs + 15 % | - |
Newsletter | 1.750 € | Printing and distribution costs |
Education program | 20.000 € | 500 € / physician |
Patient support | 10.000 € | Printing costs |
Social Media | 1.500 € | 1.000 € |
Launch Event | 15.000 € | - |
(*) These PLUS Service are included in the price of € 420.000 for the RAP Service.
The above given prices are rough estimates, based on the experience of CANTOURAGE for a basis package. Each final price depends on the extent of a chosen service and the respective service agreement.
Page 24 of 53
Bophelo - Cantourage
C. | PURCHASE PRICE |
The PURCHASE PRICE will be calculated as price per gram of END PRODUCTS received by REFINEMENT of CONTRACTUAL PRODUCTS and consists out of a 70,0 % share of the AVERAGE SELLING PRICE. It is calculated as followed:
AVERAGE SELLING PRICE per gram x 70 %
PURCHASE PRICE and AVERAGE SELLING PRICE refer to the resulting weight of END PRODUCTS.
The weight of END PRODUCTS as a basis for the PURCHASE PRICE will be lower than the weight of CONTRACTUAL PRODUCTS, due to trimming and drying losses that occur during the REFINEMENT. Moreover, CANTOURAGE must withhold a minimum quantity of refined CONTRACTUAL PRODUCTS for testing and retentions that will not be included into the END PRODUCT.
The minimum PURCHASE PRICE that CANTOURAGE has to pay to BOPHELO for CONTRACTUAL PRODUCTS is 2,80 EUR per gram of the END PRODUCT that was refined from the respective CONTRACTUAL PRODUCT (“MINIMUM PURCHASE PRICE”).
D. | SELLING PRICE |
The SELLING PRICE will be set by CANTOURAGE in its own discretion.
Page 25 of 53
Bophelo - Cantourage
ANNEX 4
-
QUALITY ASSURANCE AGREEMENT
Bophelo - Cantourage
Page 26 of 53
Bophelo - Cantourage
QUALITY ASSURANCE AGREEMENT
Production and Quality Control
of Medicinal Cannabis Starting Material
(Version 01)
between | Cantourage GmbH |
Heinrich-Mann-Str.12 | ||
14532 Kleinmachnow | ||
Germany |
– hereinafter referred to as “Cantourage” –
and | Bophelo Bio Science and Wellness (Pty) Ltd |
Khoabane Mojela, Ha Mojela, Ts’Akholo, Mafeteng | |
Lesotho |
– hereinafter referred to as “BOPHELO” –
Page 27 of 53
Bophelo - Cantourage
34.7 | Preamble |
The parties to this Agreement consent that, due to legal provisions, the quality of Medicinal Cannabis Starting Material must be assured. The corresponding provisions must be obeyed.
Against this background, the parties to this Agreement conclude the following contract which is the basis for all shipments of Cannabis Materials from BOPHELO to Cantourage.
The following agreements relate to the quality part of the business relations between Cantourage and BOPHELO. Arrangements on prices and other commercial terms are reserved for a separate agreement.
Legal Background
Cultivation of Cannabis in the country of origin must be done for medical purposes under governmental control according to articles 23 and 28 paragraph 1 of the Single Convention on Narcotic Drugs from 1961. Both Germany and Lesotho signed the UN Single Convention on Narcotic Drugs.
BOPHELO owns a cultivation license issued by the responsible authority of Lesotho. BOPHELO will undertake all measures to maintain this license. In the case BOPHELO’s license will be suspended or withdrawn by the authority, this Quality Assurance Agreement is not or no longer executed.
Page 28 of 53
Bophelo - Cantourage
Glossary
GACP
European “Guideline on Good Agricultural and Collection Practice for Starting Materials of Herbal Origin” (Doc. Ref. EMEA/HMPC/246816/2005 (20 February 2006)).
Manufacture
All activities necessary to obtain the contracted Medicinal Cannabis Material, including propagation, cultivation, harvest, post-harvest processing, packaging, quality control.
Manufacturing site
Location where BOPHELO carries out all activities to cultivate and process the contracted Medicinal Cannabis Material as specified in Appendix 1 of this agreement. The cultivation license is used for the following manufacturing site:
Bophelo Bio Science and Wellness (Pty) Ltd
Ts’Akholo, Mafeteng
Lesotho
Production
see Manufacture
Page 29 of 53
Bophelo - Cantourage
1 | Scope |
Until further notice, the provisions of this Agreement apply to all Medicinal Cannabis MaterialsBOPHELO supplies and which are listed in Appendix (1) to this Agreement together with the agreed specifications.
This Quality Assurance Agreement outlines the responsibilities of Cantourage and BOPHELO with respect to the quality assurance of Medicinal Cannabis Materials produced and supplied by BOPHELO. The responsibilities of Cantourage and BOPHELO are outlined in Appendix (2). Important contact persons are listed in Appendix (3).
2 | Supplier / manufacturer |
In case of this agreement, BOPHELO is the supplier and producer of the Medicinal Cannabis Materials.
BOPHELO has reported its activities to the competent authority under the national requirements and is under survey of this authority.
3 | Requirements to the production of Medicinal Cannabis Materials |
3.1 | BOPHELO is obliged to name the manufacturing site/s of the supplied Medicinal Cannabis Materials. |
The manufacturing site is:
Bophelo Bio Science and Wellness (Pty) Ltd
Ts’Akholo, Mafeteng
Lesotho
3.2 | BOPHELO must inform Cantourage about any changes in the manufacturing site or manufacturing procedure that can affect the quality and safety of the products prior to the first delivery of concerned products. |
3.3 | BOPHELO ensures that the requirements of the GACP guidelines are fulfilled. BOPHELO will undertake all measures to maintain this GACP conformity. |
3.4 | BOPHELO must inform Cantourage about all substances used in the cultivation and processing of the Medicinal Cannabis Material, especially about all used fertilizer and pesticides. All pesticides used must be approved for use on medicinal plants by both local and European governments at application levels intended to meet established tolerance levels for the Cannabis. |
3.5 | BOPHELO ensures that the legislative limits for pesticides and heavy metals as well as the microbiological purity and all other specifications as defined in Appendix (1) are kept (to be certified in the Certificate of Analysis). |
3.6 | BOPHELO is obliged to give all information about the Cannabis Material that is or could be necessary to fulfil statutory requirements (e.g. import licence into the EU) or any information relevant for the European market as requested by Cantourage. |
Page 30 of 53
Bophelo - Cantourage
4 | Stability data |
4.1 | BOPHELO provides Cantourage with available stability data related to the contracted Cannabis Material. The primary packaging material used for stability tests must be identical with the packaging material as defined in Appendix (4). |
4.2 | Cantourage considers all stability data provided by BOPHELO for the determination of shelf-life and storage conditions for products for the European market. |
5 | Packaging / Delivery |
5.1 | In order to keep the quality of Medicinal Cannabis Materials and the integrity of individual containers, BOPHELO uses suitable primary and transport packaging systems. Primary packaging materials are agreed between Cantourage and BOPHELO and defined in Appendix (4). |
5.2 | BOPHELO will take all measures to avoid any mix-ups or cross-contaminations or microbial contamination during packaging and labelling. Each single primary container is labelled at least with Material name, batch number, filling weight. Each single transport container (shipping box) is also labelled at least with Material name, batch number, number of contained primary containers. Mix-ups of different materials in one transport container should be avoided. |
5.3 | The following documents must be provided with each delivery: |
- | Batch-specific Certificate of Analysis (CoA) showing which parameters have been checked in each batch (including found values and specified limits) and which have been found on a statistical basis (skip lot testing); |
- | Batch-specific Certificate of Manufacture (CoM) according to GACP; |
- | a proper delivery note; |
The delivery is not complete unless all mentioned documents are available.
5.4 | The relevant legal provisions on safety and transport must be observed. Relevant Import Permits must be applied and submitted by Cantourage. Export permits must be applied and submitted by BOPHELO. |
5.5 | BOPHELO is responsible for the transport of the Medicinal Cannabis Materials from BOPHELO to Cantourage. |
6 | Quality Control |
6.1 | BOPHELO will proceed the quality control according to the agreed specifications and test procedures as defined in Appendix (1) by using its own laboratory (in-house) and/or a third-party laboratory. |
6.2 | BOPHELO is responsible for testing the contracted products in accordance with approved validated or qualified methods and specifications using calibrated equipment. BOPHELO is responsible for having a program for qualification, calibration, and preventive maintenance of all analytical equipment. |
6.3 | BOPHELO must ensure that the third-party laboratory has been fully qualified via BOPHELO’s third-party qualification process prior to performing such activities. BOPHELO shall, however, retain all obligations under this Agreement. |
6.3 | BOPHELO will inform Cantourage about changes in the testing procedures that can affect the quality and safety of the products prior to the first delivery of concerned products. |
Page 31 of 53
Bophelo - Cantourage
7 | Flaw management |
7.1 | Any visual flaws at incoming deliveries (e.g. outer packaging) are recorded on the delivery note and must be notified to BOPHELO. The measures to be taken are agreed between BOPHELO and Cantourage on a case-by-case basis. |
7.2 | If any flaws are discovered afterwards, BOPHELO must be informed immediately. The measures to be taken are also agreed between BOPHELO and Cantourage on a case-by-case basis. |
7.3 | Cantourage informs about hidden flaws as soon as they become known. |
8 | Quality Assurance System |
8.1 | The quality assurance system applied by BOPHELO bases on the guidelines of GACP and the relevant national legal stipulations. |
8.2 | BOPHELO will undertake all measures to maintain GACP certification issued by the competent authority. |
8.3 | BOPHELO allows Cantourage and its representatives or third persons authorised by Cantourage to perform audits on site to check and evaluate the QA system (audit) and relevant rooms, procedures and equipment, and to look into all the documentations that relate to the Medicinal Cannabis Materials to be supplied. |
9 | Deviations and Change Control |
9.1 | According to its Deviation SOP, BOPHELO categorizes events as Incidents, Deviations and Critical Deviations – depending on the quality impact on the product and/or patient. BOPHELO will inform Cantourage about Deviations and Critical Deviations from the specified and agreed manufacturing and testing procedures, product specifications and batch results (OOS) with regard to the Medicinal Cannabis Materials in writing. |
The deviation must be evaluated by BOPHELO with regard to the impact on the product quality and impact on patient safety.
9.2 | BOPHELO will inform Cantourage about changes in the manufacturing site, the testing location, the manufacturing and/or testing procedure as well as the product specification/s of the Medicinal Cannabis Materials to Cantourage in writing. This relates to changes that can affect the quality and safety of the products. BOPHELO must inform Cantourage about those changes prior to the first delivery of concerned products. |
10 | Documentation |
10.1 | All documents necessary to trace back quality and products of the contracted Medicinal Cannabis Materials should be stored at the site of BOPHELO, for at least 5 years after releasing the batch. |
10.2 | The following documents must be provided with each delivery: |
- | Batch-specific Certificate of Analysis (CoA) showing which parameters have been checked in each batch (including found values and specified limits) and which have been found on a statistical basis (skip lot testing); |
- | Batch-specific Certificate of Manufacture (CoM) according to GACP; |
Page 32 of 53
Bophelo - Cantourage
- | a proper delivery note. |
11 | Confidentiality |
11.1 | BOPHELO and Cantourage mutually undertake to observe secrecy on each other’s know-how that became known to them in the course of this Agreement. This also applies for a period of three years after the co-operation has ended. |
11.2 | The obligation of confidentiality and of not using information does not apply if that information |
a) | was already known to the other party before its disclosure under the Agreement and the other party declares this fact immediately, or |
b) | has become common property through publication or by other means, or |
c) | becomes known to one of the parties without originated directly or indirectly from the other party. |
d) | is made available to Authorities due to legal requirements. |
12 | Term / Termination |
12.1 | This Agreement shall come into force and effect once signed by the both parties hereby. It shall be concluded for an indefinite period and may be terminated with due observance of a notice period of six months. |
12.2 | The right for an extraordinary termination for good cause (e.g. invalidity of GACP conformity) is not affected. |
12.3 | Each termination must be effected in writing. |
13 | Miscellaneous |
13.1 | Amendments and addenda to this Agreement and its appendices shall be invalid unless made in writing. |
13.2 | Should a provision of this Agreement prove to be invalid either in part or in full or lose its validity at a later date, the validity of the other provisions shall not be affected. Another appropriate provision shall apply in place of the invalid provision, insofar as legally permissible, that comes closest in economic terms to what the parties wanted or would have wanted had they been aware of the invalidity of the provision. |
13.3 | The defendant’s seat is determined as the place of jurisdiction according to the legal requirement. |
13.4 | All rights and obligations under this contract will also devolve upon the contract parties’ legal successors. |
Page 33 of 53
Bophelo - Cantourage
14 | Signatures |
Berlin, 15/09/2021 | Kleinmachnow, 14/09/2021 | ||
Place, date | Place, date | ||
/s/ Patrick Hoffman | /s/ Constanze Pelzer | ||
Signature | Signature | ||
Cantourage GmbH | Cantourage GmbH | ||
Managing Director | Qualified Person | ||
Johannesburg, 15/09/2021 | London, UK 15/09/2021 | ||
Place, date | Place, date | ||
/s/ Trevor Scott | /s/ Dallas Dunkley | ||
Signature | Signature | ||
Bophelo Bio Science and Wellness (Pty) Ltd | Bophelo Bio Science and Wellness (Pty) Ltd | ||
Managing Director | Quality Assurance Manager |
Page 34 of 53
Bophelo - Cantourage
Appendices:
(1) | List of Medicinal Cannabis Products, agreed specifications and test methods |
(2) | Quality Responsibilities Table |
(3) | List of Contact Persons |
(4) | Quality of Primary Packaging Material |
Page 35 of 53
Bophelo - Cantourage
APPENDIX (1)
List of contracted Medicinal Cannabis Products,
agreed specifications and test methods
(Version 01)
To the
QUALITY ASSURANCE AGREEMENT
Production and Quality Control
of Medicinal Cannabis Starting Materials
between | Cantourage GmbH |
Heinrich-Mann-Str.12 | |
14532 Kleinmachnow | |
Germany |
– hereinafter referred to as “Cantourage” –
and | Bophelo Bio Science and Wellness (Pty) Ltd |
Khoabane Mojela, | |
Ha Mojela, Ts’Akholo, Mafeteng, | |
Lesotho |
– hereinafter referred to as “BOPHELO” –
Page 36 of 53
Bophelo - Cantourage
1.1. | List of contracted Medicinal Cannabis Products |
Contracted Medicinal Cannabis Products are GACP Cannabis Starting Materials of agreed genetics (Cannabis strains).
For each single contract product, an individual specification sheet based on Annex 2 of the Supply Agreement is issued and signed by BOPHELO and submitted to Cantourage.
1.2. | List of agreed specifications and test methods |
See Annex 2 of the Supply Agreement.
For each single contract product, an individual specification sheet based on Annex 2 of the Supply Agreement is issued and signed by BOPHELO and submitted to Cantourage.
1.3. | History |
Version | Status | Changes of previous version | ||
01 | 06 / 2020 | --- |
Page 37 of 53
Bophelo - Cantourage
APPENDIX (2)
Quality Responsibilities Table
(Version 01)
To the
QUALITY ASSURANCE AGREEMENT
Production and Quality Control
of Medicinal Cannabis Starting Materials
between | Cantourage GmbH |
Heinrich-Mann-Str.12 | |
14532 Kleinmachnow | |
Germany |
– hereinafter referred to as “Cantourage” –
and | Bophelo Bio Science and Wellness (Pty) Ltd |
Khoabane Mojela, | |
Ha Mojela, Ts’Akholo, Mafeteng, | |
Lesotho |
– hereinafter referred to as “BOPHELO” –
Page 38 of 53
Bophelo - Cantourage
2.1. | Quality Responsibilities |
Responsibilities | Cantourage | BOPHELO | |
1 | Compliance Requirements | ||
1.1 | Implement procedures and/or documented training to meet obligations under this Agreement. | x | |
1.2 | Follow applicable current GACP and locally imposed requirements. | x | |
1.3 | Cultivation, harvesting, drying, packaging, testing, storage in an environment meeting the applicable regulations, which is designed, constructed and maintained in a manner that a) permits the operation therein to be performed under clean, sanitary and orderly conditions; b) permits the effective cleaning of pertinent surfaces; and c) prevents the contamination of Medical Cannabis Starting Materials and the addition of extraneous material on Medical Cannabis Starting Materials. | x | |
1.4 | Operate in compliance with applicable environmental, occupational health and safety laws and regulations. | x | |
1.5 | Maintain a quality unit that is independent of production that fulfils both quality assurance and quality control responsibilities. | x | |
1.6 | Involve the quality unit in all quality related matters and have them review and approve all quality critical related documents. | x | |
1.7 | As it relates to this Quality Agreement, notify the other party of name changes, corporate reorganization, consolidation, merger or acquisition or sale of the party’s company. Notify other party of key personnel changes. | x | x |
1.8 | Maintain internal audit program (self-inspection). | x | x |
1.9 | Further Processing of the Cannabis Starting Material according GMP Guidelines to receive Medicinal Cannabis Products of a quality as defined by related monographs of the German and European Pharmacopoeia. | x | |
1.10 | Preparation of Product Quality Review according to GMP with regard to any changes to the processes or analytical methods, results of stability monitoring, quality related returns (EU market), complaints, recalls, adequacy of corrective actions. | x | |
2 | Right to Audit | ||
2.1 | Cantourage has the right to audit BOPHELO´s facilities and systems and review documents as they relate to the manufacture of Medical Cannabis Starting Materials. Such inspections and document review shall be conducted by Cantourage at a time, date and duration mutually agreeable to BOPHELO and Cantourage. | x | |
2.2 | Cantourage retains the right to conduct reasonable “for cause” audits. Specific goals/scope of the audit, proposed dates and names of the auditors will be agreed upon mutually by Cantourage and BOPHELO. | x | |
2.3 | Cantourage provides BOPHELO with a confidential audit report summarizing audit observations. | x | |
2.4 | BOPHELO provides Cantourage with responses to all observations documented in the issued audit report in writing to Cantourage’ Quality Assurance within 30 days of receipt of the report. | x |
Page 39 of 53
Bophelo - Cantourage
Responsibilities | Cantourage | BOPHELO | |
3 | Regulatory Inspections and Exchanges | ||
3.1 | Notifies Cantourage within three business days of the receipt of a Regulatory Authority inspection report, deficiency letter or written regulatory compliance observation, which contains any significant adverse findings that relate to Medical Cannabis Starting Materials or the facilities used to produce, test or warehouse Medical Cannabis Starting Materials sold to Cantourage. A significant adverse finding is herein defined as the following: conditions, practices, or processes that adversely affect or may potentially adversely affect product or service quality and/or the rights, safety or well- being of subjects/patients and/or quality and integrity of data, documentation, or other materials or information addressed in the inspection. | x | |
4 | Complaints | ||
4.1 | Has written procedures in place to document, investigate, and respond to all quality related complaints. | x | x |
4.2 | Assists in investigations as reasonably requested by Cantourage for complaints associated with Medical Cannabis Starting Materials. | x | |
4.3 | Retains complaint investigation records and evaluate trends and severity. Implement corrective and preventive actions as necessary. | x | |
4.4 | Cantourage will evaluate all complaints and respond to the complaining side. | x | |
5 | Qualification/Validation | ||
5.1 | Follows a written qualification master plan for the facilities, equipment/instruments, and computerized systems as appropriate. | x | |
5.2 | Follows a written validation master plan for related production and testing steps. | x | |
5.3 | Qualify all necessary all critical systems and equipment used for the manufacture and control of the contracted products. | x | |
5.4 | Allow viewing the qualification/validation documentation during an onsite audit. | x | |
6 | Documents and Records | ||
6.1 | Has a controlled system to initiate, review, revise, approve, obsolete and archive all manufacturing documentation. At a minimum, all production, control, and distribution records should be retained for at least 5 year after the release of the batch. | x | |
6.2 | Has a written procedure for the review and approval of all batch documentation. | x | |
6.3 | Maintain a document control system for specifications and test methods, including product labelling, packaging materials and other materials that would likely affect product quality. | x |
Page 40 of 53
Bophelo - Cantourage
Responsibilities | Cantourage | BOPHELO | |
6.4 | Provide a complete Certificate of Analysis for the product, containing “at minimum” the following information: | x | |
Name (variety) of the material, | |||
Batch number, | |||
Package size, | |||
Manufacturing site, | |||
Harvest date, | |||
Package date, | |||
Testing site, | |||
Name of the test, | |||
Specification limit, | |||
Test result (as a numerical value, unless designated Pass/Fail in the specification limit), | |||
Testing date, | |||
Quality Assurance/Control approval and date. | |||
6.5 | Provides confirmation that the Medical Cannabis Starting Material was manufactured (cultivated, harvested, primary processed), packed and tested in accordance with GACP requirements, and was tested in accordance with and meets agreed specification. | x | |
7 | Change Control | ||
7.1 | Has established written procedures for control of changes impacting the product. | x | x |
7.2 | Notifies Cantourage within a reasonable time about changes that can affect the quality and safety of the products (called significant). | x | |
7.3 | Has significant changes reviewed and approved by its quality unit. | x | |
8 | Deviations/OOS | ||
8.1 | Has procedures for the identification, investigation of deviations and Out-of-Specification (OOS) results that occur during the manufacture and testing of Medical Cannabis Starting Materials. | x | |
8.2 | Documents and explains all deviation. Investigates OOS results and critical deviations. | x | |
8.3 | Notifies Cantourage within a reasonable time about Major and Critical deviations. Deviations are categorized as Minor, Major and Critical (depending on the quality impact on the product) according to BOPHELOs deviation SOP. | x | |
9 | Production and In-Process Controls, Packaging and Labelling | ||
9.1 | Procures, tests as required, and releases packaging and labelling materials used in manufacture of the contracted products. | x | |
9.2 | Defines specifications for product labelling and packaging materials and other materials that would likely affect product quality. | x | |
9.3 | Establish and document specifications for product labelling and packaging materials and other materials that would likely affect product quality. | x | |
9.4 | Manufactures the contracted Cannabis Starting Materials in a manner that prevents contamination by other materials including carryovers. | x | |
9.5 | Records all production steps and related in-process controls in a Batch Record. | x | |
9.6 | Releases Medical Cannabis Starting Materials by its quality unit. | x |
Page 41 of 53
Bophelo - Cantourage
Responsibilities | Cantourage | BOPHELO | |
10 | Storage and Distribution | ||
10.1 | Maintains storage facilities appropriate for conditions having no negative impact on the quality and integrity of the Medicinal Cannabis Starting Materials. Maintain records of any critical storage conditions. | x | |
10.2 | Has systems for controlling quarantined, rejected or recalled materials. | x | |
10.3 | Notifies Cantourage in a timely manner in the case of finding a quality issue post release/shipment. | x | |
10.4 | Organization and realization of transport of the contracted materials to the responsible custom site in Germany (Airport Berlin Tegel). | X | |
10.5 | Organization and realization of transport of the contracted materials after customs clearance to the contracted storage partner in Germany. | x | |
11 | Laboratory Controls | ||
11.1 | Has a written procedure for sample management, testing, approval, disposition, recording, storage, retention and disposal of laboratory data. | x | |
11.2 | Retains samples of the Cannabis Starting Materials as required by regulatory agencies. | x | x |
11.3 | Has written procedures and appropriately document the preparation, use and management of reagents, solutions, and standards for testing the Cannabis Starting Materials. | x | |
11.4 | Defines release specifications for Medicinal Cannabis Starting Materials. | x | |
11.5 | Responsible for having appropriate test procedures for Medical Cannabis Starting Materials. | x | |
11.6 | Responsible for testing the contracted materials in accordance with approved validated or qualified methods and specifications using calibrated equipment. | x | |
11.7 | Responsible for the third party laboratory testing Medical Cannabis Starting Materials in accordance with approved validated or qualified methods and specifications using calibrated equipment. | x | |
11.8 | Responsible for having a program for qualification, calibration, and preventive maintenance of all analytical equipment. | x | |
11.9 | Responsible for the third party laboratory having a program for qualification, calibration, and preventive maintenance of all analytical equipment. | x | |
11.10 | Responsible for analytical method development, qualification and/or validation as appropriate. | x | |
12 | Recalls | ||
12.1 | In the event that either Cantourage or BOPHELO determines an event or circumstances has occurred relating to the manufacture, testing or stability of the contracted materials which may result in the need for a recall, stock recovery or market withdrawal, BOPHELO and Cantourage shall consult with each other in a timely manner. The final decision to recall products from the European market shall be made by Cantourage. | x | x |
12.2 | Notification of the recall or similar action to the competent authorities and customers in Europe. | x | |
12.3 | Notification of the recall or similar action to the competent authorities and customers in Lesotho. | x |
Page 42 of 53
Bophelo - Cantourage
2.2. | History |
Version | Status | Changes of previous version |
01 | 06 / 2020 | --- |
Page 43 of 53
Bophelo - Cantourage
APPENDIX (3)
List of Contact Persons
(Version 01)
To the
QUALITY ASSURANCE AGREEMENT
Production and Quality Control
of Medicinal Cannabis Starting Material
between | Cantourage GmbH |
Heinrich-Mann-Str.12 | |
14532 Kleinmachnow | |
Germany |
– hereinafter referred to as “Cantourage” –
and | Bophelo Bio Science and Wellness (Pty) Ltd |
Khoabane Mojela, | |
Ha Mojela, Ts’Akholo, Mafeteng, | |
Lesotho |
– hereinafter referred to as “BOPHELO” –
Page 44 of 53
Bophelo - Cantourage
3.1. | List of Contact Persons at Cantourage |
Function | Name | Contact Data |
Managing Director | Philip Schetter | schetter@cantourage.com |
Qualified Person | Constanze Pelzer | pelzer@cantourage.com |
Head of Quality Assurance | Constanze Pelzer | pelzer@cantourage.com |
Head of Quality Control | Constanze Pelzer | pelzer@cantourage.com |
Head of Sales | Bernhard Retzer | retzer@cantourage.com |
3.2. | List of Contact Persons at BOPHELO |
Function | Name | Contact Data |
CEO | Tej Virk | tej@akandacorp.com |
Quality Assurance Manager | Dallas Dunkley | dallas@akandacorp.com |
CFO | Trevor Scott | trevor@akandacorp.com |
3.3. | History |
Version | Status | Changes of previous version |
01 | 06 / 2020 | --- |
Page 45 of 53
Bophelo - Cantourage
APPENDIX (4)
Quality of Primary Packaging Material
(Version 01)
To the
QUALITY ASSURANCE AGREEMENT
Production and Quality Control
of Medicinal Cannabis Starting Material
between | Cantourage GmbH |
Heinrich-Mann-Str.12 | |
14532 Kleinmachnow | |
Germany |
– hereinafter referred to as “Cantourage” –
and | Bophelo Bio Science and Wellness (Pty) Ltd |
Khoabane Mojela, | |
Ha Mojela, Ts’Akholo, Mafeteng, | |
Lesotho |
– hereinafter referred to as “BOPHELO” –
Page 46 of 53
Bophelo - Cantourage
4.1. Quality of Primary Packaging Material
Cannabis Starting Material
Part of Packaging System | Material | Quality |
Aluminium Foil Bag |
Aluminium composite film
(e.g. PET/ALU/PE) |
The product touching layer consists of Polyethylene (PE) and complies with Regulation (EU) 10/2011 incl. all changes and corrections. |
4.2. | History |
Version | Status | Changes of previous version |
01 | 06 / 2020 | --- |
Page 47 of 53
Bophelo - Cantourage
ANNEX 5
(END PRODUCTS)
Bulk Sizes
To be determined between both PARTIES following the conclusion of the contract.
Specification
Method | Specification | |
Characteristics | DAB Cannabis flos (Characteristics) | Characteristic smell |
Identity | ||
appearance | DAB Cannabis flos (Identity A) | Comply with monograph |
microscopy | DAB Cannabis flos (Identity B) | Comply with monograph |
thin layer chromatography | DAB Cannabis flos (Identity C), Ph.Eur. 2.2.27 | Comply with monograph |
Purity | ||
Foreign material | DAB Cannabis flos / Ph.Eur. 2.8.2 | Max. 2 % (m/m) |
Loss on Drying | DAB Cannabis flos / Ph.Eur. 2.2.32 | Max. 10 % |
Pesticides | Ph.Eur. 2.8.13 | Comply with Ph.Eur. 2.8.13 |
Absence of heavy metals | Ph.Eur. 2.4.27 | |
Lead | Max. 5.0 ppm | |
Mercury | Max. 0.1 ppm | |
Cadmium | Max. 1.0 ppm | |
Aflatoxin B1 | Ph.Eur. 2.8.18 | ≤ 2 ppb |
Total Ash | Ph.Eur. 2.4.16 | Max. 20 % |
Microbiological purity | Ph.Eur. 2.6.31 | Comply with Ph.Eur. 5.1.8 C |
Total aerobic microbial count (TAMC) | Max. 500.000 cfu/gram | |
Total yeast and molds count (TYMC) | Max. 50.000 cfu/gram | |
Bile- tolerant Gram negative bacteria | ≤ 104 cfu/gram | |
E. coli | Absent in 1 g | |
Salmonella | Absent in 25 g | |
Related substance | DAB Cannabis flos / Ph.Eur. 2.2.29 | |
Cannabinol (CBN) | ≤ 1.0 % | |
Assay | ||
Dronabinol (THC) | DAB Cannabis flos / Ph.Eur. 2.2.29 | Depends on product (to be defined for each product) |
Cannabidiol (CBD) | Depends on product (to be defined for each product) |
Page 48 of 53
Bophelo - Cantourage
ANNEX 6
(RAP PLUS SERVICES)
Homepage:
Creating a Homepage (English and German) that complies the legal regulations of Germany and Europe.
Content:
- | Landing Page: Background picture or animation, Company Slogan, Logo |
- | About: Company description, Company Backstory, Particularities |
- | Team: Introductions of Board and Staff members |
- | Product Information (not allowed for medical Cannabis, Extracts or substantives because of advertising ban – see DocCheck) |
- | Press: latest Press releases, Contact information of PR manager |
- | News: constant uploads of company and market news |
- | FAQ: frequently asked questions |
- | Contact us: Contact Data and possibility for visitors to leave a direct message. |
- | Terms and Conditions (mandatory) |
- | Privacy Policy (mandatory) |
- | Social Media links |
- | Newsletter sign up |
DocCheck:
Special section on the Homepage with restricted access for physicians and pharmacists only. It provides detailed information about products for target audience.
Listing at Wholesales:
An alternative sales channel to direct sales to pharmacies; in Germany. Cantourage will select appropriate wholesalers and will negotiate standard agreements with them. This includes the terms of contract, translation of contracts, stockpiling, retour handling.
Pharma Representatives:
Selection and Employment of suitable Pharma Representatives
- | Cantourage makes a suggestion of suitable representatives |
- | Cantourage educates and guides those representatives about END PRODUCTS and BOPHELO’s philosophy |
Tasks of Pharma Representative:
- | Advice and support for physicians of relevant specialization in a result-oriented manner |
- | Specialization: General practitioner, Neurologists, pain therapists, gastroenterologists, palliative care physicians |
- | Taking care of opinion makers |
- | Competent explanation and communication of complex medical matters |
Page 49 of 53
Bophelo - Cantourage
- | Well informed about product portfolio |
- | Submission of samples and information material |
- | Operating according to achievement of goals |
- | Independent area management and building customer relationships |
- | Implementation of specified communication and product strategies and the further development of those |
- | Evaluation of market data (observation of market and competitive developments) |
- | Regular reporting |
- | Participation in congresses, trainings, and further education |
Qualification and Profile of our Pharma Representatives:
- | Certified pharmaceutical representative in accordance with § 75 AMG |
- | Most of your Representatives have several years of experience |
- | Already existing network of physicians and pharmacists |
- | Marketing and sales-oriented way of thinking and working |
- | Well-versed in common office software |
- | Excellent command of German and English |
Education Program:
Event for physicians and pharmacists about medical cannabis
- | Elaborate education program |
- | Placing products as one alternative treatment option |
- | Case studies of patients and treatments |
- | Being named as sponsor for a training event |
- | Having a stand close to the event premises |
Press announcements:
- | Drafting of press announcement in accordance with local law and alignment with BOPHELO |
- | Selection of targeted group of recipients (few hundreds to thousands) of relevant press, especially in medicinal field. |
- | Analysis of spread/success |
- | Follow up on requests and alignment with BOPHELO (e.g. interviews, stories on client company etc.) |
- | Following announcements for additional products or similar updates |
Press announcement in German and in English and client national language
Page 50 of 53
Bophelo - Cantourage
Info material:
Professional information material for physicians and pharmacists on END PRODUCT details
- | Generating a small brochure with the necessary information about all END PRODUCTS |
- | Generating a big brochure with all information and details about END PRODUCTS, company and other relevant information |
- | Creating product flyers for physicians and pharmacists |
- | Compilation of a welcome book |
Newsletter:
Monthly newsletter on company and product news
- | Monthly newsletter with all company and product updates |
- | Weekly newsletter with all company and product news |
- | Translating existing Newsletter in German or English |
Advertisement in Journals:
Spreading product and company information through physician and pharmacist magazines and journals
- | Half page Article |
- | Full page article |
- | Small advertisement |
- | Big advertisement |
Social Media:
- | Translating existing social media posts |
- | Creating Post on existing accounts for | |
o |
o |
o |
o |
- | Creating Accounts “Europe”-Accounts on | |
o |
o |
o |
o | ||
▪ | Uploading Posts monthly |
▪ | Uploading Posts weekly |
▪ | Uploading Posts daily |
Page 51 of 53
Bophelo - Cantourage
Brand protection:
We register BOPHELO’s brands name and protect it against misuse by third parties.
- | Protection of the company name in Germany |
- | Protection of the company name throughout Europe |
Release Event
- | Get together with important and influential guest of the German medical cannabis industry (high prescribers, pharmacists and influencers). Cantourage organizes the whole event management incl. (location, invitations, entertainment program, drinks, snacks, etc.) |
Page 52 of 53
Bophelo - Cantourage
ANNEX 7
(BRANDS, LABELLING)
To be determined by Bophelo following the conclusion of the contract.
Page 53 of 53
Exhibit 10.11
Heads of Terms
Between:
Akand Corp. (“Akanda")
1a,1b Learoyd Road, New Romney, TN28 8XU, United Kingdom
Cellen Limited (“Cellen“ or “the Company”)
{insert address}
Bridge Loan Facility
These heads of terms set out the main terms and conditions on and subject to which Akanda will provide Cellen with a line of credit subject to meeting the criteria set out herein (the “Bridge Loan Facility”).
These heads of terms are not exhaustive, and it is intended that the parties will enter into more detailed agreements, which will be negotiated in good faith following execution of these heads of terms and as described herein, but these heads of terms are intended to be legally binding between the parties, save as expressly set out herein.
The parties acknowledge that they have, on or around 5 October 2021, entered into a conditional, non-binding agreement regarding the acquisition by Akanda of 100% of the issued and outstanding share capital of Cellen (the “Proposed Acquisition”). The purpose of the Bridge Loan Facility is to assist Cellen in funding its business expenses and working capital requirements in anticipation of the Proposed Acquisition. The parties’ obligations are now as set out in these heads of terms.
1. LINE OF CREDIT
Akanda will arrange to lend to Cellen the sum of not more than US$500,000.00 in the form of a line of credit (the “LOC”) and on the following terms appropriate to such a facility:
a. | The LOC to be made within 30 days of signature by all parties of these heads of terms (“Effective Date”); |
b. | Requests to draw down upon the LOC are to be made by Cellen in the form of a Drawdown Notice. Each Drawdown Notice shall, at a minimum, have the minimum content: |
i. | acknowledgement that the request is made pursuant to the Bridge Loan Facility as set out in these heads of terms; |
ii. | the proposed draw down date (minimum notice period of 2 (two) business days); |
iii. | the proposed draw down amount in USD and GBP, including the applicable rate of exchange; |
iv. | the bank details for which the proceeds of the proposed draw down should be credited; |
v. | acknowledgement that the draw down is irrevocable; and |
vi. | details of the person authorised to make the draw down request. |
1
c. | Draw down requests should be made for operating expenses and working capital requirements in the ordinary course of business for a period not exceeding more than 30 (thirty) days. Any draw down requests in relation to funding earmarked for expenses or transactions out of the ordinary course of business; or for working capital requirements exceeding a 30 (thirty) day period shall be made at the discretion of Akanda. |
d. | The proceeds of the LOC shall not be used to make any payments to any director, officer, shareholder or related party of Cellen without the prior approval of Akanda, acting in its sole discretion; |
e. | Amounts borrowed under the Bridge Loan Facility shall bear interest at a rate of 5% per annum, compounded on a monthly basis. Interest will be calculated and shall accrue on a monthly basis, and shall be based on the closing outstanding balance of Bridge Loan Facility at the end of each month; |
f. | Amounts borrowed under the Bridge Loan Facility are to be secured by a first charge and debenture on all of the Company’s assets, and a first charge over the shares of the Company held by its existing shareholders; |
g. | The total amount borrowed under the Bridge Loan Facility shall be repaid by no later than 31 December 2022; |
h. | Akanda shall have the option to convert any amounts borrowed under the Bridge Loan Facility into ordinary shares or preference shares of the Company at a valuation of the Company as determined by an independent firm of chartered accountants as may be selected by Akanda. |
i. | The parties will enter into a formal bridge loan facility agreement. |
2. CONDITIONS PRECEDENT
The obligations of the parties to implement the Bridge Loan Facility are subject to:
i. | Cellen delivering to Akanda, copies of written resolutions of its board of directors, and its shareholders, approving the Bridge Loan Facility; |
ii. | Cellen delivering to Akanda, its latest management accounts including (but not limited to) a statement of financial performance, a statement of financial position, a statement of cash flow, as well as a detailed month-by-month budget for the period commencing 1 December 2021 through to 31 December 2022. |
3. COVENANTS
3.1 Conduct of Business
Cellen covenants to Akanda that, for the duration of the period that it has borrowed under the Bridge Loan Facility, it shall conduct its business in the ordinary course, consistent with past practice and shall use its commercially reasonable efforts to preserve its assets and the existing goodwill and contract of its customers, suppliers, vendors, service providers, personnel and others having business relations with it.
Cellen further covenants to Akanda that it shall not dispose of any major or significant part of its business, or significantly change its business strategy for the duration of the period that it has borrowed under the Bridge Loan Facility.
3.2 Notice of Certain Events
Cellen covenants to Akanda that, for the duration of the period that it has borrowed under the Bridge Loan Facility, it shall promptly notify Akanda in writing of any events, circumstances, facts, or occurrences that would materially:
i. | affect the Company’s ability to repay amounts borrowed under the Bridge Loan Facility; |
ii. | affect its valuation; |
iii. | result in a change of shareholding exceeding 10% of the issued and outstanding share capital prior to the commencement of any transaction resulting in a change of shareholding; and |
iv. | affect the Company’s ability to operate. |
2
4. REPRESENTATIONS AND WARRANTIES
Cellen represents and warrants to Akanda as follows:
i. | it is a properly incorporated legal entity, validly existing and in good standing under the laws of England and Wales; |
ii. | it has proper standing and is able to enter into and perform its obligations under these heads of terms; |
iii. | it is not aware of any litigation or claims, threatened or otherwise, that may be pending against it; |
iv. | no consents or approvals from any applicable government authority are required in connection with the execution and delivery of these heads of terms; |
v. | there are no material factors, events, circumstances or happenings that would adversely affect Cellen’s valuation, solvency and ability to undertake its operations that it has not disclosed to Akanda; |
vi. | there are no secured borrowings which would affect Akanda’s ability to perfect its security as contemplated in these heads of terms. |
5. CONFIDENTIALITY
The content of these heads of terms is confidential to the parties. No party may disclose anything contained herein to any third-party, including the existence of this agreement, without the express written consent of the other party.
6. COSTS
The parties will pay their own costs and expenses incurred in connection with the Bridge Loan Facility whether or not it proceeds to Completion, including (without limitation) any costs and expenses relating to the preparation and negotiation of these heads of terms and any other documents contemplated by them.
7. GOVERNING LAW AND JURISDICTION
These heads of terms and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with them or their subject matter or formation shall be governed by and construed in accordance with the law of England and Wales.
Akanda and Cellen irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with these heads of terms or their subject matter or formation. The parties hereto further also irrevocably waive any conflict of law or further legal procedures in the execution of any court order or settlement reached, in their country of residence or operations.
These heads of terms may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all counterparts together shall constitute a single agreement.
Please sign and return the enclosed copy of these heads of terms as soon as possible to confirm your agreement to the above.
3
We confirm our agreement to the above heads of terms. | ||
Signed | ||
For and on behalf of Akanda Corp. | ||
Date | ||
Signed | ||
For and on behalf of Cellen Ltd. | ||
Date |
4
Exhibit 10.12
Service agreement
Dated: 24 January 2022
Canmart Limited
(Company)
Akanda Corp.
(Akanda)
Louisa Mojela
(Executive)
Contents
This agreement is dated 24 January 2022.
Between
(1) | Canmart Ltd a company incorporated and registered in England and Wales with registered company number 11741517 and whose registered office is at Units 1a/1b Learoyd Road, New Romney, Kent TN28 8XU (the Company); |
(2) | Akanda Corp. a company incorporated and registered in Ontario, Canada with a registered company number 002854618 and whose registered office is 77 King Street West, Suite 400 Toronto-Dominion Centre Toronto, ON M5K 0A1 Canada; and |
(3) | Louisa Mojela (the Executive). |
It is agreed:
1 | Interpretation |
1.1 | In this agreement the following terms and expressions shall have the following meanings: |
Akanda means Akanda Corporation, Registration number 002854618, Province of Ontario.
Appointment means the employment of the Executive by the Company on the terms of this agreement.
Board means the board of directors of the Company and any committees duly constituted by the board.
Capacity means as agent, consultant, director, the holder of any office, employee, worker, owner, partner, Shareholder or in any other capacity.
Cash Shell Company means any undertaking (including a special purpose acquisition company) (a) which is listed/quoted or becomes listed/quoted on a Recognised Investment Exchange and (b) of which the Company is or becomes a wholly-owned subsidiary, but excluding for the avoidance of doubt Halo Labs Inc.
Control means in relation to a body corporate, the power of a person to secure that the affairs of the body corporate are conducted in accordance with the wishes of that person:
(a) | by means of the holding of shares, or the possession of voting power, in or in relation to that or any other body corporate; or |
(b) | as a result of any powers conferred by the articles of association or any other document regulating that or any other body corporate. |
Change of Control occurs if a person (whether alone or together with any person acting in concert with that person) who controls any body corporate ceases to do so or if another person acquires Control of it.
Commencement Date means 1 July 2021.
Competitor means a business concern which is, or intends to be, in competition with any Restricted Business.
Page 1
Confidential Information means information of a confidential nature (in any form) concerning the business, affairs and/or finances of the Company or any Group Company or their respective customers, clients, suppliers, agents, distributors, investors and shareholders which the Executive receives, obtains, creates or develops at any time by reason of or in connection with the Executive's service with the Company or any Group Company (whether or not marked as confidential). This includes: trade secrets; technical information, data, research and development; customer, client and supplier lists, contact details of customers, clients and suppliers and individuals within those organisations; inventions and patent applications in the course of preparation and all other Intellectual Property Rights; financial projections, target details and accounts; details of funding and resource allocation; fee levels, pricing policies, commissions and commission charges; budgets, forecasts, reports, records and corporate and business plans; planned or potential products and services; marketing and advertising plans, requirements and materials, marketing surveys and research reports; market share and pricing statistics; disputes (whether existing, threatened or prior), settlement discussions and terms; details of employees, workers, officers and consultants including their roles and responsibilities, remuneration, benefits and organisational structures, legally privileged material; computer software and passwords.
Copies means copies or records of any Confidential Information in whatever form (including in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) including extracts, analysis, studies, plans, compilations or any other way of representing or recording and recalling information which contains, reflects or is derived or generated from Confidential Information.
Executive Equity has the meaning given to it in Clause 12.
Executive Equity Rights means the rights to be granted to the Executive as set out and materially on the terms described in Schedule 1.
Garden Leave means any period during which the Company has exercised its rights under Clause 22.
Group Company means any company which is from time to time a subsidiary or holding company of the Company and any subsidiary of any holding company of the Company (and references to the Group shall be construed accordingly), including but not limited to Akanda. The words "subsidiary" and "holding company" have the meanings given to them in section 1159 of the Companies Act 2006 and a person shall be treated, for the purposes only of the membership requirement contained in subsections 1159(1)(b) and (c) of that Act, as a member of another company even if its shares in that other company are registered in the name of: (i) another person (or its nominee), whether by way of security or in connection with the taking of security, or (ii) a nominee.
Halo means Halo Labs, Inc. a company incorporated in Canada whose registered office is 77 King Street West, Suite 400, Toronto-Dominion Centre, Toronto, Ontario, Canada.
Holiday Year means 1 January to 31 December or such other period as the Company notifies the Executive in writing.
Incapacity means any sickness, injury or other incapacity or medical disorder or condition which prevents the Executive from carrying out her duties.
Page 2
Intellectual Property Rights means patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.
Invention means any invention, idea, discovery, development, improvement or innovation, whether or not patentable or capable of registration, and whether or not recorded in any medium.
Investor means any person, firm, company or other entity who or which is an investor in the Company or any Group Company at the Termination Date or who or which invested in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible investment in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Lender means any person, firm, company or other entity who or which is a lender of funds to the Company or any Group Company at the Termination Date or who or which lent funds to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible lending to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Listing means the admission, approved by the Board, of the entire issued share capital of the Company or a Cash Shell Company, or securities representing those shares (including without limitation depositary interests, American depositary receipts, American depositary shares and/or other instruments) on a Recognised Investment Exchange.
Long Stop Date means the date falling 12 months from the date of this agreement.
Personal Data means personal data about or relating to the Executive including her name, date of birth, home address, telephone number, driver's licence number, passport number, family information (such as marital status and dependant details), emergency contact information, education and training details (such as qualifications and professional expertise), employment details (such as employment status, employee type, performance and evaluation information, work phone number and email, intranet user log in and department and supervisor details), financial information (such as compensation, benefits, bank account information and pensions information) and hiring information (such as CV, prior employment history and personal references).
Policies and Procedures means the policies and procedures of the Company applicable to employees and officers of the Company as amended from time to time.
Prospective Customer means any firm, company or person who, during the 12 months before the Termination Date, was in negotiations with the Company or any Group Company about becoming a customer of the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of her duties or responsibilities, about whom she became aware or informed to a material extent in the course of the Appointment.
Page 3
Qualifying Equity Finance means a bona fide transaction (or series of transactions, provided that the type of share issued and the price paid per share is consistent across the series of transactions), approved by the Board, with the principal purpose of raising capital, pursuant to which the Company (or a Cash Shell Company) issues equity shares (but excluding any equity shares issued on conversion of any convertible securities or any equity securities issued to Halo) with an aggregate subscription price of not less than £10,000,000.
Recognised Investment Exchange means NASDAQ, the New York Stock Exchange, the Official List of the United Kingdom Listing Authority, the AIM Market operated by the London Stock Exchange Group Plc, the Toronto Stock Exchange, the NEO Exchange or the TSX Venture Exchange or any other recognised investment exchange (as defined in section 285 of the Financial Services and Markets Act 2000).
Regulatory Requirements means all legal and regulatory obligations, codes of practice and recommendations and similar which apply to the Executive, the Company or any Group Company, including:
(a) | in relation to transactions in securities, related party transactions and inside information (including any share dealing policy of the Company); |
(b) | pursuant to the Financial Services and Markets Act 2000 and the Criminal Justice Act 1993; and |
(c) | any other laws, rules and regulations of, or applicable to companies admitted to, a Recognised Investment Exchange on which the Company (or a Cash Shell Company) is Listed, |
Restricted Business means those parts of the business of the Company and any Group Company with which the Executive was involved to a material extent in the 12 months before the Termination Date.
Restricted Customer means any firm, company or person who, during the 12 months before the Termination Date, was a customer of or in the habit of dealing with the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of her duties or responsibilities, about whom she became aware or informed to a material extent in the course of the Appointment.
Restricted Person means anyone employed or engaged by the Company or any Group Company with whom the Executive dealt in the 12 months before the Termination Date in the course of the Appointment.
Restricted Supplier means any person, firm or company which at any time during the 12 months prior to the Termination Date was a supplier of any goods, products or services (other than utilities and goods or services supplied for administrative purposes) to the Company or any Group Company and with whom or which the Executive had personal dealings during that period other than in a de minimis way and where such entities remain suppliers of the Company and/or the Group Company at or immediately before the Termination Date.
Page 4
Shareholder means holding an investment by way of shares or other securities of over 5% of the total issued share capital of any company, other than a Cash Shell Company, whether or not it is listed or dealt in on a recognised stock exchange.
Termination Date means the date on which the Executive's employment with the Company terminates however caused.
1.2 | The headings in this agreement are inserted for convenience only and shall not affect its construction. |
1.3 | A reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension or re-enactment and includes any subordinate legislation for the time being in force made under it. |
1.4 | Unless the context otherwise requires: |
1.4.1 | a reference to one gender shall include a reference to the other genders; and |
1.4.2 | words in the singular include the plural and in the plural include the singular. |
1.5 | References to a "person" include any individual, company, any other body corporate, partnership or unincorporated association (whether or not having separate legal personality). |
1.6 | The words "including", "include", "in particular", "for example" and words of similar effect shall not limit the general effect of the words that precede them. |
2 | Employment |
2.1 | The Executive agrees to serve Akanda as Executive Chairperson subject to the terms and conditions of this agreement. It is envisaged that the Company will be subject to a reverse takeover and there will be a Listing. Accordingly, the terms of this agreement may require amendments to comply with any applicable Regulatory Requirements and if so, the Executive will be paid a cash sum equivalent to any amounts (including benefits) that she is entitled to under this agreement that are not included in the amended agreement. |
2.2 | The Executive's employment will commence on the Commencement Date and shall continue, subject to the remaining terms of this agreement, until terminated by either party giving the other not less than 6 months prior written notice, save that the Company can only give notice after 18 months following the Commencement Date (except that this limitation shall not apply in respect of termination rights under Clause 21.1(a), (c) or (g)). If the Company does give notice sooner, the amount of Basic Salary and contractual benefits that the Executive would otherwise have been entitled to up to the first day on which termination could have been effective in accordance with this clause will be paid to the Executive as a lump sum within 28 days of the Termination Date. For the avoidance of doubt, nothing in this Clause 2.2 shall prevent or limit the Company's right to terminate this agreement without notice and without payment for any Basic Salary and contractual benefits for any reason that falls within Clause 21.1(a), (c) or (g). |
2.3 | No period of employment with the Company or any other employer counts towards the period of continuous employment between the Executive and the Company which therefore will begin on the Commencement Date. Past service with any Group Company will count towards any employment or service measurement period in respect of any leave benefit, Executive Equity and employee share ownership incentive award that is issued under an approved employee share ownership incentive plan. |
Page 5
2.4 | The parties acknowledge and agree that the Company intends to pursue a Listing, either directly or via a Cash Shell Company, and that as part of that process the Company's advisers (including its brokers) may require certain terms of this Agreement to be varied, amended or deleted. The parties agree that they will act reasonably in agreeing any such variations, amendments or deletions and the Executive agrees that (without limitation) the following provisions, amendments or variations, if required or reasonably requested by the Company (on the advice of its brokers) pursuant to such Listing, will be acceptable: |
(a) | any lock-in and/or orderly market restrictions on market-standard terms (where, in respect of the length of any such restriction, "market-standard" means no longer than two years in respect of each of any lock-in and any orderly market restriction); |
(b) | the Executive ceasing to be entitled to any or all of the Executive Equity Rights; and |
(c) | a vesting, or reverse vesting, period of up to four years and otherwise on market-standard terms, |
and the Executive agrees that she will take all action reasonably necessary to give effect to any such amendments, variations or deletions. For the avoidance of doubt, under no circumstances shall the Executive be required to surrender or otherwise lose the ownership of whole or any part of the Executive Equity pursuant to this Clause 2.4.
3 | Conditions to employment |
3.1 | The Company shall take appropriate professional advice as to the best way in which to achieve the proposed Listing of the business operated or proposed to be operated by it. If, following such advice, the Board decides that it would be in the best interests of the Company and its members as a whole to achieve a Listing via a Cash Shall Company then, before the Long Stop Date, the Company will: |
(a) | establish or acquire or be acquired by a Cash Shell Company; |
(b) | in respect thereof and subject always to Clause 2.4, grant the Executive the Executive Equity; and |
(c) | at the Executive’s election and in her sole discretion, transfer her engagement as Executive Chairperson to the Cash Shell Company, |
(together, the Conditions Subsequent).
3.2 | In the event that the Conditions Subsequent have not been satisfied by the Long Stop Date and such non-satisfaction is predominantly or primarily the result of either or both of (a) some action or inaction by or on behalf of Halo and/or (b) another factor or factors beyond the reasonable control of the Executive, the parties shall, in good faith, use reasonable endeavours to grant equity interests in Halo (or the Company if it is directly subject to a Listing) to the Executive that give the Executive an approximately equivalent monetary valuation as would have been held by her in a Cash Shell Company that held the businesses of Cannahealth, Canmart and Bophelo only, pursuant to the terms of this Agreement. |
Page 6
4 | Fundamental terms and warranties |
4.1 | The Executive represents and warrants to the Company that (in each case as a fundamental term of this agreement): |
(a) | the Executive is, to the best of her knowledge, not subject to any restrictions which prevent the Executive from holding office as a director; |
(b) | by entering into this agreement or fully performing any of the Executive's obligations under it, the Executive will not be in breach of any court order or any express or implied terms of any contract or other obligation binding on the Executive; and |
(c) | the Executive has not used or disclosed to the Company or any Group Company any confidential information belonging to any previous employer or any other person. |
4.2 | Notwithstanding (and without prejudice to) any other provision of this agreement, the Company may terminate this agreement summarily if the Executive is in breach of any of the terms and/or warranties in this Clause 4. |
5 | Duties |
5.1 | The Executive acknowledges that she will be a fiduciary in a position of seniority and trust. |
5.2 | At all times during the course of employment the Executive will: |
(a) | faithfully and diligently serve Akanda, the Company and the Group, and exercise such powers and perform such duties as may from time to time be assigned to the Executive by Akanda or the Board or perform such other duties as the Company may reasonably require; |
(b) | devote the whole of the Executive's working time, attention and abilities to the business and affairs of Akanda, the Company and the Group; |
(c) | comply with all reasonable directions of and regulations made by Akanda, the Company and the Board; |
(d) | promptly make such reports to Akanda and the Board in connection with the affairs of Akanda, the Company and of any Group Company on such matters and at such times as are reasonably required, and otherwise keep Akanda and the Board fully informed of all matters relating to the business and affairs of Akanda, the Company and the Group; |
(e) | immediately upon becoming aware, report: |
(i) | any wrongdoing (including the Executive's own wrongdoing) whether committed, contemplated or discussed by any person employed or engaged by Akanda, the Company or any Group Company irrespective of whether this would or may involve self-incrimination; |
(ii) | any plans or proposals or discussions by any person employed or engaged by Akanda as a senior executive or as a senior member of management of, the Company or any Group Company to leave the employment or engagement of the Company or Group Company, whether alone or in concert with any other person and whether to join a competitor or any other business; and |
Page 7
(iii) | any misuse of Confidential Information by any person (including the Executive) irrespective of whether this would or may involve self-incrimination; |
(f) | use all reasonable endeavours to promote, protect, develop and extend the business of Akanda, the Company and Group Companies; |
(g) | comply with all Policies and Procedures; |
(h) | comply with all Regulatory Requirements and promptly provide Akanda, the Company with all information that it requires or may require to comply with the Regulatory Requirements; and |
(i) | not: |
(i) | offer, promise or provide any bribe, inducement or reward to any third party in order to gain any commercial, contractual, regulatory or personal advantage; |
(ii) | receive or accept any bribe, inducement or reward from any third party in order to gain any commercial, contractual, regulatory or personal advantage; or |
(iii) | receive any gifts, goods, service, rebates or commission from any third party other than in accordance with Akanda or Company policy from time to time in force. |
5.3 | The Executive agrees and accepts that: |
(a) | the Policies and Procedures do not form part of this agreement or the terms of the Executive's employment and the Company may amend the Policies and Procedures at any time; and |
(b) | a breach of the Regulatory Requirements may lead to civil or criminal liability for the Executive, action being taken against the Executive by any relevant regulatory authority and/or disciplinary action by the Company up to and including summary dismissal if the Executive's conduct falls within the categories in Clause 21.1. |
6 | Place of work |
6.1 | The normal place of work of the Executive is Lesotho and Johannesburg (or such other place as agreed by the parties) or any other place as the Company may reasonably require for the proper performance and exercise of the Executive's duties. |
6.2 | The Executive will be required to travel in appropriate circumstances on the business of the Company and the Group (to the United Kingdom, Malta and/or abroad). |
7 | Hours of work |
7.1 | The Executive's normal hours of work are from 8.30am to 5:30pm Monday to Friday, inclusive of one hour for lunch daily, and such additional hours as may be necessary for the proper performance of the Executive's duties. The Executive is not entitled to any further remuneration for additional hours outside normal office hours. |
7.2 | The parties agree that the nature of the Executive's position is such that the Executive's working time cannot be measured and, accordingly, the Executive's employment falls within the scope of regulation 20 of the Working Time Regulations 1998. |
Page 8
8 | Salary |
8.1 | The Executive will be paid an annual salary of £400,000 (Basic Salary) subject to applicable deductions as required by any local laws including for tax and social security. |
8.2 | The Basic Salary will be paid in equal monthly instalments (or pro rata where the Executive is only employed during part of a month) in arrears to the Executive's nominated bank account in Lesotho, or any other bank account in any location designated by the Executive in her sole discretion. For convenience, payment will usually be slightly in advance of the end of the calendar month to which the payment relates. |
8.3 | The Executive authorises the Company to deduct (and retain) from the Basic Salary, or any other sum due to the Executive at any time, any mutually agreed sum due to the Company or any Group Company from the Executive. |
8.4 | Further to the Executive’s Basic Salary, the Executive shall be entitled to a further amount of £100,000 per annum in deferred compensation (Deferred Compensation); which shall be settled in arrears on the six-month anniversary of the Commencement Date. Deferred Compensation shall be settled on behalf of the Company by Akanda through an issue of an equity award, which shall be comprised of Akanda common shares, share options, or restricted share units or similar, or a combination thereof. Should Akanda be listed on a Recognised Investment Exchange, then the equity awards due in terms of this clause shall be issued at the 30-day volume weighed average price of Akanda’s ruling price of Akanda’s trading securities. In the event that Akanda is not listed on a Recognise dInvestment Exchange, then the equity awards due in terms of this clause shall be issued at a price not less than the price per share achieved by Akanda in its most recent financing, provided that such a financing is not for a gross total amount less than USD $1 million, The Deferred Compensation arrangement is at the election of the Executive, who shall have the right, acting in her sole discretion, to convert the Deferred Compensation arrangement to a Basic Salary to be settled by way of a cash payment. |
9 | Pension |
The Company will comply with the employer pension duties in accordance with Part 1 of the Pension Act 2008.
10 | Expenses |
Subject to any Company policy in operation from time to time and to production of VAT receipts or other appropriate evidence to the reasonable satisfaction of the Company, the Company will reimburse (or procure the reimbursement of) all reasonable expenses wholly, properly and necessarily incurred by the Executive in the performance of the Executive's duties.
11 | Incentive payments & bonus |
11.1 | Subject to Clause 11.7, on a Listing, the Executive shall be entitled to receive an incentive payment of £200,000, which shall be paid on or around the payroll in the subsequent month following the Listing. |
11.2 | Subject to Clause 11.7, on completion of a Qualifying Equity Finance, the Executive shall be entitled to receive an incentive payment of £200,000, which shall be paid on or around the payroll in the month following receipt by the Company of the Qualifying Equity Finance. |
Page 9
11.3 | Subject to Clause 11.7, on a Listing and on Completion of the Qualifying Equity Finance, the Executive shall be entitled to receive a further amount of £100,000 in Deferred Compensation, to be settled on behalf of the Company by Akanda through an issue of an equity award, which shall be comprised of Akanda common shares, share options, or restricted share units or similar, or a combination thereof. The settlement of the Deferred Compensation contemplated in this clause 11.3 shall be made no later than six months following the payments made in terms of clause 11.1 and 11.2 of this Agreement. Equity awards due in terms of this clause shall be issued at the 30-day volume weighed average price of Akanda’s ruling price of Akanda’s trading securities, The Deferred Compensation arrangement is at the election of the Executive, who shall have the right, acting in her sole discretion, to convert the Deferred Compensation arrangement to an incentive payment be settled by way of a cash payment. |
11.4 | The Executive is entitled to participate in the Company's bonus scheme with an annual bonus opportunity of: |
(a) | up to 100% of Basic Salary based on meeting achievable KPIs as determined by the Board using its reasonable discretion on or around the beginning of each financial year; and |
(b) | an additional bonus opportunity based on achievable stretch targets which is to be determined by the Board using its reasonable discretion. |
11.5 | The Board may award any such bonus in cash, equity or such other instrument or arrangement with the Company undertaking that it will act reasonably in making any such award in a way which is tax efficient and cost effective for the Executive. |
11.6 | Any bonus made pursuant to Clause 11.3 may, at the Board's absolute discretion, be reduced pro rata by reference to any period for which the Executive has been absent from work for any reason during the period to which the bonus relates. |
11.7 | Other than as provided in this clause, the Executive will not be entitled to compensation for loss of bonus (whether pursuant to this Clause 11 or otherwise) on termination of employment. Payment of a bonus in one year will not entitle the Executive to a bonus in any other year. Should the Executive’s employment be terminated for any reason other than as set out in clause 21.1 of this Agreement, then the Executive shall be entitled to a partial bonus determined on a pro-rata basis with reference to the number of months of service provided in the current financial year or bonus measurement period. |
11.8 | Payment of any incentive payment or bonus under this Clause 11 will be conditional on: |
(a) | notice not having been served by the Executive; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct (in which case payment of any incentive or bonus will be postponed pending the final outcome of that disciplinary procedure save where the procedure results in dismissal in which case no incentive or bonus shall be payable); and/or |
(c) | the Executive not having committed a repudiatory breach of this agreement; |
in each case, as at the payment date.
11.9 | If any payment or other obligation under this agreement or any related benefit or remuneration plan does not comply with any applicable Regulatory Requirement, the Company may, by mutual agreement with the Executive, amend the terms of the payment or other obligation (including by reducing, revoking, cancelling or recovering any payment or award) to make it compliant. |
Page 10
11.10 | Any payments under this Clause 11 will be subject to applicable deductions for tax and National Insurance (excluding employer National Insurance contributions) and will not be pensionable. |
12 | Shares |
12.1 | If the Board considers it likely that a Cash Shell Company will acquire Control of the Company, the Company shall procure that the Executive is granted an award of an equity interest in the Cash Shell Company (which could be a subscription/award of shares or share options, depending on the taxation implications for both the Company and the Executive, with the Company undertaking that it will act reasonably in procuring the offer of an incentive structure at its own cost which is tax efficient and cost effective for the Executive provided there are no adverse consequences for the Company or the Cash Shell Company) (the Executive Equity). |
12.2 | The Executive Equity is intended to represent 10% of the issued share capital of the Cash Shell Company before the Cash Shell Company acquires the Company or any other company or business, and/or issues equity to participants in a placing or public offering to occur on or around the date of Listing, when, pursuant to each of such events, the percentage equity interest held by the Executive will be diluted in accordance with the terms of such transactions. |
12.3 | Subject always to Clause 2.4, the Executive Equity will be subject to monthly vesting (or reverse vesting if shares are awarded) over a three year period, with a one year vesting cliff (33.3% vesting 12 months after date of grant of the award), and will be subject to customary good leaver, intermediate leaver and bad leaver conditions. |
12.4 | In the event that there is a Change of Control of the Company or Cash Shell Company (other than as part of the fundraising on or around the date of Listing or an internal re-organisation) after the date falling 12 months after the date of the grant of Executive Equity and before the end of the three year vesting period (or such other period as required in accordance with Clause 2.4), and the Executive is an employee of the Company (or the Cash Shell Company as the case may be) at such time, it is agreed that vesting of the Executive Equity will automatically be accelerated immediately prior to such Change of Control. |
12.5 | The Executive's participation in the Executive Equity shall be determined by the applicable rules (or other documents) of the scheme to be implemented. |
12.6 | In the event a Cash Shell Company does not acquire Control of the Company, the Company and the Executive will both act in good faith to agree an alternative incentive arrangement to that referred to in Clause 12.1 above and, if applicable, Clause 3.2. |
13 | Other benefits and paid leave |
13.1 | The Company will endeavour to put in place a private medical insurance scheme as soon as reasonably practicable after the Commencement Date. The Executive, her spouse and dependents shall be entitled to participate in such scheme. |
13.2 | The Executive's rights and entitlements and the Company's obligations to pay premiums for the private medical insurance scheme shall be subject always to: |
(a) | the rules and terms of such scheme from time to time in force; |
Page 11
(b) | the Company's absolute discretion to change scheme and/or scheme provider and/or to discontinue providing the benefit at any time; |
(c) | the Executive satisfying any underwriting or other requirements of the relevant scheme provider; and |
(d) | the Executive co-operating with the Company and the relevant scheme provider when making any claim. |
13.3 | The Executive agrees that: |
(a) | the Company shall have no obligation to pursue any claim for benefits on behalf of the Executive or the Executive's spouse or dependants or any other beneficiaries or potential beneficiaries if it is not accepted by the scheme provider; |
(b) | the Company will have no liability to the Executive or the Executive's spouse or dependants for failure or refusal by the scheme provider for whatever reason to pay benefits or for cessation of benefits on the termination of the Executive's employment and the Company is entitled to terminate the Executive's employment notwithstanding the fact that the Executive may lose entitlement to benefits under these arrangements as a result; |
(c) | The Executive is not contractually entitled to any benefit she receives which is not expressly referred to in this agreement (whether payment of insurance scheme premiums or otherwise). |
13.4 | The Executive may be eligible to take the following types of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules applicable to each type of leave in force from time to time: |
(a) | statutory maternity leave; |
(b) | family responsibility leave; |
(c) | statutory adoption leave; |
(d) | shared parental leave; and |
(e) | parental bereavement leave. |
14 | Training |
In addition to general training the Company provides during the Executive's induction and throughout her employment, the Company will specify certain mandatory training modules from time to time. These cover matters that are essential for working for the Company, or for the Executive's role. The subject matter will vary from time to time and the Company will update the Executive on the requirements. Details of the current compliance training that is mandatory for all employees are available on the intranet.
15 | Holidays |
15.1 | The Executive will be entitled to 30 days' paid holiday in each Holiday Year in addition to the usual public holidays in the Republic of South Africa and/or the Kingdom of Lesotho. The first 28 days of holiday (including any public holidays) taken in any Holiday Year will be the Executive's statutory holiday for the purpose of both the Working Time Regulations 1998 and Clause 15.6 below |
Page 12
15.2 | If the Executive's employment commences or terminates part way through a Holiday Year, the entitlement of the Executive during that Holiday Year shall be calculated on a pro rata basis rounded up to the nearest half day. |
15.3 | Holidays shall be taken at such time or times as shall be approved in advance by the Company. The Company may require the Executive to take holiday on particular dates. |
15.4 | The Executive will be entitled to carry over up to 5 days' holiday at the end of each Holiday Year provided that the Executive uses that holiday by 31 March in the following Holiday Year (all other holiday remaining at the end of the Holiday Year will lapse). Any carried over holiday not used by that date will lapse. |
15.5 | The Executive shall have no entitlement to any payment in lieu of accrued but untaken holiday except on termination of the Executive's employment. Subject to Clause 15.6, the amount of any payment in lieu will be 1/260th of the Executive’s Basic Salary for each untaken day of holiday entitlement for the Holiday Year in which termination takes place. |
15.6 | If: |
(a) | the Company has terminated or would have been entitled to terminate the Executive's employment under Clause 21; or |
(b) | the Executive terminates in breach of this agreement, |
any payment due under Clause 15.5 will be limited to the statutory entitlement of the Executive under the Working Time Regulations 1998 (and any holiday (including public holidays) taken shall be deemed first to have been taken in satisfaction of that statutory entitlement as set out in Clause 15.1).
15.7 | If on termination of the Executive's employment the Executive has taken in excess of her accrued holiday entitlement, the Company shall be entitled to recover from the Executive, by way of deduction from any payments due to the Executive or otherwise, one day's pay calculated at 1/260th of the Basic Salary of the Executive for each excess day. |
15.8 | If either party has served notice to terminate the Executive's employment, the Company may require the Executive to take any accrued but unused holiday entitlement during the notice period. Any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave. |
15.9 | During any continuous period of absence due to Incapacity of one month or more the Executive shall not accrue holiday under this contract and the entitlement of the Executive under Clause 15.1 for the Holiday Year(s) in which such absence takes place shall be reduced pro rata save that it shall not fall below the entitlement of the Executive under the Working Time Regulations 1998. |
16 | Incapacity |
16.1 | If the Executive is absent from work due to Incapacity, the Executive shall notify the Company of the reason for the absence as soon as possible on the first day of absence. |
Page 13
16.2 | Immediately following the Executive's return to work after a period of absence due to Incapacity of seven days or less the Executive must complete a self-certification form. For periods of absence of more than seven consecutive days the Executive must produce a doctor's fit note verifying that the absence is due to Incapacity. |
16.3 | Subject to complying with the Company’s absence requirements above and to the remaining provisions of this Clause 16, the Executive shall be entitled to receive full Basic Salary and contractual benefits during any periods of absence due to Incapacity up to a maximum of 12 weeks in aggregate in any rolling 52-week period. Any such payments shall be inclusive of any statutory sick pay. The Executive's qualifying days for statutory sick pay purposes are Monday to Friday. |
16.4 | The Executive agrees to consent to medical examinations (at the Company's expense) by a doctor or clinic nominated by the Company should the Company so require. The Executive agrees that any report produced in connection with any such examination may be disclosed to the Company and the Company may discuss the contents of the report with the relevant doctor. |
16.5 | If the Incapacity is or appears to be occasioned by actionable negligence, nuisance or breach of any statutory duty on the part of a third party in respect of which damages are or may be recoverable, the Executive shall immediately notify the Company of that fact and of any claim, settlement or judgment made or awarded in connection with it and provide all relevant particulars that the Company may reasonably require. The Executive shall, if required by the Company, co-operate in any related legal proceedings and refund to the Company that part of any damages or compensation recovered by the Executive relating to the loss of earnings for the period of the Incapacity as the Company may reasonably determine less any costs borne by the Executive in connection with the recovery of such damages or compensation, provided that the amount to be refunded to the Company shall not exceed the total amount paid to the Executive by the Company in respect of the period of Incapacity. |
16.6 | The Company is entitled to terminate the Executive's employment under the terms of this agreement notwithstanding that any such termination would or might cause the Executive to forfeit any entitlement to sick pay or other benefits. |
16.7 | The payment of the Executive's Basic Salary and other contractual benefits during absence due to Incapacity is conditional on: |
(a) | notice not having been served by either party; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct; and |
(c) | the Executive not being under a performance improvement plan. |
17 | Outside interests |
17.1 | Subject to Clause 17.2,, the Executive shall not at any time during employment (including during any period of notice) save for any existing arrangements as disclosed in Schedule 2 of this Agreement: |
(a) | be directly or indirectly engaged, concerned or have any financial interest in any Capacity in any other business, trade, profession or occupation (or the setting up of any business, trade, profession or occupation) other than that of the Company and the Group, whether paid or unpaid; or |
Page 14
(b) | hold any directorship (or other office) of any company other than that of the Company and any Group Company, whether paid or unpaid. |
17.2 | Notwithstanding Clause 17.1, the Executive: |
(a) | save for any existing arrangements as disclosed in Schedule 2 of this Agreement, may hold an investment by way of shares or other securities of not more than 5% of the total issued share capital of any company (whether or not it is listed or dealt in on a recognised stock exchange) provided that such company does not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company; |
(b) | has disclosed to the Company the external interests and activities listed in Schedule 2 including the Executive's Capacity with regard to each such interest and activity. The Company consents to the Executive continuing these activities on the strict condition that it reserves the right to require (at any time) the Executive to cease any or all of such interests or activities to the extent that, in the opinion of the Company, they interfere, may be likely to interfere or could be perceived to interfere with the discharge of the Executive's obligations to the Company or Group or create or may be likely to create a conflict of interest or perceived conflict of interest; and |
(c) | may engage in external interests and activities provided that such companies do not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company and such interests or activities do not interfere with the Executive's performance of her duties for the Company, and any board level appointments shall require prior written approval of the governance committee of the Company, not to be unreasonably withheld, and subject to being permitted by the rules of any applicable regulatory framework. |
17.3 | Without prejudice to the Executive's obligations above, the Executive must promptly disclose to the Company any matter relating to the Executive's spouse, civil partner, partner, children, parents or other immediate family and/or any entity whose affairs the Executive or any such person controls which may (or may be perceived to) interfere, conflict or compete with the proper performance of the obligations of the Executive under this agreement. |
18 | Confidential information |
18.1 | Without prejudice to the Executive's common law duties, the Executive shall not (except in the proper course of the Executive's duties, as authorised or required by law or as authorised in advance by the Company), either during the Executive's employment or at any time after termination of employment (howsoever arising): |
(a) | use any Confidential Information; |
(b) | make or use any Copies; or |
(c) | disclose any Confidential Information to any person whatsoever. |
18.2 | The Executive shall be responsible for protecting the confidentiality of the Confidential Information and shall: |
Page 15
(a) | use best endeavours to prevent the use or communication of any Confidential Information by any person (except in the proper course of that person’s duties, as required by law or as authorised in advance by the Company); and |
(b) | inform the Company immediately upon becoming aware, or suspecting, that any unauthorised person knows, has access to, has been provided with or has used any Confidential Information. |
18.3 | All Confidential Information and Copies are and shall remain at all times the property of the Company and on termination of the Executive's employment (or at the request of the Company at any time during employment), the Executive shall: |
(a) | hand over all Copies to such person as is nominated by the Company; |
(b) | irretrievably delete any Confidential Information (including any Copies) stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in the Executive's possession or under the Executive's control; and |
(c) | on the request of the Company, provide a signed statement that the Executive has complied fully with all obligations under this Clause 18.3 together with such evidence of compliance as the Company may reasonably request . |
18.4 | Clause 18 shall not apply to any Confidential Information which the Executive can demonstrate: |
(a) | is already in the public domain at the time of disclosure; |
(b) | is identifiable without requiring significant expenditure of time, skill or money; and |
(c) | came into the public domain other than by reason of or as a direct or indirect result of the disclosure by the Executive of any Confidential Information. |
18.5 | Nothing in this Clause 18 shall prevent the Executive from: |
(a) | making a protected disclosure within the meaning of Part 4A of the Employment Rights Act 1996 (this includes protected disclosures made about matters previously disclosed to another recipient); |
(b) | making a disclosure to a regulator regarding any misconduct, wrongdoing or serious breach of a Regulatory Requirement; |
(c) | reporting a criminal offence to the police or a law enforcement agency; or |
(d) | co-operating with the police or a law enforcement agency regarding any criminal investigation or prosecution or with a regulator regarding any investigation by that regulator. |
19 | Intellectual property |
19.1 | All Intellectual Property Rights made, discovered, originated, produced or developed by the Executive during the course of employment with the Company (whether or not during working hours or using the premises or resources of the Company or the Group) shall immediately be disclosed in writing to the Company by the Executive and shall automatically, on creation, vest absolutely in the Company or such Group Company as the Company may nominate for that purpose to the fullest extent permitted by law. |
Page 16
19.2 | The Executive: |
(a) | acknowledges for the purposes of section 39 of the Patents Act 1977 that because of the nature of the Executive's duties, and the particular responsibilities arising from those duties, the Executive has, and at all times during employment will have, a special obligation to further the interests of the business of the Company and the Group; |
(b) | undertakes to promptly, whenever requested by the Company, and in any event upon the termination of employment, deliver up to the Company all such Intellectual Property Rights and all related correspondence, documents, papers and records and all copies of any such Intellectual Property Rights in the Executive's possession or control; |
(c) | undertakes to hold upon trust for the benefit of the Company (or its nominee) all Intellectual Property Rights in respect of all Intellectual Property Rights made, originated or developed by the Executive during employment by the Company (whether or not during working hours or using the premises or resources of the Company or the Group) to the extent that they do no vest automatically in the Company, until the same are vested absolutely in the Company (or its nominee); |
(d) | assigns absolutely with full title guarantee by way of present assignment of present and future rights, all Intellectual Property Rights made, originated or developed by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group); |
(e) | acknowledges that, other than as required by law, no further remuneration or compensation other than that set out in this agreement is or may become due to the Executive in respect of the performance of the Executive's obligations under this Clause 19; |
(f) | undertakes, at the reasonable expense of the Company, to execute all such documents, make such applications, give such assistance and do all such acts and things as may in the opinion of the Company be necessary or desirable to vest, register or obtain any Intellectual Property in the name of the Company (or its nominee), and otherwise to protect and maintain any Intellectual Property Rights made, originated or developed by the Executive and all related Intellectual Property Rights; |
(g) | waives any moral rights (as provided for by Chapter IV of the Copyright Designs & Patents Act 1988 (the 1988 Act) or any similar provisions of law in any jurisdiction) in any Intellectual Property Rights created, made, originated, developed or produced by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group) and agrees to grant all necessary consents and further agrees not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such Intellectual Property Rights infringes the Executive's moral rights, including the right to be identified, the right of integrity and the right against false attribution provided for in the 1988 Act; |
(h) | will not, except in the proper performance of the Executive's duties, disclose any Intellectual Property Rights (or any related correspondence, documents, papers and records and copies) belonging to the Company (or its nominee) without the prior written consent of the Company; and |
Page 17
(i) | will give all necessary assistance to the Company (or its nominee) to enable the Company (or its nominee) to enforce its Intellectual Property Rights against third parties and/or to defend claims for infringement of third-party Intellectual Property Rights. |
19.3 | The Executive irrevocably appoints the Company to be the Executive's attorney in the Executive's name and on the Executive's behalf to execute and/or sign all such instruments, and/or do all such things and generally to use the Executive's name for the purpose of giving to the Company (or its nominee) the full benefit of the provisions of this Clause 19. With respect to any third party, a certificate in writing signed by any director of the Company or the company secretary of the Company that any instrument or act falls within the authority conferred by this Clause 19.3 shall be conclusive evidence that such is the case. |
20 | Payment in lieu of notice |
20.1 | Notwithstanding any other provision of this agreement, the Company may, in its sole and absolute discretion, terminate the Executive's employment under this agreement summarily by giving the Executive written notice that it is exercising its discretion under this Clause 20.1. In such circumstances the Company shall pay the Executive her Basic Salary and contractual benefits in lieu of the notice period referred to in Clause 2.2 or any unexpired part of it. Payment will be made subject to such deductions as are required by law, including for tax and national insurance. The Company's right to make a payment under this Clause 20.1 does not give the Executive any right to demand such payment. |
20.2 | The Executive shall not be entitled to any payment in lieu of notice if the Company would otherwise have been entitled to terminate the Executive's employment without notice in accordance with Clause 21 and the Company shall be entitled to recover from the Executive any payment in lieu of notice already made. |
21 | Termination without notice |
21.1 | The Company may terminate the Executive's employment with immediate effect without notice (and with no liability to make any further payment to the Executive) if the Executive: |
(a) | is disqualified from acting as a director; |
(b) | commits, in the reasonable opinion of the Board, an act of gross misconduct; |
(c) | commits, in the reasonable opinion of the Board, any serious or repeated breach or failure to observe of any of the provisions of this agreement or the Policies and Procedures or the Regulatory Requirements or any anti-bribery and corruption policies and the Executive has previously been given written notice of such and a reasonable opportunity to improve or comply as the case may be; |
(d) | refuses to comply with any reasonable and lawful direction of the Board; |
(e) | is declared bankrupt or makes any arrangement with or for the benefit of her creditors or has a county court administration order made against the Executive under the County Court Act 1984; |
Page 18
(f) | is convicted of any criminal offence (other than an offence under any road traffic legislation in the United Kingdom or elsewhere for which a fine or non-custodial penalty is imposed); |
(g) | is guilty of fraud or dishonesty or acts in any manner which, in the reasonable opinion of the Board, brings or is likely to bring the Executive, the Company or any Group Company into disrepute or is materially adverse to the interests of the Company or any Group Company (in each case whether or not in the course of employment); or |
(h) | ceases to hold any qualification, approval, registration or authorisation required for the proper performance of the Executive's duties. |
21.2 | The rights of the Company under Clause 21.1 are without prejudice to any other rights that it may have at law to terminate the Executive's employment or to accept any breach of this agreement by the Executive as having brought the agreement to an end. Any delay by the Company in exercising any right to terminate shall not constitute a waiver of that right. |
21.3 | If the Executive's employment is terminated at any time by reason of any reconstruction or amalgamation of the Company or any Group Company, whether by winding up or otherwise, and the Executive is offered employment with any concern or undertaking involved in or resulting from the reconstruction or amalgamation on terms which (considered in their entirety) are no less favourable to any material extent than the terms of this agreement, the Executive shall have no claim against the Company, any Group Company or the undertaking arising out of or in connection with such termination. |
21.4 | This Clause 21.4 applies if the Executive subscribes for or is awarded shares in the Company or any Group Company or participates in any share option, restricted share, restricted share unit, long term incentive, carried interest or co-invest, or any other form of profit sharing, incentive, bonus or equity plan or arrangement (each an Incentive) or may do so. Upon termination of the Executive's employment (whether lawful or unlawful), the Executive's rights (if any) in respect of each Incentive shall be solely determined by the applicable rules or other documents governing each Incentive and the Executive hereby irrevocably waives any other claims or rights in respect of the loss of any rights or benefits under or in respect of any Incentive granted or not yet granted to the Executive (including any loss relating to the lapse of, or the Executive's ineligibility to exercise, any share options, the value of any shares, the operation of any compulsory transfer provisions or the operation of any vesting criteria). |
22 | Garden leave |
22.1 | Following service of notice to terminate the Executive's employment by either party, or if the Executive purports to terminate her employment in breach of contract and/or without serving the period of notice required by Clause 2.2, the Company may in its absolute discretion place the Executive on garden leave for the whole or part of the Executive's notice period (Garden Leave). |
22.2 | During any period of Garden Leave the Company: |
(a) | shall be under no obligation to provide any work to the Executive and may revoke any powers she holds on behalf of the Company or any Group Company; |
(b) | may exclude the Executive from any premises of the Company or any Group Company; |
Page 19
(c) | may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser, investor or other business contact of the Company or any Group Company; |
(d) | may require the Executive to resign as a director of the Company or any Group Company; |
(e) | may cease to provide the Executive with access to the Company and Group Company information systems; |
(f) | may appoint another person(s) to perform the Executive's responsibilities jointly with the Executive or in the Executive's place; and/or |
(g) | may require the Executive to take any accrued holiday due to the Executive. |
22.3 | During any period of Garden Leave the Executive: |
(a) | will continue to receive Basic Salary and all contractual benefits including the incentives in Clauses 11.1 and 11.2 in the usual way and subject to the terms of any benefit arrangement; |
(b) | will remain an employee of the Company and bound by the terms of this agreement (including her fiduciary duties and duties of good faith and fidelity); and |
(c) | must ensure that the Board knows where the Executive will be and how the Executive can be contacted during each working day (except during any periods taken as holiday in the usual way); |
22.4 | The Executive agrees that she shall have no claim against the Company in respect of any action set out in this Clause 22. |
23 | Obligations upon termination |
23.1 | On termination of the Executive's employment (however arising) or, if the Company so requires, at any time following the service of notice by either party or purported notice of termination by the Executive, the Executive shall: |
(a) | resign immediately from any directorship held by her in or on behalf of the Company or any Group Company and from any other offices she may hold as nominee or representative of the Company or any Group Company, save for any directorship held by her in Bophelo Bioscience & Wellness Pty. Ltd ("Bophelo"), which shall continue subject to the articles of association of Bophelo, and save for any trusteeship in any environmental, social and governance related trust (the “ESG Trust”) formed to hold investments in Akanda or elsewhere for the purposes of advancing the interests of the beneficiaries of the ESG Trust |
(b) | immediately deliver to the Company all property of the Company or any Group Company or any of its or their respective customers, clients, suppliers, investors and other business contacts (including documents, books, materials, records, correspondence, papers and information on whatever media and wherever located relating to the business or affairs of the Company or any Group Company or their respective customers, clients, investors, suppliers and other business contacts), which is in her possession or under her control and she/ shall not retain any Copies; |
Page 20
(c) | irretrievably delete any information relating to the business or affairs of the Company or any Group Company stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in her possession or under her control; |
(d) | deliver to the Company on request any computer or other device in her possession or control to allow the Company to remove all Confidential Information and any software of the Company; and |
(e) | on the request of the Company, provide a signed statement that she has complied fully with her obligations under this Clause 23.1 together with such reasonable evidence of compliance as the Company may require. |
23.2 | The Executive hereby irrevocably appoints the Company to be her attorney to appoint any director of the Company as her attorney to execute such instrument or do any such thing and generally to use her name for the purpose of giving effect to and providing to the Company or its nominee the full benefit of Clause 23.1(a). |
23.3 | The obligations in Clause 23.1 shall not be affected by the fact that any document or device may include the Executive's Personal Data. It shall be the Executive's responsibility to notify the Company of any Personal Data that may exist so that the Company can make proper arrangements for its disposal. |
23.4 | The Executive will, on the Company's reasonable request, co-operate with and assist the Company or any Group Company in any internal investigation, administrative, regulatory, quasi-judicial proceedings or any threatened or actual litigation concerning it or them. The Company will only make such a request where the Executive has in her possession or knowledge any facts or other matters which the Company or any Group Company reasonably considers is relevant to such process or legal proceedings. This assistance may include giving statements/affidavits, meeting with the Company or any Group Company's legal and other professional advisers, attending any legal hearing and giving evidence. The Company or relevant Group Company will pay the Executive's reasonable expenses and loss of income incurred in providing such assistance provided that the Executive notifies the Company or relevant Group Company of the amount of any expenses or anticipated loss of income in advance. |
24 | Post-termination restrictions |
24.1 | In order to protect the Confidential Information and business connections of the Company and each Group Company to which she has access as a result of the Appointment , the Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that she shall not: |
24.1.1 | for 12 months after the Termination Date, solicit or endeavour to entice away from the Company or any Group Company the business or custom of a Restricted Customer with a view to providing goods or services to that Restricted Customer in competition with any Restricted Business; |
24.1.2 | for 12 months after the Termination Date in the course of any business concern which is in competition, or intends to compete, with the Company or any Group Company, offer to employ or engage or otherwise endeavour to entice away from the Company or any Group Company any Restricted Person who could damage the interests of the Company or any Group Company as a result of any such employment, engagement or enticement; |
Page 21
24.1.3 | for 12 months after the Termination Date in the course of any business concern which is in competition, or which intends to compete, with any Restricted Business, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person who could damage the interests of the Company or any Group Company as a result of that employment or engagement, whether or not such person would be in breach of contract as a result of such employment or engagement; |
24.1.4 | for six months after the Termination Date, be involved in any Capacity with any business concern which is (or intends to be) in competition with any Restricted Business; |
24.1.5 | for 12 months after the Termination Date, be involved with the provision of goods or services to (or otherwise have any business dealings with) any Restricted Customer or Prospective Customer in the course of any business concern which is in competition with any Restricted Business; |
24.1.6 | for 12 months after the Termination Date damage (or attempt to do so) any relationship between the Company or any Group Company and the Restricted Supplier; or |
24.1.7 | at any time after the Termination Date, represent herself as connected with the Company or any Group Company in any capacity, other than as a former employee, director or shareholder, or use any registered names or trading names associated with the Company or any Group Company. |
24.1.8 | at any time after the Termination Date, make any comments or statements of any nature that are derogatory to or disparaging of, or have the effect of lowering the reputation of the Company or any Group Company or any of its or their directors, officers, employees or agents; and/or take part in any conduct which may bring into disrepute the Company, any Group Company or any of its or their directors, officers, employees or agents. |
24.2 | None of the restrictions in Clause 24.1 shall prevent the Executive from: |
24.2.1 | being engaged or concerned in any business concern insofar as the Executive's duties or work shall relate solely to geographical areas where the business concern is not in competition with any Restricted Business; or |
24.2.2 | being engaged or concerned in any business concern, provided that the Executive's duties or work shall relate solely to services or activities of a kind with which the Executive was not concerned to a material extent in the 12 months before the Termination Date. |
24.3 | The restrictions imposed on the Executive by this Clause 24 apply to her acting: |
24.3.1 | directly or indirectly; and |
24.3.2 | on her own behalf or on behalf of, or in conjunction with, any firm, company or person. |
24.4 | Subject to Clause 24.12, the Executive agrees that the Board may review the Prospective Customer, Restricted Business, Restricted Customer, Restricted Person and Restricted Supplier definitions and revise, delete and amend these (to include but not be limited to adding new customers, persons and suppliers or deleting or revising named customers, persons and suppliers) from time to time. |
Page 22
24.5 | The periods for which the restrictions in Clause 24 apply shall be reduced by any period that the Executive spends on Garden Leave immediately before the Termination Date. |
24.6 | If the Executive receives an offer to be involved in a business concern in any Capacity during the Appointment, or before the expiry of the last of the covenants in this Clause 24, the Executive shall give the person making the offer a copy of this Clause 24 and shall tell the Company the identity of that person as soon as possible after accepting the offer. |
24.7 | This Clause 24.7 applies if, at any time during the Executive's employment, two or more Restricted Persons have left their employment, appointment or engagement with the Company and have subsequently performed work for a Competitor. Where this clause applies, the Executive will not, at any time during the six months following the last date on which any of those Restricted Persons were employed or engaged by the Company, be employed or engaged in any way by the Competitor if the Executive would perform work for or on behalf of the Competitor that is competitive with the Restricted Business. |
24.8 | The Executive has had the opportunity to take legal advice on the restrictions in this Clause 24. |
24.9 | Each of the restrictions in this Clause 24 is intended to be separate and severable. If any of the restrictions shall be held to be void but would be valid if part of their wording were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective. |
24.10 | If the Executive's employment is transferred to any firm, company, person or entity other than a Group Company (the "New Employer") pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, the Executive will, if required, enter into an agreement with the New Employer containing post-termination restrictions corresponding to those restrictions in this Clause 24, protecting the Confidential Information, trade secrets and business connections of the New Employer. |
24.11 | The Executive will, at the request and expense of the Company, enter into a separate agreement with any Group Company in which she agrees to be bound by restrictions corresponding to those restrictions in this Clause 24 (or such of those restrictions as may be appropriate) in relation to that Group Company. |
24.12 | No variation of this Clause 24 will be effective unless it is in writing and signed by the parties. |
24.13 | The Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that she shall not for 12 months after the Termination Date: |
24.13.1 | interfere or take such steps as may be likely to interfere with the continuance of investment or funding to the Company (or the terms relating to such investment or funding) from any Investor or Lender; or |
24.13.2 | seek to damage the relationship between any Investor or Lender and the Company. |
25 | Disciplinary and grievance procedures |
25.1 | The Executive is subject to the disciplinary and grievance procedures of the Company, copies of which are available on the Company's intranet. These procedures do not form part of this agreement or the terms and conditions of the Executive's employment. |
25.2 | The Executive should refer: |
Page 23
(a) | any appeal the Executive wishes to make against a disciplinary sanction/decision to a member of the Board (or such other person as the Company may specify from time to time); or |
(b) | any grievance the Executive wishes to raise to a member of the Board (or such other person as the Company may specify from time to time), |
in accordance with the Company's disciplinary and grievance procedures.
25.3 | The Company may suspend the Executive from any or all of her duties during any period in which the Company is investigating any disciplinary matter involving the Executive or until the conclusion of any disciplinary procedure (including any appeal). During any period of suspension: |
(a) | subject to Clause 11.5, the Executive will continue to receive Basic Salary and all contractual benefits in the usual way; |
(b) | the Company may suspend the Executive's access to the Company's and Group's systems and internal communications; |
(c) | the Company may require the Executive to return temporarily any Company or Group IT equipment and communication devices (including any smartphones, tablets, laptops and hard drives); |
(d) | the Executive shall remain an employee of the Company and bound by the terms of this agreement; |
(e) | the Executive shall ensure that the Company knows where she will be and how she can be contacted during each working day (except during any periods taken as holiday in the usual way); |
(f) | the Company may exclude the Executive from her place of work or any other premises of the Company or any Group Company; and |
(g) | the Company may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company or any Group Company. |
26 | Change of Control |
26.1 | In the event that there is a Change of Control of the Company or the Cash Shell Company (other than as part of the Listing, the fundraising on or around the date of Listing or an internal re-organisation) and, within 365 days of the Change of Control, the Appointment is terminated by the Company (other than where the Company is entitled to terminate the Appointment without notice or payment in lieu of notice in accordance with Clause 21.1) the Company shall, within one month of the date of the Termination Date, pay or provide the Prescribed Sum to her as provided by this Clause. |
26.2 | The Prescribed Sum shall be an amount equal to one year's Basic Salary in accordance with Clause 8.1 as adjusted in accordance with Clause 26.3. |
26.3 | If the Company or the Cash Shell Company (as the case may be) terminates the Appointment by giving a period of notice whether under Clause 2.2 or otherwise, or terminates the Appointment under Clause 20, the Prescribed Sum shall be reduced pro rata by the number of complete months of service for which the Executive remains employed following notice being given to her or shall be reduced by the amount paid to the Executive under Clause 20. |
Page 24
26.4 | The payment or provision of the Prescribed Sum shall be conditional upon and in consideration of: |
(a) | the Executive having complied with Clause 23; and |
(b) | the Executive having complied with and continuing to comply with her obligations relating to confidentiality and intellectual property in Clauses 18 and 19 respectively. |
26.5 | For the avoidance of doubt, the payment or provision of the Prescribed Sum shall not affect the Executive's entitlement as at the Termination Date to any of the following: |
(a) | any accrued but unpaid Basic Salary; |
(b) | any payment in lieu of accrued but unused holiday; or |
(c) | the reimbursement of her expenses, provided that all claims for reimbursement are submitted within four weeks of the Termination Date. |
26.6 | To the extent that the Prescribed Sum is damages (which is not admitted), the parties agree that the terms of this Clause 26 represent a genuine pre-estimate of the loss to the Executive that would arise on termination of the Appointment in the circumstances described and does not constitute a penalty. |
27 | Data protection |
27.1 | The Company will collect and process Personal Data in accordance with the data privacy notice which is annexed to this agreement and which is also available on the Company intranet. The Executive shall sign and date the privacy notice and return it to the Company within five working days of the date of this agreement. |
27.2 | The Executive shall comply with the Policies and Procedures in relation to privacy and data protection when handling personal data in the course of employment including personal data relating to any employee, worker, contractor, customer, client, supplier, agent or other contact of the Company or any Group Company. |
28 | Collective agreements |
There is no collective agreement applicable to the Company or to the Executive's employment with the Company.
29 | Notices |
29.1 | A notice given to a party under this agreement shall be in writing in the English language and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the party at the address given in this agreement or as otherwise notified in writing to the other party. |
29.2 | Any such notice shall be deemed to have been received: |
(a) | if delivered by hand, at the time the notice is left at the address or given to the addressee; |
Page 25
(b) | in the case of pre-paid first class UK post or other next working day delivery service, at 9.00 a.m. on the second business day after posting or at the time recorded by the delivery service; |
(c) | in the case of email, at the time of transmission. |
29.3 | A notice shall have effect from the earlier of its actual or deemed receipt by the addressee. For the purpose of calculating deemed receipt: |
(a) | all references to time are to local time in the place of deemed receipt; and |
(b) | if deemed receipt would occur on a Saturday or Sunday or a public holiday when banks are not open for business, deemed receipt is at 9.00 a.m. on the next business day. |
29.4 | This Clause does not apply to the service of any proceedings or other documents in any legal action. |
30 | General |
30.1 | No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives). |
31 | Entire agreement |
This agreement contains the entire and only agreement between the parties, and both parties acknowledge that, on entering into this agreement, they have not relied on any written or oral representation or undertaking other than as expressly stated in this agreement, and that this agreement supersedes any previous contract or arrangement between the parties.
32 | Counterparts |
This agreement may be executed in any number of counterparts, each of which, when executed, shall be an original, and all the counterparts together shall constitute one and the same instrument.
33 | Third party rights |
Except as expressly provided elsewhere in this agreement, no person other than the Executive and the Company or any Group Company shall have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.
34 | Governing law |
This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.
35 | Jurisdiction |
Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).
Page 26
EXECUTED as a DEED by Louisa Mojela | |
at | |
on 2022 | |
before the following witness: |
Witness Signature: | |
Full name: | |
Address: | |
EXECUTED as a DEED for and on behalf of
Canmart Ltd |
|
at | |
Director/Authorised Signatory | |
on 2022 | |
before the following witness: |
Page 27
EXECUTED as a DEED for and on behalf of
Akanda Corp. |
|
at | |
Director/Authorised Signatory | |
on 2022 | |
before the following witness: |
Witness Signature: | |
Full name: | |
Address: | |
Page 28
Schedule 1
Executive Equity Rights
• | Board seat for so long as the Executive is appointed as the Executive Chairperson of the Company |
• | Up to 5% of the options available for grant pursuant to a share option pool to be created which constitutes, in aggregate, 15% (or, in relation to the maximum number of share options, such other amount as may be decided by the Board, subject always to applicable laws) of the fully diluted share capital of the Company (i.e. up to 0.75% of the aggregate fully diluted equity), subject always to approval by a remuneration or compensation committee to be established by the Company |
• | Market standard pre-emption rights on a new issuance of shares for cash in the Company except where such rights are not held by another minority shareholder of the Company with an equivalent percentage shareholding to the Executive or greater |
• | Tag rights (on a fully diluted basis) except where such rights are not held by another minority shareholder of the Company with an equivalent percentage shareholding to the Executive or greater |
• | Prior to a Listing, a right of consent in respect of the following matters: |
o | passing any resolution or presenting any petition for the Company's winding up or administration (unless the Company is insolvent) |
o | proposing any amendment to the Articles of Association of the Company that would prejudice the rights of the shares held by the Executive, other than with respect to administrative matters or approved by the Board (acting reasonably) in contemplation of a Listing |
o | reducing the capital of the Company or undertaking a purchase by the Company of any of its own shares |
o | changing the Company's accounting reference date or accounting standards falling outside of either UK GAAP, IAS or IFRS |
o | transferring the whole or any material part of the assets or undertaking of the Company |
• | Information rights, on and subject to the same terms as agreed with other shareholders of the Company with an equivalent percentage shareholding to the Executive |
Page 29
Schedule 2
Outside Interests
Mophuthi Matsoso Development Trust – Founder and Trustee
WIPHOLD – Founder and Executive Chairman
Boiketlo Biomed Pty Ltd – Founder, Executive Director and Shareholder
Boiketlo Property Development Pty Ltd Founder, Executive Director and Shareholder
Page 30
Exhibit 10.13
Service agreement
Dated: 24 January 2022
Canmart Limited
(Company)
Akanda Corp.
(Akanda)
Trevor Scott
(Executive)
Contents
32 | Counterparts | 26 |
33 | Third party rights | 26 |
34 | Governing law | 26 |
35 | Jurisdiction | 26 |
This agreement is dated 24 January 2022.
Between
(1) | Canmart Ltd a company incorporated and registered in England and Wales with registered company number 11741517 and whose registered office is at Units 1a/1b Learoyd Road, New Romney, Kent TN28 8XU (the Company); |
(2) | Akanda Corp. a company incorporated and registered in Ontario, Canada with a registered company number 002854618 and whose registered office is 77 King Street West, Suite 400 Toronto-Dominion Centre Toronto, ON M5K 0A1 Canada; and |
(3) | Trevor Scott (the Executive). |
It is agreed:
1 | Interpretation |
1.1 | In this agreement the following terms and expressions shall have the following meanings: |
Akanda means Akanda Corporation, Registration number 002854618, Province of Ontario
Appointment means the employment of the Executive by the Company on the terms of this agreement.
Board means the board of directors of the Company and any committees duly constituted by the board.
Capacity means as agent, consultant, director, the holder of any office, employee, worker, owner, partner, Shareholder or in any other capacity.
Cash Shell Company means Akanda or any undertaking (including a special purpose acquisition company) (a) which is listed/quoted or becomes listed/quoted on a Recognised Investment Exchange and (b) of which the Company is or becomes a wholly-owned subsidiary, but excluding for the avoidance of doubt Halo Labs Inc.
Control means in relation to a body corporate, the power of a person to secure that the affairs of the body corporate are conducted in accordance with the wishes of that person:
(a) | by means of the holding of shares, or the possession of voting power, in or in relation to that or any other body corporate; or |
(b) | as a result of any powers conferred by the articles of association or any other document regulating that or any other body corporate. |
Change of Control occurs if a person (whether alone or together with any person acting in concert with that person) who controls any body corporate ceases to do so or if another person acquires Control of it.
Commencement Date means 1 July 2021.
Competitor means a business concern which is, or intends to be, in competition with any Restricted Business.
26 January 2022 | Page 1 |
Confidential Information means information of a confidential nature (in any form) concerning the business, affairs and/or finances of the Company or any Group Company or their respective customers, clients, suppliers, agents, distributors, investors and shareholders which the Executive receives, obtains, creates or develops at any time by reason of or in connection with the Executive's service with the Company or any Group Company (whether or not marked as confidential). This includes: trade secrets; technical information, data, research and development; customer, client and supplier lists, contact details of customers, clients and suppliers and individuals within those organisations; inventions and patent applications in the course of preparation and all other Intellectual Property Rights; financial projections, target details and accounts; details of funding and resource allocation; fee levels, pricing policies, commissions and commission charges; budgets, forecasts, reports, records and corporate and business plans; planned or potential products and services; marketing and advertising plans, requirements and materials, marketing surveys and research reports; market share and pricing statistics; disputes (whether existing, threatened or prior), settlement discussions and terms; details of employees, workers, officers and consultants including their roles and responsibilities, remuneration, benefits and organisational structures, legally privileged material; computer software and passwords.
Copies means copies or records of any Confidential Information in whatever form (including in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) including extracts, analysis, studies, plans, compilations or any other way of representing or recording and recalling information which contains, reflects or is derived or generated from Confidential Information.
Executive Equity has the meaning given to it in Clause 12.
Executive Equity Rights means the rights to be granted to the Executive as set out and materially on the terms described in Schedule 1.
Garden Leave means any period during which the Company has exercised its rights under Clause 22.
Group Company means any company which is from time to time a subsidiary or holding company of the Company and any subsidiary of any holding company of the Company (and references to the Group shall be construed accordingly), including but not limited to Akanda. The words "subsidiary" and "holding company" have the meanings given to them in section 1159 of the Companies Act 2006 and a person shall be treated, for the purposes only of the membership requirement contained in subsections 1159(1)(b) and (c) of that Act, as a member of another company even if its shares in that other company are registered in the name of: (i) another person (or its nominee), whether by way of security or in connection with the taking of security, or (ii) a nominee.
Halo means Halo Labs, Inc. a company incorporated in Canada whose registered office is 77 King Street West, Suite 400, Toronto-Dominion Centre, Toronto, Ontario, Canada.
Holiday Year means 1 January to 31 December or such other period as the Company notifies the Executive in writing.
Incapacity means any sickness, injury or other incapacity or medical disorder or condition which prevents the Executive from carrying out his duties.
26 January 2022 | Page 2 |
Intellectual Property Rights means patents, rights to Inventions, copyright and related rights, trade marks, trade names and domain names, rights in get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database rights, topography rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.
Invention means any invention, idea, discovery, development, improvement or innovation, whether or not patentable or capable of registration, and whether or not recorded in any medium.
Investor means any person, firm, company or other entity who or which is an investor in the Company or any Group Company at the Termination Date or who or which invested in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible investment in the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Lender means any person, firm, company or other entity who or which is a lender of funds to the Company or any Group Company at the Termination Date or who or which lent funds to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date or with whom or which the Company or any Group Company had negotiations or meaningful discussions regarding possible lending to the Company or any Group Company at any time in the 12 months immediately preceding the Termination Date and with whom or which the Executive had material contact or material involvement in the course of the Appointment.
Listing means the admission, approved by the Board, of the entire issued share capital of the Company or a Cash Shell Company, or securities representing those shares (including without limitation depositary interests, American depositary receipts, American depositary shares and/or other instruments) on a Recognised Investment Exchange.
Long Stop Date means the date falling 12 months from the date of this agreement.
Personal Data means personal data about or relating to the Executive including his name, date of birth, home address, telephone number, driver's licence number, passport number, family information (such as marital status and dependant details), emergency contact information, education and training details (such as qualifications and professional expertise), employment details (such as employment status, employee type, performance and evaluation information, work phone number and email, intranet user log in and department and supervisor details), financial information (such as compensation, benefits, bank account information and pensions information) and hiring information (such as CV, prior employment history and personal references).
Policies and Procedures means the policies and procedures of the Company applicable to employees and officers of the Company as amended from time to time.
Prospective Customer means any firm, company or person who, during the 12 months before the Termination Date, was in negotiations with the Company or any Group Company about becoming a customer of the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of his duties or responsibilities, about whom he became aware or informed to a material extent in the course of the Appointment.
26 January 2022 | Page 3 |
Recognised Investment Exchange means NASDAQ, the New York Stock Exchange, the Official List of the United Kingdom Listing Authority, the AIM Market operated by the London Stock Exchange Group Plc, the Toronto Stock Exchange, the NEO Exchange or the TSX Venture Exchange or any other recognised investment exchange (as defined in section 285 of the Financial Services and Markets Act 2000).
Regulatory Requirements means all legal and regulatory obligations, codes of practice and recommendations and similar which apply to the Executive, the Company or any Group Company, including:
(a) | in relation to transactions in securities, related party transactions and inside information (including any share dealing policy of the Company); |
(b) | pursuant to the Financial Services and Markets Act 2000 and the Criminal Justice Act 1993; and |
(c) | any other laws, rules and regulations of, or applicable to companies admitted to, a Recognised Investment Exchange on which the Company (or a Cash Shell Company) is Listed, |
Restricted Business means those parts of the business of the Company and any Group Company with which the Executive was involved to a material extent in the 12 months before the Termination Date.
Restricted Customer means any firm, company or person who, during the 12 months before the Termination Date, was a customer of or in the habit of dealing with the Company or any Group Company with whom the Executive had contact or material involvement or, in respect of the exercise of his duties or responsibilities, about whom he became aware or informed to a material extent in the course of the Appointment.
Restricted Person means anyone employed or engaged by the Company or any Group Company with whom the Executive dealt in the 12 months before the Termination Date in the course of the Appointment.
Restricted Supplier means any person, firm or company which at any time during the 12 months prior to the Termination Date was a supplier of any goods, products or services (other than utilities and goods or services supplied for administrative purposes) to the Company or any Group Company and with whom or which the Executive had personal dealings during that period other than in a de minimis way and where such entities remain suppliers of the Company and/or the Group Company at or immediately before the Termination Date.
Shareholder means holding an investment by way of shares or other securities of over 5% of the total issued share capital of any company, other than a Cash Shell Company, whether or not it is listed or dealt in on a recognised stock exchange.
Termination Date means the date on which the Executive's employment with the Company terminates however caused.
1.2 | The headings in this agreement are inserted for convenience only and shall not affect its construction. |
26 January 2022 | Page 4 |
1.3 | A reference to a particular law is a reference to it as it is in force for the time being taking account of any amendment, extension or re-enactment and includes any subordinate legislation for the time being in force made under it. |
1.4 | Unless the context otherwise requires: |
1.4.1 | a reference to one gender shall include a reference to the other genders; and |
1.4.2 | words in the singular include the plural and, in the plural, include the singular. |
1.5 | References to a "person" include any individual, company, any other body corporate, partnership or unincorporated association (whether or not having separate legal personality). |
1.6 | The words "including", "include", "in particular", "for example" and words of similar effect shall not limit the general effect of the words that precede them. |
2 | Employment |
2.1 | The Executive agrees to be employed by the Company and shall serve Akanda as its Chief Financial Officer subject to the terms and conditions of this agreement. It is envisaged that the Company will be subject to a reverse takeover by Akanda and there will be a Listing of Akanda. Accordingly, the terms of this agreement may require amendments to comply with any applicable Regulatory Requirements and if so, the Executive will be paid a cash sum equivalent to any amounts (including benefits) that he is entitled to under this agreement that are not included in the amended agreement. |
2.2 | The Executive's employment will commence on the Commencement Date and shall continue, subject to the remaining terms of this agreement, until terminated by either party giving the other not less than 6 months prior written notice, save that the Company can only give notice after 18 months following the Commencement Date (except that this limitation shall not apply in respect of termination rights under Clause 21.1(a), (c) or (g)). If the Company does give notice sooner, the amount of Basic Salary and contractual benefits that the Executive would otherwise have been entitled to up to the first day on which termination could have been effective in accordance with this clause will be paid to the Executive as a lump sum within 28 days of the Termination Date. For the avoidance of doubt, nothing in this Clause 2.2 shall prevent or limit the Company's right to terminate this agreement without notice and without payment for any Basic Salary and contractual benefits for any reason that falls within Clause 21.1(a), (c) or (g). |
2.3 | No period of employment with the Company or any other employer counts towards the period of continuous employment between the Executive and the Company which therefore will begin on the Commencement Date. Past service with any Group Company will count towards any employment or service measurement period in respect of any leave benefit, Executive Equity and employee share ownership incentive award that is issued under an approved employee share ownership plan . |
2.4 | The parties acknowledge and agree that the Company intends to pursue a Listing, either directly or via a Cash Shell Company, and that as part of that process the Company's advisers (including its brokers) may require certain terms of this Agreement to be varied, amended or deleted. The parties agree that they will act reasonably in agreeing any such variations, amendments or deletions and the Executive agrees that (without limitation) the following provisions, amendments or variations, if required or reasonably requested by the Company (on the advice of its brokers) pursuant to such Listing, will be acceptable: |
26 January 2022 | Page 5 |
(a) | any lock-in and/or orderly market restrictions on market-standard terms (where, in respect of the length of any such restriction, "market-standard" means no longer than two years in respect of each of any lock-in and any orderly market restriction); |
(b) | the Executive ceasing to be entitled to any or all of the Executive Equity Rights; and |
(c) | a vesting, or reverse vesting, period of up to four years and otherwise on market-standard terms, |
and the Executive agrees that he will take all action reasonably necessary to give effect to any such amendments, variations or deletions. For the avoidance of doubt, under no circumstances shall the Executive be required to surrender or otherwise lose the ownership of whole or any part of the Executive Equity pursuant to this Clause 2.4.
3 | Conditions to employment |
3.1 | The Company shall take appropriate professional advice as to the best way in which to achieve the proposed Listing of the business operated or proposed to be operated by it. If, following such advice, the Board decides that it would be in the best interests of the Company and its members as a whole to achieve a Listing via a Cash Shall Company then, before the Long Stop Date, the Company will: |
(a) | establish or acquire or be acquired by a Cash Shell Company; |
(b) | in respect thereof and subject always to Clause 2.4, grant the Executive the Executive Equity; and |
(c) | at the Executive’s election and in his sole discretion, transfer his engagement as Chief Financial Officer to the Cash Shell Company or any other Group Company, For the avoidance of doubt, and upon such a transfer, any benefits, leave entitlements, equity awards, compensation, salary or employment related benefit accruing to the Executive under this Agreement shall similarly be transferred to the Cash Shell Company or any other Group Company. |
(together, the Conditions Subsequent).
3.2 | In the event that the Conditions Subsequent have not been satisfied by the Long Stop Date and such non-satisfaction is predominantly or primarily the result of either or both of (a) some action or inaction by or on behalf of Halo and/or (b) another factor or factors beyond the reasonable control of the Executive, the parties shall, in good faith, use reasonable endeavours to grant equity interests in Halo (or the Company if it is directly subject to a Listing) to the Executive that give the Executive an approximately equivalent monetary valuation as would have been held by him in a Cash Shell Company that held the businesses of Cannahealth, Canmart and Bophelo only, pursuant to the terms of this Agreement. |
4 | Fundamental terms and warranties |
4.1 | The Executive represents and warrants to the Company that (in each case as a fundamental term of this agreement): |
(a) | the Executive is, to the best of his knowledge, not subject to any restrictions which prevent the Executive from holding office as a director; |
26 January 2022 | Page 6 |
(b) | by entering into this agreement or fully performing any of the Executive's obligations under it, the Executive will not be in breach of any court order or any express or implied terms of any contract or other obligation binding on the Executive; and |
(c) | the Executive has not used or disclosed to the Company or any Group Company any confidential information belonging to any previous employer or any other person. |
4.2 | Notwithstanding (and without prejudice to) any other provision of this agreement, the Company may terminate this agreement summarily if the Executive is in breach of any of the terms and/or warranties in this Clause 4. |
5 | Duties |
5.1 | The Executive acknowledges that he will be a fiduciary in a position of seniority and trust. |
5.2 | At all times during the course of employment the Executive will: |
(a) | faithfully and diligently serve Akanda, the Company and the Group, and exercise such powers and perform such duties as may from time to time be assigned to the Executive by Akanda or the Board or perform such other duties as the Company may reasonably require; |
(b) | devote the whole of the Executive's working time, attention and abilities to the business and affairs of Akanda, the Company and the Group; |
(c) | comply with all reasonable directions of and regulations made by Akanda, the Company and the Board; |
(d) | promptly make such reports to Akanda and the Board in connection with the affairs of Akanda, the Company and of any Group Company on such matters and at such times as are reasonably required, and otherwise keep Akanda and the Board fully informed of all matters relating to the business and affairs of Akanda, the Company and the Group; |
(e) | immediately upon becoming aware, report: |
(i) | any wrongdoing (including the Executive's own wrongdoing) whether committed, contemplated or discussed by any person employed or engaged by Akanda, the Company or any Group Company irrespective of whether this would or may involve self-incrimination; |
(ii) | any plans or proposals or discussions by any person employed or engaged by Akanda, as a senior executive or as a senior member of management of the Company or any Group Company to leave the employment or engagement of the Company or Group Company, whether alone or in concert with any other person and whether to join a competitor or any other business; and |
(iii) | any misuse of Confidential Information by any person (including the Executive) irrespective of whether this would or may involve self-incrimination; |
(f) | use all reasonable endeavours to promote, protect, develop and extend the business of Akanda, the Company and Group Companies; |
(g) | comply with all Policies and Procedures; |
26 January 2022 | Page 7 |
(h) | comply with all Regulatory Requirements and promptly provide Akanda, the Company with all information that it requires or may require to comply with the Regulatory Requirements; and |
(i) | not: |
(i) | offer, promise or provide any bribe, inducement or reward to any third party in order to gain any commercial, contractual, regulatory or personal advantage; |
(ii) | receive or accept any bribe, inducement or reward from any third party in order to gain any commercial, contractual, regulatory or personal advantage; or |
(iii) | receive any gifts, goods, service, rebates or commission from any third party other than in accordance with Akanda or Company policy from time to time in force. |
5.3 | The Executive agrees and accepts that: |
(a) | the Policies and Procedures do not form part of this agreement or the terms of the Executive's employment and the Company may amend the Policies and Procedures at any time; and |
(b) | a breach of the Regulatory Requirements may lead to civil or criminal liability for the Executive, action being taken against the Executive by any relevant regulatory authority and/or disciplinary action by the Company up to and including summary dismissal if the Executive's conduct falls within the categories in Clause 21.1. |
6 | Place of work |
6.1 | The normal place of work of the Executive is South Africa (or such other place as agreed by the parties) or any other place as the Company may reasonably require for the proper performance and exercise of the Executive's duties. |
6.2 | The Executive will be required to travel in appropriate circumstances on the business of the Company and the Group (to the United Kingdom, Malta and/or abroad). |
7 | Hours of work |
7.1 | The Executive's normal hours of work are from 8.30am to 5:30pm Monday to Friday, inclusive of one hour for lunch daily, and such additional hours as may be necessary for the proper performance of the Executive's duties. The Executive is not entitled to any further remuneration for additional hours outside normal office hours. |
7.2 | The parties agree that the nature of the Executive's position is such that the Executive's working time cannot be measured and, accordingly, the Executive's employment falls within the scope of regulation 20 of the Working Time Regulations 1998. |
8 | Salary |
8.1 | The Executive will be paid an annual salary of £250,000 (Basic Salary) subject to applicable deductions as required by any local laws applicable to the Company including for tax and social security. |
26 January 2022 | Page 8 |
8.2 | The Basic Salary will be paid in equal monthly instalments (or pro rata where the Executive is only employed during part of a month) in arrears to the Executive's nominated bank account in the United Kingdom, or any other bank account in any location designated by the Executive in his sole discretion . For convenience, payment will usually be slightly in advance of the end of the calendar month to which the payment relates. |
8.3 | The Executive authorises the Company to deduct (and retain) from the Basic Salary, or any other sum due to the Executive at any time, any sum due to the Company or any Group Company from the Executive. |
9 | Pension |
The Company will comply with the employer pension duties in accordance with Part 1 of the Pension Act 2008.
10 | Expenses |
Subject to any Company policy in operation from time to time and to production of VAT receipts or other appropriate evidence to the reasonable satisfaction of the Company, the Company will reimburse (or procure the reimbursement of) all reasonable expenses wholly, properly and necessarily incurred by the Executive in the performance of the Executive's duties.
11 | Incentive payments & bonus |
11.1 | Subject to Clause 11.7, on a Listing, the Executive shall be entitled to receive an incentive payment of £150,000, which shall be paid on or around the payroll in the subsequent month following the Listing. |
11.2 | Subject to Clause 11.7, on completion of the Listing , the Executive shall be entitled to receive an incentive payment of £150,000, which shall be paid on or around the payroll in the month following receipt by the Company of the Qualifying Equity Finance. |
11.3 | The Executive is entitled to participate in the Company's bonus scheme with an annual bonus opportunity of: |
(a) | up to 100% of Basic Salary based on meeting achievable KPIs as determined by the Board using its reasonable discretion on or around the beginning of each financial year; and |
(b) | an additional bonus opportunity based on achievable stretch targets which is to be determined by the Board using its reasonable discretion. |
11.4 | The Board may award any such bonus in cash, equity or such other instrument or arrangement with the Company undertaking that it will act reasonably in making any such award in a way which is tax efficient and cost effective for the Executive. |
11.5 | Any bonus made pursuant to Clause 11.3 may, at the Board's absolute discretion, be reduced pro rata by reference to any period for which the Executive has been absent from work for any reason during the period to which the bonus relates. |
11.6 | Other than as provided in this clause, the Executive will not be entitled to compensation for loss of bonus (whether pursuant to this Clause 11 or otherwise) on termination of employment. Payment of a bonus in one year will not entitle the Executive to a bonus in any other year. Should the Executive’s employment be terminated for any reason other than as set out in clause 21.1 of this Agreement, then the Executive shall be entitled to a partial bonus determined on a pro-rata basis with reference to the number of months of service provided in the current financial year or bonus measurement period |
26 January 2022 | Page 9 |
11.7 | Payment of any incentive payment or bonus under this Clause 11 will be conditional on: |
(a) | notice not having been served by the Executive; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct (in which case payment of any incentive or bonus will be postponed pending the final outcome of that disciplinary procedure save where the procedure results in dismissal in which case no incentive or bonus shall be payable); and/or |
(c) | the Executive not having committed a repudiatory breach of this agreement; |
in each case, as at the payment date.
11.8 | If any payment or other obligation under this agreement or any related benefit or remuneration plan does not comply with any applicable Regulatory Requirement, the Company may, by mutual agreement with the Executive, amend the terms of the payment or other obligation (including by reducing, revoking, cancelling or recovering any payment or award) to make it compliant. |
11.9 | Any payments under this Clause 11 will be subject to applicable deductions for tax and National Insurance (excluding employer National Insurance contributions) and will not be pensionable. |
12 | Shares |
12.1 | The Company shall procure that the Executive is granted, through an employee share ownership scheme or otherwise, an award of an equity interest in the Cash Shell Company (which could be a subscription/award of shares/award of restricted share units or share options, depending on the taxation implications for both the Company and the Executive, with the Company undertaking that it will act reasonably in procuring the offer of an incentive structure at its own cost which is tax efficient and cost effective for the Executive provided there are no adverse consequences for the Company or the Cash Shell Company) (the Executive Equity). |
12.2 | The Executive Equity is intended to represent 500,000 common shares in the issued share capital of the Cash Shell Company before the Cash Shell Company acquires the Company or any other company or business, and/or issues equity to participants in a placing or public offering to occur on or around the date of Listing, when, pursuant to each of such events, the percentage equity interest held by the Executive will be diluted in accordance with the terms of such transactions. |
12.3 | Subject always to Clause 2.4, the Executive Equity will be subject to monthly vesting (or reverse vesting if shares are awarded) over a three year period, with a one year vesting cliff (33.3% vesting 12 months after date of grant of the award), and will be subject to customary good leaver, intermediate leaver and bad leaver conditions. |
12.4 | In the event that there is a Change of Control of the Company or Cash Shell Company (other than as part of the fundraising on or around the date of Listing or an internal re-organisation) after the date falling 12 months after the date of the grant of Executive Equity and before the end of the three year vesting period (or such other period as required in accordance with Clause 2.4), and the Executive is an employee of the Company (or the Cash Shell Company as the case may be) at such time, it is agreed that vesting of the Executive Equity will automatically be accelerated immediately prior to such Change of Control. |
26 January 2022 | Page 10 |
12.5 | The Executive's participation in the Executive Equity shall be determined by the applicable rules (or other documents) of the scheme to be implemented. |
In the event a Cash Shell Company does not acquire Control of the Company, the Company and the Executive will both act in good faith to agree an alternative incentive arrangement to that referred to in Clause 12.1 above and, if applicable, Clause 3.2.
13 | Other benefits and paid leave |
13.1 | The Company will endeavour to put in place a private medical insurance scheme as soon as reasonably practicable after the Commencement Date. The Executive, his spouse and dependents shall be entitled to participate in such scheme. |
13.2 | The Executive's rights and entitlements and the Company's obligations to pay premiums for the private medical insurance scheme shall be subject always to: |
(a) | the rules and terms of such scheme from time to time in force; |
(b) | the Company's absolute discretion to change scheme and/or scheme provider and/or to discontinue providing the benefit at any time; |
(c) | the Executive satisfying any underwriting or other requirements of the relevant scheme provider; and |
(d) | the Executive co-operating with the Company and the relevant scheme provider when making any claim. |
13.3 | The Executive agrees that: |
(a) | the Company shall have no obligation to pursue any claim for benefits on behalf of the Executive or the Executive's spouse or dependants or any other beneficiaries or potential beneficiaries if it is not accepted by the scheme provider; |
(b) | the Company will have no liability to the Executive or the Executive's spouse or dependants for failure or refusal by the scheme provider for whatever reason to pay benefits or for cessation of benefits on the termination of the Executive's employment and the Company is entitled to terminate the Executive's employment notwithstanding the fact that the Executive may lose entitlement to benefits under these arrangements as a result; |
(c) | The Executive is not contractually entitled to any benefit he receives which is not expressly referred to in this agreement (whether payment of insurance scheme premiums or otherwise). |
26 January 2022 | Page 11 |
13.4 | The Executive may be eligible to take the following types of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules applicable to each type of leave in force from time to time: |
(a) | statutory paternity leave; |
(b) | family responsibility leave; |
(c) | statutory adoption leave; |
(d) | shared parental leave; and |
(e) | parental bereavement leave. |
14 | Training |
In addition to general training the Company provides during the Executive's induction and throughout his employment, the Company will specify certain mandatory training modules from time to time. These cover matters that are essential for working for the Company, or for the Executive's role. The subject matter will vary from time to time and the Company will update the Executive on the requirements. Details of the current compliance training that is mandatory for all employees are available on the intranet. The Company acknowledges that the Executive may hold one or more professional designations that require mandatory continuing professional development. The Executive shall be entitled to undertake at least 40 hours of continuing professional development training at the expense of the Company.
15 | Holidays |
15.1 | The Executive will be entitled to 30 days' paid holiday in each Holiday Year in addition to the usual public holidays in the Republic of South Africa. The first 28 days of holiday (including any public holidays) taken in any Holiday Year will be the Executive's statutory holiday for the purpose of both the Working Time Regulations 1998 and Clause 15.6 below. |
15.2 | If the Executive's employment commences or terminates part way through a Holiday Year, the entitlement of the Executive during that Holiday Year shall be calculated on a pro rata basis rounded up to the nearest half day. |
15.3 | Holidays shall be taken at such time or times as shall be approved in advance by the Company. The Company may require the Executive to take holiday on particular dates. |
15.4 | The Executive will be entitled to carry over up to 5 days' holiday at the end of each Holiday Year provided that the Executive uses that holiday by 31 March in the following Holiday Year (all other holiday remaining at the end of the Holiday Year will lapse). Any carried over holiday not used by that date will lapse. |
15.5 | The Executive shall have no entitlement to any payment in lieu of accrued but untaken holiday except on termination of the Executive's employment. Subject to Clause 15.6, the amount of any payment in lieu will be 1/260th of the Executive’s Basic Salary for each untaken day of holiday entitlement for the Holiday Year in which termination takes place. |
15.6 | If: |
(a) | the Company has terminated or would have been entitled to terminate the Executive's employment under Clause 21; or |
(b) | the Executive terminates in breach of this agreement, |
26 January 2022 | Page 12 |
any payment due under Clause 15.5 will be limited to the statutory entitlement of the Executive under the Working Time Regulations 1998 (and any holiday (including public holidays) taken shall be deemed first to have been taken in satisfaction of that statutory entitlement as set out in Clause 15.1).
15.7 | If on termination of the Executive's employment the Executive has taken in excess of his accrued holiday entitlement, the Company shall be entitled to recover from the Executive, by way of deduction from any payments due to the Executive or otherwise, one day's pay calculated at 1/260th of the Basic Salary of the Executive for each excess day. |
15.8 | If either party has served notice to terminate the Executive's employment, the Company may require the Executive to take any accrued but unused holiday entitlement during the notice period. Any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave. |
15.9 | During any continuous period of absence due to Incapacity of one month or more the Executive shall not accrue holiday under this contract and the entitlement of the Executive under Clause 15.1 for the Holiday Year(s) in which such absence takes place shall be reduced pro rata save that it shall not fall below the entitlement of the Executive under the Working Time Regulations 1998. |
16 | Incapacity |
16.1 | If the Executive is absent from work due to Incapacity, the Executive shall notify the Company of the reason for the absence as soon as possible on the first day of absence. |
16.2 | Immediately following the Executive's return to work after a period of absence due to Incapacity of seven days or less the Executive must complete a self-certification form. For periods of absence of more than seven consecutive days the Executive must produce a doctor's fit note verifying that the absence is due to Incapacity. |
16.3 | Subject to complying with the Company’s absence requirements above and to the remaining provisions of this Clause 16, the Executive shall be entitled to receive full Basic Salary and contractual benefits during any periods of absence due to Incapacity up to a maximum of 12 weeks in aggregate in any rolling 52-week period. Any such payments shall be inclusive of any statutory sick pay. The Executive's qualifying days for statutory sick pay purposes are Monday to Friday. |
16.4 | The Executive agrees to consent to medical examinations (at the Company's expense) by a doctor or clinic nominated by the Company should the Company so require. The Executive agrees that any report produced in connection with any such examination may be disclosed to the Company and the Company may discuss the contents of the report with the relevant doctor. |
16.5 | If the Incapacity is or appears to be occasioned by actionable negligence, nuisance or breach of any statutory duty on the part of a third party in respect of which damages are or may be recoverable, the Executive shall immediately notify the Company of that fact and of any claim, settlement or judgment made or awarded in connection with it and provide all relevant particulars that the Company may reasonably require. The Executive shall, if required by the Company, co-operate in any related legal proceedings and refund to the Company that part of any damages or compensation recovered by the Executive relating to the loss of earnings for the period of the Incapacity as the Company may reasonably determine less any costs borne by the Executive in connection with the recovery of such damages or compensation, provided that the amount to be refunded to the Company shall not exceed the total amount paid to the Executive by the Company in respect of the period of Incapacity. |
26 January 2022 | Page 13 |
16.6 | The Company is entitled to terminate the Executive's employment under the terms of this agreement notwithstanding that any such termination would or might cause the Executive to forfeit any entitlement to sick pay or other benefits. |
16.7 | The payment of the Executive's Basic Salary and other contractual benefits during absence due to Incapacity is conditional on: |
(a) | notice not having been served by either party; |
(b) | the Executive not being the subject of a disciplinary investigation which could result in the Executive's dismissal for gross misconduct; and |
(c) | the Executive not being under a performance improvement plan. |
17 | Outside interests |
17.1 | Subject to Clause 17.2, the Executive shall not at any time during employment (including during any period of notice) save for any existing arrangements as disclosed in Schedule 2 of this Agreement : |
(a) | be directly or indirectly engaged, concerned or have any financial interest in any Capacity in any other business, trade, profession or occupation (or the setting up of any business, trade, profession or occupation) other than that of the Company and the Group, whether paid or unpaid; or |
(b) | hold any directorship (or other office) of any company other than that of the Company and any Group Company, whether paid or unpaid. |
17.2 | Notwithstanding Clause 17.1, the Executive: |
(a) | save for any existing arrangements as disclosed in Schedule 2 of this Agreement, may hold an investment by way of shares or other securities of not more than 5% of the total issued share capital of any company (whether or not it is listed or dealt in on a recognised stock exchange) provided that such company does not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company; |
(b) | has disclosed to the Company the external interests and activities listed in schedule 2 including the Executive's Capacity with regard to each such interest and activity. The Company consents to the Executive continuing these activities on the strict condition that it reserves the right to require (at any time) the Executive to cease any or all of such interests or activities to the extent that, in the opinion of the Company, they interfere, may be likely to interfere or could be perceived to interfere with the discharge of the Executive's obligations to the Company or Group or create or may be likely to create a conflict of interest or perceived conflict of interest; and |
(c) | may engage in external interests and activities provided that such companies do not carry on (or propose to carry on) any business similar to or competitive with any business for the time being carried on by the Company or any Group Company and such interests or activities do not interfere with the Executive's performance of his duties for the Company, and any board level appointments shall require prior written approval of the governance committee of the Company, not to be unreasonably withheld, and subject to being permitted by the rules of any applicable regulatory framework. |
26 January 2022 | Page 14 |
17.3 | Without prejudice to the Executive's obligations above, the Executive must promptly disclose to the Company any matter relating to the Executive's spouse, civil partner, partner, children, parents or other immediate family and/or any entity whose affairs the Executive or any such person controls which may (or may be perceived to) interfere, conflict or compete with the proper performance of the obligations of the Executive under this agreement. |
18 | Confidential information |
18.1 | Without prejudice to the Executive's common law duties, the Executive shall not (except in the proper course of the Executive's duties, as authorised or required by law or as authorised in advance by the Company), either during the Executive's employment or at any time after termination of employment (howsoever arising): |
(a) | use any Confidential Information; |
(b) | make or use any Copies; or |
(c) | disclose any Confidential Information to any person whatsoever. |
18.2 | The Executive shall be responsible for protecting the confidentiality of the Confidential Information and shall: |
(a) | use best endeavours to prevent the use or communication of any Confidential Information by any person (except in the proper course of that person’s duties, as required by law or as authorised in advance by the Company); and |
(b) | inform the Company immediately upon becoming aware, or suspecting, that any unauthorised person knows, has access to, has been provided with or has used any Confidential Information. |
18.3 | All Confidential Information and Copies are and shall remain at all times the property of the Company and on termination of the Executive's employment (or at the request of the Company at any time during employment), the Executive shall: |
(a) | hand over all Copies to such person as is nominated by the Company; |
(b) | irretrievably delete any Confidential Information (including any Copies) stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in the Executive's possession or under the Executive's control; and |
(c) | on the request of the Company, provide a signed statement that the Executive has complied fully with all obligations under this Clause 18.3 together with such evidence of compliance as the Company may reasonably request . |
18.4 | Clause 18 shall not apply to any Confidential Information which the Executive can demonstrate: |
(a) | is already in the public domain at the time of disclosure; |
(b) | is identifiable without requiring significant expenditure of time, skill or money; and |
(c) | came into the public domain other than by reason of or as a direct or indirect result of the disclosure by the Executive of any Confidential Information. |
26 January 2022 | Page 15 |
18.5 | Nothing in this Clause 18 shall prevent the Executive from: |
(a) | making a protected disclosure within the meaning of Part 4A of the Employment Rights Act 1996 (this includes protected disclosures made about matters previously disclosed to another recipient); |
(b) | making a disclosure to a regulator regarding any misconduct, wrongdoing or serious breach of a Regulatory Requirement; |
(c) | reporting a criminal offence to the police or a law enforcement agency; or |
(d) | co-operating with the police or a law enforcement agency regarding any criminal investigation or prosecution or with a regulator regarding any investigation by that regulator. |
19 | Intellectual property |
19.1 | All Intellectual Property Rights made, discovered, originated, produced or developed by the Executive during the course of employment with the Company (whether or not during working hours or using the premises or resources of the Company or the Group) shall immediately be disclosed in writing to the Company by the Executive and shall automatically, on creation, vest absolutely in the Company or such Group Company as the Company may nominate for that purpose to the fullest extent permitted by law. |
19.2 | The Executive: |
(a) | acknowledges for the purposes of section 39 of the Patents Act 1977 that because of the nature of the Executive's duties, and the particular responsibilities arising from those duties, the Executive has, and at all times during employment will have, a special obligation to further the interests of the business of the Company and the Group; |
(b) | undertakes to promptly, whenever requested by the Company, and in any event upon the termination of employment, deliver up to the Company all such Intellectual Property Rights and all related correspondence, documents, papers and records and all copies of any such Intellectual Property Rights in the Executive's possession or control; |
(c) | undertakes to hold upon trust for the benefit of the Company (or its nominee) all Intellectual Property Rights in respect of all Intellectual Property Rights made, originated or developed by the Executive during employment by the Company (whether or not during working hours or using the premises or resources of the Company or the Group) to the extent that they do no vest automatically in the Company, until the same are vested absolutely in the Company (or its nominee); |
(d) | assigns absolutely with full title guarantee by way of present assignment of present and future rights, all Intellectual Property Rights made, originated or developed by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group); |
(e) | acknowledges that, other than as required by law, no further remuneration or compensation other than that set out in this agreement is or may become due to the Executive in respect of the performance of the Executive's obligations under this Clause 19; |
26 January 2022 | Page 16 |
(f) | undertakes, at the reasonable expense of the Company, to execute all such documents, make such applications, give such assistance and do all such acts and things as may in the opinion of the Company be necessary or desirable to vest, register or obtain any Intellectual Property in the name of the Company (or its nominee), and otherwise to protect and maintain any Intellectual Property Rights made, originated or developed by the Executive and all related Intellectual Property Rights; |
(g) | waives any moral rights (as provided for by Chapter IV of the Copyright Designs & Patents Act 1988 (the 1988 Act) or any similar provisions of law in any jurisdiction) in any Intellectual Property Rights created, made, originated, developed or produced by the Executive in the course of employment (whether or not during working hours or using the premises or resources of the Company or the Group) and agrees to grant all necessary consents and further agrees not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such Intellectual Property Rights infringes the Executive's moral rights, including the right to be identified, the right of integrity and the right against false attribution provided for in the 1988 Act; |
(h) | will not, except in the proper performance of the Executive's duties, disclose any Intellectual Property Rights (or any related correspondence, documents, papers and records and copies) belonging to the Company (or its nominee) without the prior written consent of the Company; and |
(i) | will give all necessary assistance to the Company (or its nominee) to enable the Company (or its nominee) to enforce its Intellectual Property Rights against third parties and/or to defend claims for infringement of third party Intellectual Property Rights. |
19.3 | The Executive irrevocably appoints the Company to be the Executive's attorney in the Executive's name and on the Executive's behalf to execute and/or sign all such instruments, and/or do all such things and generally to use the Executive's name for the purpose of giving to the Company (or its nominee) the full benefit of the provisions of this Clause 19. With respect to any third party, a certificate in writing signed by any director of the Company or the company secretary of the Company that any instrument or act falls within the authority conferred by this Clause 19.3 shall be conclusive evidence that such is the case. |
20 | Payment in lieu of notice |
20.1 | Notwithstanding any other provision of this agreement, the Company may, in its sole and absolute discretion, terminate the Executive's employment under this agreement summarily by giving the Executive written notice that it is exercising its discretion under this Clause 20.1. In such circumstances the Company shall pay the Executive his Basic Salary and contractual benefits in lieu of the notice period referred to in Clause 2.2 or any unexpired part of it. Payment will be made subject to such deductions as are required by law, including for tax and national insurance. The Company's right to make a payment under this Clause 20.1 does not give the Executive any right to demand such payment. |
20.2 | The Executive shall not be entitled to any payment in lieu of notice if the Company would otherwise have been entitled to terminate the Executive's employment without notice in accordance with Clause 21 and the Company shall be entitled to recover from the Executive any payment in lieu of notice already made. |
26 January 2022 | Page 17 |
21 | Termination without notice |
21.1 | The Company may terminate the Executive's employment with immediate effect without notice (and with no liability to make any further payment to the Executive) if the Executive: |
(a) | is disqualified from acting as a director; |
(b) | commits, in the reasonable opinion of the Board, an act of gross misconduct; |
(c) | commits, in the reasonable opinion of the Board, any serious or repeated breach or failure to observe of any of the provisions of this agreement or the Policies and Procedures or the Regulatory Requirements or any anti-bribery and corruption policies and the Executive has previously been given written notice of such and a reasonable opportunity to improve or comply as the case may be; |
(d) | refuses to comply with any reasonable and lawful direction of the Board; |
(e) | is declared bankrupt or makes any arrangement with or for the benefit of his creditors or has a county court administration order made against the Executive under the County Court Act 1984; |
(f) | is convicted of any criminal offence (other than an offence under any road traffic legislation in the United Kingdom or elsewhere for which a fine or non-custodial penalty is imposed); |
(g) | is guilty of fraud or dishonesty or acts in any manner which, in the reasonable opinion of the Board, brings or is likely to bring the Executive, the Company or any Group Company into disrepute or is materially adverse to the interests of the Company or any Group Company (in each case whether or not in the course of employment); or |
(h) | ceases to hold any qualification, approval, registration or authorisation required for the proper performance of the Executive's duties. |
21.2 | The rights of the Company under Clause 21.1 are without prejudice to any other rights that it may have at law to terminate the Executive's employment or to accept any breach of this agreement by the Executive as having brought the agreement to an end. Any delay by the Company in exercising any right to terminate shall not constitute a waiver of that right. |
21.3 | If the Executive's employment is terminated at any time by reason of any reconstruction or amalgamation of the Company or any Group Company, whether by winding up or otherwise, and the Executive is offered employment with any concern or undertaking involved in or resulting from the reconstruction or amalgamation on terms which (considered in their entirety) are no less favourable to any material extent than the terms of this agreement, the Executive shall have no claim against the Company, any Group Company or the undertaking arising out of or in connection with such termination. |
21.4 | This Clause 21.4 applies if the Executive subscribes for or is awarded shares in the Company or any Group Company or participates in any share option, restricted share, restricted share unit, long term incentive, carried interest or co-invest, or any other form of profit sharing, incentive, bonus or equity plan or arrangement (each an Incentive) or may do so. Upon termination of the Executive's employment (whether lawful or unlawful), the Executive's rights (if any) in respect of each Incentive shall be solely determined by the applicable rules or other documents governing each Incentive and the Executive hereby irrevocably waives any other claims or rights in respect of the loss of any rights or benefits under or in respect of any Incentive granted or not yet granted to the Executive (including any loss relating to the lapse of, or the Executive's ineligibility to exercise, any share options, the value of any shares, the operation of any compulsory transfer provisions or the operation of any vesting criteria). |
26 January 2022 | Page 18 |
22 | Garden leave |
22.1 | Following service of notice to terminate the Executive's employment by either party, or if the Executive purports to terminate his employment in breach of contract and/or without serving the period of notice required by Clause 2.2, the Company may in its absolute discretion place the Executive on garden leave for the whole or part of the Executive's notice period (Garden Leave). |
22.2 | During any period of Garden Leave the Company: |
(a) | shall be under no obligation to provide any work to the Executive and may revoke any powers he holds on behalf of the Company or any Group Company; |
(b) | may exclude the Executive from any premises of the Company or any Group Company; |
(c) | may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser, investor or other business contact of the Company or any Group Company; |
(d) | may require the Executive to resign as a director of the Company or any Group Company; |
(e) | may cease to provide the Executive with access to the Company and Group Company information systems; |
(f) | may appoint another person(s) to perform the Executive's responsibilities jointly with the Executive or in the Executive's place; and/or |
(g) | may require the Executive to take any accrued holiday due to the Executive. |
22.3 | During any period of Garden Leave the Executive: |
(a) | will continue to receive Basic Salary and all contractual benefits including the incentives in Clauses 11.1 and 11.2 in the usual way and subject to the terms of any benefit arrangement; |
(b) | will remain an employee of the Company and bound by the terms of this agreement (including his fiduciary duties and duties of good faith and fidelity); and |
(c) | must ensure that the Board knows where the Executive will be and how the Executive can be contacted during each working day (except during any periods taken as holiday in the usual way); |
22.4 | The Executive agrees that he shall have no claim against the Company in respect of any action set out in this Clause 22. |
26 January 2022 | Page 19 |
23 | Obligations upon termination |
23.1 | On termination of the Executive's employment (however arising) or, if the Company so requires, at any time following the service of notice by either party or purported notice of termination by the Executive, the Executive shall: |
(a) | resign immediately from any directorship held by him in or on behalf of the Company or any Group Company and from any other offices he may hold as nominee or representative of the Company or any Group Company, save for any directorship held by him in Bophelo Bioscience & Wellness Pty. Ltd ("Bophelo"), which shall continue subject to the articles of association of Bophelo; |
(b) | immediately deliver to the Company all property of the Company or any Group Company or any of its or their respective customers, clients, suppliers, investors and other business contacts (including documents, books, materials, records, correspondence, papers and information on whatever media and wherever located relating to the business or affairs of the Company or any Group Company or their respective customers, clients, investors, suppliers and other business contacts), which is in his possession or under his control and he/ shall not retain any Copies; |
(c) | irretrievably delete any information relating to the business or affairs of the Company or any Group Company stored on any magnetic or optical disk or memory, including personal computer networks, personal email accounts or personal accounts on websites, and all matter derived from such sources which is in his possession or under his control; |
(d) | deliver to the Company on request any computer or other device in his possession or control to allow the Company to remove all Confidential Information and any software of the Company; and |
(e) | on the request of the Company, provide a signed statement that he has complied fully with his obligations under this Clause 23.1 together with such reasonable evidence of compliance as the Company may require. |
23.2 | The Executive hereby irrevocably appoints the Company to be his attorney to appoint any director of the Company as his attorney to execute such instrument or do any such thing and generally to use his name for the purpose of giving effect to and providing to the Company or its nominee the full benefit of Clause 23.1(a). |
23.3 | The obligations in Clause 23.1 shall not be affected by the fact that any document or device may include the Executive's Personal Data. It shall be the Executive's responsibility to notify the Company of any Personal Data that may exist so that the Company can make proper arrangements for its disposal. |
23.4 | The Executive will, on the Company's reasonable request, co-operate with and assist the Company or any Group Company in any internal investigation, administrative, regulatory, quasi-judicial proceedings or any threatened or actual litigation concerning it or them. The Company will only make such a request where the Executive has in his possession or knowledge any facts or other matters which the Company or any Group Company reasonably considers is relevant to such process or legal proceedings. This assistance may include giving statements/affidavits, meeting with the Company or any Group Company's legal and other professional advisers, attending any legal hearing and giving evidence. The Company or relevant Group Company will pay the Executive's reasonable expenses and loss of income incurred in providing such assistance provided that the Executive notifies the Company or relevant Group Company of the amount of any expenses or anticipated loss of income in advance. |
26 January 2022 | Page 20 |
24 | Post-termination restrictions |
24.1 | In order to protect the Confidential Information and business connections of the Company and each Group Company to which he has access as a result of the Appointment , the Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that he shall not: |
24.1.1 | for 12 months after the Termination Date, solicit or endeavour to entice away from the Company or any Group Company the business or custom of a Restricted Customer with a view to providing goods or services to that Restricted Customer in competition with any Restricted Business; |
24.1.2 | for 12 months after the Termination Date in the course of any business concern which is in competition, or intends to compete, with the Company or any Group Company, offer to employ or engage or otherwise endeavour to entice away from the Company or any Group Company any Restricted Person who could damage the interests of the Company or any Group Company as a result of any such employment, engagement or enticement; |
24.1.3 | for 12 months after the Termination Date in the course of any business concern which is in competition, or which intends to compete, with any Restricted Business, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person who could damage the interests of the Company or any Group Company as a result of that employment or engagement, whether or not such person would be in breach of contract as a result of such employment or engagement; |
24.1.4 | for six months after the Termination Date, be involved in any Capacity with any business concern which is (or intends to be) in competition with any Restricted Business; |
24.1.5 | for 12 months after the Termination Date, be involved with the provision of goods or services to (or otherwise have any business dealings with) any Restricted Customer or Prospective Customer in the course of any business concern which is in competition with any Restricted Business; |
24.1.6 | for 12 months after the Termination Date damage (or attempt to do so) any relationship between the Company or any Group Company and the Restricted Supplier; or |
24.1.7 | at any time after the Termination Date, represent himself as connected with the Company or any Group Company in any capacity, other than as a former employee, director or shareholder, or use any registered names or trading names associated with the Company or any Group Company. |
24.1.8 | at any time after the Termination Date, make any comments or statements of any nature that are derogatory to or disparaging of, or have the effect of lowering the reputation of the Company or any Group Company or any of its or their directors, officers, employees or agents; and/or take part in any conduct which may bring into disrepute the Company, any Group Company or any of its or their directors, officers, employees or agents. |
24.2 | None of the restrictions in Clause 24.1 shall prevent the Executive from: |
26 January 2022 | Page 21 |
24.2.1 | being engaged or concerned in any business concern insofar as the Executive's duties or work shall relate solely to geographical areas where the business concern is not in competition with any Restricted Business; or |
24.2.2 | being engaged or concerned in any business concern, provided that the Executive's duties or work shall relate solely to services or activities of a kind with which the Executive was not concerned to a material extent in the 12 months before the Termination Date. |
24.3 | The restrictions imposed on the Executive by this Clause 24 apply to him acting: |
24.3.1 | directly or indirectly; and |
24.3.2 | on his own behalf or on behalf of, or in conjunction with, any firm, company or person. |
24.4 | Subject to Clause 24.12, the Executive agrees that the Board may review the Prospective Customer, Restricted Business, Restricted Customer, Restricted Person and Restricted Supplier definitions and revise, delete and amend these (to include but not be limited to adding new customers, persons and suppliers or deleting or revising named customers, persons and suppliers) from time to time. |
24.5 | The periods for which the restrictions in Clause 24 apply shall be reduced by any period that the Executive spends on Garden Leave immediately before the Termination Date. |
24.6 | If the Executive receives an offer to be involved in a business concern in any Capacity during the Appointment, or before the expiry of the last of the covenants in this Clause 24, the Executive shall give the person making the offer a copy of this Clause 24 and shall tell the Company the identity of that person as soon as possible after accepting the offer. |
24.7 | This Clause 24.7 applies if, at any time during the Executive's employment, two or more Restricted Persons have left their employment, appointment or engagement with the Company and have subsequently performed work for a Competitor. Where this clause applies, the Executive will not, at any time during the six months following the last date on which any of those Restricted Persons were employed or engaged by the Company, be employed or engaged in any way by the Competitor if the Executive would perform work for or on behalf of the Competitor that is competitive with the Restricted Business. |
24.8 | The Executive has had the opportunity to take legal advice on the restrictions in this Clause 24. |
24.9 | Each of the restrictions in this Clause 24 is intended to be separate and severable. If any of the restrictions shall be held to be void but would be valid if part of their wording were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective. |
24.10 | If the Executive's employment is transferred to any firm, company, person or entity other than a Group Company (the "New Employer") pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, the Executive will, if required, enter into an agreement with the New Employer containing post-termination restrictions corresponding to those restrictions in this Clause 24, protecting the Confidential Information, trade secrets and business connections of the New Employer. |
24.11 | The Executive will, at the request and expense of the Company, enter into a separate agreement with any Group Company in which he agrees to be bound by restrictions corresponding to those restrictions in this Clause 24 (or such of those restrictions as may be appropriate) in relation to that Group Company. |
26 January 2022 | Page 22 |
24.12 | No variation of this Clause 24 will be effective unless it is in writing and signed by the parties. |
24.13 | The Executive covenants with the Company (for itself and as trustee and agent for each Group Company) that he shall not for 12 months after the Termination Date: |
24.13.1 | interfere or take such steps as may be likely to interfere with the continuance of investment or funding to the Company (or the terms relating to such investment or funding) from any Investor or Lender; or |
24.13.2 | seek to damage the relationship between any Investor or Lender and the Company. |
25 | Disciplinary and grievance procedures |
25.1 | The Executive is subject to the disciplinary and grievance procedures of the Company, copies of which are available on the Company's intranet. These procedures do not form part of this agreement or the terms and conditions of the Executive's employment. |
25.2 | The Executive should refer: |
(a) | any appeal the Executive wishes to make against a disciplinary sanction/decision to a member of the Board (or such other person as the Company may specify from time to time); or |
(b) | any grievance the Executive wishes to raise to a member of the Board (or such other person as the Company may specify from time to time), |
in accordance with the Company's disciplinary and grievance procedures.
25.3 | The Company may suspend the Executive from any or all of his duties during any period in which the Company is investigating any disciplinary matter involving the Executive or until the conclusion of any disciplinary procedure (including any appeal). During any period of suspension: |
(a) | subject to Clause 11.5, the Executive will continue to receive Basic Salary and all contractual benefits in the usual way; |
(b) | the Company may suspend the Executive's access to the Company's and Group's systems and internal communications; |
(c) | the Company may require the Executive to return temporarily any Company or Group IT equipment and communication devices (including any smartphones, tablets, laptops and hard drives); |
(d) | the Executive shall remain an employee of the Company and bound by the terms of this agreement; |
(e) | the Executive shall ensure that the Company knows where he will be and how he can be contacted during each working day (except during any periods taken as holiday in the usual way); |
(f) | the Company may exclude the Executive from his place of work or any other premises of the Company or any Group Company; and |
26 January 2022 | Page 23 |
(g) | the Company may require the Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company or any Group Company. |
26 | Change of Control |
26.1 | In the event that there is a Change of Control of the Company or the Cash Shell Company (other than as part of the Listing, the fundraising on or around the date of Listing or an internal re-organisation) and, within 365 days of the Change of Control, the Appointment is terminated by the Company (other than where the Company is entitled to terminate the Appointment without notice or payment in lieu of notice in accordance with Clause 21.1) the Company shall, within one month of the date of the Termination Date, pay or provide the Prescribed Sum to him as provided by this Clause. |
26.2 | The Prescribed Sum shall be an amount equal to one year's Basic Salary in accordance with Clause 8.1 as adjusted in accordance with Clause 26.3. |
26.3 | If the Company or the Cash Shell Company (as the case may be) terminates the Appointment by giving a period of notice whether under Clause 2.2 or otherwise, or terminates the Appointment under Clause 20, the Prescribed Sum shall be reduced pro rata by the number of complete months of service for which the Executive remains employed following notice being given to him or shall be reduced by the amount paid to the Executive under Clause 20. |
26.4 | The payment or provision of the Prescribed Sum shall be conditional upon and in consideration of: |
(a) | the Executive having complied with Clause 23; and |
(b) | the Executive having complied with and continuing to comply with his obligations relating to confidentiality and intellectual property in Clauses 18 and 19 respectively. |
26.5 | For the avoidance of doubt, the payment or provision of the Prescribed Sum shall not affect the Executive's entitlement as at the Termination Date to any of the following: |
(a) | any accrued but unpaid Basic Salary; |
(b) | any payment in lieu of accrued but unused holiday; or |
(c) | the reimbursement of his expenses, provided that all claims for reimbursement are submitted within four weeks of the Termination Date. |
26.6 | To the extent that the Prescribed Sum is damages (which is not admitted), the parties agree that the terms of this Clause 26 represent a genuine pre-estimate of the loss to the Executive that would arise on termination of the Appointment in the circumstances described and does not constitute a penalty. |
27 | Data protection |
27.1 | The Company will collect and process Personal Data in accordance with the data privacy notice which is annexed to this agreement and which is also available on the Company intranet. The Executive shall sign and date the privacy notice and return it to the Company within five working days of the date of this agreement. |
26 January 2022 | Page 24 |
27.2 | The Executive shall comply with the Policies and Procedures in relation to privacy and data protection when handling personal data in the course of employment including personal data relating to any employee, worker, contractor, customer, client, supplier, agent or other contact of the Company or any Group Company. |
28 | Collective agreements |
There is no collective agreement applicable to the Company or to the Executive's employment with the Company.
29 | Notices |
29.1 | A notice given to a party under this agreement shall be in writing in the English language and signed by or on behalf of the party giving it. It shall be delivered by hand or sent to the party at the address given in this agreement or as otherwise notified in writing to the other party. |
29.2 | Any such notice shall be deemed to have been received: |
(a) | if delivered by hand, at the time the notice is left at the address or given to the addressee; |
(b) | in the case of pre-paid first class UK post or other next working day delivery service, at 9.00 a.m. on the second business day after posting or at the time recorded by the delivery service; |
(c) | in the case of email, at the time of transmission. |
29.3 | A notice shall have effect from the earlier of its actual or deemed receipt by the addressee. For the purpose of calculating deemed receipt: |
(a) | all references to time are to local time in the place of deemed receipt; and |
(b) | if deemed receipt would occur on a Saturday or Sunday or a public holiday when banks are not open for business, deemed receipt is at 9.00 a.m. on the next business day. |
29.4 | This Clause does not apply to the service of any proceedings or other documents in any legal action. |
30 | General |
30.1 | No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives). |
31 | Entire agreement |
This agreement contains the entire and only agreement between the parties, and both parties acknowledge that, on entering into this agreement, they have not relied on any written or oral representation or undertaking other than as expressly stated in this agreement, and that this agreement supersedes any previous contract or arrangement between the parties.
26 January 2022 | Page 25 |
32 | Counterparts |
This agreement may be executed in any number of counterparts, each of which, when executed, shall be an original, and all the counterparts together shall constitute one and the same instrument.
33 | Third party rights |
Except as expressly provided elsewhere in this agreement, no person other than the Executive and the Company or any Group Company shall have any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.
34 | Governing law |
This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.
35 | Jurisdiction |
Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).
26 January 2022 | Page 26 |
EXECUTED as a DEED by Trevor Scott | |
at | |
on 2022 | |
before the following witness: | |
Witness Signature: | |
Full name: | |
Address: | |
EXECUTED as a DEED for and on behalf of
Akanda Corp. |
|
at | |
Director/Authorised Signatory | |
on 2022 | |
before the following witness: | |
Witness Signature: | |
Full name: | |
Address: | |
EXECUTED as a DEED for and on behalf of
Canmart Ltd |
|
at | |
Director/Authorised Signatory | |
on 2022 | |
before the following witness: | |
Witness Signature: | |
Full name: | |
Address: | |
26 January 2022 | Page 27 |
Schedule 1
Executive Equity Rights
Not applicable
26 January 2022 | Page 28 |
Schedule 2
Outside Interests
1. | Director and shareholder of Bearingway Limited. |
2. | Director and shareholder of Mokwele Incorporated. |
3. | Advisor to Stallion Group. |
26 January 2022 | Page 29 |
Exhibit 14.1
CODE OF BUSINESS CONDUCT
AND
ETHICS
(Adopted as of November 14, 2021)
T A B L E O F C O N T E N T S
1 Introduction | 2 |
1.1 Purpose | 2 |
1.2 Responsibilities And Behaviors | 2 |
1.3 Supervisory Responsibility | 2 |
1.4 Seeking Help And Information | 3 |
1.5 Reporting Violations Or Suspected Violations | 3 |
1.6 Investigating Reports | 3 |
1.7 Policy Against Retaliation | 3 |
1.8 Waivers Of Code | 4 |
1.9 Monitoring Compliance And Enforcement In General | 4 |
2 CONFLICTS OF INTEREST | 4 |
2.1 Identifying Potential Conflicts Of Interest | 4 |
2.2 Disclosing Conflicts Of Interest | 6 |
2.3 Resolving Conflicts Of Interest | 6 |
3 BUSINESS ENTERTAINMENT, MEALS, AND GIFTS | 6 |
4 CONFIDENTIAL INFORMATION | 7 |
5 COMPETITION AND FAIR DEALING | 7 |
5.1 Relationships With Customers | 8 |
5.2 Relationships With Suppliers | 8 |
5.3 Relationships With Competitors | 8 |
6 PROTECTION AND USE OF COMPANY ASSETS | 8 |
7 COMPANY RECORDS | 9 |
8 POLITICAL CONTRIBUTIONS AND ACTIVITIES | 9 |
9 COMPLIANCE WITH LAWS | 10 |
9.1 Anti - Bribery | 10 |
9.2 Export Control | 11 |
9.3 Antitrust | 11 |
9.4 Insider Trading | 12 |
10 ACCURACY OF FINANCIAL REPORTS | 13 |
11 PUBLIC COMMUNICATIONS | 13 |
12 CONCLUSION | 14 |
1 Introduction
1.1 Purpose
This Code of Business Conduct and Ethics (“Code”) of Akanda Corp. (the “Company”) contains general guidelines for conducting the business of the Company consistent with the highest standards of business ethics. In many cases, the Company has adopted specific written policies to implement various provisions of this Code. To the extent this Code or those policies require a higher standard than required by commercial practice or applicable laws, we adhere to the higher standard.
This Code applies to all of our directors, officers and employees. Except where otherwise noted, all persons covered by this Code are referred to as “Company employees” or simply “employees.”
1.2 Responsibilities And Behaviors
The Company is committed to the highest ethical standards in the conduct of its business and therefore the integrity of each employee, officer, and director is of paramount importance. All employees, officers, and directors are accountable for their actions and must conduct themselves with the utmost integrity. As part of conducting business ethically, employees, officers, and directors must conduct business in strict observance of all applicable federal, state, and local laws and regulations as set forth by those bodies that regulate the Company’s business, and those that regulate public companies, such as the Securities and Exchange Commission. Persons who act unethically or violate this Code and supplementing written policies may be subject to disciplinary action, up to and including termination or removal, and, if applicable, referral to the appropriate authorities for prosecution.
As a representative of the Company, your responsibility is to act ethically and with the highest level of integrity. Employees who violate the law or this Code may expose themselves to substantial civil damages, criminal fines and prison. The Company may also face substantial fines and penalties, and many incur damage to its reputation and standing in the community. If you are unclear about the appropriate response to a particular situation, it is your responsibility to use all the resources available to you to seek guidance. One point should be clear: each employee, officer and director are individually responsible for his or her own actions.
1.3 Supervisory Responsibility
It is incumbent upon supervisors to take every opportunity to model behaviors consistent with our core values and this Code. If you are a supervisor, you are expected to demonstrate the highest standards of ethical conduct by encouraging open and honest discussions of the ethical, legal, and regulatory implications of business decisions, and by creating an open and supportive environment where your employees are comfortable asking questions, raising concerns and reporting misconduct. You should also ensure that everyone under your supervision clearly understands the legal and ethical expectations of the Company, including all aspects of the Code, policies and applicable laws. You must also work with the Human Resources department when you become aware of any suspected violations of this Code.
2 |
1.4 Seeking Help And Information
This Code is not intended to be a comprehensive rulebook and cannot address every situation that you may face. If you feel uncomfortable about a situation or have any doubts about whether it is consistent with the Company’s ethical standards, seek help. We encourage you to contact your supervisor for help first. If your supervisor cannot answer your question or if you do not feel comfortable contacting your supervisor, contact the Chief Financial Officer or send an inquiry through the Company website.
1.5 Reporting Violations Or Suspected Violations
The Company is committed to establishing and maintaining an effective process for employees, officers, and directors to report, and for the Company to respond to and correct, any type of misconduct. All employees, officers, and directors have a continuing responsibility and duty to report any known or suspected violation of this Code, including any violation of the laws, rules, regulations or policies that apply to the Company. If you know of or suspect a violation of this Code, immediately report the conduct to your supervisor, or the Company’s Chief Financial Officer. Your supervisor or the Chief Financial Officer will contact the proper legal counsel, who will work with you and your supervisor to investigate your concern. If you do not feel comfortable reporting the conduct to your supervisor or you do not get a satisfactory response, you may contact the proper legal counsel directly.
While providing your identity may assist the Company in addressing your questions or concerns, please note that if you choose, you may remain anonymous and will not be required to reveal your identity.
1.6 Investigating Reports
All reports of known or suspected violations will be handled sensitively and with discretion. Your supervisor, the Chief Financial Officer and the Company will protect your confidentiality to the extent possible, consistent with law and the Company’s need to investigate your concern. During an investigation of suspected violations, you are required to cooperate fully in the investigation, and must take certain steps to do so. You must be honest and forthcoming at all times during an investigation, must provide investigators with full, accurate, timely, and truthful information, and must not interfere or obstruct the investigation. You may not discuss an investigation with others unless authorized to do so. Failure to take any of these steps during an investigation is a violation of this Code.
Any person accused of violating this Code will be given an opportunity to present his or her version of the events prior to any determination that a violation has occurred, or any Company decision regarding the appropriate discipline.
1.7 Policy Against Retaliation
The Company prohibits retaliation against an employee who, in good faith, seeks help or reports known or suspected violations. If you report an actual or suspected violation by another, you will not be subject to discipline or retaliation of any kind for making a report in good faith. Any reprisal or retaliation against an employee because the employee, in good faith, sought help or filed a report will be subject to disciplinary action, including potential termination of employment.
3 |
1.8 Waivers Of Code
Only the entire Board of Directors may waive provisions of this Code for employees (unless legally required). Any waiver of this Code for our directors, executive officers or principal financial officers may be made only by our Board of Directors or an appropriate committee of our Board of Directors and will be disclosed to the public as required by law or the rules of The Nasdaq Capital Market.
1.9 Monitoring Compliance And Enforcement In General
The Company’s management, under the supervision of its Board of Directors or a committee thereof or, in the case of accounting, internal accounting controls, auditing or securities law matters, the Audit Committee, shall take reasonable steps from time to time to (i) monitor compliance with the Code, and (ii) when appropriate, impose and enforce appropriate disciplinary measures for violations of the Code.
Disciplinary measures for violations of the Code will be determined in the Company’s sole discretion and may include, but are not limited to, counseling, oral or written reprimands, warnings, probation or suspension with or without pay, demotions, reductions in salary, termination of employment or service, and restitution.
The Company’s management shall periodically report to the Board of Directors or a committee thereof on these compliance efforts including, without limitation, periodic reporting of alleged violations of the Code and the actions taken with respect to any such violation.
2 CONFLICTS OF INTEREST
2.1 Identifying Potential Conflicts Of Interest
The Company’s reputation may be impaired by conflicting relationships or activities. A conflict of interest can occur when an employee’s private interest interferes, or reasonably appears to interfere, with the interests of the Company. You must conduct your outside associations and personal business, financial, and other relationships in a manner that avoids any conflict of interest, or appearance of a conflict of interest, between yourself and the Company. You must avoid any private interest that influences your ability to act in the interests of the Company or that makes it difficult to perform your work objectively and effectively. The term “outside association” includes any affiliation, association, interest, relationship, or employment that you have with anyone other than the Company. Further, you must not give the appearance of Company representation in any of your personal affairs.
It is impractical to conceive and set forth rules that cover every situation in which a conflict of interest may arise. The following is not an exhaustive list of problem areas, but rather a guide in applying the Company’s basic conflict of interest policy to any situation.
4 |
· | Employment Relationships. A conflict of interest may arise when you or a member of your immediate family holds a position as an employee, officer or director of an entity with which the Company has or is likely to have a business relationship, or with which the Company competes or is likely to compete. No employee or officer should accept employment with any entity that is a customer, supplier or competitor of the Company. You must also report when a family member has a relationship with an entity with which the Company has or is likely to have a business relationship or with which the Company competes or is likely to compete. |
· | Improper Personal Benefits. You may not obtain any improper personal benefits or favors because of your position with the Company. |
· | Financial Interests. You should not have a financial interest (ownership or otherwise) in any company that is a customer, supplier or competitor of the Company, unless pre-approved by the proper legal counsel. Generally, a significant financial interest will not be permitted except in exceptional circumstances. Significant financial interest means (i) ownership of greater than 1% of the equity of a customer, supplier or competitor or (ii) an investment in a customer, supplier or competitor that represents more than 5% of the total assets of the employee making the investment. |
· | Corporate Opportunities. You are prohibited from taking advantage of an opportunity to engage in a business activity in which the Company has an actual interest or a reasonable expectation of an interest. |
· | Use of Company Assets. You are prohibited from using Company assets to pursue personal interests. |
· | Loans or Other Financial Transactions. You should not obtain loans or guarantees of personal obligations from, or enter into any other personal financial transaction with, the Company or any company that is a customer, supplier or competitor of the Company. This guideline does not prohibit arms-length transactions with banks, brokerage firms or other financial institutions. |
· | Service on Boards and Committees. You should not serve on a board of directors or trustees or on a committee of any entity (whether profit or not-for-profit) whose interests reasonably would be expected to conflict with those of the Company. |
· | Actions of Family Members. The actions of family members outside the workplace may also give rise to the conflicts of interest described above because they may influence an employee’s objectivity in making decisions on behalf of the Company. For purposes of this Code, “family members” include your spouse or life-partner, parents, children and siblings, whether by blood, marriage or adoption, and anyone residing in your home. |
5 |
2.2 Disclosing Conflicts Of Interest
While it is incumbent on each employee to act in a manner at all times that is in the best interests of the Company, and avoid conflicts of interest, the Company recognizes that from time to time, situations may occur in which a conflict or appearance of a conflict of interest is unavoidable. The Company requires that employees disclose any situations that reasonably would be expected to give rise to a conflict of interest. If you suspect that you have a conflict of interest, or something that others could reasonably perceive as a conflict of interest, you must report it to the Company. If you are an employee, you must report it to the Vice President of your department, the Chief Financial Officer, or the proper legal counsel. If you are an officer or director, you must report the matter to the proper legal counsel or to the Audit Committee. If you are an employee, your Vice President or the Chief Financial Officer will coordinate with the proper legal counsel to review the matter and resolve it as necessary.
2.3 Resolving Conflicts Of Interest
When a conflict or appearance of a conflict of interest occurs, or is reasonably likely to occur, the Company is committed to resolving the situation in a way that protects the best interests of the Company. Such resolution can take many forms, such as requiring the employee to recuse himself or herself from participating in a particular matter, reassigning duties, or additional measures designed to ensure that the best interests of the Company are not compromised by the conflict of interest. In all cases, conflicts of interest must be handled in an ethical manner; meaning they must be fully disclosed and considered prior to being resolved. The Chief Financial Officer or the proper legal counsel, as applicable, will handle all questions of conflicts of interest, including coordinating with the Audit Committee as necessary. Conflicts may be permitted only after full disclosure has been made, the Company (or the Audit Committee, as appropriate) has given prior written approval, and the employee has agreed to adhere to any safeguards put into place to ensure that the best interests of the Company are fully protected in the situation in question. Conflicts of interest resulting from a violation of this Code may also be subject to discipline.
3 BUSINESS ENTERTAINMENT, MEALS, AND GIFTS
The Company recognizes that occasional exchanges of business courtesies between vendors, suppliers, and our employees, such as entertainment, meals, or gifts, can be helpful in building and maintaining business relationships. However, you should exercise extreme caution when accepting offers of entertainment, meals or gifts, as regular or excessive entertainment, meals or gifts can easily create a conflict or appearance of a conflict of interest, and irreparably damage your reputation and the reputation of the Company. Generally, entertainment and gifts must have a clear business purpose and should benefit the Company by building trust and goodwill in the business relationship. Participating in entertainment such as meals, sports events, golf outings, and celebration functions, etc. with our business partners is acceptable provided the entertainment with the same partner is infrequent, in good taste, in moderation, and not extravagant. Similarly, gifts should be of only nominal value (generally less than $100), infrequent, in good taste, in moderation, and not extravagant. Efforts should also be made so that even when a clear business purpose has been established, the costs for the entertainment or meals are shared, or reciprocated when appropriate and possible. In no event should you ever solicit offers of entertainment, meals or gifts, and similarly, you must never accept entertainment, meals or gifts if there is no clear business purpose, or if such acceptance would create or appear to create a conflict of interest.
6 |
Attending supplier sponsored conferences, seminars, and entertainment events where air travel, hotel, or other accommodations are provided, creates more serious concerns. Your participation in events where the sponsor provides both business and entertainment activities are acceptable when your participation is important to the business of the Company. You should not attend these events if it does not serve a significant business purpose for the Company or could cause, or appear to cause, you to favor that supplier over others. If you are invited by suppliers to attend conferences, seminars, or entertainment events where the supplier pays for air travel or other accommodations, you must obtain prior approval from an appropriate senior executive.
Likewise, when interacting with customers and vendors, you are expected to adhere to the policies and procedures established by those entities concerning meals, entertainment and gifts.
If you receive an offer for entertainment or meals that do not accord with these standards, you should politely decline. Similarly, gifts that do not accord with these standards should be returned, with an explanation that the Company’s standards do not permit the employee to retain the gift. The Company, as well as the employee’s supervisor, may also put additional limits and policies in place with respect to entertainment, meals and gifts, including appropriate documentation and notice and approval requirements.
4 CONFIDENTIAL INFORMATION
Employees have access to a variety of confidential information as a result of their relationship with the Company. Confidential information includes but is not limited to all non-public information of the Company, or its customers or suppliers, and personally identifiable information of employees, or persons associated with the Company’s business partners. You must safeguard all confidential information of the Company or third parties with which the Company conducts business, except when disclosure is authorized or legally mandated. Your obligation to protect confidential information continues after you leave the Company. Unauthorized disclosure of confidential information could cause competitive harm to the Company or its business partners and could result in legal liability to you and the Company.
Any questions or concerns regarding whether disclosure of Company information is legally mandated should be promptly referred to the Chief Executive Office of Chief Financial Officer.
5 COMPETITION AND FAIR DEALING
All employees should endeavor to deal fairly with fellow employees and with the Company’s customers, suppliers and competitors. Employees should not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice.
7 |
5.1 Relationships With Customers
Our business success depends upon our ability to foster lasting customer relationships. The Company is committed to dealing with customers fairly, honestly, and with integrity. Specifically, you should keep the following guidelines in mind when dealing with customers:
· | Information we supply to customers should be accurate and complete to the best of our knowledge. Employees should not deliberately misrepresent information to customers. |
· | Employees should not refuse to sell the Company’s products or services simply because a customer is buying products or services from another supplier. |
· | Customer entertainment should not exceed reasonable and customary business practice. |
Employees should not provide entertainment or other benefits that could be viewed as an inducement to, or a reward for, customer purchase decisions.
5.2 Relationships With Suppliers
The Company deals fairly and honestly with its suppliers. This means that our relationships with suppliers are based on price, quality, service and reputation, among other factors. Employees dealing with suppliers should carefully guard their objectivity. Specifically, you should not accept or solicit any personal benefit from a supplier or potential supplier that might compromise, or appear to compromise, your objective assessment of the supplier’s products and prices.
5.3 Relationships With Competitors
The Company is committed to free and open competition in the marketplace. You should avoid actions that would be contrary to laws governing competitive practices in the marketplace, including federal and state antitrust laws. Such actions include misappropriation and/or misuse of a competitor’s confidential information or making false statements about the competitor’s business and business practices. For a further discussion of appropriate and inappropriate business conduct with competitors, see “Compliance with Laws: Antitrust” below.
6 PROTECTION AND USE OF COMPANY ASSETS
Employees should protect the Company’s assets and ensure their efficient use for legitimate business purposes only. Theft, carelessness and waste have a direct impact on the Company’s profitability. The use of Company funds or assets for any unlawful or improper purpose is prohibited.
To ensure the protection and proper use of the Company’s assets, you should:
· | Exercise reasonable care to prevent theft, damage or misuse of Company property. |
8 |
· | Report the actual or suspected theft, damage or misuse of Company property to a supervisor. |
· | Use the Company’s telephone system, other electronic communication services, written materials and other property for business-related purposes. |
· | Safeguard all electronic programs, data, communications and written materials from inadvertent access by others. |
· | Use Company property only for legitimate business purposes, as authorized in connection with your job responsibilities. |
You should also be aware that Company property includes all data and communications transmitted or received to or by, or contained in, the Company’s electronic or telephonic systems. Company property also includes all written communications. Employees and other users of this property should have no expectation of privacy with respect to these communications and data. To the extent permitted by law, the Company has the ability, and reserves the right, to monitor all electronic and telephonic communication. These communications may also be subject to disclosure to law enforcement or government officials.
7 COMPANY RECORDS
Accurate and reliable records are crucial to our business. Our records are the basis of our earnings statements, financial reports and other disclosures to the public and guide our business decision-making and strategic planning. Company records include booking information, payroll, timecards, travel and expense reports, e-mails, accounting and financial data, measurement and performance records, electronic data files and all other records maintained in the ordinary course of our business.
All Company records must be complete, accurate and reliable in all material respects. Undisclosed or unrecorded funds, payments or receipts are inconsistent with our business practices and are prohibited. You are also responsible for understanding and complying with record keeping policies as established by the Company from time to time. Ask your supervisor if you have any questions.
8 POLITICAL CONTRIBUTIONS AND ACTIVITIES
The Company encourages its employees to participate in the political process as individuals and on their own time. However, federal and state contribution and lobbying laws severely limit the contributions the Company can make to political parties or candidates. It is Company policy that Company funds or assets are not be used to make a political contribution to any political party or candidate, unless prior approval has been given by the proper legal counsel.
9 |
The following guidelines are intended to ensure that any political activity you pursue complies with this policy:
· | Contribution of Funds. You may contribute your personal funds to political parties or candidates. The Company will not reimburse you for personal political contributions. |
· | Volunteer Activities. You may participate in volunteer political activities during non-work time. You may not participate in political activities during work time. |
· | Use of Company Facilities. The Company’s facilities should not be used for political activities (including fundraisers or other activities related to running for office). The Company may make its facilities available for limited political functions, including speeches by government officials and political candidates, with the approval of the proper legal counsel. |
· | Use of Company Name. When you participate in political affairs, you should be careful to make it clear that your views and actions are your own, and not made on behalf of the Company. For instance, Company letterhead should not be used to send out personal letters in connection with political activities. |
These guidelines are intended to ensure that any political activity you pursue is done voluntarily and on your own resources and time. Please contact the Chief Financial Officer if you have any questions about this policy.
9 COMPLIANCE WITH LAWS
Each employee has an obligation to comply with all laws, rules and regulations applicable to the Company. These include, without limitation, laws covering bribery and kickbacks, copyrights, trademarks and trade secrets, information privacy, insider trading, illegal political contributions, antitrust prohibitions, foreign corrupt practices, offering or receiving gratuities, environmental hazards, employment discrimination or harassment, occupational health and safety, false or misleading financial information or misuse of corporate assets. You are expected to understand and comply with all laws, rules and regulations that apply to your job position. If any doubt exists about whether a course of action is lawful, you should seek advice from your supervisor or the Chief Financial Officer, which will contact the proper legal counsel, if necessary.
9.1 Anti - Bribery
The Company’s anti-bribery prohibition is simple: No employee, officer or director may offer a bribe nor receive a bribe, under any circumstances. The Company maintains an Anti-Bribery Policy, which contains other prohibitions and requirements, for example: reporting of red flag events, restricting hiring of foreign agents and reporting of any violations of the Company’s Anti-Bribery Policy.
If there are any questions regarding the Company’s Anti-Bribery Policy, you should contact the Chief Financial Officer.
10 |
9.2 Export Control
Various government agencies maintain lists that identify individuals or entities barred or restricted from entering into certain types of transactions. The Company must ensure that the Company does not engage in a transaction with a barred entity or person. All employees have an obligation to notify the Company’s Chief Financial Officer if any person with whom they are engaging on behalf of the Company are identified on any of these lists. If in doubt, contact the legal department or Chief Financial Officer for more information on screening to ensure compliance.
Similarly, various countries are subject to comprehensive Canadian economic sanctions and trade embargoes, and the Company is prohibited from engaging in transactions that result in any goods, technology or monies being diverted to any customer or end user in such countries. From time to time Canada also has limited sanctions pertaining to other countries (e.g. Russia, Syria and Libya), so it is important to check if any party to a proposed Company transaction is from a country for which Canada has imposed complete embargoes or partial sanctions. When in doubt, discuss any potential transaction with the Legal department.
9.3 Antitrust
Antitrust laws of Canada and other countries are designed to protect consumers and competitors against unfair business practices and to promote and preserve competition. Our policy is to compete vigorously and ethically while complying with all antitrust, monopoly, competition or cartel laws in all countries, states or localities in which the Company conducts business.
In general, U.S. antitrust laws forbid agreements or actions “in restraint of trade.” All employees should be familiar with the general principles of the U.S. antitrust laws. The following is a summary of actions that are violations of U.S. antitrust laws:
· | Price Fixing. The Company may not agree with its competitors to raise, lower or stabilize prices or any element of price, including discounts and credit terms. |
· | Limitation of Supply. The Company may not agree with its competitors to limit its production or restrict the supply of its services. |
· | Allocation of Business. The Company may not agree with its competitors to divide or allocate markets, territories or customers. |
· | Boycott. The Company may not agree with its competitors to refuse to sell or purchase products from third parties. In addition, the Company may not prevent a customer from purchasing or using non-Company products or services. |
· | Tying. The Company may not require a customer to purchase a product that it does not want as a condition to the sale of a different product that the customer does wish to purchase. |
11 |
Employees should exercise caution in meetings with competitors. Any meeting with a competitor may give rise to the appearance of impropriety. As a result, if you are required to meet with a competitor for any reason, you should obtain the prior approval of the Chief Executive Officer, who will contact the proper legal counsel, if necessary. You should try to meet with competitors in a closely monitored and controlled environment for a limited period of time. The contents of your meeting should be fully documented. Specifically, you should avoid any communications with a competitor regarding:
· | Prices; |
· | Costs; |
· | Market share; |
· | Allocation of sales territories; |
· | Profits and profit margins; |
· | Supplier’s terms and conditions; |
· | Product or service offerings; |
· | Terms and conditions of sale; |
· | Facilities or capabilities; |
· | Bids for a particular contract or program; |
· | Selection, retention or quality of customers; or |
· | Distribution methods or channels. |
Employees should also be cautious when attending meetings of professional organizations and trade associations at which competitors are present. Attending meetings of professional organizations and trade associations is both legal and proper, if such meetings have a legitimate business purpose. At such meetings, you should not discuss pricing policy or other competitive terms, plans for new or expanded facilities or any other proprietary or competitively sensitive information.
Violations of antitrust laws carry severe consequences and may expose the Company and employees to substantial civil damages, criminal fines and, in the case of individuals, prison terms. Whenever any doubt exists as to the legality of a particular action or arrangement, it is your responsibility to contact the Chief Executive Officer or Chief Financial Officer, who will contact the proper legal counsel promptly for assistance, approval and review.
9.4 Insider Trading
The laws against insider trading are specific and complex. The Company also maintains extensive policies concerning insider trading designed to help the Company and an employee comply with the laws on insider trading. Employees are responsible for reading and complying with these policies. As a guideline, employees are prohibited from trading in the stock or other securities of the Company while in possession of material, nonpublic information about the Company. In addition, Company employees are prohibited from recommending, “tipping” or suggesting that anyone else buy or sell stock or other securities of the Company on the basis of material, nonpublic information. Company employees who obtain material nonpublic information about another company in the course of their employment are prohibited from trading in the stock or securities of the other company while in possession of such information or “tipping” others to trade on the basis of such information. Violation of insider trading laws can result in severe fines and criminal penalties, as well as disciplinary action by the Company, up to and including termination of employment.
12 |
Information is “non-public” if it has not been made generally available to the public by means of a press release or other means of widespread distribution. Information is “material” if a reasonable investor would consider it important in a decision to buy, hold or sell stock or other securities. As a rule of thumb, any information that would affect the value of stock or other securities should be considered material. Examples of information that is generally considered “material” include:
· | Financial results or forecasts, or any information that indicates a company’s financial results may exceed or fall short of forecasts or expectations; |
· | Important new products or services; |
· | Pending or contemplated acquisitions or dispositions, including mergers, tender offers or joint venture proposals; |
· | Possible management changes or changes of control; |
· | Pending or contemplated public or private sales of debt or equity securities; |
· | Acquisition or loss of a significant customer or contract; |
· | Significant write-offs; |
· | Initiation or settlement of significant litigation; and |
· | Changes in the Company’s auditors or a notification from its auditors that the Company may no longer rely on the auditor’s report. |
Any questions about information you may possess or about any dealings you have had in the Company’s securities should be promptly brought to the attention of the Chief Financial Officer.
10 ACCURACY OF FINANCIAL REPORTS
As a public company we are subject to various securities laws, regulations and reporting obligations. Both U.S. federal law and our policies require the disclosure of accurate and complete information regarding the Company’s business, financial condition and results of operations. Inaccurate, incomplete or untimely reporting will not be tolerated and can severely damage the Company and result in legal liability.
Employees working in financial, public relations and legal roles have a special responsibility to ensure that all of our financial disclosures are full, fair, accurate, timely and understandable. If you work in such a capacity, you are expected to understand and strictly comply with generally accepted accounting principles and all standards, laws and regulations for accounting and financial reporting of transactions, estimates and forecasts.
11 PUBLIC COMMUNICATIONS
The Company places a high value on its credibility and reputation in the community. What is written or said about the Company in the news media and investment community directly impacts our reputation, positively or negatively. Our policy is to provide timely, accurate and complete information in response to public requests (media, analysts, etc.), consistent with our obligations to maintain the confidentiality of competitive and proprietary information and to prevent selective disclosure of market-sensitive financial data. In addition, the Company is required to periodically make public certain information about itself, and file regular reports concerning its financial and operational performance. The Company also from time to time may choose to issue information of interest to its shareholders or the general public. The Company is committed to ensuring that its communications are truthful, meaningful, consistent, and in compliance with all laws.
13 |
To ensure compliance with its standards and its legal obligations, the Company limits the persons who may speak on behalf of the Company and has extensive procedures in place to review and approve all public communications. You should direct all news media or other public requests for information regarding the Company to the Company’s media relations personnel. The media relations personnel will work with you and the appropriate Company departments to evaluate and coordinate a response to the request. Only persons designated by the Company to speak on its behalf are authorized to disclose information about the Company. Similarly, even when designated as authorized to speak for the Company, an employee should never disseminate any information that has not been pre-approved for release.
Company employees who regularly interact with the media, the securities market, investors or the general public also have a special responsibility to understand and comply with specific laws regarding disclosure, including but not limited to Regulation Fair Disclosure. Contact the Chief Financial Officer if you have any questions about the scope or application of the laws applicable to your job responsibilities, including Regulation FD.
12 CONCLUSION
This Code of Business Conduct and Ethics contains general guidelines for conducting the business of the Company consistent with the highest standards of business ethics. If you are faced with making a challenging decision regarding a particular situation, you are not alone. There are many resources available to help resolve ethical questions or concerns. If you have any questions, you may contact:
· | Your immediate supervisor; |
· | Other supervisors or management personnel; |
· | The Human Resources department; |
· | Chief Financial Officer |
We expect all Company employees to adhere to these standards.
14 |
CERTIFICATION
The undersigned hereby acknowledges receipt of Akanda Corp.’s Code of Business Conduct and Ethics (the “Code”), and certifies that the undersigned has read, understands and will comply with the Code.
Date:___________________, 20___ | |
Signature | |
Print Name | |
Title |
One signed copy of this certificate should be sent to:
Akanda Corp. | |
via email: trevor@akandacorp.com |
Exhibit 14.2
WHISTLEBLOWER POLICY
PROCEDURES FOR RECEIPT OF COMPLAINTS AND SUBMISSIONS
RELATING TO ILLEGAL OR UNETHICAL CONDUCT
(Adopted as of 14 November 2021)
INTRODUCTION
Akanda Corp. (the “Company”) expects directors, officers, employees and key consultants (being, those who are engaged in an employee-like capacity) (collectively, “Personnel”) of the Company to take all responsible steps to prevent violations of its Code of Business Conduct and Ethics (the “Code”), to identify and raise potential issues before they lead to problems, and to seek additional guidance when necessary.
These Procedures are designed to provide an atmosphere of open communication for compliance issues and to ensure that Personnel acting in good faith have the means to report actual or potential violations and to reassure Personnel that they should be able to raise genuine concerns without fear of reprisals, even if they turn out to be mistaken.
REPORTING RESPONSIBILITY
If any Personnel observe or become aware of an actual or potential violation of the Code or of any applicable law or regulation (including securities laws and regulations), whether committed by Personnel or by others associated with the Company (for example, external parties with whom the Company has contracted), it is his/her responsibility to promptly report the circumstances as outlined herein and to cooperate with any investigation by the Company.
It is also the responsibility of Personnel who have concerns regarding questionable accounting, internal financial controls or auditing matters to report such concerns in accordance with the procedures outlined herein.
Examples of issues to be reported are set out in Schedule “A” to these Procedures.
NO RETALIATION AND ACTING IN GOOD FAITH
The Company prohibits Personnel from retaliating or taking adverse action against anyone for raising suspected conduct violations or helping to resolve a conduct concern. Any individual who has been found to have engaged in retaliation against any of the Company’s Personnel for raising, in good faith, a conduct concern or for participating in the investigation of such a concern may be subject to discipline, up to and including termination of employment or other business relationship. If any individual believes that he or she has been subjected to such retaliation, that person is encouraged to report the situation as soon as possible to one of the people identified in the “Reporting Procedures” section below.
Anyone filing a complaint concerning a violation or suspected violation of the Code, or reporting concerns relating to accounting and auditing matters must be acting in good faith and have reasonable grounds for believing the information disclosed indicates a violation of the Code. Any allegations that prove not to be substantiated and which prove to have been made maliciously or knowingly to be false will be viewed as a serious disciplinary offense, and may be subject to legal and civil action in addition to employment review.
REPORTING PROCEDURES
For assistance with compliance matters or clarification as to the way to report actual or potential compliance infractions, Personnel should contact the Chief Financial Officer or the Chair of the Audit Committee of the Board of Directors of the Company (the “Audit Committee”).
All Compliance matters
Personnel or External parties with direct knowledge of the violation or fraud concern may submit reports of alleged violations of this Code in writing on a confidential basis to the Chair of the Audit Committee through submitting a Fraud Alert Email via email to the Chair of the Audit Committee at charles@akandacorp.com.
In reporting any actual or potential violation of the Code, an individual should provide, to the extent possible, such relevant documents to support the allegations being made, such as e-mails, handwritten notes, photographs, or physical evidence.
Any report of actual or potential violation of the Code should include, at a minimum the following information:
· | the names of the parties involved. |
· | any witnesses to the incident(s). |
· | the location, date, and time of the incident(s). |
· | details about the incident (behaviour and/or words used). |
· | any additional details that would help with an investigation. |
Violations or suspected violations may be submitted on a confidential basis by the complainant or may be submitted anonymously.
COMPLIANCE OFFICER
As at the date hereof, the Company’s Compliance Officer can be contacted as outlined below:
Trevor Scott (interim Compliance Officer)
Tel: +27 83 380 8040
E-mail: trevor@akandacorp.com
Any future changes to the Compliance Officer can be found on the Company’s website and anonymous ways to report any Company violations.
The Compliance Officer shall report to the Audit Committee as frequently as such Compliance Officer deems appropriate, but in any event no less frequently than on a quarterly basis at the quarterly meeting of the Audit Committee called to approve interim and annual financial statements of the Company.
The Compliance Officer will keep any reported violations confidential and that the identity of employees making complaints or submissions shall be kept confidential and shall only be communicated to the Chair of the Audit Committee.
HANDLING OF REPORTED VIOLATIONS
Upon receipt of a report from the Chair of the Audit Committee, or the Compliance Officer, the Audit Committee (as applicable) shall discuss the report and take such steps as that committee of the Company’s Board of Directors (the “Board”) may deem appropriate. At a minimum, the Audit Committee, as applicable, should initiate an investigation of the alleged violation(s). Additional steps could include, if appropriate:
• | Advising the alleged subject of the report; and |
• | Considering a review and revisions to workplace procedures to prevent any future violations of the Code. |
Reports of violations or suspected violations will be kept confidential to the extent possible, consistent with the need to conduct an adequate investigation.
The Compliance Officer or Chair of the Audit Committee (as applicable) shall retain a record of a complaint or submission received for a period of six years following resolution of the complaint or submission.
Any complaint about a member of the Audit Committee shall be considered by the Board, with the person accused recused from any discussion in connection with the complaint.
INVESTIGATION OF REPORTED VIOLATIONS
Following the receipt of any complaints submitted hereunder, the Audit Committee, will investigate each matter so reported and recommend corrective disciplinary actions to the Board, if appropriate, up to and including termination of employment.
At a minimum, investigations will:
• | be undertaken promptly and diligently, and be as thorough as necessary, given the circumstances. |
• | be fair and impartial, providing both the complainant and respondent equal treatment in evaluating the allegations. |
• | be sensitive to the interests of all parties involved and maintain confidentiality. |
• | be focused on finding facts and evidence, including interviews of the complainant, respondent, and any witnesses. |
• | incorporate, where appropriate, any need or request from the complainant or respondent for assistance during the investigation process. |
SCHEDULE ‘A’
Examples of Matters to be Reported
· | Fraud, theft and other criminal activity |
· | Accounting irregularities, Financial Statement Disclosure issues |
· | Non-compliance with Internal Accounting Controls |
· | Workplace violence, related to an executive |
· | Substance abuse, related to an executive |
· | Discrimination, bullying and harassment, related to an executive |
· | Falsification of company records |
· | Conflicts of Interest |
· | Release of proprietary information |
· | Safety/security violations |
· | Malicious property damage |
· | Violations of securities laws (including insider trading) |
· | Breaches of other applicable laws (environmental, employment, health and safety laws) |
· | Ethics violations |
CERTIFICATION
The undersigned hereby acknowledges receipt of Akanda Corp.’s Whistleblower Policy (the “Policy”), and certifies that the undersigned has read and understands the Policy.
Date:___________, 20_____ | |
Signature | |
Print Name | |
Title |
One signed copy of this certificate should be sent to:
Akanda Corp. 1a, 1b Learoyd Road
New Romney TN28 8XU, United Kingdom
Exhibit 14.3
RELATED PARTY TRANSACTIONS POLICY
(Adopted as of 14 November, 2021)
PURPOSE
At Akanda Corp. (the “Company”) we aim to lead by example. We set high standards for our people at all levels and strive to meet them consistently. Our sound business principles and practices foster our commitment to ethical behavior, accountability and transparency. We expect our directors, officers and employees to avoid conflicts of interest, that is, any activity that interferes with the performance of their duties or that might deprive us of their undivided loyalty in business dealings. Conflicts of interest can come up in various ways, even in situations where the transaction may benefit the Company and our stockholders and thus make it unclear whether a conflict even exists. This Related Party Transactions Policy (this “Policy”) deals specifically with those situations where the Company (including any of our subsidiaries) is a party to a transaction with a “Related Party” (as defined below). A Related Party is a party whose material interest in a transaction could be an actual or potential conflict of interest, or at least create the appearance of such a conflict. Although our Code of Business Conduct and Ethics addresses this issue generally, we have adopted this Policy to formalize our procedures for the identification, review, and consideration and approval of the Audit Committee of our Board of Directors (the “Audit Committee”) of any transactions involving the Company and a Related Party. This Policy has been approved by our Board of Directors (“Board”). The Audit Committee may recommend future amendments to this Policy for consideration by our Board as our business evolves.
PERSONS COVERED BY THIS POLICY
This Policy is applicable to all members of our Board and director nominees, each of our executive officers and any person the Company knows to own an interest in the voting power of the Company that gives them significant influence over the Company (each, a “significant stockholder”). Any direct or indirect beneficial owner of more than 5% of any class of the Company’s voting securities is deemed to be a significant stockholder.
APPROVAL AUTHORITY
Our “Approval Authority” will be our Audit Committee. In a situation where a member of our Audit Committee is a Related Party in the proposed transaction, the other members of the Audit Committee or, if requested by the Audit Committee, our Board will be the Approval Authority.
WHO IS A RELATED PARTY?
You are a Related Party if you are:
1. a person who is, or at any time since the beginning of our last fiscal year was, a director or executive officer of the Company or a nominee to become a director;
2. a significant stockholder;
3. an immediate family member of a director, director nominee, executive officer or significant stockholder. This includes a person’s spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law, and anyone (other than domestic employees or tenant) who share such person’s home; or
4. entities controlled by a director, director nominee, executive officer or significant stockholder or in which a director, director nominee, executive officer or significant stockholder has a greater than 10% beneficial interest.
WHAT TYPES OF TRANSACTIONS ARE COVERED BY THIS POLICY?
Any transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness, or any series of similar transactions, arrangements or relationships) that:
1. the Company or any of its subsidiaries is or will be a participant;
2. any Related Party has or will have a direct or indirect material interest; and
3. the aggregate amount involved will or may be expected to exceed $120,000 in any fiscal year (or the reduced threshold based on Smaller Reporting Company status, if applicable).
Any transaction that meets the above criteria is referred to as a “Related Party Transaction.”
IDENTIFYING RELATED PARTIES
We have established a process to identify any Related Party to assist us in enforcing this Policy.
Directors and Executive Officers
Our finance team or compliance or legal department will collect, at least annually, the following information from each of our directors and executive officers (typically in the annual Directors’ and Officers’ Questionnaire):
1. A list of all entities in which they serve as a director or executive officer, or in which they have 10% or greater beneficial ownership interest.
2. A list of all their immediate family members, and for each immediate family member listed:
2
· | whether they are (a) an executive officer of any entity, or (b) employed by the Company’s independent auditor (or an affiliate, member firm or other entity associated with our independent auditor), and if so, the name of their employer and job title or a brief job description; and |
· | all entities in which they serve as a director or in which they are a significant stockholder. |
This list also will include the name of each charitable or non-profit organization for which each director, executive officer and any immediate family member is a major fundraiser or otherwise serves as a director or trustee, or in a similar capacity.
Directors and executive officers are expected to notify our finance team or compliance or legal department of any updates to the list of Related Parties, including updates to their employment and relationships with charitable organizations.
Significant Stockholders
When the Company learns that a person has become a significant stockholder, our finance team or compliance or legal department will examine relevant filings with the U.S. Securities and Exchange Commission (“SEC”) (to the extent such information is available) to determine (a) if the person is an individual, the same information requested of directors and executive officers under this Policy, and (b) if the person is a firm, corporation or other entity, a list of principals or executive officers of such firm, corporation or entity.
APPROVAL PROCESS
Advance Approval
Any transaction the Company intends to undertake with a Related Party, irrespective of the amounts involved (unless the transaction is subject to standing pre-approval as provided below or pursuant to a resolution adopted by the Approval Authority), must be submitted to our Compliance Officer for his or her determination of the approvals required under this Policy. The Compliance Officer will refer to the Approval Authority any Related Party Transaction, and any other transaction he or she determines should be considered for evaluation by the Approval Authority, consistent with the purpose of this Policy. The Compliance Officer may do so irrespective of any pre-approval or other technical exemption from this Policy.
The legal or compliance department or finance team will provide the Approval Authority with all relevant information available about the proposed transaction, including:
1. the Related Party’s relationship to the Company and interest in the transaction;
2. the material facts of the proposed transaction, including the anticipated aggregate dollar value of the transaction or, in the case of indebtedness, the largest amount of principal outstanding at any time during the current fiscal year plus all amounts of interest payable on it during the fiscal year;
3
3. the rationale for the proposed transaction; and
4. any other relevant information with respect to the proposed transaction.
In deciding whether to approve a proposed transaction, the Approval Authority may take into account any relevant information and considerations, including the impact on a director’s independence if the Related Party is a director, their immediate family member or an entity with which a director is affiliated. The Approval Authority may impose such conditions as it deems appropriate on the Company or on the Related Party in connection with approving the proposed transaction.
The Approval Authority will convey the decision, including any conditions imposed on the transaction, to our Compliance Officer, who then will convey the decision to the appropriate people within the Company.
Review of Ongoing Transactions
At least annually, the Approval Authority will review any previously approved or ratified transactions with Related Parties that remain ongoing, and that have a remaining term of more than six months and remaining amounts payable to or receivable from us of more than $120,000 during the fiscal year (or the reduced threshold based on Smaller Reporting Company status, if applicable). Based on all relevant facts and circumstances, the Approval Authority will determine whether it is in the best interests of the Company and its stockholders to continue, modify or terminate the transaction.
Ratification
Members of our finance team will produce quarterly reports of any amounts paid or payable to, or received or receivable from, any Related Party. These reports will be provided (a) to our legal or compliance department and used to determine whether there are any Related Party Transactions or other transactions with Related Parties that were not previously approved or previously ratified under this Policy, and (b) to our Compliance Officer for appropriate reporting in our periodic reports.
If the Compliance Officer learns of a transaction with a Related Party that required but did not receive approval or ratification under this Policy, he or she will promptly submit the transaction to the Approval Authority. The Approval Authority will undertake the review described above. Based on the conclusions reached, the Approval Authority will evaluate all options, including but not limited to ratification, amendment or termination of the transaction with the Related Party, and determine whether disciplinary action is appropriate.
A transaction with a Related Party entered into without pre-approval of the Approval Authority will not be deemed to violate this Policy, or be invalid or unenforceable, provided that the transaction is brought to the Approval Authority as promptly as reasonably practical after it is entered into, or after it becomes reasonably apparent that the transaction is covered by this Policy.
4
Standing Pre-Approval for Certain Related Party Transactions
Unless there are special or unusual benefits to the Related Party in a proposed transaction, the following categories of Related Party Transactions do not need to be presented to the Approval Authority for review and approval under this Policy:
1. Employment of executive officers: Any employment by us of an executive officer if:
· | the executive officer is a “named executive officer” whose compensation must be reported in our proxy statement; or |
· | the executive officer is not an immediate family member of another executive officer or director, the related compensation would be reported in our proxy if the executive officer were a “named executive officer,” and the Company’s Board; |
2. Director compensation: Any compensation paid to a director (in such capacity) if the compensation is required to be reported in our proxy statement;
3. Transactions where all stockholders receive proportional benefits: Any transaction in which the Related Party’s interest arises solely from the ownership of our capital shares and all holders of our capital shares receive the same benefit on a pro rata basis (e.g., dividends);
4. Ordinary-course expenses, advances and reimbursements: Ordinary-course business travel and expenses, advances and reimbursements; and
5. Indemnification: Indemnification payments and other payments made pursuant to (a) directors and officers insurance policies, (b) our formation document or charter (as may be amended and/or restated from time to time), and/or (c) any other policy or agreement approved by the Board.
5
Exhibit 21.1
LIST OF SUBSIDIARIES OF AKANDA CORP.
Subsidiary | Jurisdiction | |
Bophelo Bio Science and Wellness (Pty) Limited | Kingdom of Lesotho | |
Bophelo Holdings Limited | England and Wales | |
Canmart Limited | England and Wales | |
Cannahealth Limited | Malta | |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors of
Akanda Corp.
Bophelo Bio Science and Wellness (Pty) Limited
Bophelp Holdings Limited
Canmart Limited
Cannaheath Limited
We consent to the inclusion in the Form F-1 Registration Statement of Akanda Corp. (the “Company”) our report dated November 18, 2021 relating to our audit of statement of financial position as of July 16, 2021, and statements of operations, shareholders’ equity and cash flows for the period from July 16, 2021 (inception) through to August 31, 2021.
We consent to the inclusion in the Form F-1 Registration Statement of Bophelo Bio Science and Wellness (Pty) Limited our report dated November 18, 2021 relating to our audit of the statements of financial position as of December 31, 2020 and December 31, 2019 and statements of operations, shareholders’ equity and cash flows for the period from January 01, 2020 through December 31, 2020 and January 01, 2019 through December 31, 2019.
We consent to the inclusion in the Form F-1 Registration Statement of Bophelo Holdings Limited our report dated November 18, 2021 relating to our audit of the statement of financial position as of August 4, 2021, and statements of operations, shareholder’s equity and cash flows for the period from August 4, 2021 (inception) through August 31, 2021.
We consent to the inclusion in the Form F-1 Registration Statement of Canmart Limited our report dated November 18, 2021 relating to our audit of the statements of financial position as of December 31, 2020 and December 31, 20219, and statements of operations, shareholders’ equity and cash flows for the period from January 01, 2020 through December 31, 2020 and January 01, 2019 through December 31, 2019.
We consent to the inclusion in the Form F-1 Registration Statement of Cannaheath Limited. our report dated November 18, 2021 relating to our audit of the statement of financial position as of December 31, 2020, and statements of operations, shareholder’s equity and cash flows for the period from July 01, 2020 (inception) through December 31, 2020.
We also consent to the reference to us under the caption “Experts” in the Registration Statement.
/s/ BF Borgers CPA PC
Certified Public Accountants
Lakewood, Colorado
January 31, 2022
Exhibit 99.1
AKANDA CORP.
1a, 1b Learovd Road
New Romney TN28 8XU, United Kingdom
January 31, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Akanda Corp. | |
Registration Statement on Form F-1 | ||
Request for Waiver and Representation under Item 8.A.4 of Form 20-F |
Ladies and Gentlemen:
The undersigned, Akanda Corp., a company formed under the laws of the Province of Ontario, Canada (the “Company”), is submitting this letter via EDGAR to the U.S. Securities and Exchange Commission (the “Commission”) in connection with the Company’s registration statement on Form F-1 filed on the date hereof (the “Registration Statement”), relating to a proposed initial public offering and listing in the United States of the Company’s common shares.
The Company has included in the Registration Statement prepared in accordance with the International Financial Reporting Standards, the following financial statements:
· | audited financial statements of Akanda Corp. as of August 31, 2021 and for the period from July 16, 2021 (inception) to August 31, 2021; |
· | audited financial statements of Cannahealth Limited as of December 31, 2020 and for the period from July 1, 2020 (inception) to December 31, 2020; |
· | audited financial statements of Bophelo Holdings Ltd. as of August 31, 2021 and for the period from August 4, 2021 (inception) to August 31, 2021; |
· | audited financial statements of Bophelo Bioscience and Wellness (PTY) Ltd. for the fiscal years ended December 31, 2020 and 2019; |
· | audited financial statements of Canmart Ltd. for the fiscal years ended December 31, 2020 and 2019; |
· | unaudited interim consolidated financial statements and pro forma consolidated financial statements of Akanda Corp. as of September 30, 2021. |
· | unaudited financial statements of Cannahealth Limited as of September 30, 2021; |
· | unaudited financial statements of Bophelo Holdings Ltd. as of September 30, 2021; |
· | unaudited financial statements of Bophelo Bioscience and Wellness (PTY) Ltd. as of September 30, 2021; and |
· | unaudited financial statements of Canmart Ltd. as of September 30, 2021. |
The Company respectfully requested that the Commission waive the requirement of Item 8.A.4 of Form 20-F (the “Waiver Request”), which states that in the case of a company’s initial public offering, the registration statement on Form F-1 must contain audited financial statements of a date not older than 12 months from the date of the filing (the “12-Month Requirement”).
The Company is submitting this Waiver Request pursuant to Instruction 2 to Item 8.A.4 of Form 20-F, which provides that the Commission will waive the 12-Month Requirement “in cases where the company is able to represent adequately to us that it is not required to comply with this requirement in any other jurisdiction outside the United States and that complying with this requirement is impracticable or involves undue hardship.” In addition, in International Reporting and Disclosure Issues in the Division of Corporation Finance, dated November 1, 2004 (available on the Commission’s website at http://www.sec.gov/divisions/corpfin/internatl/cfirdissues1104.htm), at Section III. B. c), staff of the Commission notes that:
“the instruction indicates that the staff will waive the 12-month requirement where it is not applicable in the registrant’s other filing jurisdictions and is impracticable or involves undue hardship. As a result, we expect that the vast majority of IPOs will be subject only to the 15-month rule. The only times that we anticipate audited financial statements will be filed under the 12-month rule are when the registrant must comply with the rule in another jurisdiction, or when those audited financial statements are otherwise readily available.”
In connection with the Waiver Request, the Company represents to the Commission that:
1. | The Company is not currently a public reporting company in any jurisdiction. |
2. | The Company is not required by any jurisdiction outside the United States to prepare consolidated financial statements audited under any generally accepted auditing standards for any interim period. |
3. | Full compliance with Item 8.A.4 of Form 20-F at present is impracticable and involves undue hardship for the Company. |
4. | The Company does not anticipate that its audited financial statements for the year ended December 31, 2021 will be available until April 2022. |
5. | In no event will the Company seek effectiveness of its registration statement on Form F-1 if its audited financial statements are older than 15 months at the time of the Company’s initial public offering. |
The Company has filed this letter as an exhibit to the Registration Statement pursuant to Instruction 2 to Item 8.A.4 of Form 20-F.
Sincerely, | ||
AKANDA CORP. | ||
By: | /s/ Tejinder Virk | |
Name: | Tejinder Virk | |
Title: | Chief Executive Officer and Director |
Exhibit 99.2
05 October 2021
Non-Binding Acquisition Proposal for Cellen Life Sciences Limited
Dear Mr. Eric Bystrom,
This term sheet (this “Term Sheet”) summarizes certain terms and conditions for the non-binding proposed acquisition (the “Transaction”) of 100% ownership of Cellen Life Sciences Limited (the “Target” or “Cellen”), by Akanda Corp. (“Purchaser”).
The Transaction is expected to proceed on a friendly basis with the approval of the board of directors of Purchaser and the shareholders of Target. Indicative terms of the Transaction, subject to due diligence, are set out in the attached Schedule A.
The existence of this Term Sheet and the terms herein are to be kept strictly confidential. All currency figures below are denoted in British Pound Sterling (GBP).
1. | Conditions |
The implementation of this Term Sheet and the completion of the Transaction are subject to the following conditions:
(a) | the negotiation and entering into by Purchaser and Target of mutually satisfactory definitive agreements in respect of the Transaction (the "Definitive Agreements") providing for the definitive terms and conditions upon which the Transaction will be completed, which are anticipated to reflect the indicative terms and conditions set out in Schedule A as well as customary representations, warranties, covenants, closing conditions and indemnification which are mutually acceptable to the parties. The Definitive Agreements, upon execution, shall supersede this Term Sheet in its entirety; |
(b) | receipt of the approval of the board of directors of Purchaser and the Target for the Transaction and the Definitive Agreements; |
(c) | receipt of all required third party and regulatory approvals for the Transaction; |
(d) | completion of audited annual financial statements for Target; |
(e) | confirmation that Target does not have any debt, other than payables incurred as a result of operating activities; and |
(f) | satisfactory completion of a detailed due diligence investigations by Purchaser in accordance with Section 4. |
STRICTLY PRIVATE & CONFIDENTIAL | 1 | P a g e |
2. | Exclusivity |
From the date hereof until the Termination Date (defined below) (the "Exclusivity Period"), Target agrees to negotiate exclusively and in good faith with Purchaser with a view to settling the Definitive Agreements as soon as possible. Target agrees that, during the Exclusivity Period, neither it nor any of its respective owners, affiliates, representatives, officers, managers, members, employees, advisors or agents will, directly or indirectly, make, solicit or initiate inquiries from, or the submission of proposals or offers from, any other person relating to any acquisition, sale, lease, license or other disposition of the assets or equity of Target or any of its subsidiaries or participate in any discussions or negotiations regarding, or furnish to any other person any further information with respect to, or otherwise co-operate in any way with, or assist or participate in or facilitate, any effort or attempt by any person to do or seek to do any of the foregoing and, to the extent any such discussions or negotiations have occurred with third parties prior to the date hereof, they shall be terminated immediately.
3. | Announcement |
The entry into this Term Sheet and the terms herein are confidential. The Definitive Agreements will govern the public disclosure rights and obligations of the parties following the signing of the Definitive Agreements.
4. | Due Diligence; Access and Cooperation |
Target covenants and agrees that during the Exclusivity Period and subject to the Confidentiality and Non-Circumvention provisions set forth herein, Purchaser, through its employees and representatives, shall be entitled to make such reasonable investigation of the Target as Purchaser reasonably deems necessary, with such reasonable investigation to include the examination of the books, records, financial condition and prospects of the Target. Any such investigation shall be conducted at reasonable times and under reasonable circumstances, and Purchaser and Target shall cooperate fully with each other in connection therewith. In order for Purchaser to have a full opportunity to make such investigation and examination, Target agrees to make available, and to cause each of its respective subsidiaries and affiliates to make available, to representatives of Purchaser all such information and copies of such documents concerning the Target and its affairs as such representatives reasonably request, and to permit such representatives access to their respective properties during business hours upon reasonable prior notice and to use commercially reasonable efforts to cause their respective members, managers, employees, agents, consultants, and representatives to cooperate fully with such representatives in connection with such investigations and examinations.
STRICTLY PRIVATE & CONFIDENTIAL | 2 | P a g e |
5. | Confidentiality; Non Circumvention |
Each of Purchaser and Target:
(a) | acknowledges that information that is non-public, confidential, and proprietary in nature will be provided to it. Each of Purchaser and Target (and any of their respective directors, officers, managers, members, affiliates, representatives, agents, and employees) will keep such information confidential and will not, except as otherwise provided below, disclose such information or use such information for any purpose other than for the evaluation and consummation of the Transaction. The foregoing will not apply to information that: (i) becomes generally available to the public absent any breach of the foregoing; (ii) was available on a non-confidential basis to a party prior to its disclosure pursuant to this Term Sheet; or (iii) becomes available on a non-confidential basis from a third party who is not bound to keep such information confidential; |
(b) | agrees that it will not make any public disclosure of the existence of this Term Sheet, any of its terms or that the parties are engaged in discussions with respect to the Transaction without first advising the other party and obtaining the written consent of the other party to the proposed disclosure, unless such disclosure is required by applicable law, regulation or the rules and policies of any securities regulatory authority having jurisdiction, in which event the party contemplating disclosure will inform the other party of, and obtain its consent to, the form and content of such disclosure, which consent will not be unreasonably withheld or delayed; |
(c) | agrees that immediately upon request, or upon any discontinuance of activities by any party that results in the Transaction not being consummated, it will return to the other party all of its confidential information; and |
(e) | the provisions of this Section 5 shall explicitly survive: 1) expiration or termination of this Term Sheet; 2) the return of Confidential Information to Target; and 3) the conclusion of any discussions regarding the Transaction contemplated herein. |
6. | Expenses |
Each of the parties hereto shall be responsible for their own expenses incurred in connection with this Term Sheet, the Definitive Agreements and the Transaction.
7. | Non-Binding Obligation; Termination |
Except with respect to Section 2 (Exclusivity), Section 3 (Announcement); Section 4 (Due Diligence; Access and Cooperation), Section 5 (Confidentiality; Non-Circumvention), Section 6 (Expenses), Section 7 (Non-Binding Obligation; Termination), Section 8 (Governing Law; Attornment), Section 9 (Assignment; No Third-Party Beneficiaries), and Section 10 (Execution; Entire Agreement), which are intended to be, and are, legally binding provisions between the parties, the terms and conditions of this Term Sheet and all of the rights and obligations of the parties contained herein shall be non-binding upon and unenforceable.
STRICTLY PRIVATE & CONFIDENTIAL | 3 | P a g e |
For greater certainty, Section 1 of this Term Sheet and the attached Schedule A are intended to describe the basis upon which the parties will attempt to negotiate the Definitive Agreements in connection with the Transaction and do not, nor are they intended to, constitute binding obligations.
This Term Sheet will terminate and be of no further force and effect upon the earlier of: (a) on written notice by Target to Purchaser or by Purchaser to Target at any time after 120 days following the date that this Term Sheet is accepted by Target; (b) the date on which the Definitive Agreements are entered into; or (c) such other date as may be mutually agreed between Purchaser and Target in writing (the "Termination Date"). Notwithstanding the foregoing, Section 5 (Confidentiality; Non-Circumvention), Section 6 (Expenses) and Section 8 (Governing Law; Attornment) shall survive the termination of this Term Sheet and the termination of this Term Sheet shall not affect any rights any party has with respect to the breach of this Term Sheet by another party prior to such termination.
8. | Governing Law; Attornment |
This Term Sheet will be governed by and construed in accordance with the laws of the province of Ontario, Canada.
9. | Assignment; No Third-Party Beneficiaries |
No party shall be entitled to assign its rights and obligations hereunder without the prior written consent of the other party. Except as specifically set forth or referred to herein, nothing herein is intended or will be construed to confer upon any person or entity other than the parties and their successors or assigns, any rights or remedies under or by reason of this Term Sheet.
10. | Execution; Entire Agreement |
This Term Sheet may be executed in one or more counterparts, each of which will be deemed to be an original and all of which together will be deemed to be one and the same document. This Term Sheet incorporates the entire agreement between the parties with respect to the subject matter of this Term Sheet and may not be amended or modified except in writing.
The Term Sheet does not address all of the terms of the proposed transaction, which will be addressed in the Definitive Agreements.
< Signatures on next page>
STRICTLY PRIVATE & CONFIDENTIAL | 4 | P a g e |
If the foregoing accurately reflects the terms and conditions of our agreement, would you kindly indicate your acceptance hereof by signing and returning by 12h00 (GMT) , 6 August 2021.
Truly yours,
Akanda Corp. | ||
By: | ||
Name: Tejinder Virk | ||
Title: Chief Executive Officer & Director |
The undersigned agrees and accepts the terms of this Term Sheet.
Cellen Life Sciences Limited | ||
By: | ||
Name: | ||
Title: |
STRICTLY PRIVATE & CONFIDENTIAL | 5 | P a g e |
SCHEDULE A
The principal terms are as follows:
Structure: |
The Purchaser intends to list on a U.S. stock exchange within the next 6 months, and is in the process of selecting a syndicate of NASD broker dealers.
The business of Cellen would be complementary to the Purchaser which would (and subject to the satisfaction of the conditions described in this Term Sheet, at the closing of the Transaction), seek to acquire all of the outstanding and issued Cellen ordinary shares (the “Transaction”).
The acquisition of 100% of the outstanding and issued ordinary shares of the Target (the "Sale Equity"), for the consideration set forth below shall be pursuant to Definitive Agreements containing representations, warranties, covenants, conditions and indemnities customary for a transaction of this type. Except as otherwise set forth in the schedules to the Definitive Agreements, Purchaser shall acquire the Sale Equity free and clear of all encumbrances. Whether the Transaction is structured as one or more asset purchases, equity purchases or mergers will be mutually determined by the parties based upon tax, accounting, securities, legal and other considerations.
|
Subject of the Acquisition: |
100% of the outstanding and issued ordinary shares in the Target.
|
Consideration: |
Total purchase consideration for the Sale Equity shall be settled through an issue of common shares in the Purchaser, with a post-listing value of GBP 10 million, subject to customary lock-up and leak out arrangements, as required.
|
Audit Fee expenses: |
Purchaser shall arrange for, and cover the cost of, the Target’s annual financial statements being prepared in accordance with International financial Reporting Standards and audited by the Purchaser’s UK registered auditor responsible for the audit of it’s UK based subsidiaries. Such audit fee expenses shall be held over by the Purchaser on loan account with the target. These costs shall be limited to no more than $20,000. The loan account shall have no fixed terms of repayment for the first six months following disbursement by the Purchaser. Thereafter, the loan account shall become immediately due and payable.
|
STRICTLY PRIVATE & CONFIDENTIAL | 6 | P a g e |
Bridge Financing: |
The Purchaser and the Target shall, in good faith, enter into negotiations concerning commercial terms for a Bridge Financing Facility (“the Bridge Loan”) to the amount of between GBP 300,000 and GBP 500,000 for the purposes of assisting the funding of the Target’s working capital requirements prior to the completion of the Transaction. The Bridge Loan shall be subject to the completion and entering into of separate definitive agreements governing the Bridge Loan.
|
Closing Conditions: | The Transaction will be subject to standard closing conditions for transactions of this nature, including, among other things, (i) accuracy of representations and warranties and compliance with covenants and obligations, (ii) the absence of litigation, restraining orders, injunctions or other legal restraints, except as otherwise set forth in the schedules to the Definitive Agreements, (iii) receipt of required regulatory and third party consents, officers' and secretary's certificates; (iv) non-competition agreements from certain personnel of the Target covering various jurisdictions, as appropriate and to the extent necessary, for two years following the Closing Date; (v) employment agreements for key personnel of Target, (vii) evidence that the Sale Equity is free and clear of all encumbrance, except as otherwise set forth in the schedules to the Definitive Agreements, and (vi) other customary closing documentation. At the Closing Date, the Target shall have satisfied all of its outstanding debt, except for such liabilities assumed by the Purchaser and will have a reasonable level of working capital, to be reasonably negotiated by the parties. |
STRICTLY PRIVATE & CONFIDENTIAL | 7 | P a g e |
Exhibit 99.3
Memorandum of Understanding
Memorandum of Understanding
Between
Akanda Corp.
With registered office at 77 King Street West, Suite 400, Toronto, Ontario M5K 0A1
(hereafter: Akanda)
and
Cellen Life Sciences Limited
With registered office at Cms Cameron Mckenna Nabarro Olswang LLP Cannon Place, 78 Cannon Street, London, United Kingdom, EC4N 6AF
(hereafter: Cellen)
Effective Date: October 1, 2021
This Memorandum of Understanding (“MOU”) sets the terms and understanding between Akanda or its nominees and Cellen to establish a formal working relationship to optimize in medical cannabis supply chain activities and pursue opportunities in this regard within the territory of UK.
Background
Akanda and Cellen are established leaders in the international medical cannabis space. Akanda is a cannabis cultivation, manufacturing, and distribution company with operations in the United Kingdom and the Kingdom of Lesotho. Cellen is a cannabis telehealth, research and medical brands company with operations in the United Kingdom. Cellen is a medical cannabis supplier to Project Twenty21, a large-scale medical cannabis observational study in the United Kingdom. Cellen also owns and operates digital pain clinic: Leva Clinic, which is licensed and regulated by the Care Quality Commission (‘CQC’) in the United Kingdom. Akanda is in the process of consolidating 100% ownership in CanMart Ltd, which has licenses in place with the Home Office and MHRA, allowing for the importation, manufacturing and distribution of medical cannabis within the United Kingdom.
Purpose
This MOU is to establish a formal working relationship to optimize medical cannabis supply chain activities across Cellen and Akanda business interests, to consistently increase supply and choice for patients in the United Kingdom.
The above goals will be accomplished by undertaking the following activities:
- | Akanda identifying third party suppliers of medical cannabis products to be prescribed through Leva clinic, under mutually agreed upon brands; |
- | Akanda group employed GMC registered consultants to prioritize patients of Leva Clinic for medical cannabis; |
- | Cellen to integrate CanMart into their systems for seamless fulfillment of medical cannabis prescriptions for patients; |
- | Collaboration on new product development and manufacturing processes, which could include third party vendors; |
CONFIDENTIAL
Page 1 of 2
- | Publicly recognizing the existence of this MOU through media and discussions with third party vendors; |
- | Akanda and Cellen to jointly pursue distribution and branding opportunities within the United Kingdom market area; and |
- | Akanda and Cellen to share knowledge and relationship resources to further the businesses of both parties. |
Reporting
The successful undertaking of this MOU will be evaluated by Tej Virk, CEO of Akanda and Eric Bystrom, CEO of Cellen. Evaluation of goals will be checked on monthly basis, at a mutually agreed upon meeting time.
Funding
This MOU is not a formal commitment of funds of by either Akanda or Cellen.
Duration
This MOU is at-will and may be modified by mutual consent, in writing, of authorized officials from Akanda and Cellen. This MOU shall become effective upon signature by the authorized officials from the Akanda and Cellen and will remain in force and effect until modified or terminated by any one of the partners by mutual consent. In the absence of mutual agreement by the authorized officials from Akanda and Cellen to extend the duration period, this MOU shall end on October 1, 2022.
Contact Information
Tej Virk
Akanda Corp
CEO & Director
Address: 39 Landau, 72 Farm Lane, SW6 1QA, London, United Kingdom
Telephone: +44 (0) 7912 741995
E-mail: tej@akandacorp.com
Eric Bystrom
Cellen Life Sciences Ltd
CEO
Address: 1 Shorrolds Rod, Flat 8, SW6 7TR
Telephone: +44 (0) 7931 331100
E-mail: eric@cellenhealth.com
IN WITNESS WHEREOF the Akanda and Cellen have signed this MOU as of the Effective Date.
Name: Tej Virk | |
Title: CEO & Director of Akanda Corp |
Name: Eric Bystrom | |
Title: CEO of Cellen Life Sciences Ltd |
CONFIDENTIAL
Page 2 of 2
Exhibit 99.4
Consent of Director Nominee
The undersigned hereby consents to being named in the registration statement on Form F-1 and in all subsequent amendments and post-effective amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended (collectively, the “Registration Statement”), of Akanda Corp., a corporation formed under the laws of the Province of Ontario, Canada (the “Company”), as an individual to become a director of the Company and to the inclusion of her biographical and other information in the Registration Statement. The undersigned also hereby consents to being named in any registration statement on Form S-8 filed by the Company that incorporates by references the prospectus forming part of the Registration Statement.
/s/ Gila Jones | |
Name: Gila Jones | |
Date: January 31, 2022 |
Exhibit 99.5
Consent of Director Nominee
The undersigned hereby consents to being named in the registration statement on Form F-1 and in all subsequent amendments and post-effective amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended (collectively, the “Registration Statement”), of Akanda Corp., a corporation formed under the laws of the Province of Ontario, Canada (the “Company”), as an individual to become a director of the Company and to the inclusion of her biographical and other information in the Registration Statement. The undersigned also hereby consents to being named in any registration statement on Form S-8 filed by the Company that incorporates by references the prospectus forming part of the Registration Statement.
/s/ Gugu Dingaan | |
Name: Gugu Dingaan | |
Date: January 31, 2022 |
EX-FILING FEES
Calculation of Filing Fee Tables
F-1
(Form Type)
Akanda
Corp.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type |
Security
Class Title |
Fee
Calculation or Carry Forward Rule |
Amount
Registered |
Proposed
Maximum Offering Price Per Unit |
Maximum
Aggregate Offering Price |
Fee Rate |
Amount of
Registration Fee |
Carry
Forward Form Type |
Carry
Forward File Number |
Carry
Forward Initial effective date |
Filing Fee
Previously Paid In Connection with Unsold Securities to be Carried Forward |
|||||||||||||||||||||||
Newly Registered Securities | ||||||||||||||||||||||||||||||||||
Fees to Be Paid | Equity | Common Shares(1)(2) | 457(o) | $ | 27,600,000 | (3) | .0000927 | $ | 2,558.52 | |||||||||||||||||||||||||
Fees to Be Paid | Other | Purchase Warrants | 457(g) | — | — | — | — | (4) | ||||||||||||||||||||||||||
Fees to Be Paid | Equity | Common Shares(2)(5) | 457(g) | 322,000 | $ | 7.50 | (6) | $ | 2,415,000 | .0000927 | $ | 223.87 | ||||||||||||||||||||||
Fees Previously Paid | ||||||||||||||||||||||||||||||||||
Carry Forward Securities | ||||||||||||||||||||||||||||||||||
Carry Forward Securities | ||||||||||||||||||||||||||||||||||
Total Offering Amounts | $ | 30,015,000 | $ | 2,782.39 | ||||||||||||||||||||||||||||||
Total Fees Previously Paid | ||||||||||||||||||||||||||||||||||
Total Fee Offsets | ||||||||||||||||||||||||||||||||||
Net Fee Due | $ | 2,782.39 |
1 |
(1) | Includes the Common Shares that the underwriters have the option to purchase to cover any over-allotments. |
(2) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), there is also being registered hereby such indeterminate number of additional Common Shares of the Registrant as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions. |
(3) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. |
(4) | No fee required pursuant to Rule 457(g) under the Securities Act. |
(5) | Represents Common Shares underlying one or more warrants (the “Representative’s Warrants”) issuable to the representative of the several underwriters to purchase up to an aggregate of 7% of the Common Shares sold in the offering at an exercise price equal to 125% of the public offering price. The Representative’s Warrants will be exercisable upon issuance, will have a cashless exercise provision and will terminate five years from the commencement of sales of the public offering. |
(6) | As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price per share of the Representative’s Warrants is $7.50 (125% of $6.00). |
2 |